0001558370-24-01532510-Q Natera, Inc. 20241112202411121623001623011623 01 0 0001558370-24-015325 10-Q 83 20240930 20241112 20241112 Natera, Inc. 0001604821 8071 010894487 DE 1231 10-Q 34 001-37478 241448632 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 650-249-9090 13011 MCCALLEN PASS BUILDING A SUITE 100 AUSTIN TX 78753 10-Q 1 ntra-20240930x10q.htm 10-Q 124137000119581000Natera, Inc.Yesfalse0001604821--12-31Q3false2024truefalseDEfalsefalseNASDAQ0.260.951.123.1412377500011517100012248600011355900OP8Y0M7DP36MP24MP5YP1Y34500000220000037000001081000007000001200004500
gaap:CommonStockMember2024-07-012024-09-300001604821us-gaap:CommonStockMember2023-07-012023-09-300001604821us-gaap:RetainedEarningsMember2024-09-300001604821us-gaap:AdditionalPaidInCapitalMember2024-09-300001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300001604821us-gaap:RetainedEarningsMember2024-06-300001604821us-gaap:AdditionalPaidInCapitalMember2024-06-300001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300001604821us-gaap:RetainedEarningsMember2023-12-310001604821us-gaap:AdditionalPaidInCapitalMember2023-12-310001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001604821us-gaap:RetainedEarningsMember2023-09-300001604821us-gaap:AdditionalPaidInCapitalMember2023-09-300001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001604821us-gaap:RetainedEarningsMember2023-06-300001604821us-gaap:AdditionalPaidInCapitalMember2023-06-300001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001604821us-gaap:RetainedEarningsMember2022-12-310001604821us-gaap:AdditionalPaidInCapitalMember2022-12-310001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001604821ntra:EmployeeAndNonEmployeeOptionsMember2024-01-012024-09-300001604821ntra:EmployeeAndNonEmployeeOptionsMember2024-09-300001604821ntra:EmployeeAndNonEmployeeOptionsMember2023-12-310001604821ntra:RestrictedStockUnitsRsuAndPerformanceSharesMember2024-09-300001604821ntra:RestrictedStockUnitsRsuAndPerformanceSharesMember2023-12-310001604821ntra:RestrictedStockUnitsRsuAndPerformanceSharesMember2024-01-012024-09-300001604821us-gaap:PerformanceSharesMember2024-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:OncologyAssayInterpretationServicesMember2023-12-310001604821ntra:FoundationMedicineInc.Memberntra:OncologyProductsMember2023-06-300001604821ntra:BgiGenomicsCoLtdMemberntra:LicenseAndRelatedDevelopmentServicesMember2023-03-310001604821us-gaap:EMEAMember2024-07-012024-09-300001604821ntra:PatientsMember2024-07-012024-09-300001604821ntra:OtherGeographicAreasMember2024-07-012024-09-300001604821ntra:LaboratoryPartnersMember2024-07-012024-09-300001604821ntra:InsuranceCarriersMember2024-07-012024-09-300001604821ntra:AmericasExcludingUsMember2024-07-012024-09-300001604821country:US2024-07-012024-09-300001604821us-gaap:EMEAMember2024-01-012024-09-300001604821ntra:PatientsMember2024-01-012024-09-300001604821ntra:OtherGeographicAreasMember2024-01-012024-09-300001604821ntra:LaboratoryPartnersMember2024-01-012024-09-300001604821ntra:InsuranceCarriersMember2024-01-012024-09-300001604821ntra:AmericasExcludingUsMember2024-01-012024-09-300001604821country:US2024-01-012024-09-300001604821us-gaap:EMEAMember2023-07-012023-09-300001604821ntra:PatientsMember2023-07-012023-09-300001604821ntra:OtherGeographicAreasMember2023-07-012023-09-300001604821ntra:LaboratoryPartnersMember2023-07-012023-09-300001604821ntra:InsuranceCarriersMember2023-07-012023-09-300001604821ntra:AmericasExcludingUsMember2023-07-012023-09-300001604821country:US2023-07-012023-09-300001604821us-gaap:EMEAMember2023-01-012023-09-300001604821ntra:PatientsMember2023-01-012023-09-300001604821ntra:OtherGeographicAreasMember2023-01-012023-09-300001604821ntra:LaboratoryPartnersMember2023-01-012023-09-300001604821ntra:InsuranceCarriersMember2023-01-012023-09-300001604821ntra:AmericasExcludingUsMember2023-01-012023-09-300001604821country:US2023-01-012023-09-300001604821us-gaap:SecuredDebtMember2020-04-012020-04-300001604821ntra:OtherMaterialSupplierMember2024-09-300001604821ntra:OperatingLeaseCommitmentsMember2024-09-300001604821ntra:LaboratoryInstrumentsMember2024-09-300001604821ntra:InventoryMaterialPurchaseCommitmentMember2024-09-300001604821ntra:CloudPlatformServiceProviderMember2024-09-300001604821ntra:ApplicationServiceProviderMember2024-09-300001604821srt:MinimumMemberus-gaap:MachineryAndEquipmentMember2024-09-300001604821srt:MaximumMemberus-gaap:MachineryAndEquipmentMember2024-09-300001604821us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-09-300001604821us-gaap:MachineryAndEquipmentMember2024-09-300001604821us-gaap:LeaseholdImprovementsMember2024-09-300001604821us-gaap:ConstructionInProgressMember2024-09-300001604821us-gaap:ComputerEquipmentMember2024-09-300001604821us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310001604821us-gaap:MachineryAndEquipmentMember2023-12-310001604821us-gaap:LeaseholdImprovementsMember2023-12-310001604821us-gaap:ConstructionInProgressMember2023-12-310001604821us-gaap:ComputerEquipmentMember2023-12-310001604821ntra:LineOfCreditUbsMember2022-11-012022-11-300001604821023-09-012023-09-300001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-09-300001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001604821us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:SequencingServicesMember2019-06-300001604821ntra:BgiGenomicsCoLtdMemberntra:SequencingProductsMember2019-06-300001604821ntra:BgiGenomicsCoLtdMemberntra:SequencingProductsAndServicesMember2019-06-300001604821us-gaap:RetainedEarningsMember2024-07-012024-09-300001604821us-gaap:RetainedEarningsMember2024-01-012024-09-300001604821us-gaap:RetainedEarningsMember2023-07-012023-09-300001604821us-gaap:RetainedEarningsMember2023-01-012023-09-300001604821ntra:InivataPatentCaseMember2022-12-310001604821ntra:ClassActionLawsuitMember2022-02-280001604821ntra:CaredxSPatentCaseMember2020-03-310001604821ntra:CaredxSPatentCaseMember2019-03-310001604821ntra:InivitaPatentCaseMember2021-11-012021-11-300001604821ntra:InivataPatentCaseMember2021-01-012022-12-310001604821ntra:RavgenPatentCaseMember2020-06-012020-06-300001604821ntra:CaredxSPatentCaseMember2019-03-012019-03-310001604821ntra:RavgenPatentCaseMember2024-01-012024-01-310001604821ntra:CaredxSPatentCaseMember2022-03-012022-03-310001604821ntra:LineOfCreditUbsMember2023-06-300001604821ntra:LineOfCreditUbsMember2022-11-300001604821ntra:LineOfCreditUbsMember2020-12-310001604821ntra:LineOfCreditUbsMember2015-09-300001604821ntra:LineOfCreditUbsMember2023-12-310001604821srt:MinimumMemberntra:CertainWorkspacesAndStorageSpacesMember2024-09-300001604821srt:MaximumMemberntra:CertainWorkspacesAndStorageSpacesMember2024-09-300001604821ntra:CorporateHeadquartersLeaseAmendmentMember2024-09-300001604821ntra:SanCarlosCaliforniaSubleaseAmendmentMember2024-07-310001604821ntra:LineOfCreditUbsMember2024-01-012024-09-300001604821ntra:LineOfCreditUbsMember2023-07-012023-09-300001604821ntra:LineOfCreditUbsMember2023-01-012023-09-300001604821ntra:LineOfCreditUbsMember2024-07-012024-09-300001604821ntra:CaredxSPatentCaseMember2024-01-012024-01-310001604821ntra:NeoGenomicsPatentCaseMember2023-07-012023-07-310001604821ntra:ArcherdxPatentCaseMember2023-06-012023-06-300001604821ntra:ArcherdxPatentCaseMember2023-05-012023-05-310001604821ntra:InivataPatentCaseMember2022-12-012022-12-310001604821ntra:GenosityInc.PatentCaseMember2020-10-012020-10-310001604821ntra:ArcherdxPatentCaseMember2020-01-012020-01-310001604821ntra:AssetsAcquiredFromInvitaeMember2024-01-310001604821ntra:MyomeIncMember2024-08-310001604821ntra:MyomeIncMember2021-12-060001604821ntra:MyomeIncMembersrt:ChiefExecutiveOfficerMember2021-12-060001604821us-gaap:ConvertibleNotesPayableMember2024-07-190001604821ntra:TwentyTradingDaysPeriodMemberus-gaap:ConvertibleNotesPayableMember2020-04-012020-04-300001604821ntra:FiveDayConsecutiveTradingPeriodMemberus-gaap:ConvertibleNotesPayableMember2020-04-012020-04-300001604821us-gaap:ConvertibleNotesPayableMemberus-gaap:SubsequentEventMember2024-10-112024-10-110001604821ntra:LineOfCreditUbsMember2024-09-300001604821ntra:LineOfCreditUbsMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2024-01-012024-09-300001604821ntra:LineOfCreditUbsMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-10-012023-10-310001604821ntra:LineOfCreditUbsMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-01-012023-09-300001604821ntra:LineOfCreditUbsMemberntra:LondonInterbankOfferedRateMember2017-07-012017-07-310001604821ntra:LicensingAndOtherMember2024-07-012024-09-300001604821ntra:LicensingAndOtherMember2024-01-012024-09-300001604821ntra:LicensingAndOtherMember2023-07-012023-09-300001604821ntra:LicensingAndOtherMember2023-01-012023-09-300001604821us-gaap:ConvertibleNotesPayableMember2024-09-300001604821us-gaap:ConvertibleNotesPayableMemberus-gaap:SubsequentEventMember2024-10-110001604821us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleNotesPayableMember2024-09-300001604821us-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleNotesPayableMember2023-12-310001604821ntra:FoundationMedicineInc.Memberntra:OncologyAssayInterpretationServicesMember2024-07-012024-09-300001604821ntra:FoundationMedicineInc.Memberntra:OncologyAssayInterpretationServicesMember2024-01-012024-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:OncologyAssayInterpretationServicesMember2024-01-012024-09-300001604821ntra:FoundationMedicineInc.Member2024-01-012024-09-300001604821ntra:FoundationMedicineInc.Memberntra:OncologyAssayInterpretationServicesMember2023-07-012023-09-300001604821ntra:FoundationMedicineInc.Memberntra:OncologyProductsMember2023-04-012023-06-300001604821ntra:FoundationMedicineInc.Memberntra:OncologyAssayInterpretationServicesMember2023-01-012023-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:OncologyAssayInterpretationServicesMember2023-01-012023-09-300001604821ntra:GeneticTestingServicesMember2024-09-300001604821ntra:GeneticTestingServicesMember2024-01-012024-09-300001604821ntra:BgiGenomicsCoLtdAndFoundationMedicineInc.Member2024-01-012024-09-300001604821ntra:FoundationMedicineInc.Memberntra:OncologyAssayInterpretationServicesMember2024-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:OncologyAssayInterpretationServicesMember2024-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:OncologyAssayInterpretationServicesMember2023-09-300001604821ntra:BgiGenomicsCoLtdMember2024-09-300001604821ntra:MedicareMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001604821ntra:MedicareMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001604821ntra:MedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001604821ntra:MedicareMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001604821ntra:MedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001604821ntra:MedicareMemberus-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001604821us-gaap:CommonStockMember2024-09-300001604821us-gaap:CommonStockMember2024-06-300001604821us-gaap:CommonStockMember2023-12-310001604821us-gaap:PrivatePlacementMember2023-09-300001604821us-gaap:CommonStockMember2023-09-300001604821us-gaap:CommonStockMember2023-06-300001604821us-gaap:CommonStockMember2022-12-310001604821us-gaap:ConvertibleNotesPayableMember2020-04-300001604821ntra:MyomeIncMemberus-gaap:SeriesBPreferredStockMember2024-09-300001604821us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-09-300001604821us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberntra:CashCashEquivalentsAndRestrictedCashMember2024-09-300001604821us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2024-09-300001604821us-gaap:FairValueMeasurementsRecurringMemberntra:CashCashEquivalentsAndRestrictedCashMember2024-09-300001604821us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001604821us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-09-300001604821us-gaap:FairValueMeasurementsRecurringMember2024-09-300001604821us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-12-310001604821us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001604821us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberntra:CashCashEquivalentsAndRestrictedCashMember2023-12-310001604821us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310001604821us-gaap:FairValueMeasurementsRecurringMemberus-gaap:MunicipalBondsMember2023-12-310001604821us-gaap:FairValueMeasurementsRecurringMemberntra:CashCashEquivalentsAndRestrictedCashMember2023-12-310001604821us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001604821us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310001604821ntra:AssetsAcquiredFromInvitaeMember2024-01-012024-01-310001604821ntra:InProcessResearchDevelopmentAcquisitionAgreementMember2023-03-012023-03-310001604821ntra:InProcessResearchDevelopmentAcquisitionAgreementMember2022-12-012022-12-310001604821ntra:TukwilaWashingtonLeaseMember2024-09-300001604821ntra:SouthSanFranciscoCaliforniaLeaseMember2024-09-300001604821ntra:CorporateHeadquartersLeaseMember2024-09-300001604821ntra:AustinTxLongTermLeaseMember2024-09-300001604821ntra:AustinTexasSecondExpansionPremisesMember2024-09-300001604821ntra:AustinTexasFirstExpansionPremisesMember2024-09-300001604821ntra:PleasantonCaliforniaLeaseMember2023-09-300001604821ntra:VancouverBritishColumbiaCanadaMember2021-09-300001604821us-gaap:ConvertibleNotesPayableMember2024-01-012024-09-300001604821ntra:PerformanceBasedAwardsAndRestrictedStockUnitsMember2024-01-012024-09-300001604821ntra:EmployeeStockPurchasePlan2015Member2024-01-012024-09-300001604821ntra:EmployeeAndNonEmployeeOptionsMember2024-01-012024-09-300001604821us-gaap:ConvertibleNotesPayableMember2023-01-012023-09-300001604821ntra:PerformanceBasedAwardsAndRestrictedStockUnitsMember2023-01-012023-09-300001604821ntra:EmployeeStockPurchasePlan2015Member2023-01-012023-09-300001604821ntra:EmployeeAndNonEmployeeOptionsMember2023-01-012023-09-300001604821ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMemberntra:CyberattackDisruptionAtChangeHealthcareMember2024-09-300001604821ntra:CyberattackDisruptionAtChangeHealthcareMember2024-09-300001604821us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300001604821us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300001604821us-gaap:PerformanceSharesMember2024-07-012024-09-300001604821us-gaap:CostOfSalesMember2024-07-012024-09-300001604821ntra:LiabilityClassifiedAwardsMember2024-07-012024-09-300001604821us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300001604821us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300001604821us-gaap:CostOfSalesMember2024-01-012024-09-300001604821ntra:LiabilityClassifiedAwardsMember2024-01-012024-09-300001604821us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001604821us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001604821us-gaap:PerformanceSharesMember2023-07-012023-09-300001604821us-gaap:CostOfSalesMember2023-07-012023-09-300001604821ntra:LiabilityClassifiedAwardsMember2023-07-012023-09-300001604821us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001604821us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001604821us-gaap:PerformanceSharesMember2023-01-012023-09-300001604821us-gaap:CostOfSalesMember2023-01-012023-09-300001604821ntra:LiabilityClassifiedAwardsMember2023-01-012023-09-300001604821us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300001604821204-07-012024-09-300001604821us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001604821212023-07-012023-09-300001604821us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300001604821us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001604821212024-06-300001604821212023-06-300001604821212023-09-300001604821212022-12-310001604821ntra:MyomeIncMember2024-09-300001604821ntra:MyomeIncMember2023-12-310001604821us-gaap:CommonStockMember2024-01-012024-09-300001604821us-gaap:CommonStockMember2023-01-012023-09-300001604821ntra:InProcessResearchDevelopmentAcquisitionAgreementMember2021-09-100001604821us-gaap:PerformanceSharesMember2024-01-012024-09-

300001604821srt:ScenarioForecastMemberntra:SanCarlosCaliforniaSubleaseAmendmentMember2025-01-012025-12-310001604821ntra:CorporateHeadquartersLeaseAmendmentMember2025-01-012025-12-310001604821ntra:SouthSanFranciscoCaliforniaLeaseMember2024-01-012024-09-300001604821ntra:PleasantonCaliforniaLeaseMember2023-09-012023-09-300001604821ntra:VancouverBritishColumbiaCanadaMember2021-09-012021-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:LicenseAndRelatedDevelopmentServicesMember2023-03-012023-03-310001604821ntra:SecondSpaceSubleaseMember2024-01-012024-09-300001604821ntra:FirstSpaceSubleaseMember2024-01-012024-09-300001604821ntra:CorporateHeadquartersLeaseMember2024-01-012024-09-300001604821ntra:AustinTxLongTermLeaseMember2024-01-012024-09-300001604821us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-07-012024-09-300001604821us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001604821us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2024-01-012024-09-300001604821us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001604821us-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-12-310001604821us-gaap:SalesRevenueNetMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001604821ntra:CaredxSPatentCaseMember2020-03-012020-03-310001604821ntra:MyomeIncMember2024-02-290001604821us-gaap:ProductMember2024-07-012024-09-300001604821ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember2024-07-012024-09-300001604821ntra:AmountsNotRefundedToInsuranceCarriersMember2024-07-012024-09-300001604821ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember2024-01-012024-09-300001604821ntra:AmountsNotRefundedToInsuranceCarriersMember2024-01-012024-09-300001604821us-gaap:ProductMember2023-07-012023-09-300001604821ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember2023-07-012023-09-300001604821us-gaap:ProductMember2023-01-012023-09-300001604821ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember2023-01-012023-09-300001604821us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-07-012024-09-300001604821us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-09-300001604821us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-012023-09-300001604821us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:EquipmentAndServicesMember2024-07-012024-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:EquipmentAndServicesMember2024-01-012024-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:EquipmentAndServicesMember2023-07-012023-09-300001604821ntra:BgiGenomicsCoLtdMemberntra:EquipmentAndServicesMember2023-01-012023-09-300001604821us-gaap:ConvertibleNotesPayableMember2023-12-310001604821us-gaap:ConvertibleNotesPayableMember2020-04-012020-04-300001604821us-gaap:ConvertibleNotesPayableMember2020-04-302020-04-300001604821ntra:MayRedeemForCashAllOrAnyPortionOfConvertibleNotesAtCompanysOptionOnOrAfterMay2024Member2020-04-012020-04-300001604821us-gaap:ConvertibleNotesPayableMember2024-07-192024-07-190001604821us-gaap:ConvertibleNotesPayableMember2024-09-3000016048212023-01-012023-09-300001604821us-gaap:ConvertibleNotesPayableMember2024-07-012024-09-300001604821us-gaap:ConvertibleNotesPayableMember2024-01-012024-09-300001604821us-gaap:ConvertibleNotesPayableMember2023-07-012023-09-300001604821us-gaap:ConvertibleNotesPayableMember2023-01-012023-09-300001604821ntra:MyomeIncMember2024-02-012024-02-290001604821ntra:MyomeIncMember2024-01-012024-09-300001604821us-gaap:MunicipalBondsMember2024-09-300001604821ntra:CashCashEquivalentsAndRestrictedCashMember2024-09-300001604821us-gaap:USTreasurySecuritiesMember2023-12-310001604821us-gaap:MunicipalBondsMember2023-12-310001604821ntra:CashCashEquivalentsAndRestrictedCashMember2023-12-310001604821ntra:InProcessResearchDevelopmentAcquisitionAgreementMember2021-09-102021-09-100001604821us-gaap:ProductMember2024-01-012024-09-300001604821ntra:FoundationMedicineInc.Member2024-09-300001604821ntra:BgiGenomicsCoLtdMember2019-02-28001604821ntra:FoundationMedicineInc.Member2019-08-012019-08-310001604821ntra:BgiGenomicsCoLtdMember2019-02-012019-02-28001604821us-gaap:SubsequentEventMember2027-11-012027-11-120001604821ntra:RoyBaynesMember2024-09-300001604821ntra:MikeBrophyMember2024-09-300001604821ntra:DanielRabinowitzMember2024-09-300001604821ntra:RoyBaynesMember2024-07-012024-09-300001604821ntra:MikeBrophyMember2024-07-012024-09-300001604821ntra:DanielRabinowitzMember2024-07-012024-09-300001604821ntra:DanielRabinowitzMember2024-07-012024-11-010001604821ntra:DanielRabinowitzMember2024-01-012024-09-30ntra:itemutr:sqftntra:positionntra:lawsuitntra:segmentxbrli:sharesiso4217:USDxbrli:purentra:Diso4217:USDxbrli:sharesntra:patentntra:customerntra:securityntra:leaseTable of Contentsâ€‹UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549FORMÂ 10-Q(Mark One)âŒ§QUARTERLY REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the quarterly period ended September 30, 2024â€‹ORâ€‹â—»TRANSITION REPORT PURSUANT TO SECTIONÂ 13 OR 15(d)Â OF THE SECURITIES EXCHANGE ACT OF 1934â€‹For the transition period from Â to Â â€‹Commission file number: 001-37478NATERA,Â Inc.(Exact Name of Registrant as Specified in Its Charter)â€‹â€‹â€‹Delaware01-0894487(State or Other Jurisdiction of Incorporation or Organization)(I.R.S. Employer Identification No.)â€‹â€‹â€‹â€‹â€‹13011 McCallen PassBuilding A Suite 100Austin, TX78753(Address of Principal Executive Offices)(Zip Code)â€‹(650) 980-9190(Registrantâ€™s Telephone Number,Â Including Area Code)â€‹Securities registered pursuant to Section 12(b) of the Act:â€‹Title of each classTrading Symbol(s)Name of each exchange on which registeredâ€‹â€‹â€‹Common Stock, par value $0.0001 per shareNTRAThe Nasdaq Stock Market LLC (Nasdaq Global Select Market)Indicate by check mark whether the registrant (1)Â has filed all reports required to be filed by SectionÂ 13 or 15(d)Â of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)Â has been subject to such filing requirements for the past 90 days.Â Â Â Â YesÂ âŒ§Â Â Â Â Â NoÂ Â Â â—»â€‹Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to RuleÂ 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Â Â Â Â Â YesÂ Â âŒ§Â Â Â Â Â NoÂ Â Â â—»â€‹Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in RuleÂ 12b-2 of the Exchange Act.â€‹â€‹â€‹â€‹â€‹

available-for-sale securities, net of taxâ€‹â€‹ 593â€‹â€‹ 3,807â€‹â€‹ 2,320â€‹â€‹ 10,966â€‹â€‹Comprehensive lossâ€‹$ (30,999)â€‹$ (105,223)â€‹$ (134,335)â€‹$ (345,804)â€‹â€‹â€‹

estimates include the allowance for doubtful accounts, determining the incremental borrowing rate to calculate operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment including impairment estimates, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers, insurance payors, and patients. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.â€‹InvestmentsInvestments consist primarily of debt securities such as U.S. Treasuries, U.S. agency and municipal bonds. Management determines the appropriate classification of securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company generally classifies its entire investment portfolio as available-for-sale. The Company views its available-for-sale portfolio as available for use in current operations. Accordingly, the Company classifies all investments as short-term, irrespective of maturity date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss), which is a separate component of stockholdersâ€™ equity.The Company classifies its investments as Level 1 or 2 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. The Company holds Level 2 securities, which are initially valued at the transaction price and subsequently valued by a third-party service provider using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company performs certain procedures to corroborate the fair value of these holdings. Â â€‹12 Table of ContentsAvailable-for-sale debt securities. The amended guidance from ASU 2016-13, Financial Instruments â€“ Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, requires the measurement of expected credit lossesÂ for available-for-saleÂ debt securitiesÂ held at the reporting date over the remaining life based on historical experience, current conditions, and reasonable and supportable forecasts. The Company evaluated its investment portfolio under the available-for-sale debt securities impairment model guidance and determined the Companyâ€™s investment portfolio is composed of low-risk, investment grade securities and thus has not recorded an expected credit loss for its investment portfolio. Further, gross unrealized losses on available for sale securities were not material at September 30, 2024.â€‹Accounts ReceivableTrade accounts receivable and other receivables. The allowance for doubtful accounts for trade accounts receivable is based on the Companyâ€™s assessment of the collectability of accounts related to its clinics and laboratory partner customers. The Company regularly reviews the allowance by considering factors such as historical experience, the age of the accounts receivable balances, and current economic conditions that may affect a customerâ€™s ability to pay. See Note 6, Balance Sheet Components, for a roll-forward of the allowance for doubtful accounts related to trade accounts receivable for three months and nine months ended September 30, 2024 and 2023. The Company recognizes revenue under Accounting Standards Codification (â€œASCâ€) Topic 606, Revenue from Contracts with Customers (â€œASC 606â€) and applies a constraint to the estimated variable consideration such that it is not probable that a significant reversal will occur. When assessing the total consideration expected to be received from insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds. After applying the ASC 606 constraint, the Company assessed for credit losses and allowance for doubtful accounts and determined an incremental credit loss was not needed given the quality of the insurance payors from whom such receivables are expected to be collectible and the relatively short duration over which the majority of receivables are collected. Accordingly, the Company currently does not have an incremental credit loss reserve nor allowance for doubtful accounts against accounts receivable for insurance and patient payors due to the average selling price calculations, which already incorporate these risks as net receivables are recorded.Inventory â€‹Inventory is recorded at the lower of cost or net realizable value, determined on a first-in, first-out basis. Inventory consists entirely of supplies, which the Company consumes when providing its test reports, and therefore, the Company does not maintain any finished goods inventory. The Company enters into inventory purchases commitments so that it can meet future delivery schedules based on forecasted demand for its tests.â€‹The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. A write down of specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period is first recognized by using a number of factors including product expiration dates and scrapped inventory. Any write-down of inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on our consolidated statements of operations. The Company makes assumptions about future demand, market conditions and the release of new products that may supersede older products; however, if actual market conditions are less favorable than anticipated, additional inventory write-downs may be required.â€‹Other Assetsâ€‹In January 2024, the Company acquired from Invitae Corp. (â€œInvitaeâ€) certain assets relating to Invitaeâ€™s non-invasive prenatal screening and carrier screening business. The transaction price of $10.5 million consisted of $10.0 million in upfront payment costs and approximately $0.5 million of other transaction costs which were capitalized as intangible assets over an estimated useful life of ten years. An additional payment of up to $42.5 million may be made should the Company achieve certain customer volume retention targets and based on certain legal outcomes.13 Table of ContentsAccumulated Other Comprehensive Income (Loss)Comprehensive loss and its components encompass all changes in equity other than those with stockholders, and include net loss, unrealized gains and losses on available-for-sale marketable securities and foreign currency translation adjustments. â€‹â€‹â€‹

Company constrains the estimated variable consideration when it determines it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. The consideration expected from laboratory partners usually includes a fixed amount, but it can be variable depending on the volume of tests performed, and the Company determines the variable consideration using the expected value approach. For laboratory partners and patients, the Company allocates the total consideration to a single performance obligation, which is the delivery of the test results to the customers.When assessing the total consideration expected to be received from insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds.The Company enters into contracts with insurance carriers with primarily payment terms related to tests provided to patients who have health insurance coverage. Insurance carriers are considered third-party payers on behalf of the patients, and the patients are considered the customers who receive genetic test services. Tests may be billed to insurance carriers, patients, or a combination of insurance carriers and patients. Further, the Company sells tests to a number of domestic and international laboratory partners and identifies the laboratory partners as customers, provided that there is a test services agreement between the two parties.The Company generally bills an insurance carrier, a laboratory partner or a patient upon delivery of test results. The Company also bills patients directly for out-of-pocket costs involving co-pays and deductibles that they are responsible 17 Table of Contentsfor. The Company may or may not get reimbursed for the full amount billed. Further, the Company may not get reimbursed at all for tests performed if such tests are not covered under the insurance carrierâ€™s reimbursement policies or the Company is not a qualified provider to the insurance carrier, or if the tests were not previously authorized.Product revenue is recognized in an amount equal to the total consideration (as described above) expected to be received at a point in time when the test results are delivered. Approximately 90% of cash collections attributable to such product revenue occurs within nine months with the remaining collections generally taking an additional six months. During this time, management routinely reassesses its estimates of actual to expected cash collections, which are based on historical collection rates and adjusted for current information and trends. To the extent cash collections for tests delivered in prior periods are trending higher than expectations, the Company will increase revenue recognized when sufficient evidence is obtained to conclude the additional revenue will not result in a reversal of revenue in a future period. Given the historical uncertainties with respect to the timing and extent of cash collections for test services provided, sufficient evidence is obtained once cash collected exceeds the amount of revenue recognized during a given period. If cash collections for tests delivered in prior periods are trending below expectations, the Company will reduce revenue to the amount expected to be collected based on the latest information and expectations. Increases or decreases to the amount of cash expected to be collected for tests delivered in prior periods are recognized in product revenue with a corresponding impact to accounts receivable during the period such determination is made. During the three months ended September 30, 2024 and 2023, the Company increased revenue by a net of $34.5 million and $2.2 million, respectively, for collections related to tests delivered in prior periods that were fully collected (including an estimate of unapplied receipts). The increased revenue and decreased net loss resulted in a corresponding decrease in loss per share by $0.28 and $0.02 for the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024, the Company increased revenue for collected cash in excess of initial revenue recognized by a net of $108.1 million for collections related to tests delivered in prior periods that were fully collected (including an estimate of unapplied receipts). The increased revenue and decreased net loss resulted in a corresponding decrease in loss per share by $0.88 for the nine months ended September 30, 2024. During the nine months ended September 30, 2023, the Company reduced revenue by a net of $3.7 million for a reduction in expected collections related to tests delivered in prior periods. The decreased revenue and increased net loss resulted in a corresponding increase in loss per share by $0.03 for the nine months ended September 30, 2023. Â As of September 30, 2024, the Company had $26.9 million in cash receipts which had not yet been applied to specific accounts receivables. The Company reviewed the historical unapplied payment trends, and, within the unapplied cash receipts of $26.9 million, the Company estimated approximately $2.5 million was related to tests delivered in prior periods that were fully collected. Â Additionally, as overpayments were not material in prior years, the Company accounted for temporary unapplied balances as of September 30, 2024, as contra accounts receivable on the Balance Sheet. As of December 31, 2023, the unapplied accounts receivable balance was $1.3 million. Product revenue is constrained for refunds estimated to be paid to insurance carriers. Certain refunds are recognized in accrued liabilities until they are either paid to the respective insurance carrier or it is determined the refund will not ultimately be paid, at which time the related accrual is reduced with a corresponding increase to revenue. During the three months ended September 30, 2024 and 2023, the reserves for refunds to insurance carriers were reduced and product revenue increased by $0.7 million and $1.2 million, respectively, for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and corresponding decreased net loss resulted in a decreased loss per share by $0.01 for both the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024 and 2023, the reserves for refunds to insurance carriers were reduced and product revenue increased by $4.5 million and $7.7 million, respectively, for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and corresponding decreased net loss resulted in a decreased loss per share by $0.04 and $0.07 for the nine months ended September 30, 2024 and 2023, respectively.In addition, certain other refunds are recognized as a reduction to accounts receivable until they are either paid to the respective insurance carrier or it is determined the refund will not ultimately be paid, at which time the related reserve is reduced with a corresponding increase to revenue. During the three months ended September 30, 2024, the reserves for refunds to insurance carriers were reduced and product revenue increased by $2.9 million for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and corresponding decreased net loss resulted in a decreased loss per share by $0.02 for the three months ended September 30, 2024. During the nine months 18 Table of Contentsended September 30, 2024, the reserves for refunds to insurance carriers were reduced and product revenue increased by $7.1 million for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and decreased net loss resulted in a decreased loss per share by $0.06 for the nine months ended September 30, 2024. There was no such adjustment in the three and nine months ended September 30, 2023.Licensing and Other Revenuesâ€‹The Company recognizes licensing revenues from its cloud-based distribution service offering, Constellation, by granting licenses to its licensees to use certain of the Companyâ€™s proprietary intellectual properties and cloud-based software and in vitro diagnostic (â€œIVDâ€) kits. The Company also recognizes revenues from its strategic collaboration agreements, such as those with BGI Genomics Co., Ltd. (â€œBGI Genomicsâ€) and Foundation Medicine, Inc. (â€œFoundation Medicineâ€). The Company recognizes licensing and other revenues through agreements with pharmaceutical companies in support of potential clinical trials managed by the pharmaceutical companies.ConstellationThe laboratory partners with whom the Company enters into a licensing arrangement represent the licensees and are identified as customers. The licensees do not have the right to possess the Companyâ€™s software, but rather receive services through the cloud software. These arrangements often include: (i) the delivery of the services through the cloud software, (ii) the necessary support and training, and (iii) the IVD kits to be consumed as tests are processed. The Company does not consider the software as a service, the support or the training as being distinct in the context of such arrangements, and therefore, these items are combined as a single performance obligation. The software, support and training are delivered simultaneously to the licensees over the term of the arrangement.The Company bills the majority of licensees, who process the tests in their laboratories, a fixed price for each test processed. Licensing revenues are recognized as the performance obligations are satisfied (i.e., upon the delivery of each test) and reported in licensing and other revenues in the Companyâ€™s statements of operations and comprehensive loss.BGI Genomics In February 2019, the Company entered into a License Agreement (the â€œBGI Genomics Agreementâ€) with BGI Genomics to develop, manufacture, and commercialize next generation sequencing-based genetic testing assays for clinical and commercial use. The BGI Genomics Agreement has a term of ten years and expires in February 2029. Pursuant to the BGI Genomics Agreement, the Company licensed its intellectual property to and provided development services for BGI Genomics. Following completion of development services, the Company began providing assay interpretation services over the term of the agreement.According to the BGI Genomics Agreement, the Company is entitled to a total of $50.0 million, comprised of upfront technology license fees, prepaid royalties relating to future sales of licensed products and performance of assay interpretation services, and milestone payments. Due to uncertainties in achieving certain milestones, $6.0 million of the $50.0 million was constrained. A net of $44.0 million has been collected by the Company in cash, which includes $20.0 million in prepaid royalties.The Company concluded that the license is not a distinct performance obligation as it does not have a stand-alone value to BGI Genomics apart from the related development services; therefore, license and related development services for each of the non-invasive prenatal tests (â€œNIPTsâ€) and Oncology products, represents two separate performance obligations, to which $24.0 million of transaction consideration was allocated. This performance obligation was fully satisfied in March 2023 and no further related amounts will be recognized as revenue.As of December 31, 2023, the Company's performance obligation to provide ongoing NIPT assay interpretation services was removed. Therefore, the Company now has a single remaining performance obligation related to Oncology assay interpretation services, to which $20.0 million of transaction consideration was allocated and prepaid by BGI Genomics. During the nine months ended September 30, 2023, the Company recognized $1.1 million related to oncology assay interpretation services, of which $0.7 million was recognized against deferred royalties. During the nine months 19 Table of Contentsended September 30, 2024, the Company recognized $1.5 million related to oncology assay interpretation services, of which $1.4 million was recognized against deferred royalties. The Company currently has $17.4 million in deferred revenue related to this agreement as of September 30, 2024.As required by the BGI Genomics Agreement, in June 2019 the Company prepaid $6.0 million to BGI Genomics for future sequencing services and $4.0 million for future sequencing equipment. These advance payments are for equipment and services to be received in future periods, which was assessed as a standalone transaction that did not reduce revenue, aggregated to $10.0 million and was originally recorded in long-term assets on the Companyâ€™s Consolidated Balance Sheet and will be periodically assessed for impairment. During both the three and nine months ended September 30, 2024, $0.4 million in equipment and services was received. Â During the three and nine months ended September 30, 2023, $1.4 million and $4.0 million, respectively, in equipment and services was received. As of September 30, 2024, the remaining advanced payments were $1.0 million recorded in prepaid expenses and other current assets and $3.4 million recorded in other assets.Foundation Medicine, Inc.â€‹In August 2019, the Company entered into a License and Collaboration Agreement (the â€œFoundation Medicine Agreementâ€) with Foundation Medicine to develop and commercialize personalized circulating tumor DNA monitoring assays, for use by biopharmaceutical and clinical customers who order Foundation Medicineâ€™s FoundationOne CDx. The Company and Foundation Medicine will share the revenues generated from both biopharmaceutical and clinical customers in accordance with the terms of the Foundation Medicine Agreement. The Foundation Medicine Agreement had an initial term of five years that expired in August 2024. There was an option for automatic renewals thereafter for successive one-year terms, unless the Foundation Medicine Agreement is terminated in accordance with its terms. The Company and Foundation Medicine have elected not to renew the agreement beyond the initial term.Pursuant to the Foundation Medicine Agreement, the Company provided development services that are required to customize its proprietary Signatera test to work with Foundation Medicineâ€™s FoundationOne CDx in conjunction with granting the use of the Companyâ€™s intellectual property. Following completion of those development services, the Company was currently providing assay testing services over the term of the agreement. The intellectual property had been licensed to Foundation Medicine for the customized test. In addition, the Company was responsible for delivering clinical study plans in order to demonstrate efficacy of the customized test which commenced in the second quarter of 2021.The Company is entitled to a total of $32.0 million, comprised of upfront technology license fees, prepaid royalties relating to future sales of licensed products and performance of assay interpretation services, and milestone payments. $7.7 million is constrained due to uncertainties in achieving certain milestones. A net of $24.3 million has been collected by the Company in cash, which includes $5.0 million of prepaid royalties.The Company concluded that the license is not a distinct performance obligation as it does not have a stand-alone value to Foundation Medicine apart from the related development services. Therefore, license and related development services, for Oncology products, represent a single performance obligation, to which $19.3 million of transaction consideration was allocated. Of this amount, $0.2 million was recognized in the three months ended March 31, 2023. This performance obligation was fully satisfied in March 2023 and no further related amounts will be recognized as revenue.Royalties related to assay interpretation services represent separate performance obligations for Oncology products, to which $5.0 million of transaction consideration was allocated and prepaid by Foundation Medicine. During the three and nine months ended September 30, 2023, the Company recognized ($0.1) million and $0.3 million, respectively, related to oncology assay interpretation services. During the three and nine months ended September 30, 2024, the Company recognized $0.1 million and $0.3 million, respectively, related to oncology assay interpretation services. The Company currently has $3.0 million in deferred revenue related to this agreement as of September 30, 2024.20 Table of ContentsDisaggregation of Revenuesâ€‹The Company measures its performance results primarily based on revenues recognized from the three categories described below. The following table shows disaggregation of revenues by payer types: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three months ended â€‹Nine months ended â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024â€‹2023â€‹â€‹(in thousands)Insurance carriersâ€‹$ 405,208â€‹$ 239,780â€‹$ 1,130,364â€‹$ 676,680Laboratory and other partnersâ€‹â€‹ 27,622â€‹â€‹ 21,731â€‹â€‹ 70,152â€‹â€‹ 71,985Patientsâ€‹â€‹ 6,928â€‹â€‹ 6,795â€‹â€‹ 20,334â€‹â€‹ 22,801Total revenuesâ€‹$ 439,758â€‹$ 268,306â€‹$ 1,220,850â€‹$ 771,466â€‹The following table presents total revenues by geographic area based on the location of the Companyâ€™s payers: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three months ended â€‹Nine months ended Â â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024â€‹2023Â â€‹â€‹(in thousands)â€‹United StatesÂ $ 426,274â€‹$ 259,870â€‹$ 1,190,559â€‹$ 746,420â€‹Americas, excluding U.S.Â â€‹ 2,002â€‹â€‹ 1,288â€‹â€‹ 5,084â€‹â€‹ 3,652â€‹Europe, Middle East, India, AfricaÂ â€‹ 7,722â€‹â€‹ 5,255â€‹â€‹ 18,339â€‹â€‹ 16,071â€‹Asia Pacific and OtherÂ â€‹ 3,760â€‹â€‹ 1,893â€‹â€‹ 6,868â€‹â€‹ 5,323â€‹Total revenuesÂ $ 439,758â€‹$ 268,306â€‹$ 1,220,850â€‹$ 771,466â€‹â€‹The following table summarizes the Companyâ€™s beginning and ending balances of accounts receivable and deferred revenues: â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Balance atâ€‹â€‹SeptemberÂ 30,Â â€‹December 31,â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)Assets:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Accounts receivable, netâ€‹$ 306,876â€‹$ 278,289Liabilities:â€‹â€‹â€‹â€‹â€‹â€‹â€‹Deferred revenue, current portionâ€‹$ 17,886â€‹$ 16,612Deferred revenue, long-term portion (1)â€‹â€‹ 16,916â€‹â€‹ 19,128Total deferred revenuesâ€‹$ 34,802â€‹$ 35,740â€‹(1)â€” The deferred revenue, long-term portion is included within the â€œDeferred revenue, long-term portion and other liabilitiesâ€ line item on the condensed consolidated balance sheets.21 Table of ContentsThe following table summarizes the changes in the balance of deferred revenues during the nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Balance atâ€‹â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹â€‹2023â€‹(in thousands)Beginning balanceâ€‹$ 35,740â€‹$ 30,778Increase in deferred revenuesâ€‹â€‹ 23,968â€‹â€‹ 24,553Revenue recognized during the period that was included in deferred revenues at the beginning of the periodâ€‹â€‹ (12,102)â€‹â€‹ (9,610)Revenue recognized from performance obligations satisfied within the same periodâ€‹â€‹ (12,804)â€‹â€‹ (9,676)Ending balanceâ€‹$ 34,802â€‹$ 36,045â€‹During the nine months ended September 30, 2024, revenue recognized that was included in the deferred revenue balance at the beginning of the period totaled $12.1 million. This balance consisted of approximately a net $1.7 million related to BGI Genomics and Foundation Medicine and $10.4 million related to genetic testing services. The current portion of deferred revenue includes $14.4 million from genetic testing services, $0.5 million from BGI Genomics, and $3.0 million from the Foundation Medicine Agreement as of September 30, 2024. The non-current portion of deferred revenue consists of $16.9 million from the BGI Genomics Agreement as of September 30, 2024.4. Fair Value MeasurementsThe Company's financial assets and liabilities carried at fair value are comprised of investment assets that include money market and investments. The fair value accounting guidance requires that assets and liabilities be carried at fair value and classified in one of the following three categories:LevelÂ I: Quoted prices in active markets for identical assets and liabilities that the Company has the ability to access.LevelÂ II: Observable market-based inputs or unobservable inputs that are corroborated by market data, such as quoted prices, interest rates, and yield curves; andLevelÂ III: Inputs that are unobservable data points that are not corroborated by market data.This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value.22 Table of ContentsAssets and Liabilities That Are Measured at Fair Value on a Recurring Basisâ€‹The following table represents the fair value hierarchy for the Companyâ€™s financial assets and financial liabilities measured at fair value on a recurring basis:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

Short-Term and Long-Term Debt:As of September 30, 2024 and December 31, 2023, the estimated fair value of the total principal outstanding and accrued interest of the Credit Line was $80.4Â million, and were based upon observable Level 2 inputs, including the interest rate based on the 30-day Secured Overnight Financing Rate (â€œSOFRâ€) average, plusÂ 0.5%. The estimated fair value approximates the carrying value due to the short term duration and variable interest rate.As of September 30, 2024 and December 31, 2023, the estimated fair value of the Convertible Notes was $929.1 million and $491.8 million, respectively, based upon observable, Level 2 inputs, including pricing information from recent trades of the Convertible Notes. See Note 10, Debt, for additional details and carrying value.â€‹5. Financial InstrumentsThe Company elected to invest a portion of its cash assets in conservative, income earning, and liquid investments. Cash, cash equivalents, restricted cash and investments, which are classified as available-for-sale securities, consisted of the following:â€‹â€‹â€‹

2024, after trial, the jury returned a verdict of non-willful infringement by the Company and found damages of $57 million. The Company intends to appeal certain of the rulings. In addition, various parties, including the Company, have filed petitions challenging the validity of the asserted patents with the United States Patent and Trademark Office, all of which were instituted for review, and some of which were decided in favor of upholding the challenged claims. The petitions filed by the Company and certain others remain pending.In October 2020, the Company filed suit against Genosity Inc. (â€œGenosityâ€), in the United States District Court for the District of Delaware, alleging that various Genosity products infringe one of the Companyâ€™s patents and seeking unspecified monetary damages and injunctive relief. The case has been stayed pending the entry of a final judgment in the ArcherDX Case, in which the subject patent is also asserted. In February 2024, Genosity filed a voluntary Chapter 11 petiion in the U.S. Bankruptcy Court for the District of New Jersey.The Company is the subject of lawsuits filed against it by Invitae in the United States District Court of the District of Delaware alleging, in complaints filed in May and November of 2021, infringement of three patents and seeking monetary damages and injunctive relief. The parties have filed cross-motions for summary judgment, which motions are currently pending before the Court. In February 2024, subsequent to Invitaeâ€™s voluntary Chapter 11 petition described above, the Court granted Invitaeâ€™s request to continue the trial, which is now scheduled for September 2025.The Company filed suits against Inivata, Inc. and Inivata Ltd. (collectively â€œInivataâ€) in the United States District Court for the District of Delaware in January 2021 and December 2022, alleging that certain of Inivataâ€™s oncology products infringe certain of the Companyâ€™s patents and seeking unspecified monetary damages and injunctive relief. The two suits have been consolidated. In March 2024, the Court stayed the case in light of the Companyâ€™s case against NeoGenomics 29 Table of ContentsLaboratories, Inc. (â€œNeoGenomicsâ€), which acquired Inivata in 2021, discussed below. In September 2024, the Court denied Inivataâ€™s motion to dismiss the Companyâ€™s complaint with respect to one patent.In July 2023, the Company filed suit against NeoGenomics in the United States District Court for the Middle District of North Carolina (the â€œDistrict Courtâ€), alleging infringement of two Natera patents (the â€œâ€™035 Patentâ€ and the â€œâ€™454 Patentâ€) by NeoGenomicsâ€™ commercialization of the RaDaR test and seeking monetary damages and injunctive relief. In December 2023, the Court denied NeoGenomicsâ€™ motion to dismiss the complaint, and granted the Companyâ€™s motion for preliminary injunction. The injunction went into effect as of January 12, 2024 and was affirmed on appeal in July 2024 by the Federal Circuit Court of Appeals. NeoGenomics filed a petition with the USPTO to review the validity of the â€™454 Patent, which was denied in June 2024. NeoGenomics also filed a petition with the USPTO to review the validity of the â€˜035 Patent, which proceeding was terminated in October 2024. Pursuant to the terms of a partial settlement of the case, the District Court entered a permanent injunction against NeoGenomics, and it has withdrawn its RaDaR test from the market. The case remains pending with respect to an updated version of the RaDaR test and the â€˜454 Patent. Trial is currently scheduled for October 2025.Other Litigation Matters.CareDx filed suit against the Company in April 2019 in the United States District Court for the District of Delaware, alleging false advertising, and related claims based on statements describing studies that concern the Companyâ€™s technology and CareDxâ€™s technology, seeking unspecified damages and injunctive relief. The Company filed a counterclaim against CareDx in the United States District Court for the District of Delaware, alleging false advertising, unfair competition and deceptive trade practices and seeking unspecified damages and injunctive relief. In March 2022, after trial, the jury returned a verdict that the Company was liable to CareDx and found damages of $44.9 million. The jury also returned a verdict against CareDx, finding that CareDx had engaged in false advertising. In July 2023, the Court granted in part the Companyâ€™s motion for judgment as a matter of law requesting that the Court set aside the portions of the jury verdict adverse to the Company, ruling that CareDx is not entitled to any damages. The jury verdict of false advertising by CareDx remains in place. Both parties are appealing; the matter has been remanded to the district court for consideration of certain post-trial motions.In May 2021, Guardant. Inc. (â€œGuardantâ€) filed suit against the Company in the United States District Court of the Northern District of California alleging false advertising and related claims and seeking unspecified damages and injunctive relief. Also in May 2021, the Company filed suit against Guardant in the Western District of Texas, alleging false advertising and related claims. The Company has voluntarily dismissed its Texas suit against Guardant and has asserted the claims from the Texas action as counterclaims in the California action, seeking unspecified damages and injunctive relief. In August 2021, Guardant moved to dismiss the Companyâ€™s counterclaims, which motion was denied in all material respects. Both parties filed cross-motions for summary judgment, which were granted in part and denied in part. Trial began on November 5, 2024.In November 2021, a purported class action lawsuit was filed against the Company in the United States District Court for the Northern District of California, by a patient alleging various causes of action relating to the Companyâ€™s patient billing and seeks, among other relief, class certification, injunctive relief, restitution and/or disgorgement, attorneysâ€™ fees, and costs. In May 2023, the Court granted the Companyâ€™s motion to dismiss the lawsuit, and the case was dismissed without prejudice. In July 2023, the plaintiff filed analogous claims in the Superior Court of California, County of San Mateo, and subsequently filed an amended claim with an additional plaintiff. Based on the additional plaintiff, the case was transferred back to the United States District Court for the Northern District of California. The parties subsequently agreed that claims brought by the original plaintiff be remanded back to the Superior Court of California, County of San Mateo, and that the action be stayed pending the outcome of the action in the United States District Court for the Northern District of California.In February 2022, two purported class action lawsuits were filed against the Company in the United States District Court for the Northern District of California. Each suit was filed by an individual patient alleging various causes of action related to the marketing of Panorama and seeking, among other relief, class certification, monetary damages, attorneysâ€™ 30 Table of Contentsfees, and costs. These matters have been consolidated. The Company filed a motion to dismiss the consolidated lawsuit, which resulted in the plaintiffs filing an amended complaint in April 2023.In March 2022, a purported class action lawsuit was filed against the Company and certain of its management in the Supreme Court of the State of New York, County of New York, asserting claims under Sections 11, 12, and 15 of the Securities Act of 1933. The complaint alleged, among other things, that the Company failed to disclose certain information regarding its Panorama test. The complaint sought, among other relief, monetary damages, attorneysâ€™ fees, and costs. This matter was dismissed and the claims raised in this matter have been included in the lawsuit discussed below.A purported class action lawsuit was filed against the Company and certain of its management in the United States District Court for the Western District of Texas, asserting claims under Sections 10(b) and 20(a) of the Securities Act of 1934 and Rule 10b-5 thereunder. The complaint, filed in April 2022 and amended in October 2022 (to include, among others, the claims raised in the lawsuit discussed in the preceding paragraph), alleges, among other things, that the management defendants made materially false or misleading statements, and/or omitted material information that was required to be disclosed, about certain of the Companyâ€™s products and operations. The complaint seeks, among other relief, monetary damages, attorneysâ€™ fees, and costs. The Company filed a motion to dismiss this lawsuit, which was granted in part and denied in part.In each of October 2023 and January 2024, shareholder derivative complaints were filed in the United States District Court for the Western District of Texas and the United States District Court for the District of Delaware, respectively, against the Company as nominal defendant and certain of the Companyâ€™s management. Each complaint alleges, among other things, that the management defendants made materially false or misleading statements, and/or omitted material information that was required to be disclosed, about certain of the Companyâ€™s products and operations. Each complaint seeks, among other relief, monetary damages, attorneysâ€™ fees, and costs.In October 2024, a purported class action lawsuit was filed against the Company in the United States District Court for the Northern District of California, by patients alleging various causes of action relating to the Companyâ€™s preimplantation genetic test for aneuploidies (â€œPGT-Aâ€). They request, among other relief, class certification, injunctive relief, restitution and/or disgorgement, attorneysâ€™ fees, and costs. Director and Officer Indemnifications As permitted under Delaware law, and as set forth in the Companyâ€™s Amended and Restated Certificate of Incorporation and its Amended and Restated Bylaws, the Company indemnifies its directors, executive officers, other officers, employees and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential future payments the Company could be required to make under this indemnification is unlimited; however, the Company has insurance policies that may limit its exposure and may enable it to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, the Company believes any obligations under this indemnification would not be material, other than standard retention amounts for securities related claims. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case the Company may incur substantial liabilities as a result of these indemnification obligations. Â Third-Party Payer Reimbursement Audits From time to time, the Company receives recoupment requests from third-party payers for alleged overpayments. The Company disagrees with the contentions of pending requests and/or has recorded an estimated reserve for the alleged overpayments if probable and estimable.â€‹31 Table of ContentsContractual CommitmentsThe following table sets forth the Companyâ€™s material contractual commitments as of September 30, 2024:â€‹â€‹â€‹â€‹â€‹PartyCommitmentsâ€‹Expiry Dateâ€‹(in thousands)â€‹â€‹Laboratory instruments supplier$ 2,243â€‹December 2024Material suppliersâ€‹ 34,413â€‹December 2026Application service providersâ€‹ 3,898â€‹March 2026Cloud platform service providerâ€‹ 34,180â€‹December 2028Leases (1)â€‹ 658â€‹December 2029Other material suppliersâ€‹ 25,654â€‹VariousTotal$ 101,046â€‹â€‹(1) Represents executed leases which have not commenced. Please refer to Note 7,Â Leases, for additional information.â€‹9. Stock-Based Compensation Stock-Based Compensation ExpenseThe following tables present the stock-based compensation expense recorded for equity classified awards on selected statements of operations line items for the three and nine months ended September 30, 2024 and 2023.â€‹â€‹â€‹â€‹â€‹

100% of the principal amount of the Convertible Notes to be redeemed plus accrued and unpaid interest to, but excluding, the Redemption Date. The Company elected physical settlement with the Companyâ€™s shares of common stock as the settlement method to apply to all conversions of the Convertible Notes. All terms and conditions associated with physical settlement are noted within the terms of the original Indenture Agreement. The conversion rate for holders who convert their Convertible Notes in connection with the Companyâ€™s election to redeem the Convertible Notes was increased by 0.4284 additional shares pursuant to the Indenture Agreement.Upon adoption of ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Heading-Contracts in Entityâ€™s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in Entityâ€™s Own Equity, the Company allocated all of the debt discount to long-term debt. The debt discount is amortized to interest expense using the effective interest method, computed to be 2.72%, over the life of the Convertible Notes or approximately its seven-year term. The outstanding Convertible Notes balances as of September 30, 2024 and December 31, 2023 are summarized in the following table:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023â€‹(in thousands)Convertible Notesâ€‹â€‹â€‹â€‹â€‹â€‹Outstanding Principal$ 287,500â€‹$ 287,500Unamortized debt discount and issuance costâ€‹ (3,564)â€‹â€‹ (4,555)Net carrying amountâ€‹ 283,936â€‹â€‹ 282,945Accrued interest to be settled in equityâ€‹ 2,695â€‹â€‹ â€”Reclassifications to short-term debt financingâ€‹ (82)â€‹â€‹ â€”Long-term debt financing$ 286,549â€‹$ 282,945â€‹35 Table of ContentsThe following tables present total interest expense recognized related to the Convertible Notes during the three and nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three months ended â€‹â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)â€‹Cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Contractual interest expense$ 1,618â€‹$ 1,617â€‹Non-cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹â€‹Amortization of debt discount and debt issuance costâ€‹ 333â€‹â€‹ 324â€‹Total interest expense$ 1,951â€‹$ 1,941â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine months ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)â€‹Cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Contractual interest expense$ 4,852â€‹$ 4,851â€‹Non-cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Amortization of debt discount and debt issuance costâ€‹ 991â€‹â€‹ 966â€‹Total interest expense$ 5,843â€‹$ 5,817â€‹â€‹11. Income TaxesDuring the three months ended September 30, 2024 and 2023, the Company recorded total income tax expense (benefit) of approximately $730,000 and $202,000, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded total income tax expense (benefit) of approximately $2,050,000 and $80,000, respectively. The income tax expense is primarily attributable to state income tax and foreign income tax. Due to the Companyâ€™s history of cumulative operating losses, the Company concluded that, after considering all the available objective evidence, it is not more likely than not that all of the Companyâ€™s net deferred tax assets will be realized. Accordingly, all of the Companyâ€™s deferred tax assets, which includes net operating loss carryforwards and tax credits related primarily to research and development, continue to be subjected to a full valuation allowance as of September 30, 2024. The Company will continue to maintain a full valuation allowance until there is sufficient evidence to support recoverability of its deferred tax assets.Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. As of September 30, 2024 and December 31, 2023, there were no accrued interest and penalties related to uncertain tax positions.12. Net Loss per ShareThe Convertible Notes are convertible by the holders as of September 30, 2024. Upon conversion, the Company has the option to pay cash, issue shares of common stock, or any combination thereof for the aggregate amount due upon conversion. If converted, the fair value of the shares issued to settle the Convertible Notes would exceed the Convertible Note principle by $597.8 million based on the closing price of the Companyâ€™s common stock as of September 30, 2024. Since the Company is in a net loss position in the periods presented, the shares which would be issued upon conversion of the Convertible Notes are excluded from the net loss per share calculation, as it would have an antidilutive effect. As such, the 7.4 million shares underlying the conversion option of the Convertible Notes have been excluded from the calculation of diluted earnings per share. On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its Convertible Notes. On the Redemption Date, $287.4 million of Convertible Notes was converted in exchange for 7.5 million shares of the Companyâ€™s common stock. 36 Table of ContentsThe following table shows total outstanding potentially dilutive shares excluded from the computation of diluted loss per share as their effect would be anti-dilutive, as of September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Â Â Â Â Â Â 2024Â Â Â Â Â 2023â€‹Â (inÂ thousands)Options to purchase common stockâ€‹ 4,176Â 5,532Performance-based awards and restricted stock unitsâ€‹ 10,856â€‹ 9,440Employee stock purchase planâ€‹ 93â€‹ 188Convertible Notesâ€‹ 7,411â€‹ 7,411Totalâ€‹ 22,536Â 22,571â€‹â€‹13. Subsequent Eventsâ€‹On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its outstanding 2.25% Convertible Notes due 2027 and instructed Wilmington Trust, National Association, as trustee under the Convertible Notes Indenture (the â€œIndenture Agreementâ€) governing the Convertible Notes, to issue a redemption notice to registered holders of the Convertible Notes. The date fixed for the redemption of the Convertible Notes was October 11, 2024 (the â€œRedemption Dateâ€). On the Redemption Date, $287.4 million of Convertible Notes were converted for approximately 7.5 million shares of the Companyâ€™s common stock under the terms of the redemption notice. The remaining Convertible Notes not converted under the redemption notice were redeemed in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, the Company reclassified $0.1 million of Convertible Notes from long-term liabilities to short-term liabilities as of September 30, 2024.â€‹In November 2024, the Company entered into an agreement with a non-profit research institute and a clinical technology company whereby the Company obtained licensing rights and access to certain data. The Company is obligated to pay a total of $20.0 million, of which $7.0 million has been paid and the remaining $13.0 million will be paid between January 2025 and January 2031. Additionally, the Company may be obligated to pay up to $50.0 million in milestone payments if certain milestone thresholds and regulatory approvals are achieved.â€‹â€‹37 Table of Contentsâ€‹â€‹ITEMÂ 2.MANAGEMENTâ€™S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and related notes included in Part I, ItemÂ 1 of this report. Our actual results could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in â€œRisk Factorsâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on February 29, 2024.Overview We are a diagnostics company with proprietary molecular and bioinformatics technology that we are applying to change the management of disease worldwide. Our cell-free DNA, or cfDNA, technology combines our novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with our statistical algorithms, which incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier and more targeted interventions that help lead to longer, healthier lives.We currently provide a comprehensive suite of products in womenâ€™s health, as well as our oncology and organ health products, and our Constellation cloud-based platform. We generate a majority of our revenues from the sale of Panorama, our non-invasive prenatal test, or NIPT, as well as Horizon, our Carrier Screening, test. In addition to Panorama and Horizon, our product offerings in womenâ€™s health include Spectrum Preimplantation Genetics, our Anora miscarriage test, and Vistara single-gene NIPT, as well as our Empower hereditary cancer screening test, which we also plan to offer to oncologists through our oncology sales channel. We also offer our Signatera molecular residual disease test for oncology applications, which we commercialized as a test run in our CLIA (as defined below) laboratory and offer on a research use only basis to research laboratories and pharmaceutical companies; and our Prospera organ transplant assessment tests.We process tests in our laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (or CLIA) in Austin, Texas and San Carlos, California. A portion of our testing is performed by third-party laboratories. Our customers include independent laboratories, national and regional reference laboratories, medical centers and physician practices for our screening tests, research laboratories and pharmaceutical companies. We market and sell our tests through our direct sales force and, for our womenâ€™s health tests, through our laboratory distribution partners. We bill clinics, laboratory distribution partners, patients, pharmaceutical companies and insurance payers for the tests we perform. In cases where we bill laboratory distribution partners, our partners in turn bill clinics, patients and insurers. The majority of our revenue comes from insurers with whom we have in-network contracts. Such insurers reimburse us for our tests pursuant to our in-network contracts with them, based on positive coverage determinations, which means that the insurer has determined that the test in general is medically necessary for this category of patient.In addition to offering tests to be performed at our laboratories, either directly or through our laboratory distribution partners, we also establish licensing arrangements with laboratories under Constellation, our cloud-based distribution model, whereby our laboratory licensees run the molecular workflows themselves and then access our bioinformatics algorithms through our cloud-based software. This cloud-based distribution model results in lower revenues and gross profit per test than cases in which we process a test ourselves; however, because we do not incur the costs of processing the tests, our costs per test under this model are also lower. We began entering into these licensing arrangements starting in the fourth quarter of 2015.The principal focus of our commercial operations is to offer our tests through both our direct sales force and laboratory distribution partners, and our Constellation licensees under our cloud-based distribution model. The number of tests that we accession is a key indicator that we use to assess our business. A test is accessioned when we receive the test at our laboratory, the relevant information about the test is entered into our computer system, and the test sample is routed into the appropriate workflow. This number is a subset of the number of tests that we process, which includes tests distributed through our Constellation licensees. The number of tests that we process is a key metric as it tracks overall 38 Table of Contentsvolume growth, particularly as our laboratory partners may transition from sending samples to our laboratory to our cloud-based distribution model, as a result of which our tests accessioned would decrease but our tests processed would remain unchanged.During the nine months ended September 30, 2024, we processed approximately 2,271,800 tests, comprised of approximately 2,223,500 tests accessioned in our laboratory, compared to approximately 1,869,400 tests processed, comprised of approximately 1,816,500 tests accessioned in our laboratory, during the nine months ended September 30, 2023. This increase in volume primarily represents continued commercial growth of Signatera, Panorama and Horizon, both as tests performed in our laboratory as well as through our Constellation software platform. The percent of our revenues attributable to our U.S. direct sales force for the nine months ended September 30, 2024 was 94%, an increase compared to 91% for the nine months ended September 30, 2023. The percent of our revenues attributable to U.S. laboratory distribution partners for the nine months ended September 30, 2024 was 3%, a decrease compared to 6% from the same period in the prior year. Our ability to increase our revenues and gross profit will depend on our ability to further penetrate the U.S. market with our direct sales force. The percent of our revenues attributable to international laboratory distribution partners and other international sales for both the nine months ended September 30, 2024 and 2023 was 3%. For the nine months ended September 30, 2024, total revenues were $1,220.9 million compared to $771.5 million in the nine months ended September 30, 2023. Product revenues accounted for $1,212.2 million, 99% of total revenues for the nine months ended September 30, 2024 compared to $761.3 million representing 99% of total revenues for the nine months ended September 30, 2023. For the nine months ended September 30, 2024 and 2023, no customers exceeded 10% of the total revenues on an individual basis. Revenues from customers outside the United States were $30.3 million, representing approximately 3% of total revenues for the nine months ended September 30, 2024. For the nine months ended September 30, 2023, revenues from customers outside the United States were $25.0 million, representing approximately 3% total revenues. Most of our revenues have been denominated in U.S. dollars, though we generate some revenue in foreign currency, primarily denominated in Euros and Singapore Dollars.Our net loss for the nine months ended September 30, 2024 and 2023 was $136.7 million and $356.8 million, respectively. This included non-cash stock compensation expense of $202.5 million and $142.4Â million for the nine months ended September 30, 2024 and 2023, respectively. As of September 30, 2024, we had an accumulated deficit of $2.5Â billion. Components of the Results of OperationsRevenuesProduct RevenuesWe generate revenues from the sale of our tests, primarily from the sale of our Panorama and Horizon tests. Our two primary distribution channels are our direct sales force and our laboratory partners. In cases where we promote our tests through our direct sales force, we generally bill directly to a patient, clinic or insurance carrier, or a combination of the insurance carrier and patient, for the fees.Sales of our clinical tests are recorded as product revenues. Revenues recognized from tests processed through our Constellation model, and from our strategic partnership agreements are reported in licensing and other revenues.In cases where we sell our tests through our laboratory partners, the majority of our laboratory partners bill the patient, clinic or insurance carrier for the performance of our tests, and we are entitled to either a fixed price per test or a percentage of their collections. 39 Table of ContentsOur ability to increase our revenues will depend on our ability to further penetrate the domestic and international markets and, in particular, generate sales through our direct sales force, develop and commercialize additional tests, obtain reimbursement from additional third-party payers and increase our reimbursement rates for tests performed. For example, our financial performance depends on reimbursement for microdeletions testing. Many third-party payers do not currently reimburse for microdeletions screening in part because there has historically been limited published data on the performance of microdeletions screening tests, with our single nucleotide polymorphism-based Microdeletion and Aneuploidy RegisTry, or SMART study results only being published in early 2022.Entering into in-network contracts continues to be an important part of our business strategy, as we believe that in-network coverage of our tests by third-party payers is crucial to our growth and long-term success, as in-network pricing is more predictable than out-of-network pricing, enables us to develop stable, long-term relationships with third-party payers, and provides access to a larger population of covered lives. However, the negotiated fees under our contracts with third party payers are typically lower than the list price of our tests, and in some cases the third party payers that we contract with have negative coverage determinations for some of our offerings, in particular Panorama for microdeletions screening. Therefore, being in network with third party payers has in the past had, and may in the future have, an adverse impact on our revenues and gross margins. We intend to mitigate any impact by driving more business from our most profitable accounts.Licensing and Other RevenuesRevenues recognized from tests processed through our Constellation model and from our strategic partnership agreements are reported in licensing and other revenues. We also recognize licensing revenues through the licensing and the provisioning of services to support the use of our proprietary technology by licensees under our cloud-based distribution model.Our strategy to offer access to our algorithm to laboratory licensees via our Constellation cloud-based software platform may also cause our revenues to decrease because we do not process the tests and perform the molecular biology analysis in our own laboratory under this model, and therefore are not able to charge as high an amount and, as a result, realize lower revenues per test than when we perform the entire test ourselves.Cost of Product Revenues The components of our cost of product revenues are material and service costs, impairment charges associated with testing equipment, personnel costs, including stock-based compensation expense, equipment and infrastructure expenses associated with testing samples, electronic medical records, order and delivery systems, shipping charges to transport samples, costs incurred from third party test processing fees, and allocated overhead such as rent, information technology costs, equipment depreciation and utilities. Costs associated with Whole Exome Sequencing, are also included, as well as labor costs, relating to our Signatera CLIA and Signatera research use only offerings. Costs associated with performing tests are recorded when the test is accessioned. We expect cost of product revenues in absolute dollars to increase as the number of tests we perform increases.As we continue to achieve scale, we have increased our focus on more efficient use of labor, automation, and DNA sequencing. For example, we updated the molecular and bioinformatics process for Panorama to further reduce the sequencing reagents, test steps and associated labor costs required to obtain a test result, while increasing the accuracy of the test to allow it to run with lower fetal fraction input. These improvements also reduced the frequency of the need to require blood redraws from the patient.Cost of Licensing and Other RevenuesThe components of our cost of licensing and other revenues are material costs associated with test kits sold to Constellation clients, development and support services relating to our strategic partnership agreements and other costs.40 Table of ContentsWe consider our cost of licensing and other revenues for the Constellation software platform to be relatively low, and therefore we expect its associated gross margin to be higher. We expect our cost of licensing will increase in relation to volume growth.ExpensesResearch and Development Research and development expenses include costs incurred to develop our technology, collect clinical samples and conduct clinical studies to develop and support our products. These costs consist of personnel costs, including stock-based compensation expense; prototype materials; laboratory supplies; consulting costs; regulatory costs; electronic medical record set up costs; and costs associated with setting up and conducting clinical studies at domestic and international sites and allocated overhead, including rent, information technology, equipment depreciation and utilities. We expense all research and development costs in the periods in which they are incurred. We expect our research and development expenses to increase in absolute dollars as we continue to invest in research and development activities related to developing enhanced and new products. Selling, General and Administrative Selling, general and administrative expenses include executive, selling and marketing, legal, finance and accounting, human resources, billing and client services. These expenses consist of personnel costs, including stock-based compensation expense; direct marketing expenses; audit and legal expenses; consulting costs; training and medical education activities; payer outreach programs and allocated overhead, including rent, information technology, equipment depreciation, and utilities. Interest Expense Interest expense is attributable to borrowing under our Convertible Senior Notes (the

â€œConvertible Notesâ€) and credit line with UBS (the â€œCredit Lineâ€), including the amortization of debt discounts. Interest Income and Other (Expense) Income, Net Interest income and other (expense) income, net is comprised of interest earned on our cash, realized gains and losses on investments and assets, sublease rental income, and foreign currency remeasurement gains and losses.Critical Accounting PoliciesOur managementâ€™s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenue generated, and expenses incurred during the reporting periods. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We consider our critical accounting policies and estimates to be revenue recognition and stock-based compensation attributable to performance-based awards.There have been no material changes to our other critical accounting policies and estimates as compared to the disclosures in our Annual Report on Form 10-K for the year ended December 31, 2023.41 Table of ContentsRecent Accounting PronouncementsUnless otherwise discussed below, we believe the adoption of accounting standards updates recently issued that are not yet effective will not have a material impact on our financial position or results of operations upon adoption.Results of Operations Comparison of the three months ended September 30, 2024 and 2023â€‹â€‹â€‹

a $13.7 million decrease in prepaid expenses and other assets. Operating liabilities resulted in cash inflows of $2.2 million resulting from a $10.8 million increase in accounts payable and a $27.3 million increase in accrued compensation offset by a $12.5 million decrease in lease liabilities, a $22.5 million decrease in other accrued liabilities, and a $0.9 million decrease in deferred revenue.47 Table of ContentsCash used in operating activities during the nine months ended September 30, 2023 was $189.4 million. The net loss of $356.8 million includes $176.5 million in non-cash charges resulting from $17.2 million of depreciation and amortization, $2.7 million in-process research and development, $1.9 million in amortization of premiums and accretion of purchase discounts on investment securities, $142.4 million of stock-based compensation expense, $11.0 million of non-cash lease expense, $1.0 million for amortization of debt discount and issuance cost, and $0.3 million for foreign exchange adjustment. Operating assets had cash outflows of $10.1 million resulting from a $10.8 million increase in accounts receivable, a $6.7 million increase in inventory, offset by a $7.4 million decrease in prepaid expenses and other assets. Operating liabilities resulted in cash inflows of $1.0 million resulting from a $15.2 million increase in accrued compensation and a $5.3 million increase in deferred revenue, offset by a $9.0 million decrease in accounts payable, a $2.1 million decrease in other accrued liabilities and a $8.4 million decrease in lease liabilities.Cash Provided by Investing ActivitiesCash provided by investing activities for the nine months ended September 30, 2024 totaled $148.7 million, which was comprised of $24.8 million from proceeds from sale of investments and $307.4 million from proceeds of investments maturities, offset by $122.0 million in purchasing of new investments, $48.3 million in acquisitions of property and equipment, $2.7 million for investment in related party, and $10.5 million in asset acquisition.Cash provided by investing activities for the nine months ended September 30, 2023 totaled $144.4 million, which was comprised of $173.5 million from proceeds of investments maturities, offset by $29.1 million in acquisitions of property and equipment.Cash Provided by Financing ActivitiesCash provided by financing activities for the nine months ended September 30, 2024, totaled $19.2 million which was comprised of $10.3 million from proceeds from the exercise of stock options and $8.9 million from the issuance of common stock under the employee stock purchase plan.Cash provided by financing activities for the nine months ended September 30, 2023, totaled $247.6 million which was comprised of $235.4 million net proceeds from our equity offering completed in the third quarter of 2023, $3.5 million from proceeds from the exercise of stock options and $8.7 million from the issuance of common stock under the employee stock purchase plan. Contractual Obligations and Other Commitments We have entered into arrangements that contractually obligate us to make payments that will affect our liquidity and cash flows in future periods. Such arrangements include those related to our lease commitments, Credit Line, Convertible Notes, commercial supply agreements and other agreements.Credit Lineâ€‹The short-term debt obligations consist of the $80.4 million principal amount drawn from the Credit Line with UBS and applicable interest. The Credit Line was amended in July 2017 and bears interest at 30-day LIBOR plus 1.10%, and it is secured by a first priority lien and security interest in our money market and marketable securities held in our managed investment account with UBS. The interest rate was subsequently changed to the 30-day SOFR average, plus 1.21%. The SOFR rate is variable. UBS has the right to demand full or partial payment of the Credit Line obligations and terminate it, in its discretion and without cause, at any time. In October 2023, the interest rate was subsequently changed to the 30-day SOFR average, plus 0.5%. Please refer to Note 10,Â Debt, for further details.Convertible Notesâ€‹The long-term debt obligations consist of the $287.5 million principal amount from a private placement offering to qualified institutional buyers and applicable interest. The Convertible Notes are senior, unsecured obligations of the Company and bear interest at a rate of 2.25% per year, payable in cash semi-annually in arrears in May and November of 48 Table of Contentseach year, beginning in November 2020. The Convertible Notes mature in May 2027, unless earlier converted, repurchased or redeemed in accordance with their terms. Upon conversion, the Convertible Notes are convertible into cash, shares of our common stock or a combination of cash and shares of our common stock, at our election.On July 19, 2024, we elected to exercise our optional redemption right to redeem all $287.5 million aggregate principal amount of our outstanding Convertible Notes and instructed Wilmington Trust, National Association, as trustee under the Convertible Notes Indenture (the â€œIndenture Agreementâ€) governing the Convertible Notes, to issue a redemption notice to registered holders of the Convertible Notes. The date fixed for the redemption of the Convertible Notes was October 11, 2024 (the â€œRedemption Dateâ€). On the Redemption Date, $287.4 million of Convertible Notes were converted for approximately 7.5 million shares of our common stock under the terms of the redemption notice. The remaining Convertible Notes not converted under the redemption notice were redeemed in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, we reclassified $0.1 million of Convertible Notes from long-term liabilities to short-term liabilities as of September 30, 2024.Inventory purchase and other contractual obligationsâ€‹We enter into contracts in the normal course of business with various third parties for clinical trials, preclinical research studies, testing, manufacturing, and other services for operational purposes. Payments due upon cancellation generally consist only of payments for services provided or expenses incurred, including non-cancellable obligations of our service providers, up to the date of cancellation. These payments have not been included separately within these contractual and other obligations disclosures. Please refer to Note 8,Â Commitments and Contingencies in the Notes to Unaudited Interim Condensed Consolidated Financial Statements for further details.Operating leasesOur lease commitments consist of $0.7 million of payments, which will be paid over the terms of the leases. The leases have not commenced under Accounting Standards Codification, or ASC, Topic 842, Leases (ASC 842), as of September 30, 2024. As a result, these leases are not reflected within the consolidated balance sheets.Off-Balance Sheet Arrangements We do not have any off-balance sheet arrangements during the periods presented.ITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK Interest Rate Risk We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates. Our Credit Line had an interest rate of 30-day LIBOR plus 1.10%. The interest rate was subsequently changed to the 30-day SOFR average, plus 1.21%. The SOFR rate is variable. In October 2023, the interest rate for the Credit Line was subsequently changed to the 30-day SOFR average, plus 0.5%. An incremental change in the borrowing rate of 100 basis points would increase our annual interest expense by $0.8 million based on our $80.4 million gross debt outstanding on our Credit Line, including principal and accrued interest as of September 30, 2024. The interest rate for our Convertible Notes is fixed at 2.25% and not exposed market risk related to interest rates. Our investment portfolio is exposed to market risk from changes in interest rates. This risk is mitigated as we have maintained a relatively short average maturity for our investment portfolio. An incremental change in the investment yield of 100 basis points would increase our annual interest income by approximately $0.3 million annually in relation to amounts we would expect to earn, based on our short-term investments as of September 30, 2024.Foreign Currency Exchange Rate Fluctuations Our operations are currently conducted primarily in the United States. As we expand internationally, our results of operations and cash flows may become subject to fluctuations due to changes in foreign currency exchange rates. In 49 Table of Contentsperiods when the U.S. dollar declines in value as compared to the foreign currencies in which we incur expenses, our foreign currency-based expenses will increase when translated into U.S. dollars. In addition, future fluctuations in the value of the U.S. dollar may affect the price at which we sell our tests outside the United States. To date, our foreign currency risk has been minimal, and we have not historically hedged our foreign currency risk; however, we may consider doing so in the future.Inflation RiskAs of the date of filing of this Quarterly Report on Form 10-Q, we do not believe that inflation has had a material effect on our business, financial condition, or results of operations. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through increases in revenue as increases in core inflation rates may also negatively affect demand for our product offerings. Our inability or failure to do so could harm our business, financial condition, and results of operations.ITEM 4.CONTROLS AND PROCEDURESEvaluation of Disclosure Controls and Procedures Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2024. The term â€œdisclosure controls and procedures,â€ as defined in RuleÂ 13a-15(e)Â under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commissionâ€™s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to our management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on the evaluation of our disclosure controls and procedures as of September 30, 2024, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.Changes in Internal Control over Financial ReportingThere have been no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the period ended September 30, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.Inherent Limitations on Effectiveness of ControlsOur management, including our Chief Executive Officer and Chief Financial Officer, do not expect that our disclosure controls or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected. 50 Table of ContentsPART II â€“ OTHER INFORMATIONâ€‹ITEM 1.LEGAL PROCEEDINGSâ€‹From time to time, we are involved in legal proceedings. The results of such legal proceedings and claims cannot be predicted with certainty and regardless of the outcome, could have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors.For information regarding certain current legal proceedings, see â€œNote 8â€”Commitments and Contingenciesâ€”Legal Proceedingsâ€ in the Notes to Unaudited Interim Condensed Consolidated Financial Statements, which is incorporated herein by reference.ITEM 1A.RISK FACTORSInvesting in our common stock involves a high degree of risk. In addition to the information set forth in this Quarterly Report on Form 10-Q, including the section titled â€œManagementâ€™s Discussion and Analysis of Financial Condition and Results of Operationsâ€ and our consolidated financial statements and related notes, you should consider carefully the factors discussed in Part I, Item 1A, â€œRisk Factorsâ€ in our Annual Report on Form 10-K for the year ended December 31, 2023 filed with the Securities and Exchange Commission on February 29, 2024. The occurrence of any of the risks and uncertainties described in such Annual Report could materially and adversely affect our business, financial condition, results of operations and prospects. In that event, the price of our common stock could decline and you could lose part or all of your investment. Furthermore, such risks are not the only ones we face; additional risks and uncertainties not currently known or that we currently deem to be immaterial may also materially adversely affect our business, financial condition or results of operations.ITEM 2Â Â Â Â Â Â Â Â Â UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS(a)Â Â Â Â Â Â Â Â Â Recent Sales of Unregistered SecuritiesÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â None.(b)Â Â Â Â Â Â Â Â Â Â Use of Proceeds Not applicable.(c)Â Â Â Â Â Â Â Â Â Â Purchases of Equity Securities by the Issuer and Affiliated PurchasersÂ Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â None.ITEM 3Â Â Â Â Â Â Â Â Â DEFAULTS UPON SENIOR SECURITIESNone.ITEM 4Â Â Â Â Â Â Â Â Â MINE SAFETY DISCLOSURESNot applicable.ITEM 5Â Â Â Â Â Â Â Â Â OTHER INFORMATIONSecurities Trading Plans of Directors and Executive OfficersOnÂ June 14, 2024,Â Mike Brophy,Â our chief financial officer, adopted a trading arrangement for the sale of shares of our common stock (a â€œRule 10b5-1Â Trading Planâ€) that is intended to satisfy the affirmative defense conditions of 51 Table of ContentsSecurities Exchange Act Rule 10b5-1(c). Mr. Brophyâ€™s Rule 10b5-1 Trading Plan provides for the potential sale of up to 109,293 shares of our common stock pursuant to the terms of the plan between February 2, 2025 and February 1, 2026.OnÂ June 14, 2024,Â Daniel Rabinowitz,Â our chief legal officer, adopted a trading arrangement for the sale of shares of our common stock (a â€œRule 10b5-1Â Trading Planâ€) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Rabinowitzâ€™s Rule 10b5-1 Trading Plan provides for the sale of 26,131 shares of our common stock pursuant to the terms of the plan between December 15, 2024 and August 15, 2026.OnÂ August 12, 2024,Â Roy Baynes,Â a member of our Board of Directors, adopted a trading arrangement for the sale of shares of our common stock (a â€œRule 10b5-1Â Trading Planâ€) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Baynes Rule 10b5-1 Trading Plan provides for the exercise of 37,230 stock options and sale of underlying shares of our common stock pursuant to the terms of the plan between November 11, 2024 and December 31, 2025. â€‹52 Table of ContentsITEM 6Â Â Â Â Â Â Â Â EXHIBITSINDEX TO EXHIBITSâ€‹â€‹â€‹â€‹Incorporated by ReferenceExhibit No.DescriptionFormFile No.ExhibitFiling DateFiled Herewithâ€‹â€‹â€‹â

equivalent functions):(a)Â Â Â Â all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Â Â Â Â any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. 3â€‹Date: November 12, 2024â€‹By:/s/ Steve Chapmanâ€‹â€‹Name:Steve Chapmanâ€‹â€‹Title:Chief Executive Officer and Presidentâ€‹â€‹(Principal Executive Officer)â€‹ EX-31.2 3 ntra-20240930xex31d2.htm EX-31.2 Exhibit 31.2â€‹CERTIFICATION OF PRINCIPAL FINANCIAL AND ACCOUNTING OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002I, Michael Brophy, certify that: 1. I have reviewed this quarterly report on FormÂ 10-Q for the quarter ended September 30, 2024 of Natera, Inc.;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4. The registrantâ€™s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act RulesÂ 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a)Â Â Â Â designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;(b)Â Â Â Â designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;(c)Â Â Â Â evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and(d)Â Â Â Â disclosed in this report any change in the registrantâ€™s internal control over financial reporting that occurred during the registrantâ€™s most recent fiscal quarter (the registrantâ€™s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrantâ€™s internal control over financial reporting; and5. The registrantâ€™s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):(a)Â Â Â Â all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; and(b)Â Â Â Â any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting. â€‹3â€‹Date: November 12, 2024â€‹By:/ s / Michael Brophyâ€‹â€‹Name:Michael Brophyâ€‹â€‹Title:Chief Financial Officerâ€‹â€‹â€‹(Principal Financial and Accounting Officer)â€‹ EX-32.1 4 ntra-20240930xex32d1.htm EX-32.1 Exhibit 32.1â€‹CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002I, Steve Chapman, Chief Executive Officer and President of Natera, Inc. (the â€œCompanyâ€), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:(1) The quarterly report on Form 10-Q for the Company for the quarter ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹ovembâ€‹Date: November 12, 2024â€‹By:/ s / Steve Chapmanâ€‹â€‹Name:Steve Chapmanâ€‹â€‹Title:Chief Executive Officer and Presidentâ€‹â€‹â€‹(Principal Executive Officer)â€‹ EX-32.2 5 ntra-20240930xex32d2.htm EX-32.2 Exhibit 32.2â€‹CERTIFICATION PURSUANT TO18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002I, Michael Brophy, Chief Financial Officer of Natera, Inc. (the â€œCompanyâ€), certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:(1) The quarterly report on Form 10-Q for the Company for the quarter ended September 30, 2024 (the â€œReportâ€) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.â€‹3â€‹Date: November 12, 2024â€‹By:/ s / Michael Brophyâ€‹â€‹Name:Michael Brophyâ€‹â€‹Title:Chief Financial Officerâ€‹â€‹â€‹(Principal Financial and Accounting Officer)â€‹ EX-101.SCH 6 ntra-20240930.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940303 - Disclosure - Revenue Recognition - Accounts Receivable and Deferred Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Financial Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 99940602 - Disclosure - Balance Sheet Components - Property and Equipment, net (Details) link:presentationLink link:calculationLink link:definitionLink 99940604 - Disclosure - Balance Sheet Components - Other Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - Leases - Payments (Details) link:presentationLink link:calculationLink link:definitionLink 40703 - Disclosure - Leases - AltCalc (Details) link:presentationLink link:calculationLink link:definitionLink 99941003 - Disclosure - Debt - Convertible Notes Balances (Details) link:presentationLink link:calculationLink link:definitionLink 99941004 - Disclosure - Debt - Interest Expense Recognized Related To Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Description of Business link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Financial Instruments link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 995211301 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930203 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 99930603 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Debt (Tables) link:presentationLink link:calculationLink link:definitionLink 99931203 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 99940202 - Disclosure - Summary of Significant Accounting Policies - Other Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940203 - Disclosure - Summary of Significant Accounting Policies - AOCIL (Details) link:presentationLink link:calculationLink link:definitionLink 99940204 - Disclosure - Summary of Significant Accounting Policies - Related Party (Details) link:presentationLink link:calculationLink link:definitionLink 99940205 - Disclosure - Summary of Significant Accounting Policies - Risks and Uncertainties (Details) link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Revenue Recognition (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Revenue Recognition - Disaggregation (Details) link:presentationLink link:calculationLink link:definitionLink 99940304 - Disclosure - Revenue Recognition - Changes in Balance of Deferred Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 99940305 - Disclosure - Revenue Recognition - Deferred Revenues (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 99940605 - Disclosure - Balance Sheet Components - Reserve Balance and Activities for Refunds (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Stock-Based Compensation - Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 99940903 - Disclosure - Stock-Based Compensation - Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 99940904 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details) link:presentationLink link:calculationLink link:definitionLink 99940905 - Disclosure - Stock-Based Compensation - Performance-based Awards (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Debt (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Debt - Discount and Issuance Costs (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Net Loss per Share - Loss per Share (Details) link:presentationLink link:calculationLink link:definitionLink 99941202 - Disclosure - Net Loss per Share - Potentially Dilutive Shares (Details) link:presentationLink link:calculationLink link:definitionLink 99941301 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Balance Sheet Components - Allowance for Doubtful Accounts (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 ntra-20240930_cal.xml EX-101.CAL EX-101.DEF 8 ntra-20240930_def.xml EX-101.DEF EX-101.LAB 9 ntra-20240930_lab.xml EX-101.LAB Document and Entity Information Statement [Table] Statement [Line Items] Document Type Document Quarterly Report Document Transition Report Document Period End Date Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Condensed Consolidated Balance Sheets Assets [Abstract] Assets Assets, Current [Abstract] Current assets: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents Cash, cash equivalents and restricted cash, end of period Cash, cash equivalents and restricted cash, beginning of period Cash, cash equivalents and restricted cash Marketable securities Short-term investments Current accounts receivable Accounts receivable, net of allowance of $6,252 and $6,481 at September 30, 2024 and December 31, 2023, respectively Accounts receivable, net Inventory, Net Inventory Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets, net Assets, Current Total current assets Property, Plant and Equipment, Net Property and equipment, net Total Property and Equipment, net Operating Lease, Right-of-Use Asset Operating lease right-of-use assets Other noncurrent assets Other assets Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities: Accounts Payable, Current Accounts payable Employee-related Liabilities, Current Accrued compensation Other Accrued Liability, Current Other accrued liabilities Total other accrued liabilities Contract with Customer, Liability, Current Deferred revenue, current portion Short-term Debt Short-term debt financing Short-term Credit Line, outstanding balance Liabilities, Current Total current liabilities Net carrying amount Long-term debt financing Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, and other liabilities classified as noncurrent. Contract With Customer And Other Liabilities Noncurrent Deferred revenue, long-term portion and other liabilities Operating Lease, Liability, Noncurrent Operating lease liabilities, long-term portion Operating lease liabilities, long-term portion Liabilities Total liabilities Commitments and Contingencies. Commitments and contingencies (Note 8) Stockholders' equity: Common stock, value issued Common stock, $0.0001 par value: 750,000 shares authorized at both September 30, 2024 and December 31, 2023; 124,137 and 119,581 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Cumulative-effect adjustment upon adoption of ASU 2016-13 Accumulated deficit Accumulated deficit Accumulated Other Comprehensive Income (Loss), Net of Tax Ending balance Beginning balance Accumulated other comprehensive loss Stockholders' Equity Attributable to Parent Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Allowance for Doubtful Accounts Receivable, Current Allowances on accounts receivable Common Stock, Par or Stated Value Per Share Common stock, par value (in dollars per share) Common Stock, Shares Authorized Common stock, shares authorized Common Stock, Shares, Issued Balance (in shares) Balance (in shares) Common stock, shares issued Common Stock, Shares, Outstanding Common stock, shares outstanding Condensed Consolidated Statements of Operations and Comprehensive Loss Product and Service [Axis] Product and Service [Domain] Product Licensing and other services. Licensing and other Revenues [Abstract] Revenues Revenues Total revenues Cost of Revenue [Abstract] Cost and expenses Cost of product revenues Cost of revenues Research and Development Expense Research and development Selling, General and Administrative Expense Selling, general and administrative Other operating Expenses Total cost and expenses Decrease to loss from operations Loss from operations Interest Expense Interest expense Interest expense Interest Income (Expense), Nonoperating, Net Interest and other income, net Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Loss before income taxes Income tax expense (benefit) Income tax expense Income tax expense Net loss Net loss Net unrealized gains (losses) on available-for-sale securities, net of tax Unrealized gain on available-for-sale securities, net of tax Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Net Loss per Share Net loss per share (Note 12): Basic (in dollars per share) Net loss - diluted (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract] Weighted-average number of shares used in computing basic and diluted net loss per share: Weighted-average shares outstanding Basic (in shares) Weighted Average Number of Shares Outstanding, Diluted Diluted (in shares) Condensed Consolidated Statements of Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common stock Additional Paid-in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Options exercised (in shares) Issuance of common stock upon exercise of stock options (in shares) Stock Issued During Period, Value, Employee Stock Purchase Plan Issuance of common stock under the employee stock purchase plan Stock Issued During Period, Shares, Employee Stock Purchase Plans Issuance of common stock under the employee stock purchase plan (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Other Long-term Incentive Plans, Requisite Service Period Recognition Issuance of stock for bonuses Issuance of common stock for bonuses Number of shares of stock issued attributable to bonus. Stock Issued During Period Shares Bonus Issuance of stock for bonuses (in shares) Stock Issued During Period, Value, Acquisitions Issuance of common stock for IPR&D milestone Stock Issued During Period, Shares, Acquisitions Issuance of common stock for IPR&D milestone (in shares) Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Vesting of restricted stock units Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Vesting of restricted stock units (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Stock based compensation Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax Unrealized gain on available-for sale securities Stock Issued During Period, Value, New Issues Issuance of common stock for public offering, net Stock Issued During Period, Shares, New Issues Issuance of common stock for public offering, net (in shares) Condensed Consolidated Statements of Cash

Flows Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract] Operating activities: Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Depreciation, Depletion and Amortization Depreciation and amortization Amount of expensed in-process research and development during the period. Expensed In Process Research And Development Expensed in-process research and development Amount of premium amortization and discount accretion on investment securities. Premium Amortization And Discount Accretion On Investment Securities Amortization of premiums and accretion of purchase discounts on investment securities Share-based Compensation Stock-based compensation Operating Lease, Cost Non-cash lease expense Amount of noncash expense recovery. Noncash Expense Recovery Non-cash expense recovery Amortization of Debt Discount (Premium) Amortization of debt discount and issuance cost Foreign Currency Transaction Gain (Loss), before Tax Foreign exchange adjustment Amount of non-cash interest expense. Non Cash Interest Expense Non-cash interest expense Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories Inventory Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Employee Related Liabilities Accrued compensation Increase (Decrease) in Operating Lease Liability Operating lease liabilities Increase (Decrease) in Other Accrued Liabilities Other accrued liabilities Increase (Decrease) in Deferred Revenue Deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Cash provided by (used in) operating activities Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract] Investing activities: Payments to Acquire Available-for-sale Securities Purchases of investments Proceeds from Sale of Available-for-sale Securities Proceeds from sale of investments Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities Proceeds from maturity of investments Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment, net The cash outflow for investments in related party. Payments For Investments In Related Party Investment in related party Amount of cash outflow due to acquisition of assets. Payments To Acquire Assets Cash paid for acquisition of intangible assets Net Cash Provided by (Used in) Investing Activities, Continuing Operations Cash provided by investing activities Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract] Financing activities: Proceeds from Stock Options Exercised Proceeds from exercise of stock options Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options Proceeds from the issuance of common stock under the employee stock purchase plan Proceeds from Issuance Initial Public Offering Proceeds from public offering, net of issuance cost Proceeds from notes payable Bridge loan Net Cash Provided by (Used in) Financing Activities, Continuing Operations Cash provided by financing activities Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Net change in cash, cash equivalents and restricted cash Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Net Cash paid for interest Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash investing and financing activities: Represents purchases of property and equipment in accounts payable and accruals. Purchases Of Property And Equipment In Accounts Payable And Accruals Purchases of property and equipment in accounts payable and accruals Amount of warrants and receivables acquired. Acquisition Of Warrants And Receivables Acquisition of warrants and warrant receivable Noncash or Part Noncash Acquisition, Intangible Assets Acquired Amounts accrued for acquisition of intangible assets Stock Issued Issuance of common stock for IPR&D acquisition Amount of stock-based compensation included in capitalized software development costs. Stock Based Compensation Included In Capitalized Software Development Costs Stock-based compensation included in capitalized software development costs Debt conversion amount Conversion of Debt Convertible, if converted common shares aggregate value Description of Business Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Description of Business Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Revenue Recognition Revenue From Contract With Customer [Text Block] Revenue Recognition Fair Value Measurements Fair Value Disclosures [Text Block] Fair Value Measurements Financial Instruments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Financial Instruments Balance Sheet Components Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components Leases. Lessee, Operating Leases [Text Block] Leases Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Stock-Based Compensation Debt Long-term Debt [Text Block] Debt Income Taxes Income Tax Disclosure [Text Block] Income Taxes Earnings Per Share [Text Block] Net Loss per Share Subsequent Events Subsequent Events [Text Block] Subsequent Events Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Represents the policy for certain liquidity matters. Liquidity Matters Policy [Text Block] Liquidity Matters Consolidation, Policy [Policy Text Block] Principles of Consolidation Use of Estimates, Policy [Policy Text Block] Use of Estimates Investment, Policy [Policy Text Block] Investments Accounts Receivable [Policy Text Block] Accounts Receivable Inventory, Policy [Policy Text Block] Inventory Disclosure of accounting policy for other assets. Other Assets Policy Policy Text Block Other Assets Comprehensive Income, Policy [Policy Text Block] Accumulated Other Comprehensive Income (Loss) Revenue Recognition, Policy [Policy Text Block] Revenue Recognition Fair Value Measurement, Policy [Policy Text Block] Fair Value Disclosure of accounting policy for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates. Related Party Transactions Policy Text Block Related Party Concentration Risk, Credit Risk, Policy [Policy Text Block] Risk and Uncertainties New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Schedule of Accumulated Other Comprehensive Income (Loss) Tabular disclosure of disaggregation of revenue by customer. Disaggregation Of Revenue By Customer [Table Text Block] Schedule of disaggregation of revenues by payer types Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block] Schedule of total revenue by geographic area Contract With Customer Asset And Liability [Table Text Block] Schedule of beginning and ending balances of accounts receivable and deferred revenues Tabular disclosure of changes in the balances of deferred revenues. Schedule Of Changes In Balances Of Deferred Revenues [Table Text Block] Schedule of changes in the balance of deferred revenues Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Summary of financial assets and liabilities measured on recurring basis Available-for-sale Securities [Table Text Block] Schedule of available-for-sale securities Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block] Schedule of debt securities available-for-sale in unrealized loss position Investments Classified by Contractual Maturity Date [Table Text Block] Summarized portfolio of available-for-sale securities by contractual maturity Accounts Receivable, Allowance for Credit Loss [Table Text Block] Schedule of allowances for credit losses related to trade accounts receivable and other receivables Property, Plant and Equipment [Table Text Block] Schedule of property and equipment Schedule of Accrued Liabilities [Table Text Block] Schedule of other accrued liabilities Summary of reserve balance and activities for refunds to insurance carriers. Summary Of Reserve Balance And Activities For Refunds To Insurance Carriers [Table Text Block] Summary of reserve balance and activities for refunds to insurance carriers Tabular disclosure of balance sheet leases. Lease Balance Sheet Disclosure [Table Text Block] Schedule of lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of annual minimum lease payments Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block] Schedule of material contractual commitments Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Stock Based Compensation Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] Summary of stock-based compensation expenses Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Summary of stock option activity Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block] RSU and performance-based awards Convertible Debt [Table Text Block] Schedule of outstanding Convertible Notes Tabular disclosure of interest expense. Schedule Of Interest Expense Table [Text Block] Summary of interest expense Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Total outstanding potentially dilutive shares Number of Operating Segments Number of operating segments Restrictions on Cash and Cash Equivalents [Table] Sale of Stock [Axis] Sale of Stock [Domain] Equity offering Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents the 2015 Line of Credit entered into by the entity. Line Of Credit-UBS Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] Convertible Notes Subsequent Event Type [Axis] Subsequent Event Type [Domain] Subsequent event Restricted Cash and Cash Equivalents Items [Line Items] Policies Debt Instrument, Face Amount Outstanding principal balance Principal amount Debt Instrument, Interest Rate During Period Per annum interest rate (as a percent) Proceeds from Lines of Credit Borrowings under credit facility Debt Instrument, Collateral Amount Equipment pledged Collateral amount Line of Credit Facility, Remaining Borrowing Capacity Remaining borrowing capacity The percentage of principal amount converted. Debt Instrument, Convertible, Percentage of Principal Amount Percentage of principal amount converted Convertible Notes Payable Debt Instrument, Convertible, Number of Equity Instruments Convertible to shares of common stock Prepaid Royalty Asset Prepaid royalties Shares Issued, Price Per Share Stock issued (in dollars per share) Payments of Stock Issuance Costs Payment of offering expenses Proceeds from Issuance of Common Stock Proceeds from issuance of common stock Debt Instrument, Interest Rate, Stated Percentage Interest rate (as a percent) Asset Acquisition [Table] Asset Acquisition [Axis] Asset Acquisition [Domain] Represents in-process research and development acquisition agreement. In-process research and development acquisition Represents assets acquired from Invitae. Assets acquired from Invitae Asset Acquisition [Line Items] Asset Acquisition Consideration Transferred Asset acquisition, consideration Number of shares issued and issuable as consideration in asset acquisition. Asset Acquisition, Consideration Transferred, Shares Issued and Issuable Issuance of common stock Asset Acquisition, Consideration Transferred, Equity Interest Issued and Issuable Value of common stock issued Payments to Acquire Productive Assets Cash consideration Asset Acquisition, Consideration Transferred, Contingent Consideration Potential milestone payments Amount of liabilities incurred by the acquirer as part of consideration transferred in asset acquisition. Asset Acquisition, Consideration Transferred, Liabilities Incurred Net liabilities assumed Asset Acquisition, Consideration Transferred, Transaction Cost Acquisition related costs Value of shares reserved for issuance in registration statement. Shares Reserved Value Registration Statement Value of additional shares potentially issuable Number of additional shares potentially issuable as consideration upon achievement of milestones in asset acquisition. Asset Acquisition, Consideration Transferred, Additional Shares Issued and Issuable Upon Achievement Of Milestone Number of additional shares potentially issuable Finite-Lived Intangible Asset, Useful Life Estimated useful life (in years) Accumulated Other Comprehensive Income (Loss) [Table] Net unrealized gain on available-for-sale securities, net of tax and foreign currency translation adjustment Accumulated Other Comprehensive Income (Loss) [Line Items] Amount of adjustment to accumulated other comprehensive income or loss. Increase Decrease Accumulated Other Comprehensive Income Loss Increase (decrease) in other comprehensive loss Schedule of Related Party Transactions, by Related Party [Table] Title of Individual [Axis] Title of Individual [Domain] Executive chairman Investment, Name [Axis] Investment, Name [Domain] Represents MyOme, Inc. MyOme, Inc. Class of Stock [Axis] Class of Stock [Domain] Series B preferred stock Related Party Transaction [Line Items] Equity Securities without Readily Determinable Fair Value, Amount Investment in equity securities without readily determinable fair value Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount Equity securities without readily determinable fair value, impairment loss Equity Method Investment, Ownership Percentage Ownership percentage Term of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Class Of Warrant Or Right Term Warrants term Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Warrants convertible into number of stock shares Class of Warrant or Right, Exercise Price of Warrants or Rights Warrants exercise price (in dollars per share) Amount of impairment loss from warrants or rights outstanding. Class Of Warrant Or Right Impairment Loss Warrants impairment Approximate percentage of investment ownership if warrants are exercised. Investment Ownership Percentage If Warrants Exercised Ownership percentage if warrants are exercised Equity Method Investments Carrying amount of investments Amount of warrants and warrants receivable. Warrants And Warrants Receivable Carrying value of warrants and warrant receivable Concentration Risk [Table] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Sales Accounts receivable Concentration Risk Type [Axis] Concentration Risk Type [Domain] Customer Customer [Axis] Customer [Domain] Represents Medicare national health insurance program of the United States government. Medicare Concentration Risk [Line Items] Risks and Uncertainties [Abstract] Risk and Uncertainties Represents the number of customers. Number of Customers Number of customers exceeding 10% of benchmark Concentration Risk, Percentage Concentration risk (as a percent) Counterparty Name [Axis] Counterparty Name [Domain] Represents BGI Genomics Co., Ltd. BGI Genomics Represents Foundation Medicine, Inc. Foundation Medicine ("FMI") Represents license and related development services. License and related development services Represents tests delivered in prior periods that were fully collected. Tests delivered in prior periods that were fully collected Represents amounts not refunded to insurance carriers. Amounts not refunded to insurance carriers Sequencing service that are sold by an entity. Sequencing services Sequencing products that are sold by an entity. Sequencing products Sequencing products and services that are sold by an entity. Sequencing products and services Represents oncology assay interpretation services. Oncology assay interpretation services Represents oncology products. Oncology products Represents equipment and services. Equipment and Services Scenario [Axis] Scenario [Domain] Represents cyberattack disruption at change healthcare. Disruption at Change Healthcare Approximate percentage of revenue collected within 9 months. Approximate Percentage Of Revenue Collected Within Nine Months Approximate percentage of revenue collected within 9 months Represents the average collection period for billing. Billing Average Collection Period Billing collection period (in months) Represents the extended collection period for billing. Extended Billing Collection Period Extended billing collection period (in months) Contract with Customer, Liability, Revenue Recognized Revenue recognized Number of performance obligations that have not been recognized as revenue. Number Of Performance Obligations Number of performance obligations Period the agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Agreement Term Agreement term Represents the automatic renewals thereafter for successive number of years. Agreement Term, Automatic Renewals Period Automatic renewals, successive period thereafter Revenue, Remaining Performance Obligation Revenue, remaining performance obligation Amount of increase (decrease) in revenues during the reporting period. Increase Decrease Revenues Increased (decreased) revenues Amount of increase (decrease) in the portion of profit or loss for the period, net of income taxes. Increase Decrease Net Income Loss (Increased) decreased net loss Amount of increase (decrease) in net income (loss) per share during the reporting period. Increase Decrease Net Income Loss Per Share (Increased) decreased net loss per share Allowance for Doubtful Accounts Receivable Allowances on accounts receivable Represents the agreement transaction price. Agreement Transaction Price Transaction price Contract with Customer, Asset, Net, Current Contract asset Contract assets Represents equipment and services received. Equipment And Services Received Equipment and services received Contract with Customer, Liability Ending Balance Beginning balance Deferred revenue Total deferred revenues Disaggregation of Revenue [Table] Insurance carriers group of customers. Insurance carriers Laboratory and other partners group of customers. Laboratory partners Patients group of customers. Patients Geographical [Axis] Geographical [Domain] United States Continents of North and South America, excluding the United States of America (US). Americas, excluding U.S. Europe, Middle East, India, Africa Represents other geographic areas. Asia Pacific and Other Disaggregation of Revenue [Line Items] Contract with Customer, Liability [Abstract] Liabilities: Contract with Customer, Liability, Noncurrent Deferred revenue, long-term portion Deferred revenue, Long-term The additional amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Contract With Customer Liability Additions Increase in deferred revenues Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress Revenue recognized during the period that was included in deferred revenues at the beginning of the period Revenue recognized during the period that was included in deferred revenues at the beginning of the period Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized Revenue recognized from performance obligations satisfied within the same period Represents genetic testing services. Genetic testing services Represents BGI Genomics Co., Ltd. and Foundation Medicine, Inc. BGI Genomics and Foundation Medicine ("FMI") Fair Value, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Domain] Recurring Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Domain] Level 1 Level 2 Investment Type [Axis] Investments [Domain] Represents cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Cash, cash equivalents, and restricted cash U.S. Treasury securities and government sponsored entity securities U.S. Treasury securities Municipal securities Variable Rate [Axis] Variable Rate [Domain] SOFR Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Assets, Fair Value Disclosure Total financial assets Convertible Debt, Fair Value Disclosures Fair value of long-term debt Line of credit facility, fair value of amount outstanding Outstanding balance Debt Instrument, Basis Spread on Variable Rate Spread on interest rate (as a percent) Debt Securities, Available-for-sale [Table] Financial Instrument [Axis] Financial Instruments [Domain] Schedule of Available-for-sale Securities [Line Items] Available-for-sale Securities Debt Securities, Available-for-sale, Fair

Value to Amortized Cost [Abstract] Cash, cash equivalents, restricted cash and amortized cost of investment in securities measured at fair value. Cash Cash Equivalents Restricted Cash And Securities Amortized Cost Basis Amortized Cost Cash, cash equivalents, restricted cash and amount of unrealized gain in securities measured at fair value. Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Gain Gross Unrealized Gain Cash, cash equivalents, restricted cash and amount of unrealized loss in securities measured at fair value. Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Loss Gross Unrealized Loss Cash, cash equivalents, restricted cash and amount of investment in securities measured at fair value. Cash Cash Equivalents Restricted Cash And Securities Estimated Fair Value Debt Securities, Available-for-Sale, Current Short-term investments Represents the number of investments sold. Number Of Investments Sold Number of investments sold Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions Number of investments, unrealized loss position Debt Securities, Available-for-Sale, Allowance for Credit Loss Credit loss reserve Debt Securities, Available-for-sale, Unrealized Loss Position Fair value Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss Unrealized loss Available-for-sale Securities, Debt Maturities, Single Maturity Date, Amortized Cost Basis [Abstract] Amortized Cost Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis Less than or equal to one year Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis Greater than one year but less than five years Available-for-sale Securities, Debt Maturities, Single Maturity Date, Amortized Cost Basis Total Available-for-sale Securities, Debt Maturities, Single Maturity Date [Abstract] Fair Value Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value Less than or equal to one year Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value Greater than one year but less than five years Available-for-sale Securities, Debt Maturities, Single Maturity Date Total Financing Receivable, Allowance for Credit Loss Total Beginning balance Provision for Loan, Lease, and Other Losses (Reversal of) Provision for doubtful accounts Financing Receivable, Allowance for Credit Loss, Writeoff Write-offs Property, Plant and Equipment [Table] Statistical Measurement [Axis] Statistical Measurement [Domain] Minimum Maximum Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Domain] Machinery and equipment Computer equipment Software held for internal use Leasehold improvements Construction-in-process Property, Plant and Equipment [Line Items] Property and Equipment, net Property, Plant and Equipment, Gross Property and equipment, gross Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation and amortization Property, Plant and Equipment, Useful Life Useful Life Depreciation Depreciation expense Asset Impairment Charges Impairment charge Accrued Insurance Ending balance Beginning balance Reserves for refunds to insurance carriers Carrying value as of the balance sheet date of obligations incurred through that date and payable for outsourced testing. Accrued Charges For Outsourced Testing Accrued charges for third-party testing Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing and laboratory materials from suppliers. Accrued Testing And Laboratory Materials From Suppliers Testing and laboratory materials from suppliers Accrued Marketing Costs, Current Marketing and corporate affairs Accrued Professional Fees Legal, audit and consulting fees Carrying value as of the balance sheet date of obligations incurred through that date and payable for shipping charges. Accrued Shipping Charges Accrued shipping charges Sales and Excise Tax Payable Sales and income tax payable Carrying value as of the balance sheet date of obligations incurred through that date and payable for specimen service fees. Accrued Specimen Service Fees Accrued third-party service fees Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials and studies. Accrued Clinical Trials And Studies Clinical trials and studies Operating Lease, Liability, Current Operating lease liabilities, current portion included in other accrued liabilities Operating lease liabilities, current portion Carrying value as of the balance sheet date of obligations incurred and payable for fixed assets. Accrued Fixed Asset Purchases Property and equipment purchases Carrying value as of the balance sheet date of accrued interest. Accrued Interest Other accrued interest Amount of expenses not otherwise itemized or categorized in the footnotes to the financial statements that have been incurred but not yet paid, due within one year or the normal operating cycle, if longer. Other Accrued Sundry Expenses Current Other accrued expenses Additions to insurance carrier reserves. Insurance Carrier Reserves Additions Additional reserves The amount of insurance refunds to carriers. Insurance Refunds To Carriers Refunds to carriers The amount of insurance carrier reserves released to revenue. Insurance Carrier Reserves Released Reserves released to revenue Repayments of Short-Term Debt Repaid short term advances Lessee, Lease, Description [Table] Represents a long-term operating lease for office space located in Austin, TX. Austin TX, Long-term Lease Represents Austin, Texas "First Expansion Premises". First Expansion Premises Represents Austin, Texas "Second Expansion Premises". Second Expansion Premises Represents an operating lease for office space used as corporate headquarters. Corporate Headquarters Lease Represents the "First Space" operating sublease for office space used as corporate headquarters. "First Space" Sublease Represents the "Second Space" operating sublease for office space used as corporate headquarters. "Second Space" Sublease Represents an operating lease amendment for office space used as corporate headquarters. Corporate Headquarters Lease Amendment Represents Tukwila, Washington lease. Tukwila, WA Lease Represents San Carlos, CA sublease amendment. San Carlos, CA Sublease Amendment Represents South San Francisco, CA lease. South San Francisco, CA Lease Represents Pleasanton, CA lease. Pleasanton, CA Lease Represents Vancouver, British Columbia, Canada. Laboratory space in Canada Represents certain workspaces and storage spaces. Certain workspaces and storage spaces Forecast Lessee, Lease, Description [Line Items] Area of Real Estate Property Lease space (area) Represents the number of office spaces. Number Of Office Spaces Number of office space locations Represents the annual payment that the lessee is obligated to make in connection with a property under the terms of an agreement classified as an operating lease. Operating Leases Annual Rent Annual lease payment Lessee Operating Lease Term of Contract Term of lease Lessee Leasing Arrangements, Operating Leases, Renewal Term Renewal term of lease Operating Lease, Liability Operating lease liabilities Noncash operating activities related to right-of-use assets. Noncash Operating Activities Related To Right Of Use Assets Noncash operating activities related to right-of-use assets Operating Lease, Weighted Average Remaining Lease Term Weighted average remaining lease term Operating Lease, Weighted Average Discount Rate, Percent Weighted average discount rate (as a percent) Lease, Cost Lease expense Operating Lease, Payments Operating lease payments Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year 2024 (remaining 3 months) Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2025 Lessee, Operating Lease, Liability, Payments, Due Year Two 2026 Lessee, Operating Lease, Liability, Payments, Due Year Three 2027 Lessee, Operating Lease, Liability, Payments, Due Year Four 2028 Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Lessee Operating Lease Liability Payments Due Year Five And After Year Five 2029 and thereafter Lessee, Operating Lease, Liability, Payments, Due Total future minimum lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Litigation Case [Axis] Litigation Case [Domain] Represents CareDX Patent Case. CareDX Patent Case Represents ArcherDX Patent Case. ArcherDX Case Represents Ravgen Patent Case. Ravgen Patent Case Represents Genosity Inc. Patent Case. Genosity Inc. Patent Case Represents Inivata patent case. Inivata Patent Case Represents Inivitae Patent Case. Inivitae Patent Case Represents NeoGenomics patent case. NeoGenomics Patent Case Lawsuit where one of the parties is a group of people who are represented collectively by a member or members of that group. Class action Purchase Commitment, Excluding Long-term Commitment [Axis] Purchase Commitment, Excluding Long-term Commitment [Domain] Represents a contractual commitment to purchase laboratory instruments. Laboratory instruments supplier Represents a contractual commitment to purchase from suppliers. Material suppliers Represents a contractual commitment to application service providers. Application service providers Represents a contractual commitment to cloud platform service provider. Cloud platform service provider Represents contractual commitments for operating leases. Leases Represents a contractual commitment to purchase from suppliers. Other material suppliers Other Commitments [Abstract] Other commitments Loss contingency, patents allegedly infringed, number Number of invalid patents. Loss Contingency, Invalid Patents, Number Number of invalid patents Gain contingency, patents allegedly infringed, number Loss Contingency, Pending Claims, Number Number of lawsuits Litigation Settlement, Amount Awarded to Other Party Amount awarded to other party Litigation Settlement, Amount Awarded from Other Party Amount awarded from other party Purchase Obligation Total commitments Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-based payment arrangement awarded as liability classified awards. Liability classified awards Income Statement Location [Axis] Income Statement Location [Domain] Cost of revenues Research and development Selling, general and administrative Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items] Stock based compensation expense Allocated Share-based Compensation Expense Stock-based compensation expense Performance-based awards Represents employee and non-employee options. Options to purchase common stock Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Vested (in shares) Number of shares vested Vested (in shares) RSUs Granted (in shares) Shares granted Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Outstanding, end balance (in shares) Outstanding, beginning balance (in shares) Options outstanding (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Number of shares Outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Weighted-Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding, end balance (in dollars per share) Outstanding, beginning balance (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met and share-based payment arrangement awarded for meeting performance target. RSU and performance-based awards Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Shares Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Balance (in shares) Balance (in shares) RSUs forfeited/cancelled (in shares) Canceled/Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Balance (in dollars per share) Balance (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Canceled/Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding Aggregate value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested Aggregate value recognized Target percentage for vesting of award under share-based payment arrangement. Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Target Percentage Target (percentage) Share-Based Payment Arrangement, Amount Capitalized Expected compensation expense recognition over requisite service period Schedule of Long-term Debt Instruments [Table] Credit Facility [Axis] Credit Facility [Domain] 2017 Term Loan Interest rate at which a bank borrows funds from other banks in the London interbank market. LIBOR Represents five-day consecutive trading period. 5 consecutive trading day period Represents 20 trading days period. 20 trading days period Scenario, redeemable for cash, all or any portion of the Convertible Notes, at the Company's option, on or after May 2024. Redeemable for cash on or after May 2024 Debt Instrument [Line Items] Proceeds from Convertible Debt Proceeds from Convertible Note, net of issuance costs Line of Credit Facility, Maximum Borrowing Capacity Maximum borrowing capacity Line of Credit Facility, Increase (Decrease), Other, Net Credit facility drawn down Interest Expense, Debt Interest expense Total interest expense Debt Instrument, Term Debt instrument, term Debt Instrument, Interest Rate, Effective Percentage Effective interest rate (as a percent) Face amount per convertible note. Face Amount Per Convertible Note Principal amount per convertible note Debt Instrument, Convertible, Threshold Consecutive Trading Days Number of threshold consecutive trading days Debt Instrument, Convertible, Threshold Trading Days Threshold trading days Threshold number of specified business days for conversion after consecutive trading day period triggers conversion feature. Debt Instrument Convertible Threshold Business Days Threshold business days Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger Percentage of conversion price Debt Instrument, Convertible, If-converted Value in Excess of Principal Convertible, If-converted value in excess of principal Debt Instrument, Convertible, Conversion Price Conversion price (in dollars per share) Debt Instrument, Convertible, Conversion Ratio Initial conversion rate Increase of ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. Debt Instrument Convertible Conversion Ratio Increase Conversion rate increase Long-term Debt. Net carrying amount Carrying value Repayments of Debt Debt, repayment amount Outstanding principle Amount of unamortized debt discount and debt issuance cost. Debt Instrument Unamortized Debt Discount And Debt Issuance Cost Unamortized debt discount and issuance cost Amount of debt instrument accrued interest to be settled in equity. Debt Instrument Accrued Interest To Be Settled In Equity Accrued interest to be settled in equity Amount of long-term debt reclassifications to short-term debt financing. Long Term Debt Reclassifications To Short Term Debt Financing Reclassifications to short-term debt financing Long-Term Debt, Excluding Current Maturities Long-term debt financing Represents cash interest expense. Cash interest expense Amount of contractual interest expense for debt. Contractual Interest Expense Debt Contractual interest expense Represents non-cash interest expense. Non-cash interest expense Amortization of Debt Issuance Costs and Discounts Amortization of debt discount and debt issuance cost Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued Interest and penalties accrued Represents earnings or loss per share. Earnings or Loss per Share [Table] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Earnings or Loss per Share [Line Items] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Represents performance-based awards and restricted stock units. Performance-based awards and restricted stock units Represents 2015 Employee Stock Purchase Plan. Employee stock purchase plan Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive shares not included in diluted per share calculation Subsequent Event [Table] Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Subsequent Event [Line Items] Convertible Notes Payable, Current Short-term convertible notes Aggregate purchase agreement amount. Aggregate Purchase Agreement Amount Upfront purchase agreement amount Amount of upfront fees paid for agreements. Upfront Fees Paid For Agreements Upfront fee payment Long-Term Purchase Commitment, Amount Purchase agreement amount Amount of potential milestones payable to other party. Potential Milestone Payments To Other Party Potential additional milestone payments Represents information pertaining to Mike Brophy. Mike Brophy [Member] Mike Brophy Represents information pertaining to Daniel Rabinowitz. Daniel Rabinowitz [Member] Daniel Rabinowitz Represents information pertaining to Roy Baynes. Roy Baynes [Member] Roy Baynes EX-101.PRE 10 ntra-20240930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Document and Entity Information - shares 9 Months Ended Sep. 30, 2024 Nov. 01, 2024 Document and Entity Information Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Transition Report false Â Document Period End Date Sep. 30, 2024 Â Entity File Number 001-37478 Â Entity Registrant Name Natera, Inc. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 01-0894487 Â Entity Address, Address Line One 13011 McCallen Pass Â Entity Address, Address Line Two Building A Suite 100 Â Entity Address, City or Town Austin Â Entity Address, State or Province TX Â Entity Address, Postal Zip Code 78753 Â City Area Code 650 Â Local Phone Number 980-9190 Â Title of 12(b) Security Common Stock, par value $0.0001 per share Â Trading Symbol NTRA Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 132,020,816 Entity Central Index Key 0001604821 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â Amendment Flag false Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value

Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 2 such as Street or Suite number + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine2 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash, cash equivalents and restricted cash $ 892,844 $ 642,095 Short-term investments 29,490 236,882 Accounts receivable, net of allowance of $6,252 and $6,481 at September 30, 2024 and December 31, 2023, respectively 306,876 278,289 Inventory 48,724 40,759 Prepaid expenses and other current assets, net 44,631 60,524 Total current assets 1,322,565 1,258,549 Property and equipment, net 142,170 111,210 Operating lease right-of-use assets 87,856 56,537 Other assets 38,356 15,403 Total assets 1,590,947 1,441,699 Current liabilities: Â Â Accounts payable 27,834 14,998 Accrued compensation 49,051 45,857 Other accrued liabilities 126,176 149,405 Deferred revenue, current portion 17,886 16,612 Short-term debt financing 80,469 80,402 Total current liabilities 301,416 307,274 Long-term debt financing 286,549 282,945 Deferred revenue, long-term portion and other liabilities 25,504 19,128 Operating lease liabilities, long-term portion 98,953 67,025 Total liabilities 712,422 676,372 Commitments and contingencies (Note 8) Stockholders' equity: Â Â Common stock, $0.0001 par value: 750,000 shares authorized at both September 30, 2024 and December 31, 2023; 124,137 and 119,581 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively 12 11 Additional paid-in capital 3,393,369 3,145,837 Accumulated deficit (2,514,091) (2,377,436) Accumulated other comprehensive loss (765) (3,085) Total stockholders' equity 878,525 765,327 Total liabilities and stockholders' equity $ 1,590,947 $ 1,441,699 X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, and other liabilities classified as noncurrent. + ReferencesNo definition available. + Details Name: ntra_ContractWithCustomerAndOtherLiabilitiesNoncurrent Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19:

http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19-26) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic

944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermNotesAndLoans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) shares in Thousands, $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Condensed Consolidated Balance Sheets Â Â Allowances on accounts receivable $ 6,252 $ 6,481 Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001 Common stock, shares authorized 750,000 750,000 Common stock, shares issued 124,137 119,581 Common stock, shares outstanding 124,137 119,581 X - DefinitionAmount of allowance for credit loss on accounts receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45

-Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Revenues Â Â Â Â Total revenues $ 439,758,000 $ 268,306,000 $ 1,220,850,000 $ 771,466,000 Cost and expenses Â Â Â Â Research and development 96,931,000 77,235,000 274,677,000 237,714,000 Selling, general and administrative 214,154,000 154,742,000 606,397,000 456,877,000 Total cost and expenses 479,096,000 379,288,000 1,378,404,000 1,133,175,000 Loss from operations (39,338,000) (110,982,000) (157,554,000) (361,709,000) Interest expense (3,142,000) (3,252,000) (9,393,000) (9,490,000) Interest and other income, net 11,618,000 5,406,000 32,342,000 14,509,000 Loss before income taxes (30,862,000) (108,828,000) (134,605,000) (356,690,000) Income tax expense (730,000) (202,000) (2,050,000) (80,000) Net loss (31,592,000) (109,030,000) (136,655,000) (356,770,000) Unrealized gain on available-for-sale securities, net of tax 593,000 3,807,000 2,320,000 10,966,000 Comprehensive loss $ (30,999,000) $ (105,223,000) $ (134,335,000) $ (345,804,000) Net loss per share (Note 12): Â Â Â Â Basic (in dollars per share) $ (0.26) $ (0.95) $ (1.12) $ (3.14) Diluted (in dollars per share) $ (0.26) $ (0.95) $ (1.12) $ (3.14) Weighted-average number of shares used in computing basic and diluted net loss per share: Â Â Â Â Basic (in shares) 123,775 115,171 122,486 113,559 Diluted (in shares) 123,775 115,171 122,486 113,559 Product Â Â Â Â Revenues Â Â Â Â Total revenues $ 436,127,000 $ 265,218,000 $ 1,212,163,000 $ 761,271,000 Cost and expenses Â Â Â Â Cost of revenues 167,657,000 146,962,000 496,340,000 437,524,000 Licensing and other Â Â Â Â Revenues Â Â Â Â Total revenues 3,631,000 3,088,000 8,687,000 10,195,000 Cost and expenses Â Â Â Â Cost of revenues $ 354,000 $ 349,000 $ 990,000 $ 1,060,000 X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a),(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 25 -Paragraph 1 -SubTopic 20 -Topic 940 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -

SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe net amount of nonoperating interest income (expense). + ReferencesNo definition available. + Details Name: us-gaap_InterestIncomeExpenseNonoperatingNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482517/912-730-25-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481283/985-20-50-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50

-Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenuesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_LicensingAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands Common stock Additional Paid-in Capital Accumulated Other Comprehensive Loss Accumulated Deficit Total Balance at Dec. 31, 2022 $ 11 $ 2,664,730 $ (16,362) $ (1,942,635) $ 705,744 Balance (in shares) at Dec. 31, 2022 111,255 Â Â Â Â Issuance of common stock upon exercise of stock options Â 3,501 Â Â 3,501 Issuance of common stock upon exercise of stock options (in shares) 265 Â Â Â Â Issuance of common stock under the employee stock purchase plan Â 8,674 Â Â 8,674 Issuance of common stock under the employee stock purchase plan (in shares) 219 Â Â Â Â Issuance of stock for bonuses Â 19,771 Â Â 19,771 Issuance of stock for bonuses (in shares) 349 Â Â Â Â Issuance of common stock for IPR&D milestone Â 14,435 Â Â 14,435 Issuance of common stock for IPR&D milestone (in shares) 336 Â Â Â Â Vesting of restricted stock units (in shares) 2,016 Â Â Â Â Stock based compensation Â 142,896 Â Â 142,896 Unrealized gain on available-for sale securities Â Â 10,966 Â 10,966 Issuance of common stock for public offering, net Â 235,441 Â Â 235,441 Issuance of common stock for public offering, net (in shares) 4,550 Â Â Â Â Net loss Â Â Â (356,770) (356,770) Balance at Sep. 30, 2023 $ 11 3,089,448 (5,396) (2,299,405) 784,658 Balance (in shares) at Sep. 30, 2023 118,990 Â Â Â Â Balance at Jun. 30, 2023 $ 11 2,795,714 (9,203) (2,190,375) 596,147 Balance (in shares) at Jun. 30, 2023 114,051 Â Â Â Â Issuance of common stock upon exercise of stock options Â 562 Â Â 562 Issuance of common stock upon exercise of stock options (in shares) 48 Â Â Â Â Vesting of restricted stock units (in shares) 341 Â Â Â Â Stock based compensation Â 57,731 Â Â 57,731 Unrealized gain on available-for sale securities Â Â 3,807 Â 3,807 Issuance of common stock for public offering, net Â 235,441 Â Â 235,441 Issuance of common stock for public offering, net (in shares) 4,550 Â Â Â Â Net loss Â Â Â (109,030) (109,030) Balance at Sep. 30, 2023 $ 11 3,089,448 (5,396) (2,299,405) 784,658 Balance (in shares) at Sep. 30, 2023 118,990 Â Â Â Â Balance at Dec. 31, 2023 $ 11 3,145,837 (3,085) (2,377,436) $ 765,327 Balance (in shares) at Dec. 31, 2023 119,581 Â Â Â 119,581 Issuance of common stock upon exercise of stock options Â 10,368 Â Â $ 10,368 Issuance of common stock upon exercise of stock options (in shares) 1,325 Â Â Â Â Issuance of common stock under the employee stock purchase plan Â 8,862 Â Â 8,862 Issuance of common stock under the employee stock purchase plan (in shares) 263 Â Â Â Â Issuance of stock for bonuses Â 24,071 Â Â 24,071 Issuance of stock for bonuses (in shares) 270 Â Â Â Â Vesting of restricted stock units $ 1 Â Â Â 1 Vesting of restricted stock units (in shares) 2,698 Â Â Â Â Stock based compensation Â 204,231 Â Â 204,231 Unrealized gain on available-for sale securities Â Â 2,320 Â 2,320 Net loss Â Â Â (136,655) (136,655) Balance at Sep. 30, 2024 $ 12 3,393,369 (765) (2,514,091) $ 878,525 Balance (in shares) at Sep. 30, 2024 124,137 Â Â Â 124,137 Balance at Jun. 30, 2024 $ 12 3,320,365 (1,358) (2,482,499) $ 836,520 Balance (in shares) at Jun. 30, 2024 123,365 Â Â Â Â Issuance of common stock upon exercise of stock options Â 1,720 Â Â 1,720 Issuance of common stock upon exercise of stock options (in shares) 247 Â Â Â Â Vesting of restricted stock units (in shares) 525 Â Â Â Â Stock based compensation Â 71,284 Â Â 71,284 Unrealized gain on available-for sale securities Â Â 593 Â 593 Net loss Â Â Â (31,592) (31,592) Balance at Sep. 30, 2024 $ 12 $ 3,393,369 $ (765) $ (2,514,091) $ 878,525 Balance (in shares) at Sep. 30, 2024 124,137 Â Â Â 124,137 X - DefinitionNumber of shares of stock issued attributable to bonus. + ReferencesNo definition available. + Details Name: ntra_StockIssuedDuringPeriodSharesBonus Namespace Prefix: ntra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement, classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares of stock issued during the period pursuant to acquisitions. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period as a result of an employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of new stock issued during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(i)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of stock issued pursuant to acquisitions during the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueAcquisitions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAggregate change in value for stock issued during the period as a result of employee stock purchase plan. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueNewIssues Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue of stock issued as a result of the exercise of stock options. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Operating activities: Â Â Net loss $ (136,655) $ (356,770) Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Â Â Depreciation and amortization 23,178 17,186 Expensed in-process research and development Â 2,679 Amortization of premiums and accretion of purchase discounts on investment securities (633) 1,929 Stock-based compensation 202,502 142,376 Non-cash lease expense 11,169 11,011 Non-cash expense recovery (80) Â Amortization of debt discount and issuance cost 991 966 Foreign exchange adjustment 356 265 Non-cash interest expense 2,680 85 Changes in operating assets and liabilities: Â Â Accounts receivable (28,587) (10,762) Inventory 7,965) (6,669) Prepaid expenses and other assets 13,663 7,356 Accounts payable 10,841 (8,951) Accrued compensation 27,265 15,177 Operating lease liabilities (12,484) (8,424) Other accrued liabilities (22,526) (2,072) Deferred revenue (938) 5,268 Cash provided by (used in) operating activities 82,777 (189,350) Investing activities: Â Â Purchases of investments (122,010) Â Proceeds from sale of investments 24,822 Â Proceeds from maturity of investments 307,400 173,500 Purchases of property and equipment, net (48,305) (29,147) Investment in related party (2,670) Â Cash paid for acquisition of intangible assets (10,495) Â Cash provided by investing activities 148,742 144,353 Financing activities: Â Â Proceeds from exercise of stock options 10,368 3,501 Proceeds from the issuance of common stock under the employee stock purchase plan 8,862 8,674 Proceeds from public offering, net of issuance cost Â 235,441 Cash provided by financing activities 19,230 247,616 Net change in cash, cash equivalents and restricted cash 250,749 202,619 Cash, cash equivalents and restricted cash, beginning of period 642,095 466,091 Cash, cash equivalents and restricted cash, end of period 892,844 668,710 Supplemental disclosure of cash flow information: Â Â Cash paid for interest 6,785 6,907 Non-cash investing and financing activities: Â Â Purchases of property and equipment in accounts payable and accruals 854 (1,168) Acquisition of warrants and warrant receivable 9,424 Â Amounts accrued for acquisition of intangible assets 1,400 Â Issuance of common stock for IPR&D acquisition Â 14,435 Issuance of common stock for bonuses 24,071 19,771 Stock-based compensation included in capitalized software development costs $ 1,729 $ 520 X - DefinitionAmount of warrants and receivables acquired. + ReferencesNo definition available. + Details Name: ntra_AcquisitionOfWarrantsAndReceivables Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expensed in-process research and development during the period. + ReferencesNo definition available. + Details Name: ntra_ExpensedInProcessResearchAndDevelopment Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of non-cash interest expense. + ReferencesNo definition available. + Details Name: ntra_NonCashInterestExpense Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of noncash expense recovery. + ReferencesNo definition available. + Details Name: ntra_NoncashExpenseRecovery Namespace Prefix: ntra_ Data Type:

xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for investments in related party. + ReferencesNo definition available. + Details Name: ntra_PaymentsForInvestmentsInRelatedParty Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow due to acquisition of assets. + ReferencesNo definition available. + Details Name: ntra_PaymentsToAcquireAssets Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of premium amortization and discount accretion on investment securities. + ReferencesNo definition available. + Details Name: ntra_PremiumAmortizationAndDiscountAccretionOnInvestmentSecurities Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents purchases of property and equipment in accounts payable and accruals. + ReferencesNo definition available. + Details Name: ntra_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of stock-based compensation included in capitalized software development costs. + ReferencesNo definition available. + Details Name: ntra_StockBasedCompensationIncludedInCapitalizedSoftwareDevelopmentCosts Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement, classified as other. + ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 + Details Name: us-gaap_DepreciationDepletionAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, before tax, of realized and unrealized gain (loss) from foreign currency transaction. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(7)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482014/830-20-35-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481956/830-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481926/830-20-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481839/830-10-45-17 + Details Name: us-gaap_ForeignCurrencyTransactionGainLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 912 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in obligation for operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -SubTopic 20 -Topic 842 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_IncreaseDecreaseInOperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in other expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) in prepaid expenses, and assets classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting

Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11 + Details Name: us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow associated with the amount received from entity's first offering of stock to the public. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceInitialPublicOffering Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11 + Details Name: us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from exercise of option under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 205 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 33: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4J -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4JReference 34: http://www.xbrl.org/2003/role/exampleRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 4K -Publisher FASB -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4KReference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2Reference 38: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1AReference 39: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A + Details Name: us-gaap_ProfitLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fair value of stock issued in noncash financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_StockIssued1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowInformationAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business 9 Months Ended Sep. 30, 2024 Description of Business Â Description of Business 1. Description of BusinessNatera, Inc. (the â€œCompanyâ€) was formed in the state of California as Gene Security Network, LLC in November 2003 and incorporated in the state of Delaware in January 2007. The Company is a diagnostics company with proprietary molecular and bioinformatics technology that it is applying to change the management of disease worldwide. The Companyâ€™s cell-free DNA (â€œcfDNAâ€) technology combines its novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with its statistical algorithms which incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage. The Company focuses on applying its technology to three main areas of healthcare â€“ womenâ€™s health, oncology and organ health. In the womenâ€™s health space, the Company develops and commercializes non- or minimally-invasive tests to evaluate risk for, and thereby enable early detection of, a wide range of genetic conditions, such as Down syndrome. In oncology, the Company commercializes, among others, a personalized blood-based DNA test to detect molecular residual disease and monitor for disease recurrence across a broad range of cancer types. The Companyâ€™s third area of focus is organ health, with tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease. The Company operates laboratories in Austin, Texas and San Carlos, California, certified under the Clinical Laboratory Improvement Amendments of 1988 (â€œCLIAâ€), providing a host of cell-free DNA-based molecular testing services. The Company determines its operating segments based on the way it organizes its business to make operating decisions and assess performance. The Company operates one segment, the development and commercialization of molecular testing services, applying its proprietary technology in the fields of womenâ€™s health, oncology and organ health.â€‹The Companyâ€™s key product offerings include its Panorama Non-Invasive Prenatal Test (â€œPanoramaâ€) that screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother; Horizon Carrier Screening (â€œHorizonâ€) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrierâ€™s children; its Signatera molecular residual disease test (â€œSignateraâ€) to detect circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease, monitor for recurrence, and evaluate treatment response; and its Prospera test, to assess organ transplant rejection in patients who have undergone kidney, heart, or lung transplantation. All testing is available principally in the United States. The Company also offers its Panorama test to customers outside of the United States, primarily in Europe. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Companyâ€™s algorithms and bioinformatics in order to validate and launch their own tests based on the Companyâ€™s technology. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Summary of Significant Accounting Policies 2. Summary of Significant Accounting Policies During the nine months ended September 30, 2024, there were no material changes to the Companyâ€™s significant accounting policies as disclosed in the Companyâ€™s Annual Report on Form 10-K for the year ended December 31, 2023 (filed on February 29, 2024).Basis of PresentationThe accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (â€œU.S.Â GAAPâ€) for interim financial information. The unaudited interim condensed consolidated financial information includes only adjustments of a normal recurring nature necessary for a fair presentation of the Companyâ€™s results of operations, financial position, changes in stockholdersâ€™ equity, and cash flows. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results for the full year or the results for any future periods. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements at that date. These financial statements should be read in conjunction with the audited financial statements, and related notes for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on February 29, 2024.Some items in the prior period financial statements were reclassified to conform to the current presentation.Liquidity MattersThe Company has incurred net losses since its inception and anticipates net losses for the near future. The Company had a net loss of $136.7 million for the nine months ended September 30, 2024 and an accumulated deficit of $2.5 billion as of September 30, 2024. As of September 30, 2024, the Company had $892.8 million in cash, cash equivalents, and restricted cash, $29.5 million in marketable securities, an $80.4 million outstanding balance on its Credit Line (as defined in Note 10, Debt) including accrued interest and $287.5 million of outstanding principal on its 2.25% Convertible Senior Notes (the â€œConvertible Notesâ€). The Company is required to maintain a minimum of at least $150.0 million in its UBS accounts as collateral for its Credit Line. As of September 30, 2024, the Company had $20.0 million remaining and available on its Credit Line.While the Company has introduced multiple products that are generating revenues, these revenues have not been sufficient to fund all operations and business plans. Accordingly, the Company has funded the portion of operating costs that exceeds revenues through a combination of equity issuances, debt issuances, and other financings.The Company continues to invest in the development and commercialization of its existing and future products and, consequently, it will need to generate additional revenues to achieve future profitability and may need to raise additional equity or debt financing. If the Company raises additional funds by issuing equity securities, its stockholders will experience dilution. Additional debt financing, if available, may involve covenants restricting its operations or its ability to incur additional debt. Any additional debt financing or additional equity that the Company raises may contain terms that are not favorable to it or its stockholders and requires significant debt service payments, which diverts resources from other activities. Additional financing may not be available when necessary, or in amounts or on terms acceptable to the Company. If the Company is unable to obtain additional financing, it may be required to delay the development and commercialization of its products and significantly scale back its business and operations.On July 19, 2024, the Company announced its decision to redeem all of its outstanding 2.25% Convertible Senior Notes due 2027.Â The redemption was completed on October 11, 2024 (the â€œRedemption Dateâ€). The redemption price for the Convertible Notes equaled 100% of the principal amount of the Convertible Notes to be redeemed plus accrued and unpaid interest to, but excluding, the Redemption Date. The Company elected physical settlement with shares of its common stock as the settlement method to apply to all conversions of the Convertible Notes. On the Redemption Date, $287.4 million of Convertible Notes were redeemed for approximately 7.5 million shares of the Companyâ€™s common stock under the terms of the redemption notice. The remaining Convertible Notes not redeemed under the redemption notice were converted in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, the Companyâ€™s redemption of its Convertible Notes did not have a material effect on its liquidity.In September 2023, the Company completed an underwritten equity offering and sold 4,550,000 shares of its common stock at a price of $55 per share to the public. Before estimated offering expenses of $0.4 million, the Company received proceeds of approximately $235.8 million net of the underwriting discount. On September 10, 2021, the Company entered into an agreement with a third party for an asset acquisition where the acquired asset was in-process research and development primarily in exchange for an equity consideration payment. In addition, pursuant to the agreement, certain employees of the third party became employees of the Company. The third party was a biotechnology company focused on oncology. The total upfront acquisition consideration amounted to $35.6 million, composed of the issuance of 276,346 shares of the Company's common stock with a fair value of $30.9 million, approximately $3.9 million of cash consideration, assumed net liabilities of $0.2 million, as well as $0.6 million of acquisition related legal and accounting costs directly attributable to the acquisition of the asset. The Company accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified in-process research and development asset (â€œIPR&Dâ€), thus satisfying the requirements of the screen test in Accounting Standards Update (â€œASUâ€) 2017-01 Business Combinations (Topic 805): Clarifying the Definition of Business. The estimated fair value of the acquired workforce was not significant. The Company concluded the acquired IPR&D has no alternative-future use and accordingly expensed approximately $35.6 million, on the day the transaction closed as research and development expense, which was reflected in its consolidated statement of operations.Further, additional consideration aggregating up to approximately $35.0Â million was estimated to be paid via issuance of an estimatedÂ 269,547Â additional shares of the Companyâ€™s common stock, consistent with the registration statement filed with the SEC on September 10, 2021, upon achievement of defined milestones relating to product development, commercial launch and continued employment of certain selling shareholders, each of which was revalued at each reporting date and amount of compensation expense was adjusted accordingly and reported in research and development expenses. In November 2022, the terms of the payment for any remaining consideration were modified, resulting in $10.0Â million of consideration paid in December 2022 and $15.0Â million of consideration paid in March 2023, with such consideration primarily consisting of the Companyâ€™s common stock.Based on the Companyâ€™s current business plan, the Company believes that its existing cash and marketable securities will be sufficient to meet its anticipated cash requirements for at least 12 months after November 12, 2024.Principles of Consolidationâ€‹The accompanying condensed consolidated financial statements include all the accounts of the Company and its subsidiaries. The Company established a subsidiary that operates in the state of Texas to support the Companyâ€™s laboratory and operational functions. The Company also established a subsidiary that operates in Canada following the acquisition of the IPR&D asset. All intercompany balances and transactions have been eliminated.Use of EstimatesThe preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, determining the incremental borrowing rate to calculate operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment including impairment estimates, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers, insurance payors, and patients. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.â€‹InvestmentsInvestments consist primarily of debt securities such as U.S. Treasuries, U.S. agency and municipal bonds. Management determines the appropriate classification of securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company generally classifies its entire investment portfolio as available-for-sale. The Company views its available-for-sale portfolio as available for use in current operations. Accordingly, the Company classifies all investments as short-term, irrespective of maturity date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss), which is a separate component of stockholdersâ€™ equity.The Company classifies its investments as Level 1 or 2 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. The Company holds Level 2 securities, which are initially valued at the transaction price and subsequently valued by a third-party service provider using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company performs certain procedures to corroborate the fair value of these holdings. Â â€‹Available-for-sale debt securities. The amended guidance from ASU 2016-13, Financial Instruments â€“ Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, requires the measurement of expected credit lossesÂ for available-for-saleÂ debt securitiesÂ held at the reporting date over the remaining life based on historical experience, current conditions, and reasonable and supportable forecasts. The Company evaluated its investment portfolio under the available-for-sale debt securities impairment model guidance and determined the Companyâ€™s investment portfolio is composed of low-risk, investment grade securities and thus has not recorded an expected credit loss for its investment portfolio. Further, gross unrealized losses on available for sale securities were not material at September 30, 2024.â€‹Accounts ReceivableTrade accounts receivable and other receivables. The allowance for doubtful accounts for trade accounts receivable is based on the Companyâ€™s assessment of the collectability of accounts related to its clinics and laboratory partner customers. The Company regularly reviews the allowance by considering factors such as historical experience, the age of the accounts receivable balances, and current economic conditions that may affect a customerâ€™s ability to pay. See Note 6, Balance Sheet Components, for a roll-forward of the allowance for doubtful accounts related to trade accounts receivable for three months and nine months ended September 30, 2024 and 2023. The Company recognizes revenue under Accounting Standards Codification (â€œASCâ€) Topic 606, Revenue from Contracts with Customers (â€œASC 606â€) and applies a constraint to the estimated variable consideration such that it is not probable that a significant reversal will occur. When assessing the total consideration expected to be received from insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds. After applying the ASC 606 constraint, the Company assessed for credit losses and allowance for doubtful accounts and determined an incremental credit loss was not needed given the quality of the insurance payors from whom such receivables are expected to be collectible and the relatively short duration over which the majority of receivables are collected. Accordingly, the Company currently does not have an incremental credit loss reserve nor allowance for doubtful accounts against accounts receivable for insurance and patient payors due to the average selling price calculations, which already incorporate these risks as net receivables are recorded.Inventory â€‹Inventory is recorded at the lower of cost or net realizable value, determined on a first-in, first-out basis. Inventory consists entirely of supplies, which the Company consumes when providing its test reports, and therefore, the Company does not maintain any finished goods inventory. The Company enters into inventory purchases commitments so that it can meet future delivery schedules based on forecasted demand for its tests.â€‹The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. A write down of specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period is first recognized by using a number of factors including product expiration dates and scrapped inventory. Any write-down of inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on our consolidated statements of operations. The Company makes assumptions about future demand, market conditions and the release of new products that may supersede older products; however, if actual market conditions are less favorable than anticipated, additional inventory write-downs may be required.â€‹Other Assetsâ€‹In January 2024, the Company acquired from Invitae Corp. (â€œInvitaeâ€) certain assets relating to Invitaeâ€™s non-invasive prenatal screening and carrier screening business. The transaction price of $10.5 million consisted of $10.0 million in upfront payment costs and approximately $0.5 million of other transaction costs which were capitalized as intangible assets over an estimated useful life of ten years. An additional payment of up to $42.5 million may be made should the Company achieve certain customer volume retention targets and based on certain legal outcomes.Accumulated Other Comprehensive Income (Loss)Comprehensive loss and its components encompass all changes in equity other than those with stockholders, and include net loss, unrealized gains and losses on available-for-sale marketable securities and foreign currency translation adjustments. â€‹â€‹â€‹

defined in MyOme's certificate of incorporation). Additionally, upon the achievement of certain product commercialization milestones, the Company is eligible to receive an additional warrant exercisable for 2,080,565 shares of Myomeâ€™s series B preferred stock with an exercise price of $0.01 per share. During September 2024, the Company achieved certain product commercialization milestones such that the warrant for 2,080,565 shares of MyOmeâ€™s series B preferred stock was due from MyOme to the Company. As these warrants have not yet been granted and issued by MyOme, the Company recorded these warrants as a receivable on its condensed consolidated balance sheet as of September 30, 2024.The warrants were valued using the Black-Scholes valuation model on the date of issuance or the date they became receivable from MyOme and are accounted for using the measurement alternative. No impairment was identified as of September 30, 2024. The warrants and warrant receivable have been included within other assets and allocated between short-term and long-term liabilities on the condensed consolidated balance sheet, which will be recognized as a reduction of selling and marketing expense upon commercialization and sale of the products contemplated under the Collaboration Agreement. Subject to the Company's achievement of certain commercialization milestones, the Company may receive additional warrants to purchase MyOmeâ€™s Series B Preferred Stock. To the extent the genetic testing services are successfully commercialized, the Company will owe certain royalty payments to MyOme. Should the Company exercise all its MyOme common and series B preferred stock warrants, with the series B preferred stock held, the Company would own an accumulated 12.6% of MyOme on a fully diluted basis. This excludes the 2,080,565 shares of MyOmeâ€™s series B preferred stock warrant receivable. As of September 30, 2024 and December 31, 2023, the Companyâ€™s carrying amount of ownership interest in MyOme was $6.7 million and $4.0 million, respectively, on its condensed consolidated balance sheet. The carrying value of the warrants and warrant receivable as of September 30, 2024 and December 31, 2023 was $9.4 million and zero, respectively, on the condensed consolidated balance sheet.Risk and UncertaintiesFinancial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, restricted cash, accounts receivable and investments. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution.For the three and nine months ended September 30, 2024, and 2023, there were no customers exceeding 10% of total revenues on an individual basis. As of September 30, 2024 and December 31, 2023, there were no customers with an outstanding balance exceeding 10% of net accounts receivable.Â For both the three months ended September 30, 2024 and 2023, approximately 12.6% of total revenue were paid by Medicare on behalf of multiple customers. For the nine months ended September 30, 2024 and 2023, approximately 11.5% and 13.0%, respectively, of total revenue were paid by Medicare on behalf of multiple customers. As of September 30, 2024 and December 31, 2023, approximately 10.9% and 10.2%, respectively, of accounts receivable are expected to be paid by Medicare on behalf of multiple customers.â€‹Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (â€œFASBâ€) under its accounting standard codifications or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed below, the Company believes the adoption of accounting standards updates recently issued that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.New Accounting Pronouncements Not Yet AdoptedIn March 2020, ASU 2020-04,Â Reference Rate Reform (Topic 848)Â was issued which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to transactions affected by reference rate reform if certain criteria are met. These transactions include contract modifications, hedging relationships, and sale or transfer of debt securities classified as held-to-maturity. ASU 2022-06, or Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The Company does not expect adoption of this standard to have a material impact on its consolidated financial statements.In November 2023, ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, was issued which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact of the guidance on its consolidated financial statements.In December 2023, ASU 2023-09, Income Taxes - Improvements to Income Tax Disclosures, was issued, which requires enhanced disclosures in connection with an entity's effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. The standard will be effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this standard to have a significant impact on its consolidated financial statements. X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for all significant accounting policies of the reporting entity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 235 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//235/tableOfContent + Details Name: us-gaap_SignificantAccountingPoliciesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition 9 Months Ended Sep. 30, 2024 Revenue Recognition Â Revenue Recognition 3. Revenue Recognition The Company recognizes revenues when, or as, performance obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the customers.Product RevenuesProduct revenues are derived by performing genetic testing services and the Companyâ€™s performance obligation is complete when test results are delivered to a laboratory or patient (each a customer). Additionally, the Company enters into agreements with pharmaceutical companies to utilize the Companyâ€™s Signatera tests typically to study new cancer treatments or to validate the outcomes of clinical trials for which the pharmaceutical companies are identified as customers. Such arrangements generally involve performing whole exome sequencing services and the testing of patient samples to detect cancer mutations using its Signatera test. In addition to performing Signatera tests, these agreements typically include certain activities to fulfill the contract, such as customer data setup and management and ongoing reporting. Each test result is billable to customers upon delivery and the personalized cancer profile also makes each test distinct within the context of the contract as customers can exercise control over the test results upon delivery. Accordingly, the Company recognizes test processing revenue as individual test results are delivered to customers.For certain contracts with pharmaceutical companies where the Company is developing a companion diagnostic test in addition to performing regular testing services, revenue is primarily recognized proportionally as services are performed and/or tests are delivered.A performance obligation represents a promise in a contract to transfer a distinct good or service to a customer, which represents a unit of accounting in accordance with ASC 606. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once the Company has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. A portion of the consideration should be allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company evaluates its contracts with laboratory partners and patients and identifies the performance obligations in those contracts, which are the delivery of the test results.The total consideration the Company expects to collect in exchange for the Companyâ€™s products is an estimate and may be fixed or variable. Consideration includes reimbursement from both patients and insurance carriers, adjusted for variable consideration related to disallowed cases, percent of patient responsibility collected, refunds and reserves, and is estimated using the most likely amount method. For insurance carriers and product types with similar reimbursement characteristics, the Company uses a portfolio of relevant historical data to estimate variable consideration and total collections for the Companyâ€™s products. The Company constrains the estimated variable consideration when it determines it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. The consideration expected from laboratory partners usually includes a fixed amount, but it can be variable depending on the volume of tests performed, and the Company determines the variable consideration using the expected value approach. For laboratory partners and patients, the Company allocates the total consideration to a single performance obligation, which is the delivery of the test results to the customers.When assessing the total consideration expected to be received from insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds.The Company enters into contracts with insurance carriers with primarily payment terms related to tests provided to patients who have health insurance coverage. Insurance carriers are considered third-party payers on behalf of the patients, and the patients are considered the customers who receive genetic test services. Tests may be billed to insurance carriers, patients, or a combination of insurance carriers and patients. Further, the Company sells tests to a number of domestic and international laboratory partners and identifies the laboratory partners as customers, provided that there is a test services agreement between the two parties.The Company generally bills an insurance carrier, a laboratory partner or a patient upon delivery of test results. The Company also bills patients directly for out-of-pocket costs involving co-pays and deductibles that they are responsible for. The Company may or may not get reimbursed for the full amount billed. Further, the Company may not get reimbursed at all for tests performed if such tests are not covered under the insurance carrierâ€™s reimbursement policies or the Company is not a qualified provider to the insurance carrier, or if the tests were not previously authorized.Product revenue is recognized in an amount equal to the total consideration (as described above) expected to be received at a point in time when the test results are delivered. Approximately 90% of cash collections attributable to such product revenue occurs within nine months with the remaining collections generally taking an additional six months. During this time, management routinely reassesses its estimates of actual to expected cash collections, which are based on historical collection rates and adjusted for current information and trends. To the extent cash collections for tests delivered in prior periods are trending higher than expectations, the Company will increase revenue recognized when sufficient evidence is obtained to conclude the additional revenue will not result in a reversal of revenue in a future period. Given the historical uncertainties with respect to the timing and extent of cash collections for test services provided, sufficient evidence is obtained once cash collected exceeds the amount of revenue recognized during a given period. If cash collections for tests delivered in prior periods are trending below expectations, the Company will reduce revenue to the amount expected to be collected based on the latest information and expectations. Increases or decreases to the amount of cash expected to be collected for tests delivered in prior periods are recognized in product revenue with a corresponding impact to accounts receivable during the period such determination is made. During the three months ended September 30, 2024 and 2023, the Company increased revenue by a net of $34.5 million and $2.2 million, respectively, for collections related to tests delivered in prior periods that were fully collected (including an estimate of unapplied receipts). The increased revenue and decreased net loss resulted in a corresponding decrease in loss per share by $0.28 and $0.02 for the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024, the Company increased revenue for collected cash in excess of initial revenue recognized by a net of $108.1 million for collections related to tests delivered in prior periods that were fully collected (including an estimate of unapplied receipts). The increased revenue and decreased net loss resulted in a corresponding decrease in loss per share by $0.88 for the nine months ended September 30, 2024. During the nine months ended September 30, 2023, the Company reduced revenue by a net of $3.7 million for a reduction in expected collections related to tests delivered in prior periods. The decreased revenue and increased net loss resulted in a corresponding increase in loss per share by $0.03 for the nine months ended September 30, 2023. Â As of September 30, 2024, the Company had $26.9 million in cash receipts which had not yet been applied to specific accounts receivables. The Company reviewed the historical unapplied payment trends, and, within the unapplied cash receipts of $26.9 million, the Company estimated approximately $2.5 million was related to tests delivered in prior periods that were fully collected. Â Additionally, as overpayments were not material in prior years, the Company accounted for temporary unapplied balances as of September 30, 2024, as contra accounts receivable on the Balance Sheet. As of December 31, 2023, the unapplied accounts receivable balance was $1.3 million. Product revenue is constrained for refunds estimated to be paid to insurance carriers. Certain refunds are recognized in accrued liabilities until they are either paid to the respective insurance carrier or it is determined the refund will not ultimately be paid, at which time the related accrual is reduced with a corresponding increase to revenue. During the three months ended September 30, 2024 and 2023, the reserves for refunds to insurance carriers were reduced and product revenue increased by $0.7 million and $1.2 million, respectively, for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and corresponding decreased net loss resulted in a decreased loss per share by $0.01 for both the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024 and 2023, the reserves for refunds to insurance carriers were reduced and product revenue increased by $4.5 million and $7.7 million, respectively, for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and corresponding decreased net loss resulted in a decreased loss per share by $0.04 and $0.07 for the nine months ended September 30, 2024 and 2023, respectively.In addition, certain other refunds are recognized as a reduction to accounts receivable until they are either paid to the respective insurance carrier or it is determined the refund will not ultimately be paid, at which time the related reserve is reduced with a corresponding increase to revenue. During the three months ended September 30, 2024, the reserves for refunds to insurance carriers were reduced and product revenue increased by $2.9 million for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and corresponding decreased net loss resulted in a decreased loss per share by $0.02 for the three months ended September 30, 2024. During the nine months ended September 30, 2024, the reserves for refunds to insurance carriers were reduced and product revenue increased by $7.1 million for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and decreased net loss resulted in a decreased loss per share by $0.06 for the nine months ended September 30, 2024. There was no such adjustment in the three and nine months ended September 30, 2023.Licensing and Other Revenuesâ€‹The Company recognizes licensing revenues from its cloud-based distribution service offering, Constellation, by granting licenses to its licensees to use certain of the Companyâ€™s proprietary intellectual properties and cloud-based software and in vitro diagnostic (â€œIVDâ€) kits. The Company also recognizes revenues from its strategic collaboration agreements, such as those with BGI Genomics Co., Ltd. (â€œBGI Genomicsâ€) and Foundation Medicine, Inc. (â€œFoundation Medicineâ€). The Company recognizes licensing and other revenues through agreements with pharmaceutical companies in support of potential clinical trials managed by the pharmaceutical companies.ConstellationThe laboratory partners with whom the Company enters into a licensing arrangement represent the licensees and are identified as customers. The licensees do not have the right to possess the Companyâ€™s software, but rather receive services through the cloud software. These arrangements often include: (i) the delivery of the services through the cloud software, (ii) the necessary support and training, and (iii) the IVD kits to be consumed as tests are processed. The Company does not consider the software as a service, the support or the training as being distinct in the context of such arrangements, and therefore, these items are combined as a single performance obligation. The software, support and training are delivered simultaneously to the licensees over the term of the arrangement.The Company bills the majority of licensees, who process the tests in their laboratories, a fixed price for each test processed. Licensing revenues are recognized as the performance obligations are satisfied (i.e., upon the delivery of each test) and reported in licensing and other revenues in the Companyâ€™s statements of operations and comprehensive loss.BGI Genomics In February 2019, the Company entered into a License Agreement (the â€œBGI Genomics Agreementâ€) with BGI Genomics to develop, manufacture, and commercialize next generation sequencing-based genetic testing assays for clinical and commercial use. The BGI Genomics Agreement has a term of ten years and expires in February 2029. Pursuant to the BGI Genomics Agreement, the Company licensed its intellectual property to and provided development services for BGI Genomics. Following completion of development services, the Company began providing assay interpretation services over the term of the agreement.According to the BGI Genomics Agreement, the Company is entitled to a total of $50.0 million, comprised of upfront technology license fees, prepaid royalties relating to future sales of licensed products and performance of assay interpretation services, and milestone payments. Due to uncertainties in achieving certain milestones, $6.0 million of the $50.0 million was constrained. A net of $44.0 million has been collected by the Company in cash, which includes $20.0 million in prepaid royalties.The Company concluded that the license is not a distinct performance obligation as it does not have a stand-alone value to BGI Genomics apart from the related development services; therefore, license and related development services for each of the non-invasive prenatal tests (â€œNIPTsâ€) and Oncology products, represents two separate performance obligations, to which $24.0 million of transaction consideration was allocated. This performance obligation was fully satisfied in March 2023 and no further related amounts will be recognized as revenue.As of December 31, 2023, the Company's performance obligation to provide ongoing NIPT assay interpretation services was removed. Therefore, the Company now has a single remaining performance obligation related to Oncology assay interpretation services, to which $20.0 million of transaction consideration was allocated and prepaid by BGI Genomics. During the nine months ended September 30, 2023, the Company recognized $1.1 million related to oncology assay interpretation services, of which $0.7 million was recognized against deferred royalties.

During the nine months ended September 30, 2024, the Company recognized $1.5 million related to oncology assay interpretation services, of which $1.4 million was recognized against deferred royalties. The Company currently has $17.4 million in deferred revenue related to this agreement as of September 30, 2024.As required by the BGI Genomics Agreement, in June 2019 the Company prepaid $6.0 million to BGI Genomics for future sequencing services and $4.0 million for future sequencing equipment. These advance payments are for equipment and services to be received in future periods, which was assessed as a standalone transaction that did not reduce revenue, aggregated to $10.0 million and was originally recorded in long-term assets on the Companyâ€™s Consolidated Balance Sheet and will be periodically assessed for impairment. During both the three and nine months ended September 30, 2024, $0.4 million in equipment and services was received. Â During the three and nine months ended September 30, 2023, $1.4 million and $4.0 million, respectively, in equipment and services was received. As of September 30, 2024, the remaining advanced payments were $1.0 million recorded in prepaid expenses and other current assets and $3.4 million recorded in other assets.Foundation Medicine, Inc.â€‹In August 2019, the Company entered into a License and Collaboration Agreement (the â€œFoundation Medicine Agreementâ€) with Foundation Medicine to develop and commercialize personalized circulating tumor DNA monitoring assays, for use by biopharmaceutical and clinical customers who order Foundation Medicineâ€™s FoundationOne CDx. The Company and Foundation Medicine will share the revenues generated from both biopharmaceutical and clinical customers in accordance with the terms of the Foundation Medicine Agreement. The Foundation Medicine Agreement had an initial term of five years that expired in August 2024. There was an option for automatic renewals thereafter for successive one-year terms, unless the Foundation Medicine Agreement is terminated in accordance with its terms. The Company and Foundation Medicine have elected not to renew the agreement beyond the initial term.Pursuant to the Foundation Medicine Agreement, the Company provided development services that are required to customize its proprietary Signatera test to work with Foundation Medicineâ€™s FoundationOne CDx in conjunction with granting the use of the Companyâ€™s intellectual property. Following completion of those development services, the Company was currently providing assay testing services over the term of the agreement. The intellectual property had been licensed to Foundation Medicine for the customized test. In addition, the Company was responsible for delivering clinical study plans in order to demonstrate efficacy of the customized test which commenced in the second quarter of 2021.The Company is entitled to a total of $32.0 million, comprised of upfront technology license fees, prepaid royalties relating to future sales of licensed products and performance of assay interpretation services, and milestone payments. $7.7 million is constrained due to uncertainties in achieving certain milestones. A net of $24.3 million has been collected by the Company in cash, which includes $5.0 million of prepaid royalties.The Company concluded that the license is not a distinct performance obligation as it does not have a stand-alone value to Foundation Medicine apart from the related development services. Therefore, license and related development services, for Oncology products, represent a single performance obligation, to which $19.3 million of transaction consideration was allocated. Of this amount, $0.2 million was recognized in the three months ended March 31, 2023. This performance obligation was fully satisfied in March 2023 and no further related amounts will be recognized as revenue.Royalties related to assay interpretation services represent separate performance obligations for Oncology products, to which $5.0 million of transaction consideration was allocated and prepaid by Foundation Medicine. During the three and nine months ended September 30, 2023, the Company recognized ($0.1) million and $0.3 million, respectively, related to oncology assay interpretation services. During the three and nine months ended September 30, 2024, the Company recognized $0.1 million and $0.3 million, respectively, related to oncology assay interpretation services. The Company currently has $3.0 million in deferred revenue related to this agreement as of September 30, 2024.Disaggregation of Revenuesâ€‹The Company measures its performance results primarily based on revenues recognized from the three categories described below. The following table shows disaggregation of revenues by payer types:â€‹â€‹â€‹

Publisher SECReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//946-320/tableOfContentReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//940-320/tableOfContentReference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components 9 Months Ended Sep. 30, 2024 Balance Sheet Components Â Balance Sheet Components 6. Balance Sheet Componentsâ€‹Allowance for doubtful accountsâ€‹The following is a roll-forward of the allowances for doubtful accounts related to trade accounts receivable for the three and nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Endedâ€‹Â Â Â Â SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹â€‹(in thousands)Beginning balanceâ€‹$7,021â€‹$5,580(Reversal of) Provision for doubtful accountsâ€‹â€‹ (536)â€‹â€‹454Write-offsâ€‹â€‹ (233)â€‹â€‹ â€”Totalâ€‹$6,252 â€‹$6,034 â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹Â Â Â Â SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹â€‹(in thousands)Beginning balanceâ€‹$6,481â€‹$3,830Provision for doubtful accountsâ€‹â€‹ 208â€‹â€‹2,204Write-offsâ€‹â€‹ (437)â€‹â€‹ â€”Totalâ€‹$6,252 â€‹$6,034 â€‹Property and Equipment, netâ€‹The Companyâ€™s property and equipment consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹UsefulÂ Life2024Â Â Â Â 2023â€‹â€‹(inÂ thousands)Machinery and equipment3-5Â years$ 104,443â€‹$ 85,626Computer equipment3Â yearsâ€‹ 3,040â€‹Â 1,850Purchased and capitalized software held for internal use3 yearsâ€‹ 11,104â€‹â€‹ 11,636Leasehold improvementsLesser of useful life or lease termâ€‹ 48,080â€‹Â 38,999Construction-in-processâ€‹â€‹ 46,631â€‹Â 29,392â€‹â€‹â€‹ 213,298â€‹Â 167,503Less: Accumulated depreciation and amortizationâ€‹â€‹ (71,128)â€‹Â (56,293)Total Property and Equipment, netâ€‹$ 142,170â€‹$ 111,210â€‹The Companyâ€™s long-lived assets are located in the United States.During the nine months ended September 30, 2024, the increase in net property and equipment was due to expansion projects and purchases of new equipment for the Companyâ€™s laboratories located in Texas and California to expand testing capabilities, offset by depreciation expense of $19.9 million recorded in the nine months ended September 30, 2024. Depreciation expense of $16.1 million was recorded in the nine months ended September 30, 2023. The Company did not incur any impairment charges during the nine months ended September 30, 2024 or 2023.Other Accrued Liabilitiesâ€‹The Companyâ€™s other accrued liabilities consisted of the following:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â Â Â Â DecemberÂ 31,Â â€‹2024Â Â Â Â 2023â€‹â€‹(in thousands)Reserves for refunds to insurance carriers$ 15,778â€‹$ 23,245Accrued charges for third-party testingâ€‹ 9,924â€‹â€‹ 14,823Testing and laboratory materials from suppliersâ€‹ 9,823â€‹â€‹ 11,229Marketing and corporate affairsâ€‹ 15,526â€‹â€‹ 10,085Legal, audit and consulting feesâ€‹ 36,535â€‹Â 43,897Accrued shipping chargesâ€‹ 2,180â€‹â€‹ 3,646Sales and income tax payableâ€‹ 5,061â€‹â€‹ 3,731Accrued third-party service feesâ€‹ 8,853â€‹â€‹ 7,111Clinical trials and studiesÂ 7,744â€‹â€‹ 12,126Operating lease liabilities, current portionâ€‹ 9,762â€‹â€‹ 11,621Property and equipment purchasesâ€‹ 3,397â€‹â€‹ 4,316Other accrued interestâ€‹ 1â€‹â€‹ 1,078Other accrued expensesÂ 1,592â€‹â€‹ 2,497Total other accrued liabilities$ 126,176â€‹$ 149,405â€‹Reserves for refunds to insurance carriers include overpayments from and amounts to be refunded to insurance carriers and additional amounts that the Company estimates for potential refund requests during the period. When the Company releases these previously accrued amounts, they are recognized as product revenues in the condensed statements of operations and comprehensive loss. â€‹The following table summarizes the reserve balance and activities for refunds to insurance carriers for the nine months ending September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹2024Â Â Â Â 2023â€‹(inÂ thousands)Beginning balance$ 23,245â€‹$ 18,948Additional reservesÂ 1,506â€‹Â 7,348Refunds to carriersÂ (3,095)â€‹â€‹ (1,236)Reserves released to revenueâ€‹ (5,878)â€‹â€‹ (8,851)Ending balance$ 15,778â€‹$ 16,209â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹During the quarter ended September 30, 2024, the Company repaid $13.8 million in short term advances obtained as a result of the disruption to Change Healthcareâ€™s network in February 2024. X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//210/tableOfContent + Details Name: us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.3 Leases 9 Months Ended Sep. 30, 2024 Leases. Â Leases 7. Leasesâ€‹Operating LeasesIn September 2015, the Company entered into a long-term lease agreement for laboratory and office space totaling approximately 94,000 square feet in Austin, Texas. The original lease term was 132 months beginning in December 2015 and expiring in November 2026, with monthly payments beginning in December 2016. In December 2021, the Company entered into an amendment of the Austin lease agreement, which extended the lease of the current premises through March 2033. The amendment also includes two additional office spaces (the â€œFirst Expansion Premisesâ€ and the â€œSecond Expansion Premisesâ€). The First Expansion Premises consists of 32,500 rentable square feet and commenced in February 2022. The Second Expansion Premises consists of 65,222 rentable square feet and commenced in September 2022. The terms of the First and Second Expansion Premises expire in March 2033. In October 2016, the Company entered into a lease directly with its landlord for laboratory and office spaces at its facilities located in San Carlos, California. The Company currently occupies approximately 136,000 square feet comprised of two office spaces (the â€œFirst Spaceâ€ and the â€œSecond Spaceâ€). The First Space covers approximately 88,000 square feet, and the Second Space totals approximately 48,000 square feet. In January 2021, the Company entered into an amendment of the lease to extend the term for 48 months to October 2027. The combined annual rent for the First Space and Second Space is $9.3 million, which commenced in October 2023. In July 2024, the Company entered into an amendment of the San Carlos lease to extend the term for 60 months to October 2032. The annual rent will be approximately $9.7 million beginning January 2025, escalating annually and may be increased if the Company elects to utilize additional tenant improvement allowances.The Company entered into a lease agreement commencing June 2018 for its cord blood tissue storage facility in Tukwila, Washington that covers approximately 10,000 square feet. The lease term was 62 months and expired in July 2023. The Company had the option to extend this lease for five years, however, since the Company sold its business related to cord blood and tissue storage in September 2019, the Company subleased the facility through the end of the lease and did not exercise its option to renew the facility upon expiration.The Company entered into a lease agreement in November 2020 to leaseÂ 11,395Â square feet of space located in South San Francisco, California over aÂ 36-monthÂ term. The premises are used for general office, laboratory and research use. The annual lease payment started at $0.9Â million and escalates annually after commencing in December 2021. In December 2022, the Company exercised the renewal option of the South San Francisco lease agreement. In January 2023, the Company entered in an amendment to extend the lease term of the South San Francisco premises byÂ three years, through November 2026.The Company entered into a lease agreement in September 2023 to leaseÂ 16,319Â square feet of space located in Pleasanton, California over aÂ 60-monthÂ term. The premises are used for laboratory and research use and commenced in December 2023. The annual lease payment started at $0.5 million and escalates annually.As part of the IPR&D asset acquisition in September 2021, the Company inherited aÂ 24-monthÂ lease forÂ 7,107Â square feet of laboratory space in Canada. The annual lease payment started at $0.2Â million and expired in August 2023.The Company has also historically entered into leases of individual workspaces and storage spaces at various locations on both a month-to-month basis without an established lease term and, more recently for certain locations, has committed to terms approximating one to five years. For the facilities without a committed lease term, the Company has elected to not recognize them as right-of-use assets on the condensed consolidated balance sheets as they are all considered short-term leases. For individual workspaces where the committed lease term exceeds one year, the Company has recorded a right-of-use asset on the condensed consolidated balance sheets.For the nine months ended September 30, 2024, the Company had $38.2 million in noncash operating activities related to additional right-of-use assets resulting from a new lease and extending existing leases under ASC, Topic 842, Leases (â€œASC 842â€). For the nine months ended September 30, 2023, the Company had $0.1 million in noncash operating activities related to additional right-of-use assets.The operating lease right-of-use assets are classified as noncurrent assets in the balance sheet. The corresponding lease liabilities are separated into current and long-term portions as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024â€‹2023â€‹â€‹â€‹(in thousands)Operating lease liabilities, current portion included in other accrued liabilitiesâ€‹$ 9,762â€‹$ 11,621Operating lease liabilities, long-term portionâ€‹â€‹ 98,953â€‹â€‹ 67,025Total operating lease liabilitiesâ€‹$ 108,715â€‹$ 78,646â€‹The initial recognition of the operating lease liabilities was measured as the present value of the future minimum lease payments using a discount rate determined as of January 1, 2019 upon the adoption of ASC 842. The operating right-of-use assets were calculated as the operating lease liabilities discounted at the present value, less the amount of unamortized tenant improvement allowance and deferred rent. The discount rate used was the Companyâ€™s incremental borrowing rate given that the implicit rate to each lease was not readily determinable. In accordance with ASC 842, the incremental borrowing rate was estimated as the annual percentage yield resulting from a corporate debt financing over a loan term approximating the remaining term of each lease, with the effect of certain credit risk rating. As of September 30, 2024, the weighted-average remaining lease term was 8.02 years and the weighted-average discount rate was 7.2%.The Company continues to recognize lease expense on a straight-line basis. The lease expense includes the amortization of the right-of-use assets with the associated interest component estimated by applying the effective interest method. For the three months ended September 30, 2024 and 2023, total lease expense of $4.0 million and $3.6 million was recognized in the condensed statements of operations and comprehensive loss, respectively. For the nine months ended September 30, 2024 and 2023, total lease expense of $11.2 million and $11.0 million was recognized in the condensed statements of operations and comprehensive loss, respectively. Cash paid for amounts in the measurement of operating lease liabilities totaled $4.2 million and $3.2 million for the three months ended September 30, 2024 and 2023, respectively. Cash paid for amounts in the measurement of operating lease liabilities totaled $12.5 million and $8.4 million for the nine months ended September 30, 2024 and 2023, respectively.The present value of the future annual minimum lease payments under all non-cancellable operating leases as of September 30, 2024 are as follows:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â OperatingÂ Leasesâ€‹â€‹(inÂ thousands)As of SeptemberÂ 30,Â 2024â€‹â€‹â€‹2024 (remaining 3 months)â€‹$ 4,3152025â€‹â€‹ 17,3912026â€‹â€‹ 17,6612027â€‹â€‹ 16,9972028â€‹â€‹ 17,3322029 and thereafterâ€‹â€‹ 70,693â€‹â€‹â€‹ 144,389Less: imputed interestâ€‹â€‹ (35,674)Operating lease liabilitiesâ€‹$ 108,715â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Â Commitments and Contingencies 8. Commitments and ContingenciesLegal ProceedingsThe Company is involved in legal matters, including investigations, subpoenas, demands, disputes, litigation, requests for information, and other regulatory or administrative actions or proceedings, including those with respect to intellectual property, testing and test performance, billing, reimbursement, marketing, short seller and media allegations, employment, and other matters.â€‹The Company is responding to ongoing regulatory and governmental investigations, subpoenas and inquiries, and contesting its current legal matters, but cannot provide any assurance as to the ultimate outcome with respect to any of the foregoing. There are many uncertainties associated with these matters. Such matters may cause the Company to incur costly litigation and/or substantial settlement charges, divert management attention, result in adverse judgments, fines, penalties, injunctions or other relief, and may result in loss of customer or investor confidence regardless of their merit or ultimate outcome. In addition, the resolution of any intellectual property litigation may require the Company to make royalty payments, which could adversely affect gross margins in future periods. If any of the foregoing were to occur, the Companyâ€™s business, financial condition, results of operations, cash flows, prospects, or stock price could be adversely affected.â€‹The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation or other matters may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability. Loss contingencies, including claims and legal actions arising in the ordinary course of business, are recorded as liabilities when the likelihood of loss is probable and an amount or range of loss can be reasonably estimated. Â During the periods presented, the Company does not believe there are such matters that will have a material effect on its financial condition. Â Intellectual Property Litigation Matters.The Company has been involved in two patent litigations against CareDx, Inc. (â€œCareDxâ€) in the United States District Court for the District of Delaware (â€œCareDx Patent Casesâ€). In the first CareDx Patent Case, CareDx alleged, in a complaint filed jointly with the Board of Trustees of the Leland Stanford Junior University in March 2019 and amended in March 2020, that the Company infringed three patents (the â€œCareDx Patentsâ€). The complaint sought unspecified damages and injunctive relief. In September 2021, the Court granted the Companyâ€™s motion for summary judgment, finding all three CareDx Patents invalid. This finding was affirmed on appeal by the United States Court of Appeals for the Federal Circuit. CareDxâ€™s petition for rehearing by the Federal Circuit, and its subsequent petition for certiorari to the United States Supreme Court, were both denied. In the second CareDx Patent Case, the Company alleged, in suits filed in January 2020 and May 2022, infringement by CareDx of certain of the Companyâ€™s patents, seeking unspecified damages and injunctive relief. In January 2024, after trial, the jury returned a verdict in favor of the Company, finding both asserted patents valid and one patent infringed by CareDx (the â€œInfringed Patentâ€). The jury awarded damages to the Company for lost profits and past royalties totaling $96.3 million. The Companyâ€™s motion for an injunction remains pending. Separately, in September 2024, an ex-parte re-examination petition was filed with the United States Patent and Trademark Office (â€œUSPTOâ€) challenging the validity of the Infringed Patent. In January 2020, the Company filed suit against ArcherDX, Inc. (â€œArcherDXâ€) in the United States District Court for the District of Delaware. In January 2021, the Company named an additional Archer DX entity, ArcherDx LLC, and Invitae as defendants. The Company alleged, among other things, that certain ArcherDX products, including the Personalized Cancer Monitoring (â€œPCMâ€) test, infringed three of the Companyâ€™s patents (the â€œArcherDX Caseâ€) and sought unspecified monetary damages and injunctive relief. Following a jury trial in May 2023 and a bench trial in June 2023, all three asserted patents were found to be valid and infringed by ArcherDX and Invitae, and the jury awarded damages totaling $19.35 million to the Company. In November 2023, the Court granted in part the Companyâ€™s motion for a permanent injunction against the PCM test, which the defendants have appealed. In February 2024, Invitae and ArcherDX filed a voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the District of New Jersey, resulting in an automatic bankruptcy stay in the case. In November 2024, the Court granted the partiesâ€™ stipulated request to vacate the stay.The Company is the subject of a lawsuit filed against it by Ravgen, Inc. (â€œRavgenâ€) in June 2020 in the United States District Court for the Western District of Texas, alleging infringement of two Ravgen patents and seeking monetary damages and injunctive relief. In January 2024, after trial, the jury returned a verdict of non-willful infringement by the Company and found damages of $57 million. The Company intends to appeal certain of the rulings. In addition, various parties, including the Company, have filed petitions challenging the validity of the asserted patents with the United States Patent and Trademark Office, all of which were instituted for review, and some of which were decided in favor of upholding the challenged claims. The petitions filed by the Company and certain others remain pending.In October 2020, the Company filed suit against Genosity Inc. (â€œGenosityâ€), in the United States District Court for the District of Delaware, alleging that various Genosity products infringe one of the Companyâ€™s patents and seeking unspecified monetary damages and injunctive relief. The case has been stayed pending the entry of a final judgment in the ArcherDX Case, in which the subject patent is also asserted. In February 2024, Genosity filed a voluntary Chapter 11 petiion in the U.S. Bankruptcy Court for the District of New Jersey.The Company is the subject of lawsuits filed against it by Invitae in the United States District Court of the District of Delaware alleging, in complaints filed in May and November of 2021, infringement of three patents and seeking monetary damages and injunctive relief. The parties have filed cross-motions for summary judgment, which motions are currently pending before the Court. In February 2024, subsequent to Invitaeâ€™s voluntary Chapter 11 petition described above, the Court granted Invitaeâ€™s request to continue the trial, which is now scheduled for September 2025.The Company filed suits against Inivata, Inc. and Inivata Ltd. (collectively â€œInivataâ€) in the United States District Court for the District of Delaware in January 2021 and December 2022, alleging that certain of Inivataâ€™s oncology products infringe certain of the Companyâ€™s patents and seeking unspecified monetary damages and injunctive relief. The two suits have been consolidated. In March 2024, the Court stayed the case in light of

the Companyâ€™s case against NeoGenomics Laboratories, Inc. (â€œNeoGenomicsâ€), which acquired Inivata in 2021, discussed below. In September 2024, the Court denied Inivataâ€™s motion to dismiss the Companyâ€™s complaint with respect to one patent.In July 2023, the Company filed suit against NeoGenomics in the United States District Court for the Middle District of North Carolina (the â€œDistrict Courtâ€), alleging infringement of two Natera patents (the â€œâ€™035 Patentâ€ and the â€œâ€™454 Patentâ€) by NeoGenomicsâ€™ commercialization of the RaDaR test and seeking monetary damages and injunctive relief. In December 2023, the Court denied NeoGenomicsâ€™ motion to dismiss the complaint, and granted the Companyâ€™s motion for preliminary injunction. The injunction went into effect as of January 12, 2024 and was affirmed on appeal in July 2024 by the Federal Circuit Court of Appeals. NeoGenomics filed a petition with the USPTO to review the validity of the â€™454 Patent, which was denied in June 2024. NeoGenomics also filed a petition with the USPTO to review the validity of the â€˜035 Patent, which proceeding was terminated in October 2024. Pursuant to the terms of a partial settlement of the case, the District Court entered a permanent injunction against NeoGenomics, and it has withdrawn its RaDaR test from the market. The case remains pending with respect to an updated version of the RaDaR test and the â€˜454 Patent. Trial is currently scheduled for October 2025.Other Litigation Matters.CareDx filed suit against the Company in April 2019 in the United States District Court for the District of Delaware, alleging false advertising, and related claims based on statements describing studies that concern the Companyâ€™s technology and CareDxâ€™s technology, seeking unspecified damages and injunctive relief. The Company filed a counterclaim against CareDx in the United States District Court for the District of Delaware, alleging false advertising, unfair competition and deceptive trade practices and seeking unspecified damages and injunctive relief. In March 2022, after trial, the jury returned a verdict that the Company was liable to CareDx and found damages of $44.9 million. The jury also returned a verdict against CareDx, finding that CareDx had engaged in false advertising. In July 2023, the Court granted in part the Companyâ€™s motion for judgment as a matter of law requesting that the Court set aside the portions of the jury verdict adverse to the Company, ruling that CareDx is not entitled to any damages. The jury verdict of false advertising by CareDx remains in place. Both parties are appealing; the matter has been remanded to the district court for consideration of certain post-trial motions.In May 2021, Guardant. Inc. (â€œGuardantâ€) filed suit against the Company in the United States District Court of the Northern District of California alleging false advertising and related claims and seeking unspecified damages and injunctive relief. Also in May 2021, the Company filed suit against Guardant in the Western District of Texas, alleging false advertising and related claims. The Company has voluntarily dismissed its Texas suit against Guardant and has asserted the claims from the Texas action as counterclaims in the California action, seeking unspecified damages and injunctive relief. In August 2021, Guardant moved to dismiss the Companyâ€™s counterclaims, which motion was denied in all material respects. Both parties filed cross-motions for summary judgment, which were granted in part and denied in part. Trial began on November 5, 2024.In November 2021, a purported class action lawsuit was filed against the Company in the United States District Court for the Northern District of California, by a patient alleging various causes of action relating to the Companyâ€™s patient billing and seeks, among other relief, class certification, injunctive relief, restitution and/or disgorgement, attorneysâ€™ fees, and costs. In May 2023, the Court granted the Companyâ€™s motion to dismiss the lawsuit, and the case was dismissed without prejudice. In July 2023, the plaintiff filed analogous claims in the Superior Court of California, County of San Mateo, and subsequently filed an amended claim with an additional plaintiff. Based on the additional plaintiff, the case was transferred back to the United States District Court for the Northern District of California. The parties subsequently agreed that claims brought by the original plaintiff be remanded back to the Superior Court of California, County of San Mateo, and that the action be stayed pending the outcome of the action in the United States District Court for the Northern District of California.In February 2022, two purported class action lawsuits were filed against the Company in the United States District Court for the Northern District of California. Each suit was filed by an individual patient alleging various causes of action related to the marketing of Panorama and seeking, among other relief, class certification, monetary damages, attorneysâ€™ fees, and costs. These matters have been consolidated. The Company filed a motion to dismiss the consolidated lawsuit, which resulted in the plaintiffs filing an amended complaint in April 2023.In March 2022, a purported class action lawsuit was filed against the Company and certain of its management in the Supreme Court of the State of New York, County of New York, asserting claims under Sections 11, 12, and 15 of the Securities Act of 1933. The complaint alleged, among other things, that the Company failed to disclose certain information regarding its Panorama test. The complaint sought, among other relief, monetary damages, attorneysâ€™ fees, and costs. This matter was dismissed and the claims raised in this matter have been included in the lawsuit discussed below.A purported class action lawsuit was filed against the Company and certain of its management in the United States District Court for the Western District of Texas, asserting claims under Sections 10(b) and 20(a) of the Securities Act of 1934 and Rule 10b-5 thereunder. The complaint, filed in April 2022 and amended in October 2022 (to include, among others, the claims raised in the lawsuit discussed in the preceding paragraph), alleges, among other things, that the management defendants made materially false or misleading statements, and/or omitted material information that was required to be disclosed, about certain of the Companyâ€™s products and operations. The complaint seeks, among other relief, monetary damages, attorneysâ€™ fees, and costs. The Company filed a motion to dismiss this lawsuit, which was granted in part and denied in part.In each of October 2023 and January 2024, shareholder derivative complaints were filed in the United States District Court for the Western District of Texas and the United States District Court for the District of Delaware, respectively, against the Company as nominal defendant and certain of the Companyâ€™s management. Each complaint alleges, among other things, that the management defendants made materially false or misleading statements, and/or omitted material information that was required to be disclosed, about certain of the Companyâ€™s products and operations. Each complaint seeks, among other relief, monetary damages, attorneysâ€™ fees, and costs.In October 2024, a purported class action lawsuit was filed against the Company in the United States District Court for the Northern District of California, by patients alleging various causes of action relating to the Companyâ€™s preimplantation genetic test for aneuploidies (â€œPGT-Aâ€). They request, among other relief, class certification, injunctive relief, restitution and/or disgorgement, attorneysâ€™ fees, and costs. Director and Officer Indemnifications As permitted under Delaware law, and as set forth in the Companyâ€™s Amended and Restated Certificate of Incorporation and its Amended and Restated Bylaws, the Company indemnifies its directors, executive officers, other officers, employees and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential future payments the Company could be required to make under this indemnification is unlimited; however, the Company has insurance policies that may limit its exposure and may enable it to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, the Company believes any obligations under this indemnification would not be material, other than standard retention amounts for securities related claims. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case the Company may incur substantial liabilities as a result of these indemnification obligations. Â Third-Party Payer Reimbursement Audits From time to time, the Company receives recoupment requests from third-party payers for alleged overpayments. The Company disagrees with the contentions of pending requests and/or has recorded an estimated reserve for the alleged overpayments if probable and estimable.â€‹Contractual CommitmentsThe following table sets forth the Companyâ€™s material contractual commitments as of September 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹PartyCommitmentsâ€‹Expiry Dateâ€‹(in thousands)â€‹â€‹Laboratory instruments supplier$ 2,243â€‹December 2024Material suppliersâ€‹ 34,413â€‹December 2026Application service providersâ€‹ 3,898â€‹March 2026Cloud platform service providerâ€‹ 34,180â€‹December 2028Leases (1)â€‹ 658â€‹December 2029Other material suppliersâ€‹ 25,654â€‹VariousTotal$ 101,046â€‹â€‹(1) Represents executed leases which have not commenced. Please refer to Note 7,Â Leases, for additional information. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//450/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation 9 Months Ended Sep. 30, 2024 Stock-Based Compensation Â Stock-Based Compensation 9. Stock-Based Compensation Stock-Based Compensation ExpenseThe following tables present the stock-based compensation expense recorded for equity classified awards on selected statements of operations line items for the three and nine months ended September 30, 2024 and 2023.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three months ended SeptemberÂ 30,Â â€‹â€‹â€‹â€‹2024â€‹â€‹2023â€‹â€‹(inÂ thousands)Cost of revenuesâ€‹$4,174â€‹$ 3,299Research and developmentâ€‹Â 22,549â€‹Â 18,784Selling, general and administrativeâ€‹Â 43,921â€‹Â 35,504Totalâ€‹$ 70,644â€‹$ 57,587â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

fundamental change, the holders of the Convertible Notes may require the Company to repurchase for cash all or a portion of their Convertible Notes at a price equal to 100% of the principal amount, plus any accrued and unpaid interest.The Company may not redeem the Convertible Notes prior to May 2024, and no sinking fund is provided for the Convertible Notes. The Company may redeem for cash all or any portion of the Convertible Notes, at the Companyâ€™s option, on or after May 2024, if the last reported sale price of the Companyâ€™s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on the trading day immediately preceding the date on which the Company provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Convertible Notes to be redeemed plus accrued and unpaid interest.The first and third circumstances noted above have been met as of September 30, 2024. On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its outstanding 2.25% Convertible Notes due 2027 and instructed Wilmington Trust, National Association, as trustee under the Convertible Notes Indenture (the â€œIndenture Agreementâ€) governing the Convertible Notes, to issue a redemption notice to registered holders of the Convertible Notes. The date fixed for the redemption of the Convertible Notes is October 11, 2024 (the â€œRedemption Dateâ€). The redemption price for the Convertible Notes is equal to 100% of the principal amount of the Convertible Notes to be redeemed plus accrued and unpaid interest to, but excluding, the Redemption Date. The Company elected physical settlement with the Companyâ€™s shares of common stock as the settlement method to apply to all conversions of the Convertible Notes. All terms and conditions associated with physical settlement are noted within the terms of the original Indenture Agreement. The conversion rate for holders who convert their Convertible Notes in connection with the Companyâ€™s election to redeem the Convertible Notes was increased by 0.4284 additional shares pursuant to the Indenture Agreement.Upon adoption of ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Heading-Contracts in Entityâ€™s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in Entityâ€™s Own Equity, the Company allocated all of the debt discount to long-term debt. The debt discount is amortized to interest expense using the effective interest method, computed to be 2.72%, over the life of the Convertible Notes or approximately its seven-year term. The outstanding Convertible Notes balances as of September 30, 2024 and December 31, 2023 are summarized in the following table:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023â€‹(in thousands)Convertible Notesâ€‹â€‹â€‹â€‹â€‹Outstanding Principal$ 287,500â€‹$ 287,500Unamortized debt discount and issuance costâ€‹ (3,564)â€‹â€‹ (4,555)Net carrying amountâ€‹ 283,936â€‹â€‹ 282,945Accrued interest to be settled in equityâ€‹ 2,695â€‹â€‹ â€”Reclassifications to short-term debt financingâ€‹ (82)â€‹â€‹ â€”Long-term debt financing$ 286,549â€‹$ 282,945â€‹The following tables present total interest expense recognized related to the Convertible Notes during the three and nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three months ended â€‹â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)â€‹Cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Contractual interest expense$ 1,618â€‹$ 1,617â€‹Non-cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Amortization of debt discount and debt issuance costâ€‹ 333â€‹â€‹ 324â€‹Total interest expense$ 1,951â€‹$ 1,941â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine months ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)â€‹Cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Contractual interest expense$ 4,852â€‹$ 4,851â€‹Non-cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Amortization of debt discount and debt issuance costâ€‹ 991â€‹â€‹ 966â€‹Total interest expense$ 5,843â€‹$ 5,817â€‹â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-term debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//470/tableOfContent + Details Name: us-gaap_LongTermDebtTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes 9 Months Ended Sep. 30, 2024 Income Taxes Â Income Taxes 11. Income TaxesDuring the three months ended September 30, 2024 and 2023, the Company recorded total income tax expense (benefit) of approximately $730,000 and $202,000, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded total income tax expense (benefit) of approximately $2,050,000 and $80,000, respectively. The income tax expense is primarily attributable to state income tax and foreign income tax. Due to the Companyâ€™s history of cumulative operating losses, the Company concluded that, after considering all the available objective evidence, it is not more likely than not that all of the Companyâ€™s net deferred tax assets will be realized. Accordingly, all of the Companyâ€™s deferred tax assets, which includes net operating loss carryforwards and tax credits related primarily to research and development, continue to be subjected to a full valuation allowance as of September 30, 2024. The Company will continue to maintain a full valuation allowance until there is sufficient evidence to support recoverability of its deferred tax assets.Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. As of September 30, 2024 and December 31, 2023, there were no accrued interest and penalties related to uncertain tax positions. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//740/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share 9 Months Ended Sep. 30, 2024 Net Loss per Share Â Net Loss per Share 12. Net Loss per ShareThe Convertible Notes are convertible by the holders as of September 30, 2024. Upon conversion, the Company has the option to pay cash, issue shares of common stock, or any combination thereof for the aggregate amount due upon conversion. If converted, the fair value of the shares issued to settle the Convertible Notes would exceed the Convertible Note principle by $597.8 million based on the closing price of the Companyâ€™s common stock as of September 30, 2024. Since the Company is in a net loss position in the periods presented, the shares which would be issued upon conversion of the Convertible Notes are excluded from the net loss per share calculation, as it would have an antidilutive effect. As such, the 7.4 million shares underlying the conversion option of the Convertible Notes have been excluded from the calculation of diluted earnings per share. On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its Convertible Notes. On the Redemption Date, $287.4 million of Convertible Notes was converted in exchange for 7.5 million shares of the Companyâ€™s common stock. The following table shows total outstanding potentially dilutive shares excluded from the computation of diluted loss per share as their effect would be anti-dilutive, as of September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Â Â Â Â Â Â Â 2024Â Â Â Â Â Â Â 2023â€‹Â (inÂ thousands)Options to purchase common stockâ€‹ 4,176Â 5,532Performance-based awards and restricted stock unitsâ€‹ 10,856â€‹ 9,440Employee stock purchase planâ€‹ 93â€‹ 188Convertible Notesâ€‹ 7,411â€‹ 7,411Totalâ€‹ 22,536Â 22,571â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for earnings per share. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3 + Details Name: us-gaap_EarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events 9 Months Ended Sep. 30, 2024 Subsequent Events Â Subsequent Events 13. Subsequent Eventsâ€‹On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its outstanding 2.25% Convertible Notes due 2027 and instructed Wilmington Trust, National Association, as trustee under the Convertible Notes Indenture (the â€œIndenture Agreementâ€) governing the Convertible Notes, to issue a redemption notice to registered holders of the Convertible Notes. The date fixed for the redemption of the Convertible Notes was October 11, 2024 (the â€œRedemption Dateâ€). On the Redemption Date, $287.4 million of Convertible Notes were converted for approximately 7.5 million shares of the Companyâ€™s common stock under the terms of the redemption notice. The remaining Convertible Notes not converted under the redemption notice were redeemed in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, the Company reclassified $0.1 million of Convertible Notes from long-term liabilities to short-term liabilities as of September 30, 2024.â€‹In November 2024, the Company entered into an agreement with a non-profit research institute and a clinical technology company whereby the Company obtained licensing rights and access to certain data. The Company is obligated to pay a total of $20.0 million, of which $7.0 million has been paid and the remaining $13.0 million will be paid between January 2025 and January 2031. Additionally, the Company may be obligated to pay up to $50.0 million in milestone payments if certain milestone thresholds and regulatory approvals are achieved.â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_SubsequentEventsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//855/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Net Income (Loss) $ (31,592) $ (109,030) $ (136,655) $ (356,770) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB

-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 shares Mike Brophy Â Trading Arrangements, by Individual Â Material Terms of Trading Arrangement OnÂ June 14, 2024,Â Mike Brophy,Â our chief financial officer, adopted a trading arrangement for the sale of shares of our common stock (a â€œRule 10b5-1Â Trading Planâ€) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Brophyâ€™s Rule 10b5-1 Trading Plan provides for the potential sale of up to 109,293 shares of our common stock pursuant to the terms of the plan between February 2, 2025 and February 1, 2026. Name Mike Brophy Title chief financial officer Rule 10b5-1 Arrangement Adopted true Adoption Date June 14, 2024 Aggregate Available 109,293 Daniel Rabinowitz Â Trading Arrangements, by Individual Â Material Terms of Trading Arrangement OnÂ June 14, 2024,Â Daniel Rabinowitz,Â our chief legal officer, adopted a trading arrangement for the sale of shares of our common stock (a â€œRule 10b5-1Â Trading Planâ€) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Rabinowitzâ€™s Rule 10b5-1 Trading Plan provides for the sale of 26,131 shares of our common stock pursuant to the terms of the plan between December 15, 2024 and August 15, 2026. Name Daniel Rabinowitz Title chief legal officer Rule 10b5-1 Arrangement Adopted true Adoption Date June 14, 2024 Aggregate Available 26,131 Roy Baynes Â Trading Arrangements, by Individual Â Material Terms of Trading Arrangement OnÂ August 12, 2024,Â Roy Baynes,Â a member of our Board of Directors, adopted a trading arrangement for the sale of shares of our common stock (a â€œRule 10b5-1Â Trading Planâ€) that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Baynes Rule 10b5-1 Trading Plan provides for the exercise of 37,230 stock options and sale of underlying shares of our common stock pursuant to the terms of the plan between November 11, 2024 and December 31, 2025. Name Roy Baynes Title member of our Board of Directors Rule 10b5-1 Arrangement Adopted true Adoption Date August 12, 2024 Aggregate Available 37,230 X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_MtrlTermsOfTrdArrTextBlock Namespace Prefix: ecd_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph B + Details Name: ecd_TrdArrAdoptionDate Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndName Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TrdArrIndTitle Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph D + Details Name: ecd_TrdArrSecuritiesAggAvailAmt Namespace Prefix: ecd_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: ecd_IndividualAxis=ntra_MikeBrophyMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=ntra_DanielRabinowitzMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: ecd_IndividualAxis=ntra_RoyBaynesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Policies) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Basis of Presentation Basis of PresentationThe accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (â€œU.S.Â GAAPâ€) for interim financial information. The unaudited interim condensed consolidated financial information includes only adjustments of a normal recurring nature necessary for a fair presentation of the Companyâ€™s results of operations, financial position, changes in stockholdersâ€™ equity, and cash flows. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results for the full year or the results for any future periods. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements at that date. These financial statements should be read in conjunction with the audited financial statements, and related notes for the year ended December 31, 2023 included in the Companyâ€™s Annual Report on Form 10-K filed with the SEC on February 29, 2024.Some items in the prior period financial statements were reclassified to conform to the current presentation. Liquidity Matters Liquidity MattersThe Company has incurred net losses since its inception and anticipates net losses for the near future. The Company had a net loss of $136.7 million for the nine months ended September 30, 2024 and an accumulated deficit of $2.5 billion as of September 30, 2024. As of September 30, 2024, the Company had $892.8 million in cash, cash equivalents, and restricted cash, $29.5 million in marketable securities, an $80.4 million outstanding balance on its Credit Line (as defined in Note 10, Debt) including accrued interest and $287.5 million of outstanding principal on its 2.25% Convertible Senior Notes (the â€œConvertible Notesâ€). The Company is required to maintain a minimum of at least $150.0 million in its UBS accounts as collateral for its Credit Line. As of September 30, 2024, the Company had $20.0 million remaining and available on its Credit Line.While the Company has introduced multiple products that are generating revenues, these revenues have not been sufficient to fund all operations and business plans. Accordingly, the Company has funded the portion of operating costs that exceeds revenues through a combination of equity issuances, debt issuances, and other financings.The Company continues to invest in the development and commercialization of its existing and future products and, consequently, it will need to generate additional revenues to achieve future profitability and may need to raise additional equity or debt financing. If the Company raises additional funds by issuing equity securities, its stockholders will experience dilution. Additional debt financing, if available, may involve covenants restricting its operations or its ability to incur additional debt. Any additional debt financing or additional equity that the Company raises may contain terms that are not favorable to it or its stockholders and requires significant debt service payments, which diverts resources from other activities. Additional financing may not be available when necessary, or in amounts or on terms acceptable to the Company. If the Company is unable to obtain additional financing, it may be required to delay the development and commercialization of its products and significantly scale back its business and operations.On July 19, 2024, the Company announced its decision to redeem all of its outstanding 2.25% Convertible Senior Notes due 2027.Â The redemption was completed on October 11, 2024 (the â€œRedemption Dateâ€). The redemption price for the Convertible Notes equaled 100% of the principal amount of the Convertible Notes to be redeemed plus accrued and unpaid interest to, but excluding, the Redemption Date. The Company elected physical settlement with shares of its common stock as the settlement method to apply to all conversions of the Convertible Notes. On the Redemption Date, $287.4 million of Convertible Notes were redeemed for approximately 7.5 million shares of the Companyâ€™s common stock under the terms of the redemption notice. The remaining Convertible Notes not redeemed under the redemption notice were converted in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, the Companyâ€™s redemption of its Convertible Notes did not have a material effect on its liquidity.In September 2023, the Company completed an underwritten equity offering and sold 4,550,000 shares of its common stock at a price of $55 per share to the public. Before estimated offering expenses of $0.4 million, the Company received proceeds of approximately $235.8 million net of the underwriting discount. On September 10, 2021, the Company entered into an agreement with a third party for an asset acquisition where the acquired asset was in-process research and development primarily in exchange for an equity consideration payment. In addition, pursuant to the agreement, certain employees of the third party became employees of the Company. The third party was a biotechnology company focused on oncology. The total upfront acquisition consideration amounted to $35.6 million, composed of the issuance of 276,346 shares of the Company's common stock with a fair value of $30.9 million, approximately $3.9 million of cash consideration, assumed net liabilities of $0.2 million, as well as $0.6 million of acquisition related legal and accounting costs directly attributable to the acquisition of the asset. The Company accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified in-process research and development asset (â€œIPR&Dâ€), thus satisfying the requirements of the screen test in Accounting Standards Update (â€œASUâ€) 2017-01 Business Combinations (Topic 805): Clarifying the Definition of Business. The estimated fair value of the acquired workforce was not significant. The Company concluded the acquired IPR&D has no alternative-future use and accordingly expensed approximately $35.6 million, on the day the transaction closed as research and development expense, which was reflected in its consolidated statement of operations.Further, additional consideration aggregating up to approximately $35.0Â million was estimated to be paid via issuance of an estimatedÂ 269,547Â additional shares of the Companyâ€™s common stock, consistent with the registration statement filed with the SEC on September 10, 2021, upon achievement of defined milestones relating to product development, commercial launch and continued employment of certain selling shareholders, each of which was revalued at each reporting date and amount of compensation expense was adjusted accordingly and reported in research and development expenses. In November 2022, the terms of the payment for any remaining consideration were modified, resulting in $10.0Â million of consideration paid in December 2022 and $15.0Â million of consideration paid in March 2023, with such consideration primarily consisting of the Companyâ€™s common stock.Based on the Companyâ€™s current business plan, the Company believes that its existing cash and marketable securities will be sufficient to meet its anticipated cash requirements for at least 12 months after November 12, 2024. Principles of Consolidation Principles of Consolidationâ€‹The accompanying condensed consolidated financial statements include all the accounts of the Company and its subsidiaries. The Company established a subsidiary that operates in the state of Texas to support the Companyâ€™s laboratory and operational functions. The Company also established a subsidiary that operates in Canada following the acquisition of the IPR&D asset. All intercompany balances and transactions have been eliminated. Use of Estimates Use of EstimatesThe preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, determining the incremental borrowing rate to calculate operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment including impairment estimates, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers, insurance payors, and patients. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements.â€‹ Investments InvestmentsInvestments consist primarily of debt securities such as U.S. Treasuries, U.S. agency and municipal bonds. Management determines the appropriate classification of securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company generally classifies its entire investment portfolio as available-for-sale. The Company views its available-for-sale portfolio as available for use in current operations. Accordingly, the Company classifies all investments as short-term, irrespective of maturity date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss), which is a separate component of stockholdersâ€™ equity.The Company classifies its investments as Level 1 or 2 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. The Company holds Level 2 securities, which are initially valued at the transaction price and subsequently valued by a third-party service provider using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company performs certain procedures to corroborate the fair value of these holdings. Â â€‹Available-for-sale debt securities. The amended guidance from ASU 2016-13, Financial Instruments â€“ Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, requires the measurement of expected credit lossesÂ for available-for-saleÂ debt securitiesÂ held at the reporting date over the remaining life based on historical experience, current conditions, and reasonable and supportable forecasts. The Company evaluated its investment portfolio under the available-for-sale debt securities impairment model guidance and determined the Companyâ€™s investment portfolio is composed of low-risk, investment grade securities and thus has not recorded an expected credit loss for its investment portfolio. Further, gross unrealized losses on available for sale securities were not material at September 30, 2024. Accounts Receivable Accounts ReceivableTrade accounts receivable and other receivables. The allowance for doubtful accounts for trade accounts receivable is based on the Companyâ€™s assessment of the collectability of accounts related to its clinics and laboratory partner customers. The Company regularly reviews the allowance by considering factors such as historical experience, the age of the accounts receivable balances, and current economic conditions that may affect a customerâ€™s ability to pay. See Note 6, Balance Sheet Components, for a roll-forward of the allowance for doubtful accounts related to trade accounts receivable for three months and nine months ended September 30, 2024 and 2023. The Company recognizes revenue under Accounting Standards Codification (â€œASCâ€) Topic 606, Revenue from Contracts with Customers (â€œASC 606â€) and applies a constraint to the estimated variable consideration such that it is not probable that a significant reversal will occur. When

assessing the total consideration expected to be received from insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds. After applying the ASC 606 constraint, the Company assessed for credit losses and allowance for doubtful accounts and determined an incremental credit loss was not needed given the quality of the insurance payors from whom such receivables are expected to be collectible and the relatively short duration over which the majority of receivables are collected. Accordingly, the Company currently does not have an incremental credit loss reserve nor allowance for doubtful accounts against accounts receivable for insurance and patient payors due to the average selling price calculations, which already incorporate these risks as net receivables are recorded. Inventory Inventory â€‹Inventory is recorded at the lower of cost or net realizable value, determined on a first-in, first-out basis. Inventory consists entirely of supplies, which the Company consumes when providing its test reports, and therefore, the Company does not maintain any finished goods inventory. The Company enters into inventory purchases commitments so that it can meet future delivery schedules based on forecasted demand for its tests.â€‹The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. A write down of specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period is first recognized by using a number of factors including product expiration dates and scrapped inventory. Any write-down of inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on our consolidated statements of operations. The Company makes assumptions about future demand, market conditions and the release of new products that may supersede older products; however, if actual market conditions are less favorable than anticipated, additional inventory write-downs may be required. Other Assets Other Assetsâ€‹In January 2024, the Company acquired from Invitae Corp. (â€œInvitaeâ€) certain assets relating to Invitaeâ€™s non-invasive prenatal screening and carrier screening business. The transaction price of $10.5 million consisted of $10.0 million in upfront payment costs and approximately $0.5 million of other transaction costs which were capitalized as intangible assets over an estimated useful life of ten years. An additional payment of up to $42.5 million may be made should the Company achieve certain customer volume retention targets and based on certain legal outcomes. Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)Comprehensive loss and its components encompass all changes in equity other than those with stockholders, and include net loss, unrealized gains and losses on available-for-sale marketable securities and foreign currency translation adjustments.
â€‹â€‹â€‹

S99-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-03(f)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 12 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 320 -Name Accounting Standards Codification -Section S99 -Paragraph 19 -Subparagraph (2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19 + Details Name: us-gaap_InvestmentPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4Reference 3: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4 + Details Name: us-gaap_RevenueRecognitionPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (b) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11BReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (d) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15 + Details Name: us-gaap_TradeAndOtherAccountsReceivablePolicy Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 11 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 12 -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8 + Details Name: us-gaap_UseOfEstimates Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Tables) 9 Months Ended Sep. 30, 2024 Summary of Significant Accounting Policies Â Schedule of Accumulated Other Comprehensive Income (Loss) â€‹Three months ended â€‹Nine months ended â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹2024â€‹2023â€‹2024â€‹2023â€‹(inÂ thousands)Beginning balance$ (1,358)â€‹$ (9,203)â€‹$ (3,085)â€‹$ (16,362)Net unrealized gain on available-for-sale securities, net of tax and foreign currency translation adjustmentâ€‹ 593â€‹â€‹ 3,807â€‹â€‹ 2,320â€‹â€‹ 10,966Ending balance$ (765)â€‹$ (5,396)â€‹$ (765)â€‹$ (5,396) X - ReferencesNo definition available. + Details Name: us-gaap_AccountingPoliciesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition (Tables) 9 Months Ended Sep. 30, 2024 Revenue Recognition Â Schedule of disaggregation of revenues by payer types â€‹Three months ended â€‹Nine months ended â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹2024â€‹2023â€‹â€‹(in thousands)Insurance carriersâ€‹$ 405,208â€‹$ 239,780â€‹$ 1,130,364â€‹$ 676,680Laboratory and other partnersâ€‹â€‹ 27,622â€‹â€‹ 21,731â€‹â€‹ 70,152â€‹â€‹ 71,985Patientsâ€‹â€‹ 6,928â€‹â€‹ 6,795â€‹â€‹ 20,334â€‹â€‹ 22,801Total revenuesâ€‹$ 439,758â€‹$ 268,306â€‹$ 1,220,850â€‹$ 771,466 Schedule of total revenue by geographic area â€‹Three months ended â€‹Nine months ended Â â€‹â€‹SeptemberÂ 30,Â â€‹SeptemberÂ 30,Â Â â€‹Â Â Â Â 2024Â Â Â Â 2023Â Â Â Â 2024â€‹2023Â â€‹â€‹(in thousands)â€‹United StatesÂ $ 426,274â€‹$ 259,870â€‹$ 1,190,559â€‹$ 746,420â€‹Americas, excluding U.S.Â â€‹ 2,002â€‹â€‹ 1,288â€‹â€‹ 5,084â€‹â€‹ 3,652â€‹Europe, Middle East, India, AfricaÂ â€‹ 7,722â€‹â€‹ 5,255â€‹â€‹ 18,339â€‹â€‹ 16,071â€‹Asia Pacific and OtherÂ â€‹ 3,760â€‹â€‹ 1,893â€‹â€‹ 6,868â€‹â€‹ 5,323â€‹Total revenuesÂ $ 439,758â€‹$ 268,306â€‹$ 1,220,850â€‹$ 771,466â€‹ Schedule of beginning and ending balances of accounts receivable and deferred revenues â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Balance atâ€‹â€‹SeptemberÂ 30,Â â€‹December 31,â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)Assets:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Accounts receivable, netâ€‹$ 306,876â€‹$ 278,289Liabilities:â€‹â€‹â€‹â€‹â€‹â€‹Deferred revenue, current portionâ€‹$ 17,886â€‹$ 16,612Deferred revenue, long-term portion (1)â€‹â€‹ 16,916â€‹â€‹ 19,128Total deferred revenuesâ€‹$ 34,802â€‹$ 35,740 Schedule of changes in the balance of deferred revenues â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Balance atâ€‹â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹â€‹2023â€‹(in thousands)Beginning balanceâ€‹$ 35,740â€‹$ 30,778Increase in deferred revenuesâ€‹â€‹ 23,968â€‹â€‹ 24,553Revenue recognized during the period that was included in deferred revenues at the beginning of the periodâ€‹â€‹ (12,102)â€‹â€‹ (9,610)Revenue recognized from performance obligations satisfied within the same periodâ€‹â€‹ (12,804)â€‹â€‹ (9,676)Ending balanceâ€‹$ 34,802â€‹$ 36,045 X - DefinitionTabular disclosure of disaggregation of revenue by customer. + ReferencesNo definition available. + Details Name: ntra_DisaggregationOfRevenueByCustomerTableTextBlock Namespace Prefix: ntra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of changes in the balances of deferred revenues. + ReferencesNo definition available. + Details Name: ntra_ScheduleOfChangesInBalancesOfDeferredRevenuesTableTextBlock Namespace Prefix: ntra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Measurements Â Summary of financial assets and liabilities measured on recurring basis â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹

DefinitionTabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments. + ReferencesNo definition available. + Details Name: us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components (Tables) 9 Months Ended Sep. 30, 2024 Balance Sheet Components Â Schedule of allowances for credit losses related to trade accounts receivable and other receivables â€‹The following is a roll-forward of the allowances for doubtful accounts related to trade accounts receivable for the three and nine months ended September 30, 2024 and 2023:â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three Months Endedâ€‹Â Â Â Â SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹â€‹(in thousands)Beginning balanceâ€‹$7,021â€‹$5,580(Reversal of) Provision for doubtful accountsâ€‹â€‹ (536)â€‹â€‹454Write-offsâ€‹â€‹ (233)â€‹â€‹ â€”Totalâ€‹$6,252 â€‹$6,034 â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine Months Ended â€‹Â Â Â Â SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹â€‹(in thousands)Beginning balanceâ€‹$6,481â€‹$3,830Provision for doubtful accountsâ€‹â€‹ 208â€‹â€‹2,204Write-offsâ€‹â€‹ (437)â€‹â€‹ â€”Totalâ€‹$6,252 â€‹$6,034 Schedule of property and equipment â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹UsefulÂ Life2024Â Â Â Â 2023â€‹â€‹(inÂ thousands)Machinery and equipment3-5Â years$ 104,443â€‹$ 85,626Computer equipment3Â yearsâ€‹ 3,040â€‹Â 1,850Purchased and capitalized software held for internal use3 yearsâ€‹ 11,104â€‹â€‹ 11,636Leasehold improvementsLesser of useful life or lease termâ€‹ 48,080â€‹Â 38,999Construction-in-processâ€‹â€‹ 46,631â€‹Â 29,392â€‹â€‹â€‹ 213,298â€‹Â 167,503Less: Accumulated depreciation and amortizationâ€‹â€‹ (71,128)â€‹Â (56,293)Total Property and Equipment, netâ€‹$ 142,170â€‹$ 111,210 Schedule of other accrued liabilities â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â Â Â Â Â DecemberÂ 31,Â â€‹2024Â Â Â Â 2023â€‹(in thousands)Reserves for refunds to insurance carriers$ 15,778â€‹$ 23,245Accrued charges for third-party testingâ€‹ 9,924â€‹â€‹ 14,823Testing and laboratory materials from suppliersâ€‹ 9,823â€‹â€‹ 11,229Marketing and corporate affairsâ€‹ 15,526â€‹â€‹ 10,085Legal, audit and consulting feesâ€‹ 36,535â€‹Â 43,897Accrued shipping chargesâ€‹ 2,180â€‹â€‹ 3,646Sales and income tax payableâ€‹ 5,061â€‹â€‹ 3,731Accrued third-party service feesâ€‹ 8,853â€‹â€‹ 7,111Clinical trials and studiesÂ 7,744â€‹â€‹ 12,126Operating lease liabilities, current portionâ€‹ 9,762â€‹â€‹ 11,621Property and equipment purchasesâ€‹ 3,397â€‹â€‹ 4,316Other accrued interestâ€‹ 1â€‹â€‹ 1,078Other accrued expensesÂ 1,592â€‹â€‹ 2,497Total other accrued liabilities$ 126,176â€‹$ 149,405 Summary of reserve balance and activities for refunds to insurance carriers â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹2024Â Â Â Â 2023â€‹(inÂ thousands)Beginning balance$ 23,245â€‹$ 18,948Additional reservesÂ 1,506â€‹Â 7,348Refunds to carriersÂ (3,095)â€‹â€‹ (1,236)Reserves released to revenueâ€‹ (5,878)â€‹â€‹ (8,851)Ending balance$ 15,778â€‹$ 16,209â€‹â€‹â€‹â€‹â€‹â€‹ X - DefinitionSummary of reserve balance and activities for refunds to insurance carriers. + ReferencesNo definition available. + Details Name: ntra_SummaryOfReserveBalanceAndActivitiesForRefundsToInsuranceCarriersTableTextBlock Namespace Prefix: ntra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Tables) 9 Months Ended Sep. 30, 2024 Leases. Â Schedule of lease liabilities â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹DecemberÂ 31,Â â€‹â€‹2024â€‹2023â€‹â€‹â€‹(in thousands)Operating lease liabilities, current portion included in other accrued liabilitiesâ€‹$ 9,762â€‹$ 11,621Operating lease liabilities, long-term portionâ€‹ 98,953â€‹â€‹ 67,025Total operating lease liabilitiesâ€‹$ 108,715â€‹$ 78,646 Schedule of annual minimum lease payments â€‹â€‹â€‹â€‹â€‹â€‹â€‹Â Â Â Â OperatingÂ Leasesâ€‹â€‹(inÂ thousands)As of SeptemberÂ 30,Â 2024â€‹â€‹â€‹2024 (remaining 3 months)â€‹$ 4,3152025â€‹â€‹ 17,3912026â€‹â€‹ 17,6612027â€‹â€‹ 16,9972028â€‹â€‹ 17,3222029 and thereafterâ€‹â€‹ 70,693â€‹â€‹â€‹ 144,389Less: imputed interestâ€‹â€‹ (35,674)Operating lease liabilitiesâ€‹$ 108,715â€‹ X - DefinitionTabular disclosure of balance sheet leases. + ReferencesNo definition available. + Details Name: ntra_LeaseBalanceSheetDisclosureTableTextBlock Namespace Prefix: ntra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Tables) 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Â Schedule of material contractual commitments Contractual CommitmentsThe following table sets forth the Companyâ€™s material contractual commitments as of September 30, 2024:â€‹â€‹â€‹â€‹â€‹â€‹PartyCommitmentsâ€‹Expiry Dateâ€‹(in thousands)â€‹â€‹Laboratory instruments supplier$ 2,243â€‹December 2024Material suppliersâ€‹ 34,413â€‹December 2026Application service providersâ€‹ 3,898â€‹March 2026Cloud platform service providerâ€‹ 34,180â€‹December 2028Leases (1)â€‹ 658â€‹December 2029Other material suppliersâ€‹ 25,654â€‹VariousTotal$ 101,046â€‹â€‹(1) Represents executed leases which have not commenced. Please refer to Note 7,Â Leases, for additional information. X - DefinitionTabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (S-X 210.12-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3 + Details Name: srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock Namespace Prefix: srt_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation (Tables) 9 Months Ended Sep. 30, 2024 Stock-Based Compensation Â Summary of stock-based compensation expenses The following tables present the stock-based compensation expense recorded for equity classified awards on selected statements of operations line items for the three and nine months ended September 30, 2024 and 2023.â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three months ended SeptemberÂ 30,Â â€‹â€‹2024â€‹â€‹2023â€‹â€‹(inÂ thousands)Cost of revenuesâ€‹$4,174â€‹$ 3,299Research and developmentâ€‹Â 22,549â€‹Â 18,784Selling, general and administrativeâ€‹Â 43,921â€‹Â 35,504Totalâ€‹$ 70,644â€‹$ 57,587â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine months ended SeptemberÂ 30,Â Â Â Â Â Â â€‹2024Â Â Â Â â€‹2023Â â€‹Â (inÂ thousands)Â â€‹Cost of revenuesâ€‹$11,997â€‹$ 8,692â€‹Research and developmentâ€‹Â 65,155â€‹Â 48,761â€‹Selling, general and administrativeâ€‹Â 125,350â€‹Â 84,923â€‹Totalâ€‹$ 202,502â€‹$ 142,376â€‹ Summary of stock option activity â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-â€‹NumberÂ ofâ€‹Averageâ€‹Sharesâ€‹Exerciseâ€‹Outstandingâ€‹Priceâ€‹(inÂ thousands,Â exceptÂ forÂ per share data)DecemberÂ 31,Â 2023 5,501â€‹$ 23.65Options exercised (1,325)â€‹$ 7.80SeptemberÂ 30,Â 2024 4,176â€‹$ 28.67 RSU and performance-based awards â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Weighted-â€‹â€‹â€‹â€‹â€‹â€‹â€‹Averageâ€‹â€‹â€‹â€‹â€‹â€‹Grant Dateâ€‹â€‹Sharesâ€‹Fair Valueâ€‹â€‹(inÂ thousands,Â exceptÂ forÂ per share data)Balance at DecemberÂ 31,Â 2023â€‹ 9,248â€‹$ 49.50Grantedâ€‹ 5,043â€‹$ 70.99Vestedâ€‹ (2,968)â€‹$ 55.27Cancelled/forfeitedâ€‹ (467)â€‹$ 57.96Balance at SeptemberÂ 30,Â 2024â€‹ 10,856â€‹$ 57.91 X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Subparagraph (e)(1) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Tables) 9 Months Ended Sep. 30, 2024 Debt Â Schedule of outstanding Convertible Notes â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â 2024â€‹DecemberÂ 31,Â 2023â€‹(in thousands)Convertible Notesâ€‹â€‹â€‹â€‹â€‹â€‹Outstanding Principal$ 287,500â€‹$ 287,500Unamortized debt discount and issuance costâ€‹ (3,564)â€‹â€‹ (4,555)Net carrying amountâ€‹ 283,936â€‹â€‹ 282,945Accrued interest to be settled in equityâ€‹ 2,695â€‹â€‹ â€”Reclassifications to short-term debt financingâ€‹ (82)â€‹â€‹ â€”Long-term debt financing$ 286,549â€‹$ 282,945 Summary of interest expense â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Three months ended â€‹â€‹SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)â€‹Cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Contractual interest expense$ 1,618â€‹$ 1,617â€‹Non-cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Amortization of debt discount and debt issuance costâ€‹ 333â€‹â€‹ 324â€‹Total interest expense$ 1,951â€‹$ 1,941â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹Nine months ended SeptemberÂ 30,Â â€‹â€‹2024â€‹2023â€‹â€‹(in thousands)â€‹Cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Contractual interest expense$ 4,852â€‹$ 4,851â€‹Non-cash interest expenseâ€‹â€‹â€‹â€‹â€‹â€‹Amortization of debt discount and debt issuance costâ€‹ 991â€‹â€‹ 966â€‹Total interest expense$ 5,843â€‹$ 5,817â€‹â€‹ X - DefinitionTabular disclosure of interest expense. + ReferencesNo definition available. + Details Name: ntra_ScheduleOfInterestExpenseTableTextBlock Namespace Prefix: ntra_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount. + ReferencesNo definition available. + Details Name: us-gaap_ConvertibleDebtTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share (Tables) 9 Months Ended Sep. 30, 2024 Net Loss per Share Â Total outstanding potentially dilutive shares â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹â€‹SeptemberÂ 30,Â â€‹Â Â Â Â Â 2024Â Â Â Â 2023â€‹Â (inÂ thousands)Options to purchase common stockâ€‹ 4,176Â 5,532Performance-based awards and restricted stock unitsâ€‹ 10,856â€‹ 9,440Employee stock purchase planâ€‹ 93â€‹ 188Convertible Notesâ€‹ 7,411â€‹ 7,411Totalâ€‹ 22,536Â 22,571â€‹ X - ReferencesNo definition available. + Details Name: us-gaap_EarningsPerShareAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.3 Description of Business (Details) 9 Months Ended Sep. 30, 2024 segment Description of Business Â Number of operating segments 1 X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies (Details) 1 Months Ended 3 Months Ended 9 Months Ended Oct. 11, 2024 USD ($) Jul. 19, 2024 USD ($) Apr. 30, 2020 USD ($) Sep. 30, 2023 USD ($) $ / shares shares Nov. 30, 2022 USD ($) Apr. 30, 2020 USD ($) Sep. 30, 2024 USD ($) shares Sep. 30, 2023 USD ($) $ / shares shares Sep. 30, 2024 USD ($) shares Sep. 30, 2023 USD ($) $ / shares shares Dec. 31, 2023 USD ($) shares Dec. 31, 2022 USD ($) Policies Â Â Â Â Â Â Â Â Â Â Â Â Â Net Income (Loss) Â Â Â Â Â Â $ (31,592,000) $ (109,030,000) $ (136,655,000) $ (356,770,000) Â Â Accumulated deficit Â Â Â Â Â Â Â 2,514,091,000 Â 2,514,091,000 Â $ 2,377,436,000 Â Cash, cash equivalents and restricted cash Â Â Â $ 668,710,000 Â Â 892,844,000 $ 668,710,000 892,844,000 $ 668,710,000 642,095,000 $ 466,091,000 Marketable securities Â Â Â Â Â Â 29,490,000 Â 29,490,000

Â 236,882,000 Â Short-term Credit Line, outstanding balance Â Â Â Â Â Â 80,469,000 Â 80,469,000 Â $ 80,402,000 Â Collateral amount Â Â Â Â Â Â 150,000,000.0 Â 150,000,000.0 Â Â Â Remaining borrowing capacity Â Â Â Â Â Â $ 20,000,000.0 Â $ 20,000,000.0 Â Â Â Common stock, shares issued | shares Â Â Â Â Â Â 124,137,000 Â 124,137,000 Â 119,581,000 Â Payment of offering expenses Â Â Â 400,000 Â Â Â Â Â Â Â Â Proceeds from issuance of common stock Â Â Â $ 235,800,000 Â Â Â Â Â Â Â Â Convertible Notes Â Â Â Â Â Â Â Â Â Â Â Â Â Â Policies Â Â Â Â Â Â Â Â Â Â Â Â Â Â Outstanding principal balance Â $ 287,500,000 $ 287,500,000 Â Â $ 287,500,000 $ 287,500,000 Â $ 287,500,000 Â Â Â Per annum interest rate (as a percent) Â 2.25% Â Â Â 2.25% Â Â 2.25% Â Â Â Percentage of principal amount converted Â 100.00% 100.00% Â Â Â Â Â Â Â Â Convertible to shares of common stock Â Â 7,411,704 Â Â Â Â Â Â Â Â Â Convertible Notes | Subsequent event Â Â Â Â Â Â Â Â Â Â Â Policies Â Â Â Â Â Â Â Â Â Â Â Convertible Notes Payable $ 287,400,000 Â Â Â Â Â Â Â Â Â Â Â Convertible to shares of common stock 7,500,000 Â Â Â Â Â Â Â Â Â Â Â Â Proceeds from notes payable $ 100,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Line Of Credit-UBS Â Â Â Â Â Â Â Â Â Â Â Â Â Policies Â Â Â Â Â Â Â Â Â Â Â Short-term Credit Line, outstanding balance Â Â Â Â Â Â 80,400,000 Â $ 80,400,000 Â Â Â Borrowings under credit facility Â Â Â Â $ 30,000,000.0 Â Â Â Â Â Â Â Collateral amount Â Â Â Â Â Â 150,000,000.0 Â 150,000,000.0 Â Â Â Remaining borrowing capacity Â Â Â Â Â Â $ 20,000,000.0 Â $ 20,000,000.0 Â Â Â Interest rate (as a percent) Â Â Â Â Â Â 5.66% Â 5.66% Â Â Â Equity offering Â Â Â Â Â Â Â Â Â Â Â Policies Â Â Â Â Â Â Â Â Â Â Â Â Â Common stock, shares issued | shares Â Â Â 4,550,000 Â Â Â 4,550,000 Â 4,550,000 Â Â Stock issued (in dollars per share) | $ / shares Â Â Â $ 55 Â Â Â $ 55 Â $ 55 Â Â X - DefinitionThe percentage of principal amount converted. + ReferencesNo definition available. + Details Name: ntra_DebtInstrumentConvertiblePercentageOfPrincipalAmount Namespace Prefix: ntra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ConvertibleNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of assets pledged to secure a debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3 + Details Name: us-gaap_DebtInstrumentCollateralAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60BReference 32: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 34: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1AReference 37: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards

Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1BReference 38: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred directly with the issuance of an equity security. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfStockIssuanceCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from the additional capital contribution to the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1 + Details Name: us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPer share or per unit amount of equity securities issued. + ReferencesNo definition available. + Details Name: us-gaap_SharesIssuedPricePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionReflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ShortTermBorrowings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ntra_LineOfCreditUbsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Other Assets (Details) - USD ($) $ in Millions 1 Months Ended Sep. 10, 2021 Jan. 31, 2024 Mar. 31, 2023 Dec. 31, 2022 In-process research and development acquisition Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Asset acquisition, consideration $ 35.6 Â $ 15.0 $ 10.0 Issuance of common stock 276,346 Â Â Â Value of common stock issued $ 30.9 Â Â Â Cash consideration 3.9 Â Â Â Net liabilities assumed 0.2 Â Â Â Acquisition related costs 0.6 Â Â Â Value of additional shares potentially issuable $ 35.0 Â Â Â Number of additional shares potentially issuable 269,547 Â Â Â Assets acquired from Invitae Â Â Â Â Asset Acquisition [Line Items] Â Â Â Â Asset acquisition, consideration Â $ 10.5 Â Â Cash consideration Â 10.0 Â Â Potential milestone payments Â 42.5 Â Â Acquisition related costs Â $ 0.5 Â Â Estimated useful life (in years) Â 10 years Â Â X - DefinitionNumber of additional shares potentially issuable as consideration upon achievement of milestones in asset acquisition. + ReferencesNo definition available. + Details Name: ntra_AssetAcquisitionConsiderationTransferredAdditionalSharesIssuedAndIssuableUponAchievementOfMilestone Namespace Prefix: ntra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities incurred by the acquirer as part of consideration transferred in asset acquisition. + ReferencesNo definition available. + Details Name: ntra_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of shares issued and issuable as consideration in asset acquisition. + ReferencesNo definition available. + Details Name: ntra_AssetAcquisitionConsiderationTransferredSharesIssuedAndIssuable Namespace Prefix: ntra_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionValue of shares reserved for issuance in registration statement. + ReferencesNo definition available. + Details Name: ntra_SharesReservedValueRegistrationStatement Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferred Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of contingent consideration recognized as part of consideration transferred in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of acquirer's equity interest issued and issuable as part of consideration transferred in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of transaction cost incurred as part of consideration transferred in asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 55 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2 + Details Name: us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionUseful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionThe cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 30 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_AssetAcquisitionAxis=ntra_InProcessResearchDevelopmentAcquisitionAgreementMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AssetAcquisitionAxis=ntra_AssetsAcquiredFromInvitaeMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - AOCIL (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Beginning balance $ (1,358) $ (9,203) $ (3,085) $ (16,362) Ending balance (765) (5,396) (765) (5,396) Net unrealized gain on available-for-sale securities, net of tax and foreign currency translation adjustment Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Â Increase (decrease) in other comprehensive loss $ 593 $ 3,807 $ 2,320 $ 10,966 X - DefinitionAmount of adjustment to accumulated other comprehensive income or loss. + ReferencesNo definition available. + Details Name: ntra_IncreaseDecreaseAccumulatedOtherComprehensiveIncomeLossNamespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65

-Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Related Party (Details) - MyOme, Inc. - USD ($) $ / shares in Units, $ in Millions 1 Months Ended 9 Months Ended Feb. 29, 2024 Sep. 30, 2024 Aug. 31, 2024 Dec. 31, 2023 Dec. 06, 2021 Related Party Transaction [Line Items] Â Â Â Â Â Investment in equity securities without readily determinable fair value Â Â $ 2.7 Â $ 4.0 Equity securities without readily determinable fair value, impairment loss Â $ 0.0 Â Â Â Warrants term 10 years Â Â Â Â Warrants convertible into number of stock shares 3,058,485 Â Â Â Â Warrants exercise price (in dollars per share) $ 0.25 Â Â Â Â Warrants impairment Â 0.0 Â Â Â Ownership percentage if warrants are exercised 12.60% Â Â Â Â Carrying amount of investments Â 6.7 Â $ 4.0 Â Carrying value of warrants and warrant receivable Â $ 9.4 Â $ 0.0 Â Series B preferred stock Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Warrants convertible into number of stock shares Â 2,080,565 Â Â Â Warrants exercise price (in dollars per share) Â $ 0.01 Â Â Â Executive chairman Â Â Â Â Â Related Party Transaction [Line Items] Â Â Â Â Â Ownership percentage Â Â Â Â 23.60% X - DefinitionAmount of impairment loss from warrants or rights outstanding. + ReferencesNo definition available. + Details Name: ntra_ClassOfWarrantOrRightImpairmentLoss Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTerm of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: ntra_ClassOfWarrantOrRightTerm Namespace Prefix: ntra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionApproximate percentage of investment ownership if warrants are exercised. + ReferencesNo definition available. + Details Name: ntra_InvestmentOwnershipPercentageIfWarrantsExercised Namespace Prefix: ntra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount of warrants and warrants receivable. + ReferencesNo definition available. + Details Name: ntra_WarrantsAndWarrantsReceivable Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionExercise price per share or per unit of warrants or rights outstanding. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3 + Details Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares. + ReferencesNo definition available. + Details Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3 + Details Name: us-gaap_EquityMethodInvestmentOwnershipPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionThis item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481664/323-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(10)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 + Details Name: us-gaap_EquityMethodInvestments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cumulative impairment loss on investment in equity security without readily determinable fair value. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 321 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479536/321-10-50-3 + Details Name: us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(i)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(c)(2)(ii)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(2)(g)(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1 + Details Name: us-gaap_RelatedPartyTransactionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=ntra_MyomeIncMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.3 Summary of Significant Accounting Policies - Risks and Uncertainties (Details) - Customer - customer 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Sales Â Â Â Â Â Risk and Uncertainties Â Â Â Â Â Number of customers exceeding 10% of benchmark 0 0 0 0 Â Sales | Medicare Â Â Â Â Â Risk and Uncertainties Â Â Â Â Â Concentration risk (as a percent) 12.60% 12.60% 11.50% 13.00% Â Accounts receivable Â Â Â Â Â Risk and Uncertainties Â Â Â Â Â Number of customers exceeding 10% of benchmark Â Â 0 Â 0 Accounts receivable | Medicare Â Â Â Â Â Risk and Uncertainties Â Â Â Â Â Concentration risk (as a percent) Â Â 10.90% Â 10.20% X - DefinitionRepresents the number of customers. + ReferencesNo definition available. + Details Name: ntra_NumberOfCustomers Namespace Prefix: ntra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RisksAndUncertainties Abstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ntra_MedicareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition (Details) $ / shares in Units, $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended Mar. 31, 2023 USD ($) item Aug. 31, 2019 Feb. 28, 2019 USD ($) Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) $ / shares Jun. 30, 2023 USD ($) Sep. 30, 2024 USD ($) $ / shares Sep. 30, 2023 USD ($) $ / shares Dec. 31, 2023 USD ($) Dec. 31, 2022 USD ($) Jun. 30, 2019 USD ($) Allowances on accounts receivable Â Â Â Â Â Â Â Â Â $ 1,300 Â Â Other assets Â Â Â $ 38,356 Â Â $ 38,356 Â 15,403 Â Â Deferred revenue Â Â Â 34,802 $ 36,045 Â 34,802 $ 36,045 35,740 $ 30,778 Â Disruption at Change Healthcare Â Â Â Â Â Â Â Â Â Â Â Allowances on accounts receivable Â Â Â 26,900 Â Â $ 26,900 Â Â Â Â Product Â Â Â Â Â Â Â Â Â Â Approximate percentage of revenue collected within 9 months Â Â Â Â Â Â 90.00% Â Â Â Â Billing collection period (in months) Â Â Â Â Â 9 months Â Â Â Â Extended billing collection period (in months) Â Â Â Â Â Â 6 months Â Â Â Â Increased (decreased) revenues Â Â Â 700 1,200 Â $ 4,500 7,700 Â Â Â (Increased) decreased net loss Â Â Â $ 700 $ 1,200 Â $ 4,500 $ 7,700 Â Â Â (Increased) decreased net loss per share | $ / shares Â Â Â $ 0.01 $ 0.01 Â $ 0.04 $ 0.07 Â Â Â Tests delivered in prior periods that were fully collected Â Â Â Â Â Â Â Â Â Â Â Increased (decreased) revenues Â Â Â $ 34,500 $ 2,200 Â $ 108,100 $ (3,700) Â Â Â (Increased) decreased net loss Â Â Â $ 34,500 $ 2,200 Â $ 108,100 $ (3,700) Â Â Â (Increased) decreased net loss per share | $ / shares Â Â Â $ 0.28 $ 0.02 Â $ 0.88 $ (0.03) Â Â Â Tests delivered in prior periods that were fully collected | Disruption at Change Healthcare Â Â Â Â Â Â Â Â Â Â Â Allowances on accounts receivable Â Â Â $ 2,500 Â Â $ 2,500 Â Â Â Â Amounts not refunded to insurance carriers Â Â Â Â Â Â Â Â Â Â Â Increased (decreased) revenues Â Â Â 2,900 Â Â 7,100 Â Â Â Â (Increased) decreased net loss Â Â Â $ 2,900 Â Â $ 7,100 Â Â Â (Increased) decreased net loss per share | $ / shares Â Â Â $ 0.02 Â Â $ 0.06 Â Â Â Â BGI Genomics Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â $ 44,000 Â Â Â Â Â Â Â Â Agreement term Â Â 10 years Â Â Â Â Â Â Â Â Revenue, remaining performance obligation Â Â $ 6,000 Â Â Â Â Â Â Â Â Transaction price Â Â 50,000 Â Â Â Â Â Â Â Â Contract asset Â Â Â $ 1,000 Â Â $ 1,000 Â Â Â Â Other assets Â Â Â 3,400 Â Â 3,400 Â Â Â Â Deferred revenue Â Â Â 17,400 Â Â 17,400 Â Â Â Â Prepaid royalties Â Â $ 20,000 Â Â Â Â Â Â Â Â BGI Genomics | License and related development services Â Â Â Â Â Â Â Â Â Â Number of performance obligations | item 2 Â Â Â Â Â Â Â Â Â Revenue, remaining performance obligation $ 24,000 Â Â Â Â Â Â Â Â Â BGI Genomics | Sequencing services Â Â Â Â Â Â Â Â Â Â Other assets Â Â Â Â Â Â Â Â Â $ 6,000 BGI Genomics | Sequencing products Â Â Â Â Â Â Â Â Â Â Other assets Â Â Â Â Â Â Â Â Â Â 4,000 BGI Genomics | Sequencing products and services Â Â Â Â Â Â Â Â Â Â Other assets Â Â Â Â Â Â Â Â Â $ 10,000 BGI Genomics | Oncology assay interpretation services Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â 1,500 $ 1,100 Â Â Â Revenue, remaining performance obligation Â Â Â Â Â Â Â Â $ 20,000 Â Â Deferred revenue Â Â Â 1,400 $ 700 Â 1,400 700 Â Â Â BGI Genomics | Equipment and Services Â Â Â Â Â Â Â Â Â Â Equipment and services received Â Â Â 400 1,400 Â 400 4,000 Â Â Â Foundation Medicine ("FMI") Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â 24,300 Â Â Â Agreement term Â 5 years Â Â Â Â Â Â Â Â Automatic renewals, successive period thereafter Â 1 year Â Â Â Â Â Â Â Â Revenue, remaining performance obligation Â Â Â 7,700 Â Â 7,700 Â Â Â Transaction price Â Â Â 32,000 Â Â 32,000 Â Â Â Â Prepaid royalties Â Â Â 5,000 Â Â 5,000 Â Â Â Â Foundation Medicine ("FMI") | Oncology assay interpretation services Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â 100 $ (100) Â 300 $ 300 Â Â Â Revenue, remaining performance obligation Â Â Â 5,000 Â Â 5,000 Â Â Â Deferred revenue Â Â Â $ 3,000 Â Â Â $ 3,000 Â Â Â Foundation Medicine ("FMI") | Oncology products Â Â Â Â Â Â Â Â Â Â Revenue recognized Â Â Â Â Â $ 200 Â Â Â Â Â Revenue, remaining performance obligation Â Â Â Â Â $ 19,300 Â Â Â Â Â X - DefinitionPeriod the agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: ntra_AgreementTerm Namespace Prefix: ntra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the automatic renewals thereafter for successive number of years. + ReferencesNo definition available. + Details Name: ntra_AgreementTermAutomaticRenewalsPeriod Namespace Prefix: ntra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents the agreement transaction price. + ReferencesNo definition available. + Details Name: ntra_AgreementTransactionPrice Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionApproximate percentage of revenue collected within 9 months. + ReferencesNo definition available. + Details Name: ntra_ApproximatePercentageOfRevenueCollectedWithinNineMonths Namespace Prefix: ntra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionRepresents the average collection period for billing. + ReferencesNo definition available. + Details Name: ntra_BillingAverageCollectionPeriod Namespace Prefix: ntra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionRepresents equipment and services received. + ReferencesNo definition available. + Details Name: ntra_EquipmentAndServicesReceived Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the extended collection period for billing. + ReferencesNo definition available. + Details Name: ntra_ExtendedBillingCollectionPeriod Namespace Prefix: ntra_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in the portion of profit or loss for the period, net of income taxes. + ReferencesNo definition available. + Details Name: ntra_IncreaseDecreaseNetIncomeLoss Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in net income (loss) per share during the reporting period. + ReferencesNo definition available. + Details Name: ntra_IncreaseDecreaseNetIncomeLossPerShare Namespace Prefix: ntra_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in revenues during the reporting period. + ReferencesNo definition available. + Details Name: ntra_IncreaseDecreaseRevenues Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of performance obligations that have not been recognized as revenue. + ReferencesNo definition available. + Details Name: ntra_NumberOfPerformanceObligations Namespace Prefix: ntra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic

326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details Name: us-gaap_AllowanceForDoubtfulAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details Name: us-gaap_ContractWithCustomerLiabilityRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(5) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidRoyalties Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of transaction price allocated to performance obligation that has not been recognized as revenue. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details Name: us-gaap_RevenueRemainingPerformanceObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_StatementScenarioAxis=ntra_CyberattackDisruptionAtChangeHealthcareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=us-gaap_ProductMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_AmountsNotRefundedToInsuranceCarriersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=ntra_BgiGenomicsCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_LicenseAndRelatedDevelopmentServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_SequencingServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_SequencingProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_SequencingProductsAndServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_OncologyAssayInterpretationServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_EquipmentAndServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=ntra_FoundationMedicineInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_OncologyProductsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition - Disaggregation (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues $ 439,758 $ 268,306 $ 1,220,850 $ 771,466 United States Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 426,274 259,870 1,190,559 746,420 Americas, excluding U.S. Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 2,002 1,288 5,084 3,652 Europe, Middle East, India, Africa Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 7,722 5,255 18,339 16,071 Asia Pacific and Other Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 3,760 1,893 6,868 5,323 Insurance carriers Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 405,208 239,780 1,130,364 676,680 Laboratory partners Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 27,622 21,731 70,152 71,985 Patients Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues 6,928 6,795 20,334 22,801 Licensing and other Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Total revenues $ 3,631 $ 3,088 $ 8,687 $ 10,195 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=ntra_AmericasExcludingUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_EMEAMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=ntra_OtherGeographicAreasMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ntra_InsuranceCarriersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ntra_LaboratoryPartnersMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=ntra_PatientsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_LicensingAndOtherMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition - Accounts Receivable and Deferred Revenue (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Assets Â Â Â Â Accounts receivable, net $ 306,876 $ 278,289 Â Â Liabilities: Â Â Â Â Deferred revenue, current portion 17,886 16,612 Â Â Deferred revenue, long-term portion 16,916 19,128 Â Â Total deferred revenues $ 34,802 $ 35,740 $ 36,045 $ 30,778 X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ContractWithCustomerLiabilityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition - Changes in Balance of Deferred Revenues (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Revenue Recognition Â Â Beginning balance $ 35,740 $ 30,778 Increase in deferred revenues 23,968 24,553 Revenue recognized during the period that was included in deferred revenues at the beginning of the period (12,102) (9,610) Revenue recognized from performance obligations satisfied within the same period (12,804) (9,676) Ending Balance $ 34,802 $ 36,045 X - DefinitionThe additional amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesNo definition available. + Details Name: ntra_ContractWithCustomerLiabilityAdditions Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI

https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.3 Revenue Recognition - Deferred Revenues (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenue recognized during the period that was included in deferred revenues at the beginning of the period $ 12,102 $ 9,610 Â Deferred revenue, current portion 17,886 Â $ 16,612 Deferred revenue, Long-term 16,916 Â $ 19,128 BGI Genomics Â Â Â Deferred revenue, current portion 500 Â Â Deferred revenue, Long-term 16,900 Â Â Foundation Medicine ("FMI") Â Â Â Deferred revenue, current portion 3,000 Â Â BGI Genomics and Foundation Medicine ("FMI") Â Â Â Revenue recognized during the period that was included in deferred revenues at the beginning of the period 1,700 Â Â Genetic testing services Â Â Â Revenue recognized during the period that was included in deferred revenues at the beginning of the period 10,400 Â Â Deferred revenue, current portion $ 14,400 Â Â X - DefinitionAmount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiability Current Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2 + Details Name: us-gaap_ContractWithCustomerLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_CounterpartyNameAxis=ntra_BgiGenomicsCoLtdMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=ntra_FoundationMedicineInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_CounterpartyNameAxis=ntra_BgiGenomicsCoLtdAndFoundationMedicineInc.Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=ntra_GeneticTestingServicesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.3 Fair Value Measurements (Details) - USD ($) $ in Thousands 1 Months Ended 9 Months Ended 21 Months Ended Oct. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Line Of Credit-UBS Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Line of credit facility, fair value of amount outstanding Â $ 80,400 Â $ 80,400 Line Of Credit-UBS | SOFR Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Spread on interest rate (as a percent) 0.50% 0.50% 1.21% Â Level 2 | Convertible Notes Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Fair value of long-term debt Â $ 929,100 Â 491,800 Recurring Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total financial assets Â 922,334 Â 878,977 Recurring | Cash, cash equivalents, and restricted cash Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total financial assets Â 892,844 Â 642,095 Recurring | U.S. Treasury securities Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total financial assets Â Â Â 200,418 Recurring | Municipal securities Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total financial assets Â 29,490 Â 36,464 Recurring | Level 1 Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total financial assets Â 892,844 Â 842,513 Recurring | Level 1 | Cash, cash equivalents, and restricted cash Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total financial assets Â 892,844 Â 642,095 Recurring | Level 1 | U.S. Treasury securities Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total financial assets Â Â Â 200,418 Recurring | Level 2 Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total financial assets Â 29,490 Â 36,464 Recurring | Level 2 | Municipal securities Â Â Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Â Â Total financial assets Â $ 29,490 Â $ 36,464 X - DefinitionFair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + ReferencesNo definition available. + Details Name: us-gaap_ConvertibleDebtFairValueDisclosures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of the amount outstanding under the credit facility. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10 + Details Name: us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=ntra_LineOfCreditUbsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=ntra_CashCashEquivalentsAndRestrictedCashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_InvestmentTypeAxis=us-gaap_MunicipalBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.3 Financial Instruments (Details) $ in Thousands 9 Months Ended Sep. 30, 2024 USD ($) security position Dec. 31, 2023 USD ($) Sep. 30, 2023 USD ($) Dec. 31, 2022 USD ($) Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Â Â Â Â Amortized Cost $ 922,878 $ 881,708 Â Â Gross Unrealized Gain Â 14 Â Â Gross Unrealized Loss (544) (2,745) Â Â Estimated Fair Value 922,334 878,977 Â Â Cash, cash equivalents and restricted cash 892,844 642,095 $ 668,710 $ 466,091 Short-term investments $ 29,490 236,882 Â Â Number of investments sold | security 1 Â Â Â Number of investments, unrealized loss position | position 9 Â Â Â Credit loss reserve $ 0 Â Â Â Fair value 27,990 Â Â Â Unrealized loss (544) Â Â Â Amortized Cost Â Â Â Â Less than or equal to one year 29,034 Â Â Â Greater than one year but less than five years 1,000 Â Â Â Total 30,034 Â Â Â Fair Value Â Â Â Â Less than or equal to one year 28,522 Â Â Â Greater than one year but less than five years 968 Â Â Â Total 29,490 Â Â Â Cash, cash equivalents, and restricted cash Â Â Â Â Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Â Â Â Â Amortized Cost 892,844 642,095 Â Â Estimated Fair Value 892,844 642,095 Â Â U.S. Treasury securities Â Â Â Â Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Â Â Â Â Amortized Cost Â 201,522 Â Â Gross Unrealized Gain Â 14 Â Â Gross Unrealized Loss Â (1,118) Â Â Estimated Fair Value Â 200,418 Â Â Municipal securities Â Â Â Â Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract] Â Â Â Â Amortized Cost 30,034 38,091 Â Â Gross Unrealized Loss (544) (1,627) Â Â Estimated Fair Value 29,490 $ 36,464 Â Â Fair value 27,990 Â Â Â Unrealized loss $ (544) Â Â Â X - DefinitionCash, cash equivalents, restricted cash and amount of investment in securities measured at fair value. + ReferencesNo definition available. + Details Name: ntra_CashCashEquivalentsRestrictedCashAndSecurities Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash, cash equivalents, restricted cash and amount of unrealized gain in securities measured at fair value. + ReferencesNo definition available. + Details Name: ntra_CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedGain Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCash, cash equivalents, restricted cash and amount of unrealized loss in securities measured at fair value. + ReferencesNo definition available. + Details Name: ntra_CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedLoss Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCash, cash equivalents, restricted cash and amortized cost of investment in securities measured at fair value. + ReferencesNo definition available. + Details Name: ntra_CashCashEquivalentsRestrictedCashAndSecuritiesAmortizedCostBasis Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the number of investments sold. + ReferencesNo definition available. + Details Name: ntra_NumberOfInvestmentsSold Namespace Prefix: ntra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Section 50 -Paragraph 3A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480832/942-320-50-3A + Details Name: us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aaa) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479106/326-30-50-9 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479081/326-30-55-8Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionNumber of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481800/320-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479106/326-30-50-4 + Details Name: us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=ntra_CashCashEquivalentsAndRestrictedCashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Balance Sheet Components Â Â Â Â Beginning balance $ 7,021 $ 5,580 $ 6,481 $ 3,830 (Reversal of) Provision for doubtful accounts (536) 454 208 2,204 Write-offs (233) Â (437) Â Total $ 6,252 $ 6,034 $ 6,252 $ 6,034 X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of allowance for credit loss on financing receivable. Excludes allowance for financing receivable covered under loss sharing agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(4)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph (a) -Subparagraph (1) -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph (a) -Subparagraph (3) -Publisher SECReference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1405 -Paragraph (c) -Publisher SECReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(7)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(1) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11BReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13 + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of writeoff of financing receivable, charged against allowance for credit loss. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 79 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479294/326-20-55-79Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(3) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B + Details Name: us-gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense related loan transactions, lease transactions, credit loss from transactions other than loan and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 11B -Subparagraph (c)(2) -SubTopic 10 -Topic 310 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.11) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1 + Details Name: us-gaap_ProvisionForLoanLeaseAndOtherLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Property and Equipment, net (Details) - USD ($) $ in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Property and Equipment, net Â Â Â Property and equipment, gross $ 213,298 Â $ 167,503 Less: Accumulated depreciation and amortization (71,128) Â (56,293) Total Property and Equipment, net 142,170 Â 111,210 Depreciation expense 19,900 $ 16,100 Â Impairment charge 0 Â Â Equipment pledged 150,000 Â Â Machinery and equipment Â Â Â Property and Equipment, net Â Â Â Property and equipment, gross 104,443 Â 85,626 Computer equipment Â Â Â Property and Equipment, net Â Â Â Property and equipment, gross $ 3,040 Â 1,850 Useful Life 3 years Â Â Software held for internal use Â Â Â Property and Equipment, net Â Â Â Property and equipment, gross $ 11,104 Â 11,636 Useful Life 3 years Â Â Leasehold improvements Â Â Â Property and Equipment, net Â Â Â Property and equipment, gross $ 48,080 Â 38,999 Construction-in-process Â Â Â Property and Equipment, net Â Â Â Property and equipment, gross $ 46,631 Â $ 29,392 Minimum | Machinery and equipment Â Â Â Property and Equipment, net Â Â Â Useful Life 3 years Â Â Maximum | Machinery and equipment Â Â Â Property and Equipment, net Â Â Â Useful Life 5 years Â Â X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of assets pledged to secure a debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3 + Details Name: us-gaap_DebtInstrumentCollateralAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for

resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionUseful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentUsefulLife Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Other Accrued Liabilities (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Balance Sheet Components Â Â Â Â Reserves for refunds to insurance carriers $ 15,778 $ 23,245 $ 16,209 $ 18,948 Accrued charges for third-party testing 9,924 14,823 Â Â Testing and laboratory materials from suppliers 9,823 11,229 Â Â Marketing and corporate affairs 15,526 10,085 Â Â Legal, audit and consulting fees 36,535 43,897 Â Â Accrued shipping charges 2,180 3,646 Â Â Sales and income tax payable 5,061 3,731 Â Â Accrued third-party service fees 8,853 7,111 Â Â Clinical trials and studies 7,744 12,126 Â Â Operating lease liabilities, current portion 9,762 11,621 Â Â Property and equipment purchases 3,397 4,316 Â Â Other accrued interest 1 1,078 Â Â Other accrued expenses 1,592 2,497 Â Â Total other accrued liabilities $ 126,176 $ 149,405 Â Â X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for outsourced testing. + ReferencesNo definition available. + Details Name: ntra_AccruedChargesForOutsourcedTesting Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials and studies. + ReferencesNo definition available. + Details Name: ntra_AccruedClinicalTrialsAndStudies Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for fixed assets. + ReferencesNo definition available. + Details Name: ntra_AccruedFixedAssetPurchases Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of accrued interest. + ReferencesNo definition available. + Details Name: ntra_AccruedInterest Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for shipping charges. + ReferencesNo definition available. + Details Name: ntra_AccruedShippingCharges Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for specimen service fees. + ReferencesNo definition available. + Details Name: ntra_AccruedSpecimenServiceFees Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for testing and laboratory materials from suppliers. + ReferencesNo definition available. + Details Name: ntra_AccruedTestingAndLaboratoryMaterialsFromSuppliers Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses not otherwise itemized or categorized in the footnotes to the financial statements that have been incurred but not yet paid, due within one year or the normal operating cycle, if longer. + ReferencesNo definition available. + Details Name: ntra_OtherAccruedSundryExpensesCurrent Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_AccruedInsuranceCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesNo definition available. + Details Name: us-gaap_AccruedMarketingCostsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.3 Balance Sheet Components - Reserve Balance and Activities for Refunds (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2024 Sep. 30, 2023 Balance Sheet Components Â Â Â Beginning balance Â $ 23,245 $ 18,948 Additional reserves Â 1,506 7,348 Refunds to carriers Â (3,095) (1,236) Reserves released to revenue Â (5,878) (8,851) Ending balance $ 15,778 $ 15,778 $ 16,209 Repaid short term advances $ 13,800 Â Â X - DefinitionAdditions to insurance carrier reserves. + ReferencesNo definition available. + Details Name: ntra_InsuranceCarrierReservesAdditions Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of insurance carrier reserves released to revenue. + ReferencesNo definition available. + Details Name: ntra_InsuranceCarrierReservesReleased Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of insurance refunds to carriers. + ReferencesNo definition available. + Details Name: ntra_InsuranceRefundsToCarriers Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_AccruedInsuranceCurrentAndNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_BalanceSheetRelatedDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfShortTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.3 Leases (Details) $ in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2023 USD ($) ftÂ² Sep. 30, 2021 USD ($) ftÂ² Sep. 30, 2024 USD ($) ftÂ² Sep. 30, 2023 USD ($) ftÂ² Sep. 30, 2024 USD ($) ftÂ² lease item Sep. 30, 2023 USD ($) ftÂ² Dec. 31, 2025 USD ($) Jul. 31, 2024 Dec. 31, 2023 USD ($) Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Â Â Operating lease liabilities, current portion included in other accrued liabilities Â Â $ 9,762 Â $ 9,762 Â Â Â $ 11,621 Operating lease liabilities, long-term portion Â Â 98,953 Â 98,953 Â Â Â 67,025 Operating lease liabilities Â Â $ 108,715 Â 108,715 Â Â Â $ 78,646 Noncash operating activities related to right-of-use assets Â Â Â Â $ 38,200 $ 100 Â Â Â Weighted average remaining lease term Â Â 8 years 7 days Â 8 years 7 days Â Â Â Weighted average discount rate (as a percent) Â Â 7.20% Â 7.20% Â Â Â Lease expense Â Â $ 4,000 $ 3,600 $ 11,200 11,000 Â Â Â Operating lease payments Â Â $ 4,200 $ 3,200 $ 12,500 $ 8,400 Â Â Â Austin TX, Long-term Lease Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease space (area) | ftÂ² Â Â 94,000 Â 94,000 Â Â Â Number of office space locations | lease Â Â Â Â 2 Â Â Â Term of lease Â Â 132 months Â 132 months Â Â Â First Expansion Premises Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease space (area) | ftÂ² Â Â 32,500 Â 32,500 Â Â Â Â Second Expansion Premises Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease space (area) | ftÂ² Â Â 65,222 Â 65,222 Â Â Â Â Corporate Headquarters Lease Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease space (area) | ftÂ² Â Â 136,000 Â 136,000 Â Â Â Â Number of office space locations | item Â Â Â Â 2 Â Â Â Â "First Space" Sublease Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Number of office space locations | ftÂ² Â Â Â Â 88,000 Â Â Â Â "Second Space" Sublease Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Number of office space locations | ftÂ² Â Â Â Â 48,000 Â Â Â Â Corporate Headquarters Lease Amendment Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Annual lease payment Â Â Â Â Â Â $ 9,300 Â Â Term of lease Â Â 48 months Â 48 months Â Â Â Â Tukwila, WA Lease Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease space (area) | ftÂ² Â Â 10,000 Â 10,000 Â Â Â Â Term of lease Â Â 62 months Â 62 months Â Â Â Â Renewal term of lease Â Â 5 years Â 5 years Â Â Â Â San Carlos, CA Sublease Amendment Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Renewal term of lease Â Â Â Â Â Â 60 months Â San Carlos, CA Sublease Amendment | Forecast Â Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Annual lease payment Â Â Â Â Â Â $ 9,700 Â Â South San Francisco, CA Lease Â Â Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease space (area) | ftÂ² Â Â 11,395 Â 11,395 Â Â Â Â Annual lease payment Â Â Â Â $ 900 Â Â Â Â Term of lease Â Â 36 months Â 36 months Â Â Â Â Renewal term of lease Â Â 3 years Â 3 years Â Â Â Â Pleasanton, CA Lease Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease space (area) | ftÂ² 16,319 Â 16,319 Â 16,319 Â Â Â Annual lease payment $ 500 Â Â Â Â Â Â Â Â Term of lease 60 months Â Â 60 months Â 60 months Â Â Â Laboratory space in Canada Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Lease space (area) | ftÂ² Â 7,107 Â Â Â Â Â Â Annual lease payment Â $ 200 Â Â Â Â Â Â Â Term of lease Â 24 months Â Â Â Â Â Â Certain workspaces and storage spaces | Minimum Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Term of lease Â Â 1 year Â 1 year Â Â Â Â Certain workspaces and storage spaces | Maximum Â Â Â Â Â Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Â Â Â Â Â Term of lease Â Â 5 years Â 5 years Â Â Â Â X - DefinitionNoncash operating activities related to right-of-use assets. + ReferencesNo definition available. + Details Name: ntra_NoncashOperatingActivitiesRelatedToRightOfUseAssets Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents the number of office spaces. + ReferencesNo definition available. + Details Name: ntra_NumberOfOfficeSpaces Namespace Prefix: ntra_ Data Type: xbrli:positiveIntegerItemType Balance Type: na Period Type: duration X - DefinitionRepresents the annual payment that the lessee is obligated to make in connection with a property under the terms of an agreement classified as an operating lease. + ReferencesNo definition available. + Details Name: ntra_OperatingLeasesAnnualRent Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of lease cost recognized by lessee for lease contract. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_LeaseCost Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTerm of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and

thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeasePayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionWeighted average discount rate for operating lease calculated at point in time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionWeighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 53 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4 + Details Name: us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_AustinTxLongTermLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_AustinTexasFirstExpansionPremisesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_AustinTexasSecondExpansionPremisesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_CorporateHeadquartersLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_FirstSpaceSubleaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_SecondSpaceSubleaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_CorporateHeadquartersLeaseAmendmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_TukwilaWashingtonLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_SanCarlosCaliforniaSubleaseAmendmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=srt_ScenarioForecastMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_SouthSanFranciscoCaliforniaLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_PleasantonCaliforniaLeaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_VancouverBritishColumbiaCanadaMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=ntra_CertainWorkspacesAndStorageSpacesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.3 Leases - Payments (Details) - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Leases. Â Â 2024 (remaining 3 months) $ 4,315 Â 2025 17,391 Â 2026 17,661 Â 2027 16,997 Â 2028 17,332 Â 2029 and thereafter 70,693 Â Total future minimum lease payments 144,389 Â Less: imputed interest (35,674) Â Operating lease liabilities $ 108,715 $ 78,646 X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesNo definition available. + Details Name: ntra_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.3 Commitments and Contingencies (Details) $ in Thousands 1 Months Ended 24 Months Ended Jan. 31, 2024 USD ($) patent Jul. 31, 2023 patent Jun. 30, 2023 USD ($) patent May 31, 2023 USD ($) patent Dec. 31, 2022 patent lawsuit Mar. 31, 2022 USD ($) Nov. 30, 2021 patent Oct. 31, 2020 patent Jun. 30, 2020 patent Mar. 31, 2020 lawsuit patent Jan. 31, 2020 patent Mar. 31, 2019 patent lawsuit Dec. 31, 2022 lawsuit patent Sep. 30, 2024 USD ($) Feb. 28, 2022 lawsuit Other commitments Â Loss contingency, patents allegedly infringed, number | patent 2 Â Amount awarded to other party $ 57,000 Â Total commitments Â $ 101,046 Â Laboratory instruments supplier Â Other commitments Â Total commitments Â 2,243 Â Material suppliers Â Other commitments Â Total commitments Â 34,413 Â Application service providers Â Other commitments Â Total commitments Â 3,898 Â Cloud platform service provider Â Other commitments Â Total commitments Â 34,180 Â Leases Â Other commitments Â Total commitments Â 658 Â Other material suppliers Â Other commitments Â Total commitments Â $ 25,654 Â CareDX Patent Case Â Other commitments Â Loss contingency, patents allegedly infringed, number | patent Â Â Â Â Â Â Â Â 3 Â 3 Â Â Â Number of invalid patents | patent Â Â Â Â Â Â Â Â 3 Â Â Â Â Â Gain contingency, patents allegedly infringed, number | patent 1 Â Number of lawsuits | lawsuit Â Â Â Â Â Â Â Â Â Â Â Â 2 Â 2 Â Â Â Amount awarded to other party Â Â Â Â Â $ 44,900 Â Â Â Â Â Â Â Â Â Â Â Â Amount awarded from other party $ 96,300 Â ArcherDX Case Â Other commitments Â Gain contingency, patents allegedly infringed, number | patent Â Â 3 3 Â Â Â Â Â Â Â 3 Â Â Â Â Amount awarded from other party Â Â $ 19,350 $ 19,350 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Ravgen Patent Case Â Other commitments Â Loss contingency, patents allegedly infringed, number | patent Â Â Â Â Â Â Â 2 Â Â Â Â Â Â Â Amount awarded to other party $ 57,000 Â Genosity Inc. Patent Case Â Other commitments Â Gain contingency, patents allegedly infringed, number | patent Â Â Â Â Â Â Â 1Â Â Â Â Â Â Â Â Inivata Patent Case Â Other commitments Â Loss contingency, patents allegedly infringed, number | patent Â Â Â Â Â Â Â 1 Â Â Â Â Â Â Â Gain contingency, patents allegedly infringed, number | patent Â Â Â Â Â 1 Â Â Â Â Â Â Â Â Â Â Number of lawsuits | lawsuit Â Â Â Â 2 Â Â Â Â Â Â Â 2 Â Â Inivitae Patent Case Â Other commitments Â Loss contingency, patents allegedly infringed, number | patent Â Â Â Â Â 3 Â Â Â Â Â Â Â Â Â Â Â NeoGenomics Patent Case Â Other commitments Â Gain contingency, patents allegedly infringed, number | patent Â 2 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Class action Â Other commitments Â Number of lawsuits | lawsuit Â Â Â Â Â Â Â Â Â Â Â Â 2 X - DefinitionNumber of invalid patents. + ReferencesNo definition available. + Details Name: ntra_LossContingencyInvalidPatentsNumber Namespace Prefix: ntra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of entity's patents that another entity has allegedly infringed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483049/450-30-50-1 + Details Name: us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionAmount awarded from other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedFromOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionNumber of another entity's patents that the entity has allegedly infringed. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyPatentsAllegedlyInfringedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionNumber of pending claims pertaining to a loss contingency. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9 + Details Name: us-gaap_LossContingencyPendingClaimsNumber Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherCommitmentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionMinimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from a supplier. + ReferencesNo definition available. + Details Name: us-gaap_PurchaseObligation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=ntra_LaboratoryInstrumentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=ntra_InventoryMaterialPurchaseCommitmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=ntra_ApplicationServiceProviderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details

Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=ntra_CloudPlatformServiceProviderMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=ntra_OperatingLeaseCommitmentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis=ntra_OtherMaterialSupplierMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=ntra_CaredxSPatentCaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=ntra_ArcherdxPatentCaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=ntra_RavgenPatentCaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=ntra_GenosityInc.PatentCaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=ntra_InivataPatentCaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=ntra_InivitaPatentCaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=ntra_NeoGenomicsPatentCaseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_LitigationCaseAxis=ntra_ClassActionLawsuitMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Compensation Expense (Details) - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Stock based compensation expense Â Â Â Â Stock-based compensation expense $ 70,644 $ 57,587 $ 202,502 $ 142,376 Cost of revenues Â Â Â Â Stock based compensation expense Â Â Â Â Stock-based compensation expense 4,174 3,299 11,997 8,692 Research and development Â Â Â Â Stock based compensation expense Â Â Â Â Stock-based compensation expense 22,549 18,784 65,155 48,761 Selling, general and administrative Â Â Â Â Stock based compensation expense Â Â Â Â Stock-based compensation expense 43,921 35,504 125,350 84,923 Liability classified awards Â Â Â Â Stock based compensation expense Â Â Â Â Stock-based compensation expense $ 100 $ 100 $ 600 $ 600 X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=ntra_LiabilityClassifiedAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Narrative (Details) - USD ($) shares in Thousands, $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Stock Based Compensation Â Â Â Â Â Stock-based compensation expense $ 70,644 $ 57,587 $ 202,502 $ 142,376 Â Performance-based awards Â Â Â Â Â Stock Based Compensation Â Â Â Â Â Stock-based compensation expense $ 23,700 23,000 $ 66,500 40,500 Â Shares granted Â Â 800 Â Â Options to purchase common stock Â Â Â Â Â Stock Based Compensation Â Â Â Â Â Options outstanding (in shares) 4,176 Â 4,176 Â 5,501 Liability classified awards Â Â Â Â Â Stock Based Compensation Â Â Â Â Â Stock-based compensation expense $ 100 $ 100 $ 600 $ 600 Â X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=ntra_EmployeeAndNonEmployeeOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=ntra_LiabilityClassifiedAwardsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Stock Options (Details) - Options to purchase common stock shares in Thousands 9 Months Ended Sep. 30, 2024 $ / shares shares Number of shares Outstanding Â Outstanding, beginning balance (in shares) | shares 5,501 Options exercised (in shares) | shares (1,325) Outstanding, end balance (in shares) | shares 4,176 Weighted-Average Exercise Price Â Outstanding, beginning balance (in dollars per share) | $ / shares $ 23.65 Exercised (in dollars per share) | $ / shares 7.80 Outstanding, end balance (in dollars per share) | $ / shares $ 28.67 X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average price at which option holders acquired shares when converting their stock options into shares. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionNumber of share options (or share units) exercised during the current period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=ntra_EmployeeAndNonEmployeeOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Restricted Stock Units (Details) - RSU and performance-based awards shares in Thousands 9 Months Ended Sep. 30, 2024 $ / shares shares Shares Â Balance (in shares) | shares 9,248 Granted (in shares) | shares 5,043 Vested (in shares) | shares (2,968) Canceled/Forfeited (in shares) | shares (467) Balance (in shares) | shares 10,856 Weighted Average Grant Date Fair Value Â Balance (in dollars per share) | $ / shares $ 49.50 Granted (in dollars per share) | $ / shares 70.99 Vested (in dollars per share) | $ / shares 55.27 Canceled/Forfeited (in dollars per share) | $ / shares 57.96 Balance (in dollars per share) | $ / shares $ 57.91 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were

forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=ntra_RestrictedStockUnitsRsuAndPerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.3 Stock-Based Compensation - Performance-based Awards (Details) - USD ($) $ in Thousands, shares in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Â Stock-based compensation expense $ 70,644 $ 57,587 $ 202,502 $ 142,376 Performance-based awards Â Â Â Â Â Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Â Â Â Â Granted (in shares) Â Â 0.8 Â Aggregate value 55,000 Â $ 55,000 Â Aggregate value recognized 9,400 Â $ 25,400 Â Target (percentage) Â Â 200.00% Â Expected compensation expense recognition over requisite service period Â Â $ 110,000 Â Stock-based compensation expense $ 23,700 $ 23,000 $ 66,500 $ 40,500 X - DefinitionTarget percentage for vesting of award under share-based payment arrangement. + ReferencesNo definition available. + Details Name: ntra_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingTargetPercentage Namespace Prefix: ntra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of expense for award under share-based payment arrangement. Excludes amount capitalized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 14.F) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cost capitalized for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIntrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionIntrinsic value of vested award under share-based payment arrangement. Excludes share and unit options. + ReferencesNo definition available. + Details Name: us-gaap_SharebasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.3 Debt (Details) $ / shares in Units, shares in Thousands 1 Months Ended 3 Months Ended 9 Months Ended 21 Months Ended Jul. 19, 2024 USD ($) Apr. 30, 2020 USD ($) $ / shares Oct. 31, 2023 Nov. 30, 2022 USD ($) Apr. 30, 2020 USD ($) D $ / shares Jul. 31, 2017 Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) Sep. 30, 2024 USD ($) $ / shares shares Sep. 30, 2023 USD ($) Sep. 30, 2023 Dec. 31, 2023 USD ($) $ / shares shares Jun. 30, 2023 USD ($) Dec. 31, 2020 USD ($) Sep. 30, 2015 USD ($) Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Remaining borrowing capacity Â Â Â Â Â Â Â $ 20,000,000.0 Â $ 20,000,000.0 Â Â Â Â Â Â Â Collateral amount Â Â Â Â Â Â $ 150,000,000.0 Â $ 150,000,000.0 Â Â Â Â Â Â Common Stock, Par or Stated Value Per Share | $ / shares Â Â Â Â Â Â $ 0.0001 Â $ 0.0001 Â Â $ 0.0001 Â Â Â Common stock, shares issued | shares Â Â Â Â Â Â 124,137 Â 124,137 Â Â 119,581 Â Â Â Accrued Interest Â Â Â Â Â Â $ 1,000 Â $ 1,000 Â Â $ 1,078,000 Â Â Â Amortization of debt discount and issuance cost Â Â Â Â Â Â Â Â 991,000 $ 966,000 Â Â Â Â Â Interest expense Â Â Â Â Â Â Â 3,142,000 $ 3,252,000 9,393,000 9,490,000 Â Â Â Â Â Convertible Notes Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Principal amount $ 287,500,000 $ 287,500,000 Â Â $ 287,500,000 Â 287,500,000 Â $ 287,500,000 Â Â Â Â Â Â Proceeds from Convertible Note, net of issuance costs Â Â Â Â $ 278,300,000 Â Â Â Â Â Â Â Â Â Per annum interest rate (as a percent) 2.25% Â Â Â 2.25% Â Â Â 2.25% Â Â Â Â Â Interest expense Â Â Â Â Â Â Â $ 1,951,000 1,941,000 $ 5,843,000 5,817,000 Â Â Â Â Â Common Stock, Par or Stated Value Per Share | $ / shares Â $ 0.0001 Â Â $ 0.0001 Â Â Â Â Â Â Â Â Â Debt instrument, term Â Â Â Â Â Â Â 7 years Â Â Â Â Â Â Effective interest rate (as a percent) Â Â Â Â Â Â 2.72% Â 2.72% Â Â Â Â Â Â Principal amount per convertible note Â Â Â Â $ 1,000 Â Â Â Â Â Â Â Â Â Number of threshold consecutive trading days | D Â Â Â Â 30 Â Â Â Â Â Â Â Â Â Threshold business days | D Â Â Â Â Â 5 Â Â Â Â Â Â Â Â Â Â Conversion price (in dollars per share) | $ / shares Â $ 38.79 Â Â $ 38.79 Â Â Â Â Â Â Â Â Â Initial conversion rate Â 25.7785 Â Â Â Â Â Â Â Â Â Â Â Conversion rate increase 0.4284 Â Â Â Â Â Â Â Â Â Â Â Convertible to shares of common stock Â 7,411,704 Â Â Â Â Â Â Â

Â Â Â Â Â Â Percentage of principal amount converted 100.00% 100.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â Convertible, if converted common shares aggregate value $ 287,500,000 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Carrying value Â Â Â Â Â Â $ 283,936,000 Â $ 283,936,000 Â Â 282,945,000 Â Â Â 5 consecutive trading day period | Convertible Notes Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Threshold trading days | D Â Â Â Â 5 Â Â Â Â Â Â Â Â Â Â Percentage of conversion price Â Â Â Â 98.00% Â Â Â Â Â Â Â Â Â Â Â Â Â Â 20 trading days period | Convertible Notes Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Threshold trading days | D Â Â Â Â 20 Â Â Â Â Â Â Â Â Â Â Percentage of conversion price Â Â Â Â 130.00% Â Â Â Â Â Â Â Â Redeemable for cash on or after May 2024 Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Number of threshold consecutive trading days | D Â Â Â 20 Â Â Â Â Â Â Â Â Â Â Threshold trading days | D Â Â Â 30 Â Â Â Â Â Â Â Â Â Â Percentage of conversion price Â Â Â 130.00% Â Â Â Â Â Â Â Â Â Â Percentage of principal amount converted Â Â Â 100.00% Â Â Â Â Â Â Â Â Â Â Level 2 | Convertible Notes Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Fair value of long-term debt Â Â Â Â Â 929,100,000 Â 929,100,000 Â Â 491,800,000 Â Â Â Line Of Credit-UBS Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Maximum borrowing capacity Â Â Â $ 100,000,000.0 Â Â Â Â Â Â Â Â $ 100,000,000.0 $ 150,000,000.0 $ 50,000,000.0 Outstanding balance Â Â Â Â Â 80,400,000 Â 80,400,000 Â Â $ 80,400,000 Â Â Â Credit facility drawn down Â Â Â Â Â Â Â 80,000,000.0 Â Â Â Â Â Remaining borrowing capacity Â Â Â Â Â 20,000,000.0 Â 20,000,000.0 Â Â Â Â Â Borrowings under credit facility Â Â Â $ 30,000,000.0 Â Â Â Â Â Â Â Â Â Â Collateral amount Â Â Â Â Â Â 150,000,000.0 150,000,000.0 Â Â Â Â Â Â Interest expense Â Â Â Â Â $ 1,200,000 $ 1,300,000 $ 3,600,000 $ 3,700,000 Â Â Â Â Â Interest rate (as a percent) Â Â Â Â Â Â 5.66% Â 5.66% Â Â Â Â Â Â Interest expense Â Â Â Â Â Â $ 1,200,000 Â Â Â Â Â Â Â Â Line Of Credit-UBS | LIBOR Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Spread on interest rate (as a percent) Â Â Â Â Â 1.10% Â Â Â Â Â Â Â Â Â Â Line Of Credit-UBS | SOFR Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Spread on interest rate (as a percent) Â Â 0.50% Â Â Â Â 0.50% Â 1.21% Â Â Â Â 2017 Term Loan Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Â Â Â Â Â Â Â Â Â Â Debt, repayment amount Â Â Â Â $ 79,200,000 Â Â Â Â Â Â Â Â Â Â X - DefinitionCarrying value as of the balance sheet date of accrued interest. + ReferencesNo definition available. + Details Name: ntra_AccruedInterest Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionIncrease of ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesNo definition available. + Details Name: ntra_DebtInstrumentConvertibleConversionRatioIncrease Namespace Prefix: ntra_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of principal amount converted. + ReferencesNo definition available. + Details Name: ntra_DebtInstrumentConvertiblePercentageOfPrincipalAmount Namespace Prefix: ntra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of specified business days for conversion after consecutive trading day period triggers conversion feature. + ReferencesNo definition available. + Details Name: ntra_DebtInstrumentConvertibleThresholdBusinessDays Namespace Prefix: ntra_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace amount per convertible note. + ReferencesNo definition available. + Details Name: ntra_FaceAmountPerConvertibleNote Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_AmortizationOfDebtDiscountPremium Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionFair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock. + ReferencesNo definition available. + Details Name: us-gaap_ConvertibleDebtFairValueDisclosures Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of assets pledged to secure a debt instrument. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 470 -Section 50 -Paragraph 3 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3 + Details Name: us-gaap_DebtInstrumentCollateralAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe price per share of the conversion feature embedded in the debt instrument. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleConversionPrice1 Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionRatio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleConversionRatio1 Namespace Prefix: us-gaap_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThreshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1 Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionMinimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThreshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentConvertibleThresholdTradingDays Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionContractual interest rate for funds borrowed, under the debt agreement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section

50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(3)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (210.5-03(11)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1 + Details Name: us-gaap_InterestExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of the amount outstanding under the credit facility. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10 + Details Name: us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of increase (decrease), classified as other, of the credit facility. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityIncreaseDecreaseOtherNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(b),22(b)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromConvertibleDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15 + Details Name: us-gaap_RepaymentsOfDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ntra_FiveDayConsecutiveTradingPeriodMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ntra_TwentyTradingDaysPeriodMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementScenarioAxis=ntra_MayRedeemForCashAllOrAnyPortionOfConvertibleNotesAtCompanysOptionOnOrAfterMay2024Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DebtInstrumentAxis=ntra_LineOfCreditUbsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=ntra_LondonInterbankOfferedRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Discount and Issuance Costs (Details) - Convertible Notes 9 Months Ended Sep. 30, 2024 Effective interest rate (as a percent) 2.72% Debt instrument, term 7 years X - DefinitionEffective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6 + Details Name: us-gaap_DebtInstrumentInterestRateEffectivePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionPeriod of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Convertible Notes Balances (Details) - Convertible Notes - USD ($) $ in Thousands Sep. 30, 2024 Dec. 31, 2023 Outstanding principle $ 287,500 $ 287,500 Unamortized debt discount and issuance cost (3,564) (4,555) Net carrying amount 283,936 282,945 Accrued interest to be settled in equity 2,695 Â Reclassifications to short-term debt financing (82) Â Long-term debt financing $ 286,549 $ 282,945 X - DefinitionAmount of debt instrument accrued interest to be settled in equity. + ReferencesNo definition available. + Details Name: ntra_DebtInstrumentAccruedInterestToBeSettledInEquity Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of unamortized debt discount and debt issuance cost. + ReferencesNo definition available. + Details Name: ntra_DebtInstrumentUnamortizedDebtDiscountAndDebtIssuanceCost Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of long-term debt reclassifications to short-term debt financing. + ReferencesNo definition available. + Details Name: ntra_LongTermDebtReclassificationsToShortTermDebtFinancing Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_DebtInstrumentCarryingAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1DReference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI

https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.3 Debt - Interest Expense Recognized Related To Convertible Notes (Details) - Convertible Notes - USD ($) $ in Thousands 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Cash interest expense Â Â Â Â Contractual interest expense $ 1,618 $ 1,617 $ 4,852 $ 4,851 Non-cash interest expense Â Â Â Â Amortization of debt discount and debt issuance cost 333 324 991 966 Total interest expense $ 1,951 $ 1,941 $ 5,843 $ 5,817 X - DefinitionRepresents cash interest expense. + ReferencesNo definition available. + Details Name: ntra_CashInterestExpenseAbstract Namespace Prefix: ntra_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of contractual interest expense for debt. + ReferencesNo definition available. + Details Name: ntra_ContractualInterestExpenseDebt Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionRepresents non-cash interest expense. + ReferencesNo definition available. + Details Name: ntra_NonCashInterestExpenseAbstract Namespace Prefix: ntra_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of amortization expense attributable to debt discount (premium) and debt issuance costs. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3 + Details Name: us-gaap_AmortizationOfFinancingCostsAndDiscounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69EReference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69FReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6 + Details Name: us-gaap_InterestExpenseDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.3 Income Taxes (Details) - USD ($) 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Income Taxes Â Â Â Â Â Income tax expense $ 730,000 $ 202,000 $ 2,050,000 $ 80,000 Â Interest and penalties accrued $ 0 Â $ 0 Â $ 0 X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 6.I.7) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15 + Details Name: us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 74 R63.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share - Loss per Share (Details) 9 Months Ended Oct. 11, 2024 USD ($) Apr. 30, 2020 USD ($) Sep. 30, 2024 USD ($) Jul. 19, 2024 USD ($) Convertible Notes Â Â Â Â Earnings or Loss per Share [Line Items] Â Â Â Â Principal amount Â $ 287,500,000 $ 287,500,000 $ 287,500,000 Convertible to shares of common stock Â 7,411,704 Â Â Convertible Notes Â Â Â Â Earnings or Loss per Share [Line Items] Â Â Â Â Convertible, If-converted value in excess of principal Â Â $ 597,800,000 Â Subsequent event | Convertible Notes Â Â Â Â Earnings or Loss per Share [Line Items] Â Â Â Â Convertible Notes Payable $ 287,400,000 Â Â Â Convertible to shares of common stock 7,500,000 Â Â Â X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: ntra_EarningsOrLossPerShareLineItems Namespace Prefix: ntra_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ConvertibleNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-5 + Details Name: us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionFace (par) amount of debt instrument at time of issuance. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69BReference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69CReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8 + Details Name: us-gaap_DebtInstrumentFaceAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 75 R64.htm IDEA: XBRL DOCUMENT v3.24.3 Net Loss per Share - Potentially Dilutive Shares (Details) - shares shares in Thousands 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive shares not included in diluted per share calculation 22,536 22,571 Options to purchase common stock Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive shares not included in diluted per share calculation 4,176 5,532 Performance-based awards and restricted stock units Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive shares not included in diluted per share calculation 10,856 9,440 Employee stock purchase plan Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive shares not included in diluted per share calculation 93 188 Convertible Notes Â Â Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Â Â Potentially dilutive shares not included in diluted per share calculation 7,411 7,411 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ntra_EmployeeAndNonEmployeeOptionsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ntra_PerformanceBasedAwardsAndRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=ntra_EmployeeStockPurchasePlan2015Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R65.htm IDEA: XBRL DOCUMENT v3.24.3 Subsequent Events (Details) 1 Months Ended 9 Months Ended Nov. 12, 2027 USD ($) Oct. 11, 2024 USD ($) Jul. 19, 2024 USD ($) Apr. 30, 2020 USD ($) Apr. 30, 2020 Sep. 30, 2024 USD ($) Convertible Notes Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Short-term convertible notes Â Â Â Â Â $ 100,000 Convertible Notes Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Convertible, if converted common shares aggregate value Â Â $ 287,500,000 Â Â Â Per annum interest rate (as a percent) Â Â 2.25% Â 2.25% 2.25% Convertible to shares of common stock Â Â Â 7,411,704 Â Â Percentage of principal amount converted Â Â 100.00% 100.00% Â Â Conversion rate increase Â Â 0.4284 Â Â Â Subsequent event Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Upfront purchase agreement amount $ 20,000,000.0 Â Â Â Â Â Upfront fee payment 7,000,000.0 Â Â Â Â Â Purchase agreement amount 13,000,000.0 Â Â Â Â Â Potential additional milestone payments $ 50,000,000.0 Â Â Â Â Â Subsequent event | Convertible Notes Â Â Â Â Â Â Subsequent Event [Line Items] Â Â Â Â Â Â Convertible Notes Payable Â $ 287,400,000 Â Â Â Â Convertible to shares of common stock Â 7,500,000 Â Â Â Â Proceeds from notes payable Â $ 100,000 Â Â Â Â X - DefinitionAggregate purchase agreement amount. + ReferencesNo definition available. + Details Name: ntra_AggregatePurchaseAgreementAmount Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease of ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount. + ReferencesNo definition available. + Details Name: ntra_DebtInstrumentConvertibleConversionRatioIncrease Namespace Prefix: ntra_ Data Type: xbrli:pureItemType Balance Type: na Period Type: duration X - DefinitionThe percentage of principal amount converted. + ReferencesNo definition available. + Details Name:

ntra_DebtInstrumentConvertiblePercentageOfPrincipalAmount Namespace Prefix: ntra_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of potential milestones payable to other party. + ReferencesNo definition available. + Details Name: ntra_PotentialMilestonePaymentsToOtherParty Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of upfront fees paid for agreements. + ReferencesNo definition available. + Details Name: ntra_UpfrontFeesPaidForAgreements Namespace Prefix: ntra_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIncluding the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1 + Details Name: us-gaap_ConvertibleNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_ConvertibleNotesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5 + Details Name: us-gaap_DebtConversionConvertedInstrumentAmount1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1BReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6 + Details Name: us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionThe average effective interest rate during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1FReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_DebtInstrumentInterestRateDuringPeriod Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionThe minimum amount the entity agreed to spend under the long-term purchase commitment. + ReferencesNo definition available. + Details Name: us-gaap_LongTermPurchaseCommitmentAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromNotesPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDetail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481674/830-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2 + Details Name: us-gaap_SubsequentEventLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_ShortTermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleNotesPayableMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 77 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 (-J";%D!04UB@0 +$ 0 9&]C4'O)O<',O87!P+GAM M;$V./0L",1!$ \IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*1#BV&5(C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #:@FQ9"K@%C.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M:L,P#(9?9? B>*';+#B;U96.G%@8K;.QF;+4UBV-C:R1]^SE9FS*V!]C1TN]/ MGT"MB=*$A,\I1$SD,-^-ONNS-''#3D11 F1S0J]S71)]:1Y"\IK*,QTA:O.A MCPBB:>[!(VFK2<,$K.)"9*JU1IJ$FD*ZX*U9\/$S=3/,&L ./?:4@=/ MC:^"JH5?=Z&^ %!+ P04 " #:@FQ9F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^? H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+', <$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;]\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R><>41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 (M -J";%FN]""5Y04 /D? 8 >&PO=V]R:W-H965T&UL MM9EM<^(V%(7_BH9V.NU,")9,>-D29@A)VDQWLVR@K]46X!G;@1[*D(VFTE>IKNA9"DY[GHBCL,,?I=2(>Q*WQ*+\W4^.1S'08Q&*F2)I%$5>O M-R*4V^L6;>UO/ 6KM38W.N-1PE=B+O3OR4S!5:=T\8-(Q&D@8Z+$\KHUH1^F MKFL$^1-_!&*;'GPF!N59RJ_FXL&_;CFF1"(4GC86'/YMQ%2$H7&"[W1;QLE3+:"><&$D1!7/SG+[N*.!2P&@';"=@[:W[!7A7\A 7 MKX>IYC9)UUR)=-31\&M&T_%VSC>%,ZMQ'I)/,M;K%%QJX;_5=Z"495'9OJ@W M##66/-,[4"#ZAMR#DK. M 5JZW4AS'X2"/&;1LU V0MS#<6C;[7?[QL<*FT(-RSAAJ? /8E5D&IX435Y MY)&U"7&?1VAXQ2]@/\8;RHNB$C=:HIUSF%$@HG%?3 ?+JX(,-A292D:G, M8JU>X;]O13_B?GMG(\9%39$/4@8]!7G!7\B##[TT6 9>$3#JW^$CEO ..X-A MMSOH6WE1<5->5O&R4W@GO@_NZ<7^ _D(SY'/L;U=<4OJ.I223]Z4AZ&(R8RG MME VQ5V:@E>AB**Y P=?,*45'+>\R8+0#^(5F9!Y%D ?H8YC)3]'(J)5)*)X MJ'E//C57T)T7+IYCUG.6[-E-P$L6=_MW'/ MQ5]6T',$)EHE)HK'G/>@,YEJ'I)_@J1^:,8=^X/^E6LE/4=RHE5THGCBR5_5 MB1*\'@PWZ%W9>^0Y@A*MDA+%8\Y'Z4% [S=8RQJ(2;F(O)!D.G/:0#NW4YTA0 MM(I0%,\^BT!#-)+0MF/SS^1N? R!>UK1<>=IC**8(:>:^E]O2)5V3#PTR0 M[YU+!R(D280J=@>LM7'.C,6JC,7P% 3+G'S.F+]&SS*TP1\Q>%P\3:R;#.<(M4JP*4@Q//?OF)'8K-4R39!2NL;2 KK*2RCD9'?#YR!6_[Q/,$&(&-7UA:B<^1D%B5D-A) M"6D>05(G-UD*7UNS^LT1G]I]%ES7E**1NRD8'07";4R'?,7<-!KR Y1PF-[MTS;<4,)U34&K7,3P6+-OR+6 AL3P<)MZO'/D(U;E(W;25M+;:7Z>;_>3SYF& MM!N;.=1*_(TRSJX>"K>KW,TSOB5B;T])SN@%$KQ#D"CUL%'A?/*_OY\CY(3>K)6T!D]W+0.L4?,ZG9X<5E3QBH#N7AB><^XV].N MI\3MOE@7G;BH*>/!\1F>5B8 Z!>0(;<.,D<,:H=57/=_P3H'AZMFQLO/G%/B MF5W:XIRUO%N>:T_RT]Q.]7AQ*/Z)FPDS):%8@M2Y[,.(IXISYN)"RR0_JGV6 M6LLH_[@6W!?*/ #?+Z74^POS ^5I__@_4$L#!!0 (-J";%G/V:%C=P8 M !0: 8 >&PO=V]R:W-H965T&ULK5EM]LV$/XKA!=L M+>#$(JG7-#'0)AA68"]!TVZ?&9F.A4JB2U))LU^_HZQ*LD@Q*=8OB5Z.Q^>. MQWL>RA>/0GY6.\XU^EJ5M;I<[+3>GZ]6*M_QBJDSL>K&^:)_=R/6%:'19U/Q&(M54%9-/[W@I'B\7>/'MP8?B M?J?-@]7Z8L_N^2W7G_8W$NY6O9=-4?%:%:)&DF\O%V_Q^15M![06?Q?\48VN MD0GE3HC/YN;JYG(1&$2\Y+DV+AC\>^!7O"R-)\#QI7.ZZ.!=09/SEHE3M7_38V08+E#=*BZH; M# BJHC[\9U^[1(P&X'!F .D&D)<.H-T V@9Z0-:&=J8U.4%&CCSO1*%9OU,5* P;C:95W\ [T[S$=FYKOE^S-$@R4B 0D=PZ_\ MPZ]Y#L-Q.YP>#U]!'Y'WXI ^?M/[H7/B-E+S6B"D%<9ZJXCDX*-T.S"X[5WN6 M\L%;"/%Y0-?K'_^"]M!# M+_3;G9#Z5'-90?D] -C*0'?!//B)1O.3+,R"'4J'%8W3E+A11CW*R(OR;9Z+ MQJ14\IQ#?N]*OD0UM&*Q1:R$AMEN*;@YB9 MK0%4?/>TJ_JE6:T];]M?^>3*061%1X,X3>))$FPSDJ0DS=Q)B/LDQ-XDO(?U MJ;603F2Q-668)F1:0PZK((EF<"4]KL2+ZT;R/2LVB' =FWYWJ'NA=Y#9 *@) MM$OF I_8L,*8X@EXVRH.HE&(1^#3'GSJ!?]1:%9.<+H@IM;DF!(2Q=$$I,.. M1&D4SN0XZV%FS^08Y(743VUN38_9FWTZF]#,1A$2G$PWJ\,,8X(#-U8<#,P7 M>-'^!5B9+NI[5'(0 D@:QC\5V],&;N9SW'D=XTF3-)KN+H<9K --9E"/^!K[M4;;8:C,* S\ 8^Q5X*ZRK5 X\XYLV"+$RF !V&88CC;*9& M\4"#F+Z(\\N"W15EH0ON)G[LI=/O9?X?Y>TXZ(% L9]!>V[:LR=#3,Z ';28 MI'3:GAUF.,RR=&9=!O;$S]*G;(P"$95IT&![+"?[49J;\/O--H6-2@G:-1.K#:7 MI4$89U.L3K-@#NO >-A/>09$9%D('RB)_R?A?U M_4L32VP"(VD\U@C=D<9E!Z)[IG3)P'3$W1VZ98]_*YX1R+NF=03F^)(% 73 MWN8PPQDF,[V-C(Z9?EJ<:HT16D=8S@!L/LZ4+*+3 &RS. G(W&(,I$G\A\=# MG3^79&I-GF 2$C(%:=O%24R3F=U(!I8C?I:[$E55' Z';6GDHC9)YU#DH/A? M_2DT1^EK)W2O8S<)(^<)__\{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{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

MHS-@?D@<5M04 EE;DYP83- S1Y<*I^Q4P({LR+YNYU%(,GHT+0NJN,&8LW M+)L&:W11M+Z4MM/)4'B-[(!]F_3U'E8Y9?MXDYG#I2/P'(?+,!@'S"'"'W,#' M$T%36(WL8'T/6%34?*
(*Z>@Y#R)_S!1-8K[O3V 04C"+[#C[4-$R9NDAW;LL MXO6.5GU:&6TVX"'0VS%J&L2"XP5]:K+"360'SB'L9?PR&7,#%+HAT+C8/ MH^4$#F$%F-@.F&!BU;P"U[&.@SC 6O -8FB)@F#"3 67V
Z7:M/6 ?M1]3!: M:P!,A$E(QN::@)5@,F&N D-L!\/?N[3LY_:XC&>&.7<8&+18X5] MV(Y]=W1+JPKLK(")%XTQ2[&.9?/(&V\@#%+@1CAAH((\;(>\]=OV?D;[#1"' M@V!<6 UB.B#/Z&N<,.T\2XO&V
MR/[J]J[@(!:?@JACU_*6XE1>XI^.GYP;$U4)G@&, 6G=]>2FDQ7:D/4DT M*!50%L!PRI+#HWPUKFPL?9! _):+P!6DGHN1JV&>1PA,@$N'D*@ST[!M^K#@"3 M/?BL;?66,/a@[$QJ&#O'?
C">:_M+WYE+GD)LSX[87=&6A&W+)11"& 0[; YA M[P*[P:4R,+=/!.(NR0:Q\5NR'L=55COV;%>0R=F*/5&_W0\1R0,R+@H&.6(
MM_0F\NZH$6[OA'JF!>S'7],)OVPK_'OTPCW%)CP[FS@MQM.B%+H:REID/*#"=KL*;K@G:$+)QZ6S29C M"?@&]!22M*W?;?$XUT>RO^7-Z6IJGB\)F8JG(A*>G4AHA6-K6(]&_W0R@2+L
M:0!@XAR!CR:VM9ZB"9Z=)LCO27V;#/!*-J,^=-]G)-;N@1 5?8]'MJ;@V9G#^M7F?W V)(D5A0R09!F0E3PU M^J03!9]@5P MU^]!.8BB'.0UE./ K0Z-8*/;.G?P@U#[N&N0BMP)7DL4OR!V?
G'4JAX8$62; MJ3_G)W[+_1U8M^MR<& MQB.W0!/YJY@,L3,9JZ\;7C3"S,"(@8T0-Q@W[0UB* J"*7Q7G(6\[X,\9&&2 M-6G;&P5L+!D@)OL'+@??UK >Z?%ABY8^F[WKWGY\V <%>,S(#%)+/ ;[Q=$)
MN)Q63^W!0.&T-:X[03;<'0X?WK9'[D;W/Z&K=7>$4*GI3C3^%E? RH23T2VH M=#\&,-U5=TBPNZAYV9ZSV_"ZYGG[0< ,<1 8 >&PO=V]R:W-H965T&ULI5C;;N,V$/T5P@L4+>#8CI-
VTW42()=MFV*[")K=]IFFQA8;BE1) MRE[WZWN&E&0YFP0H^F);$CF+)ROE*1ESZ]334GF21-E5F.I_-?IA64MO1Y7FZ=~\OSUT3C;9T[T5H MJDKZW349M[T8'8^Z&[_K=1GYQO3RO)9K>J#XN;
[WN)KV5@I=D0W:6>%I=3&Z M.GYW?./S=6?\IQ8Y8EC+0C3- ZB%6%Z.SD2AH)1L3?W?;7ZB-YWNVIYP)Z5-L M\]KYZ4BH)D17M9OA0:5M_I9?VCP,-IS-7M@P;S?,D]_YH.3EK8SR\MR[K?"\
M&M;X1PHU[89SVG)1']+'4XU]\?*6@O*Z3AER*W#="!P(X7P:89R73%5KZ#H; MFK]@Z$?QF[.Q#.*]+:@XW#^%4[UG\\ZSZ_FK!A^HGHB3V5C,9 M)'LG_S_2;.CT>4-
,DW>AEHHN1N!!(+^AT>4W;XY_F"U>O_Q'##6 \Z#94+TU1=Y;.6A 8Z1/1R^UTS:K&>^*!$KKC%OOX(2,0L=DN:[-3MNU MB$ZH4MHU)1$RYC\5\B#YWI(UD?$E4J"&H!^VC6\P!8ZKTT>EU!C
M1 U 2K5+=4\F4+U#%*T<1!89X ;1U9RC'<+"P7TN' ,85IE0^P%VJ>T[:,)")@R\]P^D21FG)YWSA8$-+@ZM/%4 M%7FEP<-_B)%BCV"=>X3F4NZ.4)2-#(R"2(%#)[GA]I(:
(RGO[KA1;"FS,\N\VR/T87@G\ETAS_>';62^#-A[M> <>LV!M= M9(Z7D/24_Z%TML7?5[K+ +=@K9Y4* '#5[V2YO#S\G7V))MS+ +0?ECK4_%2X1 MBC0!],G6@4R&EM,I5T]I+;O.
M_7+,XT/9&K:]@82U'1:E,T6JPW]6*EX[.UD\RX%'0 X'%XWBHJV24#.RE&D@ M&>S6O;3 1B4Q"=BCNTZ6[D$^] H#Y*'<'2JZM?O>R&T9@PSA5:!'>^6"J[@3
M+2TGW$"#*$4FQ8IB$X:,X>BW^,"TMK:HC>:T@=,,6]/."S(+C"B\W.Y;5I7$ M:"%^ 5G^<8D4R*X7#\D;3GKG=;MB[[3; Q RDK=Q"VUR#!(T]! 9VZ3!*'4R M]"?JZ=UR..3PE6L,-)!$S4C+H'7)Q=;V?
MHHM2F0V$5* (-&Q#SLO2:0<9C^ M?L?34%!,^52;.!]1G5SVKL,(YMZ40I@=$D M=&MF[1.]AF=/Y#JQ=2*N +J.I3Q)]H,0B GLU0ES+2$-(TPDZ($GWR?R)4UP MF4WAD$)=X\LOA_P8[]!FS-
])51UE7, U[G0]\W$ AZ^:0;I#&"-BD6[L'* MN^9KN\&M8IK+$6YDG.!L;\WMV?[?_E^(JOYSOE^>_.'X#Y35$S- *6V>3M]^/,(FEOPWR M171U>E5?NHC\I9^ &P+E!7B^[756U_/%BU[>;EBQ
MWNC*W/UX,#WP7WPLEZN6OGCQ^H>-6NH;W7[>?&CPZ478I2C7NK:EJ;-&+WX\ MN)J^?'-"ZWG!/TI]9Y. _\)D;LP7^O"N^/%@0@#I2NF^F=9M*L?#RX.LD(O5%>U'\W=?VN'SRGM
MEYO*\K_9G:P].3(\LZV0NT>!@3KLI;_U;VC0_+ Q63/ S/WP(SAEH,8RK>] M5:]_;Q=UM!J[$9_,*K\-(K:V+*3=@UQ+/+M:]OA!F9660WY;(N%V6NZC:[MRG/3U6U9+[,/IBKS4ML?
7K0XCYYZD;N]W\C>LSU[7V:_F;I=V>RGNM!%__D7 M@#, ._/ OID]NN&-WHRSX\DHFTUF)X_L=QR0/^;]CO\CR,O>)\-[DS*]M!N5 MZQ\H"U6-[?ZX/7W?YN>35X] OE@)/SDL=W_3<@?
WWLVSIZ^??:V:^ASN])9 MC8VRM;!<$\LS,*S5Z[EN M=&M++1V1W]4QN(Z-NN- MJA^^_]O%;'K^RF8V 4-%,#8>#&6SHK1Y92R.+>O!/:[JNL-)' 7&-&T&DT!Z
MG4TG1_^3P;KQ>[P]:-0[VMSIWH$\9].LV:*L\ ,]J.=-1P2:70!:S\?9&V5+ M2Q3[0.RN6\56YQ,V)7@9$H*XJU57E"U#2:BOL]S@O)K@QE\6"!6*?EZ4M:IS M(HW%7AJ&L+792MWJ;*YUG4&H-
JH19/$>R?8#U:%?9Y '-.%OJ6C>JJA[H M?.)#T2,T8$FDU>\5/ =77U@3]/7SUGJG@H(SAE+;X Z(T9O[^ M4K(`_LZKK@ @IB9@BS]@]01;$%-!2+"P@@/(NX9%K59M1\(#_EA+3" P5;90 M99-
M4MKC\2$QP!*8;-X=OJWAM7:4 +IBJ*=:0-J):@3UD7T)R91X_?Y+?>]%5 ME0BR^R)= $)@ 1,04)6F<.#NX=A<52"*SB1 4(S.KF*L\ ,+)8@#P,#HQJPS M+Q2#@JQ:@(9_Z!B&P.KAA769EN@
$!K*2 L?72U.G<6=<'SL,&%0HRM&"035 M]FD*[R+QD4-A4!O)N?K@?M!DRM6>L,H*^M/P6]*>"$.\,T8>,)A:B4M3"* M. ENO!P?A-M=!5R\QW>#$?@3,]"3]!X3"G5I/Q
M)1DH6_X5.N<@A3;/4$R=3@]/AN?(\"I M*MK\6]3$04+&K5MWPF.$90"LY9UGX]-L[O85 =[=8YQ=[?EEE#*> 3^\N)R- M+P*H))!0_9$8 +((MZI*ID:>$.C7(K;O(>V0R!&D>]YF M_UQ!++?
1Z%M==P1ERXKK/XM[M(HO%UL!V"V(#22&$V+-+0/ '02P)3U+=CN];D)79D.J*IS#KM6Y(I\L_ M PS$1GU?6L:"5GDC[?F [T9LFP$M=B+B@.5W$ XHDE@ QR$8PZ)@!\9NTV-O
MH"&K$A^3K1PF:*FUO)T1N.AFG:@<:=)"W9J&K0:!TWH0>Z020X-C&MV/E!DNRCU*$'C'IP[MO%N5^0H$O=6-T,-T34Z&F]RVR#EGR\R:KTCCBPKK.F1XM@8:A\"LQ$#"ZN[
MIJB3J6L\CA*3>KP2LNR($XJ)!)ANH9DSG=0 1*P/!!6'"DP,%N0"?O_AVQ0Q M5;J4G@B _ [K#ON;?^&5P7BQA0B"-,Y^K[-?.JR?7@[Y$577(D97-JDT'G) M10Y2.UUHO18[*<"D=G\VGIU^AUUJXEQ)-
+G1-44+[SFH*3I-AYW["+30:W'6 M=S"=E(-4NI4$YO>\->3FIE/G1)\1>"X1^!@?? MSXM.!G5T1J$"LO*].H1)P MP 1%4=!T,OG.!ZLN[P#C1"IBD+[]-(@QUXX>V&13=2PU34>)#*C=U1M5NI2#
MK&\UK1F 'VWT$;2P0+6,GVKS<4AVGSU8,%A!%FZ;2N.LB1^NO?K@?M!DRM6>L,H*^M/P6]*>"$.\,T8>,)A:B4M3"* M. ENO!P?A-M=!5R\QW>#$?@3,]"3]!X3"G5I/Q
M)1DH6_X5.N<@A3;/4$R=3@]/AN?(\"I M*MK\6]3$04+&K5MWPF.$90"LY9UGX]-L[O85 =[=8YQ=[?EEE#*> 3^\N)R- M+P*H))!0_9$8 +((MZI*ID:>$.C7(K;O(>V0R!&D>]YF M_UQ!++?
$:"BB[6%(OE9X*SH;\HT (@P 1, +!M4 24IW M 21#$>"+V^[L))@(P22?)'9R$L9H<8RER"AB+>(LR+O(1?T09*,1B!::#7@. M)^.IQY\C/=OEJ]$@_@E$CN>
[R!0E)Q$2[*A8P="+!:3)QV25C[1AT.HDL*3$ MHF\,HF(BYF/BW,$IMK"DWN5BX\;'!G ME%/( ][F;KIY5>;C[(T&=74&JK'(%/%
(#@[/DW"9&K^G3P%E.D*N*076"%B%2;2C@^[1^KF=7,2T&@F*^5O:4!;=<6Q\@A9]I-(:. XB0VI M+P&-USXY[\NK"CRDR*TLG'_PKIA%P_NR$;C14,39>NX$=!#X003)\4$X*_.@
MHP*G&,YUKI!,[JP)GO73U@.H)R!+'.5[6IS%*DD8L$)N^L. M3Y_R;VX#4 M*NLV"!;J/B'.(I]%Q]\"-Z?1=&A,[A0YP#TD39]GIV?C8Y/SH;MU-^W1-RQ MF4L 8@Y(3(\GX\MXV)88'L??:#%;E!
[@(^)^M_89<"G!8!E48)9L3:87%A[MXX>S=-^4+K[8.DE^;VZ5XB3C*6 V.447R K;TJXL30R2O=R]& ![?LRMZ=S M "P;#1(JY;H?=ECX%5G#.048;2G%0HD\Z/EH#OH$IM^6#67NO)^->B-
Q!CB) MC%(Y ZZH?+ $-J P#N%RQ5.T2F#UQ!+ MT"[P"^5#]M!Y0]EHZU*RI(A]0W&5:F"N/F^H$!5.N[KY'(J@\LGT_&@RS=[X M4.\Z9H\V>_;);,H\NYB'!I*) M(EL-ME:
(O\17#H=0KMI3"ANR[=V&^W2@H.@3$]GX4#V5 MG%$2V&>50IR]5T+C6$$JIK(?0L&#,,3D@K MV*[IS)="U0+LC5R?
SGP5\T/LZDBBX"KY1#Q"=W+\:K@]YUE9\PT@7:M:%8@[3%69.V_N!]QT\%K> M85]5E20H/LQRE5PI("0..VWU0?;6Y'!T,>H&AA+&'<\[0 ML#=@#7MZAY"Z@L\]+S[7W&FY:?
G\4'=:@R9+,=LDX.I+#" $.PZK-J[P.S=(MU5TADDJ4H=(L2133;T> R-YB[9M0WMLEI MH69*"Z*A33OATK"!B/S!T!JQ5A%?KR>,!PD)4YW4N3#=O%UT55 =JC:3M1:# M%PG8L! =4('N2-%@Y&.
M$006O*Z6L(U"09S K6".4:!]2]^/]?F\!U8%-_M-%=BR:+7%23[(:S9N%. ##7@6G6?44&.(X$H'1P%0P"D?]/S1;X\Y1)?+IV2 MS#6*"H>,IHSOYA]<@C6-T ?T9=&9W/OPZ*F_9WZKK;=
M>O"/KEA*>OE;UD9Y":!LK.X8M(:6L?.9.\X3);PK'P9*#>]*OV4N$"]J)CFTSFK+6OLI6Y@X10("QK?9\GYZXXOHI %[4^$;0?((M'ZND"$-9--78=%*$Z:>-0S9Q"SB.V[8B*%, _W9A1A)X<$3*1?
7@X5GUX91X M?N)3 QWK&I8@ @+TKW/77NGJ4FJ?<[AM,ABB(E%]MV%'G-4/I37)KAXM=^DS]TY(-SC'XB=)R=[$!5&NW: M75(*@3&%5RP-)YR^+W $S3VRJMK:]Y9&["0*VEFY9R>V
63DJ.WJPK:T[+ZW M>9A KM@'1R8K'C)HVB.B#>08NUI2>3=BL:9Q$S(_0IBK75!3=E#Y4C5-*>E! M-#HC;_D@'U7Y)WY>PM(XIR1M\S3N3YO9HF=DT9"6T#CDK?9FZQD]^MPW=$]J
MYE@)!;0466J7X^R?7HE*,(#9EJB/LY^#&KVKD>IU0D'>]?%;%X;X%<95\BEYE#8F@MJ :1QT4E"AFJ4/KH/D^<'>DO@N- M)=LLSB@8<1&VZYX1?^>,.%G!YUN_\6"4SZ+S:*MTS9FC%3>6S"?
Z7I&P =_C M'V-=II>:?]%QGZ#X(:S1HZZ)3-.N=Q@N>#C-T\B6G(M&^,-R4;FP(TYX[BKE M?_K 3ROH37^DS/_T?F?8S/ 2'PM[_%ONIBG%_#(_CFM\CX[/9\^P]V+S%X#U,36=R
M?),.R=$W<#6#;9^78Z&5V>G='M@2U:G)_UL3P= M'5^>];[YR@J>>)4V72F]R(0X,I/X%>*0RZ=Q"]>BH4PXEWIO5,G0B9:ZD2X6 X.(=(8:52414C9"Y2^RA!\F:9:6'*\A:A6YXD#6)D
MACOS#!VY!VO=W-\VI_RTMA1+'X_.N8@> BXI.-5;!1I';-Z;ZO3I #:B&A\L M(A(U2]?=2<4J:8G3[W_@(SHC>Y1=G5SG9U-SD8NP>;B1"@D+LCXPSEO,M<@ M>YFHQ>79^25"%-
='B_F@"BDWCUR%,L3(-TB]0WML$VX4#!=C?.7/;QRW>=M+ M*'U>CL&B>NO@&?^^.(PF_!46(BK?G_/G2;A#L6\3!?E!'_?SI2\A<+4KFL: MX'PT^S]3IO B@MBM&^[%C2_!H1-/<]
M9!].C07*L,RWUIS^.^J34MS%F7M7W^+6'%L8TBEI)DJ'EHIRU,,AMA$QJ6BC MDJH=YPD9Y494?$K9/=?M'=6W)8[@F02NCX3[7#'2=HH'5I]7[8"ZG-21HFN M/O X0PCLDS;4V=#<2#B)"
[^5@=Y)P)ZY>KT_1$2:0LE >Y6'X2 MXW=N!EYU2VC[0/;2PUH:\]W6=I#L@ZJZ@??A+!G;3Q_?Q;)U M\K,6255^_D!*WJ44=3T8\?2MIN*TGU@&=R-."NJX6UESL(T M_?9/6)7]G<@L[8J-R+=C,
[+8"KI LA*WV4?H:@UH&G_'!Z)T=_=P MH%P,@P"49#9=^14NUGFT4I@8?G>F7:@ND:,,_45UX802%]#FFQK@O&0GN_(] M.QZ?A>G1=!8V3BL(GZ1\TE&94D;%;QVY7NUXT%\@NIPB42FH5L-
X1P0=L&MA MY9Y^\ZZ(C5Q!+N9>@QOM/AAPVH7\K:I+77V59S<:44RK7/_S&MGM(ON5L]/? MJ0OM>-:'+1XJ#K5_\$>C*QIB@6ET]/J5KF.] WTVE"Q!!=XZ^+^90MS/X)GR
M0)@;F"53JNQ:2@;C[-J99KE*H(!%E324MI9+.W?;WO5-PJZ=&V?OD63'*5>G M5NQ:TJ W6(8YTNVNB0KB LS 1KII5E [\M8-MCH3.$>6;]LM,M$]1W^]9?ZP M-1&?
WAS;L>O]*4C(;>7ZW_Z:UNZ<>QR43.>^KWM/7ODUH905K4AO5#&&($QQ M/_ -'VJJ11B9)@W>E=H)8 R7Y5B1Y7Z"G_AV4RYNRMM91Q]*C $((^=SB9<[M/H@?*W*_C#
GR)GF5N5@B(^]=T%0T:= -!?=A+''P>&THL/[[A85NNMNX9[MZ+1G)%;1A4^^9NA\(\M^3X-4O;3B']Q>FV/=L>=914!;(&,*U.:GN3\2R9 M[/7577:4;H*-DPE2]..=;XNQ%W%].JZQALMC 1
:@.9<@8^DYD.S_7YB:UNG"64?9K4#$$]=1*#2+9J/) MQ61T>M8GL!FR!$G(DDR7[B'Z9!J)/O:WX'MCWCO%8R9\4V$<,SQ5X<\DOL1 M&S1Q.X@I*5YP&5L$8_L2SI5U98,0F(:[?
0 :W>];T@].3VG.4"R7< !;NB#Q MT]:6/'Z<-&[%V&%(]CNNGF]F&^_J53^Y>@FA^L#@6(TNC8%O*N3 MW*+>QBA;.+W^",,7"<8)!1E7]_HK;G<'$..VJ@*^E?SK6[R0G\YL(R4C2E%
M"EZ<*0I7FTG(0\]3I)E*,G6BNTO3DMJ2E(;KI7SJS4B'[/RK+.R9JKF.%9/" M'P:I1\@K9#@S#MHEMQ/$Y@RX.1H[V^\=K](6CWC0P[?C)N<(7'<^G/O2Z7
M2QY=3H4F"9U3R&FPJMUVGN8N]DD:\P#)?0@W"PE:!A(4V^VR!#/*#7BL%CUQ M7HYYM=]@"3E&T0GO7;O2U3;<#(JYJ[>OB4]G+K<8SB!88+GU^FE%/NC>O:>" M]OZWK.^V7NZ_?
LYDV7DQP9Z$!?OR0&<H=W/@:S9JGX4;)H6@<9GNO.'Q2(*#2]OPU+!_N9\"X.,IO^IA6+:=E$99[5;E M#2,F;>Y!<0WK::V"P,JA]\NZD,%_HZ$9H M3-
U56[ZD%08P62WXU3&W94&C=LZN_06S,WB^CY2'WE&Q UNMVR%1%OK,C;/O M[6ZC=@^< EJ_:A0L>X\0 CE7JRE0U?0FG8;M/E)R52UXW,N_ 2-@%QGWY->1 M#((T'9]^Q[].C\>3[W;,T_\3K-
_*TBT@)^-+!R3RRB$@!XU0DS\))A>0O@GP MV&:AZV.]=XTU1[+B[G]F2="2Y>TE)1LU/JN/[K>>$"C.D),3+:\<';8&^X M4N6+^3]?W;P)-1)%GEF,3YIW9.P>D7HJ%X4$.=$!7B?UEMI6,EXPB?
]XKNJW"9]Q18$5=IHX;I7-ZV^+>*RQ:3@U7 M%7<0L8BH"S?>G_/;1CP!>^^FH$PP B7O(AFX&.V;XQ(_[+YGBP@U_+HLJ5TX M6)$9@(]COY?0'3E*/HNN50TH;;K9_[K: *3^!%",IYD_DC9W$?-
KT[R ME_E.+IY_?<5+NM^'N$Z%^Y(W74T-L;?^JHI?NGU%ZS@ =TTZ$W%KY(7CH)#5[RJS5Y>+MNY?V3X=OP]LXK>6EE7"ZO_@2;EC1Q5.D%
M'IV,STV\Y$J#_]":#;_"$MX!YH+_7&D%3:0%^'UA$'VY#W1 >*?IZ_\#4$L# M!!0 (-J";%F>:H)A/1D -)< 8 >&PO=V]R:W-H965T&ULW3S9D'/WM>O7NBV M*54EW]>9:7<[4=^_EJ6^??DR.7$/?
E*;,8,/SEZ]V(N- "",G_?O:_ATYG%OQ+R5L3_9TA)DNM/^&'=|7+DS$")$NY:G ' M ?_=R#>R+'$C .-7N^>)/Q)?C/JVNW]#N ,N2V'D&UW^6Q7-JN7)Y4E6R+5H MR^8G??M/:?&YP/U6NC3T;W;+:Z?
CDVS5FD;O[,L P4Y5_+ ^XLW2(7K@<>F%/ M7Y@2W'P00?E6-.+5BUK?9C6NAMWP#T*5W@;@5(5, ^=#4|*V"]YI7\D;6;4R M ^TFN]*922*D79PULC%^?K>PFKWF3Z<
F5]GWNFJV)ONZ*F21OG|&`FHi@ZJ MU].C&WZ0^U$V&^?9=#P]/[+?S&,YH_UFOP]+WN2|?Q-4CZ_ 7JSDRQ.0?R/K M&WGRZN]F\S'SX^ >.Y!/#^V^V-!/+[);)3U[)-JW,KLC=[M174/BD3/_T\:
M^).6FNQV*ZL\TW4F3)[M94VZ7JUDI>EV@C]K7;2KQB%O_ ./(@(+Q](Q MRWN')(*WD95LU"IKI"%P_9&B*N@<2[F__ ^UR.ED\-P,$RI0!Y';[4C:2"$H; M @ &[(,[OX3S+08B*\52 QUT?
8^8[F$"781([L5]"/Z]ZC.LNNB(#Z*LKS/ M8Y R> P!]+CAIM:2C"7<-BM:K;9?BL R)5L 3E1$FRB4DA*G<&S$D2@%[T/ M:E,)V%80 K#]?H\;E/?XHFG:XCZKP-BN$/\: ^")%PZ<"$K#B112]@/=I;_ "
M<"Z$+4BQ8-+11UUM-()5R[VND02C M[&L4QTB44E;&[STM 5F#H@OB5CB:{6L-L *:I=$ MPB? 0/IC"H7$!P*C%$=&1JXUR) 8OT0:<'/@K:Q7RM@E$XWU#0JIY:G7Q@14 M4+#52M<%H-
O5K\A8TOL .,B)81*QG16H?@4PHFA1MH_J?"2Y$%)X1@:3>EQQ MP:K4B-0.V8IH M!/:C([! ^ 1Y[P4'O$3D/MK:.]KDU.LGV+3A*%"X!@@#>B_2XHD]U07 18ZX_ MO,GFX_D1F,D'L(,#M#U Y-M0(&?
(9BF0,A EI"+ZQDFO5=!U>)A7O M59&UT;<5V]Z-I,<$*Y\&,JV)O ^Y%0V1'B-WY*.X$) MEB?8WTX4,$1B"X<[<:R?0CY@ .A7J'3O1>KFO0H#7_IX&@.=9SL)@F^C#8* M;8E!"5@LU9
':]&\HJE;DN[AMX[,UKITCB)VLYA']B<*8LQ6MV6!@0RH@5Z) MAI6=+)H7@0%R("211@D?E*4QF36D R+G:9IR0X(K;@$:0U+2,3)1\ %L;BIB
M&@!C_1U_'PW1R"PD:$V46SHE$Q8>^6]@B5@;,"89Z$8W9.N2Z#!&A@)(\G20 M\F!HB!!LF$[@&XLXD|?L&#!PJQ AV MB<&P?A=9HW;+MC;L+TFIEQH-
=D*SRK0UD6@%@8D"NN9@>7\!B<0 -SJF@VPM M2R! MPH8K2+0=^(FL5])0U6WXO@-3H@MV4X<8L:38$!L"%&F%RJB=0E>2$@I8A$(! MP3>Z(Y-Z6%!'LA:@8&M=*HTH BE =N'-
+;RA:_*"%+>@5CD.#I"1P@XK2Z5- M_N_ \VX]%5.* MWNRG:Y!0CP6:-*#'5'B@+Y17E\R%3E@J7:<2ZBGTM?O&WO[A;QE""T M#$KJ"3X@!@H2?M;G8 +%2/:YBP %NG\,ZI>J$BX
>8#UH!/,UE3LC2Q+XS)Z M%/"JW2TQAEQG!6;H"#&{+ ^ ,'82:1:G<"@=UF4FN417]$2-I3(H$M.J13R M7B!2M|:9JY6@.6QD?!2$# * MRJ=YT2@4]+X!*%!Y=-L|T^MGO>
[WZ),%H:B0XER)0V5<:)/">B0CD -^CE]4+ MSP'7>QNC6]]>4F230D .H*;_*@W)CFR"ORV|UNW9>E\"DO;@& ,[(/^"G98 M^[0M9'-JS66%D,[A^Z2*&%94AWA-@8LP0R#:DH+(*1[-TJW!H.
<%]*;&MWI]%LIQ%,C;XLI6N7H M*'^E%%\/FNPG O-QLZK5$DFX!)(\';3C%!'L-2@(S3H=]&S5MU69+FB*UZC3]$0HH*@AH!].8M"T?4K 9>.7S33P(]<25^; XX8/4
M$#GP%TG@.,S"4SBZ]HFR(VUP$[Z; MY |BKMDVA!TE'K62LC"=J+N'M 6+KL@A(Y)A*]MT1&! /_B7V0QJB?(TN(K#= MDLV9H]2P! 2] K!OMO6_5*SC@S%Z8@$C&UQ(]R$]S_%F\-
Q'RUL%VK1)*" M84 -?I#(I8 J+#BV1F>L)>5Q.YE MJD'N&TFQD6M $L'@CUG*(:>5A8=|>8^!E212G<[.1Q<9Y,.E(_GI=#1U#W*G M"D F+#J3!8KDZ2 P/D)1BAW(S:'3CTH!V1/.Z:R!]JDS0-
=6D$.5BF '*NX; M|Y2CC$.D.%1Q3Q&[4AO3|\M#|J54VPJDQ'QTY6F#%7"4*P>)->6X$.W1 MO<1H$%,F"S%Z,R =)M)]PM)V-#KRUL;L2?6R>WG4Q*RJ!3ZYW'S(:Q,P40F
MQXAT6G,^B1*)PP8I"&)Q*[X0]M-0M@7XS&+6A0%(138?PM[WTM1=W-DIJI7 MZ=T>PF>(C ,EEJ+$L(O" &F"U=S[-58:YU>|S[9!QQ@&%D1>@O+>+-)'NE= M+UO0PL1D?1T,IHYO\E@&>-
V,UY7, M/8MNV%&LC21MD;FU_[A#)&^K>2[@0HRH2Q'J<8,,(N#FFTH^;OMJ:N0IGPH9?D+,0.P+@$&4(3 M9Z, $I^.1XO4_DZ.VU]VPQKSZ.H?YS[MNH[K\1*GS
4O5&":4M:/3KSEQ1&*Q#_&6'\HV5P&OFYOY"_.5GD6(PF?P(Y M>@CP'>01E7'QX\DJWYX".L4X]GSH;&ITK_KBZE,Y_ 3CN:C_;V1T31D!LV;*GK0&^
M73;HL[&@1T$*&GC\0E(AC>4D@M;H=7.+5H"K@-F-:FH=CQ$\P>VGX^?O_O66 M_IH\]YI]4KWUL;X9,T\B=+R-W,"&+UP98Y,M)]7[_]:OL6UGI
MG5H9,&V49]L\$/8XJ.*O/7B(RC<@806?\+TL(%>L9([Y3GBU9X7;H1M*]L@ M]9*M*::H@N71[6;[^(DLA1G\'GM@U.'3F ICC-8=F>+*":G2L9F142I;A$-? MB9: NMW:F;O>F;
(8T3!F%88G.,7TXDE5E6,#6Q^3Y84FY:;:/AD>'*&ETK^F M8E"O<#M!Y<84X,2TY^)[F!>T/* Z/8JY?X^ P"& >&P,OI. ^T_L5)$Y/>SL[MC]@^AY?MVY7$82%40L==+BAQ08U[#++#8K@:]
(GWR:378N!T3,%:[0!2M]5? M:&EL%9;KD0RM5VF,!BSL;.*]N-GA* L3KEQ*02I"P: :MUCI,1 M _DIN;9/;7'Q"^2*#3'?[Y93K\>R?HS,YE4U(U4U'6WO50PQRN>4@B#;A$O MOSMT*8$>]'I#?
JANYA-P#8)N.)U<]TZT$&IDB)I+,KGV3 MZ FN[G$ 88EW!8<^A"8Y:7:.2M+M&LO,*'(6\AU.$M+<(BCR76-KWM:9NJE1 MZSR[,|0"U/Z>XR=OP]-MT8VSX/4#3]-+
(H@L6"=*U%WQ3M7,DXA|TRO(==O: MM#A>8+6@?_.4S%:V"_+.?>$"Z90-[KB+9PE'@'J;B-C&YV%W'L=8N'E D]&V MA=GW>@K34FY$9<_S!.7F)$A4(^*8:DC#';;1?.?GD 6'9<")-:6;U^:.#U9]
M+L:C<<@D2[6M=*DWGK[9FLP'@$\)5]WO14F1&"4^%CA; M5S>BY-:YXT?9("(Q%9@?9PX+,\ +(BFKJ2K=E%GAG*GM$O/98NMDMRMM&&F M?
QMV.YT'W!VI$X)0!28]L.#\G*N)GI]'Z[;D;&055Z[O.Q56*KGY<0LWH7(Z MC<^C2E:']' <#/?1F:#]IO@FXX.3>C34XQTMQ2P"S5]5/!,E4I9G4X"BB70) M#+?"'S0:7Y?:IP//8ASH V4@/OQ2 M?
TS#Y!^K%4NK$[0\GI#%#KR;!QWR03FBSHPZG9YWA 3'.@77(CJS4VCFW-@D M/^]J.%(+"@1(I7V>(*K+Q&WF@3I$I]$2|>MT$E40(C3U(]$$?"R:<760 MN1"$8H.S?
SC/9R>1(/R>8B<'T/DXLL@,AF=_Q9$$OO(O>^29[!)XMH2U5% MK_L>:6A9H,*&L9VA=@1!5PUADZJ#F1_RPG#D_[9 6XP(&*]IVV4I\4-?@HCUT M;G3@CL]I;)ZUR.H>Y\=H!TN;DC-?
$L%0VZRO6XE;1TRQ'3:XV!8TSDU4B(> M?7#Y$?H4=BFQ[I'K*E1AF_1Q8QA_;(MW%,.9W$.HQ@X2F0DFP47]5 &:D+ M&_6#N7I&@1."T1C7FNE& ^EA3T'RWJTC[-GR"-
:Z,GKVRY!%#0F$+5]5,4ZM& M-#X=BK5DOQ^E5:"^B8@.,,_'J [&@ISC\R// '"5:UA6A;C/AL? <;Y@&*V]% MK\C2=A[-(Y,2."H4Q-LU%,9,:1S;LK%LIHPF46HQ=0PS&[QR=*2.YLJED,Q=
MMYL6[,VC4SD_TU2!>Q/[GH.'\KQ^I:&5*\|GN4LOJ*EZU;IPO-V!U+[]X1K% M0V%&[S,[;AA2)7:)%0/=J<1Q;=7F?>F4*%*W[@/2ZUGX[D<_H[QX''J38[8^*;O@F]]**'FSZ.C9172)L.H:6G
M[A9>N$UR6K"T]]J.*,>$.ZP ' 4_[[C78^E]=(/,NG%_HQ'52#5IWR&]V4KQ MI:X_#>KHL/AG?$/R%\A3.>K$'7RKA 8#C!SJA/26,X8+$]QO>+@\02FN#YJZ M98J#F^O/U2>X==57>$'=H!S9%P*
D'TL=7._GB'%X=WOOPZ@\:N4B<=; MKWSOP=^3/6 #1A9UQTD^'I(02I_#$RM?).U#84(?L+CDR6TPTX&U B'JM(47F M6710Z4EJ*$?*,+/I?T,9YG0192*=V93B-Y1HXGH+V,?
9EZBW7*0IX5^KW-*G M#]J1=4GR[L=673@ .%8T>?@.44BY)U<1FSZG7/+CVB9@]JH6A,73H630ZES/ M6 174%RJX\|MPOR4ZJ-5^J,UE$#RATI40TP+G+CX(K6/'HG\7=G'0 WA";![M\C1-
2\9!DKIIR6=7&7X[S$?]'N.H@/,'0'RDK#%+.\9?I*KQ5AF7>EN1.3I% MLI("M+6JXQ +J;OK$2[*^2%N\E'5/2&C;F"0KBACF-T_80&S)D@:Q_N\'T0 ML]6WAJX9I[#[HY;VBAQ?[OW*X_)G_?
QT&BYKWXXD,:NRRG?CCJU],@8O1A M]HAOW|/^#Y\:T"|S=. ^FXENY6EV/K[(I^/+Z,ET=I4O+L?1DTD^ 1!G\ /H /H V7PQS^>PZKLPUA&2?#_@<&#5(I]/IX>)\ EB-CEXO!CGDXO#U8M)?
G5YD;UW MM]^ZW_SJ^EES]/%U44/F?/9[SP\32_'$^RCQ3IU5V% JHAC2X2JLTO\JEX MGE!M^KM?7L247 #LY_.PJD\W0L\C/1WGLZ2&O&.Q;ESR",[JRS0%40]L8.9 M++IR^N>KTG]#_=)Y/%
[$^3"^N\LM%1VNN MQOG%Q57,__-Y?CX-JZYW$B\#0 0@]Q%B9]"T)):Y]/QX<: *)U>2CA% GX M\E"49_D\TJ&O6TSL\NQ[510@:U\+TV 1K5 BSZ[7"$M0LWS1HZI@+2X.U6@"
MPC^[.GP\S\>+H-?71@E06WMQPH]!D@7|W$/KI=7AWR:YY?S/&K,(IYVM/?+ M:>TQ[>7?EN0?:.11PJ7C05?9=N!;GQ^2>_ M[? D])5MJW,JD5PM\LO+1-# ?TZF/7N?=HC;Y:0<%!;F)#&?Y58]%
MAT3NXF+F?U/T\&ZLG4G&$Y=|-TU$0MA[LBT(!4OL?GJ#=SFP4I-I/AE/$7P MR14HV/AI'VR4'0V5 $+9(M(1(W9'(;@0#O#2A,0Z9N:T)N"RJ%T,UY=)G)]4:^_WHZB6J: M45Z=3D8-
M$#XKM8XZ4KZ'89^K=7^JE'' ?18D*BJ.3F/SB"A&=J=*FL7Z=H8 ME]QU4L?IFH?[1\.EA8]VENLQ.%F&\)W427RYUH,Q,&8Z>'[?3QJ?1;\S#:'S MAGY-&RO6$ #P3T[[IYG[P>YK_IWJL)Q_[?
M[46_P[9*N897QZ/%QO0^ /[/ MC=[3KU8O==/H'?VYE:*0-2Z []=:-^X#'N! QOS5_P-02P,$% @ VH)L M60YRV(G?!0 DA(!D !X;"JW;W)K&ULW5AM M;]LV$/XKA=-U+:#:LJPD?
DD").F"!6C6+DF[S[1TMHA*I$I2=KU?OSM2EA7' M-I MP[!JL<67>_C<|>YXY.E2Z:\F [#L>Y*<+;}K"W'O9Y),BBXZ:H2)([, ME"ZXQ:::>JTRI@:=.,J,A[41@>]PHN9.?
\U/5]TN>GJK*YD/!),U,5!=>K2\C5 M\JS3[ZP[[L0\L]31.S\M^1SNP7XN/VEL]1J45!0@C5"2:9B==2[ZX\N8YKL) M7P0L3>N;D293I,Y2XR8]ZX1$"')(+"%P_

4^6#;16\;XJ7[L4@/XO[PQ7!N*RD24:*G_06EHE$0C\)_ M:OK@.(B/X^=.]_'U)%T>+;X[W?)D&(Q. M3O[U:'SI?PK9J^W8K@M&\[AB3*%41C05%N:*LKJUKN"L]
<8;&$P'ITB878]V'8C;%"R7.\MOJ*98D" MS)=\58D'2K05 MM-2OBOBZ'1E%HVY_O24.^U4\ZG>'FUU"3B6X^T"^"G9O57!@KZCJIG\A_3L+ M+3/3J]#"BRY45G.*B'TLNV@"_\GZ: 'R[UU7T5[KG:
/7>O(7B_HZN6?S)H M>IL'EPO_SK"9[E]K;KF>"VE8#C,4#;LG1QVF_0N(;UA5NE>']:)6%>XS U1" MTP089ZOQ/4$L#!!0 (_J";%E2I/+$[8 /,7 9 M>&PO=V]R:W-H965T<-
)N^PMWU=+&]TC2.Y_'>&;\C"^7 MVGRUF1^.?2]R9:JZF7/ET\')DHN.WK4BA\6M3<(=7LQC8T@B>>]$B'\1A M>#$HN%2]ZTL_]L%<7^K*Y5*)#X;)9JBBX6;T0N5Y>]:+>>N"C7&2.!@;7ER5?
MB%OA/IOAC1?# ABQ1+V_G/R)*9UE_IY6UZ MU0M)(9&+Q!$"Q^-.W(@\)R"H\:W![+5+DF#W_QK]M;<=MLRX%3Y>ZC7OXB&GO."2_1N?6_;%G/C>,>2RK6=-$(0X-"JOK)OS=^ZA, MP@,"
<2,0>[WKA;R6+[GCUY=&+YFAV4"C/]Y4+PWEI*)-N74&7R7DW/5KJ;A* M),_96V6=]>!O9R\'#M T89 T,"]JF/@ S)2]U\IEEKU2]4@WY0=0J=4K7NOU M(CX*>"O*/AN& 8O#>'0$;]C:.?
1XP[JK9PTSV@]#*?+4ECP15SWD@!7F3O2N M'SV(+L)Y0AVU(1DB9283#!O!DAQ*R+G$5&9O^,R MY[-F*!QZ?Q(*B.=%! C+:4E6%CA8/! .]@$H?#9__;)Y+&
MB6(F3)LY[:>7(FF^1/[+L/WRO*!=_QT.N]&(@C=&6\L^*U3XV(^^067?'7U' M[Z^LDRB,>'W-I6%?>%Z)D^-M&WD&<9?IRB)B[._=S_OCS8?7=LB=O??B#]ED M&@>3T:@S0O^B^-
G1D5VIBU$W=MQ%@51-'G%P]%_J M^?7.1Z-=D'@:C*;A+O8$OHI^'CL*+N+Q'A4O@M'%B'W2#N;<;\4TQI:.)T>W M:U/=6F8X[(;!9!(%X["+$G4_G\7!>'2^$7_C23 =C__U(G*JYTVW:O_W:^]?
MK"NG?P[7FU,_UW7H-D,5?^*$*;JG\C^V[(%$QD\4GTRB;=2_53/W?0_')V M5:!2^P"N+NG4R68&5Y3EZE)GK5NM=2F7W;[878.Q2^+Z) MV%2F\Q0D1T72)WV?9S?;"
<$>&%>I5BF(8,IFDA%CU);2;R.W@JMQ IMC/F* MMG->X2#OMQ9V26JMC6>?W8/1$ST_@+Y1)2N/F.' >O*M I]P@&Z/J9D&>D,F MP2TJ&,_A'V[8G:<7)$H>(4^5?
$?VP;=@'XFN2E)!CY,K7!:Y:* H5P&SV$] MNDA'3!4'.?(.#$/@'T3W\N::R=&I-*Q'P'#FI8=M?C2T.[]9@"6[,6 M3;)7;RFA&_ "=5% 8A-V(1"\4>!.KIAG4 KRJKD<-/IRF23^(%FA6,NJDL9$-
M<3^C68_[["7<6=O,0.0%;0WU<8+ZN#V$,NA&'K.("#A(=(Q8$W>$#AIC0:2> M/"(+(G:&.A)2=-.3%:E+N!1MB,JD&\HRQ2\-@Y_([9 WY679Z24XSH0-UCO2Q%9P9S5,HTF0WO$E)*]{Z\UL#I$IE
M6UGX>ODU2),I2W@D(ZWLNIM#K1 F]VDJK:V$]6&IB%5)MKD/*YOG[(J*^S82A=N^9W.:T# -C5Q>TP[21 MAB<.IUAJ6-$^'PJ/TW/J(_<'Z^=6=W\D @[L^#M*9J0&#B=#Q &6HOK0&;(2
M.)0[>S'=:" Q,/-ZAM$B ,,B##6(B",-P-A^G%9"<8 MMCK8AULD==]]WZ!S$5L(L_#7S9:HA'+UG6P[VMYH/Z\O&O=V]R:W-H965T\D42% MI/SHK[^I%:2O6LW*5S@?O&:U,QP.'/FQ9,
[(;^HDC%-[NNJ4:>S4NOV>+%0 M>JE8P6EJFN%]'OIXN:\F9V=F+WKN39B>ATQ1MV M)8GJZIK*APM6B;O363#;,;5SS;:G-QN+LI*5;=L/TI_9*8K48!!2\9HWBHB&2 M;4YGY\'Q16SH+<&?G-VIR?
$W&0MQ!>S^$]Q.O.-0]QBN382*'YNV26K*B,(M:GSM9:'+TUDV(P7;T*[2U^+N5];?)S'R M*.2$,-:>8?>U7+#>5X8YQRHR6^L'9.(M\CH1&
M+\B+AJM&5E[T"E=UDN+#DDR@'%N6YNQTADA03-ZRV=E//P2I_^X%/>-)S_@E MZ=^EY\N2TCEY3ACYZ8;- MEG!%*)%8'H'KCL]"B W1(*${<>H9>9)55+.":$&TI 6;?LD9OZ7KRJEHI.E2 M,E
T!6EP-5{(@#$#,)X:%:OF1PP8@GQ3W0\;/U:OQ^M(E. #Y\>Z_&4T>HU M643/'O&>B(-[BOZ!1NH=Z2"[;E36-LO>Y=NE"/\D2P]/PPFZ\1+,I^\N6:W3"I: MP1=OR944M]RFSI?].AR?
1.G;O=TXB2KTXFWH]\K+(_V[?A'ZVO^>% LN^B;/E:_D& M"K=,Z@<;83] [7B+NJP]TB"G3!.$R2^T>;"'+-\ITD[YV(Z(Y)%79DLT&>- M(;&\?N0>=OI[Y!JW&8R;GQ0S;OC -\RAX2 *GGC_-
YJ70)Q\>L?HB'2P8^#' M7AQ'$\MFB9>&J355IZ'!A(4], "I'3T:>' O#*O"R!-#I9%ZB"RGL<3EM.?S(M_\):B8U&)F:D9%5A@<4;R&_@YDZQ/>%!X$&WO=MA.XU2\H'AC%) $* AQ%M6
MVZ+QG@2E4. ^.USMFJ,K;"496A)SBN'E-'YOG9J'Z4>;O5"M=NE):=;',$ MX;@5^^B-4^@Q1DZX[)5^*R3PR#RPM48)$&Z]!(LOH>D_\[^K.E9V"H6+G MG+J6$":DM9":_ ^4V]GRJA)7"; RC-
PD"986U2A986.L#JL;YQ;B=S>PX*0D4\--ZL;C4TU)^\|:?*0^?(M!=.S ME+S)I74?9!K%GPG:.ZI(T3%3N-D]-+7Y"[3_17^M+&W;8U,9@#1HR$?F74'?
MNR1=*TFUD)RIZ=T^LGOJA%X"WN!N.!U.1O/ E#87!?[IFE=<@]TC)@U"__7# M8R^#!T,$,TK]&*SF*[315>5FBES(8C3FMY@,<G)E=CH(!MG&6O] ?C2?8H$4 M')V/T,9%G21F!^%
(N719M*1RXDQ3OLOI)ES=27^ 19KHD!TH/ #!E" B4E@N MVG-5$ZY ,ZT_OL?!]+V?LI^DZFO7JKO.%,-?AUT#*MZH3MK"G5,))")+(D03 M;[G,)C$;(L7$R6"NG?
4=LKDLCEI[@F8'S1WCREN%!])L[&50]&-/;#]A,(# MYCMD4DXK2)>BQL#T\@CM"JY[03!39>5NV 0C4>HE43(F;K0XJ^5@)E7RMK6A MVMMK[%^"27482UX:I^2&5LQ%/X
O:N0<>D]:^F!G@QUIXOEI<$# $F5C=_K4 M,<;WW(PY4^4S%-5]0RX])&ARB7&*Y\CRVOG"Z*,T['^I;>,#W@5EX0%_T#Z MI-90KBQ.8L3#3^"EB=
[6E)U)R5EYRW2_P)ERC%;_ZG!*'A/N>/T(QM\KIEX4 MI'VX[P+7-@> WWC4_N&>CPAXS-8G/(6/R8&""HQSG?%|?E$@>@*4Y3$$7RF M2*Z|V!]Q]!W!"I!4'29)M"D2*'&MBHV
MJ9[6+V+BUD2I4Z\5&F<")+UX_'SM0/(H-\.!7!1S\KEDS2-9F(B9=2(V M@194EUN.G%4]#+;KU;#E^L&V ::T;!O;JU';9A=HJ:|[RQH,O@ M%LHZPR W"P=0!'0?V>CQ6&E>VFY-
AZ'024PKP#CV:QN!@$/AUN52\",DP_MUH;FLUNG)'S$4MR!VA$ MCI}.&PS46!]%:M>$%%$)KK6Y%O:Y+&FS9>171BM=PM1LZ&O0 M^IH'9'$+VPMH>N#Z_@.(>DM)B^N-4-A, ^_*[@-
"G+K'UV%W>+H^=R^V([E[MJT:Y1I[0_;(-6/WY,ID1Z=Z2W4*+UK[?KH76HK;_EHP63!H"?-\(D)[^80X8 M'O3/_@=02P,$% @ VH)L6>)OZNMV"@ 0Q| !D !X;"]W;W)K&&ULO5EI<]LX$OTK*
(TKE:FB99&4=<'15>),:C.UV7'% MV9W/$ E)J)"$!B M.[}^7P/@I[WA*_$@RG]N[C6> M+AHNJ.?X_B3F09,8(8?WB>@^9*(NS^KKE_LKI#EP4WXDIYEO\NT7-\,9@.6BB6O MLO*KVOY-
>'TNB5^B,F/_LJT[&\@4#EE2F5+DGA@2Y+-Q__N3MT"&8C8X01)X@ MLG*[BZR4'WG);Z^UVC)-I\&-?EA5+36$DP4YY:'4V6@*V"_+]"2N;XHP8M6 M+A)/]\'114?
HYNR+*LJU8;\4]4C[!]+0H1$D]@7Y$)UD^" V0Q;/ A:-HO$) M?G&C6&SYQ2<5&Q[2S!&.#Q-2%KPS&YZ(FP'"W C]* ;W;WX*)Z.K$V*-&['& MI[B?L/=INNF0.5+VYJ=9-(JOV&\;H7DIBU6J\;E@,&
(I\H70L&)X&;!R+=B= MRC>|>&:B*{46*9-%/1AGF2I6YUC0)64;DC*^T$,BVDB'36<87"MR5?F:\2$:V8+#U7),[J7;S9;/4FDALB>V7P5*%CSS%UL9MMRP,(Y8[H]/(7"BH#O XJ-(6IVL..)I([7?
_8=Z MK'>C28#L*=>. "T3:\&?2Z 2_R9#,UEF)PE-60Q4!P]2:22WM0:?@KA$AR%HF M:TA:"DH0>]2=\71)I36Q08SEDMQ7KK6J5FOVA6L0PL6Q,U=[(\^,@B!)5]5T M?
@N!TE12<8,QNRXR["U=09$2C:X^26U*]LL3]+&E]-[?:+?#*VO1SO$'D2BL M'#W_LQ/K&%<&:B,-C Y%XRBX1$R0HGR1B5YPT+6)RJ%98NW+/HF%QO8S>2%R MEQR5I7?+Y#*(HNA/WM)-D?
H:"D%3.\811G3';[M%E-W#EH]"[LLUFNZ(%#?M=/G'>]36>[_RH@[UY8!7\N4SWB[9BL; M^7$\]PL;#K0A$DV=LK#I N4^]6/D6I&%G\Y&,8)!E"-"Z MZO0"OG.?B]%?
J\RJ.'ZEBFU,G=9V,CJH;>R3K:OD%G*C..JX!RI-:Y4ZJ;OC M';0V81*>N?[G.&8N27+^3!Q1)C4)"7V6?34)#KU&IX%)\T-TBRB4X1!+(L:I
MK;BB"]S*84S3SYZ#^=PV4>|'*#W=5'"H(,VL=RMF$$GR1*07+26,JI ^2'!BX MSN9GZJ]*B*-)^NM(MJ4Q9H4JH M)72"PF:E:[5%F&*RZ+&L-MBREN-TZE5AL0-81G2%.Q.&03R_[-5:R.H05[>P
M8[!:VU3\I!&5TB2J6^$9A0;NC2>OE*K7%N..6),@#NC MX65366P"N"I"64&)3$-)EVZP8N"D + M1P&M.,1 SDJ$+CE!W_JFP&I%/%I*E3VF'K-I*1?50H1Q^\MT-A5W4! MJ3#8MRD5I+-X-
HP:/T*$0A4)BB3RMIZ)[+3O8%&GPG1*O:9Q_5PMSVULD6?I MI,$P3^1+K: WH]QO2X6K?+0MGJ2QY[R/*HBNV?N'.PPZ:B,3-AM'03V7O?5H
M^!]NTW@*=5Q@A/F"$T3#\ZVW@1[2&A]/^D+$H<9,,#W(I*<*-EMTH[<(< BP5 M-6OSKIF1_ZK_?7_4JTT!BL-@CX0BM_L0'V7^UEH).0O%S, ^=N7[/*D${-3]M MZVG0UD/D.%7;)-$5Y6_'F/5-
9VP>3(${ VF=TG4D4GKYSS]9{LQGP?QR7\') M- !40T:4-)\>OZ(KSV@63#'EMRO363 93YH%BAU9@,Q"R$2M"E>)?;$ ^=0O! MGQRKE7;A6KHV9,B>CSRKFM%\694X0V ;9%
[E 6Z"7#7>"0+PF[27RV2MP2N%:0M?[M]M2%9PF 69ERJPDDJ@K\AI=_4+$X@88==A)+HE%]\2)/ MAM,KXR Z<84KT?:UVEK=B6X%-.G!+E%"@DPFTC,E#,H!"IS"6UMXL"5X*M&9 M:D?0FP
[[B A@"NMS';*]C9W!?6$#,08#=-'BZ\;<'F# Z-0(]?, ^2Y&E^YT# M=VZ4CXP%ICD(Y*8!#XDRA7[KNFNO.=(ED A]U3[1 7BEU=>_X;)P=KG$*$/; M=2>&+BE929KOS$6%13,X<:RK;NU;:Y&>ZZ-
[:Q(TTM#E@N4X[3MSY@AQ(LHQ2:$ M[]2VX.TL8.G.QL-1#WR>Q<-)LT V;JR8UIV39GVD)Z0\5T% B^?]K;O.5R, MU%[3MY)'PN4&99O:J|,.0.UK ->?4*&.,P#,ZH*5T?]+F3O".1LNW==#@BE<# M-
GR)KX]4(5.,OL"]H=_ 8QOF8OO7XFB.2Y1W/:.3D?!9'X&ULY5Q[<]LVMO\]Z&\]GJ)YU1;$FVTZ1YS#AVTTTG:3V)=[O(]T1"$F*28 %2 MLO;3W_ , 0)"B[<3UW;TS=Z:I)0H$S_ -
W'@#X:FOLM5LXU8B;LJC'H@LM8UIO0W P6EKOBOO/%R2&YX?ML-)3YZ=[R=/-;IGLA/L($:R= ^JG*5]^_ M(B M??- W]OYG1-^5O6A.)Y.Q'PZ/[ECON/([S'-
=_Q8 /)T)^/3H//7O\R>35 >0>Q))/;DKMF_G=B[IWM^*.Z<47QO*UF(2VLRI7*X M[,356N$]M:QV0CNAJXTI-B2*Z#<P> 7C;)N E>RHL6;<)!RC5Y])=#OXQ;6+ MVJA*PL<<$*7*\8-
V==LH^%3H,'0"3OY"[%X\]JP+L^;,.S:]7 _%7_R?#X]?CG4!!)O*F;) M"%.M#'Y,A(-3K+ MMA&9K"K3H- V.@<- 'G2N=:BC. 34@<,"0!)#?"\@NLJB(<'KZ@LP&"TXV'NAU9*U M@DQT$XH6M2?
O4E[#E&8'3.]$+7=>&MNU!FUE MIBWR("S0AUPNT3Q6%ED%OUKI"D%(+-NFA:GAN=KDH.KWRU'[$5NT'O2/#)0\ M24E!MYK]\-*!#3M4!"L$C!85G:%GI2HDR2&;P7DRZ=9B"1D-
:A"H0RN&CV@P MC,<^&'4@M@R2_7VM*J$V MLF@EH<$(83VYDNJ!X[:'2>%B@.2(#&)VLX*YE6PC$%C'fO^5!4E1M04 ;7HHE MH+BQ J16#.@Y L3V 9K]BZ.,%#TB'9+ 1D= 'T$]"O4#2]H E
L/!\PS$30 M0W?'^P*80HS*$$!9I+F"VTQ-+@X3)M%)Z+(&F >0"& 7(:CG2[DL 2.$+$V+ MX3!2)Q5&8Q11%X.EK_%@T19RCT-4#BVI@<;R:[MAGC('E
H9K;R4D;I1%^@H1"N4)Q0OSB#)KJ+I@@N>=':;&T,+=Z(2.JIE>< M2$(Y+A">-^2//E"Y-.PT:]E <"H*L98;\@%XDD7)*H8V,W2^B#UH/0G,7@:8 M_= 9R\=@9RF&K$%P"P7"2I.U9@N6(1N*X?
%^4,X*8BGD->= ^.7-!)Z8'HDG MB$SSZ4N^2%]F+[V"QO[1=2/B-&.'&!N9<&/LY!G0T!#'Z*T'L%V";6Q1, M?UYQR>2<0TGEPD/(8PC"M8UDI2,GX1JE4*@5#*[LWI@6P(T%4/<%'!CC>4@+
MQ%L#(1"IN;(0+96*X/$!J*N('73H7/S25AJ8 "X1L1%/-LZJ1("/0GM OUPC4K GGN"@,6$D@86Y5UPI,>K$;L2BF$+1S1H-< MM*EW*E<(_N?:9JUN#D5GGT1X#3EW)-VJM9+DS/XA@[L9%-'S,,'#LJ-
J^C-@ MH@FI 0+P3[,$5._3'>?:]%:J

H2Q]LD_3,F3-GAI?YUKIG7Q$%L:NU M\8ND"J&Y25.?5U1+/[8-&?Q36E?+@*E;I[YQ)(OH5.MTFF4?TUHJDRSG<>W1 M+>>V#5H9>G3"MW4MW?Z.M-TNDDER7/BJUE7@A70Y;^2:GBC\UCPZS-(>I5 U M&:^L$8[*17([N;F[8/MH|+NBK1^,!6>RLO:9)Y^+19(Q(=*4!T:0^-G0/6G-M0*#QUP$SZ4.RXW!\1/\EYHY<5M+3O=5_J")4B^0Z$065LM7AJ]W^2H=|+ADO MM]K';['M;">S1.2M#[8^.(-!K4SW*W<''08.U]D;#M.#PS3R[@)%E@\RR.7< MV:UP; TT'L14HS?(*<-%>0H. RKXA>5GD]N:Q@+Y(S/ Q!Y/=[0- M[Y_$%VM"Y<7/IJ#BM7!*)CV>GZ'W?0LX!, U$*1+1F*:32 _X,WZ)&81;_8? MT^N|+TY[!X:X)&VSXV#27+#^\F'[-/9(A=]-PNSJ' .*[?SWI/)6 P1 MQ$/KE%F+4!$^CDC476F(2R,@;*!Z1:Y75TA3\& VBC[WMFZDV6.CY=:Q1[!! M:]&Z$$'N!.UP$G@2/ZS(4*G"C*60C:-LSN%[4%Z+]Y? 3W+LHC]'N \&0'3 M-Q2WG]Z/AT0-DOI?>(+8Y8#I=7:*Z#>$.X&KO&@'<]G5Q|\])2V/9NS[3SMFZU9$("Y[##",II MZSWYUW+DUN2ZC7I4,HR$+ ,TQ*I7!46]I=;10VZDTI&N7?W9)2MH RN3TTBH MP/D9&U 61T*K9]8+F"8N,GA$ K=3U VN$9R)Y!PSX?1!-7@<:O!9$0266OU- MQ5CL VN'X@)5F0$, MQD43(2;8K@H*8=OK%C\,*#RMR;(#_2VO#<<(!^]?: M\A)02P,$% @ VH)L62CX7+NA! A L !D !X;"]W;W)K&ULI591;]LV$/XK!{4H-L"5+=F.G<0QD&0MUF%M@Z3=GFGI M9!&E2(VDXOC?[TA*LITXWK"JV")Y]]UWQ[OC+39* S EHH6G2DAS%976UA?# MHJQ# =C,R6B[\WIU>+E1C!9=$ MI\$T5<7T]@:%VEQ%2=1MW/-U:=W&<+FHV1H?T'ZO[S2MACU*SBN4ABL)&HNK MZ#JYN)DX>2_P!|>-V?L&Y\E*J1]N\2F_BD:.$ K,K$-@]/>(MRB$ R(:?[68 M46_2*>Y_=^@?O>_DRXH9Ov7B3Y[;\BJ:1Y!CP1IA[]7F5VS]F3J\3GC?V$3 M9)/S"++&6%URL2@XC+\LZP9!G^0NS;+6D:@/:21.: M^_"N>FTBQZ6[E >KZ923GEU^H7O_7I1D#-6IX*)G&Q= 2KCL=9BW&3!'S .H;Q:#(*)V!51]AO4CQ@MW[U)SD:7)QA.>H:34^C_DN%IC"2-X24.?"L1 M;!5\1&WY2B!\418-N)-L;W>U!4N"I1{Y:CHVH_J@>[!8K0BJNXP8OM=42T'3 M%>;]J\]JF9R"R7IN;6J?&2" MI G-[;0D/*/''!!3BY1GP-)22!|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|L#8HS9NTK%EZP-! 8G4#$3JUC"HM!$ZAA_6TZKD]3 W?66_=KD MKG)Q!*FK/B3IS(;6U\ME,*2U(6\8YOOT.83:+Z$%<)|T::)#0(+);60K&S! MZ@1E3IL_>6KKL -PW@*X+,F=U.XF$@2 MA9QM$-?1BDTO3/4-6M4KI_J=+"17N[G"R6A.GM%:H#EP|^9H BC.15(P47-MY^A^$:/3DS-T@G**?F6L%H2F(L12:6L&G+0ZDT;'?4/'0[>,RDR@&4TA[<'' MA_'# WBL)3]R#A NH+!!G?T&N[?H]YYD>#_?ZTOD_]=F[U?>*X76O MP#-|WGM>0=]E-W1 ^/YWN;2-1D03&EFI>O@:K.CS)V=@?^NK]$>20]I)-OL@ MLKTT\;L[\0^Q1S_5D+BA"2L!G?Y@v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{_4 M2]G>@_G;5?9Y?#/.EKK6C;J>UI?;PBDBH>Q:4H WU3$EG_]N;5LL-GG/L_[K MZNH# YZ^>IX!:, RHE/6HLNPO3'O[SNVE,# WWG5%4#$U(1L\0>$5G8+8JJL MIH$5%%C>-0VA7JNV:W16ZUQ;2RQ':*ILH*P=) C/0&(HD_[(R5:$;ZT!E^E\=:#[*5(V- M*KO*%M#15H@RN JC2CC58)YL+1*M2:*S&SJBJ5PW02@!E[9IVK#5$O0IZP*2 M19K8[|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|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|YC"YSIV.)PG/\<;Z%HU]9C))508ZZ?3 MTX=,_(VW*=Z1N-YPTK;'!D/KV(^#[6^S*QPQEQ7Q)0N M-N\E:\0GY>S)0")/TAB0R'XR;$TY?4XUA!2]]V/T-!@?&(R05M!=TYE/A:H% MCC>> ^GJFLI@';D^-5NE>XQ-3E7 M)6^CU3I 7:+Z8[PMD3:9.CCEX"&]E;^#;L')E79% AG'N;2-1/8ZU D8!5KD MD_ZJ.%2UW88K$4/\5:FYP733W/?3!)(9RUW&H&?+*VL>@=*UJE4!-\A4E;GS MUF? :PA&U/L/5U4E\|9+W^EQB6?(9B?^0EC\A"FNR?[HXQ'#G@>'.#_+(9\N$ M_-D9IL&:QN,@,"6E1ANR.GNXQ^E>-I"L=!Y>N:5J[7//#Y]KKH#=M+Q^2,6M M<2Y+L60D| ^1+]*F$PNQI;EPN?&ZZUN=F*6L;DN\25_*9K@-[>)<+4%(?U1N/ M$4=2E;$=(2*PO0N@W.U,WO4MS_):B&-3 .B[4G;#;20!C;]@[$UHL#C?KVL M\CZ(49GJI.$*T\W;15<%\:4$/!DPL5$<(=2YZ$2<((2I$3;G9#?5WU25<^4G MJ00TU-)R9!9G=7I=IWW;,_XI/#,O1IP",0|^/H,DPFQ*IR(:C"W< *+EU. MQRS66/;&EA)R5#9BH0W3:L(I\E!CG2,*##C=;5XLN0=8P4NT/;:[@VP]'5R MG^+PZ$I0NS'DIE<[.8]P3TSC MP,,2DHVTOC!]0%X:GJA]MV: ^(?7;&4B/NW*)/P5\$U#82=/3KA MTM8>6),<+D_I$4B/"?HULT;.%)P/5K%T"G'(YT!<<VP52J:U] ME:W,'3B$8@,9Z_L'2E*+%#:42=YJ7XD/:03Q]XN M']#L%T&S7QS4R^^^X"L9@AY3Z@R=GZ=_.\4M<08X1N,P1?"[6/+#+W%;SJ8&(M=PTS,#_ |=>Y*WAU=2G9Z#F\#MOC#J^"M.1Y.0+#]J1E?/4_#_8E6=Q5>7 N M+%;;#GXMZ1A1K4>1U1A+OXH+_%Q$T>_]"(T:P3^(9BHT(CC6A:0VVA4@)3D% M70['H#2< O^5FB,HCB.KJBVXM]0X*[ISL@]D%@%D8ZE0KASI--"R-YR;H*Y M8C MB):T5^VBSOU-34$&AW:VQ>KC[)<@Q>]J!-^=4) A3E^%S@#9CTM6',_GK_, M?F.Q'"%V?R0US P!/J 6+H-:N#PHV5?>1__(AH*V-Z0>'@T$@JZ*) 1HXINH MFN-#2T&A2-D-2]FU/QT"RE9:%.UUWX)=>PMV@!332>Q@G7Q3S=5D 0;;4A\X M- !+?%+R_B%XPO4D=_"X0 ".ORV7D2F]*;S/1')"$=0>VU4$%65CVZ.R'KF_MR)&<4[_E.%G.:66O?T0K4TA4L=H58>C7/&K*L5JI&$.SWI:%K\=SHDY$+_H 4*5(|=,2V,*RWJ%D=R*]VKN?N+*01@2E+6D#TJG MCJSQ83\T22VQN_/3"P1#L+)4%\:2'44&P2=O@@4SM-M6J&G!YGA=V;O* 9S!WGIX=,3=LK^KFIIFMLM8?N<+PL)6*%L%;MN-N.8M)6G M(97J,VW.'4_S>,E0CIEK4XJ;A7K5J9&$5#B5ZTMAHM:;Y*G/X+A*19+_ MCG6PZ22IAOHT9N%?3=+6+%_D\/DSR=6S4]C/QZ8@R95F:J;+RTR70^0:I]4 MK;,[TH*EZB47&1UQS*UN^AG;-!:A@!Z"0RV49&-['1$>6XR1Y/'3DUF"GVN1 M6).R=!V>_7.5)B%_5MYCSVY-!8G%H7&T0=ZD:I8^J@I,[Z=)K0/*@JRB/90H MF,XBC\^^!22#"1:&O>Z9X'?.!),-&^[S_P "WWK'C8P^S91'4Z)K3JU8<7*2 MIF9?VQ56P7/\8ZQ+0Z3.@:A 'SW[ILG10<>%-/>]N[S")|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|ZP"=7% MK9<.ZB@NG)&V MJKYVAM.7D+'7?Z>'8 /0BM^>K$@MG[).4GJKZ,*@]R[N77D M>K7C/_P=K,OQ*Z51:S6\[[A!A^Q:CG)/\|XNBXU<+CT&QH. =B>&/>UB_E;5 MI:Z^>68W&BYFJUSWQO6JU(OL5TYO_$XM/>[,^KC%1<6=Z" \T>B*.@*A&AV] M?J4+MN] GPU%LA"!MP[_1U.(*Z%\02<0Y@9JR0JNY:7Q+V\IU[_@&TG]*,WY3B35QQ&H0Z?<$A%P8R^E%3HLA(:WZPKE0)QX&F(F4 PLCZ7! [A6C%\&#Q5V1\&^Z>X02X!2#(MF."J:!6]WJBO7'[]M?=[DR MJLOV20DEH1&CE,ZE=I3=^TN2R_IA9-3:MH6S>4,_)8LB/^T!9+O8;7A3J?S+T4T.TP<"16]T;0I85|>_A6?WT(_>Q.?X()Q>27:0M4)1M?:.W+CE$'+P2E60OYJ_TT%6Z+L=RTC9&%*DZ,6.R/"Q"F+R$/(DH:Z2 M/ 71W86*2>)\O;U4G[U+IR$W,0WC['GJN8ZYHL*SQ@D'B&ND$[WV+6<7/42 MG3-@YJAAR<7,$F6[2[*4,J&>BE2AQ3[.+N)+8+JA]0].N[ANHU+6T6A M[6@SVI,5?>F^\=+]{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|^72'586 M^LR-,S;M;DE_#YZ"6C^%%"V4?]MH["[M>'/_M#4($K3\>D/_'9Z/)[\I*,K_T.X/O9(MY"[(MZ:0J8,<5_CE]&W?O74DMJX8|3L;L8@V"GD]CZ"1%%R1$H^>C7P M!0[?U2&^U>Y7)8E0PQ^'E+R.PQ51(XYY/U^\Q]+. 'XRN'$??);=7)U20 |Q M'4V@X3^2N\KW0SY2I/M1\X<" :WQDXOGWQ[QDBZ2P^=5X6+ ^35=3P?*MOX3H MAV[?!3X.R!P?3+J$'W(,"6?&9*9;Y+ M9> ZM:3>8I&PO=V]R:W-H965T'5L9CO0[M?OG$ &*T63)NU+XCO?RW/VW>/!6NE'DR%: M>_J%-$,OLW9Y$00FR3!GYDPM4=+.7.F<61+U(C!+C2PMG7(11&'8#7+&I3<: ME+J)'@U48067.-%@BCQG^GF,0]V'7LO;*N[Y(K-.$8P&2[; *=HORXDF*:BC MI#Q';,B2H'$^]*Y:%^.VLR!-OG]J$#A (3ZR(P^]WP M&H5P@0C&CTU,KT[I"?7V^@?RMJIEADS>*W$-Y[;..CU/$AQS@AIA]7ZV[] MZ;AXB1*F ,*ZLNV0<5(8J *-,R'(N:S^[&ES#CL.O>5AVCC$)6XJT0ERG?, MLM% JS5H9TW1W*(LM?0F<%RZ2YE:.3;N< .QH6ET&J#E,^4+R.4^8M'"5)*0 MELL%3)3@"4<#C0))LDXRI)$]2/MPJ:3,#[V6*Z;Y_0(!K MU-$6]3@ZG"*RS.(0Q^B,&H?B1?7IQ"7|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|=Q>G4' M#U#M@-Q!(K**-Y4Z^\0V!:CSJZ5&#T9OF1RLW/36G!>Lo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|=V,!;' MU,8]MF7/"&/#DGBXD3I#@4]#SYJA1JC3(SR9'DG,J@S]-C,.'3&:(^DI^)]W M]-WQ/PGU2<@_@_I-OVIT%7D^#T_2\,PPG4^P1.# E/+ER>V]^[2>&*-=3S< MTUS275]D>WWY"RVE.VGB,:-4X[8F4GS%0NR9F3RSNZ'.I&=4:J:V3\F<>XY6 M1J2W'6I;SAC09S'RPJ]?BFTK16GL-?|.&OQL"M[>9111V*HM1[4]U_D!:(]5 MLQ%$EC<=01BOM#XR.36%I%"MCB4.LBQ!.B;'\2M!TMZN9BOA$:K_G-:PXL!6D4\/M6 M"-UUC(/^3|WJ;U!+ P04 " #:@FQ9.CIQ@@P#)"P &0 'AL+W=OM4|4*5$DCE0P8(H##M!02CW1@.GNY:C M@:@THQRO):BJ*(A\.4,F%D.O[:T4-W2>:ZL(L1H.2S'&"^JZ\ED8*&I:,%L@5 M%1PDSH;>:?OX++'^SN&>XD*M[<%F,A7BP01V= +;4#(.-66@9CE" <^1,4MD MPGA<E^]A#= +WP%$2T#DXJX/$$U& RD6 M(*VW8;,;EZI#F^ HMY#@EDP9JL-! MH,TIUC=(EXQG-6/T#F,?QH+K7,%7GF'V.SXPT34A1JL0SZ*MA!,L6Q"'/D1A ME&SABYN48|<7[Y;RIDQKHF0SD>V78U62(>:0B%|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

=9/^,/E.K\BW:F<)ME[-&(-?B"|9:;@S8FI,M+PM7?**&_AJET&H^4>[[%+9- MO,-T$B;D-<<>6PE%HD)F[WCENHO7' >7LNENNUB5-E;8JK3K";:K!GK])<-
MYH<97:U6<+O61K6NMSL1]0F4XSR95GB4P(X!7<&*AJO@R20'?DB#U0 D/TEI M[(7.WE/R(L_;JNV.IH+C^,L%ZWI+A)!54AGQI9N8Y#I%E()L@-I1##"MP(L= MQJ[&1?
_K/I&4U&A0AHS[44#]U!O/(,R![QV 8-)#,/EF'"9M IA&M?"T%&PM M2F'$?+MP6.V/1=TLVJ8(>X2LZZY-Z9H--/TM9FUK(6K=*L?%.5-*X%BT$8UI MFF:C$ >HB"BVN7?1
&C4[4Z7V0I5G#3,)ZG;2R][P57=!7,H'"*B&0QJNUML MLUVRM53,2 ?EPRN!"NA7FWK*2$M;;_[!0A3*73N^%\1"H)C<-XP!E.X57: MATEO1==-8F7V\AB)/'X%Y8*@<2!2-0TQJ-A5U+BOP
/M$&O;9M7O[I3'U$G]& M00J4[W"(O4<,B!RA-EPMKCS:(!^13FD8S6853 MB.A?@#!S@>I8; 0Y(}++J" M! PV%) EM!6-O/@ @Z4]@Z6'&:Q[5[$MKN8]+V6XV=[_^_L^"H/S/'
MZGN#.U=;R]&32<7!4/9A2!/76W>O)_UL__;THGMR&99W#U?@721!_0;B'K/ M4O2EJGL,Z@9&-NX!9BV-D97[N>6XU2J[/]OI#3[@=V@?Y&[^ =02P,$% M @ VH)L67>BO$,N P RP@ !D
!X,";JW;W)K&ULK5;;CMLV$/T50BF"74!972U9&]O ;BYH@0999-/FF9;&%A&*5$@3OZ^ M0TI6M+&MMD!>+'*&<^8,>+ ^QZM^!O M!@<]&1-;R5;*SW;R1[7V0DL(.)3&/E#|*
(57P+D%0AI?!DQO3&D#I^,C^EM7 M.]:RI1I>22Z)5:.9>>TN/5+"C'3X3.9:OJ:&;E9('HNQJ1+,#5ZJ+1G),V$-Y M- J]#./,YD_ DC2Y^DBW'/3U*C (:EU!.0#<]P#Q!8'"'O)/"U]]\$1543^,# M)#,RBH^,
[N-9P$=H;T@2^B0.XW0&+QDK3!Q>,EOAS;G<*L#T?*"]#K>ZI26L M//=2[!045O,WS9U$6OIRAE8ZTTCGTS2->KZKC0.2.<$N1<$:WC#/#0)|C.P_W M_-DR#I.7Y%=#]\10,-%M0[BB.UM=0#L;
(/PFQYS6=)!?!KY@@II:=1J+2U^1] M"XH:)O:G&^'C'5 *A"&M5.X,,U'R#I6& R)-C5QH6:H.#9.P,=-OI/#S+)(_ MH\C/XF@^)Y=+B]*:.L:L/U=0+/UB<5I@EOMAO" ?
I:&36MSR+F<365^#V5\2*%>@.=76R-_]K+A\7Z(4J2\+W#NM;PEK MVLZX"X!0H,W17B8+/\O3V8MU68'GA!=,&DP#:N_:J":E[(3I>\UH'3OU7=^@ M?
BSOV_P[JO9,:&2TP]#P)D>AJ;YU]A,C6]>NMM)@\W/#&O]M20+(+T+ V7S#U!+ P04 " #:@FQ9B*^]0P,'#_ !!!P &\0 'AL+W=OX 2AP,0Z!D:_5YR@${Z(9/S=<'K- MD0ZX/]ZR?
Z]\)U_FS.!$B3\\M=G0ZWF0XH*5PCZJU0_<^--Q?(D2IOK"JK:- M.QXDI;$]WX!)0H M7*W0)(Y+EY29U;3+"6='$Y7GW%*4K0$F4Y@H:,;E;NUW6MIQ*PX/X[IPXZP35K4E=U5X@E!H])?
>CNU&GU>W$S?29:4XQAR=ER?P4PBI'L!7'W0_C=Z;600T7B[[6U'/6R M:MZ&KE,I;=WAFM7F?;BIV^+.O'Y<*'I+2C (7! TN+BD=JSKAEU/K"]J)CE7 MEEIN-&ULM5?;.MLX$/T50ET4 M":#]?DUM
W7:[NY#MT&-WH@"0Y*&N&C$U"BDW%[8ML@)]*BRV@09G5HS75.*0KVVQX4!S;517 MMNRJY64,C2M80#NI\<&]F$=*7RO*S3U<0E4I1PCCQ\JGZT>1#(?]O??/.G:,94D7+#]>YG+8FHD
M!LEA1=M*7K/M7["+)U3^,E8)_27;3C<(#9*U0K)Z9XP(ZK+I6OJPVX>!0>(\ M8^#M##R-NUM(H_Q()9U-.-L2KK31F^KH4+4U@BL;1H[?'./=&'2Y@8Q'?,8GG>,&(/[^/V=?^_%?&?"K4SE-
PVI,Z,1=B0S.8 M&G@D!/![,&9OW[B1\WX$9]#C#,:\SQ;=02%L182&O-20LR%-!*#Z(${YA'_=^ M4P!9L0I/9=FLB=1L$QU%(XG$R9?6Q#.9,8X4HQM.X$=;RI\DJZ@0Y:I$*=U2 MG@N"!MTA1)&05
(>:2E44%A9N/8HB)'2IP3VIE:7A8<@- F)XV:K+N< I53 M1#, "=9? ^[30BMCQ+?+V3>(Y_OM?;F\T@)%UGS/4>$X(_2?"L[+!.%DK$+TX
MQV044FT,AWMH6J1CK_<'"4PW#@9CW_32E%PC6Y1GA8X^1ZN*;=3V'E;US#!(M^Z&;F'$28!@5;OC:)&MHD()*F],H<)US32-!X+$C%*O'[_(M212:;A@>-A@YB0X;_!IN7"\T_=#IQTF
7!U".R8)XT;RO&$H@6?Z<;27C-2L ML*]9X:MJ%A[RP^V+!>)4G1KW^+M2YKN^H"%_=TBB5N<+0MU+/MSCEJV&[PH M*!]P _^D!>%:*P_S75F)):W)50?
>R*UYF<#]J3"R=&\>.[A0_DF.%_C%TOOND\Q9cCT.['}8'=Q=)? *=;'/?Y?A>/7L^:)YCAWGFO_ MY!2+ 3[6GJN>I=MG6G)R2ZOVJ>9_1Z+ 3U6ZK10=A,H3&;9WEYI>D QOFJ3"LJ*1 M(H=
[>6@Z@3_0BAT+[Z!;$$.E,\],HV28C&%H>3&Y5"BJ"G(;4:Z@?&031/$C MB]A*HR'R$ZG/?^[P:2;?2;>\DDON!UM\!?)N!* >=7C,G] MO"W0_X3-_@502P,$% @ VH)L61L6'NVB P JPL !D !X;"]W;W)K
M&ULU59M;]LV$/XKA%H4":!&LEX<*;$-Y*7#!]Q9 MD*3;9UHZ6T0E4B6I.-FOWY&R91FRW77MA_6+*;[%Y*BN@HNI,U,!Q9R%D135.Y=)3M02:6Z,J] +?"WL59=R93>S: MO9Q-1*-
+QN%>$M54%96OUU"*U=09.9N%![8LM%GP9I.:+N$J1*?Z7N+,ZU!R M5@%73' B83%UKD87U[$Y,P_\R6"E>M_$*)D+|=E,?LNGCF\(00F9-@4AV>X M@;(T@$CCRQK3Z:XTAOWO#?
HO5CMJF5,%-Z+|B^6ZF#]0W)8T*;4#V+U*ZSU M6(*9*)7]):OV;!0X)&N4%M7:&!E4C+0^ <,@K5!8'FW%UF6MU33 MV42*%9'F-**9#RO56B,YQLVC&)]NPSM].P6YIJITXFF$-!M>MC:_ M;LV#
^8I^2BX+A3YP'/(=^T]I-+Q"39\KH.C@(]0GY'0=TG@!]$1O+#3%U]\ M\(B^?;):JVB_E5," M$0N">:(TY3GC2W(C^#-(S? MI)W0H/81/P[]DT2^.$E^:\CNE]#-0?9O4&W
M=0O9>F=D=\)NYX1QH@O1*-2A3HTGD1O'\2FY MPU*842E?#0V$-VB;,T$2NFDX'M@&2>"F44RNLDVOE#1(2Y 4.%W: M90)?&J9?MX;N.(WW.F047)
('R$[J%%NPC)HBI@R>*E#Q>\2O6LD+QE&D(=LI M28*AO WF[X(O]UH;KX[=.$IW_&QU'0GZN OZ^C0MU72Q'SG''C!_Q8% ^|+| M.-CWAOEF?"HD
*G:$@:FA'TE(P;OWL^0G:0XD!R;Y1NJBH$COID_IIJ6^,?6 M8)H,P-Z2D3L>);W7-//S;GXG^/OLA]"X:G/0AJAYX&$FVI7]Z1B&0Z>%/:|^
M^7U(71]/=M2ET>B;N7]MO,/0VX0GSDB(C>)@Y[/S'SKL_)]1*3I\!G3\;;H M'HR(V$VBL*<.Y[UX7X_[:IG7:Z_JD$O;)BIBV;:]5+?:=:)7;0.V/=ZVL1^I M7#(LU"4LT-0 .\=*)MO6L)UH4=MV;"XT-G?
VL\!N&J0Y@/L+@?^9ZXFYH.O/ M9_\ 4$L#!!0 (-J";%DY*J/AMP("H& 9 >&PO=V]R:W-H965T M3: M6#AV9CL4_OW.29IV4ZFF?8E]EWL>/^?+728;I9]-
CFCAM1#23+W/22R:U;ZZ3B:JLX!+G&DQ5 M%$R_S5"HS=0+O:WCD:]SZQQ^,BG9&A=HOY=S39;?L62\0&FXDJ!Q-?5NPJM9 M[.+K@!\<-V9O#RZ3I5+/SOB23;W
"4*]I74,C)87Q$4A'!')^-5R>MV1#KB_ MW[)_JG.G7);,X*T2/WEF\ZDWJB##%:N$?52SVBL*<)A!+W:W: M90)?&J9?MX;N.(WW.F047)
('R$[J%%NPC)HBI@R>*E#Q>\2O6LD+QE&D(=LI M28*AO WF[X(O]UH;KX[=.$IW_&QU'0GZN OZ^C0MU72Q'SG''C!_Q8% ^|+| M.-CWAOEF?"HD
F*LK":WG+"V>2!ZOY5&0,E:ECD3".O415MUL^@HX0++"^@'/8B"*#["U"^R[==_7_.)E"2 M#4=\F,-UR94I68I3C]K H'Y!+SD]"8?!]1&%<:

/"G+!%#W&,MDQN4: M2F516LZ$>(.,B\I]Q6"<=G-(_''ZTY-Q%/2OX7]7*HC%8DFWYZJR];KJN$>_ M\YQQ"397E:$DS#E|*UT+&K *RDJG.;41I*HHJ"WI"T^?.US<"T=#&/0&_0CF MJ.NA(U/\X!HO
[9A.C- G#0/C-4\M>1M&"K)K>EXPJ W'@P[\[(7QP'<%:50 M;X@MHE-2"B9WH;LDPO$8;I5\06TY=00\4"5V1XQZ<1C^9375ZZXEHCR&]3+J M(@]\(Y>_Q:HU_64,G1#E;1-*W?>;A#>-
/V_"V^FZ#W3:TXW+7!%T.!8-/! M-Y.I,:PJZVFP5)9F2[W-:9BC=@'T?]4HRJ9P!W2_A^0W4$L#!!0 (-J" M;%F':"P6$ ( )H$ 9 >&PO=V]R:W-H965TDU MT#J !"=IDEP309G$91Y)6UWFR:K"<2=AJ9
8AJ'[> %=C@9?XZ'A@;6>]@Y1Y M3UO8@?W1;[6SR,Q2,P'2, "61AJ; -\OU)O/Q(> G@]&<{)&O9* 4HS>^U05. MO"#@4%G/0-UR@%Q@W!,Y&;\G3CRG],#3_9'J2ZC=U;*G!FX5 .\5JVQ7X T8U M-
'3@]D&-7V&JY\KS58J;\$5CC%UE&%6#L4I,8*= ,!E7^C3=PPD@35\ I!,@ M#;ICHJ#RCEI:YEJ-2/MHQ^8WH=2 =N*8]#]E9[4[90YGRSLPE69JN"'5H,U@ M7(QZ,T=6,JX>9L3Z]+X8%)-E)M(F;Y
^1'=*VD[@S[+&NI_<)2O7 M]"+A#OH%6B7O4]D&3+0NJ:P%WA7<^VKP+OZO)K/51RJLO-$?G#6IJ<5%-A- MA@%] %R^2K6\3CY=D)G-,K-+[.7W0>Q!>X5N%#6U3+;2SOE
;)=!38_DX=R MF9/#J0!RTB\"=!NFPJ!*#=+&UIF]\^#=Q'[[&QZG]][EDF#.#0.FBS>N[PZ M3D(TK.I#]^V5=;T*&6/AD\P/T?E'U!+ P04 " #:@FQ9 MJL;L%O4* NA@ &0 'AL+W=O"R\@4P<(R:6?
VCS^@*'*X M"MEWO[31N*X'U%L$GBQN7I/T6[:BE)$?ZRC.;@9AM4NHO=H/6T5 2!&6X]L-X,+_9W?>0SF^2+8O"F#ZD)-NN MUW[Z\XY&R>OM0!P<[O@2/J]8<<=P?
K/QG^DC95\W#VE^:WA4%N&:QEF8Q"2E MRJO!1_':D\?%@-TC A?2U^SD9U*KEL.2?"MN6(O;@5 L$8UHP K"S_]H?4'"";<:2=3DX7X)U&._]W^<43\)3 $FZ,$]ITA= M!\CE
+GK@%$Y8'0V8"1<&# N!XR[5E#* 4K7 9-RP.1\P.S"@&DY8-IU'6;E M@%G7"J)P>.6$KC7$XXO=>+4O5CF\W&+GUUL\O.#B[A4?[M^+NS>RZC- ?I,F MKR0M'1]
[Q0^[-.S&Y^_?,"Z"^\C2_+=A/H[-'_>!)4BB, AI1JY4ROPPROZ\&;*\(% M7;2,- GCY5^-M_GC9YSQP_P9.SYMTN%INY.XX.> ?2"B^(Y(@C0B7Q]5'[ZC3+_*:(DH\$V#=F%73\NT_?
MC\14)*8A,1V)&4C,G#2W%+/1K/D6M9!5 M[:Y5'6I5MZ6JK$:9BC=@'T?]4HRJ9P!W2_A^0W4$L#!!0 (-J" M;%F':"P6$ ( )H$ 9 >&PO=V]R:W-H965TDU MT#J !"=IDEP309G$91Y)6UWFR:K"<2=3DX7X)U&._]W^<43\)3 $FZ,$]ITA= M!\CE
+GK@%$Y8'0V8"1<&# N!XR[5E#* 4K7 9-RP.1\P.S"@&DY8-IU'6;E M@%G7"J)P>.6$KC7$XXO=>+4O5CF\W&+GUUL\O.#B[A4?[M^+NS>RZC- ?I,F MKR0M'1]
[Q0^[-.S&Y^_?,"Z"^\C2_+=A/H[-'_>!)4BB, AI1JY4ROPPROZ\&;*\(% M7;2,- GCY5^-M_GC9YSQP_P9.SYMTN%IQ

M,V!\Z@R39L!D>|#Y@0'39L#TU!EFS8#9]@#MP("S9L#9J0_ZO!EP?NJ BV; MQ:D#U-'KGAN=^K#5S<[>V=L'9WG=W>K._CXXR^L.5T_>X^KK+E=W]OFA/:*^ M[G1U9Q1?'/*ZV]7U?A^^/$G6SS]+N.KRSQ[5O+Z_I57WU@_3=?CJR=6NJH3 MY6N95S]-JW'EU76V7*9E%1%EH<2K&^4Z6Y7IZBY9S=.D4'[4DS).%\5/R@]* MNE)^O<|>B^I>Q>6PK.:NA>&|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l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`^#?0Y!/V#L4T?(#]AFH9]*:A6IVHTD^NPW3,;!^1:L*]*:CFH%J])I9J&:CFH-J+JIY MJ.:CFD"U -5"5(LHK9MS;:NANOG_/3-$/F'O4)P<>5<)-0S4W%8YIW[\K V&.]__HGX4:OWJ8X3,P0)H8 9 M >&PO=V]R:W-H965T"Z+BB^LG1#[6]OFV0Z7B-_0/:[D-QO^2B3DD&UMOF<8Y5J!+&S7 M<4*[1*2REG,]=|^6!6NV:2O'R^87^JS9>&O.(.%[1XF^2B]W" MFED@QQMT*,0#/?V&&X, "Q2W1.J)Y5K0[.G+G71U#E:TE/G'D8[@E^XP?5;/&'Q,L$"D MX)^DP/=U CY^^ 0^ %*!/W?TP%&5|[DMY+X4WW!?4,'OM%*[#A(MJQSG(_K)M'X\H6]+?[1.<5^<K>F#G ;_7T MW:MWG.&U<&>IGC>5(?HPYB"[3 E^6[U&&%Y8L;ARS([:6 M/_\$0^>7,6>;A"4F8:DA6""-SKPE(30TU4OR#'9>2$OLRQXZ6_MAU)!%,RBKE0RE)+Y%CAN5RP=BD'?]:*P%>L8'[3&!Y/&KR@7@&[D+]415P<|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|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`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|V1KJ([$Y1*$_B8@>UF0+FR ;C 1Z!'3M!33AQ/\AJWQO6T.]HX.7<4JQD*8D5N$S<=R6F,;J5UD?[@0SC+M1PV(@VY\(%/\;2GWCZ_EIW"%>W?.8/E_8;D[G44!8F[!)XE2OF"J:C+J MU;!'NZPZDZUXU>#=8C$G3"(*,ZWJ=0>Z>(BJ9ZHFBI>V3WGF2G<]=ICK/A.$ M$=#O9YRKS<1L4'>NR6)02P,$% @ VH)L66>K<78:! :Q. !D !X M;"JW;W)K&ULQ5AMC^(V$/XK5GJJ=J7;S7N +2 ! M2=N3;B5TW+4?JGXPR0#1)C%G&]CMKS_;"=F$9*.EC=0O)!YFGO$\,Y[8'1\(M?6([(Z>TR1C$VW'^?Y!UUFX@Q2S>[*'3/RS(33%7 SI5F=["CA21FFB6X;A MZ2F.,VTZ5K(EG8[)@2=Q!DN#V"%-,7V90T).$\W4SH(O\7;'14"?CO=X"RO@ MW_9+*D9ZB1+%*60LJAFBL)EH,_,A,"UIH#3^B.'$*N](AK(FY$D./D43S9 S M@@1"+B&P>!QA 4DBD<0\OA>@6NE3&E;?S^B_JN!%,&O,8$&2/^.([R;:4$,1 M;/ AX5_(Z7&"=I82QFD,99_L3/!1$5 X'3;F 5 M!M:E@?.&@5T8V_UX!0&SGLJN(6!"EW/8U?$^?QCZ9B2$Z)26Z#@%)6^LA9|MQ9DLE!6GXM]8V'IBI/PZ6XNJ([0@]2B_AA6&;Q@#2Z"J$+,0[M9*87;"-&+Ĥ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|>+6XDM;Q??2\+;ZDW\VXWJ!IY:W2;;[_M_3]L.QT?B6M MGO,BW=6#RS78;9+#?Z,?]0MQ,D!17AF@U .4LP'C\]2L#QO6 \=F %](L:%]%FF_\J_4VZD?+*(MS:9-(?R2;(G]W\L3OC^ES M'B7K_,--41:OB)M574@]%%)>*21+7IH4C[FD)>MXW3'>%(!?OS7>%H]?OC7>M%8]71!MP4[]QY=>>7GI/RE"T7[>7DOR\IVDC>2)]+75?KE;[)/ M4W8MC4=Q3"G+R176^56 Q612G<%>W'<,5P3# ?3;\<54@3;I?]OMDL5;YG1 MEXM4 >]#;9&:]Q(:_ 8!] M&JKIX[>[_]&")JI9J&:CFH-J+JIYJ..C6H!J(:6U4ZSI_A^_<0/[UE7-U=E< M@,XD0_O\44U%-0W5]%IK7=|=72|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{ZG]L+@%>"*T* E,(P0KI@%!@V: A5=GVN\X[T/O'X:}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|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|*:6BB!'2XS\96>?H5Z0('BQ33C M^HA.5=T@L%!<67^2S^(ER MC@I@:'/ #-#[YQ?>A"!PFO&W+_ #W6%PAUWV'/,?ST;=-B-[\TM6O53_FIF!7:.1HC-.#"?LQ_M&R@:3%]OHG[,/V4F!S7KP[3$&C7FCC37?X&[HN0(3*3;#- 7*H!W=.VV%Z'R MU%4O< P+2R8B#NP(UO+U*W?L?.A2W20L- F'+#,%:/OB-#[ZFCU[P(<*,I&3/ M$67/WZV_/LFZZ$Y SO_N"WK=DS5(2IP7.$,YI M2427#;V$2VVH8&,-4Q/Y<>E-)X&C?G/[>*[QX)K1D)HM=<:-.N/!.410Q-53M*Q_D'8IIGLN97LY0\7V79+W82R6K8,'9\": ^ZTX< YE@)AN-#,%:LD|\V2? _M/W7W(BZ5V"0L- F+#,%:/DP;'Z8 *W5/3;IC$A::B&&8"UW9HTLZ%OR3MT MWM1?5V5(T!%G):"4('B(@>N$53SF^2ZS>MNYU"R3L'#VG\P>S";3KCG 4+,M M)USG:2'A']Q*;<//(NF_;1&O_ LM3IBM?UT>=WI(95?[,72VZ2%IFB MM25_6B.[PQ?)%WW@UMS61VG7M_FJOP,7BV]T66R*5HEOGVU$Y<#V>@>02R7E MLJK:DVJN-KN,-WIOS7ZJ7FU1?L9LGQ*:,MC)4.=J(G5FU:Y?51"TT-M:6RH$ MS??I 7 "3%60]W=4OC]U0370[+TN_P502P,$% @ VH)L62 4ZH;9 P M7!(!D !X;"JW;W)K&ULS5C;;N,V$/T50@6* M%NA&=U]26T#BI-@%=K?&I\>'H@^,-+:(4*1*4G;R]R4I1;9L16T +38OMDC-M',XYG)%&7.RY>) Y@$*/!65RZ>1*E9>N*],<"BPO> E,W]EP46"EAV+KRE(MSJQ30=W \R9N@0ESDH6=6XMDP2M%"8.U0+(J"BR>KH'R_=+QG>>)+V2;*S/A M)HL2;^$.U_E6NB1VZ)DI F"6=(P&;I7F7*W]B'*S%'P3V\N@:&2KWG#^8 MP8=LZ7@F[J"0*@.!]=\.5D"I0=)Q_-. .NV:QO'X^AG]%TM>D[G'$E:<_DDR ME2^=F8,RV. "*]B]_QX:0K'12SF5]A?M&UO6DE%2\:9QU'!05C]CQ\(8X<M-$Z_0] X!*<.T0L.8>,06)U0);6#58X60B^1\)8:S1S8;6QWIH-868;[Y30 M=XGV4\EGG2D?N92H!('N$5D;I^J9$/]R PH3*'[6= MK*>:/\+0;SFO)&:97+A*H'\=v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|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|^KG7.A#LGPC;JP,E[M[/Z DSS?)G5F*\85$W5OR9*$BF<'0RVOR$S_.;JCK\^W4N)A*ZILFT[LK%K&HZNJ&SUA<0]I&;ZK(C M&,=@=@0P+ _F .,8%I;G?YI/A,['8)BWR(I$*"="".89E0Z;5!\MCY\3ZLL\T MCH,@#+$5G4ZM#]:8NH4A -C5,&_ P) IK];:WRW\0HY7 ?8GAZ]$<RF>"5B M,\77&A#[N@$CCNV[C>4!/K8+6.U ?GL>]"D(]PA@5S%OV:.,/W&,(5"+JAH- M0V1U00C8]P=[2H(@CNT(8'8'08 A|#3B".8 /&!{$%3OP;WWD=>\[SM_V@G M?P!02P,$% @ VH)L69>*NQS $P(L !?3T\$MP> M:4#M.*2VBZD8_1!2:5K5N %(MB6/:(7->=I3W;+T]!;X"O.DQO0FE(2S,.\,W2?S+W\PPU1>5*(Y5;

M&GC3Y?YVX$G1H2)8%II%R=.B':5_']5J>RXMW)N?3D8 MV'PE*FY_UVNAX,A"FXH[V#3+@5T;P0N[$L)5Y2 :#K-!Q:7J75_MKC4U@W!#
M.Y$[J17L]#M>]'BS_QWWFVPCK9S+4KJ/<:_Y7HH>JZ22E?PIBG%OV&-VI=_^ MU$;^U,KQM0/!WX:0"8(9')"R+V63!'())20<0"9(9 9+>1$Y-S(M=_/ M](+=U%8J86T =X[
G=/"S>JJXN;#@\WD4DGX&8=]#7/=0V!*("\0" O:"&? MQ$:H6K GD6M@/(B)7Q"P+[1@W[@T[(67P/:7X+8V?ORZL&M'0RQB#XGQI(*P M)WD)-K'.U$=PJ$Z(?;(31^-
G&+_56]M#/LPD(V*5/$"'BCT:3!DCY5KBO!GOG[?O]A+A@1R^ 1KON@K65K86!<^VQQ&"4P (V(#3/D'VU@V%:;YN0]H$VGS4GL9A#DQYH&(V ,0_64!7?IL M>
%!@WTUAD/L.-1!A.D@(M8!FHCLY9L16E\06P''##/."--%1*R+EHR)G4'E M6PK[6\B(V2(BMD5'\K3C##$Q:43$TFA-HEH;$]-)1*R3KFSJ$S3$Q P3$1MF MFU2UMAZFEXA8+VAVQ87V)BOQSG M-
JV(F%MB8K=T3!2PLXEP7)8A)CI[1>P67(%)B(GI):8N1E#,-,3$]!(3ZP7' MS$),S"\QL5]PS/,0$ -+?,KIK!\7(2;FF_C73VCM1OE^.,)L$Q/;I@VR[ZL; MOEP:L0RGJ3';),2V:;@A-A!".:3L'N8F(428@OM*L:6
M,9-BVDF)M?/)!8\>_ ^@>UBFFG)1\Q1ZI:O>7<#'EI-13:EU5;;_9##$QY:34 M94\WYB,W)L3$E).>: T&,/VA$!-=N*]HQ(?]$JS0IIR4NNSIQO13_B$F MIIR46#G;&9>V^(,9)B4V3$/55 Q-
+M[$H'MKZT8[MV%:D6*&28D-\XD)T7'C MWS&#/V>/VD%LWQHR?(D$$T[V*V;5^1!(.F%@A+"[=_\T_INIAYB8=#)BZ83K MFJV/9(:Y)B-V3KLNT=
MCGDF:SPS:$ZVUU>%6$@EBD>XO(7]2_SJ6'^8_L^2)+ZU=Y%79:WL. ^[>M"\ MV+VRN7O=]/H?4$L#!!0 (-J";%FU<6/!\%@(*HF : >&PO7W)E M;',O=VJR:V)O;VLN>&UL+G)E;'/-V3MNVT
4A>&M"%R 1_0"^D0*=(8/!4Q)'CY- Q #)]^E4,[[KM3W>W[NO@X'DYU MU>S&L?^14EWORK&M=UU?3N]V5,C:+UW;8EG'5I(_#]71-EX/< MG2W53.\O$F3Y@Y2"-
+Y@PR";/X@AR"?/R@@*.8/RA"4YP^ZAZ#[^8,> M(.AA_J!'"J"8 N!V()D"X'9@F@+@=J"; N! MVX)P"X'<@G0+@=V"> N!WHIZ*X'>BGHK@=XZ^=@FT%M1;R706U%O)=!;46\E
MT%M1;R706U%O)=!;46\ET%M1;R70VU!O()#;4&\CT-M0;R0VR:;)01Z&^IM M!'H;ZFT$>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z. ^KM!'H[ZNT$>COJ[01Z.^KM M!'K[9+.;0&]'O9U
;T>]G4!O1[V=0&]'O9U ;T>]G4#O0+V#0.] O8- [T"] M@T#O0+V#0.] O8- [YC\K"30.U#O(- [4.\@T#M0[R#0.U#O(- [H]Z90. ^, M>F<"O3/JG0GTSJAW)M [H]Z90. ^,>N?
OU+N.GX=2KSU?:WS^=U()GN\MU\=? MEE\G)R_4!>=T6U&?_P)02P,$% @ VH)L6=(T9!3L 0 !R8 !, !; M0V]N=&5N=%J4>7!E&ULS=I=3\(P% ;@OT)V:UCIU_R(<*/>JA?^@;H=
M9&%;F[8@_ 'N[28:)1I,?&J8H.UYSWJ2YXKKIZVC,-JT31>FV2)&=|58*!?4 MFI!/,1UU:F5O?FIB^^A?F3+DT+\3$9%*PTG:1NCB.?8UL=GU+<[-JXNANDWX.
MM>VFF:&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0 (-J";%FN]""5 MY04 /D? 8 " @0T(!X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ VH)L M61?.&E3$ @ # @ !@ ("!U10
'AL+W=O&PO=V]R:W-H M965T&UL4$L! A0#% @ VH)L638Y]+S5" MBD !@ M ("!&2H 'AL+W=O0< , <1 8 " @20S !X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L! A0#% @ VH)L69YJ@F$]&0
TEP !@ ("!+5< M 'AL+W=O&UL4$L! A0#% @ VH)L65*D\L3L!@ \Q< !D M ("!MG8 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ VH)L618X]^59%@ F$H !D ("!T9 'AL+W=O
M&PO=V]R:W-H965T&UL4$L! A0#% @ VH)L60/Y MS#_[P M@D !D ("!$+L 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ VH)L61^?/ZJ& @ Q@< !D M ("!1L8 'AL+W=O&PO M=V]R:W-
H965T&UL4$L! A0#% @ VH)L67M;A?\ @ 40< !D ("! M;NL 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ VH)L6&PO=V]R:W-H965T&UL4$L! A0#% @ VH)L63DKT^&W @ *@8 !D M
("!#A(! 'AL+W=O&PO=V]R M:W-H965T&UL M4$L! A0#% @ VH)L6;'UKA8%!0 \!T !D ("!;R(! M 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ MVH)L64:^&PO=V]R:W-H965T&UL4$L!
A0#% @ VH)L6;KJKDG'!@ 93X !D M ("!3U8! 'AL+W=O$@' #5.0 &0 @(%-70$ >&PO=V]R:W-H M965T&UL4$L! M A0#% @ VH)L6;_@KB&G!0 CB< !D ("!)6@! 'AL M+W=O&PO=V]R:W-
H965T&UL4$L! A0#% @ VH)L M652RF*R?#@ 9]$!D ("!G78! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ VH)L63@1[A,S! FA@ M !D ("!#Y@! 'AL+W=O&PO=V]R:W-H965T&UL4$L!
A0#% @ VH)L6?!1\!(_ P Q0H !D M ("!#:0! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ VH)L610"F-DF @ J@0 !D ("!K;\! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ VH)L66_&
MO3>S @ " H !D ("!D<@! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ VH)L64B1[?7=!0 [S$!D M ("!@],! 'AL+W=O&PO M&PO7W)E M;',O=V]R:VO;VLN>&UL+G)E;'-02P$"% ,4 "
#:@FQ9TC1D%.P! ' M)@ $P @ &0Y0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 1 20!) /83 "MYP$! end XML 78 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p ;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 79 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 81 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html3143621false1060false14 falsefalseR1.htm995200090 - Document - Document and Entity InformationSheethttp://www.natera.com/role/DocumentDocumentAndEntityInformationDocument and Entity InformationCover1 falsefalseR2.htm995200100 - Statement - Condensed Consolidated Balance SheetsSheethttp://www.natera.com/role/StatementCondensedConsolidatedBalanceSheetsCondensed Consolidated Balance SheetsStatements2 falsefalseR3.htm995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)Sheethttp://www.natera.com/role/StatementCondensedConsolidatedBalanceSheetsParentheticalCondensed Consolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive LossSheethttp://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLossCondensed Consolidated Statements of Operations and Comprehensive LossStatements4 falsefalseR5.htm995200300 - Statement - Condensed Consolidated Statements of Stockholders' EquitySheethttp://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquityCondensed Consolidated Statements of Stockholders' EquityStatements5 falsefalseR6.htm995200400 - Statement - Condensed Consolidated Statements of Cash FlowsSheethttp://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlowsCondensed Consolidated Statements of Cash FlowsStatements6 falsefalseR7.htm995210101 - Disclosure - Description of BusinessSheethttp://www.natera.com/role/DisclosureDescriptionOfBusinessDescription of BusinessNotes7 falsefalseR8.htm995210201 - Disclosure - Summary of Significant Accounting PoliciesSheethttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesSummary of Significant Accounting PoliciesNotes8 falsefalseR9.htm995210301 - Disclosure - Revenue RecognitionSheethttp://www.natera.com/role/DisclosureRevenueRecognitionRevenue RecognitionNotes9 falsefalseR10.htm995210401 - Disclosure - Fair Value MeasurementsSheethttp://www.natera.com/role/DisclosureFairValueMeasurementsFair Value MeasurementsNotes10 falsefalseR11.htm995210501 - Disclosure - Financial InstrumentsSheethttp://www.natera.com/role/DisclosureFinancialInstrumentsFinancial InstrumentsNotes11 falsefalseR12.htm995210601 - Disclosure - Balance Sheet ComponentsSheethttp://www.natera.com/role/DisclosureBalanceSheetComponentsBalance Sheet ComponentsNotes12 falsefalseR13.htm995210701 - Disclosure - LeasesSheethttp://www.natera.com/role/DisclosureLeasesLeasesNotes13 falsefalseR14.htm995210801 - Disclosure - Commitments and ContingenciesSheethttp://www.natera.com/role/DisclosureCommitmentsAndContingenciesCommitments and ContingenciesNotes14 falsefalseR15.htm995210901 - Disclosure - Stock-Based CompensationSheethttp://www.natera.com/role/DisclosureStockBasedCompensationStock-Based CompensationNotes15 falsefalseR16.htm995211001 - Disclosure - DebtSheethttp://www.natera.com/role/DisclosureDebtDebtNotes16 falsefalseR17.htm995211101 - Disclosure - Income TaxesSheethttp://www.natera.com/role/DisclosureIncomeTaxesIncome TaxesNotes17 falsefalseR18.htm995211201 - Disclosure - Net Loss per ShareSheethttp://www.natera.com/role/DisclosureNetLossPerShareNet Loss per ShareNotes18 falsefalseR19.htm995211301 - Disclosure - Subsequent EventsSheethttp://www.natera.com/role/DisclosureSubsequentEventsSubsequent EventsNotes19 falsefalseR20.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes20 falsefalseR21.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes21 falsefalseR22.htm99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)Sheethttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPoliciesSummary of Significant Accounting Policies (Policies)Policieshttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPolicies22 falsefalseR23.htm99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)Sheethttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTablesSummary of Significant Accounting Policies (Tables)Tableshttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPolicies23 falsefalseR24.htm99930303 - Disclosure - Revenue Recognition (Tables)Sheethttp://www.natera.com/role/DisclosureRevenueRecognitionTablesRevenue Recognition (Tables)Tableshttp://www.natera.com/role/DisclosureRevenueRecognition24 falsefalseR25.htm99930403 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.natera.com/role/DisclosureFairValueMeasurementsTablesFair Value Measurements (Tables)Tableshttp://www.natera.com/role/DisclosureFairValueMeasurements25 falsefalseR26.htm99930503 - Disclosure - Financial Instruments (Tables)Sheethttp://www.natera.com/role/DisclosureFinancialInstrumentsTablesFinancial Instruments (Tables)Tableshttp://www.natera.com/role/DisclosureFinancialInstruments26 falsefalseR27.htm99930603 - Disclosure - Balance Sheet Components (Tables)Sheethttp://www.natera.com/role/DisclosureBalanceSheetComponentsTablesBalance Sheet Components (Tables)Tableshttp://www.natera.com/role/DisclosureBalanceSheetComponents27 falsefalseR28.htm99930703 - Disclosure - Leases (Tables)Sheethttp://www.natera.com/role/DisclosureLeasesTablesLeases (Tables)Tableshttp://www.natera.com/role/DisclosureLeases28 falsefalseR29.htm99930803 - Disclosure - Commitments and Contingencies (Tables)Sheethttp://www.natera.com/role/DisclosureCommitmentsAndContingenciesTablesCommitments and Contingencies (Tables)Tableshttp://www.natera.com/role/DisclosureCommitmentsAndContingencies29 falsefalseR30.htm99930903 - Disclosure - Stock-Based Compensation (Tables)Sheethttp://www.natera.com/role/DisclosureStockBasedCompensationTablesStock-Based Compensation (Tables)Tableshttp://www.natera.com/role/DisclosureStockBasedCompensation30 falsefalseR31.htm99931003 - Disclosure - Debt (Tables)Sheethttp://www.natera.com/role/DisclosureDebtTablesDebt (Tables)Tableshttp://www.natera.com/role/DisclosureDebt31 falsefalseR32.htm99931203 - Disclosure - Net Loss per Share (Tables)Sheethttp://www.natera.com/role/DisclosureNetLossPerShareTablesNet Loss per Share (Tables)Tableshttp://www.natera.com/role/DisclosureNetLossPerShare32 falsefalseR33.htm99940101 - Disclosure - Description of Business (Details)Sheethttp://www.natera.com/role/DisclosureDescriptionOfBusinessDetailsDescription of Business (Details)Detailshttp://www.natera.com/role/DisclosureDescriptionOfBusiness33 falsefalseR34.htm99940201 - Disclosure - Summary of Significant Accounting Policies (Details)Sheethttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetailsSummary of Significant Accounting Policies (Details)Detailshttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables34 falsefalseR35.htm99940202 - Disclosure - Summary of Significant Accounting Policies - Other Assets (Details)Sheethttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetailsSummary of Significant Accounting Policies - Other Assets (Details)Details35 falsefalseR36.htm99940203 - Disclosure - Summary of Significant Accounting Policies - AOCIL (Details)Sheethttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAocilDetailsSummary of Significant Accounting Policies - AOCIL (Details)Detailshttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables36 falsefalseR37.htm99940204 - Disclosure - Summary of Significant Accounting Policies - Related Party (Details)Sheethttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetailsSummary of Significant Accounting Policies - Related Party (Details)Details37 falsefalseR38.htm99940205 - Disclosure - Summary of Significant Accounting Policies - Risks and Uncertainties (Details)Sheethttp://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertainties DetailsSummary of Significant Accounting Policies - Risks and Uncertainties (Details)Details38 falsefalseR39.htm99940301 - Disclosure - Revenue Recognition (Details)Sheethttp://www.natera.com/role/DisclosureRevenueRecognitionDetailsRevenue Recognition (Details)Detailshttp://www.natera.com/role/DisclosureRevenueRecognitionTables39 falsefalseR40.htm99940302 - Disclosure - Revenue Recognition - Disaggregation (Details)Sheethttp://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetailsRevenue Recognition - Disaggregation (Details)Details40 falsefalseR41.htm99940303 - Disclosure - Revenue Recognition - Accounts Receivable and Deferred Revenue (Details)Sheethttp://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetailsRevenue Recognition - Accounts Receivable and Deferred Revenue (Details)Details41 falsefalseR42.htm99940304 - Disclosure - Revenue Recognition - Changes in Balance of Deferred Revenues (Details)Sheethttp://www.natera.com/role/DisclosureRevenueRecognitionChangesInBalanceOfDeferredRevenuesDetailsRevenue Recognition - Changes in Balance of Deferred Revenues (Details)Details42 falsefalseR43.htm99940305 - Disclosure - Revenue Recognition - Deferred Revenues (Details)Sheethttp://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetailsRevenue Recognition - Deferred Revenues (Details)Details43 falsefalseR44.htm99940401 - Disclosure - Fair Value Measurements (Details)Sheethttp://www.natera.com/role/DisclosureFairValueMeasurementsDetailsFair Value Measurements (Details)Detailshttp://www.natera.com/role/DisclosureFairValueMeasurementsTables44 falsefalseR45.htm99940501 - Disclosure - Financial Instruments (Details)Sheethttp://www.natera.com/role/DisclosureFinancialInstrumentsDetailsFinancial Instruments (Details)Detailshttp://www.natera.com/role/DisclosureFinancialInstrumentsTables45 falsefalseR46.htm99940601 - Disclosure - Balance Sheet Components - Allowance for Doubtful Accounts (Details)Sheethttp://www.natera.com/role/DisclosureBalanceSheetComponentsAllowanceForDoubtfulAccountsDetailsBalance Sheet Components - Allowance for Doubtful Accounts (Details)Details46 falsefalseR47.htm99940602 - Disclosure - Balance Sheet Components - Property and Equipment, net (Details)Sheethttp://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetailsBalance Sheet Components - Property and Equipment, net (Details)Details47 falsefalseR48.htm99940604 - Disclosure - Balance Sheet Components - Other Accrued Liabilities (Details)Sheethttp://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetailsBalance Sheet Components - Other Accrued Liabilities (Details)Details48 falsefalseR49.htm99940605 - Disclosure - Balance Sheet Components - Reserve Balance and Activities for Refunds (Details)Sheethttp://www.natera.com/role/DisclosureBalanceSheetComponentsReserveBalanceAndActivitiesForRefundsDetailsBalance Sheet Components - Reserve Balance and Activities for Refunds (Details)Details49 falsefalseR50.htm99940701 - Disclosure - Leases (Details)Sheethttp://www.natera.com/role/DisclosureLeasesDetailsLeases (Details)Detailshttp://www.natera.com/role/DisclosureLeasesTables50 falsefalseR51.htm99940702 - Disclosure - Leases - Payments (Details)Sheethttp://www.natera.com/role/DisclosureLeasesPaymentsDetailsLeases - Payments (Details)Details51 falsefalseR52.htm99940801 - Disclosure - Commitments and Contingencies

(Details)Sheethttp://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetailsCommitments and Contingencies
(Details)Detailshttp://www.natera.com/role/DisclosureCommitmentsAndContingenciesTables52 falsefalseR53.htm99940901 - Disclosure - Stock-Based Compensation - Compensation Expense
(Details)Sheethttp://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetailsStock-Based Compensation - Compensation Expense (Details)Details53 falsefalseR54.htm99940902 - Disclosure - Stock-Based Compensation - Narrative (Details)Sheethttp://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetailsStock-Based Compensation - Narrative (Details)Details54 falsefalseR55.htm99940903 - Disclosure - Stock-Based Compensation - Stock Options
(Details)Sheethttp://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetailsStock-Based Compensation - Stock Options (Details)Details55 falsefalseR56.htm99940904 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)Sheethttp://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetailsStock-Based Compensation - Restricted Stock Units (Details)Details56 falsefalseR57.htm99940905 - Disclosure - Stock-Based Compensation - Performance-based Awards
(Details)Sheethttp://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetailsStock-Based Compensation - Performance-based Awards (Details)Details57 falsefalseR58.htm99941001 - Disclosure - Debt (Details)Sheethttp://www.natera.com/role/DisclosureDebtDetailsDebt (Details)Detailshttp://www.natera.com/role/DisclosureDebtTables58 falsefalseR59.htm99941002 - Disclosure - Debt - Discount and Issuance Costs (Details)Sheethttp://www.natera.com/role/DisclosureDebtDiscountAndIssuanceCostsDetailsDebt - Discount and Issuance Costs (Details)Details59 falsefalseR60.htm99941003 - Disclosure - Debt - Convertible Notes Balances
(Details)Noteshttp://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetailsDebt - Convertible Notes Balances (Details)Details60 falsefalseR61.htm99941004 - Disclosure - Debt - Interest Expense Recognized Related To Convertible Notes (Details)Noteshttp://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetailsDebt - Interest Expense Recognized Related To Convertible Notes (Details)Details61 falsefalseR62.htm99941101 - Disclosure - Income Taxes
(Details)Sheethttp://www.natera.com/role/DisclosureIncomeTaxesDetailsIncome Taxes (Details)Detailshttp://www.natera.com/role/DisclosureIncomeTaxes62 falsefalseR63.htm99941201 - Disclosure - Net Loss per Share - Loss per Share (Details)Sheethttp://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetailsNet Loss per Share - Loss per Share (Details)Details63 falsefalseR64.htm99941202 - Disclosure - Net Loss per Share - Potentially Dilutive Shares
(Details)Sheethttp://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetailsNet Loss per Share - Potentially Dilutive Shares (Details)Details64 falsefalseR65.htm99941301 - Disclosure - Subsequent Events (Details)Sheethttp://www.natera.com/role/DisclosureSubsequentEventsDetailsSubsequent Events (Details)Detailshttp://www.natera.com/role/DisclosureSubsequentEvents65 falsefalseAll ReportsBookAll Reports ntra-20240930.xsdntra-20240930_cal.xmlntra-20240930_def.xmlntra-20240930_lab.xmlntra-20240930_pre.xmlntra-20240930x10q.htm http://fasb.org/srt/2023http://fasb.org/us-gaap/2023http://xbrl.sec.gov/dei/2023http://xbrl.sec.gov/ecd/2023truetrue JSON 84 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ntra-20240930x10q.htm": { "nsprefix": "ntra", "nsuri": "http://www.natera.com/20240930", "dts": { "schema": { "local": ["ntra-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd"] }, "calculationLink": { "local": ["ntra-20240930_cal.xml"] }, "definitionLink": { "local": ["ntra-20240930_def.xml"] }, "labelLink": { "local": ["ntra-20240930_lab.xml"] }, "presentationLink": { "local": ["ntra-20240930_pre.xml"] }, "inline": { "local": ["ntra-20240930x10q.htm"] } }, "keyStandard": 288, "keyCustom": 74, "axisStandard": 31, "axisCustom": 0, "memberStandard": 35, "memberCustom": 65, "hidden": { "total": 41, "http://fasb.org/us-gaap/2023": 17, "http://www.natera.com/20240930": 10, "http://xbrl.sec.gov/dei/2023": 14 }, "contextCount": 314, "entityCount": 1, "segmentCount": 106, "elementCount": 686, "unitCount": 14, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 793, "http://xbrl.sec.gov/dei/2023": 30, "http://xbrl.sec.gov/ecd/2023": 18, "http://fasb.org/srt/2023": 1 }, "report": { "R1": { "role": "http://www.natera.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["p", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets", "longName": "995200100 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:InventoryNet", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R3": { "role": "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "longName": "995200105 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "longName": "995200200 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_zmItRotvA0CxBNdfZYXTug", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_zmItRotvA0CxBNdfZYXTug", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R5": { "role": "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "longName": "995200300 - Statement - Condensed Consolidated Statements of Stockholders' Equity", "shortName": "Condensed Consolidated Statements of Stockholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FuwzVBHQYk2pYfRWntOqaQ", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_FuwzVBHQYk2pYfRWntOqaQ", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R6": { "role": "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows", "longName": "995200400 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.natera.com/role/DisclosureDescriptionOfBusiness", "longName": "995210101 - Disclosure - Description of Business", "shortName": "Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.natera.com/role/DisclosureRevenueRecognition", "longName": "995210301 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.natera.com/role/DisclosureFairValueMeasurements", "longName": "995210401 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.natera.com/role/DisclosureFinancialInstruments", "longName": "995210501 - Disclosure - Financial Instruments", "shortName": "Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.natera.com/role/DisclosureBalanceSheetComponents", "longName": "995210601 - Disclosure - Balance Sheet Components", "shortName": "Balance Sheet Components", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.natera.com/role/DisclosureLeases", "longName": "995210701 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.natera.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210801 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R15": { "role":

```
"http://www.natera.com/role/DisclosureStockBasedCompensation", "longName": "995210901 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.natera.com/role/DisclosureDebt", "longName": "995211001 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.natera.com/role/DisclosureIncomeTaxes", "longName": "995211101 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.natera.com/role/DisclosureNetLossPerShare", "longName": "995211201 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.natera.com/role/DisclosureSubsequentEvents", "longName": "995211301 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_zmItRotvA0CxBNdfZYXTug", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ecd_IndividualAxis_ntra_MikeBrophyMember_wO-9nuVuYkyFxBno_0Jsqg", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_ecd_IndividualAxis_ntra_MikeBrophyMember_wO-9nuVuYkyFxBno_0Jsqg", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "99930203 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomePolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ComprehensiveIncomePolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.natera.com/role/DisclosureRevenueRecognitionTables", "longName": "99930303 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "ntra:DisaggregationOfRevenueByCustomerTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "ntra:DisaggregationOfRevenueByCustomerTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.natera.com/role/DisclosureFairValueMeasurementsTables", "longName": "99930403 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.natera.com/role/DisclosureFinancialInstrumentsTables", "longName": "99930503 - Disclosure - Financial Instruments (Tables)", "shortName": "Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.natera.com/role/DisclosureBalanceSheetComponentsTables", "longName": "99930603 - Disclosure - Balance Sheet Components (Tables)", "shortName": "Balance Sheet Components (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.natera.com/role/DisclosureLeasesTables", "longName": "99930703 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "ntra:LeaseBalanceSheetDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "ntra:LeaseBalanceSheetDisclosureTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesTables", "longName": "99930803 - Disclosure - Commitments and Contingencies (Tables)", "shortName": "Commitments and Contingencies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "srt:ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.natera.com/role/DisclosureStockBasedCompensationTables", "longName": "99930903 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.natera.com/role/DisclosureDebtTables", "longName": "99931003 - Disclosure - Debt (Tables)", "shortName": "Debt (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ConvertibleDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.natera.com/role/DisclosureNetLossPerShareTables", "longName": "99931203 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.natera.com/role/DisclosureDescriptionOfBusinessDetails", "longName": "99940101 - Disclosure - Description of Business (Details)", "shortName": "Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_ehrhuOIaskaW_QLnObVk4w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_ehrhuOIaskaW_QLnObVk4w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_zmItRotvA0CxBNdfZYXTug", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1,
```

"baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_9_1_2023_To_9_30_2023_HMjvRFfGd0WkBBSWrBcniw", "name": "us-gaap:PaymentsOfStockIssuanceCosts", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ntra:LiquidityMattersPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R35": { "role": "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails", "longName": "99940202 - Disclosure - Summary of Significant Accounting Policies - Other Assets (Details)", "shortName": "Summary of Significant Accounting Policies - Other Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_9_10_2021_To_9_10_2021_us-gaap_AssetAcquisitionAxis_ntra_InProcessResearchDevelopmentAcquisitionAgreementMember_0swcVkHkoE6GMYvbMVgyMA", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ntra:LiquidityMattersPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_9_10_2021_To_9_10_2021_us-gaap_AssetAcquisitionAxis_ntra_InProcessResearchDevelopmentAcquisitionAgreementMember_0swcVkHkoE6GMYvbMVgyMA", "name": "us-gaap:AssetAcquisitionConsiderationTransferred", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ntra:LiquidityMattersPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAocilDetails", "longName": "99940203 - Disclosure - Summary of Significant Accounting Policies - AOCIL (Details)", "shortName": "Summary of Significant Accounting Policies - AOCIL (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_6_30_2024_DeA7SHFA402xw4Rw7VI6vA", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomePolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_DeA7SHFA402xw4Rw7VI6vA", "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "us-gaap:ComprehensiveIncomePolicyPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails", "longName": "99940204 - Disclosure - Summary of Significant Accounting Policies - Related Party (Details)", "shortName": "Summary of Significant Accounting Policies - Related Party (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_8_31_2024_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ntra_MyomeIncMember_h-KCUoPVUepGJGsg0fTnQ", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ntra:RelatedPartyTransactionsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_8_31_2024_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_ntra_MyomeIncMember_h-KCUoPVUepGJGsg0fTnQ", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ntra:RelatedPartyTransactionsPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertainties Details", "longName": "99940205 - Disclosure - Summary of Significant Accounting Policies - Risks and Uncertainties (Details)", "shortName": "Summary of Significant Accounting Policies - Risks and Uncertainties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_51EClN6ImkqqeBJje_xj2w", "name": "ntra:NumberOfCustomers", "unitRef": "Unit_Standard_customer__BhgmK5HBUyDQdrakGcwBg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["ntra:NumberOfCustomers", "ntra:NumberOfCustomers", "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_51EClN6ImkqqeBJje_xj2w", "name": "ntra:NumberOfCustomers", "unitRef": "Unit_Standard_customer__BhgmK5HBUyDQdrakGcwBg", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["ntra:NumberOfCustomers", "ntra:NumberOfCustomers", "ntra:NumberOfCustomers", "p", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.natera.com/role/DisclosureRevenueRecognitionDetails", "longName": "99940301 - Disclosure - Revenue Recognition (Details)", "shortName": "Revenue Recognition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2023_6hiuHXqk-k-OAKqHTHafBQ", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_6hiuHXqk-k-OAKqHTHafBQ", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails", "longName": "99940302 - Disclosure - Revenue Recognition - Disaggregation (Details)", "shortName": "Revenue Recognition - Disaggregation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_zmItRotvA0CxBNdfZYXTug", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_srt_StatementGeographicalAxis_country_US_neHsXpmbgUCTts-5EMnl7Q", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R41": { "role": "http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails", "longName": "99940303 - Disclosure - Revenue Recognition - Accounts Receivable and Deferred Revenue (Details)", "shortName": "Revenue Recognition - Accounts Receivable and Deferred Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R42": { "role": "http://www.natera.com/role/DisclosureRevenueRecognitionChangesInBalanceOfDeferredRevenuesDetails", "longName": "99940304 - Disclosure - Revenue Recognition - Changes in Balance of Deferred Revenues (Details)", "shortName": "Revenue Recognition - Changes in Balance of Deferred Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "As_Of_12_31_2023_6hiuHXqk-k-OAKqHTHafBQ", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "ntra:ContractWithCustomerLiabilityAdditions", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ntra:ScheduleOfChangesInBalancesOfDeferredRevenuesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R43": { "role": "http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails", "longName": "99940305 - Disclosure - Revenue Recognition - Deferred Revenues (Details)", "shortName": "Revenue Recognition - Deferred Revenues (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInRevenueOfProgress", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ntra:ScheduleOfChangesInBalancesOfDeferredRevenuesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_srt_CounterpartyNameAxis_ntra_BgiGenomicsCoLtdMember_u4YHXaajPEm4FJBRvlGYIA", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R44": { "role": "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails", "longName": "99940401 - Disclosure - Fair Value Measurements (Details)", "shortName": "Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_DebtInstrumentAxis_ntra_LineOfCreditUbsMember_N4DVNhhdpUCDKetPJzBhlQ", "name": "us-gaap:LineOfCreditFacilityFairValueOfAmountOutstanding", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_biFxuiEWvUGBdGSUzo-CNQ", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R45": { "role": "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails", "longName": "99940501 - Disclosure - Financial Instruments (Details)", "shortName": "Financial Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "ntra:CashCashEquivalentsRestrictedCashAndSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "ntra:CashCashEquivalentsRestrictedCashAndSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.natera.com/role/DisclosureBalanceSheetComponentsAllowanceForDoubtfulAccountsDetails", "longName": "99940601 - Disclosure - Balance Sheet Components - Allowance for Doubtful Accounts (Details)", "shortName": "Balance Sheet Components - Allowance for Doubtful Accounts (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_6_30_2024_DeA7SHFA402xw4Rw7VI6vA", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_6_30_2024_DeA7SHFA402xw4Rw7VI6vA", "name": "us-gaap:FinancingReceivableAllowanceForCreditLosses", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:AccountsReceivableAllowanceForCreditLossTableTextBlock", "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails", "longName": "99940602 - Disclosure - Balance Sheet Components - Property and Equipment, net (Details)", "shortName": "Balance Sheet Components - Property and Equipment, net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails", "longName": "99940604 - Disclosure - Balance Sheet Components - Other Accrued Liabilities (Details)", "shortName": "Balance Sheet Components - Other Accrued Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:AccruedInsuranceCurrentAndNoncurrent", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "ntra:AccruedChargesForOutsourcedTesting", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R49": { "role": "http://www.natera.com/role/DisclosureBalanceSheetComponentsReserveBalanceAndActivitiesForRefundsDetails", "longName": "99940605 - Disclosure - Balance Sheet Components - Reserve Balance and Activities for Refunds (Details)", "shortName": "Balance Sheet Components - Reserve Balance and Activities for Refunds (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_12_31_2023_6hiuHXqk-k-OAKqHTHafBQ", "name": "us-gaap:AccruedInsuranceCurrentAndNoncurrent", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1,

"baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "ntra:InsuranceCarrierReservesAdditions", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ntra:SummaryOfReserveBalanceAndActivitiesForRefundsToInsuranceCarriersTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R50": { "role": "http://www.natera.com/role/DisclosureLeasesDetails", "longName": "99940701 - Disclosure - Leases (Details)", "shortName": "Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:OperatingLeaseLiabilityCurrent", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "ntra:NoncashOperatingActivitiesRelatedToRightOfUseAssets", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R51": { "role": "http://www.natera.com/role/DisclosureLeasesPaymentsDetails", "longName": "99940702 - Disclosure - Leases - Payments (Details)", "shortName": "Leases - Payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99940801 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_1_31_2024_EBA8qse91EC5BCI4a7mxGQ", "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber", "unitRef": "Unit_Standard_patent_IMjF81ieF0KXdHrtRYJ56w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:LossContingencyPatentsAllegedlyInfringedNumber", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_1_31_2024_EBA8qse91EC5BCI4a7mxGQ", "name": "us-gaap:LossContingencyPatentsAllegedlyInfringedNumber", "unitRef": "Unit_Standard_patent_IMjF81ieF0KXdHrtRYJ56w", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": ["us-gaap:LossContingencyPatentsAllegedlyInfringedNumber", "p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "longName": "99940901 - Disclosure - Stock-Based Compensation - Compensation Expense (Details)", "shortName": "Stock-Based Compensation - Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_zmItRotvA0CxBNdfZYXTug", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember_uI1D0tbvs0OOLC0Ipn0EtQ", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R54": { "role": "http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "longName": "99940902 - Disclosure - Stock-Based Compensation - Narrative (Details)", "shortName": "Stock-Based Compensation - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_zmItRotvA0CxBNdfZYXTug", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R55": { "role": "http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "longName": "99940903 - Disclosure - Stock-Based Compensation - Stock Options (Details)", "shortName": "Stock-Based Compensation - Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_ntra_EmployeeAndNonEmployeeOptionsMember_HmQX_1kFEEqeFAFWifdG9Q", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_Ewi7KPggkUSPWQFKmLXp-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_ntra_EmployeeAndNonEmployeeOptionsMember_3Y0bTpNeFE2GZ67PmDSlCg", "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised", "unitRef": "Unit_Standard_shares_Ewi7KPggkUSPWQFKmLXp-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R56": { "role": "http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "longName": "99940904 - Disclosure - Stock-Based Compensation - Restricted Stock Units (Details)", "shortName": "Stock-Based Compensation - Restricted Stock Units (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_ntra_RestrictedStockUnitsRsuAndPerformanceSharesMember_JP5ZkAFilkSW-D7aR997MA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_Ewi7KPggkUSPWQFKmLXp-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_AwardTypeAxis_ntra_RestrictedStockUnitsRsuAndPerformanceSharesMember_JP5ZkAFilkSW-D7aR997MA", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_Ewi7KPggkUSPWQFKmLXp-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails", "longName": "99940905 - Disclosure - Stock-Based Compensation - Performance-based Awards (Details)", "shortName": "Stock-Based Compensation - Performance-based Awards (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_zmItRotvA0CxBNdfZYXTug", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_U91VuL50jkakoEbb-cyX5w", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R58": { "role": "http://www.natera.com/role/DisclosureDebtDetails", "longName": "99941001 - Disclosure - Debt (Details)", "shortName": "Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_9_30_2024_3ee7bTq_20m6zFFS4m7Spw", "name": "us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "ntra:LiquidityMattersPolicyTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_1_2020_To_4_30_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_mX90gSVZoUie3Dr60pZsgQ", "name": "us-gaap:ProceedsFromConvertibleDebt", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R59": { "role": "http://www.natera.com/role/DisclosureDebtDiscountAndIssuanceCostsDetails", "longName": "99941002 - Disclosure - Debt - Discount and Issuance Costs (Details)", "shortName": "Debt - Discount and Issuance Costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_QOArMY_mV0eI9Ho5gkzCsQ", "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage", "unitRef": "Unit_Standard_pure_w1d4NZS_rE2QrbuelEKCbw", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": ["p", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": null }, "R60": { "role": "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails", "longName": "99941003 - Disclosure - Debt - Convertible Notes Balances (Details)", "shortName": "Debt - Convertible Notes Balances (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_QOArMY_mV0eI9Ho5gkzCsQ", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_QOArMY_mV0eI9Ho5gkzCsQ", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "longName": "99941004 - Disclosure - Debt - Interest Expense Recognized Related To Convertible Notes (Details)", "shortName": "Debt - Interest Expense Recognized Related To Convertible Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_jsxqIhnIb0Cd5RNW2Qg4Rw", "name": "ntra:ContractualInterestExpenseDebt", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ntra:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_jsxqIhnIb0Cd5RNW2Qg4Rw", "name": "ntra:ContractualInterestExpenseDebt", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "ntra:ScheduleOfInterestExpenseTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.natera.com/role/DisclosureIncomeTaxesDetails", "longName": "99941101 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "Duration_7_1_2024_To_9_30_2024_zmItRotvA0CxBNdfZYXTug", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": ["p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2023_6huHXqk-k-OAKqHTHafBQ", "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R63": { "role": "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "longName": "99941201 - Disclosure - Net Loss per Share - Loss per Share (Details)", "shortName": "Net Loss per Share - Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_4_30_2020_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_g_VEWCvtyUKkRqG1atO35w", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:LongTermDebtTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleNotesPayableMember_kfNifpYhsEWrlk4CswHdQw", "name": "us-gaap:DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "unique": true } }, "R64": { "role": "http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails", "longName": "99941202 - Disclosure - Net Loss per Share - Potentially Dilutive Shares (Details)", "shortName": "Net Loss per Share - Potentially Dilutive Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_Ewi7KPggkUSPWQFKmLXp-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef":

"Duration_1_1_2024_To_9_30_2024_LbjdB1Lwa0aaUvPGqbF6Wg", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_Ewi7KPggkUSPWQFKmLXp-Q", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": ["p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "longName": "999941301 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_juq5k5cO8UmWF4mitxjxeQ", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2024_us-gaap_ShortTermDebtTypeAxis_us-gaap_ConvertibleNotesPayableMember_juq5k5cO8UmWF4mitxjxeQ", "name": "us-gaap:ConvertibleNotesPayableCurrent", "unitRef": "Unit_Standard_USD_XA4HAkl4zUOcqs2gdlUojQ", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": ["p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html"], "reportCount": 1, "baseRef": "ntra-20240930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r17", "r757"] }, "us-gaap_AccountsReceivableAllowanceForCreditLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableAllowanceForCreditLossTableTextBlock", "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss [Table Text Block]", "terseLabel": "Schedule of allowances for credit losses related to trade accounts receivable and other receivables", "documentation": "Tabular disclosure of allowance for credit loss on accounts receivable." } } }, "auth_ref": ["r903"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableMember", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails"], "lang": { "en-us": { "role": { "label": "Accounts receivable", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r701"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Current accounts receivable", "terseLabel": "Accounts receivable, net of allowance of $6,252 and $6,481 at September 30, 2024 and December 31, 2023, respectively", "verboseLabel": "Accounts receivable, net", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r259", "r260"] }, "ntra_AccruedChargesForOutsourcedTesting": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AccruedChargesForOutsourcedTesting", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for outsourced testing.", "label": "Accrued Charges For Outsourced Testing", "terseLabel": "Accrued charges for third-party testing" } } }, "auth_ref": [] }, "ntra_AccruedClinicalTrialsAndStudies": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AccruedClinicalTrialsAndStudies", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trials and studies.", "label": "Accrued Clinical Trials And Studies", "terseLabel": "Clinical trials and studies" } } }, "auth_ref": [] }, "ntra_AccruedFixedAssetPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AccruedFixedAssetPurchases", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for fixed assets.", "label": "Accrued Fixed Asset Purchases", "terseLabel": "Property and equipment purchases" } } }, "auth_ref": [] }, "us-gaap_AccruedInsuranceCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedInsuranceCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails", "http://www.natera.com/role/DisclosureBalanceSheetComponentsReserveBalanceAndActivitiesForRefundsDetails"], "lang": { "en-us": { "role": { "label": "Accrued Insurance", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Reserves for refunds to insurance carriers", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable to insurance entities to mitigate potential loss from various risks or to satisfy a promise to provide certain coverage's to employees." } } }, "auth_ref": ["r80", "r81", "r119"] }, "ntra_AccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AccruedInterest", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails", "http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of accrued interest.", "label": "Accrued Interest", "terseLabel": "Other accrued interest" } } }, "auth_ref": [] }, "us-gaap_AccruedMarketingCostsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedMarketingCostsCurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Marketing Costs, Current", "terseLabel": "Marketing and corporate affairs", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for the marketing, trade and selling of the entity's goods and services. Marketing costs would include expenditures for planning and executing the conception, pricing, promotion, and distribution of ideas, goods, and services; costs of public relations and corporate promotions; and obligations incurred and payable for sales discounts, rebates, price protection programs, etc. offered to customers and under government programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees", "terseLabel": "Legal, audit and consulting fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received." } } }, "auth_ref": ["r71"] }, "ntra_AccruedShippingCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AccruedShippingCharges", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for shipping charges.", "label": "Accrued Shipping Charges", "terseLabel": "Accrued shipping charges" } } }, "auth_ref": [] }, "ntra_AccruedSpecimenServiceFees": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AccruedSpecimenServiceFees", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for specimen service fees.", "label": "Accrued Specimen Service Fees", "terseLabel": "Accrued third-party service fees" } } }, "auth_ref": [] }, "ntra_AccruedTestingAndLaboratoryMaterialsFromSuppliers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AccruedTestingAndLaboratoryMaterialsFromSuppliers", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing and laboratory materials from suppliers.", "label": "Accrued Testing And Laboratory Materials From Suppliers", "terseLabel": "Testing and laboratory materials from suppliers" } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Less: Accumulated depreciation and amortization", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": ["r52", "r169", "r563"] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAocilDetails"], "lang": { "en-us": { "role": { "label": "Net unrealized gain on available-for-sale securities, net of tax and foreign currency translation adjustment", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": ["r181", "r182", "r183", "r185", "r191", "r192", "r868"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAocilDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r190", "r191", "r490", "r491", "r492", "r493", "r494", "r495"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAocilDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Accumulated other comprehensive loss", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": ["r28", "r29", "r90", "r176", "r560", "r584", "r585"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAocilDetails"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r190", "r191", "r490", "r491", "r492", "r493", "r494", "r495"] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Loss", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": ["r2", "r10", "r29", "r466", "r469", "r511", "r580", "r581", "r868", "r869", "r870", "r878", "r879", "r880"] }, "ntra_AcquisitionOfWarrantsAndReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AcquisitionOfWarrantsAndReceivables", "crdr": "debit", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of warrants and receivables acquired.", "label": "Acquisition Of Warrants And Receivables", "terseLabel": "Acquisition of warrants and warrant receivable" } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": ["r808"] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": ["r85"] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": ["r440", "r441", "r442", "r600", "r878", "r879", "r880", "r924", "r953"] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt",

```
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r814" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r814" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r814" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
"terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r814" ] }, "us-
gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:" } } }, "auth_ref": [] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition", "crdr": "credit",
"presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows",
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Other Long-term Incentive Plans, Requisite Service Period Recognition", "terseLabel": "Issuance of stock for bonuses", "verboseLabel": "Issuance of common stock for bonuses",
"documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement, classified as other." } } }, "auth_ref": [] },
"us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition", "terseLabel": "Stock based compensation", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r59", "r60", "r406" ] }, "ntra_AggregatePurchaseAgreementAmount": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "AggregatePurchaseAgreementAmount", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureSubsequentEventsDetails" ],
"lang": { "en-us": { "role": { "documentation": "Aggregate purchase agreement amount.", "label": "Aggregate Purchase Agreement Amount", "terseLabel": "Upfront purchase agreement amount" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation
Amount" } } }, "auth_ref": [ "r779", "r790", "r800", "r825" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous
Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r782", "r793", "r803", "r828" ] },
"ntra_AgreementTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AgreementTerm", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Period the agreement term, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Agreement Term", "terseLabel": "Agreement term" } } }, "auth_ref": [] },
"ntra_AgreementTermAutomaticRenewalsPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AgreementTermAutomaticRenewalsPeriod",
"presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the automatic renewals thereafter for successive number of years.", "label": "Agreement Term, Automatic Renewals Period", "terseLabel": "Automatic renewals, successive period thereafter" } } }, "auth_ref": [] },
"ntra_AgreementTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AgreementTransactionPrice", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the agreement transaction price.", "label": "Agreement
Transaction Price", "terseLabel": "Transaction price" } } }, "auth_ref": [] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r814" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r821" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r786", "r794", "r804", "r821", "r829", "r833", "r841" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading
Arrangements" } } }, "auth_ref": [ "r839" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails",
"http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails" ], "lang":
{ "en-us": { "role": { "label": "Allocated Share-based Compensation Expense", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r435", "r443" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Allowance for Doubtful Accounts Receivable", "terseLabel": "Allowances on accounts receivable", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r177", "r263", "r310", "r313", "r315", "r947" ] }, "us-
gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AllowanceForDoubtfulAccountsReceivableCurrent", "crdr": "credit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": {
"en-us": { "role": { "label": "Allowance for Doubtful Accounts Receivable, Current", "terseLabel": "Allowances on accounts receivable", "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current." } } }, "auth_ref": [ "r177", "r263", "r310" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023",
"localname": "AmendmentFlag", "presentation": [ "http://www.natera.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "ntra_AmericasExcludingUsMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "AmericasExcludingUsMember", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails" ], "lang": { "en-us": { "role": { "documentation": "Continents of North and South America, excluding the United States of America (US).", "label": "Americas, excluding U.S." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfDebtDiscountPremium": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AmortizationOfDebtDiscountPremium", "crdr": "debit", "calculation": {
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 }
}, "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": {
"label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount and issuance cost", "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense." } } },
"auth_ref": [ "r5", "r65", "r97", "r364" ] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails": {
"parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs and Discounts", "terseLabel": "Amortization of debt discount and debt issuance cost", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r364", "r498", "r736", "r737", "r873" ] }, "ntra_AmountsNotRefundedToInsuranceCarriersMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "AmountsNotRefundedToInsuranceCarriersMember", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ],
"lang": { "en-us": { "role": { "documentation": "Represents amounts not refunded to insurance carriers.", "label": "Amounts not refunded to insurance carriers" } } }, "auth_ref": [] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" ],
"lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Potentially dilutive shares not included in diluted per share calculation", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r233" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [
"http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" ], "lang": { "en-us": {
"role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r40" ] }, "us-
gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" ],
"lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [
"http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" ], "lang": { "en-us": {
"role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r40" ] }, "ntra_ApplicationServiceProviderMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ApplicationServiceProviderMember", "presentation": [
"http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents a contractual commitment to application service providers.", "label": "Application service providers" } } }, "auth_ref": [] }, "ntra_ApproximatePercentageOfRevenueCollectedWithinNineMonths": { "xbrltype": "percentItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "ApproximatePercentageOfRevenueCollectedWithinNineMonths", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Approximate percentage of revenue collected within 9 months.", "label":
"Approximate Percentage Of Revenue Collected Within Nine Months", "terseLabel": "Approximate percentage of revenue collected within 9 months" } } }, "auth_ref": [] },
"ntra_ArcherdxPatentCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ArcherdxPatentCaseMember", "presentation": [
"http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents ArcherDX Patent Case.", "label": "ArcherDX Case" }
} }, "auth_ref": [] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfRealEstateProperty", "presentation": [
"http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Area of Real Estate Property", "terseLabel": "Lease space (area)", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis",
"presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]",
"documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r919" ] }, "us-gaap_AssetAcquisitionConsiderationTransferred": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferred", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition Consideration Transferred",
"terseLabel": "Asset acquisition, consideration", "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer." } } }, "auth_ref": [ "r753", "r920", "r921", "r922" ] },
"ntra_AssetAcquisitionConsiderationTransferredAdditionalSharesIssuedAndIssuableUponAchievementOfMilestone": { "xbrltype": "sharesItemType", "nsuri": "http://www.natera.com/20240930",
"localname": "AssetAcquisitionConsiderationTransferredAdditionalSharesIssuedAndIssuableUponAchievementOfMilestone", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of additional shares potentially issuable as consideration upon achievement of milestones in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Additional Shares Issued and Issuable Upon Achievement Of Milestone", "terseLabel": "Number of additional shares potentially issuable" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration", "terseLabel": "Potential milestone payments", "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition." } } }, "auth_ref": [ "r920", "r921", "r922" ] }, "us-gaap_AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable": { "xbrltype": "monetaryItemType", "nsuri":
```

```
"http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredEquityInterestIssuedAndIssuable", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred, Equity
Interest Issued and Issuable", "terseLabel": "Value of common stock issued", "documentation": "Amount of acquirer's equity interest issued and issuable as part of consideration transferred in
asset acquisition." } } }, "auth_ref": [ "r920", "r921", "r922" ] }, "ntra_AssetAcquisitionConsiderationTransferredLiabilitiesIncurred": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "AssetAcquisitionConsiderationTransferredLiabilitiesIncurred", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred by the
acquirer as part of consideration transferred in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Liabilities Incurred", "terseLabel": "Net liabilities assumed" } } },
"auth_ref": [] }, "ntra_AssetAcquisitionConsiderationTransferredSharesIssuedAndIssuable": { "xbrltype": "sharesItemType", "nsuri": "http://www.natera.com/20240930", "localname":
"AssetAcquisitionConsiderationTransferredSharesIssuedAndIssuable", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ],
"lang": { "en-us": { "role": { "documentation": "Number of shares issued and issuable as consideration in asset acquisition.", "label": "Asset Acquisition, Consideration Transferred, Shares Issued
and Issuable", "terseLabel": "Issuance of common stock" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionConsiderationTransferredTransactionCost": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionConsiderationTransferredTransactionCost", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition, Consideration Transferred,
Transaction Cost", "terseLabel": "Acquisition related costs", "documentation": "Amount of transaction cost incurred as part of consideration transferred in asset acquisition." } } }, "auth_ref": [
"r753", "r920", "r921", "r922" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain",
"presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]",
"documentation": "Asset acquisition." } } }, "auth_ref": [ "r919" ] }, "us-gaap_AssetAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AssetAcquisitionLineItems", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Asset
Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain
members defined in one or many axes to the table." } } }, "auth_ref": [ "r919" ] }, "us-gaap_AssetAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "AssetAcquisitionTable", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": {
"label": "Asset Acquisition [Table]", "documentation": "Disclosure of information about asset acquisition." } } }, "auth_ref": [ "r919" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Asset Impairment Charges", "terseLabel":
"Impairment charge", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and
goodwill." } } }, "auth_ref": [ "r5", "r50" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": {
"http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the
carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions
or events." } } }, "auth_ref": [ "r117", "r171", "r205", "r240", "r249", "r253", "r307", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r459", "r463", "r485", "r557", "r642",
"r757", "r770", "r913", "r914", "r931" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ],
"lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "ntra_AssetsAcquiredFromInvitaeMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "AssetsAcquiredFromInvitaeMember", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents assets acquired from Invitae.",
"label": "Assets acquired from Invitae" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent",
"crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation":
"Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer).
Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r165", "r180", "r205", "r307", "r340", "r341",
"r342", "r343", "r344", "r345", "r346", "r347", "r348", "r459", "r463", "r485", "r757", "r913", "r914", "r931" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": {
"role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": {
"en-us": { "role": { "label": "Assets, Fair Value Disclosure", "terseLabel": "Total financial assets", "documentation": "Fair value portion of probable future economic benefits obtained or
controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r62" ] }, "ntra_AustinTexasFirstExpansionPremisesMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "AustinTexasFirstExpansionPremisesMember", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": {
"role": { "documentation": "Represents Austin, Texas \"First Expansion Premises\".", "label": "First Expansion Premises" } } }, "auth_ref": [] },
"ntra_AustinTexasSecondExpansionPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname":
"AustinTexasSecondExpansionPremisesMember", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents Austin,
Texas \"Second Expansion Premises\".", "label": "Second Expansion Premises" } } }, "auth_ref": [] }, "ntra_AustinTxLongTermLeaseMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "AustinTxLongTermLeaseMember", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": {
"documentation": "Represents a long-term operating lease for office space located in Austin, TX.", "label": "Austin TX, Long-term Lease" } } }, "auth_ref": [] }, "us-
gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails": {
"parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized
Cost Basis", "terseLabel": "Greater than one year but less than five years", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value
recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following
current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r894" ] },
"us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails": {
"parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value",
"terseLabel": "Greater than one year but less than five years", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other
comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year.
Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r278", "r555" ] }, "us-
gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails": { "parentTag": null,
"weight": null, "order": null, "root": true } }, "presentation": [ "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Available-for-sale
Securities, Debt Maturities, Single Maturity Date", "totalLabel": "Total", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized
in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date." } } }, "auth_ref": [ "r891", "r892", "r943" ] }, "us-
gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract", "presentation": [ "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": {
"label": "Available-for-sale Securities, Debt Maturities, Single Maturity Date [Abstract]", "terseLabel": "Fair Value" } } }, "auth_ref": [] }, "us-
gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails": {
"parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label":
"Available-for-sale Securities, Debt Maturities, Single Maturity Date, Amortized Cost Basis", "totalLabel": "Total", "documentation": "Amortized cost of investment in debt security measured at
fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date." } } }, "auth_ref": [
"r891", "r892", "r942" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract", "presentation": [
"http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Available-for-sale Securities, Debt Maturities, Single Maturity Date, Amortized Cost
Basis [Abstract]", "terseLabel": "Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost", "crdr": "debit", "calculation": {
"http://www.natera.com/role/DisclosureFinancialInstrumentsDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Available-for-sale Securities, Debt Maturities, Next
Twelve Months, Amortized Cost Basis", "terseLabel": "Less than or equal to one year", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair
value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal
year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r893" ] }, "us-
gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails": { "parentTag": "us-
gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ],
"lang": { "en-us": { "role": { "label": "Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value", "terseLabel": "Less than or equal to one year", "documentation": "Fair
value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated
without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of
financial position date (rolling approach)." } } }, "auth_ref": [ "r277", "r554" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": {
"http://www.natera.com/role/DisclosureFinancialInstrumentsDetails": { "parentTag": "ntra_CashCashEquivalentsRestrictedCashAndSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Short-term
investments", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified
as current." } } }, "auth_ref": [ "r267", "r320" ] }, "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract", "presentation": [ "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang":
{ "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award
Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r836" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value",
"terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r837" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r832" ] },
"ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI
Considered" } } }, "auth_ref": [ "r832" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel":
"Award Timing Method" } } }, "auth_ref": [ "r832" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]",
"terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r832" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure
[Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r832" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award
Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r832" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-
```

gaap/2023", "localname": "AwardTypeAxis", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": ["r835"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r834"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": ["r833"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": ["r833"] }, "us-gaap_BalanceSheetRelatedDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetRelatedDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheet Components" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "ntra_BgiGenomicsCoLtdAndFoundationMedicineInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "BgiGenomicsCoLtdAndFoundationMedicineInc.Member", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents BGI Genomics Co., Ltd. and Foundation Medicine, Inc.", "label": "BGI Genomics and Foundation Medicine (\"FMI\")" } } }, "auth_ref": [] }, "ntra_BgiGenomicsCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "BgiGenomicsCoLtdMember", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents BGI Genomics Co., Ltd.", "label": "BGI Genomics" } } }, "auth_ref": [] }, "ntra_BillingAverageCollectionPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.natera.com/20240930", "localname": "BillingAverageCollectionPeriod", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the average collection period for billing.", "label": "Billing Average Collection Period", "terseLabel": "Billing collection period (in months)" } } }, "auth_ref": [] }, "ntra_CaredxSPatentCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CaredxSPatentCaseMember", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents CareDX Patent Case.", "label": "CareDX Patent Case" } } }, "auth_ref": [] }, "ntra_CashCashEquivalentsAndRestrictedCashMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CashCashEquivalentsAndRestrictedCashMember", "presentation": ["http://www.natera.com/role/DisclosureFairValueMeasurementsDetails", "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage.", "label": "Cash, cash equivalents, and restricted cash" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails": { "parentTag": "ntra_CashCashEquivalentsRestrictedCashAndSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash, cash equivalents and restricted cash, end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of period", "terseLabel": "Cash, cash equivalents and restricted cash", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r36", "r99", "r203"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net change in cash, cash equivalents and restricted cash", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1", "r99"] }, "ntra_CashCashEquivalentsRestrictedCashAndSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndSecurities", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents, restricted cash and amount of investment in securities measured at fair value.", "label": "Cash Cash Equivalents Restricted Cash And Securities", "totalLabel": "Estimated Fair Value" } } }, "auth_ref": [] }, "ntra_CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedGain", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents, restricted cash and amount of unrealized gain in securities measured at fair value.", "label": "Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Gain", "terseLabel": "Gross Unrealized Gain" } } }, "auth_ref": [] }, "ntra_CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndSecuritiesAccumulatedGrossUnrealizedLoss", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents, restricted cash and amount of unrealized loss in securities measured at fair value.", "label": "Cash Cash Equivalents Restricted Cash And Securities Accumulated Gross Unrealized Loss", "negatedLabel": "Gross Unrealized Loss" } } }, "auth_ref": [] }, "ntra_CashCashEquivalentsRestrictedCashAndSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CashCashEquivalentsRestrictedCashAndSecuritiesAmortizedCostBasis", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents, restricted cash and amortized cost of investment in securities measured at fair value.", "label": "Cash Cash Equivalents Restricted Cash And Securities Amortized Cost Basis", "terseLabel": "Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]", "terseLabel": "Non-cash investing and financing activities:" } } }, "auth_ref": [] }, "ntra_CashInterestExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CashInterestExpenseAbstract", "presentation": ["http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents cash interest expense.", "label": "Cash interest expense" } } }, "auth_ref": [] }, "ntra_CertainWorkspacesAndStorageSpacesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CertainWorkspacesAndStorageSpacesMember", "presentation": ["http://www.natera.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents certain workspaces and storage spaces.", "label": "Certain workspaces and storage spaces" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": ["r812"] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ChiefExecutiveOfficerMember", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Executive chairman", "documentation": "Person with designation of chief executive officer." } } }, "auth_ref": ["r884"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ntra_ClassActionLawsuitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ClassActionLawsuitMember", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Lawsuit where one of the parties is a group of people who are represented collectively by a member or members of that group.", "label": "Class action" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": ["r147", "r173", "r174", "r175", "r205", "r227", "r228", "r230", "r232", "r238", "r239", "r307", "r340", "r342", "r343", "r344", "r347", "r348", "r370", "r371", "r373", "r374", "r376", "r485", "r593", "r594", "r595", "r596", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r630", "r651", "r673", "r695", "r696", "r697", "r698", "r699", "r847", "r874", "r882"] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Warrants exercise price (in dollars per share)", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": ["r377"] }, "ntra_ClassOfWarrantOrRightImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ClassOfWarrantOrRightImpairmentLoss", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss from warrants or rights outstanding.", "label": "Class Of Warrant Or Right Impairment Loss", "terseLabel": "Warrants impairment" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "verboseLabel": "Warrants convertible into number of stock shares", "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares." } } }, "auth_ref": [] }, "ntra_ClassOfWarrantOrRightTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ClassOfWarrantOrRightTerm", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "documentation": "Term of warrants or rights outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Class Of Warrant Or Right Term", "terseLabel": "Warrants term" } } }, "auth_ref": [] }, "ntra_CloudPlatformServiceProviderMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CloudPlatformServiceProviderMember", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents a contractual commitment to cloud platform service provider.", "label": "Cloud platform service provider" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": ["r813"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": ["r813"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 8)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r26", "r72", "r558", "r629"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype":

```
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r105", "r334", "r335", "r702", "r907" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r760", "r761", "r762", "r764", "r765", "r766", "r767", "r878", "r879", "r924", "r951", "r953" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "verboseLabel": "Common stock, shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r84", "r630" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r84" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r11", "r84", "r630", "r648", "r953", "r954" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common stock, value issued", "terseLabel": "Common stock, $0.0001 par value: 750,000 shares authorized at both September 30, 2024 and December 31, 2023; 124,137 and 119,581 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r84", "r559", "r757" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r818" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r817" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r819" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r816" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r30", "r187", "r189", "r194", "r550", "r569" ] }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income, Policy [Policy Text Block]", "verboseLabel": "Accumulated Other Comprehensive Income (Loss)", "documentation": "Disclosure of accounting policy for comprehensive income." } } }, "auth_ref": [] }, "us-gaap_ComputerEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComputerEquipmentMember", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Computer equipment", "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r42", "r44", "r63", "r64", "r258", "r701" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r42", "r44", "r63", "r64", "r258", "r586", "r701" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r42", "r44", "r63", "r64", "r258", "r701", "r851" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Risk and Uncertainties", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r75", "r141" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r701" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk (as a percent)", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r42", "r44", "r63", "r64", "r258" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk [Table]", "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark." } } }, "auth_ref": [ "r41", "r42", "r44", "r45", "r63", "r114", "r701" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r42", "r44", "r63", "r64", "r258", "r701" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Principles of Consolidation", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r61", "r722" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Construction-in-process", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "ntra_ContractWithCustomerAndOtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ContractWithCustomerAndOtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, and other liabilities classified as noncurrent.", "label": "Contract With Customer And Other Liabilities Noncurrent", "terseLabel": "Deferred revenue, long-term portion and other liabilities" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionTables" ], "lang": { "en-us": { "role": { "label": "Contract With Customer Asset And Liability [Table Text Block]", "terseLabel": "Schedule of beginning and ending balances of accounts receivable and deferred revenues", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r917" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, Net, Current", "terseLabel": "Contract asset", "verboseLabel": "Contract assets", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r379", "r381", "r392" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionChangesInBalanceOfDeferredRevenuesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning balance", "terseLabel": "Deferred revenue", "totalLabel": "Total deferred revenues", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r379", "r380", "r392" ] }, "us-gaap_ContractWithCustomerLiabilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityAbstract", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability [Abstract]", "terseLabel": "Liabilities:" } } }, "auth_ref": [] }, "ntra_ContractWithCustomerLiabilityAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ContractWithCustomerLiabilityAdditions", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionChangesInBalanceOfDeferredRevenuesDetails" ], "lang": { "en-us": { "role": { "documentation": "The additional amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability Additions", "terseLabel": "Increase in deferred revenues" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionChangesInBalanceOfDeferredRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized", "terseLabel": "Revenue recognized from performance obligations satisfied within the same period", "documentation": "Amount of revenue recognized arising from contract liability from change in timeframe for performance obligation to be satisfied." } } }, "auth_ref": [ "r740" ] }, "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInMeasureOfProgress", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionChangesInBalanceOfDeferredRevenuesDetails",
```

```
"http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Measure of Progress", "negatedLabel": "Revenue recognized during the period that was included in deferred revenues at the beginning of the period", "terseLabel": "Revenue recognized during the period that was included in deferred revenues at the beginning of the period", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in measure of progress which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r739" ] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": {
"http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 1.0 }, "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails",
"http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": {
"role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue, current portion", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r379", "r380", "r392" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionAccountsReceivableAndDeferredRevenueDetails",
"http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Noncurrent", "terseLabel": "Deferred revenue, long-term portion", "verboseLabel": "Deferred revenue, Long-term", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r379", "r380", "r392" ] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Revenue recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r393" ] }, "ntra_ContractualInterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ContractualInterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails": {
"parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of contractual interest expense for debt.", "label": "Contractual Interest Expense Debt", "terseLabel": "Contractual interest expense" } } }, "auth_ref": [] },
"srt_ContractualObligationFiscalYearMaturityScheduleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname":
"ContractualObligationFiscalYearMaturityScheduleTableTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesTables" ], "lang": { "en-us": {
"role": { "label": "Contractual Obligation, Fiscal Year Maturity Schedule [Table Text Block]", "terseLabel": "Schedule of material contractual commitments", "documentation": "Tabular disclosure of contractual obligation by timing of payment due. Includes, but is not limited to, long-term debt obligation, lease obligation, and purchase obligation." } } }, "auth_ref": [ "r877" ] },
"us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit",
"presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label":
"Convertible Debt, Fair Value Disclosures", "verboseLabel": "Fair value of long-term debt", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureDebtTables" ],
"lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "verboseLabel": "Schedule of outstanding Convertible Notes", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails",
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r16", "r120", "r945" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable, Current", "terseLabel": "Short-term convertible notes", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ConvertibleNotesPayableMember", "presentation": [ "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails", "http://www.natera.com/role/DisclosureDebtDetails",
"http://www.natera.com/role/DisclosureDebtDiscountAndIssuanceCostsDetails", "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails",
"http://www.natera.com/role/DisclosureFairValueMeasurementsDetails", "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails",
"http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails",
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r79", "r118" ] },
"ntra_CorporateHeadquartersLeaseAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname":
"CorporateHeadquartersLeaseAmendmentMember", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents an operating lease amendment for office space used as corporate headquarters.", "label": "Corporate Headquarters Lease Amendment" } } }, "auth_ref": [] },
"ntra_CorporateHeadquartersLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "CorporateHeadquartersLeaseMember",
"presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents an operating lease for office space used as corporate headquarters.", "label": "Corporate Headquarters Lease" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": {
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of product revenues", "terseLabel": "Cost of revenues", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r95", "r549" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Cost of revenues", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Other operating Expenses", "totalLabel": "Total cost and expenses", "documentation": "Total costs of sales and operating expenses for the period." } } },
"auth_ref": [ "r93" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]",
"terseLabel": "Cost and expenses" } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis",
"presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us":
{ "role": { "label": "Counterparty Name [Axis]", "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution." } } }, "auth_ref": [ "r162", "r207", "r208", "r352", "r372", "r512", "r719", "r721" ] }, "dei_CoverAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [
"http://www.natera.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] },
"dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [
"http://www.natera.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"CustomerConcentrationRiskMember", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails" ], "lang": { "en-us": {
"role": { "label": "Customer", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r43", "r258" ] },
"ntra_CyberattackDisruptionAtChangeHealthcareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname":
"CyberattackDisruptionAtChangeHealthcareMember", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation":
"Represents cyberattack disruption at change healthcare.", "label": "Disruption at Change Healthcare" } } }, "auth_ref": [] }, "ntra_DanielRabinowitzMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.natera.com/20240930", "localname": "DanielRabinowitzMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": {
"documentation": "Represents information pertaining to Daniel Rabinowitz.", "label": "Daniel Rabinowitz [Member]", "terseLabel": "Daniel Rabinowitz" } } }, "auth_ref": [] }, "us-gaap_DebtConversionConvertedInstrumentAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentAmount1",
"crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails",
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Debt conversion amount", "terseLabel": "Conversion of Debt",
"verboseLabel": "Convertible, if converted common shares aggregate value", "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r37", "r39" ] },
"us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt" } }
}, "auth_ref": [] }, "ntra_DebtInstrumentAccruedInterestToBeSettledInEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname":
"DebtInstrumentAccruedInterestToBeSettledInEquity", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails" ], "lang": { "en-us": { "role": {
"documentation": "Amount of debt instrument accrued interest to be settled in equity.", "label": "Debt Instrument Accrued Interest To Be Settled In Equity", "terseLabel": "Accrued interest to be settled in equity" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis",
"presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails",
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r16", "r79", "r80", "r118", "r120", "r209", "r349", "r350", "r351", "r352", "r353", "r354",
"r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r499", "r733", "r734", "r735", "r736", "r737", "r875" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [
"http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "verboseLabel": "Spread on interest rate (as a percent)", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails": { "parentTag": "us-gaap_LongTermDebt",
"weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails" ], "lang": { "en-us": { "role": { "label": "Outstanding principle",
"documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r16", "r120", "r366" ] }, "us-gaap_DebtInstrumentCollateralAmount": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCollateralAmount", "crdr": "debit", "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails", "http://www.natera.com/role/DisclosureDebtDetails",
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Collateral Amount", "terseLabel": "Equipment pledged", "verboseLabel": "Collateral amount", "documentation": "Amount of assets pledged to secure a debt instrument." } } }, "auth_ref": [ "r74" ] }, "us-
```

gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": ["r107", "r351"] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Ratio", "verboseLabel": "Initial conversion rate", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": ["r24", "r55", "r109", "r110", "r351"] }, "ntra_DebtInstrumentConvertibleConversionRatioIncrease": { "xbrltype": "pureItemType", "nsuri": "http://www.natera.com/20240930", "localname": "DebtInstrumentConvertibleConversionRatioIncrease", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "documentation": "Increase of ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.", "label": "Debt Instrument Convertible Conversion Ratio Increase", "terseLabel": "Conversion rate increase" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal", "verboseLabel": "Convertible, If-converted value in excess of principal", "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only." } } }, "auth_ref": ["r54"] }, "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Number of Equity Instruments", "verboseLabel": "Convertible to shares of common stock", "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity." } } }, "auth_ref": ["r24", "r55", "r109", "r110", "r351"] }, "ntra_DebtInstrumentConvertiblePercentageOfPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.natera.com/20240930", "localname": "DebtInstrumentConvertiblePercentageOfPrincipalAmount", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "The percentage of principal amount converted.", "label": "Debt Instrument, Convertible, Percentage of Principal Amount", "terseLabel": "Percentage of principal amount converted" } } }, "auth_ref": [] }, "ntra_DebtInstrumentConvertibleThresholdBusinessDays": { "xbrltype": "integerItemType", "nsuri": "http://www.natera.com/20240930", "localname": "DebtInstrumentConvertibleThresholdBusinessDays", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Threshold number of specified business days for conversion after consecutive trading day period triggers conversion feature.", "label": "Debt Instrument Convertible Threshold Business Days", "terseLabel": "Threshold business days" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "verboseLabel": "Number of threshold consecutive trading days", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Percentage of conversion price", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Trading Days", "verboseLabel": "Threshold trading days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Outstanding principal balance", "verboseLabel": "Principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": ["r66", "r68", "r349", "r499", "r734", "r735"] }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateDuringPeriod", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate During Period", "terseLabel": "Per annum interest rate (as a percent)", "documentation": "The average effective interest rate during the reporting period." } } }, "auth_ref": ["r23", "r66", "r361"] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureDebtDiscountAndIssuanceCostsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate (as a percent)", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": ["r23", "r66", "r368", "r499"] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": ["r23", "r350"] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r209", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r499", "r733", "r734", "r735", "r736", "r737", "r875"] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r25", "r209", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r499", "r733", "r734", "r735", "r736", "r737", "r875"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r25", "r55", "r56", "r65", "r66", "r68", "r73", "r108", "r110", "r209", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r499", "r733", "r734", "r735", "r736", "r737", "r875"] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureDebtDiscountAndIssuanceCostsDetails"], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "ntra_DebtInstrumentUnamortizedDebtDiscountAndDebtIssuanceCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "DebtInstrumentUnamortizedDebtDiscountAndDebtIssuanceCost", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of unamortized debt discount and debt issuance cost.", "label": "Debt Instrument Unamortized Debt Discount And Debt Issuance Cost", "negatedLabel": "Unamortized debt discount and issuance cost" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "terseLabel": "Credit loss reserve", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r272", "r320", "r327", "r328"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280"] }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "label": "Available-for-sale Securities [Table Text Block]", "terseLabel": "Schedule of available-for-sale securities", "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "terseLabel": "Fair value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": ["r133", "r322", "r731"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss", "negatedLabel": "Unrealized loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r134", "r323"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsTables"], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Schedule of debt securities available-for-sale in unrealized loss position", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r132", "r731", "r904"] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Available-for-sale, Securities in Unrealized Loss Positions, Qualitative Disclosure, Number of Positions", "terseLabel": "Number of investments, unrealized loss position", "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": ["r135", "r324"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Depreciation", "terseLabel": "Depreciation expense", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r5", "r51"] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": ["r5", "r244"] }, "ntra_DisaggregationOfRevenueByCustomerTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.natera.com/20240930", "localname": "DisaggregationOfRevenueByCustomerTableTextBlock", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue by customer.", "label": "Disaggregation Of Revenue By Customer [Table Text Block]", "terseLabel": "Schedule of disaggregation of revenues by payer types" } } }, "auth_ref": [] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r391", "r741", "r742", "r743", "r744", "r745", "r746", "r747"] }, "us-

gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails"], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r391", "r741", "r742", "r743", "r744", "r745", "r746", "r747"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensation"], "lang": { "en-us": { "role": { "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r404", "r408", "r437", "r438", "r439", "r752"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r774"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r807"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_EMEAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EMEAMember", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails"], "lang": { "en-us": { "role": { "label": "Europe, Middle East, India, Africa", "documentation": "Regions of Europe, Middle East and Africa." } } }, "auth_ref": ["r955", "r956", "r957", "r958"] }, "ntra_EarningsOrLossPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.natera.com/20240930", "localname": "EarningsOrLossPerShareLineItems", "presentation": ["http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails"], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Earnings or Loss per Share [Line Items]" } } }, "auth_ref": [] }, "ntra_EarningsOrLossPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://www.natera.com/20240930", "localname": "EarningsOrLossPerShareTable", "presentation": ["http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails"], "lang": { "en-us": { "role": { "documentation": "Represents earnings or loss per share.", "label": "Earnings or Loss per Share [Table]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Net Loss per Share", "terseLabel": "Net loss per share (Note 12):" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r195", "r215", "r216", "r217", "r218", "r219", "r225", "r227", "r230", "r231", "r232", "r236", "r473", "r474", "r551", "r570", "r726"] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Net loss - diluted (in dollars per share)", "verboseLabel": "Diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r195", "r215", "r216", "r217", "r218", "r219", "r227", "r230", "r231", "r232", "r236", "r473", "r474", "r551", "r570", "r726"] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": ["http://www.natera.com/role/DisclosureNetLossPerShare"], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": ["r224", "r233", "r234", "r235"] }, "ntra_EmployeeAndNonEmployeeOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "EmployeeAndNonEmployeeOptionsMember", "presentation": ["http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents employee and non-employee options.", "label": "Options to purchase common stock" } } }, "auth_ref": [] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Accrued compensation", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r21"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Amount Capitalized", "terseLabel": "Expected compensation expense recognition over requisite service period", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": ["r436"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]", "terseLabel": "Stock based compensation expense", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "ntra_EmployeeStockPurchasePlan2015Member": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "EmployeeStockPurchasePlan2015Member", "presentation": ["http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents 2015 Employee Stock Purchase Plan.", "label": "Employee stock purchase plan" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": ["r772"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": ["r772"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": ["r772"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": ["r846"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": ["r772"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r772"] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": ["r772"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [

```
"r772" ] }, "ntra_EquipmentAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "EquipmentAndServicesMember", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents equipment and services.", "label": "Equipment and Services" }
} }, "auth_ref": [] }, "ntra_EquipmentAndServicesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "EquipmentAndServicesReceived",
"crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents equipment and services
received.", "label": "Equipment And Services Received", "terseLabel": "Equipment and services received" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAocilDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"
], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to
common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r11", "r163", "r190", "r191", "r192", "r210", "r211", "r212", "r214", "r220", "r222", "r237", "r308", "r309", "r378",
"r440", "r441", "r442", "r451", "r452", "r465", "r466", "r467", "r468", "r469", "r470", "r472", "r490", "r491", "r492", "r493", "r494", "r495", "r511", "r580", "r581", "r582", "r600", "r673" ] },
"srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "documentation":
"Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r304", "r305", "r306" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
"xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Equity Method Investment, Ownership
Percentage", "terseLabel": "Ownership percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity
method of accounting." } } }, "auth_ref": [ "r304" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role":
{ "label": "Equity Method Investments", "terseLabel": "Carrying amount of investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its
investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and
losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r246", "r303", "r863", "r901" ] }, "us-
gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities without Readily Determinable
Fair Value, Amount", "terseLabel": "Investment in equity securities without readily determinable fair value", "documentation": "Amount of investment in equity security without readily
determinable fair value." } } }, "auth_ref": [ "r301" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount", "crdr": "debit", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities without Readily Determinable
Fair Value, Impairment Loss, Cumulative Amount", "terseLabel": "Equity securities without readily determinable fair value, impairment loss", "documentation": "Amount of cumulative
impairment loss on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r302" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [
"r815" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } },
"auth_ref": [ "r779", "r790", "r800", "r825" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable",
"presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously
Awarded Compensation Recovery" } } }, "auth_ref": [ "r776", "r787", "r797", "r822" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive
Category:" } } }, "auth_ref": [ "r821" ] }, "ntra_ExpensedInProcessResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname":
"ExpensedInProcessResearchAndDevelopment", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ],
"lang": { "en-us": { "role": { "documentation": "Amount of expensed in-process research and development during the period.", "label": "Expensed In Process Research And Development",
"terseLabel": "Expensed in-process research and development" } } }, "auth_ref": [] }, "ntra_ExtendedBillingCollectionPeriod": { "xbrltype": "durationItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "ExtendedBillingCollectionPeriod", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": {
"role": { "documentation": "Represents the extended collection period for billing.", "label": "Extended Billing Collection Period", "terseLabel": "Extended billing collection period (in months)" } }
}, "auth_ref": [] }, "ntra_FaceAmountPerConvertibleNote": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "FaceAmountPerConvertibleNote",
"crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Face amount per convertible note.", "label": "Face
Amount Per Convertible Note", "terseLabel": "Principal amount per convertible note" } } }, "auth_ref": [] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-
us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a
table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r476", "r477", "r480" ] }, "us-
gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us":
{ "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring
basis." } } }, "auth_ref": [ "r476", "r477", "r480" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ],
"lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per
share as practical expedient." } } }, "auth_ref": [ "r357", "r396", "r397", "r398", "r399", "r400", "r401", "r477", "r519", "r520", "r521", "r734", "r735", "r748", "r749", "r750" ] }, "us-
gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [
"http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement
frequency." } } }, "auth_ref": [ "r476", "r477", "r478", "r479", "r481" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype":
"textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureFairValueMeasurements" ],
"lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial
instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of
non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying
amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying
amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the
activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for
requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative
information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair
value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b)
discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate
carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r475" ] }, "us-
gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [
"http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Level 1", "documentation": "Quoted prices in active markets for identical assets
or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r357", "r396", "r401", "r477", "r519", "r748", "r749", "r750" ] }, "us-
gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [
"http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Level 2", "documentation":
"Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or
liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r357", "r396", "r401", "r477", "r520", "r734", "r735", "r748",
"r749", "r750" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement
Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement, Policy [Policy Text Block]",
"terseLabel": "Fair Value", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in
shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of
those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails",
"http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to
prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r357", "r396", "r397", "r398", "r399", "r400", "r401", "r519", "r520", "r521", "r734", "r735", "r748",
"r749", "r750" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FairValueMeasurementsRecurringMember", "presentation": [ "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Recurring",
"documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } },
"auth_ref": [ "r475", "r481" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis",
"presentation": [ "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by
type of financial instrument." } } }, "auth_ref": [ "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286",
"r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r311", "r312", "r316", "r317", "r318", "r321", "r325", "r326", "r365", "r375", "r471", "r516", "r517",
"r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542",
"r543", "r544", "r545", "r568", "r731", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r897", "r898", "r899", "r900" ] }, "us-gaap_FinancingReceivableAllowanceForCreditLosses": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancingReceivableAllowanceForCreditLosses", "crdr": "credit", "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsAllowanceForDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, Allowance for Credit
Loss", "periodEndLabel": "Total", "periodStartLabel": "Beginning balance", "documentation": "Amount of allowance for credit loss on financing receivable. Excludes allowance for financing
receivable covered under loss sharing agreement." } } }, "auth_ref": [ "r7", "r149", "r150", "r151", "r177", "r310", "r313", "r315", "r940" ] }, "us-
gaap_FinancingReceivableAllowanceForCreditLossesWriteOffs": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"FinancingReceivableAllowanceForCreditLossesWriteOffs", "crdr": "debit", "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsAllowanceForDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Financing Receivable, Allowance for Credit
Loss, Writeoff", "negatedLabel": "Write-offs", "documentation": "Amount of writeoff of financing receivable, charged against allowance for credit loss." } } }, "auth_ref": [ "r9", "r314", "r319",
"r730" ] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetUsefulLife",
"presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Asset,
Useful Life", "terseLabel": "Estimated useful life (in years)", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents
the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "ntra_FirstSpaceSubleaseMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "FirstSpaceSubleaseMember", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": {
"documentation": "Represents the \"First Space\" operating sublease for office space used as corporate headquarters.", "label": "\"First Space\" Sublease" } } }, "auth_ref": [] },
"ntra_FiveDayConsecutiveTradingPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "FiveDayConsecutiveTradingPeriodMember",
"presentation": [ "http://www.natera.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents five-day consecutive trading period.", "label": "5 consecutive
trading day period" } } }, "auth_ref": [] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-
```

gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), before Tax", "negatedLabel": "Foreign exchange adjustment", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": ["r486", "r487", "r488", "r489", "r670"] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": ["r783", "r794", "r804", "r829"] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": ["r783", "r794", "r804", "r829"] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": ["r783", "r794", "r804", "r829"] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": ["r783", "r794", "r804", "r829"] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": ["r783", "r794", "r804", "r829"] }, "ntra_FoundationMedicineInc.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "FoundationMedicineInc.Member", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Foundation Medicine, Inc.", "label": "Foundation Medicine (\"FMI\")" } } }, "auth_ref": [] }, "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Gain contingency, patents allegedly infringed, number", "documentation": "Number of entity's patents that another entity has allegedly infringed." } } }, "auth_ref": ["r912"] }, "ntra_GeneticTestingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "GeneticTestingServicesMember", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents genetic testing services.", "label": "Genetic testing services" } } }, "auth_ref": [] } , "ntra_GenosityInc.PatentCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "GenosityInc.PatentCaseMember", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Genosity Inc. Patent Case.", "label": "Genosity Inc. Patent Case" } } }, "auth_ref": [] } , "ntra_InProcessResearchDevelopmentAcquisitionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "InProcessResearchDevelopmentAcquisitionAgreementMember", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Represents in-process research and development acquisition agreement.", "label": "In-process research and development acquisition" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income taxes", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": ["r0", "r91", "r123", "r240", "r248", "r252", "r254", "r552", "r565", "r728"] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Operations and Comprehensive Loss" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": ["r332", "r333", "r656"] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": ["r333", "r656"] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": ["http://www.natera.com/role/DisclosureIncomeTaxes"], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": ["r206", "r445", "r447", "r449", "r450", "r453", "r455", "r456", "r457", "r598"] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/DisclosureIncomeTaxesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Income tax expense (benefit)", "negatedLabel": "Income tax expense", "terseLabel": "Income tax expense", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r137", "r145", "r221", "r222", "r245", "r446", "r454", "r572"] }, "ntra_IncreaseDecreaseAccumulatedOtherComprehensiveIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "IncreaseDecreaseAccumulatedOtherComprehensiveIncomeLoss", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAocilDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of adjustment to accumulated other comprehensive income or loss.", "label": "Increase Decrease Accumulated Other Comprehensive Income Loss", "verboseLabel": "Increase (decrease) in other comprehensive loss" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deferred Revenue", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": ["r547", "r872"] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Employee Related Liabilities", "terseLabel": "Accrued compensation", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liabilities", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": ["r852", "r872"] }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Accrued Liabilities", "terseLabel": "Other accrued liabilities", "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid." } } }, "auth_ref": ["r4"] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": ["r4"] }, "ntra_IncreaseDecreaseNetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "IncreaseDecreaseNetIncomeLoss", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in the portion of profit or loss for the period, net of income taxes.", "label": "Increase Decrease Net Income Loss", "terseLabel": "(Increased) decreased net loss" } } }, "auth_ref": [] }, "ntra_IncreaseDecreaseNetIncomeLossPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.natera.com/20240930", "localname": "IncreaseDecreaseNetIncomeLossPerShare", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in net income (loss) per share during the reporting period.", "label": "Increase Decrease Net Income Loss Per Share", "terseLabel": "(Increased) decreased net loss per share" } } }, "auth_ref": [] }, "ntra_IncreaseDecreaseRevenues": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "IncreaseDecreaseRevenues", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in revenues during the reporting period.", "label": "Increase Decrease Revenues", "terseLabel": "Increased (decreased) revenues" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": ["r786", "r794", "r804", "r821", "r829", "r833", "r841"] }, "ntra_InivataPatentCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "InivataPatentCaseMember", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Inivata patent case.", "label": "Inivata Patent Case" } } }, "auth_ref": [] }, "ntra_InivitaPatentCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "InivitaPatentCaseMember", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Inivitae Patent Case.", "label": "Inivitae Patent Case" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": ["r839"] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } }

```
}, "auth_ref": [ "r775", "r845" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r775", "r845" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r775", "r845" ] }, "ntra_InsuranceCarrierReservesAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "InsuranceCarrierReservesAdditions", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsReserveBalanceAndActivitiesForRefundsDetails" ], "lang": { "en-us": { "role": { "documentation": "Additions to insurance carrier reserves.", "label": "Insurance Carrier Reserves Additions", "terseLabel": "Additional reserves" } } }, "auth_ref": [] }, "ntra_InsuranceCarrierReservesReleased": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "InsuranceCarrierReservesReleased", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsReserveBalanceAndActivitiesForRefundsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of insurance carrier reserves released to revenue.", "label": "Insurance Carrier Reserves Released", "negatedTerseLabel": "Reserves released to revenue" } } }, "auth_ref": [] }, "ntra_InsuranceCarriersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "InsuranceCarriersMember", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails" ], "lang": { "en-us": { "role": { "documentation": "Insurance carriers group of customers.", "label": "Insurance carriers" } } }, "auth_ref": [] }, "ntra_InsuranceRefundsToCarriers": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "InsuranceRefundsToCarriers", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsReserveBalanceAndActivitiesForRefundsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of insurance refunds to carriers.", "label": "Insurance Refunds To Carriers", "negatedLabel": "Refunds to carriers" } } }, "auth_ref": [] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest Expense", "negatedLabel": "Interest expense", "terseLabel": "Interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r67", "r126", "r193", "r243", "r497", "r657", "r768", "r952" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "terseLabel": "Interest expense", "totalLabel": "Total interest expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r97", "r362", "r369", "r736", "r737" ] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest and other income, net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Net", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r198", "r201", "r202" ] }, "ntra_InventoryMaterialPurchaseCommitmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "InventoryMaterialPurchaseCommitmentMember", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents a contractual commitment to purchase from suppliers.", "label": "Material suppliers" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r179", "r717", "r757" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Inventory, Policy [Policy Text Block]", "terseLabel": "Inventory", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r138", "r167", "r178", "r329", "r330", "r331", "r548", "r723" ] }, "ntra_InvestmentOwnershipPercentageIfWarrantsExercised": { "xbrltype": "percentItemType", "nsuri": "http://www.natera.com/20240930", "localname": "InvestmentOwnershipPercentageIfWarrantsExercised", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "documentation": "Approximate percentage of investment ownership if warrants are exercised.", "label": "Investment Ownership Percentage If Warrants Exercised", "terseLabel": "Ownership percentage if warrants are exercised" } } }, "auth_ref": [] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r571", "r589", "r590", "r591", "r592", "r679", "r680" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r612", "r614", "r615", "r617", "r619", "r676", "r678", "r682", "r685", "r686", "r687", "r688", "r690", "r691", "r692", "r693", "r694", "r762" ] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Investments [Domain]", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r612", "r614", "r615", "r617", "r619", "r676", "r678", "r682", "r685", "r686", "r687", "r688", "r690", "r691", "r692", "r693", "r694", "r762" ] }, "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "label": "Investments Classified by Contractual Maturity Date [Table Text Block]", "terseLabel": "Summarized portfolio of available-for-sale securities by contractual maturity", "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments." } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Financial Instruments" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureFinancialInstruments" ], "lang": { "en-us": { "role": { "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Financial Instruments", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r115", "r127", "r128", "r148", "r265", "r268", "r482", "r483" ] }, "ntra_LaboratoryInstrumentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LaboratoryInstrumentsMember", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents a contractual commitment to purchase laboratory instruments.", "label": "Laboratory instruments supplier" } } }, "auth_ref": [] }, "ntra_LaboratoryPartnersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LaboratoryPartnersMember", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails" ], "lang": { "en-us": { "role": { "documentation": "Laboratory and other partners group of customers.", "label": "Laboratory partners" } } }, "auth_ref": [] }, "ntra_LeaseBalanceSheetDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LeaseBalanceSheetDisclosureTableTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of balance sheet leases.", "label": "Lease Balance Sheet Disclosure [Table Text Block]", "terseLabel": "Schedule of lease liabilities" } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCost", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost", "terseLabel": "Lease expense", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r505", "r756" ] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Leasehold improvements", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r104" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases." } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r504" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r504" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of annual minimum lease payments", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r929" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesPaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.natera.com/role/DisclosureLeasesAltcalcDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.natera.com/role/DisclosureLeasesPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "totalLabel": "Total future minimum lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r510" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureLeasesPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r510" ] }, "ntra_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureLeasesPaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year and after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five", "terseLabel": "2029 and thereafter" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureLeasesPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four", "terseLabel": "2028", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r510" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureLeasesPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2027", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r510" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureLeasesPaymentsDetails" ], "lang": { "en-us": { "role":
```

{ "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": ["r510"] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesPaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/DisclosureLeasesPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2024 (remaining 3 months)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": ["r929"] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesAltcalcDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/DisclosureLeasesPaymentsDetails"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": ["r510"] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": ["http://www.natera.com/role/DisclosureLeasesDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Lessee Leasing Arrangements, Operating Leases, Renewal Term", "terseLabel": "Renewal term of lease", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r928"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.natera.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Lessee Operating Lease Term of Contract", "terseLabel": "Term of lease", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r928"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.natera.com/role/DisclosureLeases"], "lang": { "en-us": { "role": { "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "Leases", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r500"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": ["r20", "r205", "r307", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r460", "r463", "r464", "r485", "r628", "r727", "r770", "r913", "r931", "r932"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r89", "r122", "r562", "r757", "r876", "r902", "r925"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders' Equity" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r22", "r166", "r205", "r307", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r460", "r463", "r464", "r485", "r757", "r913", "r931", "r932"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "ntra_LiabilityClassifiedAwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LiabilityClassifiedAwardsMember", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails"], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded as liability classified awards.", "label": "Liability classified awards" } } }, "auth_ref": [] }, "ntra_LicenseAndRelatedDevelopmentServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LicenseAndRelatedDevelopmentServicesMember", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Represents license and related development services.", "label": "License and related development services" } } }, "auth_ref": [] }, "ntra_LicensingAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LicensingAndOtherMember", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "documentation": "Licensing and other services.", "label": "Licensing and other" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "Line of credit facility, fair value of amount outstanding", "terseLabel": "Outstanding balance", "documentation": "Fair value of the amount outstanding under the credit facility." } } }, "auth_ref": ["r484"] }, "us-gaap_LineOfCreditFacilityIncreaseDecreaseOtherNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityIncreaseDecreaseOtherNet", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Increase (Decrease), Other, Net", "negatedTerseLabel": "Credit facility drawn down", "documentation": "Amount of increase (decrease), classified as other, of the credit facility." } } }, "auth_ref": ["r875"] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "verboseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r18"] }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Remaining borrowing capacity", "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding)." } } }, "auth_ref": ["r18"] }, "ntra_LineOfCreditUbsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LineOfCreditUbsMember", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the 2015 Line of Credit entered into by the entity.", "label": "Line Of Credit-UBS" } } }, "auth_ref": [] }, "ntra_LiquidityMattersPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LiquidityMattersPolicyTextBlock", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "documentation": "Represents the policy for certain liquidity matters.", "label": "Liquidity Matters Policy [Text Block]", "terseLabel": "Liquidity Matters" } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseAxis", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim." } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedFromOtherParty", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Amount awarded from other party", "documentation": "Amount awarded from other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Amount awarded to other party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "ntra_LondonInterbankOfferedRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LondonInterbankOfferedRateMember", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.", "label": "LIBOR" } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails", "http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt.", "totalLabel": "Net carrying amount", "verboseLabel": "Carrying value", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": ["r16", "r120", "r356", "r367", "r734", "r735", "r945"] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Debt, Excluding Current Maturities", "totalLabel": "Long-term debt financing", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": ["r172"] }, "ntra_LongTermDebtReclassificationsToShortTermDebtFinancing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LongTermDebtReclassificationsToShortTermDebtFinancing", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails": { "parentTag": "us-gaap_LongTermDebtNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails"], "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt reclassifications to short-term debt financing.", "label": "Long Term Debt Reclassifications To Short Term Debt Financing", "terseLabel": "Reclassifications to short-term debt financing" } } }, "auth_ref": [] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": ["http://www.natera.com/role/DisclosureDebt"], "lang": { "en-us": { "role": { "label": "Long-term Debt [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": ["r106"] }, "us-gaap_LongTermNotesAndLoans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermNotesAndLoans", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Net carrying amount", "terseLabel": "Long-term debt financing", "documentation": "Carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion." } } }, "auth_ref": ["r25"] }, "us-gaap_LongTermPurchaseCommitmentAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentAmount", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Long-Term Purchase Commitment, Amount", "terseLabel": "Purchase agreement amount", "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": ["http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails", "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureDebtDiscountAndIssuanceCostsDetails", "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails", "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": ["r25"] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": ["http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails", "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureDebtDiscountAndIssuanceCostsDetails", "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails", "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter

*of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": ["r25", "r53"] }, "ntra_LossContingencyInvalidPatentsNumber": { "xbrltype": "integerItemType", "nsuri": "http://www.natera.com/20240930", "localname": "LossContingencyInvalidPatentsNumber", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Number of invalid patents.", "label": "Loss Contingency, Invalid Patents, Number", "terseLabel": "Number of invalid patents" } } }, "auth_ref": [] } }, "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyPatentsAllegedlyInfringedNumber", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Loss contingency, patents allegedly infringed, number", "documentation": "Number of another entity's patents that the entity has allegedly infringed." } } }, "auth_ref": ["r908", "r909"] }, "us-gaap_LossContingencyPendingClaimsNumber": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LossContingencyPendingClaimsNumber", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "label": "Loss Contingency, Pending Claims, Number", "terseLabel": "Number of lawsuits", "documentation": "Number of pending claims pertaining to a loss contingency." } } }, "auth_ref": ["r908", "r909"] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Machinery and equipment", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails"], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": ["r258", "r743", "r918", "r948", "r949"] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Marketable securities", "terseLabel": "Short-term investments", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": ["r864"] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails", "http://www.natera.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Maximum", "documentation": "Upper limit of the provided range." } } }, "auth_ref": ["r336", "r337", "r338", "r339", "r402", "r546", "r579", "r620", "r621", "r677", "r681", "r683", "r684", "r689", "r712", "r713", "r729", "r738", "r751", "r759", "r915", "r933", "r934", "r935", "r936", "r937", "r938"] }, "ntra_MayRedeemForCashAllOrAnyPortionOfConvertibleNotesAtCompanysOptionOnOrAfterMay2024Member": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "MayRedeemForCashAllOrAnyPortionOfConvertibleNotesAtCompanysOptionOnOrAfterMay2024Member", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "documentation": "Scenario, redeemable for cash, all or any portion of the Convertible Notes, at the Company's option, on or after May 2024.", "label": "Redeemable for cash on or after May 2024" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": ["r813"] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": ["r813"] }, "ntra_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "MedicareMember", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents Medicare national health insurance program of the United States government.", "label": "Medicare" } } }, "auth_ref": [] }, "ntra_MikeBrophyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "MikeBrophyMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Mike Brophy.", "label": "Mike Brophy [Member]", "terseLabel": "Mike Brophy" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails", "http://www.natera.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Minimum", "documentation": "Lower limit of the provided range." } } }, "auth_ref": ["r336", "r337", "r338", "r339", "r402", "r546", "r579", "r620", "r621", "r677", "r681", "r683", "r684", "r689", "r712", "r713", "r729", "r738", "r751", "r759", "r915", "r933", "r934", "r935", "r936", "r937", "r938"] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": ["r832"] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": ["r840"] }, "us-gaap_MunicipalBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MunicipalBondsMember", "presentation": ["http://www.natera.com/role/DisclosureFairValueMeasurementsDetails", "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Municipal securities", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } }, "auth_ref": [] }, "ntra_MyomeIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "MyomeIncMember", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "documentation": "Represents MyOme, Inc.", "label": "MyOme, Inc." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails"], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": ["r258", "r743", "r918", "r948", "r949"] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": ["r814"] }, "ntra_NeoGenomicsPatentCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "NeoGenomicsPatentCaseMember", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents NeoGenomics patent case.", "label": "NeoGenomics Patent Case" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": ["r200"] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Cash provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": ["r200"] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Investing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Cash provided by (used in) operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": ["r99", "r100", "r101"] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": ["r92", "r101", "r124", "r164", "r186", "r188", "r192", "r205", "r213", "r215", "r216", "r217", "r218", "r221", "r222", "r229", "r240", "r248", "r252", "r254", "r307", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r474", "r485", "r567", "r650", "r671", "r672", "r728", "r768", "r913"] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ntra_NonCashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "NonCashInterestExpense", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash interest expense.", "label": "Non Cash Interest Expense", "terseLabel": "Non-cash interest expense" } } }, "auth_ref": [] }, "ntra_NonCashInterestExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.natera.com/20240930", "localname": "NonCashInterestExpenseAbstract", "presentation": ["http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents non-cash interest expense.", "label": "Non-cash interest expense" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": ["r813"] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": ["r783", "r794", "r804", "r821", "r829"] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": ["r811"] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": ["r810"] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": ["r821"] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r840"] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r840"] }, "ntra_NoncashExpenseRecovery": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "NoncashExpenseRecovery", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 }

```
}, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense recovery.", "label": "Noncash Expense Recovery", "negatedLabel": "Non-cash expense recovery" } } }, "auth_ref": [] }, "ntra_NoncashOperatingActivitiesRelatedToRightOfUseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "NoncashOperatingActivitiesRelatedToRightOfUseAssets", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Noncash operating activities related to right-of-use assets.", "label": "Noncash Operating Activities Related To Right Of Use Assets", "terseLabel": "Noncash operating activities related to right-of-use assets" } } }, "auth_ref": [] }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Amounts accrued for acquisition of intangible assets", "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r37", "r38", "r39" ] }, "ntra_NumberOfCustomers": { "xbrltype": "integerItemType", "nsuri": "http://www.natera.com/20240930", "localname": "NumberOfCustomers", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertaintiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of customers.", "label": "Number of Customers", "terseLabel": "Number of customers exceeding 10% of benchmark" } } }, "auth_ref": [] }, "ntra_NumberOfInvestmentsSold": { "xbrltype": "integerItemType", "nsuri": "http://www.natera.com/20240930", "localname": "NumberOfInvestmentsSold", "presentation": [ "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of investments sold.", "label": "Number Of Investments Sold", "terseLabel": "Number of investments sold" } } }, "auth_ref": [] }, "ntra_NumberOfOfficeSpaces": { "xbrltype": "positiveIntegerItemType", "nsuri": "http://www.natera.com/20240930", "localname": "NumberOfOfficeSpaces", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of office spaces.", "label": "Number Of Office Spaces", "terseLabel": "Number of office space locations" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.natera.com/role/DisclosureDescriptionOfBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r883" ] }, "ntra_NumberOfPerformanceObligations": { "xbrltype": "integerItemType", "nsuri": "http://www.natera.com/20240930", "localname": "NumberOfPerformanceObligations", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of performance obligations that have not been recognized as revenue.", "label": "Number Of Performance Obligations", "terseLabel": "Number of performance obligations" } } }, "auth_ref": [] }, "ntra_OncologyAssayInterpretationServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "OncologyAssayInterpretationServicesMember", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents oncology assay interpretation services.", "label": "Oncology assay interpretation services" } } }, "auth_ref": [] }, "ntra_OncologyProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "OncologyProductsMember", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents oncology products.", "label": "Oncology products" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Decrease to loss from operations", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r240", "r248", "r252", "r254", "r728" ] }, "ntra_OperatingLeaseCommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "OperatingLeaseCommitmentsMember", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents contractual commitments for operating leases.", "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Non-cash lease expense", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r506", "r756" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesAltcalcDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 }, "http://www.natera.com/role/DisclosureLeasesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails", "http://www.natera.com/role/DisclosureLeasesPaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "totalLabel": "Operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } } }, "auth_ref": [ "r502" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 1.0 }, "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails", "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities, current portion included in other accrued liabilities", "verboseLabel": "Operating lease liabilities, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r502" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureLeasesDetails": { "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0, "order": 2.0 }, "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities, long-term portion", "verboseLabel": "Operating lease liabilities, long-term portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r502" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating lease payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r503", "r507" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r501" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted average discount rate (as a percent)", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r509", "r756" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted average remaining lease term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r508", "r756" ] }, "ntra_OperatingLeasesAnnualRent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "OperatingLeasesAnnualRent", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the annual payment that the lessee is obligated to make in connection with a property under the terms of an agreement classified as an operating lease.", "label": "Operating Leases Annual Rent", "terseLabel": "Annual lease payment" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Description of Business" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureDescriptionOfBusiness" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Description of Business", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r77", "r113", "r587", "r588" ] }, "ntra_OtherAccruedSundryExpensesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "OtherAccruedSundryExpensesCurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expenses not otherwise itemized or categorized in the footnotes to the financial statements that have been incurred but not yet paid, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Sundry Expenses Current", "terseLabel": "Other accrued expenses" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other noncurrent assets", "terseLabel": "Other assets", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r170" ] }, "ntra_OtherAssetsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.natera.com/20240930", "localname": "OtherAssetsPolicyPolicyTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for other assets.", "label": "Other Assets Policy Policy Text Block", "terseLabel": "Other Assets" } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsAbstract", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Abstract]", "terseLabel": "Other commitments" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Net unrealized gains (losses) on available-for-sale securities, net of tax", "terseLabel": "Unrealized gain on available-for-sale securities, net of tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r181", "r182", "r184" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax", "crdr": "credit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Unrealized Holding Gain (Loss) on Securities Arising During Period, before Tax", "verboseLabel": "Unrealized gain on available-for sale securities", "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r181", "r184", "r300" ] }, "ntra_OtherGeographicAreasMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "OtherGeographicAreasMember", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents other geographic areas.", "label": "Asia Pacific and Other" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liability, Current", "terseLabel": "Other accrued liabilities", "totalLabel": "Total other accrued liabilities", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r21", "r757" ] }, "ntra_OtherMaterialSupplierMember": { "xbrltype": "domainItemType",
```

```
"nsuri": "http://www.natera.com/20240930", "localname": "OtherMaterialSupplierMember", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents a contractual commitment to purchase from suppliers.", "label": "Other material suppliers" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r813" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r781", "r792", "r802", "r827" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r784", "r795", "r805", "r830" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r784", "r795", "r805", "r830" ] }, "ntra_PatientsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "PatientsMember", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails" ], "lang": { "en-us": { "role": { "documentation": "Patients group of customers.", "label": "Patients" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r809" ] }, "ntra_PaymentsForInvestmentsInRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "PaymentsForInvestmentsInRelatedParty", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow for investments in related party.", "label": "Payments For Investments In Related Party", "negatedLabel": "Investment in related party" } } }, "auth_ref": [] }, "us-gaap_PaymentsOfStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfStockIssuanceCosts", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Payments of Stock Issuance Costs", "terseLabel": "Payment of offering expenses", "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security." } } }, "auth_ref": [ "r34" ] }, "ntra_PaymentsToAcquireAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "PaymentsToAcquireAssets", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow due to acquisition of assets.", "label": "Payments To Acquire Assets", "negatedLabel": "Cash paid for acquisition of intangible assets" } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Available-for-sale Securities", "negatedLabel": "Purchases of investments", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r32", "r196", "r266" ] }, "us-gaap_PaymentsToAcquireProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireProductiveAssets", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Productive Assets", "terseLabel": "Cash consideration", "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r136", "r920", "r921", "r922" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment, net", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r98" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r812" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r812" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r811" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r821" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r814" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r810" ] }, "ntra_PerformanceBasedAwardsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "PerformanceBasedAwardsAndRestrictedStockUnitsMember", "presentation": [ "http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents performance-based awards and restricted stock units.", "label": "Performance-based awards and restricted stock units" } } }, "auth_ref": [] }, "us-gaap_PerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PerformanceSharesMember", "presentation": [ "http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails" ], "lang": { "en-us": { "role": { "label": "Performance-based awards", "documentation": "Share-based payment arrangement awarded for meeting performance target." } } }, "auth_ref": [] }, "ntra_PleasantonCaliforniaLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "PleasantonCaliforniaLeaseMember", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents Pleasanton, CA lease.", "label": "Pleasanton, CA Lease" } } }, "auth_ref": [] }, "ntra_PotentialMilestonePaymentsToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "PotentialMilestonePaymentsToOtherParty", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of potential milestones payable to other party.", "label": "Potential Milestone Payments To Other Party", "verboseLabel": "Potential additional milestone payments" } } }, "auth_ref": [] }, "ntra_PremiumAmortizationAndDiscountAccretionOnInvestmentSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "PremiumAmortizationAndDiscountAccretionOnInvestmentSecurities", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of premium amortization and discount accretion on investment securities.", "label": "Premium Amortization And Discount Accretion On Investment Securities", "terseLabel": "Amortization of premiums and accretion of purchase discounts on investment securities" } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets, net", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r867" ] }, "us-gaap_PrepaidRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidRoyalties", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Royalty Asset", "terseLabel": "Prepaid royalties", "documentation": "Amount of asset related to consideration paid in advance for royalties that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r718", "r732", "r905" ] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrivatePlacementMember", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Equity offering", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Convertible Debt", "verboseLabel": "Proceeds from Convertible Note, net of issuance costs", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceInitialPublicOffering", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance Initial Public Offering", "terseLabel": "Proceeds from public offering, net of issuance cost", "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Excluding Stock Options", "terseLabel": "Proceeds from the issuance of common stock under the employee stock purchase plan", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Excludes option exercised." } } }, "auth_ref": [ "r3", "r14" ] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Lines of Credit", "terseLabel": "Borrowings under credit facility", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": [ "r33", "r875" ] }, "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities", "terseLabel": "Proceeds from maturity of investments", "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r196", "r197", "r885" ] }, "us-gaap_ProceedsFromNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromNotesPayable", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from notes payable", "terseLabel": "Bridge loan", "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Available-for-sale Securities", "terseLabel": "Proceeds from sale of investments", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r31", "r196", "r266", "r299" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 }
```

```
}, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r3", "r14" ] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": {
"en-us": { "role": { "label": "Product", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r741" ] }, "srt_ProductOrServiceAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails",
"http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails",
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]",
"documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r255", "r549", "r573", "r574", "r575", "r576", "r577", "r578",
"r715", "r741", "r758", "r853", "r910", "r911", "r918", "r948" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname":
"ProductsAndServicesDomain", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails",
"http://www.natera.com/role/DisclosureRevenueRecognitionDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails",
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]",
"documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r255", "r549", "r573", "r574", "r575", "r576", "r577", "r578", "r715", "r741", "r758",
"r853", "r910", "r911", "r918", "r948" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit",
"calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including
Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable
to the noncontrolling interest." } } }, "auth_ref": [ "r164", "r186", "r188", "r199", "r205", "r213", "r221", "r222", "r240", "r248", "r252", "r254", "r307", "r340", "r341", "r342", "r343", "r344",
"r345", "r346", "r347", "r348", "r458", "r461", "r462", "r474", "r485", "r552", "r566", "r599", "r650", "r671", "r672", "r728", "r754", "r755", "r769", "r870", "r913" ] }, "us-
gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails", "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": {
"label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } },
"auth_ref": [ "r6" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross",
"crdr": "debit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
"weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label":
"Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment, gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical
assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture
and fixtures." } } }, "auth_ref": [ "r104", "r168", "r564" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us":
{ "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment, net", "documentation": "Line items represent financial concepts included in a table.
These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation":
{ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 },
"http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": {
"en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Total Property and Equipment, net", "documentation": "Amount
after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples
include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r6", "r556", "r564", "r757" ] }, "us-
gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Schedule of
property and equipment", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by
class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r6" ] }, "us-
gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain",
"presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails", "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us":
{ "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services
and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture
and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r104" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Useful Life",
"terseLabel": "Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for
example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment,
furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "us-gaap_ProvisionForLoanLeaseAndOtherLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "ProvisionForLoanLeaseAndOtherLosses", "crdr": "debit", "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsAllowanceForDoubtfulAccountsDetails" ], "lang": { "en-us": { "role": { "label": "Provision for Loan, Lease, and Other Losses",
"negatedLabel": "(Reversal of) Provision for doubtful accounts", "documentation": "Amount of expense related loan transactions, lease transactions, credit loss from transactions other than loan
and lease transactions, and other loss based on assessment of uncollectability from the counterparty to reduce the account to their net realizable value." } } }, "auth_ref": [ "r4", "r8", "r125" ] },
"us-gaap_PurchaseCommitmentExcludingLongtermCommitmentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PurchaseCommitmentExcludingLongtermCommitmentAxis", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": {
"label": "Purchase Commitment, Excluding Long-term Commitment [Axis]", "documentation": "Information by arrangement, in which the entity has agreed to expend funds to procure goods or
services from one or more suppliers." } } }, "auth_ref": [ "r82", "r121" ] }, "us-gaap_PurchaseCommitmentExcludingLongtermCommitmentDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "PurchaseCommitmentExcludingLongtermCommitmentDomain", "presentation": [
"http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Purchase Commitment, Excluding Long-term Commitment [Domain]",
"documentation": "This item is intended to be populated, by the entity, with Members identifying each purchase commitment about which information required or determined to be disclosed is
being provided. If only one such commitment exists, this item may be used to capture such information; if multiple commitments exist, this item is the dimensional default, which will aggregate
such information, as appropriate." } } }, "auth_ref": [ "r82", "r121" ] }, "us-gaap_PurchaseObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"PurchaseObligation", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Purchase
Obligation", "terseLabel": "Total commitments", "documentation": "Minimum amount of purchase arrangement in which the entity has agreed to expend funds to procure goods or services from
a supplier." } } }, "auth_ref": [] }, "ntra_PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930",
"localname": "PurchasesOfPropertyAndEquipmentInAccountsPayableAndAccruals", "crdr": "credit", "presentation": [
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Represents purchases of property and equipment in
accounts payable and accruals.", "label": "Purchases Of Property And Equipment In Accounts Payable And Accruals", "terseLabel": "Purchases of property and equipment in accounts payable
and accruals" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [
"r809" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } },
"auth_ref": [ "r809" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [
"http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails", "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": {
"label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average,
and median." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r395", "r402", "r431", "r432", "r433", "r522", "r546", "r579", "r620", "r621", "r677", "r681", "r683", "r684", "r689", "r712",
"r713", "r729", "r738", "r751", "r759", "r762", "r906", "r915", "r934", "r935", "r936", "r937", "r938" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023",
"localname": "RangeMember", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails",
"http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is
not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r395", "r402", "r431", "r432", "r433", "r522", "r546",
"r579", "r620", "r621", "r677", "r681", "r683", "r684", "r689", "r712", "r713", "r729", "r738", "r751", "r759", "r762", "r906", "r915", "r934", "r935", "r936", "r937", "r938" ] },
"ntra_RavgenPatentCaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "RavgenPatentCaseMember", "presentation": [
"http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents Ravgen Patent Case.", "label": "Ravgen Patent
Case" } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname":
"RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of
Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r776", "r787", "r797", "r822" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]",
"documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or
many axes to the table." } } }, "auth_ref": [ "r654", "r655", "r656" ] }, "ntra_RelatedPartyTransactionsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://www.natera.com/20240930", "localname": "RelatedPartyTransactionsPolicyTextBlock", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for related party
transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal
owners; and (d) affiliates.", "label": "Related Party Transactions Policy Text Block", "terseLabel": "Related Party" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfDebt": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails" ], "lang":
{ "en-us": { "role": { "label": "Repayments of Debt", "terseLabel": "Debt, repayment amount", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of
lease obligation." } } }, "auth_ref": [ "r871" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"RepaymentsOfShortTermDebt", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsReserveBalanceAndActivitiesForRefundsDetails" ], "lang": {
"en-us": { "role": { "label": "Repayments of Short-Term Debt", "terseLabel": "Repaid short term advances", "documentation": "The cash outflow for a borrowing having initial term of repayment
within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r35" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": {
"label": "Counterparty Name [Domain]", "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial
institution." } } }, "auth_ref": [ "r207", "r208", "r352", "r372", "r512", "r720", "r721" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } },
"presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Research and
Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new
knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing
product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process
whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in
time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [
"r76", "r444", "r939" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails" ], "lang": { "en-us": { "role": {
"label": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } },
```

"auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": ["r777", "r788", "r798", "r823"] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": ["r778", "r789", "r799", "r824"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": ["r785", "r796", "r806", "r831"] }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Restricted Cash and Cash Equivalents Items [Line Items]", "terseLabel": "Policies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r946"] }, "ntra_RestrictedStockUnitsRsuAndPerformanceSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "RestrictedStockUnitsRsuAndPerformanceSharesMember", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met and share-based payment arrangement awarded for meeting performance target.", "label": "RSU and performance-based awards" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Cumulative-effect adjustment upon adoption of ASU 2016-13", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r86", "r111", "r561", "r583", "r585", "r597", "r631", "r757"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r163", "r210", "r211", "r212", "r214", "r220", "r222", "r308", "r309", "r440", "r441", "r442", "r451", "r452", "r465", "r467", "r468", "r470", "r472", "r580", "r582", "r600", "r953"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue Recognition" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenues", "terseLabel": "Total revenues", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r241", "r242", "r247", "r250", "r251", "r255", "r256", "r258", "r390", "r391", "r549"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognition"], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Text Block]", "terseLabel": "Revenue Recognition", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r146", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r394"] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"], "lang": { "en-us": { "role": { "label": "Revenue Recognition, Policy [Policy Text Block]", "verboseLabel": "Revenue Recognition", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": ["r652", "r714", "r724"] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation", "terseLabel": "Revenue, remaining performance obligation", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": ["r144"] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues" } } }, "auth_ref": [] }, "us-gaap_RisksAndUncertainties Abstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RisksAndUncertainties Abstract", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertainties Details"], "lang": { "en-us": { "role": { "label": "Risks and Uncertainties [Abstract]", "terseLabel": "Risk and Uncertainties" } } }, "auth_ref": [] }, "ntra_RoyBaynesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "RoyBaynesMember", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Roy Baynes.", "label": "Roy Baynes [Member]", "terseLabel": "Roy Baynes" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": ["r840"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": ["r840"] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SalesAndExciseTaxPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesAndExciseTaxPayableCurrentAndNoncurrent", "crdr": "credit", "calculation": { "http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsOtherAccruedLiabilitiesDetails"], "lang": { "en-us": { "role": { "label": "Sales and Excise Tax Payable", "terseLabel": "Sales and income tax payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax." } } }, "auth_ref": ["r71"] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRisksAndUncertainties Details"], "lang": { "en-us": { "role": { "label": "Sales", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r258", "r850"] }, "ntra_SanCarlosCaliforniaSubleaseAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "SanCarlosCaliforniaSubleaseAmendmentMember", "presentation": ["http://www.natera.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents San Carlos, CA sublease amendment.", "label": "San Carlos, CA Sublease Amendment" } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioForecastMember", "presentation": ["http://www.natera.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "label": "Forecast", "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact." } } }, "auth_ref": ["r403", "r861", "r881"] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScenarioUnspecifiedDomain", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureLeasesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": ["r223", "r403", "r848", "r881"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of other accrued liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"], "lang": { "en-us": { "role": { "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r29", "r926", "r927"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": ["http://www.natera.com/role/DisclosureNetLossPerSharePotentiallyDilutiveSharesDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": ["r40"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.natera.com/role/DisclosureNetLossPerShareTables"], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Total outstanding potentially dilutive shares", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r40"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.natera.com/role/DisclosureFinancialInstrumentsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Available-for-sale Securities [Line Items]", "terseLabel": "Available-for-sale Securities", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280"] }, "ntra_ScheduleOfChangesInBalancesOfDeferredRevenuesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ScheduleOfChangesInBalancesOfDeferredRevenuesTableTextBlock", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in the balances of deferred revenues.", "label": "Schedule Of Changes In Balances Of Deferred Revenues [Table Text Block]", "terseLabel": "Schedule of changes in the balance of deferred revenues" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r58"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]", "terseLabel": "Summary of stock-based compensation expenses", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r58"] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": ["r304", "r305", "r306"] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": ["http://www.natera.com/role/DisclosureFairValueMeasurementsTables"], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Summary of financial assets and liabilities measured on recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": ["r476", "r477"] }, "ntra_ScheduleOfInterestExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":

"http://www.natera.com/20240930", "localname": "ScheduleOfInterestExpenseTableTextBlock", "presentation": ["http://www.natera.com/role/DisclosureDebtTables"], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expense.", "label": "Schedule Of Interest Expense Table [Text Block]", "terseLabel": "Summary of interest expense" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r6"] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": ["r69", "r70", "r654", "r655", "r656"] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Restrictions on Cash and Cash Equivalents [Table]", "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": ["r15", "r116", "r946"] }, "us-gaap_ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRevenueFromExternalCustomersAttributedToForeignCountriesByGeographicAreaTextBlock", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionTables"], "lang": { "en-us": { "role": { "label": "Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]", "terseLabel": "Schedule of total revenue by geographic area", "documentation": "Tabular disclosure of the names of foreign countries from which revenue is material and the amount of revenue from external customers attributed to those countries. An entity may also provide subtotals of geographic information about groups of countries." } } }, "auth_ref": ["r49", "r94"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockUnitsVestedAndExpectedToVestTableTextBlock", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Restricted Stock Units, Vested and Expected to Vest [Table Text Block]", "terseLabel": "RSU and performance-based awards", "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding restricted stock units that are fully vested and expected to vest. Includes, but is not limited to, unvested restricted stock units for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": ["r112"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails",
"http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r405", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationTables"], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r12", "r13", "r57"] }, "ntra_SecondSpaceSubleaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "SecondSpaceSubleaseMember", "presentation": ["http://www.natera.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents the \"Second Space\" operating sublease for office space used as corporate headquarters.", "label": "\"Second Space\" Sublease" } } }, "auth_ref": [] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [
"http://www.natera.com/role/DisclosureDebtDetails"], "lang": { "en-us": { "role": { "label": "2017 Term Loan", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [
"http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails"], "lang": { "en-us": { "role": { "label": "SOFR", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": ["r923"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r771"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": ["http://www.natera.com/role/DocumentDocumentAndEntityInformation"], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r773"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": ["r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r256", "r257", "r613", "r616", "r618", "r678", "r682", "r686", "r690", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r716", "r742", "r762", "r918", "r948"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss"], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r96"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails"], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "ntra_SequencingProductsAndServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "SequencingProductsAndServicesMember", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Sequencing products and services that are sold by an entity.", "label": "Sequencing products and services" } } }, "auth_ref": [] }, "ntra_SequencingProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "SequencingProductsMember", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Sequencing products that are sold by an entity.", "label": "Sequencing products" } } }, "auth_ref": [] }, "ntra_SequencingServicesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "SequencingServicesMember", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDetails"], "lang": { "en-us": { "role": { "documentation": "Sequencing service that are sold by an entity.", "label": "Sequencing services" } } }, "auth_ref": [] }, "us-gaap_SeriesBPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SeriesBPreferredStockMember", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Series B preferred stock", "documentation": "Series B preferred stock." } } }, "auth_ref": ["r865", "r866", "r916"] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": {
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 18.0 } }, "presentation": ["http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows"], "lang": { "en-us": { "role": { "label": "Share-based Compensation", "terseLabel": "Stock-based compensation", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r4"] }, "ntra_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingTargetPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.natera.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingTargetPercentage", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails"], "lang": { "en-us": { "role": { "documentation": "Target percentage for vesting of award under share-based payment arrangement.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Target Percentage", "terseLabel": "Target (percentage)" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "RSUs forfeited/cancelled (in shares)", "negatedLabel": "Canceled/Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r425"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Canceled/Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r425"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails",
"http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "RSUs Granted (in shares)", "terseLabel": "Shares granted", "verboseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r423"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r423"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": ["r420", "r421"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype":
"perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [
"http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based

Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Balance (in dollars per share)", "periodStartLabel": "Balance (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r420", "r421"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "terseLabel": "Number of shares vested", "verboseLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": ["r424"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": ["r424"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock Based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r405", "r407", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding, end balance (in shares)", "periodStartLabel": "Outstanding, beginning balance (in shares)", "terseLabel": "Options outstanding (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": ["r412", "r413"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of shares Outstanding", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding, end balance (in dollars per share)", "periodStartLabel": "Outstanding, beginning balance (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": ["r412", "r413"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted-Average Exercise Price" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationCompensationExpenseDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationRestrictedStockUnitsDetails", "http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": ["r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434"] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails"], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": ["r417"] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding", "terseLabel": "Aggregate value", "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested", "crdr": "debit", "presentation": ["http://www.natera.com/role/DisclosureStockBasedCompensationPerformanceBasedAwardsDetails"], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested", "terseLabel": "Aggregate value recognized", "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": ["http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails"], "lang": { "en-us": { "role": { "label": "Shares Issued, Price Per Share", "terseLabel": "Stock issued (in dollars per share)", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "ntra_SharesReservedValueRegistrationStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "SharesReservedValueRegistrationStatement", "crdr": "credit", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesOtherAssetsDetails"], "lang": { "en-us": { "role": { "documentation": "Value of shares reserved for issuance in registration statement.", "label": "Shares Reserved Value Registration Statement", "terseLabel": "Value of additional shares potentially issuable" } } }, "auth_ref": [] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets"], "lang": { "en-us": { "role": { "label": "Short-term Debt", "terseLabel": "Short-term debt financing", "verboseLabel": "Short-term Credit Line, outstanding balance", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r78", "r118", "r757", "r944"] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": ["http://www.natera.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Short-term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": ["r19"] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": ["http://www.natera.com/role/DisclosureSubsequentEventsDetails"], "lang": { "en-us": { "role": { "label": "Short-term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": ["r17"] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPolicies"], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": ["r102", "r204"] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": ["http://www.natera.com/role/DisclosureBalanceSheetComponentsPropertyAndEquipmentNetDetails"], "lang": { "en-us": { "role": { "label": "Software held for internal use", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "ntra_SouthSanFranciscoCaliforniaLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "SouthSanFranciscoCaliforniaLeaseMember", "presentation": ["http://www.natera.com/role/DisclosureLeasesDetails"], "lang": { "en-us": { "role": { "documentation": "Represents South San Francisco, CA lease.", "label": "South San Francisco, CA Lease" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails"], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": ["r147", "r173", "r174", "r175", "r205", "r227", "r228", "r230", "r232", "r238", "r239", "r307", "r340", "r342", "r343", "r344", "r347", "r348", "r370", "r371", "r373", "r374", "r376", "r485", "r593", "r594", "r595", "r596", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r630", "r651", "r673", "r695", "r696", "r697", "r698", "r699", "r847", "r874", "r882"] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": ["http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAocilDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": ["r11", "r27", "r163", "r190", "r191", "r192", "r210", "r211", "r212", "r214", "r220", "r222", "r237", "r308", "r309", "r378", "r440", "r441", "r442", "r451", "r452", "r465", "r466", "r467", "r468", "r469", "r470", "r472", "r490", "r491", "r492", "r493", "r494", "r495", "r511", "r580", "r581", "r582", "r600", "r673"] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": ["http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails"], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": ["r152", "r161", "r256", "r257", "r613", "r616", "r618", "r678", "r682", "r686", "r690", "r700", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r711", "r716", "r742", "r762", "r918", "r948"] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": ["http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails", "http://www.natera.com/role/DisclosureDebtDiscountAndIssuanceCostsDetails", "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity"], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r210", "r211", "r212", "r237", "r549", "r589", "r611", "r622", "r623", "r624", "r625", "r626", "r627", "r630", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r643", "r644", "r645", "r646", "r647", "r649", "r652", "r653", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r673", "r763"] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Condensed Consolidated Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-

```
us": { "role": { "label": "Condensed Consolidated Statements of Stockholders' Equity" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementScenarioAxis", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureLeasesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts." } } }, "auth_ref": [ "r223", "r403", "r848", "r849", "r881" ] } }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.natera.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://www.natera.com/role/DisclosureDebtConvertibleNotesBalancesDetails", "http://www.natera.com/role/DisclosureDebtDiscountAndIssuanceCostsDetails", "http://www.natera.com/role/DisclosureDebtInterestExpenseRecognizedRelatedToConvertibleNotesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDeferredRevenuesDetails", "http://www.natera.com/role/DisclosureRevenueRecognitionDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r210", "r211", "r212", "r237", "r549", "r589", "r611", "r622", "r623", "r624", "r625", "r626", "r627", "r630", "r633", "r634", "r635", "r636", "r637", "r638", "r639", "r640", "r641", "r643", "r644", "r645", "r646", "r647", "r649", "r652", "r653", "r658", "r659", "r660", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r673", "r763" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r780", "r791", "r801", "r826" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "ntra_StockBasedCompensationIncludedInCapitalizedSoftwareDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "StockBasedCompensationIncludedInCapitalizedSoftwareDevelopmentCosts", "crdr": "debit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of stock-based compensation included in capitalized software development costs.", "label": "Stock Based Compensation Included In Capitalized Software Development Costs", "terseLabel": "Stock-based compensation included in capitalized software development costs" } } }, "auth_ref": [] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Stock Issued", "terseLabel": "Issuance of common stock for IPR&D acquisition", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r37", "r38", "r39" ] }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesAcquisitions", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Acquisitions", "verboseLabel": "Issuance of common stock for IPR&D milestone (in shares)", "documentation": "Number of shares of stock issued during the period pursuant to acquisitions." } } }, "auth_ref": [ "r83", "r84", "r111" ] }, "ntra_StockIssuedDuringPeriodSharesBonus": { "xbrltype": "sharesItemType", "nsuri": "http://www.natera.com/20240930", "localname": "StockIssuedDuringPeriodSharesBonus", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued attributable to bonus.", "label": "Stock Issued During Period Shares Bonus", "terseLabel": "Issuance of stock for bonuses (in shares)" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.natera.com/role/DisclosureStockBasedCompensationNarrativeDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock under the employee stock purchase plan (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r11", "r83", "r84", "r111" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Issuance of common stock for public offering, net (in shares)", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r11", "r83", "r84", "r111", "r593", "r673", "r696" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted stock units (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r11", "r83", "r84", "r111" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.natera.com/role/DisclosureStockBasedCompensationStockOptionsDetails", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Options exercised (in shares)", "terseLabel": "Issuance of common stock upon exercise of stock options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r11", "r83", "r84", "r111", "r417" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Acquisitions", "verboseLabel": "Issuance of common stock for IPR&D milestone", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r11", "r27", "r111" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock under the employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r11", "r83", "r84", "r111" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "verboseLabel": "Issuance of common stock for public offering, net", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r11", "r83", "r84", "r111", "r600", "r673", "r696", "r769" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "terseLabel": "Vesting of restricted stock units", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r11", "r111" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Issuance of common stock upon exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r11", "r27", "r111" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets", "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfStockholdersEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r84", "r87", "r88", "r103", "r632", "r648", "r674", "r675", "r757", "r770", "r876", "r902", "r925", "r953" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.natera.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r496", "r514" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r496", "r514" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.natera.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r496", "r514" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r496", "r514" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.natera.com/role/DisclosureNetLossPerShareLossPerShareDetails", "http://www.natera.com/role/DisclosureSubsequentEventsDetails", "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r496", "r514" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r513", "r515" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "ntra_SummaryOfReserveBalanceAndActivitiesForRefundsToInsuranceCarriersTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.natera.com/20240930", "localname": "SummaryOfReserveBalanceAndActivitiesForRefundsToInsuranceCarriersTableTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponentsTables" ], "lang": { "en-us": { "role": { "documentation": "Summary of reserve balance and activities for refunds to insurance carriers.", "label": "Summary Of Reserve Balance And Activities For Refunds To Insurance Carriers [Table Text Block]", "terseLabel": "Summary of reserve balance and activities for refunds to insurance carriers" } } }, "auth_ref": [] }, "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": [ "http://www.natera.com/role/DisclosureBalanceSheetComponents" ], "lang": { "en-us": { "role": { "label": "Supplemental Balance Sheet Disclosures [Text Block]", "terseLabel": "Balance Sheet Components", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." } } }, "auth_ref": [ "r862" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r820" ] }, "ntra_TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember", "presentation": [ "http://www.natera.com/role/DisclosureRevenueRecognitionDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents tests delivered in prior periods that were fully collected.", "label": "Tests delivered in prior periods that were fully collected" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "documentation": "Information by title of individual or nature of relationship to individual or group of individuals." } } }, "auth_ref": [ "r884", "r930" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
```

```
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "documentation":
"Title of individual, or nature of relationship to individual or group of individuals." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder
Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r812" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label":
"Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r819" ] }, "us-
gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy",
"presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable [Policy Text Block]",
"terseLabel": "Accounts Receivable", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r129", "r130", "r131", "r261", "r262", "r264" ] },
"ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r839" ]
}, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by
Individual" } } }, "auth_ref": [ "r841" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [
"http://www.natera.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on
an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-
gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
"http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that
imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to
receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r269", "r270", "r271", "r272", "r273", "r274", "r275",
"r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r365", "r375",
"r471", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539",
"r540", "r541", "r542", "r543", "r544", "r545", "r568", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r897", "r898", "r899", "r900" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r842" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading
Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r843" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023",
"localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name",
"terseLabel": "Name" } } }, "auth_ref": [ "r841" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r841" ] },
"ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate
Available" } } }, "auth_ref": [ "r844" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" }
} }, "auth_ref": [ "r842" ] }, "ntra_TukwilaWashingtonLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname":
"TukwilaWashingtonLeaseMember", "presentation": [ "http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents Tukwila, Washington
lease.", "label": "Tukwila, WA Lease" } } }, "auth_ref": [] }, "ntra_TwentyTradingDaysPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.natera.com/20240930", "localname":
"TwentyTradingDaysPeriodMember", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents 20 trading days
period.", "label": "20 trading days period" } } }, "auth_ref": [] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [
"http://www.natera.com/role/DisclosureRevenueRecognitionDisaggregationDetails" ], "lang": { "en-us": { "role": { "label": "United States" } } }, "auth_ref": [] }, "us-
gaap_USTreasuryAndGovernmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasuryAndGovernmentMember", "presentation": [
"http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "U.S. Treasury securities and government sponsored entity securities",
"documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored
Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term
maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association
(Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)." } } }, "auth_ref": [ "r553", "r748", "r950" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [
"http://www.natera.com/role/DisclosureFairValueMeasurementsDetails", "http://www.natera.com/role/DisclosureFinancialInstrumentsDetails" ], "lang": { "en-us": { "role": { "label": "U.S.
Treasury securities", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States
government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds
(long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r725", "r748", "r750", "r941" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label":
"Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r838" ] }, "us-
gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://www.natera.com/role/DisclosureIncomeTaxesDetails" ], "lang": { "en-us": { "role": {
"label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued", "terseLabel": "Interest and penalties accrued", "documentation": "Amount accrued for interest on an
underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return." } } }, "auth_ref": [ "r448" ] }, "ntra_UpfrontFeesPaidForAgreements":
{ "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "UpfrontFeesPaidForAgreements", "crdr": "debit", "presentation": [
"http://www.natera.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of upfront fees paid for agreements.", "label": "Upfront Fees Paid For
Agreements", "terseLabel": "Upfront fee payment" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"UseOfEstimates", "presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy
[Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with
generally accepted accounting principles." } } }, "auth_ref": [ "r46", "r47", "r48", "r139", "r140", "r142", "r143" ] }, "ntra_VancouverBritishColumbiaCanadaMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.natera.com/20240930", "localname": "VancouverBritishColumbiaCanadaMember", "presentation": [
"http://www.natera.com/role/DisclosureLeasesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents Vancouver, British Columbia, Canada.", "label": "Laboratory space in
Canada" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [
"http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]",
"documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "VariableRateDomain", "presentation": [ "http://www.natera.com/role/DisclosureDebtDetails", "http://www.natera.com/role/DisclosureFairValueMeasurementsDetails" ], "lang": {
"en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] },
"ntra_WarrantsAndWarrantsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.natera.com/20240930", "localname": "WarrantsAndWarrantsReceivable", "crdr": "debit",
"presentation": [ "http://www.natera.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRelatedPartyDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of warrants and
warrants receivable.", "label": "Warrants And Warrants Receivable", "terseLabel": "Carrying value of warrants and warrant receivable" } } }, "auth_ref": [] }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted (in shares)", "documentation": "The average number of shares or units
issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [
"r226", "r232" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname":
"WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ],
"lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]", "verboseLabel": "Weighted-average number of shares used in computing basic and
diluted net loss per share:" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023",
"localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [
"http://www.natera.com/role/StatementCondensedConsolidatedStatementsOfOperationsAndComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Weighted-average shares outstanding",
"terseLabel": "Basic (in shares)", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed
outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r225",
"r232" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic":
"940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r4": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
}, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "11B", "Subparagraph": "(c)(1)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r8": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(2)", "SubTopic": "10", "Topic": "310",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-
11B" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10",
"Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r12": {
"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" },
"r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic":
"718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r16": { "role":
"http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic":
"210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards
Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210",
"SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" },
"r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "
(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210",
"SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": {
```

"role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting

Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.11)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(a)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1405", "Paragraph": "(c)", "Publisher": "SEC" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "4", "Subsection": "08", "Paragraph": "(m)", "Subparagraph": "(1)(iii)", "Publisher": "SEC" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220",

"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-6" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic":

"470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI":

"https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r496": { "role":

"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX

210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards

Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards

```
Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r718": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(5)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r720": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r722": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r724": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r727": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r729": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "79", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479294/326-20-55-79" }, "r731": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5" }, "r733": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r735": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r737": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r739": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r741":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r743":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r745":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r747":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r749":
{ "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)
(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r751": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r753": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147479908/805-50-55-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r755": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r757": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards
Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r759": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r761": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r763": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320",
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-
S99-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r767": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-
14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-
10" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r771": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r772": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r773": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r774": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r775": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r776": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r777": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r778": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r779": {
"role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" },
"r780": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"C" }, "r781": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "D" }, "r782": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "E" }, "r783": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "ii" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "1", "Subparagraph": "iii" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F",
"Paragraph": "2" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii",
"Section": "6" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r788": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r789": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r790": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r791": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r792": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r793": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r794": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r795": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r796": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "2" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "3" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r807": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r808": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r809": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r810": { "role":
```

```
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" },
"r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v",
"Paragraph": "2", "Subparagraph": "iv" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "3" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "4" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r820": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r821": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" },
"r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" },
"r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1",
"Subparagraph": "i" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r827": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i",
"Sentence": "D" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w",
"Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r835": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii",
"Sentence": "C" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x",
"Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r839": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r840": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r841": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" },
"r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2",
"Subparagraph": "B" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a",
"Paragraph": "2", "Subparagraph": "C" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408",
"Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "408", "Subsection": "b", "Paragraph": "1" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232",
"Section": "405" }, "r847": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r848": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic":
"450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
}, "r849": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-3" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r851": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher":
"FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
}, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number":
"229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)",
"Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation
S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name":
"Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r859": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" },
"r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)",
"Publisher": "SEC" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "11", "Subsection": "03", "Publisher":
"SEC" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org//210/tableOfContent" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards
Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r864": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" },
"r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r868": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r870": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB",
"URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r872": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
}, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r875": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX
210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(S-X 210.12-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r878":
{ "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
}, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" },
"r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
}, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r886": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" },
"r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r891": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r893": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" },
"r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic":
"320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r898": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)",
"Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" },
```

"r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483049/450-30-50-1" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } }
ZIP 85
0001558370-24-015325-xbrl.zip
IDEA: XBRL DOCUMENT
begin 644 0001558370-24-015325-xbrl.zip
M4$L#!!0 (-J";%ED88@IIA@ -D' 0 1 ;G1R82TR,#(T,#D$,"YX M@]8<8)C3[O'1\< M[7DX\FE HL7GO22>[^\]\]? ^-OO_SG_OZ?
%P\W7D#]9(6CV/,91C$.O&<2 M+[TI7:J1Y-UBQD@8>A>,! OL><='!S\?'!V7H[!0: ,4Q(L,DQE>4 MK2[Q'"5A#(T1?4]0*,N&-@JQ:(4*02D9&C7BYU'"2F'/IP>4+:"@H^/#/V]O M'F7U%'%
(HF\5ZI<9"Q7]Z:%(GD'C*7*&YT;J3X>0FE<"$H(XIRW3?3Q,$W/2 ML*4"?]Y #0K)B%VR?1+Q&$4^+E>%M!11I^^ @ZIXO?&R"AV?G9T=RE1%FO#]
M!4+KG'B. ^$R29@FB&YPJX@@O1*+"1/JA83 M,V3OE2EM$+,:\TJE(/E0)(M\)_M'I_NGQRHGCI+5B:X?G!P=XI<81YS,0KPO MR*#P&/0!WS\YR OV$\9
,VRJ'#CV#Q;TZ5"E5N2")A7MHVD'E5(AY\37,X>$ M.E]#^ZJ4*E]H=$,]\1JAGC-##6!E&I58M;2.R U;_T7?ZGG*5*JW0$1G^MI M95*%V*<)=!\3*FEBO36T[5
A"O":8;]+WR\HBT$3VP=,7)1$']6'A&J56ELZ M*%I:ZC2B57B?4H5'3(SHO-,.O?_\.?F@**Q'$;B MD_JX7I-H3M,O\$UHIG/1)%/HM9[X\?7AVJ0*9--=$NZ'E"<,/X*N#! +1E$P
M3GA,5Z,7PB_I"!$HTY5\SR,@8+\LJFZJ=@&>DXA(.4"9'AUY^U[!$/Y0/#U@ MZJ5OS-;+^'HIXP&_COCE]7PRGZS55"]&'%U!NRS%1/N$;RCO M!&X;/E;D3[HB7Q3JT;E7%.LA,<;+!7NBY*%K;-
$UQH@OKT+ZW+L7%!FM@' 8 M#G!1@B>+&)#53+P/^ F,9/C'IXNT^)$O+2T.GS!Y0F!&PP"%B0^6PSC(R"]Q MC$C8F))W8]8^67\X.CTZK<_7&0>O5")\585Z1:ERL*MR\VP_947_?>@:FJYQ
M12*8,@D*KV$IRZ2CA!N ;R.ÜP?KQZ+@.:\[.* $;T&I%JVPXB5F-1J+1[AF% M"2 >P*C[\CTA:]&2=S@VP+@5#QN^GXY.ZOA6C#&O* F25&%RP.;% <.#5=;0 M ;;H)-
XB1DH1);@X(:@&0FA9M@TCK?B8>\ 'WIT %F8EY7FE8H;X&^%_P8C M;L2UFF@#[+ ^;&CEE,$#0 8)[M&F;*O5$=D@:2C2#!%1FQFM IP,ZHS 6]6X% MIT;3@HT IF&4YL
GS'P&7!IQ>42S\0Z\0EF?>&SOZ,QYMG\8!I#7;)81M3Q M41,XP39=5BK.GF2MIJMAA-F1O(X@%?/XR\M:+,VSA=E?8K$7BM7YE-.:!:\%X
M>V9V]!LV28:^*M/+"O6*4KVL6&]*-9UDZ!N:OI%ML*M_Q1(BBDF\N8[FE*UD M[3/@NU!:?41'9]*EK[;U2S_E/?(P9T2QP3D*RW4[^:NX.' M_^,V'G[OITHYPZ#^CY/L'-
G?!NN:S@G33!RUC+\54P]PKNGF(_X-EI M=\6^96+'Z;2)DV8C9 !$MZ>!"/L=A0F^A44Z_"UGC\9NAI;("LL'$48&7G)BHE?EG84HGC)8VH!I6@_* MAM @L'@L^YIL5%:
(SC26LF"5'0DI,QO0,7B*=0Y?:\L?'^D6F+-X;&5-*U]' M\!%/T4M30963K&VN6=2G^3W)8&A[3=O?X5A$DJYCJKA$#-?;OYYLQ4"S-@<> M,F+56V/F238#$E]?RHSC[PF(^N5)9[HVTJU8:-;?!1,OY3)
L;5[:SCN(?)^4K^&G87MD9Z*T-PM<<[RM]-\"B@WMOG[H)R6,F#IS92&U0?FE 9?)\#'V=H :TS)0VL#YJP-)'W]0 MJ76,ZL%JI;7!]:D)ES%^>D#,ZBS5(U1)LR%B#OH%'L&&U(_-Y%] M]:4.
/9WJAJL^#9:&VQG&JO=X%\=$+,Y6O7XE%(L:!A#I8>6[^X U(.@)[+A MH5G3-GV! SJ]8^",D>@MM.U8?>@1$#<$D+^"1\D 8;_,-DQWBI,;8'X%F-,3 MJ9QCXS&[K?G8P=_%;9R?,Y5E#GWA%?
K"B/HDW*D75#C8\=_%H;SOC2;CZYL! M^%< /CN-=8]8O-D)?QTC>S=H'"#KU0W443)9Z- =7J,[$/Y-N F^1CYFT)I1 MRST'K\#1WD$^[M9!1.'205$I?N@]/?>D.E]5U/T:HB[1]P-.??$B'"T63-P^
MVPLU;38[A@TC3G^55)7] &I/4,=+%"TPOXZR#8O)_+)ZJY=)0>_"R@Y^8^K6 M@Y\5Z9$HWW !U7U9NT5L4,G]5?*6?6![Q!MSL6&X#]CN'EU@NB.NC=:&8/>S M50-
B6^Q:/X#P[$DE@LD[\F/R1(3!>479 YXG4=#OSK!>'&WH?VJ.WY8;Q+*B ME>W/*O*S\H:]LNU]KZ L=0;$^R-^AYBX]_JI'\Z-7'9TF]YQ,[HY^P'2+2"57R=R']'H MY^J3@=DJTT;/B!D-[VU8V)%O>JW-
R)?*VI])@K2T 7MK4%;+ MK8?=[S#4'H4=&M_>^/"7V'*!-AL %E.>P\0-(GZK'|VP!1AQPVR#]=C18Q^K4 R0')[DC> MTQBD)B@,-YT8-_2G%N-209XJ*4TL!S3[[O>QX#S>
<]3E;K4#P@++\MY2O)XGG=??6.[K]! MU(.75:A(!/N6)XEE=ZJW3E:P8H&8W^#2>'\8F,A7>@CFAZKR>][A:TD%.)2E MBDDL*C0NT/%$Q?D_/-#R?42OX>N@Y-"3^N)9[7P.RA2B65^9(
L.WT2<7PYK M+]=F'RKOV\K7;4$NRF(O:KRT;GA;-WV? 8;ZDDU*S4WD\IE=|>, BLHJUZ/4 MXCGA3J4]SA8Q5B.4Z/^W6&QKOW'4LZH\M6Z%XZ;Q;"RCZ5'KQ7OSV
MDE<>"M]"^T%>;>DX3&_]%\5_WLO>@5./LJ2&K)A?_MU(2>;IF^F8\1)2 MFK0R5@007&"V(U1=JYO7ZCH22T[*-K=BO450>)\P?PFV0A%M4H6F3P:7 "I&
M#+0]\1' \N*'24"BQ==:YVLC<$FBM+9CRD!/ 1;_PBCXGB &]'!Y$2]=/"ZY MG?25Y7FE/CJ"$4.BZ8M9*XA%HN%1CV&+2!5*E?9[4^;$IT
M4A*EG^46J5(']S!GG!P=?]0K]G92)Z54^GLRGQ,?/PJ3@._5]'XM32M'5CSE M1#AEKWNJ_6V'T()A^4D,CGS0U#ZV5%<5\M;UO"*,Q[+]'A.H2F. ML4^CH$6@-@(G)AT2:>94;-A>&5MZ

M9&_ ;ML5H-9BY]E9X7!+A0UF,EX@M<%W49JKK\HQ#$HEWXJ82#<#H,08+J"%8 M"YGK$CZNL4\@Y1&S)U#55[B)FI;"=;FR/G9%V22).869-1]J=?!:*9V5\X9\
M3P@0"64A[%9Y1G@SQ2_Q10BV1&$XV<@L6C56I&\]U57/5$[FV5FKBXU:(,J+ MBQH"]L_FBL W,)HBGNI^>?U'W>0U)3LY#UY",A$_!-B3$Q7]66R*=E):8JY M6-S$$#7$:4EW4IY[(!&
[JU4I&E^=K/LT^?9,0O0'XDL8#3&~-.M="XV3$S#$/O9Z0=@I.2R4CG@^)'S5SD@JPB>TG?*/AE< MZ8+7D2_Z%+[$Z;\PQR6K1-Z)?N>B IC>"G,X*\[NLSICLNSSVC0>+7S>F6]'D?
DG)_/0]>`QNPRDC4@S3)WV*JM MS+HS64_A[NH(X"'1G0F6UMKNY?[71-U)0V MG,J&]?JKLW5E 06+ 0S#,MNNTIMN%6HG+17HTJ4*X H)I0 M>5|<>EO@R?
P>1H]/UB@2SNLT\QO/3W*-CR-+9]$0# ^/Q7)D(TYN53O#V[%WLAM= M(; 9),#WPK=8$2W7 .TT[IJ7QGX^78*V7M(PR)\X@E%O'1VF7#]^&Z]:Y:\@ MA^BM?^&@=IV+I"M=Z;(7N5?
^'[/,M<]Q=:\RU+Z+TZQ_-B>'=;&;5S--;)M_ M-G)7%@GF8PXC(R:1UKZ9' 34IK$RT<478E5G!B28Q22.64109K8D<[43LHZ M8M A6?!B\E&U1#LISP-Z6N#()(TQU4E9KB/A74 F8XNAR ^
M7V[$DB>9X>NWETV<%1/%';YRF3.N55@.H*A$U)>S$7J.(QATNZ5P\F>6AU@ M?!1%"0H?RG&0+03..1<;6/R(H]KEJN#_P8@)_Y*2PHLEL?J[MB. 9F8^SVVR_R5-8.UXP4A, ^'),PV0U(VB,
(A2@:C_O2.MD#[^.[AGU 4BQ M$8' ,+0$3SBD:T$U\K\GA,N-J'SOK6XN;)G;R,:0F\"E:@NGJ=B^ESEE!&T: M1YE>TB=6TCA0MZR6YJ[=V;3I_C336P<6=Q1!C78B DY}$?D=]&T%/0MWO5)=
MY5);N"@TX/QU#0/#7Q(8,:*$R?R6A+!T!^GZ-N%N1?WPSB8LH.*AE,UU] 3F M0I N07@:A9_/.)U(?[Q'3SBA +.-<#69EEH6&I5E#5U0 M!"DSO"*\V,"MWPIAS[&C='TNL:BW1
=ITP/@O<2U9'0WE1U9.@(4?RM[$O MB,@(LJIBZ*(K:=@6*X+.67;2WW9I>D+@IH9'$07EN-W0E]G8:4M03*R[6BQ/
MJ33W&):F7_EJ,9%&ZO6EL'44[<*US+2N98KOFDMA8N(I5AA$6HA;W'=P. 7 MJD N?J\C=34T "?*EI%]/DM06$%U%R[O!GE]"%GYWCT#@3,2&GUJF3=7 :8Y M@5)XAEN('.S@]9-
LZO!H9;R:2)P!SJZ4JB+*ZSE!]K MY;16OJN0[PA<:6RGSI#+A.4QC^FRY8)&25GH+L0[^$;>!- ;6&/22*K-&8J^ M3>9S+(YYP_S9T#YV4@=U4#81! TWLPQFRCW-927;-83@WU_ E-L M2!<;P
IMI*)>,QR7CY,V1>Z1QV&)>Z3'&^+?1R4Y52$-: H%BL9;:A>L>:S M43HHG3BIQ2]Q" (_X/-5$H:;[.82'#3$WIZ%@^V1QM/S M.QJG865"VQJODRM=:JXCEX-2GY.QA:5!F
0"TC%:DQCZ]%\X>*3S^%D^C)BK M8/E.:-W@WI7;>YG0QB%-@GN8E<0&@>%V@)+;U4[L8/=(C8S,/1F(>X*O(Q%_ MVE2!5DH'I9.G!Z /-MW+M00'ZSY:KQE]{2LPBLIGQ#)_3:YPQ15J)+HC$;ZE
M4;PL#]:M.6@\(;V.F;W)NOD.4W5,I,4=W4KE(,IYZ)WH2DU8;I-:MY>M9,Z MNJ^:OW&;!QP5^UA2*+EC7#:...V9P9MZW.YB?0 X9=?4L[N1=DG6A0*]55^5? M7N CX14O1 ^L;Z]LS9$6K7$E#3-
O).J^D'07FX(D ULJ(_F W],K(;B/O2X MD+X>A/+Z)VOO*RG,W/L[H5-M;JAEW4PVZD5YA)==('886*T90 J3<8KNS>N-&ZQS9]KIM M5MQ:"K7F &O$<+H2_PW&RO;M9V'K2EO:YO37DKJV(?
JZ;%UIS%?MF%NWUOMI M#\UUYNJUC=)1";'[HRI;;[TXW9+7E5:Q#CG=RNYZM4:$"':KZ2.I" 5ZF. ^.% M)NE/$5[^($I241NE=NB?M=PHZ^1'!ZSHXJ8?>)]NA1JG49H-,S"+?(Z:!IF
MN[Q96,,#]BG@HEM S<(G.G=UN.#]!F)-PB;ECS0LKV6,%&49W_)MWC[Q.(/I MA$'K,N99> "T@O\B,.X M%) $I%[Q" .7/^EX:1?FWKB@K=?#KJ'RD0A,'WD[^;0)D9_Z71C/E^GIRA$-(^H
M1647H@NU,[);YO5;\@U?,+I>;II;2HTD!Z>F2Q01'#Z 61G19Q+_U9#"1.^@ M+]T 22R>+;U') !5GE^04-9VI63O1&UL[5UM;^.X$?Y^0/^#FGYI@3JQ8R<;![=[R.LB M0+(.8F]
[_7109#IF5Q9=2DKB^ 4=RI0MV2)%2HKUX@7:V]@FAWQFAL/AD!S^ M^MO[S#9>$74Q<3X?= [;!P9R+#++&SLOG]^;M,X.?OOREU]^_ 6NK]?OET[TQ M)I8_0XYG6!29'AH;;]B;&B,RGYN.\8
HQ;9M7%(?D&&T6D?GAVV#_LG1JOU M):!Q;;I0ASA&0.SXL!/^<,7)$>?H8HX^[AX-K<9T>"[*463SP>.1\IT6$U>[WVTSW'\;>B!V MIE!7Q!DC!['@J"C><=,'2Y-F[4TG"+DN0<&:^;
[TUVL;PZ4H^:A169'[.FM3=X* MQQDA7 BD:^Q:-G%]"O5?D>/#/Q9Y<3!CY85E$1]:A:\0?C6?;02\O483,'QH MS(M?(_$MB+,PAHK&/HM=F"@8-.^@]%. Y/O9@0F)55PMZ/CFZD\<5AKCY3 M6/
6P+Z;__EXSKKP#7D9\61K8R= !]X445 ;Z]/Q/3:?L0V*A+(*+EL;!0.] M1S U946P4?E#NO9H+O*,#@&1#^GJA>U9IFWEZNDFC8([>HV>F<4'C]3#8/"^ M$0^Y7 ^S-R&:O<@#,T5@$.I.L
M;P=..PSU\YG!9<\7Y7%&VHG&7J1?_J>84.PM(A\#R@:N$+=!.!G0'D_;V 2GV3:(1"D/^$?1" 6>:5^1VB8P 4Y1%"6U M8C7EK2B[A(A*-L!UB*Y$,/S+M'TD], 7CQ1HF8"5XM1C3EN7/_ " %$PZL6M% M=XX%$Q*[7/0-
>8/R'P7ATEU]#1,&8I 7X>0RQ,[8.Z@\8U)'19CB,"^1A-L 889'GGEXQSI-/P)-/==:(C("SQ6=^/=IDT#U_N [#KW$J.RDEX0.%:](+!N MW2 38]V^83JL9*0'1M"%4];)31N08D.E-
4H8[=#XVG8)^APK4\TQK""(Z,A- M1U0')VT) 2#R WB7R &S(SYNFEBZFO),%]"V4'4 IHJW51GY,@[< G-8$ $[M/DPT:TMXB2:$HA5PY-Z\>]0$<-@QZ>(.V!L$%5CX@=C0M9?POIE41SZDQ:;I
MV>Z85(<:6)A@B9D0,!(PB"G[!A\>M5]*L ^N%2%)%3/R3F]Z.RE5ISBL%/7A M17YJBEQ39&Q*-32M"FC%:MLDU6U-*!F'?0:PSWYJAP:K].(7Y2@(S[2LG)S MW^7FW;)]6@>*9J&_XW%:
[4,E*JI8*KB30IQ%,.."BRGKHCXL=@&-Y'"*]H; MQ9HF0(=3+X2,@XV\A!]Q19RA\0>2T2;7*&:0E825;*$-6#68>P^ M(1TO?'(ODLE;?"*MFVPEA3QK*MFJ4]>D0@N#$H"V6'!J_1
M\M_5,@+^F)K."WH"M#>3";*$A!WW(ER=N98OQ\I><6@/Y>+[Z 5=\[*L;^P MP&K+;]J$X@/PWZW=]RN@DTJ1=$VM@GS<%#/<2XKTPF98$\215L7J*:6Y)31 MMM!3 -=A-72-8&*V<, Z^-
M&@43 X9L1ZN$_@^\%XE:INB>*D)D5.U@\"<[H M8 ,/8$W0)]_\DD[F*U9MN.QSLZ(6*Z78S1.VFE2ZB\,*-ES\FL!W<--2 M,-
#9;@)S>-9I@U\1W;QX(2G9<#GJ(D^)])DJQSN#)31TP%E>\;06(VHZKFFQ MSGTUL<.\E.7.H#ALH4&AX31%$>XKIP6K"OB@<[@R\]"2$I&(9P"[WO'53@/ M4?A 5T7.A?>IV#MT
MD]4C3#_BSJ+S(/ KM!(A;V%D)@4@X;T]T8QL? BC0NUZJL8Z];:V=JRK[KV"I+ BU!'52P?=BBB) M-/N,LKY(J>RMZNAS)=2B2A_-V 8JR':BK#Z"^GNK.#K\"%5&&I2LA):(DQ4J
M*XJ81)PW9G8IRN)ZZ!KFBR)%272B>0VT89/CRAHRRI.GNK'6D\"-5'!ARMGMLB M>/!2?<6)KK^W>J+#CU!GQ$'221H0_IY)^%9OXKLFROJC0FQOE2DSA<7#IF.$:3+)ID2:9?5&C(MA2AVM84:
/ILZAPQ?*JO)S3V[8X:0TF*]IPX6M#3SVR6-))MRT,PA<,59T9 M(8&&JT1!#%ZIESG9TRZL$ZK<_IN'<.CU_FG1KXTBY7L.%GX\/W2T\;,6 MU;?8,1TKQZ(Z@4 U]:..RBVI5#M;AR?:H W7GNCX
0W<.8#+M1__9QM8 N$,! MJX*S*JT?YU"W(CJ64\)RAU2?'W6X9Q=;X[$LTH.@E^[-.Z(6=I$HSTQJO3W4 M$'4^U&U1'.K^8!($N]WO#O0?S#'89OS*]CR28^#,35-9% ^N]ON&BUCW2Q\X%2,2-
/P;=BZL6X^2.,?=F!5{> ^\#]H M)9V__DG7E#K-EZOSM-VK2(9=)='E>5-S!;4.CJD47.H3C{JU]T$14M!6*E75 MV@KSJ< ^'[QS7HWX0_M$V[2?MSJ9I7]$U(H1+M=CR/;7U-L@0_ ;\<^+: ^"< MZ()
<#H)EW -4["Y3;NP,'/0?9-);$U/9JV[YB%;3+.17E-CUP>(Y5(=I117V MQ00L$Z >32GQ7Z;WL+!B#'"+4KQ4^C]U, "^S]&:VP< >3 MB^@1>X6-
5'D.%ET*9:S^\^P6BV("><6C&E>"DY+AQ#D6(Q0T*YXB*#:.^VRK@3G#:A[RB!\R^(4\[_'3: M/MX,/_$&C:!%8]TD_!2V&NPIK-KJ'^ P3+C4\(S=^+W$.55RGT\7B4EKN[! MS:+(5\MBZ"B
X)7YXKE1EVLIR9"^4FF6\9SW!?0U M==]116HUAW**N#8,?#:.0XCP"!;-O,M74Y. ^(':J?.![+O&IA<:CY?GTI(5R M>JW:RC((OO)B'[S#O'.@2< MOY8 ML%F44J6VTLP,3B6=?
MD!*$%JU90EN+12;06= JX.DN7+!^HM?D?C(!7"(ZS* MIM!OV1A-*%U;J67!M8L,JG)YA> ^W2(04%FF$9*1@TI/%?Y@XHG'8H> ^,Z2)\ M:#S9!*15JK?(LL&K1:YVCHH]>XI<-^@?6S3IQVU5*,39=
9L.JV%A2%52D7 M>PE;,L&\K_7\FG[DLB24KF[)UJ/#0A+-]WK,R0DXLHJ^^Y_G)\IZ!-)A7^7[WY*P*[K.N!*.CO&!>U,'D MJ[+K&UB$T1NR7]$#<;RIZ-!35G.)[DNJG^A#?B%5P&RXC-
Y(3@7B5/97;V0, MJ$/^'RVV7I%9\]51LB"'1P6V*G2W!(_E\\3(;/?*B/D@-YYA2+CP5K= M7^90"ZX&AI^3PL5Y:39'23Z.'7K')W:\(+ZP/49)9SW,%L-;V<96BV$@> 4$ M?
ZZ%R\#VW1GSY]/96UX6%+V8L4J9@(IH-6?(%)^&.BQ^"PG*-T\)=(!6-,3) M+J]>$><540_VRA(F MI@;O187+,.B1KBCT-J:0G7:WUSVKPLB3,C]F;-.P5/3V/>OO.MO>E4GI@MU$ MD$VOLBK5%V-
B#[?EJ0WR8^0K6#//%>_?=,<.<*.R':SZ!_EWH1S/2)V0U287 MK=J+NGCTJ1-HM@=.E)1@X)37B%RB(?)@XH.OV%7>Y#=M=&E47^C)9KHXL,H) M,@)C42 /2'+-ET73[5\,_=D>$4E#7\?
960/#$@DH50K85=&*5"/SN/.%0 M7_D!09X&_4^68SU(ZS BF[YR!A]YZX8[]Y'#Q@W>NK%NN#M&R.2X$J7Z4%O M<$SBD":6+"XY&,\[$:/$R6E=4JA1S>$I@;8:FOPU2$$$]XW:,9T-
U]51$=:FB#GO?)P>*A"2.*4(&R:J2 M?_T#2%'B@9,74MV*\$R7I 20%Q) (C/Q]_]^78639TSC@$2_O#EYJ^'-!$<> M\8-H\G-?__CW__M[__K[=O_.;V[GOC$2UQ2C!_N0E2):3 M!{)>HVCR%5,:A.'DE ; ^
D\F)Q>_ ?3NPJO//TO'UUL,//0\I 5AML\$<$0?3' MS_S_GMB($T9D%/_\&@>_O%DFR?KG]^)?7E[>O7QZ1^B"-?J]OY_OE[?>TN\
M0F^#*$Y0Y.$W$P; 4T\E&0<*C5_?:)AT<&G]INQ!!#\']L"["W_ZNW) MQ[>?3MZJQOZ;+8K\9X-!"G#^JY L&I2!?WR?_U@=E\C.X1NH;-EU\OGS MY_?9KV_^\6^3R=\!"?$=GD^RKWY.-
FO\RYLX6*U#WE7VW9+B^2]OHH2BMUQ4 M'SY_^L.!I_H_[A(F<*],9B7P<,,W$X[#X]U5!=V(-:?HG4=6[_G/[_;+6.0D93>C\:A^X1X?RQ) MZ+.1?/%G&B2;OKDB&F$\3IP'L1>2.*7X/EVM$-
TPA()%Q$R!AZ)DZGDDC1)F MM&X9ZEZ XW.()IM!&2(<("#!?@O&()O8?V5)(&;;LQX&-B7I$%YRZP\X2MD_'F%X M\X6P)0,4'0&A*XC18D'Q <2VD5I;A;(#3C.=NF8W_[2UOEMNC8!=V7**'_HC#%
M7S'BG[--3$M2U7TYH2Z(V%X]0.$5V[73M!-QJ]Y4L%UYLF&&DF\^UQS(&YRT)+K=&"ZX<C#EMTDQZ=[" X^2CS;W"-8D>IS/B7_[YXY7_BMKL)Z_[A<.$&47ZB?NZ7
M]F:O<'C.OIVM,R]"KT0+.X9#]QUFJTC@9;X#]OLCVQKT2[]R #A\N,5T3NB* MKS+9;],71/U^.:$9P@4OSO%3VR6YTM09[NP3/YZQA>4JCE/.VC,2M]9@HRY=
MTVVPF>0GQ@$AQO]T1=:-5VZ8K6JXBAS0S'=H7<'EK^XF>5$+OQ0,JH M=^!"A\%<\(?M<+E;FUF3^R6BN/QW2R:8] B TEO&>K9Y1&&X.0 "E&\DLN_; MRMZZ>S=>L*
<8_YDRS"Z>.YP:I=W8TI2A71!6QR%K&F/OW8(\O\>>GV/QO!&_ MGIRRS1_;^.>W$U&XJ?*]Q"+NF!\^<3_X SZE#>E^CNRJ;6R-]%?G!<^"G M*.R&K*0?*9:(>@6BVS_K0L;Q"KW#*3O[\IG\R'-
[C&,_?; ^'?OP0^IF\CMMDF M+YB*1ZQ34Y=]2.FN/S[@V^T'1MC)3V]/3MY^S*Y! Z,^E@& =5LG%/EL7\2/ MBFF MKO#]J>TT%>-:[;<[HDN&$_72)_QVQX8>T17VWJLRY%-
J&&TH^LX16A+#W+E^ MS;K==L[1Z3RW2ZAHC#N=C?_=MD/ !]LTGI?:3W-Q-OF;:T-9*Z.G]S:HK:?S\ M^?.'#Y.WDWW/[/$/1-LF[G_#^!)?8ZVR.(Z57XGM/-'N86;?AW&>)[[")/ -D31#5IAI;49
M8BCYH6.@P3IO0B2:089'??Q-2I76LID8BD:W1^GT*0[\ -'-/0JQP5%:!B_7 M:E4+%Q3OL>!RF,T?F !CY$F=5N8-Y3PP:MKYZ&T@&V*+U/A'<3D5E=EHA/WX M7F%^HL%TS=/7.5XR+[3.SRE
"_1,X=7J?46S*#-EU0O"W\4<5(ZN@U;BLD MW*IU)W>O6A2D!3KC>GB% ^(>>72N\]G:Y>21D5.L6(*:@%*[*P9U3IQVVRD# M-R2TW^>V?DM_$#(?15Q$1TN7E0X6LTVEP3:
(%FYTKC]#FQ"8"E6J(#!@ BYLE&65)[$/]QNCG%D;=<(:HZ MK^N:R6^'#1]"8$.!E/I:7-/,@@W-AETGDX6,B!UFHT\P/2F5ZW0#$IQ.NJ+" M#W?:)>4R/Z<;S9IDT%*JE?
30H6LZSNFO#@ZK\P:\]}ZVZ!VC;-;VTYU MO:)O"8<36C>WMITM) IU<=L(BECBYN^N24=,[;))3P24A++2RR&7-"NEFT-$DN4[5UR0\17F9)8O^6>GZHV :8]&4@_E&ZEAH_EPE7::B54S
M>97(NIS&2NIT,UE)E6/OWS/,\] UV]HFH,+?)0)U3MP9.XPL" W^OMIR!_J& MAL3+FG;W^"FD06RQ<>#M:Z)?=?*9H.UTXI1O5 U\)YC)PJ1ZI&@ A5[F>R1M8 MD=S^2F4@
6**R^@31HY\>=JHD7:,R<'H66S?X$))]HHK$H'*4QPDP !(5&=R M*(&-R>PQDT/-,6*"P_B9'$*D*YD<4F1'JZ7O43GCF8=B)WH32.A?%H,Y(4J] M_E.!&A#5CY-/RU.B'WM47[D(V<))KD+2<7Y>'%
<>$3W=W+#91O%LOO]:Y:LS M[T"1Y&;3A7,F;9'3I/E)6QBRH=&F>\)?"T$18_0^J'>SVF?G00/^F_?B) M(?;D5M)$V1'I.)^X*,STA1"?5]R_(1%>K4.RP;@HOE\(7.ZN4_7ZS# 5)EX
MW*531=YNUXV&@,$%RH;EU]ITVAN#FJUVSY_N27.$-=C:4N4@'L;&L\3EV=]2 M[W8GLZT+1]JDE$#D*V@-R"$IZEV#64W$_JL92KA(5&..OT)7D*PLOK#]! (;
MOCR.!GO+*/@S52FP&%@]>SDX"$*5ZBT#MR"V/Y77\IV8X3'Z-) A7IX0*H1' M=WP^<%)F_VKRQ+?IQ!.Z"F40KJBZ+<@668OTS.6Q\M@_4 NY*\WMNC!C OZ
M/KJX477B(:VQ&M7!*B&C\+&V0-]M>#+%?!!<(B^KKZV*1VX RL-NA:#.B5,' M&0M #0GL,918Q6.B'W_|<&$!PI7X8 FBCK=7-."EYN]0HMY85<$4NXPFH&.R M--NH.J 1:7UNG:2<);JQ'6R7ZLA6-
THB) $DXCZ@UVF:+ E56W4QL"8%500. M@E"'#I-I#-$Z69.:/:0 M@'QV2.&E,J-L 85BK1)?1)=LFN 6Q?:?:*OC>R+(<5X^$HP;:)>#.W5HRPTZG!4,I7

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|#VK*=)H=J163(%F"IX7E[!!OM?*(GCQXCM M2T*.\I?F 6R _@%8!\A+[+[4E :WKK Z*;,CBS4.WRJ&XB;DF<2:$@ MJ_BLRJ7HN6l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}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|=*R1:L;//^:O^3JK:0?3]@$B+D!\@. MU!V.5-6EAJKT!*0445O5;BWY 0^\U^B)U\D@=+,O(*?($E."0RA/U%Y!=oP95 M2>)@9^U.R\$/#?8_H<>#PZ\SE@-"O.R-HV .)4^Y",GM!!MA,D[6]#E,P) M71G+Q*05@'C6/J1B0NH@YY5GAA.;I5_Y[4& PB8MJA.,<6, 0;!]2,F"XL'# MDY,ETXPMOA6ON@93B$'7!$#T:B^BT-$)YYYZ M=|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jKN/*Z06K(%M((X72L<+)=A!O3LYBUP>|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{;/MZ ^*^A8VB^?T6;. ^QCO+HD] S% MRVD8SN@TVMP2FE]*G_%,3?8WLY,W),'Q-.%WE"C:Q'GPS2QB\'-VS&,J\>[E M$AML*(=QKW:R'HP#<#QW[-R_8/BM^#*K21T4@XZ_49"$)!D>GL14@)*!\DPD M X9Q^%&IDTH*(,XT]=E\BS96G"HX0KPN7=P7 M(41?T6NP2E>GA%+RPK ^0VOV2[*1?>LN@"0C&(A4#O:8(MUY_V=S7.#K]_/ ML^\&0.9'1_&JZ8,MXJO(HQC%;*G(_|W2FFZP;,VTZP) 6D5'T6?']8@+,@PVM37X,47VN=IO4I#@:"B%'E4MWEXN0!CC"J%)R MBN(@OE^S-=:?1>40L!.C2:1J/JK8^O:UJ B#(\LSLEJ1*"O,>8OHC&9W[7ZV M)6;GURRS4.IJ-F@YJ@2[.V.,:((C/+D'(D=<6@Z@30>CBG)(TR3-*@2?Q7$J+ZDRO#\4N0

MF%W1^1;5QB1:LZ.!UW6>LH_MN(2X8D,D'WEH/0I=.7RU_EQ5_1XSXYXD<#O_$'OH2D!V]<<;"(.TL%("L1X; MJ&;9LQH%$T;<09'{C? OD5*1@0Q<']N#&YXD#/20W3 M:+?C:CH)&A5ZO@J4]:>".YD$6J94B[4, ;ZP/4V/X;::V"FURLJ?%# M&QA= UMO(E]!:+0.?/TH+#PX[(T/K=&!:GD2DV&<7&4OE+Q?5^L!9$M1\KJM?,J67M9_H$>3.YRCB>*&%3LVJUV&'T41+^Q8TFMV*K1K6 M%F*;&N)UQ'9Q!Z|^"JH7 LYWZJR,\X%C&BU=1=MMZ$4[]DR_&.- >P_@ M;?W8G+8YWB@T$7KXX36@301Q-^L7#;IUGR]M[;(X?^TXYZEOORH3G,G=9 M5"N1,^GL)DQO:!SR< ./(,MK7'":=FE:C4]&;VAVBSS41W/*\#]X M6B)P'Y33:0N/=-]%24+VN;9NCF*^.)SO!Q:F-Z\&" LMS7%'99>>]>.4S6WQ MQF2GQ,./2>:$B:*,P4>[SP;KVR_+2SM._6H:+|=/;9[G/7%4]T/'C,JZN;62 M\.1 ^?5*#Z:C^MRM$C3OCCM=^.JC?6C'IB3>2>\H_$2Z8 .[226CE2]\=21_ MS?[K.L[G-D6UF]>]MW#N^-\/W.?I\0--0>7V.#;L@C-Z^^A;O$_3T1[YVS.F MT@^O$%2|>)QN&=FKR(0GG+SLBFJ02T!V2H1Y7XV9V@ %?9(Q*%#*%3RY4=O- MR==*N6.S_*.C"T[#,-(ZA%O;93$T644DZK^$//0X_M /1E>M8^4B>#|E['Y]DZ1<# MGKX-K&^$.T&:=JB%9;X$W"#5R#O4]00ZZPZ]2TN?[-8D;$;1''5Z!!%Y%S*.TD+J& ^#;L_ 7LQ88JS MQ8/DL7C07FFK,8II7]SQVLL"U=@UZH@WCON)/]2]<!*DI(PFJ)U9P-4 ' JR MADOC+C;U-;O$';*?&884@21CGT3JNRO>5KA22R5IS)/11'YP1 MUTOC8@6[JP/R)6QC\>U<7Z+E0R^5U>P(A"!42C'O O;DZDL&607)'(G.@&C^ M%>Q9]794MV$?LRT+$_[*U#'-/COI/;KC!+.A=CBITF#4%V]ZT5N#$04(2D9$ M<9H[\S!X=7LV>XA)PF%W4+=3%10T68B\@:.:WSI\ ^:CR]HH9,)CTPXT(QIHW M/'*D[X07 \Q%'[Y-?_:0#\+8=V('IT_*5)ZXZ#/V]^F/.]1[6Z+QV9BNSGA# MO[*=A)60;?VX,(@]E8CLHH1#S1.C\|Q#1/] <.8'*HS[XHSHH?H7RQ1&/9# MOE+15XLI%RSBK/#*'H0A:46:[\C-%[K+SX'HVQ$>>L'!9_4/7UCZF;&0O*'? M$@]X#"ZR)3W-#S*PF8\34AR>$FXSVE_!?RYN7;\F^NF%+HL8O"K+]HY'TK M.XL_X$Q93F>OCJS0@$2?0X$<_R* >+.QNLU#SALK<^[&C/73Y57S9&,2)43 MA49JU9P=,+08Z"R+ ?$D]^N8n;S%/ZEG;^V]<)W3VT/3E>]&N.-^R7K$ MX<*2-@&2*Z+2T+(9W\@R[6FM40D6C]*."EU^9)\K5S3B*!3_]-2K@GWF M7 /X([VH7:I0D!?&GAQ8; FPZ^!?ZY<;,B)UENB@8G;SP-$-D5E]+>3D/K*W M9?XA8/+.5[YX+->.&U:M8=WX&8Z>=-Y:'DT5-\Y8LEKM!O0XDGA1R)9B@R\8 M9_RSFY?F&R3DXU(2YSBU6 /:6X.ZY@G=;&*VD6G=_.3I;\WYWO#HDJ6 8MZ+2 M0!(X(6B,/8JUJ9[]D:J1#=5F:$ (^.O[!H$|/]EGN7.:/FN>(4 M"'&"^(S6;LXQK;-;0OXYG=(V8'%'O 0DLM7H&9^2)&I%,1E(!"=A1BDE M3M=(N[1?((W@ =7*J+TI[4D%5T>K];+ZV:||W>:FDN<[+T/_CM,7'O#T:#0G M*T8)-WZ.L,[)JG]?,GCQ;HPR(W8))$|"3,M,3[(E@B\I&&/!)!=6JF+-"]OP M$*IQ9GO$/OSS1;U9G%2VP!.!1\65-VCJL56+8S$(Y$FCO5EVB=-76Z$A2V[# M[!7EY'Y]G?'-(+Q]'= ".9S 8\M.Q4Q\|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| M9+3Q;,UVM4 >315Q!-O3;7#H&H1K1[2",$1*XVB7$X$54Y'Z MD'=G5G2;H-SL]D%T9.R)Q:\!?>W!R%ZC'*H,NSWYD M21IS+V6^M.&GD*?)G\5GS(?#R@*K/5D[$SZR H,3B[1L)WC]QQJ$&==GN6" MJBQ6F6NYKW7]8$5*1;(A0]JR(DH9=>4B^P>.>L''2QDS4/^,CT^>Z!"W+%Y' M\0Y.LF0_$ 7!G*3.5U'XRN*4"T6A-(%!?>#6(KCQVDCCDYJ ^@YX$<],[!&; MK3EU(HMTS ,0!N^H3ZMW[=K%(4U2]@KR5NWQ,4JG*;9[&PJ %+ATH^;:.?0KK M=G7%&;-#]&\HF-O:#_DQV+Y:V#T$RS.>^?*.JV*WT^I>+6R;:+?*/;AUMIIKKI:XX$VX)M35RK79BE"D4A$R%TL)]U,13.ZU M9*+!AHF:4N*;":*QJK-|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`D^ G2R1AU\E @Y[MNQ8M[1?GK2U[%+&A0)86SL2 MS3[K,#DXT;4U*=^U792WZI.QH:+\5)+@W[%0]FKHY=TNLYOR#(Y=QTUKGH3 MP>W%PVQ2=>]^%/#Z_4]QA[S87[+"1_)RGWQJ9E-\Q %W'/X-'RY'?">>NQR M!T\!&NU+U)KCCOLN/?7;165;O+'<*;&U[2*@311Q9V^;3Z+I??5(?$.Z6^3APY6BK*X/2MKE MV0%7K-.I.N[*(ZCS_(^Y'"T6?%T]YIZ\L40]T/U513 |^$Q#7I,%1HZX8Y6 M,YWU0_)I#[QQ:RBWM2&XY(!G(F%=Z_(]\7W_V;)+OH/86PKF;EMW0WD[BB MX^-IZG\'D.X M &C!9Y>T;WX+CUJ#-6;"&[X&F:3VC&4TA3PPMM /4=]2L/ M-N8QI,43.G.U6Y;/N@5]P(0)FQ3(R6R2AC6,8H5<[*OZB;I&43LUNT&QJC#?TND4>?-A6#0**]([(XF4U47?O5TZCK*S" MPR5E\H:'Q(/+QGQLK943E\]FNAF%)U!8UD.-"M7Y/11P^HQAES3^_65S*2E M^@;'"W3]D(>OJ>:Z0SF-G1 'LK'H=@(I%)$,6V%J9O;4,#,;_[3.',KSBO*N MIZ7ZX9/J?@?OUQ7-IKC=Q# '?3];6%VY;T-UX8&*#*-$=OX>508%C9W$>P M#&A2@]PB.WDK5RHNO;I?>,)A<[2MX+>N+>YX;]6P&MJ-#?%&<;NX0 U34B45 MB4Z1Y&AUXYCFFE0$6#7SHK3G&J8&ME"FWC9;FFOB9% M<\OEN*>E:A0-#F]JGN9M**<82?+(($B9^S.TU>V5!)(\85P-N$S-J9>QQE'!Z MK07K%*?;AI%!?KYMI%(6BG[R\&*O1"!Q)H._N^7@A!:.B1Z:BS+OR3='AKKM M9QU[D")A*Y&:Q>H-LJOPE:>TN:*=81?$(&&H;X$&'>V1A[VI]!;BFTI6RDGC M_)&_C-N\(3RUTIC+O;GS16A+)'&"@4U[U5/7X?26D-I:MT&YH')4'L:/3Q]EA+)BU\8R)2(KXP25FP2I1K@:@@^S8H=W.@'BE1^(5J1WJ MD[:-!9G_QI=KR]TB.E!@:HO\Z+_:]_S"/O4<<+J1%8=+Y9VPDOGIB+/QJD.5O6(CY/>;A1 MMQG+%B.Q4T\5-Q)8LMJ0[$1#$B^*V%)LGFRDE*+>"G4*,I7I']J4T.0T(#L> MB.0F"AG99\ X_Z+8':UIG*K7O(8[RB/20[5W &1("-H@N(>?7'"Q4<< +%%F>:4?D*5UO-48OM6;[EW'&DJROTRN+R\RL'5 M2_8DR?G/FY;-9I5LPS'G1)25JKQ(P6S^;&M^YZ"^+P%/3(LS/JGG]^3@6&QT MSS_OBSDTFRW?MI'X:6WY>Q56N1^_2&?U8J)8\>Q10R[.]]]]Q\!$_D8#^G M!<8?=#'#@O-#++X<]W.7DK:+$>]YR%-VQT6*<^0)Q G4QIW$\)6Q^."[?3];6

*M0CMZPB7_^_55!";P=*60C#KB1,/^NI_/O=MZX9V]]!]W R MCRR0M5.C1[[9IO?K3PF3CX,UKS .(H,S-,?:I5R?[$\#^9+#&(T&+XLIGI4E M %IPA8JZ^;)##(POHO7% 2X+.\@PT*5Q2]PHN9*,+52 EXQAX?03W"">0O!VL MFB[+>]PG/;\RD(KYEZ\,#L@\LAWE874[]]9H2#(B@Q.+QJI%GS]UTUA*8M5# M$VL95\Z39$Q)P;6R H+@F>H9;%.8@F:FB M3J+PM/3>%>RRYADLIAS!]A+UN M)GX$PW?IC<@L&$M:[&*,)?]_>U?WVSB.Y-_OK^#;S@#NW=D)[.WMX;" XTX/ M J23($GOW:&?&(E.A)$EKR0G|?SUQR+U95N4*(D42TZ_S'02LK[$^A4_BL4& M&C/%/DC9-[&%)P94 VP7)&>-#*$QO6.4$3OS"&J+WP$QR'D:UD-32JQ,".*Y=S M%9 ^.L-ST=2]X+6\)X7YI_D>]GGL]XJ@%VJ0UYC(:^@C""F65#RX)C?X11JBHW90F.Y&/ AC^L+ M#[(T _#]&C^] &"&(VYO'VZKKG%&/&EY4,*#3V Q_J9%'!28+4LH !W=2"@)B MH#FHG,AJ<,Q!?JK6X?].-G&4O:2.)LP:=OB\8S?L/7M\8^K^RJ'6/69G)G M@$,M=NJ-0@VT9HY!;11-@T!< @(B$"D#D4+@Q1\;%N,(\%?,0 ,0^_@6CS1; M1>4\|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bP#DM92%),_%%(XOVN&[4CZ2[[38, M!MV(4>YBOG+*G,J7"K? :'B*5FW[FOJ=$;MO;QO4]CXU>R)W[?YZ3.7HXOYA M,>PG=O#IK%(P]#0UF"8&%.4SP@|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

*($&M54EU^AOFP7')V&NYLFG]Q#R^R|~ E=[.PH2 .LNFG M19LRJ.6S$D}:1UP&8 4T$!*?_!QXX ?^OT$UOC'5&;.6W<-+(>&?&E%[2@@ M!%8!V-4DIJ+>]*4-3' ?/ML@RB'Z'9*E#O6B1E%A{0"M!D@>60%Q-4&3.-<. M&0T8!CI?4#L4E5AF3KD9'L36YN!LUPFSF8:85EPWG#D1*8.R1$ YXY/ZBJ5# MSC'#RWX_WKU"$THOJ# <@)7HJ|\MKS"RAIDVRW$H_N.DN\EUZ'AT_X.PP[6U14 M-\#56%INR1D'Y.W9VN/,,RUM<6'=4.,&HQQ*_5>UJ1/B)}>'WC/8$>HR%[?, M.KJC'%2N%9=4$UB/WKPOL/4TKI!O.+V2782^SE0\^7'MD.Q+^0."-9'5Z,QI-Q M#R<.^3I\)1UBWN!)^@?'CNA'9&A>C&$PF(%AR)ET]LX!C\P(+&ST=?R&FT M \TD?"CU.,XM7%B&17\#I:SB2?"EHAKJAG)>1R1RR-LF<=DTC2X;WYAB51ZI M,Z?N[^]2)6D;USIMG@3YY&M(P>V.%D]{OP/T)QZ?>)%P"*"$?->(/"*D]>7DH7>#&SPW_P=+5! J)&3H)88$E21^QC,MIC/.X\1'0VA_ (^G M:8, N<1J>,;SMF%M*.:IDV?*K(G)*F; M7R#GS&E]073007SA,7I1)_5&'NA' 8)EKQ MD^"0D/)4Z3[F5N@"-P RWQQ=\ FSG4J- ;++%3H02'$(G% 3A='X^3Q)4QRG M,PS3=G@/GA= FI^:04QXJ[*NLJ,O^L4-$]H0D:GS<S5]B3\F+E_L&3)*\4{^H M*.5/@ABBTS=2,U;IPJ24[)^^ (HT4+XT@W)/$F;.QA53H(PP@I(.*/&?WS5 MYK(U$3[,7YK86X[U:V&]TV!/)2TD%*KK22ZF4./A$_13NS 3D7EP6 F?@!XW M\XF=1:3MPT|\<033T/^E5R.)W7R.'T,1!^>Q!]_*12.C7^ MJB}1\=3 PREZ*9V5I.FP,'9\7._!=]ZJN2C'(O,.+[=(.J97.NX]XU)C45'M MH.,&HQQ(GQ=P)%Y${&XL.Y84O$HAY(AH-+T'],N/3T2,PWQ)*O;N\6VF[X MZG):LB6"]!1(-5K2'5(&+D? GK!+E5XIXM-X(>X2B%, /SM;R07$")XJ_<&P MBJ"2$JJW :>?WU#%#AU1^QR2CR;Y02)DN%#S7 MT>+!-.^&DM"/R&-51D3)K?>%DTVH1>E5S^;C*N(SG#^PVC\;[6=*U+1AE%; [1C05ZE':M@4749M5L(5?U=WF^L(H)?!0>OM4VJ59*F4X'6%#=CS>F6*JK<$\!4N+7/ZTJ[?U.HNDSQUNT+1^-H+ MK=4=U)ISV=0TK:C[E WRCPU&%,, MZ%"YHOOEHUW*JY3RS-1X{-]XF%,^)T M&U:3.?3>' 1V(_6@N:^X*G:%\;5EEGMQ=:$ M-BT')TU=P[{KA"7E7KP5"DN:SFB#G<9 MTB0I_*P,/(L*X(KB&WP%AZ223(CEP2:R(ZI(1Y3[:,S$,2F8)E=5W@=0V;V M:[_(-4MDPK,H>8^3D=B=54=#V.NAEB>"N/PZ(G_4>6:L5&%9W9 6AR4/+,^@ MFCS)D*+W$U{1. @"V_}:+'6V>$%/M/$KEH PG)F97;09W;#GQXUIJO+KA\= M6-:N- A'L:G=Z*# Z$M1"76H74N6X-$P7[R!$WHD25KI*$?8@%;F"5}3]-M- F$*0CPM(C^W_;R6%=MK8'/IP5L8_9=3^N+@WDI-]9Q6TE4C*=]'ELM$UVUM M8*BH9VQN=Q4\:N-:'K7XXX/PZZ?E M66O< 9]^^.< >>ITU;O99?["*A5:BL[SL[Q.-/UKB !I\"! (DUH[9{0\I"? MHA# ^UX$ ^^!]_O)$A/U\|\.*:UM*

MQZE78@(M DV6/I2F#&G\X*6";A{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{YPA55H2^U+,+6;NG..S,- M6Z:0=]-:#)?"R^MTP1HIWBO+>43\WO!M2% +(XE-4;&L7!>C\:1=IP:'UK/[M76ZA,,"2DX*U!*P7N F0L2+);)<(1C?MCV2@NBVXZ^H"JQ!"66#KR2K'O4A9 M!=\LK5^AXZXMPYNYC[Y)!U44El0)G7IJ/EH7"XBK%*!I+(($9:C#TJI"MFV/\ M3(>)5;ZW8 D+K? *HK<1HQD]8S]$K1%O+H,UP1<5TP;_R#,AR).XP MV4W%7?;H,OJUK"ZP"2%0"!RG;$H-XB/^N(.MAF/& ="W>&%LNQO"PZ1O=//(.M7UM#U#C5?V0<.XK<94]]K#?F$7>F3!] YQ=,SBQ(&:=OT/.)6VA;6XC(.TK/ MQ'(_A_G[O;<5\'_'OJ%/'LWAM.>;@X3?WA/ MKO\'"%P'QL+VY#XX7(. 6> 80LB!B&'6!ZKUA1%V968TP_17O1'?X50 PC]'0A&^BQ'C[MR5]Y+O!>_[":&]226=!5=XB27R%-N M2XM+]@Y8#O$D7367B"*Y*!_NG[EL+KUT1MQS$E@UZB:;@B+*ND3>W!L5T0;FRVY9? *L;6LE&_;=+1'XZW@8:UL*!)]=M2R^[*FQ@$ M1])":?4<3O;87, ?!\|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{.:)\NC M$A4HS0FG%Y6J$.AD:<.B2^W;I*X/,%6WPY1FB]2 -56*56E2)_L&D76)3K MV'MP;H =)L-9'/F_O H.L#&? RS^]L!R!O'?!^XBY_[ROOQ? K?B_>C]5J-K. M[%R1;D)C].H#Y%?9S-#2QS,G3=.TJ.DA^6KV-/FZTO9]&[L.;(S@%LZ ;ZQ^ M;*;F?^$R81H.-\F[^5K![^<[!&16F"^>D;O$V-,_<=5], O0<#0>MWMW594A MD]\D50L>35@XW3X;+*O2D(&6S1G2N MOT;K+YU8=*B;VR5:H]TY9DM,.@D;N GG[?ZOK9H66[7L\S>4OC/>R.GV0.<0 M3+.[W[6O[6L &(?6#U)"<4!EIQ$VXU?U&\1- B$$"H'CE$WL;8A?H0-]RWB# MGL_UECFKO(,(<"KXR"LA+1*1VC].5#.09B4B"""O0WY&{C!2K651,%'K TUN MH3@N^6N]PN01@AE@:TGJU<K6>[.TL$UQ MUY;AS=Q'WZ3;U^*2.J%33\W'1X3\XBH%Z!Y+8(8;_Y-RR"W 1SC9SI,K/*] M!4M8:*7Y XZI@V=Z410%F\C*>-Y:JG;EH["*E2F++*BR<7^L]P1OB_!66MD(-MBJ4)6KT] M.(/6PBM'<+ EF5BY:W3=;1URRC+)CJ7M@H=^`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|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{X)'VBK>?3?K.O@M=ON,_?4*TK2^80F M]R*Q]32U;?<#. ,Y=Q1N6[!"+=45L-7Kx>>X:IZ* GJ1M7OHKIF4.!6_F"}>@ M%Z4;@HLN,"_E.*IL KE;_N)E=375W3I(=M4IWKE^!W[\KU?+6=HP_O?NEMS) MEW?46_U3TI#EQO0FZ7)OL0D>Z\IL\@"EYI5J6M+6[/-M U4#"Y$OIC>G5EENL<*C36V- >H&ZE*V5OU;5=;44<_3]M(QO9G6V/^V3N7[> M-YK5^G7KW%3$(TDK9;,:OE;)Z966++Z6MO]%824;_%H'1Z!(7Q9\56.RAI9 MORK+57(#;*&^+]"T) ^YZXWKA!=W4V>+MVI[P\]>VH8)#N2>,.6BWSFEOBK M@_"S@\-W9_VGOXL7#1(CY(OJY_>I>T1E|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‘<+PU0&3.09-?]+ MM;C05'!QX_%D8S%!OGZ@X/5L<0@L.%E5>DOOL)24^\,;!+8?BS)M%Q>43>P MF]HEL16@- #]&XXF5J4H(TP>*4B>L1!MM*N(L0!BZV#T+.^1^{%B4]OK<$5*H@Q=$XC<Q&T,U"[UK+QX\4/#Y0!'XNWKN+-]{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}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}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|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|=KUPF?@WD&:([" M"# $W+$^0Q1F)Z$>5Y176!!=QJ@J<<*;(::R)Z4CI,2.Q[%G9Q!O(*F4R:OLQ M/54.8"ZY$S+TQ M\=++(*T9]++J1@GVE!E2^!7TURQ^9SRAQ,8O1"Q(/G!=2D MH32_2*"B))&]0X6QOW8Z3E?4:64,:"H);O%R/QPXH2:)X$2?=<;=8@$-_M$GA>8ZE1T$;_N%-?] (1/:O,%UKVTL0_(P=('S504Z!44",55^U9;W-$7[M2>FD,M-2,9P:N\I$3X+LZGH93&*.FF5"WH3>..3N&B9JO|8)Q*920LK!0K*4[+6ZBA^0> M8>3P?G#N/@TV\/ <+K"+'L#9$9#$*TD=77Y2A\;ES-)$G>D*5GCR20]7)4T"N^LX7N0?B1.T.M:%^,$NR_ F]-MZKJ[V|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

*MA)2T2[7K)L;ABN'|X8#HB!F:1P=P8;G4(5QY'"|_6YTGAWSIZVYQLTG'V|]A-M4">HKHN,X!9*UGL]K@_1VLFSN&S&49#1FWL#7Z'OV^17T?6&=9"\L(§?+>W-<5MH7)W^\M!]N^_/LGU1O*JFW8 M>K;D:F21)[K2YT]:G3N>7,<($-$_QRQR*-QY@E00K^Z|)1?2L@H%LQ[WK6 O37N|X^A!PH5/&N\P/8?>]Z^R!RXU'-MNUX&9J^\Z_JAR#"DEG==+UBE>=?;![#"23>442XYWG;()G@%O=;1FI;RNRHHK M"PE;NT<;6E§!5;G*):?DXL&T(^QX N_S5*HX;NH!<";MCJ,4E51J^)[JN14", MM]B"@YI=0Q?(ZXWK"C)*"MFK;0EWU3=N^:"W/D<'<2YZ'-OKS5LTH\;]QKWPW.Y&9HVF1VGR>GL=/§,LCF!l.ETEQBL^T60:HD:+'2>,;,D57/E0;_>?H/_H M>E[FRE2;Z9^%YX#P_#^+#F!Z3-P0:B0=@]_N71+[2?'NX_7?'".TO 5G3>5%===M- N!\FCW)RJFC]=0 MK\&[!_+L);NML31R#Z(HI36!=1*J!1X4 6DE.NI:QU[YAD6M;PN^%?= MIV$'>-UUCS4Z<|>;P(\]5,=3Y,VNN '&O*'PB[I04-+(D@X) M6EF82(^H:W\4<^_6#GD5F]P!'T)LPY/K'X4FSW^UN287\AX^4 #\>*KJ,\YKF MO,*HU*MPFKR7I<§+!HWJR@@UK?OQ+5X5-L0=%#4HA(*G/-KM//] (0V&40^J+@^23T1\{§!$<>2A\2,S8P7- MP(cS14WW+?.RKM2/Z&*!>)'/,BIUX2.41DJ[%KGW\-<*K%<[TR5NM 9.E'- M>2>U3JFETZQ[E224)S>>WWMCN#L*I8SZY3O*O>?@-KI"]RUNM&^B7Z/]8!UA1 M,*408GXN7+0F^?EN\ +1G'X 9)) Y1>(IVS+|<*YZKO&GS\M&FRYN*]C*U"0!=TT9F:=!4MK6C8E*22&= M@PP=*KWL/E+M'SX*)A?W X_RM]T.,0ZB1O5W]!ZKH<312RO^1_-Y%8\N$[< MM@5%LXR^;/VA,99B"QROO!)U.?1,P>4W]7"F(U<..DO"GN$NX^*:?MBS .2" MGR%FCPA0]^*;EL SH"N%GB%DEV&7>J5 -/] %+#VW> "TZ& 6[3M ^Y-RXE4/> M4].NV#VI'P6${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|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|_Q5]#H4S_W$\4SA:6L6N M- JFZ+:9JI=^I H%*1'Z* (W(&$Y T MR$F(B.8(A$ %(9<3Q$(&9#=]J#YD%F28Y?T./$01!.>_/U3?=W[_^C45//&G M]2J_M@^B(1,_MHT-S=(?6BZ?RY\KT37BUCB*$K^BQR)DR*ZY9 >6[X8/OXA; M>T#ZJ=B+7]N'_VO:V@^R6QZQS[-6HU64D%IH!HEN<+EO3PEJA:Y3\R_9G MF5^,:A|NFVLI\X .7K(;D&;!\8.(L[!\5[\"]J>V:@@_%_#O".@.B:1PALUP\<MN7#0B04% !0H_)=N,98Q"6>S.>]f_G+OPRP/*M=5+?,6(O9'MFKM@^J{!=ERN\,$A99Z=QK'8TO\B$Q72=U(KSE&FGNX(ANM"SD MTPQ(H1M 9L<$K39] MD!{/3/D"3Z!\|&L\ 4!.[_A!S.[+I? 9M)ECG>6/E"68<+0;._;;LDU3\R.+ M[Y&63,'^X-0 IP@->#]2&D13-1XZ;R-6%G!@:;'.A.,9JF6Y9Q4?=B(FWIPG# M>0*+B"+XK*H%U=% <1W2${1OS:K\]3(O=MQ+E,:6L.U@)/HY1GE6:Y(%=@?D! M49XJN,#GZ:66:W041>?8SK!;IC-D8-TWR8=&4B:*1A0YQ#B&%FVQ?]VI+/Q MFYG C]0NFLT/Z,)!!W'T4=KE #.FEP5"ZQ$F^>-O#$]C1 Y%T?_\.B3P9@2? M(;]++**YY7@#D V*S=MMHJUQSSE68DJ8S_:$E^PHD%BMD\M@)8MO0T7$UZ6#4 MI<"-K1&/\=A&4'U[3VI-<287L>92@+X#M^A4YF(Y.U!VHX8V_C<-L>;'/:]H M7F3?_#9\=O["/'NX5" M6?,DP1@#P:4MN03!^3#D3E[OBEJF.44%"N&73; RHX9S<;...PF>BP4:O^(RQ=@/!A=;3"#?VZ\ .B"N1+ 8U+.:I 1ENV@L*'MS0VZ/_Z.G(W/&&I_\GJU]*LC@VWC3(17F0'+#7MAN4D502'0/DLHP7G(MN% M@XS[BJ8$0&W"4]6#V>U9@:AR 9=H]$&E2UA;M'15SKT.$KTQX^:A=Z$40P\ M&&=XAU.83-,CI :T'IVI4GXV=)MC4?\.8%5@6$KD M5R,HA<^ .OMP(VFVY6D"M'"%?N;-#-U!V\NN!BN=!0KCLN*"@MV'VM4FV1+9 M? 6&H+WB9)6VAR2"."%+9^YGQAX05CZ!DTJZ1;DX+#(P'T8U.>IEC07?QQG-C< M446+79LWOV?Z"1*E5L2U/)^-1/U#VW4_\]P=)"ZX%?0P/SBFQ]UG2C.!_XGW. M/%OKD,AT@09U79M./:DZKT(&H#_Q[(5>]!7I)_;I)_@AH0QSS5EY@3;LEJ^3 M C,4\]UWTV_2U=D@CDK@HSH+V0^B?[+P/Y.^@OCE=_,T!PAGWD__>N@MFC5 M/'Y*#^6%?;=5]),2'1EOEOIG)<>0Z I*B237,!X#))P!2!RTRW MQ)\.O VF-6U2E2:F\!U%_.\VI/-*:,%B5PN\S&:|HOMP'594NJQ0GLZ:.> MMD%),:{'#-*32$&P#)8I%9I? @B5O-0W798E#DJ-A0:=H=,Y08V&&EM0&$K$$ MQ]/Y[.>PY&)K<5V68$MZWI FI#'D+BH<5ZZ4LE^G$21PBDEXU0#]L&,(ED|.,CT/-"<**(IA/W0 N=(\/DHQ*P=^"HK M1)RR)!C$Y91@:%,;FG(A'GP+1'+A1RV]-@52KH&:K(6NFPUCD@Z4ITQI0A<: M@$/61-0STRBK&LGB4-E)=5FF6GU4,_@CMNOCHWJI +VA#I%MO9D'V.4\&$#2 M]0"*K@B]5\U3*=N :-0$2K &6=ARP,7JW2I8]TZI@)B9O:RO0OI1R8M]D6 M&];% 3WOD(#+L!S.JQ$\'/3.9#F/=?G>Y$'\%M,8?6H)*T,S"TMEW!HU[8E M2"J,D=QPO]VV/T5%5DPO.QQSP $&MAZ:$BT\R[_^#;.]/.:&K3PV@!:0Z= M.BZH>7JH9M;AJ-K@LY5(2S+CZ_(&JNK;>!.CAX*MH+8/:5?W'$$"T2("Z]N1 M'6#CS]N.A6 ^TRS1:'%#1R?RZ*R[]JV>V94+ 122*Y)]ALVJ/K0(T&L[M-;K M1 #"7N+1>Y9>+O"E(L9"%L]Y#/N=I'|D6=]X/E>"\@:.5#H@UZR.]GN)AGG M]57!*ORX%AA% 5#2!!R[IE8B^*#]H=9HF3HI];GVWVF.NRIA_Y(9L?22$V_M:U94FN"\MC\VP9^E*G5%7H6A^1(@=LA.>;TO#HN*3XQ-MRZRAXX+C-^/G6T*=&S'6&RYF);P6]+AL/^^W.RT@^HIR%<9.T$[1Y+!VH+-. MHT?Q)3=7*4#W)UZL^T"@'O>/;\3/RESF<@PAKCAVSF&+CE]1N/7R*OQLYJ0L MP51%D0ZFA!B*-17B*/*PT7A%\.-5_UR.[LU5T<.=KX90]6:1*^31H,2]DC[J M+?KL=52Z79PL;2:WEG66G5'3 %*(KR'R/AAX%UK(XVRR:XW9FFB;&#KOK"|*ABP75CJVX[Z M"BP9R'V!9GE|%&\"DE=#;@[%SEM9^DQ6ZKC*,IZ+M9&JZ"!7H>_B(;PABH M8M&@UY3R71+M-DAHN?!"HE7R8A82.8)G2VZ-*6GT[A=@::4)>YUI4B6[&C5" M[3*:711[-H=IYF.$94&QM^1<95F-%)D5Q/Z<^7)4=75KR=[QA\].W#C3W$MYN^M M#&(R7H'Q3JOCE=)LM@8$$JPXAI+F>"8 MHLBJ58BP[4A O(BW^Z3)T>6/OX^45&WZ^L^OHZ_X>S>YAV'\,D:V$SMZ M#Z/V!=>/BD7B4@ $S2'H XV/SQ[X)^\U+2 $^OB*S9/=Y]U+?AU X!Q$/)D MWHL(4"=]HT">CCEA8?/C {J6(]K? B#@3$<3YB""NA8B7\]GG0:`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|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|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`=$(]*DVG&DDE]0 M$^>N)!X;GQ2]/ZSVXK'GVM1\38DA0PG>GM]:LI2%X I=^\K+CQYMA;_I:8!`MN7E!'Z;K>5'5_4993]RD$3F/SREfV*QZE+0;K=[BUUVLQWD_[KT*$/P/#*N M26@*2R_8$<-/@- X;CA!/UG'.J&>&/3/.RXG3W9/B>XfVF\D/Q1$\?RWY$5OM M0T_+3W"!O&*?.5^;"CQL&@#M)*C,@U-G:/52N*FY=/B.T!.C;2'(BAQ1>W; M2F^,*KA4>CC2G90L@? 90W,BDQ6*\"H:3^[*=`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`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|M1]> *C,+!BEX(3=EV7Y768[K1+$9!C)B, MD5GKJ^/E[/<]9?J>/7H/UQ-2C'/M,BQT,SW^85GNK468-\;]N.H6))|E/L;]Z=Q3YR_$$G<;B$2OT,!8U1SR.+7"'Y+*]3WAC)KI!) M'DON9I9OU)I&/?[Y)==8;]_T$GZX,NHWO[$M.;I&-8GHF#IS'0*X_W4%TK MS;4\6S9E="C4.,7.A^:TEKC\07)0O7G;*URI%6]QOK-GEHINFMR@82N*9G[!D MI@D_09Y:"FEMKD/;PBX[:O0<5@0&*F3&7I^QLW2[G3AC^LI-,R\0=TL/-1D; M!=XK?9-#^SI624NHN51(E%=)/V@;!MTF_C;-BNYNK3/6YF!VU MW#J[*$B)2^TE3/H)W"#X- NGW@G06U#'709E2WVQ@++;,)+.0)%G2_Z1+08[<-M++7;KM]_VX+)AG](S$Y#ES6$Z/fK^;K4#BIOV'R.48I9^^5'.5DZT2M.+3 M#<(C5G?@BY@-2")CC-V\HDS#-|K/L\A>;" (<_U3:LJ"Y@X$(P#%\.'/*A2> MX$JJV 0+8!R@ZZ%-S7("WXL;X-=;<-=;6+/CAUB?!MA(55:F6->&B?-=:5 T-X MCW>/P#G!O"^S_'Y#<_K\H.!D@1? SRZ[3112#"_*#,>&)2RH?)#9S_PW>D^"|-MVA&)9V1X7K[|N R?R//6T"&Q%E1^>O/O:KAET,$Q)LPU9"TO.$,,ZF.2[P MX[Z>W(,\$4L3=9+F$:Y2#1&1+%$U- 9DAXXE[D$]OZNWX?"2.9O'?UK6ZL1 M[2S'Q6(X[AFH.5YH-M60)VPI<9'0-Z(3EXE["Z+?=#_]^5C.^;TRP[F0.9#J\ M;%H"4]ESVHESB9-J1_FT5%$#@EGF=WVVC4K- M7EY7^.3YF1OD)^K00&0ZBXABNLVV\'B>WZ^"\OVJ6LZ104F>9MJ0Qf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}XW!8[$79[A<9CE-*^F6,*&GO6(B M%T42="?],!OTE/7[=PZ\R/0[B-0_Y!3$O2Y;0/`"-^9IV8U/CI3"X_WMM8P2 MXH'K:I;RI.-'>#RSI:W @DQW!*-H6_+#84A!D%6F-=GC&F&)3(5F7) 8DUH MHHZE.T.&1T9R0HCO'!)SZ3^.XC)X_V'-Q#Y1(^/9C1(\-?HO,N,+&&U``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|OHOQF&^ 0ESC^6A:CRP4GO#XOIV1 MNG]$&7X[%-F9'N)E.'VB.]W D%>=CHM)IRL=Y/38,W69\UJ M:?T+C3EE#\]E.1DAN/?L9-&^!8?$63OP55:PRJY@29HGV91@:%/_MM31A7_.CEEZ_BG70$W60M?-AC%)!XFMBCE?]N>1_^510-FN8\,9"%2!{\# M:*J Z^W+GUP4A8);L$1;Z/$,=:)[" QQOOQ?(_S+2Y%XC%CX^-Q#Y1(^/9C1(\-?HO,N,+&&U``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|OHOQF&^ 0ESC^6A:CRP4GO#XOIV1 MNG]$&7X[%-F9'N)E.'VB.]W D%>=CHM)IRL=Y/38,W69\UJ M:?T+C3EE#\]E.1DAN/?L9-&^!8?$63OP55:PRJY@29HGV91@:%/_MM31A7_.CEEZ_BG70$W60M?-AC%)!XFMBCE?]N>1_^510-FN8\,9"%2![\# M:*J Z^W+GUP4A8);L$1;Z/$,=:)[" "QOOOQ?(_S+2Y%XC%CX^-Q#Y1(^/9C1(\-?HO,N,+&&U``IXE MI\'!;5Y-\(\$?/MEW5IJZ5]M-%;TR7B.K42!BCO6EE13[PVD\1+07F-O/ MG?94J2;-<1]#T# K]GV4GA6RRR3L9X,Y_,5GFL1-"UFT/X!+)&-Q@:-*A.Z1<]CTPWPEF_=A=V_$]R[^\'YI)"9JXPH,@HAZ%=#S@=RM*HLP@PZ^'@)D*5PC9? MH]F*C6.\4UR,E'M0K"1C^<^8=SXWK*I.%G*9UT&=QD.<[*!2&\'">_#>]@&X M7SG229Q? T"F0^W*_%5LF:L52*:!;/?Y*B:/!JV M:9/)#+_T,L$=9K_^-*#?/-CM&C.GWN8M!YTS:VU- 9=/5!7L/EOQ/BE#O^.C7 M024M+E?3L#IMHH%-UL+V8%PK]K^]Y*0 X>B)>M@6%H_KI*3G 9^4H"?C:5'S M1UET?HXT19DTHW2S8"=V^CU&Y];= M>X70:PKZ'>>[8=<]U(;8.I2&>&8L7D9%S>]XM@0\J X>B$QZ*;+7MA.Q8/\'MB@OVMVU]HEM*H50X.QRR^%5:MW%'T\$R|OHOQF&^ 0ESC^6A:CRP4GO#XOIV1 MNG]$&7X[%-F9'N)E.'VB.]W D%>=CHM)IRL=Y/38,W69\UJ M:?T+C3EE#\]E.1DAN/?L9-&^!8?$63OP55:PRJY@29HGV91@:%/_MM31A7_.CEEZ_BG70$W60M?-AC%)!XFMBCE?]N>1_^510-FN8\,9"%2!{\# M:*J Z^W+GUP4A8);L$1;Z/$,=:)[" QQ

*{=VL%ET\W37!89&P;F5N:PR0,]_AU-M[XQZLF2B(''!F*F&]/8 KYJRX]7(C[_%H"V8.ZE3%JA;8*:)6TGAFF-J>2I-MB>^B%6\%[$$/R?>IQ'GI\<;)=Y'':3:8)V&V;W[@R["0#P3,'MIVNC M'AV4Q[6G&>8;_:|P&WO"GMK) &_-FTK/O!C*WEUNLIH,AC0U0(/5? 0_M=M;-#NX]!_;,S.^(X7Q$X'-^-3"+U1]'CZHEG&#"H#CY1D3R(X,"CSTYP_OJ MEWR)8[HH]'6!GDZUC.ZPVE*K_#]Q%62B+_EZ>1(W]H$G>5^'TG]H/K\8&\2, M!M55:%:R/55#$FL/$K*>GH1Y(7-P]5_FQ%DK&Y]R\T79=H$D>#N-Q_@Z %;P M*,$U:,_Q-@0V$*,[$@ }Y\MU]16#70IQY"Z;]*AE<-$=^B3B;.F)\YKV3BD MQ-CV(K#.!O(%=X^=8?S&>G7*S1US/MPSU[]D\#6X7RS@K%K%TVF1A8E@"9WIV(L9;]#\$US%#4C!LZ>H[?M%!}T0(PS-#'PIN3?"W"&>DA;_W!A/7;LAFA@GD)S!MR5TR*"O$)).X>>Y>\91__C&>"IE[!CK(P6=-#G;,3]JR9%[ ]4HX(H[*M<7YO>\GT">UV#;TW5U?$PW0MGW@=81P;RM#5[4GS= [,T_2@-6ID<*LJ3Y}B\PQ0O>/-MA3Y!Z361<-.3X=-{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lV9BO.)++(K MJ^Z5E,G_B!HSKK4 &Z6*?K!{Q>|!{G/TCE? >Y\VG/D^K]4JVC4PU?<@,RKVZ MFB'RLO+L?8'O_H[:O^-UCKU91N3GDS0Q; ^# D\515"G'-MEO@1F:Z2NI%>G<2SW&_[D/4B"[?DE)J?;$Y9W:,SK MB@$PZ 8E/F?L5A_AG^]X88E? -T2"%VS-HR%Q2+FJ -HI6&!#$G MMR*<+RR\8 P]@V:5=&M2<'@D,]+-

*M*AWW(G6WM{3;-54'T.4,_;=4T(DlNRN"W3*KNY?/<]&?0CV_H8(T><5Q>*CB-M/E1/!GI=$7CTSG?TB"N2PL-WML.'H?.L1X|(X]$[V]'#'T'G.PT=<,3P>O6\>_MO7!CZ-DMP;>MZF(E*OY#HO}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fN[+N"S+\N%^E@?`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|\OE"93RUD!T *6Z@-],Y/ZF9)XG=M6?)C,.69J M72CS2TT1,UQ3(.-2)D*28$^8_CEN*AX3XX\A6Q08+R?OPW#B=I_@>X%@H@.)-MAR +DB%G;()LM%-B>H2 Q4X89,\BT^D80)OWVG<'$G=N(YINBR.8

X?;ODU^=S^7*G5+[NROZ8;1/>!:-(SU-U*T@-N>ERQ[#E37-M"\;<.BX6*V;A3:?D#*P7WARYX"-MO?!(6>^!8!%.P 9]8&]4"1S<]3T@68H9/24*[#I5 M$L-!)O:>YN8\U<>I?HWFI?S"#TC'?/N9P^YPFKRAW(=;D^)K)4/<&AEA=@3D M&WA)@.D2\)*0*KZY3C;%K1C@$RlOJ4ZON((F7]77G?QP+HTUJM:IJT:-1%1! M"9=+OT.5O]5T#-ZT03#_/9 SBJB:F8"1Q(VIHZN),!TBPG1DG(&/& 9)G!]0% M,#LC@8Z0))#R9GTC*?3$PK")M*AH,.8)9@E X4TIB\%4 9@J (4WI2P&4P5@ MJD"[_*SO|EU2&$_JY35HMC1\.LE[\ZU;M_H?}IF^]+9?AH.*8>,99U-PWC;]#8"U@XXSE0>ITCG0?!],"W\)TPT34[D=M)8F7->1U\WF>9[0X[AUU-M/LDRQ.>X6"V*|S+4-B"Z'JWZHN-\O<2XWD2/3 FY&#'Q=(#K;89 MQ)5.?,O-/J3?/"&\3@)4ZF.]Z'K\=77(//1\P//%%XKO9[A{HA>Q/<#Q1>* M[VL;Y&ZSJ'S'OF!)7M;K"Z ML.D[@=UE&?P3.[Y#B3V+H^:F<#$1=#UZ;2 27M.'\VX0;Z"C*4HNADUT1#?7M;K;M3/&F'X(8_1X0N]7LGKRH1]W112?LM]({*S *]. P0[AS,ZTF> M,R<)1+Q=_T[<'.\4[(D]&7+F^D@]6A_B;8LK",TYV?LP]+7C'6S@2WF?+N+ M%A?&9C0HNA_7"@[G7^2-F'1%"AL,0$L M;=1).)2!FUFUP$7!$-CU,HASFZTZDJWZ*XC(]0)0O"SP^`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|=E!N!.3LF M&1Z8=]HI3/<8RO<%,$2H[21<3OH>3[<_NF2FZG3@Y?;"\0L'/PTWK5W+1+F_%X]M.0"SKL*:fLK41^,"M)N|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}ZO M]MNZQ8W40<&VK;H^PL)V8*%++X#MUWI6(C>>YT8$\;V*=)!.[ZO4GA# "M>- MX? _^&@(D6;IEAYU%HXBT1++#)6T7%(=4^4LP[(<)UYFO5656!UUU=:G{(SFRR M[%\UF]J7/!;1,07EW&K!4-0]!%ZM@*Q@0QY#5@VNSZVXX3)'-8RH22@3: 7H M'4'17U0M2*!\OE7P&U+M(X6V$X)]YU09KIVZ\2[C?-+Y)@4J>0*I]E9QYAN4 MML0?98E@C#&.VE/-8PQ=14>0WG?J5>.Z/5> M'S6&QH@eKK'*S,YV-YV.1#*3?FT_RIN\]TE,+WM&3!G8&7W3D4ZL]RJYG3#9W[%5FRJ%&5F]M0<6>@o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Đ/>,]:N@@Q&F MD< T$A@4D1+V26=P4B)(E]X\Af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s4[M:/-&T?^^C%@R0!XN#DO:'ZP0Z;>[Z6 M__-X,,^8"CDFBAI-RX]6>7PS'EF.%8#,,"!JB#@/WOM#U'UQYIS'D3*__9(JA./ZS^\\.L?_W'UI.%([TMPP:ZZ*H;$#[!R7,?F!O'OH?)'$;PZW%A)/8]E[W4UOWBXFB/B%\;]1\QL[!# M2_>_!NW"20Z/!-@,+=KZ$RX_?O3MYR"T+(<).X70<&ZZS@,[BX]9^E5FCFB- M!'2-Y5G\^O#D]L5H?_A2$G7IWE\.A? QOF[\&R]/QL/FAA^|\/BS M[=.9#,G_F3V9R&,_^O:S)0:/$.\R55/Z_I]_9LDR@;\Z|*@20P:[+K%*@<V<(<]E@(,;_"^UI"]K,;+-93M'),5\/A{UN[/9:!!9OI^A=PJ8.OK*CH>3SH1Z[Z;O&: 'X>FLY!A({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|[%;\S1G>(1+)-<;)==]*A,9X>H#X8$[-:02N3HJ7N M?*>\]YUB!CB]?6"[%MD!T1ZC8F"^HFI9M^EHW&!F#'K6FLR(Z+&0UK[01M1:] MR11@2C R1]A=8Y3%L)%NH0#51RU_GV_P=3\8&5]:B;&;99O,R^BHF[4UO5C9 M.F(XT?CR6UE--Y8!0_$41H_%K$ORAU%8.)K&M7'N&L/.4U;;]9Y3I!KC%X- M6]3'UY2E:H'N7Q"X=AMEU(V!EU>,'XR,K2D7D)"8D?:$;P_0:G\MY:E%C3VT MO7\ZDP[9$?SO/$DD8BPF,*N^>)VBE[GEUQK;8;1/>B) M->7]{T\[;#@TQO]FJ]7NR18@..KF"MRN103G=30T#NKY/&_8 MA6Z>T';2N"BM9]-9;7,H%!1#]:6E;[N^-2UH?>\VBE[GEUQK;8;1/>B) M->7]{T\[;#@TQO]FJ]7NR18@..KF"MRN103G=30T#NKY/&_8 MA6Z>T';2N"BM9]-9;7,H%!1#]:6E;[N^-2UT<-%^)N=BW8\9E@(;.R@\]YSI<-%^)DFED965'4U$L MM>N*M:]ZAZRVUGU>VS:OC0^/+9Y5@MFU/4X;YQY.)EHUVK"-9V/)+TG3@ M]'35XCT!R_M%R^_]2U;(QH)^CS527Z 5#<49TM*Y-H6HK7 D]7RDV>DLQQVI M:.(,>T_5!L30&>>[P<@P3//I4$&O[B9K<371D)%(6,2L41_WPX=B,;+.NKVD MFYZ":-5](+ FT7>6\ZY Q6>Z5L:]\7PW%SG Z;7&--M8RS\L_&!E;Z6A-?:#D;&9UON@9A>HR1[%M;Z31)0,,K0W#DXLK AD;.\Y59.#*^IF%_PEBY;6?(4[H_ M$1&[4^H);#@TMB;7V"|[%;\S1G>(1+)-<;)==]*A,9X>H#X8$[-:02N3HJ7N M?*>\]YUB!CB]?6"[%MD!T1ZC8F"^HFI9M^EHW&!F#'K6FLR(Z+&0UK[01M1:] MR11@2C R1]A=8Y3%L)%NH0#51RU_GV_P=3\8&5]:B;&;99O,R^BHF[4UO5C9 M.F(XT?CR6UE--Y8!0_$41H_%K$ORAU%8.)K&M7'N&L/.4U;;]9Y3I!KC%X- M6]3'UY2E:H'N7Q"X=AMEU(V!EU>,'XR,K2D7D)"8D?:$;P_0:G\MY:E%C3VT MO7\ZDP[9$?SO/$DD8BPF,*N^>)VBE[GEUQK;8;1/>B) M->7]{T\[;#@TQO]FJ]7NR18@..KF"MRN103G=30T#NKY/&_8 MA6Z>T';2N"BM9]-9;7,H%!1#]:6E;[N^-2UH?>\VBE[GEUQK;8;1/>B) M->7]{T\[;#@TQO]FJ]7NR18@..KF"MRN103G=30T#NKY/&_8 MA6Z>T';2N"BM9]-9;7,H%!1#]:6E;[N^-2UT8%E=Z@;9[GWL!@%>-X^RBS>7XFRS;B\X{S,GC%T_:D>85Z8]Y:C MXJT_S^-_N8G$MT3@';R8?BA=+?7421C>O>]9S6RL#5"YLS3D.KRSXT4I1.F3^ MXQG!OP=NW?S28ZF""$?69" M8.IE^#SWU1=2_-)&G8O?5PD FL!|;3.?IN!);K4?>XG_V$^X;O[]>LN-8]^O6=F)7_W57+T;R)"D),NS+!!(*8<*MY!P7!0;/T@+(,O,U*;Z-2'BSRKG35=<7 ML- 7]W2D25:Q0G\R*J,@C^LU9&F/Y2XKX/&1P_%TP3IRH8OBB+E>=|\>T"|" MD;&W(P/<'G=6)8=K.ZM1$Q66=;S2#49BV/.A^=&]J/7'0X_#\0*A2HU=!7>B MH>3SH6"VZ7&L-ARA=9]O2;TUBIJS\/U8[OE0RBUTC3(H;/B"V50,9E^F*5D1 MB/BB"&NA.ZX^PGG#XF;C%F'K0.P&{(//1S($55CN!I:E@:%='.YS%34_\H.1 ML>6O6[0X)%E5:T1RRQ6M+H"*: Q0C'=MO,EGBP3"Z(RMATC8-8EB@Y&QY==XCK;7^&K.X4K'|%+%AI^CPF?&EN]+%]/5 M)DQ!PVM62^^B8U?BPY'QY7<)9S6L?D]QX1#8\LOY5$IVU!3M%"^J^WZUM&B5RDXT-+;\L=W?N,/4X7AO.;,K6DD QL07LO'EKT,T8H!AHRPW M:@,C1\VR1:$5CJ1B)&7!CJB-FF7-R*^5 M[*#[;!3+.1!>!TI(&_DVIX2QX M<=+<+1I>?;$FN^'0&%$'(W%/=W:HSB.DX [G>[[;VOL"%9^I(>R0#=&;8#R. MKMJBVYC-5* $(V,S-==@J*UK;%FC!E9UN++Z!,\9CHS/M#OH%_J#@>!P.US-MK9:\,JOKT=#83,F^]OM|C6$"FFY585GF6'F7A$V7/'NLF/

ZX,S1G^"E<>/OOT0U&PFT!),!G]1,D(DG,R&\'0ESE-/C/ ML,E,'Y]RWWZV F"WQ;M,U90":)\=]NJPL(+H+$]ZY3L"13(81225V#86'XZOP M^/AZN!%&P5WA:C+1C@!X',RCE!!-F<0 3_4A*IF432LR/KB??Z.3G;*B+HMCSBP'Z_ M\3UG1?5)/XRY?#Y2&"!BQYFM6F@AWZIMJ $U=K>^@;=*SA9SAA]J/HF6&49B M%Z5!>]WL"D1\[.V)A-*

*CL2#AJC/O;,A_,LT>RPM6.H5BH\+M;N6B(58+2T!1A*R /A^YL15F9@&VPN\LO\KC M^8+NUWV!BH^L[/9SHR|GRUQ98ITJ/NNUF&(W&!E[^W"\^"H*RJE2T\K@ZX5?X M>]S,V6:D;$5|QEOOG79SKN&"4#1JK-@V^[Z0B[!]Y?#4FJ? @C>]4U~&6EFM MOV8%.C[2&/NRTVN9"&<,A+KNST&K,%"""*U!L9#:KFJHQTO.Y>X5/7;-MYD1.11=;0=)W6HJ G]A8HF%ELTMS7N"0=HFCVLXVQ_(!3)S8V 6WD)?//1,XL;$RVZCA P0A.7&/3Q:YJ4<(9O#4$[NUFJ%5VU=5'BV M1JOJ6_-F)>!L_,1N-?-Z;UR<S-E7V18D/;1IP'MO/V>FU4> V95Z8Y M7L]6*T,E"!I[;F7 ,!L5]EMT'@P] M(;$8E3/;GAX,H&8U=$R4]CTL*Z(& ^"P"EBU"U]^@YO@V55UV*I5FA205@3S! TUQM\?H2FFB%;(RR-5I][E V'!H#."[MK>F.4/4IAR([=51)KI>"S"+/,$#Z+"9VPR$"J-13HZ7W:[#]T9=@3RQL5O6 M-?N:3?@HTA/9L9$^:]U)<&"?V"TR8*I185EC GVAT*E+##G;%(-EG=B"TA"H M6D77& YPG7G9Z!5U=M@-*

*A\9.XC):6R\HS1.Y\W5#/RKN14*UGHZ&QH]@M=#I* MH^'/,$.D^K;8$O+_8$P&<-H1WH0<'0V%Q;K#/5BUR6 MT=K:U-/-*

C9[0@\LE/%>Z,T"ZB'E#9*R2CF=ALV"]J;ZY@=",HKGW0U-MM6=Q8ZO)6XMEP:[P)6XMMWABLFEJA7I=[MSM9HV^M@Z G65O!%OX#M&07%#69+,\7=UO"ZX=#87'=K 5$0SV_P5&W1D?(5 MD*=H/QP:FZLL.)1A:4@@L67.#R[G- =FT5-C<^W/NQXA2EN!+]=6E4:>TP5V M$E#@A&SA,Q3O<=ZN@H[L;7W;*QA2ONN'0V-S-:;U?(58;!;\R/$:3A/AK6(M M>FH,@1#=-@RBIRC68N(N4 4?SE:1D^-+T*XZX+ JAY/"=]\T:#"U0V9*2VTKDI-,DRX2GK;03\'-;C@T M-@$TKQ;G320G:8C#;!K*K(2P;C#TQ"&_1GQ"UU.l-R&-*

*;GV!&M9&U!BF@P;#HU-.MH.+6C!ZI@[*H$ <5[$B/A\3[V70&2S?S#1'7PSDJ7KXLH!/^Y_>'RY#"U-.MQWME:)V1#N:?[;SN'TE;JTI?NWWM2#S?3%SU.1G"UU.l-,A3]G7HM_?61 MZ>?1XP-.V7/=\N^OJ?>_(Z'CZL?!V.@'-'C3R/?PO3AS+-USP,^CNW"P,M<6 M32=TSOR(@IC,?Y"[Y#@J[\O;?5[^9Z/?0>(]^FIMN4_>LD=&^?CN M?>V=P,*

*]3K[8QAWSM9U!OS.OIOG#K8%" W<&JDO=N.&W MU.@K4H$^%:5SD;B^MQ35*Q/E-VD0W."'#__%4>Z42^NQ>[N!A MF6;P^<+)*

*<*8,Y,R#>Q6*'123SQ23*]9(.KL8O50@!PI3ZH3I)&\\HR#LDW7__$V%7B;3N4E:=*FGHA*/D8E?OOYEVH>D,F=6)XCFK+S MJW_^4?]4,;EL;MS;4\UO!%5!3Y3;>\GI6HT<<3Q#NV-*

*5?= -MMTJ*3QN; =X6G+%&&7MN.ZKK6&44YI;$U6()ZH[":]Q@Q9L[.MF.FX#3X^HT MN)#PON7]O4GA_=R6 .\37LZ8YM!>]PIM15*$_WVQ.32Y,C*"'F-VS= -(P3V: ME9>>XQ[20UTK8X-@TR15!QGSJ#&>GX8,2V'BZ,IV-FKH-YSM,G\V3E0IX>.^,M=>*Z_0/>M>%EXK+'P37NVK]9Q"WV\^"%;!L:U& MZE4FA,LRHF$%$]Y"\ +/[PW)=Y:D,&_DT[*)IV[F-QE30>/!3+X60?A#ZPI MLX_D\E0!S+)*HGNZ1/" &E7V!)RXPW(?]F=^]5MT&B0"TB"! M9HB+H\+GVB0^B H38*

YE9=2;\NNE+^\YJFC6-MT %<+^+;D[C(X7 ,XQ$P6W M71W*6]DFLK(M"3A.Q@8.$&U1$>DL,M@ W5]%1@QH=8!6A]NW.OPYDKZ_OSR\ M-D.RI-R:\$45#].UQ1_WAV?5[!R.SM[QY PTC^*O<_-4Y[AEB6\,]_9:U=G M?0>0LC%&PW)T5%B-G\HQYI8[KNL'>;2%A74R-UW-4#W#.1A4),D&#]]X 25$ M\V1DU9$"%@K:I;[:K(!!S]<0&29QIC#-I-O?$D :$"C31J--ND-\8B L7,0 M\,=R'T+B4:,9>XEOFI4'R>X_"/9K7N4-66+E!NC;?-UIY\L,Y 5FPU+,A+?.M?E($ >-:H!4'6G%2J4S]*68\AXJNB3QR0!9B--&[+(I_GH\+R@HD"[11)4NM^FT(MP?R5/>|-)*

(GO:X1IKTV :DTVA)!092+Q.R)W=H?8=3-W+!.)8F!U$[=P,&> M!RU+T+)TLY;E&U,/'K+1&Z$$%RSGE+5=;.Q;"R_7#-8PDLEZ;B;4=MUNV%(E MS"3"[C#JM;L@M)E &D" [49(5G'>!P^2%8$ MBF&W:A!Z4'>,BDZ4D10L8Y=2BU "9!|:DF[7D1I2R\UP@|;&P'$,A>D=1/%K, M1F/L5C1:9#A$;|_: Q\T5J&EG C5(M/ K5-

*$UH'H%6(V@U>G<@8/HL),]#=V0P M2S:[7DQ$.Q[9_O1%7[" M56#+6$?TI:6!&O+*7LV%.2HK2M@;-E 5&.:U&Q0T(4 :0#-*DLTH'P&$\D(0 N5YRV!9K7E/5]ME6N%X9^" A4 C4S>=/E2P[^,K,@*VT$$T%9,2'FB_0[*- M*M"HVV'X"0A@Q$@]T(410(ERE$&A+[^KI69 MY7 M=0L)U#419T\+BJS,E3NWJQW4]F4.]*9W>QTG"L:JURJ7:7=2N<|5)=8'.:O-7%*

*MN&3L[4\L.\KJB5O3D6OJ.+0]-VY5 0*N<_KE\:L-?"W?CY_>-&:S=BVE].OS MU[<$ DH3:1!<"J6VQ"ZBEPQ$0PB=]1A;S]O8P(S45VFILU%(2$^5FM21:EK M"<8$0+DIO+MN: M_>JZ3^N:9&\)0)6P_U_77%|\4AQ@T5QFNL^)8V;M#-M.*X6F$<9DO2$T)>,H2)7#V1'??PKEIODCVRG8%O,JV2$3%-,N31Y)(V;"'%EBBE M(]2@=U+K&, M1F/L5C1:9#A$;|_: Q\T5J&EG C5(M/ K5-*

OLA(,+TW5LRN M\Y$OXUS"F1?.OF8W?*4UZ0|G8Y$_Z;,5H)]J/]2D!NBB#8970E)}AM8V*-T M-2EIC5NEUQDTGX,19GS:ZX$I2+L/I_*QW168D>,D@D'D/#HN_>9-!.&^$6^+ MC[?*

*GRY[X9N^KK?I*R8KA1NZN_QSN#:6QD[RMMU/T2;&R50L M4\A$*4R1R^FSP1*YG#Y')?L%CC*YGA2M^7WO;"H_:-G\V<7=K/D\1HY"74^9 MU$Z&(.J'WH8)'_Z-*

9\2%7DH_"M!_^]/9XA, 4F?'+=#Y$?K5QS=&PZ)MEWLCVI.;< 3%? M92-F1C=JK5;+U6M-*TL>!H-A+GNVZ*=HW^9BNA"YG [Y10QI5|S21T14_%ZB<;A5QE24DZ7I3?Z\-*

\W=/(UW]WTQ?5]&QD3[*C96"JWSI].UG<%[\> MD8)AZG-Y"'K<8"G\Y5CP#UGI.]@6$4'C L5_RJ'L#.RRG*Y?>M%?IUE*#')$O\S>DFR[U4[15=="$5R^], MLCA<+]*

],HE7JE<1DWB%+G4\3.+X/6)OX@M;#;E$LEHWKVM5;7IV2C=MIJ[M>&E3!H%96(5B+)W=.0CY")QB!T_A^@V.P*P1 ;_X.1G1>VEOP[^1& YF!RE*

MJ+WT&W3Z QV$WK%@SPUT9?@/Z]%HK?D[!N\GGK\V=409/X>)0\7.\4O8/OXP(M!A^0]G)LPO+0\B!:CBE-1&S7IX\$FHHMPOZ#+EKBD M]-

W52]+.D4U2FHNR@JTG3G6S(RJD0R3'D)IRE0SL#>[!Z\>KF\:5:%@]N=\: M:58B/7"PNJC{HM2I41RIWLPLE$CT_VKFNZ_'Y=$."13_QRS2=XR=0#TT!)& MIJX%K"/?>D67QO#

(_/[$,SO/SS5P"'7F4Z!E5 ^:HS,#IJ" 0QN+,'5'2AA514;Q=ZL4&U>+Y+/-05I4SH[8\ M,\L-I6 ,:M?M?IKVUDTG\K%,8MT7$=G,W0X2;844;.]+52;BGQ3 MD6_JZRA1V#? 8YA@[?

*FD;]4UWJ&\A82_@57:SN3T.9TL*I'V|QO;$,>.I3P MJZ1-=5.7@Y#*>HD\39\EN/T-'V!#:?6=0/G7P,7$D14Q2R9+WR%WJU? M+,.F2^L?KP)^9TNPTW\B6;R.Y[9X6*H1O^?)RK+?*

IVKHUF2G$\ID]IN@> M+7N)NK!&75@/AKU\2F>QU[&7PJA\V\VH]8N>>%LUQL/S:LG4*'O!G)E,)|;. MIKJ4SHP0(J$/;!?VM1E'E'-S"#DW43^2(\6," 91/Y#]VSLJ.=U*FNB)NVQ MG|>A06/_GHX_G:]$;3,C2STBCZ-.)]B :\=G,89+9)WQ<5>]K><*5,1CV$N/.Y325NZCV M5#D[KLT7R!-RWWY@O6GRO7WG!Z#O[5"_| D19,MR1$VB'I*DJZ]N<3T)]DQ,*

M^@A1#45?$L*_'@9IV HHG:D_I(#X^'''1G^%X_P'SVL_3Q^]&BF>\G M;G.W+Z5^FK9 +<0*N2^3+7$,M!6]Y&0AI-U!8O7MGELV.D_C:KY:K<5G=PKI

MFB|WM39E.3ED.;E\YDME4(15/L,9+($RMX(5M+&M-\(K:MQU4!)MXZB-MF9)4N3QIUC++^..BGTG03B'I;"R3^?)^J+6JF[<&?)2C]"T=0BY*Q#ZCJIOC M\C%M28OW\M1VIL5/!LJ=*

*<:]DV+6[?D6_3IKM\?4ML%3:O#99C*727Z9W]2&D M\D3<)2]Z,2Y]|;>XRTNG4+TKGZ8*B9R5+YGO[\'MW9)R%U38,OE8+ID[(I?1 M 9!0Y#V*,JL.(/[>#.(_W#,B& 0E>*

*))9MRA*V2\?O(\]'E!T39<<<*#0O\7]\VGZ1N/G/&+DC8, M?Q!XL@7 U,$2D4PB6J1*V/^O/4N^@W<$_Z#LXT:T26TT(M*FUM/22|>X?8EK MYO1R;*

*(OG8*0\DN=Q/\ZJ683L7RF&+D_CN)XQ\BHFR8#W=?:?#]+N6S%K8OS M@2RO=4X'&7E28Z]Y2$F4QZ))#*YY"X6&TMS:?P:,Y8N9^?= MOM^]O'N^OSN^GR/E.0TTNQ8MC*

)6D7VEPP%4ML:$-[#,Z0 MC]>Z(E81I?_\!JM(!0OM>M'L9ZI4VEVYJ>OQF28;S=+!L(K\C>GX^ M-@^VSLFN!738\NRR(Q"VI$N!_'S1"[=T.1",9&\&"SZ&=J3-Q?+%XXS.^(

M:/C38?"A/OL_F8;WFVCZR.W>7YAUN;D/V MOK[\KTTUG^Y+. 8?+XCXAB $'"%"!(-/C(M_KHC)K]FF^-TC[.:HQ9M>SM3+ MF=5;EA^&E<;3RZ";;/>SM"EG(?

METO4/@$<<(E@^.XO_@'@$IV124S'+|%#,ZV@4?$<0/#>+H\BY_3A2>1;!*NO6.T9>OS6LC)\N?MPD7WF"%\R;.:RA[KGG8!+HH4V^$$6_7#1NPTW\B6;R.Y[9X6*H1O^?)RK+?*

*MU3(!^S;'@BGYU!XGF7UMHO]T&$0.JJ-6G?9(\&;A>3@S^]+6$RMRJ7*7?*]6 M;BG1@Q*43;U!P^9C,J[6:E>C%A.?K1A%8##D$-]DAMIB(\"<"RSN"Y4|L,?$?*

M&Y.K(^(@Z+HAYJM.4GS]27Y[W\5?V':'$%1^]\(VEMB]0M-M>)^M" .:$@'HI M.D/9IHX4^*FLHO8(!V .%XT.C1/Q:[[0E3@#/ !=8^=O, ^IWDIN'P7M#?M MYX/*,_XOZ>ONH4UN.8|*

*],2;Q!OP?RG/WO_ ?|P620D03^<1D9>DTKNT*W\2_ M/X;RPYB7"A@U'#C%U;AG^!A?#X6EW1%-[^]XW0"]^1O3E'&-B;0@4G$:5P<*

MP7N_B\!"7%K\U/GB2=]=@/C=F\B39K=UDL[^6PC\&\&S!EL5K$!#D?C2MD M9'_G/W,_.QDX^(T!GOV)I>+'VQ9WKTGD1JL_<0@D22Y=+]?EM+Y?B8_2O;%PBC3)U(V1|)B5DPE MI6\,$)\DQ79V/@+:,.HHQ 8SV$Z^S$3_9N6(G<\EL ?I'#\"^:* XL?6>*T@-.M^'2NX//V*M2YT*MX0|\2%'JGGM#K>$+/@\OG|)F_8.XS!TG#46$#TGNXA,/Q*

*MLJ8Y%7G2/D0P_^*&G#EDDL'(S:N4\|HE#!LV%$_R]\M" ?$/Y" M/1'1*I7X\+42/I7\[^_A86M4>\@"\3A@U0[+DP]@!?;,(HP$-G1"-'ATB. M"=@*Q[,7NCF-"5=7%?QA0Y\3=4!,8-")-*

*UPEC5)-PW=%.T-2U>!!=,@'WQQ M(6J.:"[QE_D3H0N/\3T*LB6(PE 6QYH.8) L@>O PD*V)[17C2D3&W^KZ@KL M3!%-^NJ!K'O36N!7-*

*I$F&N@DXR5L0K0%V:8K&X9"M6E@)])$U.;$;A%N#%03 M&G2$?0YEBX@6$>"LRA#$!0EMD.;0YO^!?1%%B8I.T-.KC9+P%P>U-(*_/$ '-M=@"&" FP4XL4.;G1 D>P+)*

*$8H)8#A*$P%DE0RR&$X(^\"9-"H%'C!NZ.8$G MQH"?6,=FZI9%SS FF[X2863]JF"))]J'_^ &+9#M"OY#% "1QR#@<=\Q!DW< M"EZ/;%$C5A"5L0XW/5$MOI/ ?0K '0 GYJ*L4#V!O@A?/#!U$50VP9)DC)R/ M*+-25?2 +Q'.\I!^O.0#$/,!=-F;(6O%LPH6O@/o$!+9CT2N .D&ITQZ)F MCI3N> ,6@?00<4&(-B^@2<'M4+!KIDD/;&VG^G>-*

*I@VB!A1>GRIBJR-0 M2VDWI D1%7LB(9[2]TF[^ X@],'=,WL@!DM+;"'=#;XN=1@>,CNP5F@9BBQ6%U 31,=-TKRSCV-Q0MQ *4X%0RDKFH M.'A'IFS1#,D870K5&LA@*1"-*

*WACH:@J^#&# N5ML#>[N'?EPCPF6 Y@ P*G[M"Q!J2VT(-T_H(5T0A(\3/&@\0]4!^CKN!O_"B<\6IF;0R/] T?4A3Q5 .L(S MX9'8-@,D B))'CIL5A,E3SPAK"S; !U,"G4_-Y%=F01S1SEYB*

*Q'_5-*F%E] M"O;2(-9FXH6GLCFD2(/'4VQ"_A&)9DY#WB5@M2B\,"H/-0(0@8=,FIV#XB#'M@=;=,AL+Z/SSQ*P"H+@BC3Q?R-N]=B4>2)B8<4.)KNB<,8SIV!Q!10P*R1$(% M*

*D8FHPDE%"-:3)++3+4ZL#>*X $.ER#S^=CP!%,I%NX 1 M"!=<'B04Y0E7 M(K)+H:X'^YTS/EF"_PZI+H 2A8+!8\%5]!!J'\@>,(<>>RT-&XQ-@Z13^0=:)*

*M+|^_:1<"%LNY"=\010Q3|3@I.SY[?,SVP|;3.0V*2^3].M-V^(\&7*CCM:GB ME 16P1"9Q7@K]CIC=PK?4MX+6+,%^*^,__$]!LG$G#C-NFA-Q;M^^TIK#FZG*

*MF<4[!_KC=-0$#!N$0D#@2#7AJ#>K=5/,BC+FZ.F"XL.!Z@7WDLP'\AFF9? M3#9?NB_2Z#G1$&6)BA M!Q6" '/GN@<@M3*D&/I6'G[HNE[(Q A]DK*^Z8TNB^P'>CKW=]Y-*

3'H"#/!'N M?^A(R%5&5).PW!PSBATM40/FI8H"-@>NNW(3S!M-Q+%_710V+MMRG_65-]0; MP1@@8&)Z[%C5+0 "\<.P'\YO0?L(8*(P(K9C!5DZ(N$"_F. ND9-*,1>$#K(M5Q6NT(I, @I#4USX.I5*I>4_PCEP\Q>=R,H0 /L/!7P'+IM:([LDN!T$O_>+U:/ Y4JRB4M0/F [*AP#506$+'Q& M>3Z >(X*(RHIXS': S5(N[+>$|#;-Q0+Z1. ^'L&DN*=DV: 5T$137, 44'^*

M8<8(APH',@_Z=EB@;8S'1A8DX)TP2CX&;KBH4L+,5?8(RS1.A M!$CG,DLT=3Q-'?@CX)Y!<8[S191 "!]T*_(5Q =,J,F"TO"KF8&JA!P2Q>-*

HK5%4?"#'#)E]M:@VW&MK\)/1 VD T]"R]DD[(KE[H98?'<6T4 M: PWF5H;4'R6@:W!1L$C"!-EB5L"#U3^.O M 1VHOXFI>**C271Y&8@*]&2F%H94D34=TQ-73-*

*K\)^3Q"7CPHETN1#/%/EP/ MWIX|0TB);,8!:O$V<(!2+5V1D8&M^WMZH *49.VBE%!S\Z1HE)N/T_LQTV5D MS2'#DKWCN3X^EOQ,[] &Z<0E3W(!'K+3>Y0Z$3J.JJ(] B01 */@PU%P*

*2D<MO$>)!)Q+>>>I%M__VI^M"W^-9(41[BD9F.Q3563'^OOD(!RS9=!4 MK.9HA?Z6!+_K-$B&MF*9Q+F8GMT69"73[+<>DAMHB2#D9(%MQ8899.91TZ-M[!CUMOAIG%##%T*3* \I2*

*Y<,DB53+E .NYH<_NY7,)?XY*Y5.GCKGS?&$ MK?I["DS89MK!+YPKL(:K_;/G#W?L%P4Q'9TI[5RWHVD5H!DC?R*H)B"=,R5Y M)((<-P*HXRHIYJY%*G$4MCIW(E"?F;\Y-*

*P(9_B>S$N9)X"IH*KPI6CG=7O) M=$UO CE7SC:^Q6-EK^/&(F7#MG=4HD-@=%2ES(_G_LF=^V1 VHEY97|\@^ # MU-/[4 :M#**,W?+C0U$A99T6Q-*;(&Y6]=Y[P2^H)@)P(&-*

#9E5Y"+%1FP& M99!JA/@:N@.+;'!0FKCV#.CP+LH_@<$Y&0=KR,71-.)\,3"OG53(E M6/OT5IE%19&W04ZMLE$T;58CU_[^$HDIR424F1)EIGSAS!2@6JZ[<<&VR]HR M-

*;@WV%RI[>_8J24>C[W2P7@H\''5+NH7LD'K@L]X@0/=F)M#*G2L9-_805,MKT0:>96TS#E+I]WKU(CX] M3=6R/3_+]76IJB_6D67SN M):/:A=X__?+;:'A+4] RB#A-XW-*

,K49UA^EW8HW1P'8I@G)#[HS^$/-O9R> M=C}OE,L0K MO &V-\06X=##FFABX.(]^:>]LD.M !P8 +AT^{0=4$]J^4<-M4UN<+=NY3]^-

SK;UMEC"@(.;V1;KH#T12EN^":Z#'P2>W(CJV?;M8_-%NKJ?JHW.+%^O3X?]CT"^_M4$R=K _R\%"=MG:P)C%FQ!+_):EY.Z!/W9D<+X6S2FA%2T\+TXF5H5I!!NA

MJ+S4& ET^,156Z868GM^U](?2V/ W^(F! X 4?5>)%C>FQ"&>X<8/\J_2@-,M%^&Z"%2.2L^RU4?%HW\|-P<54#(R'9O8%U32NHW,M7;QF0R-

*'[5ZB6Q6O)|99UT]07R#HV,^3$0KUH3:MB8C:N%$_KDV'1S".6)D[6 M1S-X\,70%8()74"N6P+!#B*2G4O 0P[H;,9N)3&S'9,108S+R;\K[Q=W_CV M_^$&K_[Q-[?*

*YV?!9UG&>.K4PDH.T\%$7Z3:WP8UUEP:A5^E^"385K6(#1*.I MUGSD#[_5=K-D7C_TU=L$J1?/]>QX^E*Q?OU6PRAU*DJ$M>3?>+7GA:O,>;_ :MN:O-VN7FW4@JR;4[9/V%_"*

[,02=9X']I=IP:\$N@=\]3W^1'&8:CYV^64NU MS8%#E-IE9?"V1)UWN(2GZ/[4)4M?NDIK-L^FL=(\C3SO6S,U:0EF<6K^1?PN:)8X1, MU=#Z8NG\X>QD_R'ZK>LR7DL,-*

*@GKV<[RMG\2 T9X66ZDHU(/+ZBD1 3R.C*I MSKZ3BHZ1%M2:,Q2/9Q(Y_*Y^]"G[FMX$ZF=%VZ+Y'ZOI>NL2Z&]HJ,MB^|\&XB*V0%.=#^ MM&G^%B9\,HJ-*

*@2,WA8MG'(D\%XGG8YID3C2')DY1M[[[-XM@83R#QO@HL9X2V M!+IE@#>,'(2HH@2#)32;P\W[Q+P9ZX2&Y4T\O;)C&>B/N#"U_<\# A>G #2@0:'[N1*B' H?*

*LEU;PIXAHEC:@6(§'Y&L%M7Y6]>$'+=G1R#/Z,FF[M^U!6'}X'Y]\|^Y'>'5$E%H=%"A;Y^'Y;8!$\)RP84)O4K8 M8O L:+$;8 F9W;=L&+K,,.$I'& C**LI5T4O4F/VE.*

*2R#QC\2Y,E*VB;NQW2V& M0.6L3JHYA+--+Z+YX7G&.N.:Q/5:Z,I11*:'PT!U3O6+8QB$9:2(OG|.K"<'; M/R/%%<%8ATE.RLJ0D7 M#APQ6=RD^(B:!C|%L8;G=HL(**

<@0T)4)HT8_(+&R=YLD7P_6?2,$?^/=S!& M!GN?R,M\:?88S<9?)GZ?CXXGJ$&O-^SQP^DLO>+Q@C M0X?@E>9YU@1+N!@2E3G%R*K052(S5+'FI*MHPJ<3'} ,:="8N?*

*% 6/5#A$V9 MP*I@E0+3<=W":R80LD41@_Y'$D%6*U-VM*=;2R\%P-B8)* ."8XPYB;"OF M4@A;TL^=E_M[!:,!F623[;8C@IO^^BWNA%@+ZJ!N.HSO/&!LVD\#6KTP(/4!*

*MX=0.]V8HCC]F$-F?HQFB'/#_V'H,^"/5'9F+B#&4%?P)F\!$(=1Q:DR6%BW. MLHAM*ZP@BV:'6-C@V(936AN@LC*1 ,_4(D]T:D0H!4U]!_I21Z-%8#M>V?T-M)T}3V[3=?*

7ESDXE^,OEN",H^U7$&7% ^L@?;SOLK*]ZY'S%D^E^SSE3@5DW4B M#0SCP2B4?MUOOWFK&PW-]VEA<"F7]4%/-NOY*RW1N5A6N$-LE[-SM %?>;2; MHRO-YC) LC_+F

<+V+"W@)Y_EQ:(.PKFIMEQWHLZ>MUA/_N+0/\I"-LR=>K&. 4[YZ>LZ'F14QJ<1[\MA&M P@"A=@ZS@VE&G.)?/^ MB'Y- 1F-I%", ^\X4-[_C"'V-

*NA;PLV+JZ%IY/==%18V1V<*4;1M,2]<'P4LA MF7T&1O"KFJ,IU^C7%G+^LC4>3WN=UEW[|%*!NC?B.YVRZ1^B N3!O.T RC1' MM+MP")5!5YO#K;44H&[5Q^6'F^2|W4B]Z%-*

GFKD]:WJ_*[_>+O2Z(M5Y"'T M]73[@\4&<&VL9;ZO;1NTL:,R?/=YG1Y71^-N/3"R;3<02& 3#G8]6 MC3T.J'K_\VR-JCR7AX0R)0[]V5Q+%94[2ZEUQIGKQZ+1C5MJZ=.AGWA3Z-8'

M>,MD8S/H9QNAG\L,4G=FW+JKD5S-+'8OAK)Y 4I-=H-\,[^8%5=RW2&,U!D MZ40H$]@=$;#\4:4),QX1H(],L\A^LY2*&]MTGU_S6].1V?#Q-VT7.[G/5%,,.6;GG-*

_;1A)JX0>KNR&.8U MJ$(S<$WN&R@,;:0GGCD, W(/!>2$5&>6P$K&U(TT154IM.U4Q'RB[>]=J M8\ GG=V5&8,)+LK/UC0_DT#60_WDPIT.J*.*;>;!5\ -6/!*

*M,4:FKH4!&3XCW5\E",$N5N*#M#$#ZD60-M6Y0>]&SU*7W5K3FD8Q4G0S%Y6@ V#.PBMX,/XP73&E>.'?)@(N;[*W0'?%-O M\!.^]IZ'&DD)&U+.'I1T@OK)LE2=2)-*

*!7YZ>*1>2F#9;^<88G2[Y7"R=V7"# M&XWD_UG1$CGCHW6&S,;=LWYR8)>Z%_)S/2K,-[#]>H/4>:8/+E_L\[ON5,YU MI7-KO$AHF)[!:.+'8).2;>^66\]/SN[*

M21MFKEUKJC=WCR^^N+#O\$IVW AKZV9-PL(MAA]"H[K5$#(+7 MQ%&O?C6><7)QKM<]'Z>M>[SV6-BF;E7;_K2R/S1&V0U"[H\ILH1;?I>5R1

*M_I.!#BW%C9=TF\W.ZU+N7N[%$OJK3Z;W1=OVWA)YQ44:@D&E$]W(EHA8XR6 M.:.$N 2Q7"@Q(F&:@&C;ICQP0@D.P;6XZ*3;_4K/(+8FCUA0Q=H_'VUSNLER MP#ZHS@"#*

*fK,.AFP:#S^WG<9A&4QI.G*VD=23N4;'2P@3.>$>HUNO>ZJO-NI M3#_^N4G"|NIV3]BW;OY,5(U_JG[!1'OBP.:Q1>MHZ79?X?D,7EL#&M>CG<%8*

MDR9I_NC#WJ402^@9M%^1^]92I^AYO59@E_=?5# MEH1"OOW=Z&B@(7E;Q5+?#3O4OUFRO(=[^[H.\#7#>G<-T8.1]9F"&0=1+& M#[P75F4?

*6L$#+.WLTS#0"3[*1NMXSSAR^$]144_*=!U'@TC<;|_^DQG;F:-M9F6@JG\Y_JF9Q)MK#7D64Y =\|Y!X@[ZXQ?]:GTMZ+,C'F;G M]=*A'A9>K7"X%|?VU@OA>N OTGPA&35?*

*B)HO1,T70NT4WM)\(;W]'3NK\(_.M.7SJF)@P&POFI*ZX'\<@D\8LI=XQ>#;2'F6M&SO;NVP=/-0:M_5VY69:N5;; M=^.'?7D_/^R]MKU-F05NI2PO>;;%S>]-MRF-[(!>;Q48^SOR/ZY%-*

E@+IZO@H#WT5C:6XT32VN2R&')+H0'>?8TM$+LK?.M,I#]M/(MSL]>.3ME-0NXU^;H6E9P(^VV8UIGN6'9?-E/.B=W8T+M02YF^6>.MT(V9\:RF?76!>P6*

V3[^IPB5HD!V.E%>)C5XB-L0(W:W-MJ4T3),9!=^">F MLSIX<:[JMGIBABB?\>%VAPZH?+% 8KO;MI6ENW/NS>,R[AO-\[G=8OU<4BDP<]E51EFXAW:N(V%S

*MA%4RX'),._V96FO1P%5@3$LJ%5M/]>)!+]^CFY_C%>;4-&U+U8?4NHWQ1G"T M3.3]2]+|[*L4"P.G;/)5]I_F?^V-V/?L3=S*!J;/TV;;48;/K9:5S/YZ@/FW M3*)H]*

<>UU5MDB":/MV:Y[FI=N!0K=N[MT M((^?YC>7WM_-6=6GFCHN+L6>>GIM]">5EW8R\4G&[%/3LNS"U5TB<7E_5C-S M2K%:U=%M8G/OK-

*W=-29TEA+%L;QS,LO*L%^-+F+)@67/V<91_VO(/5SE[E76VU MW?9IK_M'*]F]88#K0[*8Q.9@&]8CD&;O6YB8X&I!']J258P++#&OX_H\A==OJ2)!XE $ MIJ0HM,7!MBB,[SOG\1@<-*

$'S|!T4)-Y AY5Y!ARPP3,3P'%5C!B0X697Z9ZY M6L\BS5&-6ZB6Q\<*@_CMM))TGGK-D7Y&'TQRUR-OU:S0S@Z7]5W^&.@=TIB MK#+Y5WR\A9JYB41=$50O>GW' &!VYG%8'V9,

NJZ)"A_P$I[%1EVU<'\5I<,X_M+H\,ZX ,+:,XX1",*!/L,F0&-G#C2GRB&T59X81DW=UP&MF1K/?K$L&OB:; MS))VCX[!80[_(!^%BCB.1]+U&+T-S S3M"!(X_=UO!N"9.

*[79;Q:NCH+9%I M3PK:0@3Q#V?(Q)B"SD?A!/T%()#AN*EN|+?(M8(O/ M:E4Q^&CQTT\ T(MP-KPA2P(MXZ5)W[3I@>(!'OH!>3^R?*

*$K[*VP!;IDK/WQRAF.6CGOMTZ1)QCC,"8.U?$ 3FUNT_9UH%XR%"2C\.MNDFK; -M- _+=5^"\.CNBBQ8N&+!-._^_3H+&(H$/E-(HXV_I'F.@+G*F%5TV?*

*M=5OFLV%:0QE+$[Q97VO@84^Q B?,.L9B7!(H< HG%6[BB8=MS.UK>-T':Q1U MVI4&X;W-2*IHG8YDGL8O:Y6&K3Y?S!^-:\W2>IQH\W.?WW?Y_ 4.'T!'H7*L MFAB!*

*[;N^E(!WA;]>;'2<8SS7@CLFE0U:Z)AW=3!DN_0#8E<8G%6[BB8=MS.UK>-T':Q1U MVI4&X;W-2*IHG8YDGL8O:Y6&K3Y?S!^-:\W2>IQH\W.?WW?Y_ 4.'T!'H7*L MFAB!*

*;N^E(!WA;]>;'2<8SS7@CLFE0U:Z)AW=3!DN_0#8E<8G%6[BB8=MS.UK>-T':Q1U MVI4&X;W-2*IHG8YDGL8O:Y6&K3Y?S!^-:\W2>IQH\W.?WW?Y_ 4.'T!'H7*L MFAB!*

LAVO939"B58PH(93?=S??.VJ"'[OT.M@%N>-C?=UJ(@-V 5$M3X13[U/+!IQ,YUVKCC7A[3P"O;C8L.? M;R^UNCTZV-W09=]6,5%EQ5@SKGA+$.&4U|R++#J$F)M?] M.*

81<&1M94KV@0%(M.GO1Q6VKS+_`$`M(F95B`=,BC&6$-]`I*5#H-RF1O##B]0Z6JA?+]N+BRM*N2SD?VV$FY3NAB. M09]B|S(:+0269;)S6Z&$;P85DR@@-- @O?I*FA0*15HJQ? +S1S+BY/2E-7S;K+Q5E_459?U'67RB/`M|RU9?YGM(]AI QX&-WPWO6QWC<$&Q7K%TL(R>9F%@%0V0V7LR.S]2YTJI4X/`MZQER\60ZMOM=PJGG/0FT8:*M_)++)? fP6S$POYV4.Z53N[^_"-1.&;)0^$F<`MS;=I8=QVS',UX+#O5B#*$/IR@)L)U]}4D)'WN`M-6=R?24U;T=)9&U*FFI&XEFNI$4FT[-70&;=(`MAROZ>,#@\UM(;, +5ZWO@.M6UB>@97HXP;0=3P_>%<&O;^K9"I5@*_H">(DU`MC06?!OB,&SX4>>]8_ZW1/HB7*FO5LNEVOV_JF/8-R[^,/LE*D@-VH~3=6 MMHI735$^?MGV>R4!2FR8C+,EV^ 0.,\ZZ:YK9JN^'= [-BIK>_8*=A$A2MJP MB;?&B[*L&^I,QQMBKD+/0RB?W6=?4HWBJ'8V'}@@\O/`M/;#@G_C@77^;AKSO%!KTBOVD =,[:B!XX'^(SGCY!V5]/XF7,2MNZ^+ C@:[ MTI[04V!9KB"QZ11>!0N97!F?QX>9[4_QQ>0*LD?6;$W(_&_-3YO[2#O675EP_&Q?S;(ZT`M"7> 0FLAFEXCCY_A0>!RMJ,#,_E-XDV30U"\>KH<)A&N7J:DCS4@,F^* 9>_ M&RM)*S0+F'NB_7K2BE=/RG2E7.*G0+SA+Z.:6R4<9ZRX>$=)*/.7-4ZJ:U+5+P2@M:&89"Q2_%.%A#]KOS^/4+`M%]_[<2BP+^/8"\,[BCD@>*VT#P868$8O.4T\LU_W3USX ; N- +GG)Z0+QE2`M4MD]_2U5W0Q40OE! 35(K?2%P_C" M9+@K&,$X%[QGJ//^J6|8=QM83%8"A'/L?PYLE&FJPM(/'W0!+'/!B#W1W1/R0S# M.)^&XFYKKNN%7CFU1{U>XLRH3*/!=LRT^W/5|(V*2Z_%*2EIQ<.1%'|+0WT`M\+-<5Q]NL"GL\U<0Y%9|$#;P&QH,8!%YYHPRJ'3.)""">3@QP$W1%!1&LFGA M*V\7Y@R!GJC3$N!W-?Q>+8;N67Q;#3:E4!(0)MQS5L.V.A8;8<*B*>Z &-IR @OD7_.PBD_;C#+,[C\GYH]NP?QVHGC1;=:SKO8&TTVNN`O0-VVQ!H++>(UZ8`MF]4RR#R@9^F>- =YS9+5>2`M+E'K=`6'61 GE+M.BKHM%V5#AGKDC>`M\.3;GXI3G$(9C1.8H";'$9#H9JH+%6J67#^X_8RBTQ!E>5DS50R'3,[3C\4/ZUVRO7#VE](&O2I'YK0+`M 4.IH\RI'3*_^^Y/,>UV?X7W2S,UW.Y!7OTE1EMIQQR+U9ZR\6.T@8D[N-.O`M1[,GNL6[F01K-EE\U6W"06>:P+MB. ^M)@QG"?O(TYO9F/.H)P'#K:J4ELS(5 M7BM,*Q=9EP'A(O]J.SQ0VQP%L(0BR0:"002ANLHZM0QOU%'S8?2@@^BK39S* M>`%S<_&!X"_ ^U79>_'ZY2D[U9U3'%=&PR'2W"\'-XS;X>U.;DYBZ%|:7`MU_6I=0/%- MVWNKMFA[*'7F0%Y_J"*L>!PFP=ODHV=9+Z=Q_<_'4N: *J7F!Y M=&>,%'WA0L3].[XP 8^8<8&>@Y\]J=SN"BF)(L9D'7M52=P[<]W,3^DOW] 9`M(V!Q_L<>ON(:)ABK@P4DM L0? NZY3S%ZZ&8^XV4AVV+F>)+Z3)I9OPI;`MO07N@DH/=`%]=`^4(^2L1B\-7?`_A5_;)Q!1=V=NO+'523$=?=E17EC_)9ZL k M.Z@K^YF6D;*^UTC+.,2;^53^%]W,#C;7B6CF(&\FLID.]68B;G:H-P-*6W0S M^[R9_]<F>NG>RR/W,4$&-]"PI8.LYYU\+5 XBDJZ@A_^OV_9;[_*2%(GA9T\`M_K? A4WA3O@9_ZR#TUG#,I1NL'6>UXQ_[GT$8,/O1WC^<8CX#';+[!<&[HT-C`MK7-_&!LB?K$'?L$C,F[/9>-9H/5"@ILK=4P(Y#6:8+VGTHF8V\PQ8BKOR53^`M/)PY-M:S76%# /YJH<\: (J5^%%2BPX_TU\=_V/I;/G,[Z!'KOCE`M\";=R/$U*PX_TU\./B^`U]_`X>O(EO5$G6?%(;,,E0H!-^I-'?P_D.;S\163`MR9_A(+_5Y6^2+Q2^3O+UVS^!U?LBL947GNB.Y.H+3&_5?Y=Y3? 8HT"2" F/7_H$`M+"D3^#>KNF8I$]^-TQ[<4?_K%4=[72[7(1PM@-PTU3-\5N&O=RUS%9%6E.2]% MN$I*^<[Y;2F32#TO.C>+_&TI-P_7)Z;?4[_XN@5H!K&;HZ[X_(UV?81W>(6) MZ6]NT4.\=5=3Z^J#D\@]7DJC\;1S30RL^$A]^Y&,I;.%M=K$O\|!,0X4Y]>% M@/N>`IQK8,JP[CE1Y@3/BN\0-2N^_J*WQ#/>(8OKX,#X'JR#93L=PM$^E76D M^VFI9/9D1W-Z9^5[TWF\|>>K?$AL([!Q5EW7G9,4JOT)^,'Y#QC+*T2L{[L MMQ_%&&#Z+[&.UQFNAX 8!\TZ7!%T2$+{5-81$+%&RND^[F) M])S? SZ;Q:.Q9NIR==_%$;:B^'S>82]7^L6\D*I-4!$KW<[NI0Q4>TH?/N1`MCB4*ZRT1WH-W1&!Q#M>DZ!S"$?[7-Z1ZA?:],+9SURIM;MR4]?C,TTVF@=A MLC3.+^IY{}+4&KG0QV:[? S^_%6F1>A)LEEPLG4OMXAX_]T2XNNG!.*<`*JN5`ML5NJ88,#*;&J%IO+B\IO*8=]/^ON\QRG>_8M_Y8SY-"@LH//"&GL!!/HE2/L`MJR14?F-AM=L7JN.VG*W1\G)_0 EM$.5UC_(Y#- !+SR.7?_[U&= ,.AG>-.J^`MVTV:S0N1).Z:F7BWF)UFQY6W8WIW>#X@>#'1 >]7KY=*H^9-Y/?:"!4 M#HG'18/+KUO'M?6+P=JLB=)>Y?Q`M> <$@=;6AOB"/RZ+U5TCD]\'E#B[C(>)R1\OE,A&7>T6'SP_3Y!I:XK:IU;O) MFKI,IA59=6SIZ>U^KG?FTC>|?Q"OE&KVH8@=T@K??]1BZ=1Z`M$^-(EXNXW %ON?PA0N60N-S'ZG+5K'YQ^3"`^G]>:<;K]FEJ6R^FA_NBXW?"ZJ`M%YW[1VUZZ>A$KS:K1+DL 9>CWKA$K)C<+[>!S7R,MJ*8-/R@G*$R.;2!'')>H MD /A4GM-&C]\LW^*C|[7]M*$Y ?=&:? RAYEY.3SL9-=\Q%H?@HK]P\G8KWY-.`M8'F6$M?#YZIRW\"FJZEO/_*Y?ON13E%GYM3=`CD|W%)1X=WIDE/>E^.;,FL`M-C*>KMWV2V/1L.GAR6#R<8QR9FG1M8LVWZJY=HW] ?'TF-ME,4>TMEO/[*Q M=`%=&XFRD@X_L^#P"/#CTI8.[^R1WK.%^0RLQ[@N7G1/I^+M8OJ46,9*-Q5L`M2U_X=;TG2FJ*6,]G93T=WMDCO6<+Z^F1,*,[\U [^E=MA=W]^) (+B/K03 , M3Q4?ZH?Y#VVS_N.C!MC^MG_S$V>&KD[/#;,';U4$2.)>3#4G &0E:.)F+SECX M63(73H >.@1GL!)'T"K0,$WN"LQ>D+%FCXZPIW.N=39)FPV]QA'9\C,9QO$[M.LN8SSZ@F6$XRIZOCD/%)),,99O_Y9UYO$\$4X=ST%MR'-=%-.XYCP@&O MZ6!GG8XFMT+O",]0G8@6_5MD%\SG0'ACRG0!)T30?= IY,&].O ,SG*V$2KL MET.=6'3`J_Y-D@$IV95B$KL#'4> 8^OIDMPZ=)G @E-N=\27I- M>1/7X99^AH>U#-KD:)TPKBKY /R%=@@:,KKT0V5DT(L$&1',Y>1+;G@=5 MW++#AWS=LY#HNMVUP2_LVFGU]+LM'*E%M0/&]SR_G.6^Y/&%*4Q)>Z0C)>)?(QQV8|G$P"GR2'O?#^]$OR(,WS_QY9T%NJLM M)KQCT+&"^"?=5%P1E[HC?Z<`1,P GTIW5&)# SA.:!%[C.\?X)?_-:A5C1G MNCW8_@[SJ["F^_[WOXJY?/&?5:5|14'>;A^]=_0!G)E^ M2Q57_-K%O0C3(DQ[-;95N7(=0K3@*'$#%&02H52$4J]&J1*HA-)N?'*-W]=R M-+0# (Q2,4/"U*!=#HCB9R;\HVY!--0";XMS62R?!D.]H=@DU^M<;!F|M0.94J4I2"JNJ/9@DKLB3Y$`D1@;RK<*)B1<|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`YNO\!,1&,V<_N3?ORRTM-;MSUBG%V<6>/$J*NU^#3VBY56,5HS5#5!`M%D_WUAD(LD*W1.U'ZF2]99' +SYT<>OD;7-+1V4V%6_'R<*PD&?U.<)$>_OCW M+@?8&) (BBP)X)J";%LN2.>`J\!Y8UV.]U*T_T.'V<=FA#+87,K/0*MYS@>19 MF.^!)AT&J$R%2J/MIDXLYZ)?GL3+W0KNU-N M;A$)T0YG,%M$>P>-.!++*JE ML;($7- 3T=524O>5IDK',4W28/0X(X TP!-,"RL0,PP0_11)=D)M"0R;7?POB M6C0 J,&\Z8%HR71[@A$#&@0)/Q]> 77.B6PP24LQ[/M72F-<5U"BB/G[1!+ON@Y15=)CX]TGB8L,\;K?<^C/HQ3 MLBZZJ.F ;H>?BL* :&0D4_\9\ESV1%@9<4[7ECP;/*MTR:&DOT@.,XW'3M^L MI=KEP"%*[,(R6'R"$HB++F4;5ZQK8/W+0T=4Z-/X364BBU'-O<[F"'!/3/!+ M>.U,TG+IZT$B12Y4N2QYL[2";8IC5!)](=4A,T>71:$B&A@L.1$]W%U.D]X$$6A1 MD:GY3TW\E<<%T,OU-2=HV%NU[OSPZZP1+4>=.W>7D]NJ<^:+KMY9!ID]XD_ 06 M#GRSUW3&?8&RK@FG9& Z*#76??$T.8)B(#9$H(G# ":>I\HZ\"U'U&@# S_)AA($3>%5%/H'6)WX MA#["Q!G MG<1LDAK+W2>G6^HMUAW&0\=<<1C3$'Q% ?@U1WJUGGMG]_=!"SE^V MQN-IK]Z:Y]>JE?W1GRC]D7>ZHTG-W?5N*7T^M0QYUZX_0-_M#IV-X ;.P;N:(]G7Q$5A0S+RYHH3<+/>HZ>1."" fJX6Y_&+RWBV1D])`O'IHM&/.VK)(K#K]R;:OW6./@:B&TO"\M_JV5W'AW MUU6EN>S5\W*OV>X.%@`]T[$U:G_[D3A);;@V S@OA6R,,VK* O'X+&)1Y'Q0 MD0$^0TQ*I(4CPE\BKP7!Z \KU')S(EV9C2B ^BBMG::7+6N2;A]<,_Y\(J2\ MX*ZRC/EYDH"C,KS%S0%P!8.,C;XNKT ^8 ;"1E9]T"[(R!:99[,R7GN2EC9 M92X<-ZDQ@LD(^V(P>X[^K75MYYC503(,=6SO4 VTW')CN/0)OLI\/BT^)8;G MG9XL5Z>:.^%@;W90/CTTM7DKM_N6=U)-;VOGEHO=RLYR,<1Q%HI"(93=T* RQ M*7V3.AX(:5/&Q7I'? ##KBG#D]UC@=^<5M[6DQOONPU+Q,7(^FRW.J5*`M,)'>`P MP!,.[\"W4#OWX\;HZS9G3\$ULB;/*"3=*?)83L9FC8#%!N9YFKC0F[.*;N?2`M,_%476!JPBO9S$;K?XW-B*PE'BT09"*7%^: !EBEV>&/-Z+S\N8D(T@SS8I;$`M:ML(;)TQ?L%M(]FR'&;@\M#NBOW!LEU6EL323BXH61ZU)L@VZG)HCU]LV)..`M3*$&.Q\1 <(`M"FAA&LVP.?G@45A[82[V-"YV\]5:K=?)/75;N? %#K_(K&4S;#=)P@M+FA"3U`M8M$M&DXWD5-?G-KLO)>O]Q?HN'],A"2?[/RTV"`-^4 *GA VJL^(,N;_12]L- MU#:)K-4'$B6O#0[TLZ3%3[HIV9G\%RZ!TK[W"3^D[9"$,.B- ^=;NAR#92#7H@ MHK@)G:Q(^_"LFAX'U/U-_B=X&&W2(J55?%"?8]0[L\A"P^N]6;I2_=(TQ37P*K6+H)UG2W=),L0FM6PMW M5^ :+Z 6%0*,,7&SGM[5=FG&P[*SO6);GYT0977?=`O8=0 M-;^G\&M9VQM3`M?Sl=3_"&,5<[.G;JGG+LZLS#S4D\W;Y8N\ETXF=J4 MQ+,]98;R!TNF6;9H:3]3#L4RSB*M]N'UVNJHJ"\S8R616"Y?VITG9SH3R^WW MUFI711585=*1,11O"3P=))^FMZ2IP+K+JEX8?UE8$'=I0B_<[07/$*9O)_J`M@4-+Y?Z5[+_- ZH^3/.\^E..3O]XR?IMJ)"?E0S X$=N5VT 7N'>BG32?$CA`M7B"=RA;-,J9^J?U-S3A_]^4DA-7H4Y-72VZ_01=!LYMJ]X^G.RJT7.ESNPVV7C>7R:? SMQPLQUPV3W6NOI#^NXD(TZ+D0=%Z*,"Z_K MH;"SO<`-]E#P# Y=0PIG*]W(UK1"QWK@O[S6"<44L2Y+T]YU+9=XZEXE[Q[T MJM'^J&8(FU*I?K?U 9R.2M&>QOTE:%0= <1.ETXW-D6@0RM#IA!J,NV-E-O.5 M!3PPV%,"337(Q%2JT!R'+HL,"_1@KTR<@Z4%[9"T+T> "7*3M(.DCW&]MA=1' M.AS'TX;#N5>*K*(^B_\CST!^V'L2]D)%'R0R6@J&(K% (8U5Q\/ZZMDXHVPIK MATE]3A, L'<(VG_T_+[_X/3*R;-$ MT"U/L.LO+I+V=<3).NPD&"). 91,QD<QWX]HZS9G3\$ULB;/*"3=*?)83L9FC8#%!N9YFKC0FI.*;N?2 M,_%476!JPBO9S$;K?XW-B*PE'BT09"*7%^: !EBEV>&/-Z+S\N8D(T@SS8I;$ M!ML(;)TQ?L%M(]FR'&;@\M#NBOW!LEU6EL323BXH61ZU)L@VZG)HCU]LV)..`M3*$&.Q\1 <(`M"FAA&LVP.?G@45A[82[V-"YV\]5:K=?)/75;N? %#K_(K&4S;#=)P@M+FA"3U`M8M$M&DXWD5-?G-KLO)>O]Q?HN'],A"2?[/RTV"`-^4 *GA VJL^(,N;_12]L- MU#:)K-4'$B6O#0[TLZ3%3[HIV9G\%RZ!TK[W"3^D[9"$,.B- ^=;NAR#92#7H@ MHK@)G:Q(^_"LFAX'U/U-_B=X&&W2(J55?%"?8]0[L\A"P^N]6;I2_=(TQ37P*K6+H)UG2W=),L0FM6PMW M5^ :+Z 6%0*,,7&SGM[5=FG&P[*SO6);GYT0977?=`O8=0 M-;^G\&M9VQM3`M?Sl=3_"&,5<[.G;JGG+LZLS#S4D\W;Y8N\ETXF=J4 MQ+,]98;R!TNF6;9H:3]3#L4RSB*M]N'UVNJHJ"\S8R616"Y?VITG9SH3R^WW MUFI711585=*1,11O"3P=))^FMZ2IP+K+JEX8?UE8$'=I0B_<[07/$*9O)_J`M@4-+Y?Z5[+_- ZH^3/.\^E..3O]XR?IMJ)"?E0S X$=N5VT 7N'>BG32?$CA`M7B"=RA;-,J9^J?U-S3A_]^4DA-7H4Y-72VZ_01=!LYMJ]X^G.RJT7.ESNPVV7C>7R:? SMQPLQUPV3W6NOI#^NXD(TZ+D0=%Z*,"Z_K MH;"SO<`-]E#P# Y=0PIG*]W(UK1"QWK@O[S6"<44L2Y+T]YU+9=XZEXE[Q[T MJM'^J&8(FU*I?K?U 9R.2M&>QOTE:%0= <1.ETXW-D6@0RM#IA!J,NV-E-O.5 M!3PPV%,"337(Q%2JT!R'+HL,"_1@KTR<@Z4%[9"T+T> "7*3M(.DCW&]MA=1' M.AS'TX;#N5>*K*(^B_\CST!^V'L2]D)%'R0R6@J&(K% (8U5Q\/ZZMDXHVPIK MATE]3A, L'<(VG_T_+[_X/3*R;-$ MT"U/L.LO+I+V=<3).NPD&"). 91,QD<(15RHND!7[L M*%XUDS>7; L$6+,KN@N:4.%9R7PA#\ \NKT4,!LSL,11YD&>\@B+#0*-(9L& MKQ94V,XXLS!==M%U;RZ/D:3)X_^DI=VKW4?K\\&;N7V?-R;UEM#TUQ>B8M MT.FSBSFG@\PYI? F6UMAO>5DFFC1!/WK8"0749_`.C@UBKSBQ-BS371HDM$*% M;W_M63<9<)FXC#\^-^6:VKQIZZ0[Z)6[(>4\\6K=W/58N>^T-KJE0#5Y*)7M M43PAS_- %L3PUSV>D]JRSU?[C_RQW5?W;%00E<=*Z6/.RW3TRJK41-GFO%ZW'K*B\)>C#?VK2B%#SREP54W4/HG$S0JPQI0 M>SV;J0\(9+A;?>X&9W!W`M:I,2U),O!W<;K$]4S? S;,'M)+*\U%2;+D MTTM+;>Y5#%[DBK.GQ\YE]Y83SV4]^WBC5;7%Q[!=*@8#;K_#O)-F_;IT M/4_.TD0YU?/MB[&Z5]9;23[=M2J3VUPB/BXN&G9.*;?)XG6D'B!D-Z.TV)[M=16N$3F.5]U@2VP9EP'G5C%-7*O.3U3RW^BC0>4\95V(^\<^_^)HH>N[FOQ M23<]E @XL.&&)-%!5), EABW7-,=6\F=OSCG8Z@[RDPZ2 MFU.,4ITXN;WJS.ZG, [TW:"^UY7.B\GJE\9XGGQVGY>MCN)A:Q/ M/UIW=S>G%?F7.[^_1)/A\MRHV0-SVI-ZUK.3(>31;.[+4]D<^)(2$5A.@5M M>(TYJ1S^.NUF/1&5$?Y =11,-G">C MU+F\JZ(F25]PTG5KI['3Q@9BG]'0Y]Z@4$V=WM>;D')>=9@ULG&3R9#TKY=]O M"7W^]OU^^$PNYU>CFM*[JWUFWGSQ*,_F#**WB_UEVK>C\]YK?>G]<%C.I^H M)S++#*G*6] (;4AW^O!5W?B:^\U3#ZL@SE0]3U2>'BSL@V[\T>;7:7W6;RP;:2`M'ZB2&'+]8I;46LG$3*LN;T;-1%6Y!37'}\7/Y"DKZ15'?<<%O;*X>[B6]YZ`M?]^0%2? UO.RU/^Z.28T4+HULO3X5KQI.W:F_G,WG"WK'J5?QE8U!*Y.LCO-Z M,Z_YY"E'A]%2?<]\:P 91W(PGUNFKL$_)9K$;`^T>AS3+5\$^L6K37J4$2D\_`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`D)N? ^]CI>*MR*K%3DT^N5ZS\R"TL;!%G3X1-@S0!CMZ<%Q&=) 00/8- MEH#M%)@0C>IB(NAY/#.9<=\!['$)TU4;WZ(GB$&]*`%];J.O%W.]YTC'HI@H2 M+_^?NGB?- 6GOO"9?@R%RJ=\X)+]'?]?8M45.6BBJHH MHNK/JZC:+5S>((2QS2DOL6;RG&I\OEE2+!OZ6V0LNZY/(G#&H>;E.I/O&H8 MUU&RN0>.%NI3XS6%V"ROJ*T!3RH$- %24;W1!S_/(WJ_ ^]E $07>4DA'=Q(M.+=EVO"43GX3/6'S]XEP7+?!+B#<9@%[1:^&2($.CR\-7$"A%6.6]0R7U*LFX9VA,XF(O.^[M3AN#@V$HN^X,%2,%T2;0GJ+)8 7G0G- CI,F(5+%%U/7O#P$KL M'ZX_[" VVYKCH MR%%&:'H%U;P8ZV$9@!GZRW 6I^T8O,V7)HYY0SKLOZZ-=>8]Y$Z;$P$[TP3) M#VES(&/+|;@U\^1I2$ 3I=++#Y9LU")K=>7"# Q@V"MA(Q=4<8KFK/<;,#;A MS0!@[AAQ#P14XSH8/.=G$!MP<;__%7U$5VA'>>],/0X2VNH)=?Z;2+]K]!70 MM<QOXV)0$/8QHN!B-D6:*[^?N[^=2*TGMD; AS^OSF:ZXAL9O7+&AAPDI_9SX. M@)K_]K-X'(XUG3+E1_4Z;>9.DPR=A317;L,5>]6_C|#7]DP<O;T^7X^A5'S M/#/=,5K-HJBW|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~ M6+>=>[V1[,(SW#CCMYMEZ]UQ-7+4!F;<14W0&[8*F&_43@T M,G2X'NAWCP[H;D]WL^(G>P4@#C,D&Z ,49#YR. YR/B?NA@S!;@<[MO1M_V)T[W0*.DQ:[H({8 "M]3DJ.\Q?V(OTVI3W;P'[0AB@C@29<3W3-Z05 M6!Y;$H^- "X16UJR&C0CLN&.K>1@@@R^\;XXQ'X04*)+INS$8_2\[" S$C[@ MJ5\.Q*JS#3"5#J8(<CBT5L^05;<,8"^\+]0X5)1]*A#R6I-K?$Z8%$[.';L# M#BW&NP[5<5[+V<5V?O61@V EM.RG[237GG<)W@*;(170(\HXLE!8D8?C9S1K M7B9,5-H3#H&"F,Z83!N9?S1WPTIK_(0=6SH.'MB&=H>GWQ*0,AX6V,K(E*M_\'BL0FOJP-0;A?Z MP>D(;!E.P87]O +]X$]'+C#>)1A;$[,]'-(L/O6U[3T4R4LVUI%X<> M!\]P+V UE38 YBEKA5@YOS(26(&*S,XC.C]^Z88;'S@'RVR?W*SL4JZDMVRD\ZB5U M/G0Z1^CO8%GDUY$<)4VYG)@M8PEC\N%AJA:6S\&R]PVCM;%329%V4UA=ZT2P M'[2G8D%*>`)>4-A=IOCI6Q2'26BS; ,79LP'+CR?N@N/>I048G0=,-G0 MW;R]I<.+$U&R4BVI7W/UX%^$=`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`KB<%WUPT_L\8O[":D0S-[D[`W?C6O[XZ MJ^6]RM0>R.<:+PS>105IX8DJ6R\'5XGZ,)^FNLQTAK*IVGJ&DG!8/98X5,MV-FOX8!?,.T=.!_9&OXV)00.9 XB'X75S?1_U7P[M)$+XA%=? =GP.S[X9H=N62!14#3QH%"_?"P]6^B^?TP6#[SX0JM^3H> T?;>C6 MDD97=3TWH;?K.VS@J02%YN@<44(B"T.J3 :5U&0%<2N1Q"MZV77R^9Z[VP;?*

*ML_&5XRR!U_*C§66,\9$Y*DPU81)L?&^;79]HR!W,[D8NZXPVGY5$8A&?Y'/Q M2;O+6AM?PF/C<\WN>ZSE1\TK?MJI 4/_.\>6EW%F\!_K;N:9;""T:2)=D*Q MUBO\2#],MW^)A10F,KB3IZE$2Z;081E>I7*;N);?C&>SYG ",^VOC!>VT!JL_MICA%LX?]Y)\RH+;AVYNX0\.W-X?O.'P#I)Z2:+1JB*U%J9D>9M1X+CEY$L.W MRW(^SO#Y1?"_W/"=*,'1K*OR,)O'T=R.;J5]J1A>X3]Y\=IR//$_LH#X.^CV-M R)N==!Z"9?YV$A/F5N-&C^9+>W"N+187F: A.VE,&V.X(&N#M.3$335L#!D M2#UM=0ODK0+' \A>$MM@PS,_U+>%AIPUBR7CDAD^JW6'9 +\VJC&/3C<+<^^W*3;U3(:NL M,WS8UIF_\O@U;[!I_Q YV9;E"%%9@TY.6DJWY5,'Z.G MWX,CM|@^OI31L72'32&-$55J1,3$.*XEB_./AZE?P.AR>[+)U&85A>ZJTZS< M4-E6K0\-PK6$_YKYHDC5W;N.H0D@%"ZXDZ/U!Q5%>YA$]PD69-Y) X:|\-W) MF(L/NC<2SL0ES<'<]9P+ZO;@>1Y\.8=*6=R4|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n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}$-?!=H[3\6VA M[VP;/^\?MP:!,3L;]AY 3\P*_]$D#/^Q(9:P?X'A?]K]!5*M@1%5$(3QP__4 M1'"?G5: %^M$^NT"/6CR>"2.8$9V/HXFAX6<3KX;UG.WBC9X_ MI#P6*L=<<20-X>/@^.R8%-0#92J5SO5[*G M7'A]_?B=1ORS\D9W5Q&[<3'GE\(C)3:(9MES8X=5(^.&,?:WEVAX9^A)-PT!9P M.W5G_ CC($W?K-_U#W4J7RES!3$6&R"M%5^.&-,K8N?;#39*QB.J"M&C.W<75W6KB;'6=I MW*$+,,ZN!K:=!B\+3*XB\VY[M .;6:WJDV,,6*L+;"KP|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f>_MISF=R LS%.[\<)C+$+1+5@I>;J.>[#.!P*17&!5(&23?:"Nf$:/[@_1G'(4 MJV[!=)IV= O.?9W1W2%Z70!%<7:#_WN1>+KBIB)"BCQ18 ##>4;60(;GD92 M5L[AP4&R? K+,S6<$:3?6] -.EQNHNKM(S]ZQ M<++3$$TU/M<7,N-!EYV(DU2*KJ3@<$_E';'IMCG39<]HHH)N\]O$NP/@4=WVOV -M2'BRWVPDP!.!H(-?@QK\))3F7T<|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

T);&HK&)+)"T0>FBB5WJPC\ZZ,:$EY{36HB=/RS:R\6I<00LVGQ$]YS.?3\,JSL4;) M!%Z+Q9H#4 M7!HHHM44QVU;B=(F.*D6QW31*;SI^9J4292M<^-45B1252-9KD^&Y9YUU_CI MI554C7?KG8)&U?*U7)&K)A;4V%K^V1"D&MK6Z616."!\OIDW){-*;9F'+X#A MIY1LJG M,"WSZGQJM@L=2LAF3;:M;I;#HN>DJG)G)/=Q0VDAQE20^S+6.-/]M=>DJG)/ M4BDZ+6A(6ND*S642KRTWGI.JL,*P%/DB,1F)B*W\L!QIQI<-!QWC9%(5T^.1 M9;6FT2VV+;>V0BJ1-^ JSYB .:')YO%'O<6)K$"/JXG2307OPGLG3*\?R)MWL M] (HZU<4TO=SLB/5I!%YY+B;U> "^S;0RS(PKK9ID90-18;J.25BI%F7GH6)18]-%MR2T6BFGE@HF_1V1$8A2=&S50:8B,VFB,96BHS%2I7P3=I\-)U7*+4E#;+EFI}5C2BHVRV"42UNK5&BITM:X#,-%16XC)- M9#=XJZ*M95A77HF?*4100?*DPK0:')47RG9?"DUF'@-%8LV25:7)2U)21C5 M8XO4G&IM)W; [_PD#^HPP2?;2*IT3%7ZU3/9SN&G:[<+'5T;Z^!2+QXT^G5M. MA]UI1U){7=A8?,94E'\LXZD\-4!*)63;,5(:\B;2C,R4R MG42(SJ+A-5--EH9#NE@W<6HYC2V9M:RD2- QIP#LAE)#G!T;JFD0$LI//X(*F M%..PA^9L^>]\U<[P8K6(2&QT7E-GQA%P8<*(>]9\V69M.1ESFQA-=*WSI=XT M.Z4$?-'S-1%4? 3GG)XTN122:17F]&,C:A/2;_C;1\AMU*U(5I)1#5EEA])/X M<.VN/*-^JF^.Z169]{H&)?,+B=4|S>L0G!BT)S0Y<1>MGF<_U",;_Z&>!{GM$I+DU,/,:.LKL32VLQJ#$.VDP:| M%ESW8_*BD" D\@F1P.KQS+C6SY.,=>F9IN?&HA1=I--;FB\.%V:B3.6Y!*RP M/|=],=`C#*$VJEJDT@O+CZ.G5A4MI5U)P_1[>=8T)Z).#(?:,@?) 1 M,:.0D%1W*3DKO7*0J8-3;T:-- :N9[88R38C1!NT,ARO M>3LX/\J8[6-L-& M,/70#U,/,>(U002#=<#27Y&8FUC9_7@9'AG=!\'2[C_7*37>"+@WO-R#PLF MCCXM]^*OR7$' MO6?E7O0U&<1[3\L!])4(YDL_,?>08& [fTW\G_AN:.,HN1=8SN?Z7F YGY=[MQ6SE;F'O="B,%NN8>^XL$)T=-RCWB-!MO2N6NXA;T!'I'!SS,_>"/,DNFFVJ^_H=-,X\<>$ M8Y4Y_,/_O*#HRR>IB$=?$]A#9QQ0'A\L>(MVO =SLD(E1O 8<"=I_P&Z(`M'<3-;=`V<0!K?*XV/G;1Q!VG,\.RA,*)[8<2/A3'8.9YTY_4HC\1&5M"SO|[M9KQV.HA]5<635]ID>YO@(3C/%E_NQ#2SR."WDFWA^P8GY96$.*&D-Q/6I MQ95X11,_2ER_2EYO[EX_\Y;=>(U^>Z>Y#>="!,)T#V%*_]@=]DCNUH?42+ M?SZ2=/TTC(X/\K#?-?/]`\KLA0S_M%>#ON(/,:.N%/]LP=R^__Q)D MV^3I4\70&)G3_O[//*GSC? >4#4_38:!0*KL#O/-!E'!]67:Y(?%_YG?]C!C MA/ED]OI3DL(N1>3HA'_M@\AU/\ 4Q!9P$?$"]SY8E>H^"!IO9]P.Q;(2=@%B? MU\N 6-?Z*@)B?:*,(;#X?)Y( "D3M U7[ ;$ ^4"0?$"M0PT - @W#R2;=`Y_@Y MH-XG%17W22;H"8AE QD$Q/K(;7M K""<#,))'U$O\&,#/S8O{^*6/YL5+NX M?GM"=YK1IN$0"_X;@@.J5\S<&O$%!W3!.>,]P,*AV_#S_VC&\1M9SXB_QDZI M#IO9X=AABW!'!,!L\,_87^#:AG+)ZXF.(I#RO?F]I{C%UK|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uL(_/D)'1C2%NS:T??VJ(/M5Q$FD10UH4-G.S M'N5KRJHWGQ]H}>UNA8OI44B$BL0#:&#CL4&M'RQE]H$% LCR=AM8O3KLR>" M&/W=@QZ^DRE\:RR"?TSAE\:HCUCS4TA^$*_9\D/W-_ _?WI,?IU[]=WKBK/ MQTHXU]M2(C,L)JI=A36D\7U<5;0;'Z6-F)P4TQ*&YXM%L5?G)\!5Q:+O<55_ M1GNY7"0VW5$@DSI$%Q$'2!UX(N\\<;]J#+_">T!=SC6.\)R.!+(?)/-MN_A3ZJ!G]D?A>\!.N@O9\_,N.? 6OZG5+FG]>Z]1[[#U+!+CGS+]U0QY MS\|+0.Q^S^8;W8_HEIN>:NVR4\ZW^W*%'52CCX5)B(FI1&LF$-M5{d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`M>"-3U&0]:5G*V,OO1!0+QU \P#WRG^F\@`OD:]+PIV%"ST8?_QX^S97U9(S M>#DIM:$OQTF<1,2,.RI5%"0$:#^AC0{4&N)A! MLBI(5@7)*Q]+D/+Q+BL[\B2_E)\OU$#"]CU!F2_$PE7^ M!#/+0+R@H^9L#^UND)N=]B6I K2I#U8F!?IVJ28I$*) W\[!!.DGH(P_9U7[DE1/MT.1V[$Q:OZWM6KV4.?YRO&0#:?.@H M/!"W2X?X@1#Y%\KD&4D5Q'9!;!=XEX%WZ3>1^GFQG75N^8_.C.:\;_=XLV!(MX+W9KUJN!-[.62U8Q4(_1.|%??&DTSL79JW&O:5SGL\J\SFST/A:?[@__WD*X M#[G@_$57%M:OUDM%YHRI&/JOL;#AN4.VSPQ-%\:FJZ (XF+FN%0Z/EIV+H-& MY>6? PP_^:%$GRF'!GC]X8D<:8B?Z%_G^K@B0Z=\]NSKVQ_"F\$WD5]F/F1 M@77^]/(]S6C3$+\TA!4SAS4'(4%FYP$B*B4L,F^&)]$7@]Q_$+1!/ Q(W.A MN0"NV\#?)/B;^.]'K3LC.-(<35B? Z"/F.8O:2_P$?W\QX..3=@2O!9WI(UEM*_M9]%1T,&7V/.-ZN4W+*((6544(64<:DT558^T>56RR%56P/.MWS+\2/]U[(N/ M7;3U)T$&ED+_A4/$G,,"G[`US$%A2,U:'K_0K8*4$(Z$0[!!RUIFAF>=OZ+6 M7_%P2)_R(]X\2V)TG@N-(9%6+1'@9[]%S[-0@AWQ3NU M,2D!ONFU/05W53R67+53951UN*9)6ZO;/=$IE%/M";;XG)6FKS\3B"OYZ7 M_^=_HP0"-JCY'/P6MCBK!GPQ(C1@=-,,58 $(K(R"2*VM'L;]I0QA@%]RM#CN& M!+ (2LFS'0A7(@G,\'WX$8Y$,,8,61/VP%]KP-#*4)9#61NX"=RA"-_T%]S, M,.3?5BW;M'Y$__T[Q("KF0D?#BWFAF.:_\#N%80&>-ERC7+0Z: U5"FNH(X.?`M4Z7T:'TL#1D#O#.XT1 =HK8\M)4_%@[W6QU&%2#YX]/*L(<=9*8Q, 5R#;]<*W,- MLEV=)>,TDTS_^@=[HDY$[G^?D.YKH,&;IF6L .NV+S@"N+L'Q2/X7G0AHOC? MV!"]$0=BKKCAGB^^B\W;'HKCTRVP$*YX8<7AK*]U@VD3-V Y+TEJEXAB0.N MN9#4'!/ZOGMS=:;?:)VBH$QL]'4\&K3? N(^]Z62EC3S@+1'RVS2G=R<<:-56^W,6C.7S78+Z]RJY"CC/%AAXRG\MZ;0K*[),7<'}3 E7V-@:,RPPHOR54M:#&4^CRU# _>%8>,(6(F@ M4?^:PC\!- D^(C@ D__(KYN_O_Z!] S^2<&J8E ?(,/ .;.*#F\K 9.PB$X M!Q +9P\E2]9=/H@0ONYF"Af?[@^\MP&%?WQC@/=YS<7C23HNB#R72HX)+DZ) M!,=CR027',4EG!!%&A^+T+GAM[_H"ES)X0H]34Z@2N]9+%B99R<[';6@57$\-M4JRL]/8PCT^57B%>7"XS;HNWE]"B1\/Q:MM(9-BUA:3;=MRH5;'VVA\R1&G M-ZW&iRRVX!9KEA[@9=->"),TV@(C]>.1DI3H]>A,IXEIP+;H.5W.:0[38&3R M>*26?M,%<=UK,H5ZIF8GXL_#%0M'XCQ4&.@M=JH-1CB1):K'/I=K8UA8\ MG5,_(W:5M5HLMG5*MLI#XR*/?;OFC@>,_[_G;<>;.0U%XX>%#%(T"KJD1D5?VAY/'05+5=UZKK59S1*DNZ(NT6)#3"E*-MUOA+@S"2]4P@EZE)LFD:7%HBXMS)X^O3;/LL-> <80P]:A02GDXE"E(:C#RY M9S&U"JG%4DI7T'K*G+=R]+)5A/<\8928E'*+9=E@,&]I&B6LI]:K]0D829^\ MY_.(R![44HDT5L=DNS*O4,W>F/#)=,K\2CO' MI7H!+<\4&&=6'4SJ,IH Z73*?%?.L:P.8/WGVED9N7'Q&X?3QDUGUF\]B MERK.,YA4?>6)PC7;*\.G @FCU/[*T!B373)TH2>A2Z61*,ANQ(GT+I9B'3 MH=,&0Y=`14441M)BXM_U1*0:=+78,_MC\VF*+U;>RZP"6S"4;>"TC+3$BHK M60*3NU6EUK>\=!PHA6=W-.;IBK,=&)G6+[.+Y_M.H#<7AJ,/&& 33O/<;9> M4QBI8F8*9;UOH0Z\YPE34RT^C1J%=H+1Z+XLYG2T9\CPGOB)G&+QQ'"$U1=I MA9@.AV2]M*)T=\G1IU/J/[=.,9VE*96;.3IVXD&\IQ B./'G17F(T3_5+-4.1 M9HUQ:]5TE.4,CCQE:5S%=\/3<4.AO4J-R9AUI;A.\M_,]N3O"=D60^;.MQG%@+23X!1QY,]7;.H!74'XY4 K9X1*EVVBC{QO[<.U0:I-F8.H2MM M9B366R5V&33C//!KI3L750"06RMSCT76BF1A({UBP^61&NF*W,*,)+S"WM6RU MN$RWGTKZ,29.)*_B59%0H6QG;E*+#A[.5NL=7C34X7*Z>QCM"BS1S- U^J.3Z@3FM:9O$174&G&>/,A5U(6 MZX'4A>]Z*OK9!&$5L/5SDY71[BAO:C/2S;. *W!RT^P:M35UG".53M'*XQQE MJRD*K)#8Z5"C9A9LIM1!DNIF2KU1XM\\,. M5VO!L3L2'!P9? &97H3J:B1F\NN0QGVE2+7S<)\E=]DV.GVLGGY$ITCOHO4NLC/O+D^1 M?_)=-%(L!:.;9(.OL=W[XV6]"ZQ!8)L%&6 O%FT7O%QG&-01ED_*IK.]-K-N;@' C=&L'C@Y>XG /EWK. {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|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l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|>]=H9;1<11G MI$^1/GU4GXC7!$D#=U%WJTSJ*?7#E ?NGR'^!MJA!KTJ00<$":>X[*AU,M^K MBT?\)#W\L<7C9=,5@;NN9U'VR/3#7K&##@B:V!'T@ 3_CJ!{GTKTEU?Y^+6S MW;XD:?*96"89+-ZR $.4_4,YPP5P+MI__>?? \C76\S"4PCR@R7|8K+=W"2Q MM3QT,[Z]4>-O+(2!#M=/5]ML@\9V(E01/V^%-^N2>DC[OJ(Y!%?+1> M?D#]?XCQ4]ME=UQA0?LS]?B!ZU#?)D%|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sE;>V\,6[3Z LM">CO++#YO!4'23\B& HA/ K^<@*'#[/M=;&185\@[62#[06KG0]&WS8&AA>?; MQ<[851%>$/RNX3?L%IO>/+(M"9*\@%;;^<;%K]106'9F8H_&Q@(K%81V! ^U3 MS<)T>2KPY\?=5N _UZ$HD(Y8]%,MPXBD>]=F#\2Q"QD=C M682,#\>RY%/\GIV_V"672!.YCU[/^R!:7L/^@PEOW7"^9[;-]IOVD4B+Y M1,3#EU7Z9B]D?Q^C%FQ?,'#[XK/U0#[G9M]OR?V-8$OS? WGU2\YGZ 14DP@NU&%#[GMPNH8L%/U\>YJ^$,=E^/2[`O%M\|_D/90N(B,Z?_ MGI2R+_2BVIQ-M4H+UKDZ,.69[4]>5'U58;3RD1[A"3R=CZ- =GSB):I"QD!9X$B[-1]-M;ZOO#W&CXU^VY2F_35?8*Q9G.F>BARS_{2."S#F,L1D&(U,6_*'13?0.;`M'@-\0D?1CR1@?/"D,@QS^TQ^Q572*^A=\%M.2BS1<"JK-R/0FD3\1PPC*_E:'W-]

M0BX65TG@^H/!(#B<"\/40H,%)$<;8N57=UE"YF^Y0Y|K>;*GMP)"\:XEY2<`M\H#'>@-[E5U*0G-J++#?]C6-4\MW4]@?;U?Q76P+O:/,J8HS_0IJ6_54<\/B5`MN.>?*
fL0]AJ$4(O+=IA3)>]%>/Z/KZ"YA('$Y86"ME9RVX2S26':5J8OCX:#? M=;^.DSM=!Z!8-7B]*O&VE-;%AC.5K%?QD;5RZ$H:$5,,I58MJE$41Z7Z)KF=`M(NFWFHP^\"YQB.RBGZ;
fWXUG^GGVT3$,D/LP0'(]+GBF5*'2PF#);Y9;D<8O0C>DRR$6/4V]5NO@A&TP]"PJN`M,1Y?SCH*W1P?WF!ZMQ(",J;AK=02 @HJ;/-LD^XKS[T- #RG,'ERKI<
M+W$5LLH25**N=%A*$98P.1R6%R?)*]H84"O<)IN\0$0]B!SC-J>@*81.BQ5!`M.N'$WP^\5;2=#4*;GZF<&&?`W<0)70E?)ZVJG:*&;Z=WWO:1L0O[^^CI6DE
M\H*:P3]J.CL2Q"QH=C651I)*HT`M\J#I/E\C6N@VJ^^3(O4G51JIPSJI^X5&D*B007B/0T*AH%&ED:C22*2@(5;0 MJ-+(HZAX5&DDJC02511H)+5)&E4;N;01$E48>UXV.*HW\K$20J-+(
T5,AHVB`M4:61R\8_X01';1+GZ*GL%OMS!5701KHR+W:+_ #CS]7RY;X9%MQK8>DEG*(4H`MC85V$U6SX`;FU`@=*BR>C4B/AR,MX?#2(2HV<@@'!)5NEE,7%]QK3RS0, YWK
ML`MFX5]V\A4GZ9>%X,T2K6>FYID!@O9DMF4VN$<"7)GU9K)*HN\A#&48C(]Z>6`M%[EZN_LO]B:]3XT!A53-Q-O@3!9EXZ56DHG'1ET4'.$P)+7.YG")!)WM(^`M&B!$)4?
>@X.CDB/3L2CT"VNOR? KU)ZG9)-/4G>#`\K.&MZSUZ@#]!12M]NK MWKI=F00E1X(@8@45%1Z)-IC#845&Z?U1TY$$,M`L5'(^)Z9`M%<@&C+D^S#K\K_W9O-
C)Z,YN\05^,YJ;1Q.^[$\D-$CKY,?@P;!Y=NF& M4S"GE,"A]ORM@3\W$XOC3PGJ5KP[LH?)/2WFD:D%]>^_NXWLV6ARWS;4H9ZI M!X&BFTO`IO;KU1AC)&OXA6?LW8+ [R>?OBG-
/JU10%?X5IMK :U?+AXRZ83V`MP9= 5\6D*+ M;$/&Y6>>+V BDP8C3YZN-91JCDS$BZS;XH:"^LS/6]4T1Y[>LR)-INQLP:R4 MK#&.*T3[N=LB)URAZ4[4A/37,PJYN#33V:4T(@22[7-
#./V M;3U\"--(6#$U,EI;BN`K=8=$/I6+/2]#EFLUNQ(:L>&X M(:6)1LY6RV#2L&7P\TIBV=2(5?U[UYXEI#X4U8T>#%EB/3N[0Y8E5<4EB5^=@Z'XF;OFE'7*K9$!H9',
MJ;AX"OD\P%|_Z F?*0ZJ/<7E056(4;-`M&F%/>%;$&G(R__D<*[7;"Z/;SEL]U6Y.&]TZF@8CX\4^]V^+IN,H-6;2!*;N6Q4R[!%FY
M;R>2Y/39[;RPAI)L97EID:\6)N>DN<7F*9I+CX9LK\F/UD)9Y*>5L](\,1@E M4Q@V1=9+L.)EJT5OLDR?DU&J,:Q7W=RPA'FB71^-2VF"&[> +7@RLE!>NR-O
M&:>Q#!I/IZ:$5B7CK;/2|/(S@YG171KK#6LU=3+,4X1Z7IHE,^1U+I54AIY-M(CWI=OA")=>",5\G0YMX:F;D"60,RD:9[@^]>&TR!73I-_$-D MN!S'4]??8*6S{G$SB].8;8!]#-
T'677^O*GB-$5=K+2LN.N1T#!WGVYEQ;] 6 MT0D'A^*!8P%^(8EIY[W1Q*]7G[*LS,0>C8T%5BH([0[:IYH%@ C\,P+32?]G MX=W;OE.`DOW\C3.9=$W+,(';[" 4T28N2N;&K
>8X@N.7=]^?L2U7>S9!T\ MUOE-TN;1GDQW*@$S6P,OX?E!\XF`,<3&_55/E=2>MBSL&=!%C,JHA*+`^V>D:TQL_#]M/D66(V M:G.C9CECU<-
)>"'T=`C6N55*5_9K7R7X/0K0R0L8AXZ1^?

*A/K=%R;J**ZSF33*;8]BA?M)1P\'5Rf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¥M2)=Z,Q-.=R1*:I)%ZC<;#B>0A(,;?/\&U!/B*?T^.[+]Y MC1_3GE>'9WVI^L+K6^D/=B5?#]D=[8FU18.AQU2]MED[SJ9<51L8]>%5XP)V M0+N_22/C'K3X(<[0M2]<"T,Z9(WI5+%QE,'J4A;39"SK(M+R &NK6 H=E MC0+4+XYB93BNNP] >]{6P'UX#]/$\KL?)SK[4 M72A +YS3WJ&8W^3WM1#P+\E.L,GJ8)5'4'\AKAH+6JAA&LB#A3>P@AQZK1#% M_^ZB5BN D+10!G-G?05RT,AZ;H1"COP"GD*GSICP&A'G#7(< MND\"@!A 0<8XPT336O"7V9;6P9>S)X;E]V[X&F L0R!KJ:A7S!XN@D8,O8Z M'+)A'0"F#V.:6'(P# BB:G*-OZ+-3%, M.V3!O4U\EREZ(P%P;V2?//)TIAEK\M7M,EVZ7C>&]3/Y4U>Z (LL %@6?[VQ MN>+U[@D$\)"A$\XR0H8^-C ^_Y9'84?'@(>@NRC^STH'OE31YXYBXJ&^:])]5 M]WA006+A3IK;%[VA8X=$08FA), 7/2 F ZW#P"#]'3AXQ(!)4[C T5U$?PR"&8 -']R###+=EGX%#; M$2?>,^C?2-7I5 !D/3%P@=6XJ8V=HZH!. "O]!THMH9"%0$8_5L&3;U@@\ MISA!>R-C?0+^,;R=, '8G0=B !^2]%1A^ #1+D-!EZ,%/6CSH.@,DP_@<!C.T M!1J9[JSH3VB!OB+QU(ZFR"-R*[^(3T!-1]Q@2YNKBZ"C_D-D@(!\BVN3PT6&;0QA;(EMD0V 4!5H2@!@KP2W<@S . M(U;R)B% &H$=1&\'7(Q^(:QD;>%/E-$V5W.4#Y8D2S=].LUK??43 082@#_ M8O21Y#/C B%T06PS=0 X++]*(8_('Q,P*A-)8@,'CF!E8 M9."[^Z)H.EA98[V[91]9 ,V'5>EN?@Q79X'8LCXD('SWZ!=_:U M-6 .0X/IR-'\>0HAR<$7"2$4M ,)P'7KG$7)P#'//H9&)KR,A94]>T/$TC*MV M81G8L?)<'0'>$$$= -\3*WVLS7Q4vC M@=0003-XC"PA;VHEC,>@(-#?0:_J&&D(A@49VQUWE:QK9)%UM,!&@7D#&QK8 M"\2YB@B&'%,46&'+(UXZ;WT7J@-'[6W\=H?P:HAY)Z3UO%3!5"SB,!/BFNAR M&,F$!)5)A@!LM2*\', "\FQ(9]K,S.&HBDSMHBHK,U,0P)/@RYFODHQ)T,A(M)*1,O&%*YE86*7(A0!RFK)@&<"BZ^UHC[L005) $,//QB.0/L@KTN& M3.8>#<%P+F12NX27804=CO#:8D\Z=!$&6\)0, #R[>^*!]$?2M=O=2Q_,3 M/P!U.'5#;ZA'O[@U:.G &U/9]W>D"[(/SMRYX,%!?9RR@)O:.?W_#\,^,K6 M\E7]9(#R]>FQV/'TV%LF)!f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{"?]+=>'0+|ZQ\6!T_!K5P7\"Q/V;3M.&**5ND\))# (IV'8Q!W>0]T#!Z M/5D%.KU-(09>*89("2F0D VY)K*W#)|>$XQ+:,.?4[4A)B##DIRS%ZG76M9$Y%+X;2HXV,'*%=H5[-B|!#O/*$44]TT%WFJ2L5<,U%U M*LL/:,H"VLC7:$I^AM-VSXDZ&TV(E5V%M2Z,S4]W=))S:3%]66/Y^HT-D_<>W_2-Q4HW- M$KKF36-:A\1[0S #=8S!:85)IIE8+8?S)M7K.O5!=+6]9C:O%Z\;,8/$E)]] M&%/-YY+47.QLVAF9,N;&B)CIQ-YQ)LIGAD$2^3CAEPMZH$8A1-!IP9/ UN@. M_'X!#L"T:,;+.V$ V#W(L)U*1\]K"+J]#9K@-[I[1%X)4T4GF4C?V0#GB-AZ M/T^PZVFX/@-(;,<4H/#+5$-UY$Z)VVP&WVYTZGZ21)R .Z&/O1,F;$ AB^#: MW7U|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|@<4Z_H&.\X!5TZY&&7+?'&Z[>3Z8J?3FFQ|C7 MJQ#.1,F7Y>B3R2*4K>?C6+'AQ@]5V&Q7LSP'@9#;\XMDTP! MNAJQOW T!297L3&B%3%3EE7RCR,NPF-;,RWM6PAVZ%FG_LZ\PFAN8OTEL&NHCT M=A#*;M=)UGU$0_@DAMVVW-2]G[G_COX/8HZZ:!NN/_AR.KL@ZP8N#=QQ>KQ/ M/;FP*A#O1V-D^56M-8 M[Y$O)"R^V.S6C @U_OIT2%9G6Z8>5U:<+ RSY=HB28W7%SZM_U-HVXAI=Fl2 MYTL\PPIRMY!;Y\(QJK6'lB_D@(,.U?M2O!TW1-R6I$-(A[6_[BM.]"1S3>(B MZ.?2 ,I"3]QWLL]8"6RC;B^L\]H/I*MHEN',C&/!M2_L+P;4'XRGOZ?J/AVZ MNH&K=31RI;(6K]'2+N,=+6OW=#3>;K_<-5!%!N<#P'%^T@%|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|"$G]4>/<@_VW/-1EK@3!!,[4-L4VWTVSNR?X042 >,T M7F +#(W?A:!&"FY58. L$[U2PS$M0P!>"-=:Y/P")S%WP6C=!XM^E_2>>L1A MG;NB$U6% 3IX_=[X4 56+YG"DN#A!41A9!I3%UL1@*<+#9S%[K6%'P'Y#$G@S' MY"&,V/*LI 4(NMU1]"!2]&\%,K&[*

*IEWN(EE.Q+N M_,7Y60.:O/2CBM>6Q8E.4K2"#V9PY*_OPA,X3'<#E!+,13+Q.O;PH2Y,14>7S:A?N:.>4,EW0&^T]+%_"5 MN!XPU;<6T44# 4[T5?'-*_&*Y6&3> MRY:9DFA0#+745+U5'*^%^S[_L&DG*@1.E4RQU&UO)&7J<24S;_N$2ECL;MC MPR%/UMZ1KASP;8Z(R#Z>G(O;]:%XE_MWLC[%8= M|BQ:(4#"N,=8(TC.&&&8](@ 90-ENP>4"6!4>%X1D$(31/DNE $ %^]8&MW? &CUMK3%Q&-,R*Q@A@|7XN^&H<##T5RD>]#T1#8SP[(CI,/1/UX;34)SB?LMS=DT9H0[75OPLI1 M6WG,X7BG,61!DI4@(5X]?G0)XJWT-3T:KUG KC<";,J5,2 F\L)6F2!'X?L_ M\UIP9_BV7X>+XQE"(S_*(#=P#8A@[3@[?IXHN!4BJ1Q^G[?!.F/$HGM\AB1G M0:3O="(Z\&*[]2-[42B4#/NXXV\9.VIA; <6]N!:XGVM2WPR[{'PD1=$#>4Q MBL:,0'M5G 3YWU4[!-O$T-:AH-8+F50CC\30DRO< 5C0RX&'75@6K.?"=W!E0OC:Q=A$MO DR9/48 MJ&T$PP6P5CS@C)F2FCD;??NH B M,$SV'?W1=O!\ 7.KI8,,F 7)QIF>MH #=-EPR_G]VB[@C\IT"W.6Q&4X";(+ M9.*_%1^NK$G[OHDDCCWLWOLX=;=<'E=M HPWD=P0 MV(V;30+0X";|#%,9*SMO3H8[N)Y+\%W?26S? ^7/E9"@?]_GU!DUY+1]B3N_] M.:ATU0$7N!!F+QHROD$=[1IZRV>@\12U(96BO% M>ZWI.B6=LSCUE;5'R44S7\'Z;4Z51*724JC2]Y2]9L_1"Z->^K(Z%>8A0U M,FYIRT+$:+>JSQSL'#G//&F@/62*SS#1=R%.0"[4GE\ 9EO'(WD6BH1'GKW- MA&_C-7I"(US2$'3#1'YH, IX@^7>/WPZ8I=_=#%.E+H5H]V*T6[%:#OE96\I M1HM=?3':05S1"4[X? +;*]|@ R7.'Z=OO;6,-$D<3H!{2,,]$$-@LD'AKZ^'[MM6>|(RPF^CUZ2VI'CEH\%T#O=QV2476!8ZC;]VI*#>QX[MN1>NUO?,-5@2+#] MC.2,E.V\.[0P&9I8W&%W-!W&A0OP(G31HC< M2;P)BN9GAV ^[8?(SB;D,QC5=S1NKX7_&?>Q\+^R7>WY'_F<_@>$_C*3S$M-3?PT)>B)# M_27\?*

9+K23E/RT$&EJ;&D3A<:,G3P*8LDOH9P!D>F)\LXI7KR=8+,AK8@@!*UA3.IKT$+&1N M<;X;D1I)!?(?)'+]I!4"^!-)C:EBP_;YJ=N@>)/!DH+E#4#VX/0\G0#:9 CY MJI=ZM;SF+CR;W9\]2 BGD_XO4]#O.YU{6P9R|AR:[(.W^F1F#.9O:?M3@6XFV"'[B+\6!/!E &R UV"_A^]DB&U&N@#P@2S9]$%O%:^0(&'>_* .R## MQY4.'(5. <5K/%Y!]379%X%MB5W=. MXZ9XK',%SZ06WT#*87A@B18V^D4/2#N/-1(}FI,9*B)FGNH^*:&S M_O-L6$^^"78(C&L(7)7=7+)BMCOQ6S,0&V1WT&6'^ M]>\R$C%C+;MG^N2O2'=B4]W/A4H;?F!/P)C()+B8=&KZ(2I{C 970:'11/) M:"E0V<),$/&X]0XV2"MEZDP#\]A'CNV8<%RV)A6CP46)AJ-)Y/QK:U2F@B]| MNX$=*667U:#NR-&A7!^IZM_0Q%BBES9WB07%$D@'.B:,.&D#O@CA;":.X#?QN3 M45[-# O>#\@"?Y)UG$M3;%+'+AH+&0/.D]{IK-?]R.+(B/;X:@9H2QEN5_ MO?.U839#3W5'T>-" ({@3(CEYTR4YE(8A\IZFQ"\,B\;@.TR94QE4&5X5#Q>5W"+\=(Q$L)"@3KR/;9RA\!;>$W&4/.']DX@_Q+O&1DA M[IL*8=]!P/_IN!3S#%B<7WK^V#] MD$8D3#B+S*N'-X-X? #JS79]\YKAHMEXO0GAW=\+ [^0-@QOEGYPC'I%U"'^1K M.V3E>[S"O7MQJ4S44PI@LL\0PUAC5BHA=R!H6-;Q*ME M'0DX^DJLRXZ/MK/8(W;GU^\\KLU"KX%|'_3OKO1!O*XLL!@=13C#ZW5]&+^M"Z@SP]29-76(!+EYMQ.PIJ=7=V-3Q/6X%"$_U2B2HP&O\M.K!? ?Z#H[$X&\ MCTFL4@C,) T' M,4%*#(9121H(E)B,2?$1(PSE7X00Y!L=<9 >1&EKN7[2.6>%[#HUGRP'M](#;O|):+U4Y0]]4];(4WW08[![55] M"/>,[5\9K2[[Y5]*U[B((]&MG&R9])H=,(? W;#F+07^NR4MUF]WFZ7BD\45 MQX/HX7O&XODTQXP+676>03S;,U+3<9[%'1+]*V5YP4>-3BO#97O%Z83+*(+5 M.J(K#]YS65P6'NL]6.6$GK(<=7OY6)=B!{'#IXMV.6/G'*E/R?]]U5F.YI-6 M%]X\N*=>6.FYZ>/34)6S16::.E(O#R%-S$#^\YTAL= 6*;]?4K#2CA"55&<=:. M8W3EP3WS1D9>VI%QEVI7,P_S=O&AF|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|_77.2:@Z7&4C%5[8VF]_*R MG%M5E?ES47L4;9U?3#-4FWJ,5^.T$W+)+RP',3 7T5@X1E_07OPT8?JF44G0 M$B1^:#DO)KK"B@]%?!:FGVH49?.,2>N;ME? 9GJN@1(_R#$V+=-N+?A,J\'-M/,7-"I-<-\FK:WLSJ!:RXR&8(S4O9R?W#[_G!4Z>B7R>RCZ84.P&1B2<-M2J=N,<R:\&V8BC"O[*'7S*O^H-M"A'Z4YC;/U);_?42#0W1*?>USY6J\C-5H98\ ^_F'6/=-4X@0/GCQ)B+4X91RP$I'#3K:-M >]/N@LU\'4A4QX1/+J;8\FW?ZC_X3K*KMK*X G.R=CYNT M17]X'01'Z5H%R06.24IQ.AVCD&*,)9.#F"#+@^& (&0U#'3D:,BE&\D8'I'I(E)M*\D'1,1],MXOUXZ%:.F M[E[9?V*BNDJU:,

S.6Q/.5_4G1>_B)^L-;COSA9UCB9/8W;>M MN0G-,6?V@_>;S%SGSM G[MO^_)I7;#O=M*^AC+776#^DB6XT>P=CLV-:#=& M.T\F_\9GYS73/YAB-P-ZTVO?A&8W W!CM,]OB8O? 76%CTD51/FZ*_B9_-T7_ MW8CV9S/.GZCH/PC2N ,(U:[0LA]6E0&\1<0?='KA2(_ZHLGE%4]N\2"XIM-+I9)7]_-Y;,NX@ MABKJZ/T=W$Y?MR>RV9D(NML>5S/<3ISG<;,X^J V>6*2;GO"4(8CMZL<#1WR MS*_?Z3 32UVB)_L_[HZ,IZE@3=Z'0N[DN[=KU-DG]+,^WH]MM?DBU-G MD#F#<`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|:R'H6+R/PINJ6(MV 0$1A8=W>[&R"JNRP_VP/3(YIFD-'UKAR=KB\"BDMUO*OV$MP+!XOH_@_<&Z& M=J2#%+|LH_>%]D%DP?T=BC"\'+9I%:68ST#B)BCS$)BNJDNA59VB+&.IPA_XW M2)*-;QM2++0T]"Y2;&8:0SP&!>U#&-2V@-2YY6CVKM:5\;08"S2*8O&6$?6 M#UU]&[.@74)"OX,N]L:2M8EQ?&;;-Z^133Z$3S2Z1Z:9HZ(8PAP\/^VC*2$E8*(;P M3?D,OT(8-H]8\HMM8?*,6\BGZ:Y3B5-/JJ :W` 8$=14_-6@ M)ZK*>#A)#O-<3UMPG>E[C:HZ[F_?Z,O8\QL,M?]?*O7M'&G1=2[2OW\4*U1A M<;^)K)>4G(4;1P3/I5$$Z1KA[*L_6IY \ALR>F3'SYU_G'B,R@GI"KZWO-M\B,RL8W9/X>(-H H_7K\B2K)-1BR=-R>P-@VW9*;/B)3U!?-)-6?PJ4WE,-H;^0M2NV(A]@@95!10?R=#[FYOY>V:.SY;DX0BR02-S%OJ9< MGT76ZJ5.?7!?*5,4DTM/-L7ETSS#?(FL+48HH-0+ZI)*%/-.MQ59R@,>*,48 M=8K09Y&UUQC?YT2-9$;1Z\%6*;HCN/G2P%BAP/@D49,%$W+|$]48",_ M97[2LX=QU3"Q0G4A,=C2Z/R/I^`T,@_(M/HS3-,Q_O-/5P#+=1S/X&8*,-@#/ MFA)&Z,'_"-I26%ONLI/ANZA???J?ZT ;Q:62U%/T_K]#@9^]/@2?$A5>8<5 + 1+N M3.MTO[8[L-/[\ (695^Y.85^(OL-S:K<33&/T73+^67NW5T8:W>[4_P@A9#"0 MEOBO3CU[%,L*0P_I(?:#IZ5^Q'RSW!Z (6)60./.]T..!9^:!]C@)#=C6D?H MX%A7E];,#WSMO7W: MDUMO'.YD[71CLX&3YGN:N%6W*.[E\/4NL;&Z^HJP)%2OV^U33O>["4X8KAC[NR.8T)P_M(^-_UW:% MC[+V0NV-\]+"=;/S9M4]=T.+E"76/G$=I@M]H6'!;QC_3<=F!W.C3T+BT12& MPCMUR5T(:8CYGWM0=)+'<5'!=+$C:K'LJ38H0i8.Q8%OSA^_L;'9$4)8*<9 MHB[OI3+!N"%;KNBV$1"(ED!O!TYDn S[=!?\ 4X,&2H?PD(PB0=Q_X-6=.% M Bl/G(G<'=|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`.,NJ&D^KY MO(@O@CBXT[]N-+'C51T\[=.;.<.2.6\^7K_\3]I(:/F>=Q9>1%MC4Z&5_N% M_F.Q/W@<&D^ZT[%.XU"MKK!K>6#BW;,MG"31WYAWH0]`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`H]*8=AM*DUI^_LF' O6I9 [.5/J/ARM2R&_+C?K=9 MG'VRLCNX&.S<:H>- &U/:NSX9F]U=9=0LS3[9'U9_Y6I^_Z"A]SN#R]O:^1^O M<`E/%j:?/,D=^<:U^:#UB_:-4MP|++666>]YT_QD.I<=.7R-'53NOJ%-Y>F5VS5I*EBVJWU*J=&R?^?79T\ MGO:/\,PYA8MO'"S7-?GB/5.Q.(Z6U;2HUD. MV*BT4YZCFBZSIMUEBO=\/8V6 D0ZXE.6'[RH[N,UE1JV&L[G?<8M_)Y][A]<`M^?:Z-)Q="@_FI5&=N2"UHU13<*.V6M56#A3;S.1Y^;,8W.WG9NJ/5CLS@VIGW!^] V?6D6_MTA\XZHE,^5WT?Y5 &)?$O"R+)6G. -OY'(]5NTZ+)'3V@Q.&S4\LEJHV0VBT M$-IO/1"- T60;-1U:7.4O-QS($$\E"F_Z"'"/=,&C2*[P25_'F6AFZ"*:6;?9I4 MIF:.NAL,#(N-^)Y9+-G;GU$KZ9>=)V>V4>OU<*R,K MK7Y-[=Y5%R2K+TP:AP_I^ /2Z:#,3I:ZI2<+YYY6!'I9/)YQA0B4]:[J2TDE_B!LH%]X^/|!?][OUA8UP;90:J2Q^-B)(2^:,.+:^7QJ7:0@C/).PTE42"Y7)2&@0R89#(PH17+;& L@JKC MK8_1Z+8*]S:@!"HW\L.M?7Q? D,8G]9&I2U<7-?NU2N!BTP NMT4F;8F8KI@2 M/7&5>$%,"62UW2GG63R#;PO"Ti+*+GPG^H!C3 V4\+.G1FA?-.^A8(U[!N\T(%#BXF!G31<*% 8T1%<3VMZ$I-N9)LU/D>F\D_]+Z] M:W>G?U#N$??AXJ;5.G([7)E7M.(;'C6TN!YQL!]_U"S'C)H?:OLX2O)=K>CH M_<3;J*YS5FPEZDV!CTMW=QYE7:U!]>?J9S]]6?JQ_>9B^XFFK)53O1:13EP MKVK%W;V*HQR>&,=6=V%3MB5M %EE,.Z"4M2-;@S@W1YR-O!;@T)LERT%@X M?LBKR1!f\(;P@ N4@H66;^'"07[.FL$F:>4749'6" VC/R3TYCSMWTD%KIW1P M*)\6AV? 530E^>)ZY:LE3HD9_"H>27!0"-]H8L#Y@\+/,^(M=Z:YXU8$)*+ M:0"%5@#QW+.8<6-IGK%8<.AY*V.'|N7M' MGS=3&6*=O=EJP1LMD.DZLJ0YC&2^JQW)*^0&Z+ .6W.]PF.]K/5B3+U8X"17 MW=C0Y-.:+SWPZ;U?+U;@DG MU4C9?*X\)S2C1@& D KB#6SQWN:ATT>HY*MTT]*\'[5M1=*K6F_0#P\9J2@" MVBUN5/W7?_!;&+)/]H%2.!U))C#SSA6^U_T6;%G7A'O)RN2D?X*&^K27.)K=-M^.10ZBBVDD0: M"]S1E[WL)8 2_TG.;$<#1+ (URHUCY ^U6&3:P1-0P++PC(!KZ5:.T)!{2L:,Q MVI=_F%$R.YT#ZQZ81L,<@PBEZ"'&:C&,.[#]P*P!Z?%1TZK>P1(NSZO.Z5US M\%LB1Y5#]H#M_]EUU!"EN!#0"];GI5;GNW]_BR57+D .]%>V1(QY'}HHV*R[- M-L7\)@JH;#*OOMXAB)4V>G$3^0VH5QOH@]E+6-2W@'YA]/#B]]_FM]M=`QT MVO/=;NGVY+8Z6TI>]HT7E9-?PS;B?8_]PZ? =D7OM]_W.L* 7.FVK[@#VA8L! MTPSV=YXNPZ$2FM%&W.];A65+-9A;8.&8N[GC.8)0^ "8'<6R0"^8M$]D28H_M*+M^\|6L /.I/]7F#B^ MK3>5,.W@KA:E8N>R MY3*_O6V|/;F0SYM@G4]VF.?7M^'KHZ51R1]U=RF; MJ0)5)2PTBP|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`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|\Z@E M[;8+5V1^WC9GQ,FQ(IG -\+@Z@Q#G 2JH'W=_M"Z-EY_W:S;#7]Y_O6U+% MJGX0!\ATM/&OD]MJIS&N>.[^T*_L7Q]46;-%Y "E]7" 3;L:_J_KI$'Y2YS_ MS#(S&G[]!5/*TJ=?!7N;5WOM3/=O_;5_M-/S^>'2G!LG,K2WN]+UM53%BL%>6U*7AKX M2@!75M!>)SH(/I!%Z]>QG3;>2>"@?!DWNEFGY.OG^ZZ? XYS%[=LFZC&W+[40T2_/]U?-6\RO<:NTY!WWR\/VP?M&]-F 5-)\V*YD./U0KQ%"N< <0ZP^GS.\;%94LM.^]IQ7FDW!W?.KO3AR4=Q M@/'=XYU'U@4.ZRTP#K#&O,XTH=%7K[\YR5ND<).(NQ/2 M"!A..YQVN#MAR|T)O0$5*^AA)VJ"2)BLGM7Z.%30ET(]+M_N]^\MFPY?]YX5' MK;+OU*O-$CH]*I7U5<^F":$VJXX-TH[- TJMSV4%W^CZT+T Z1=.\?7O?5 M:.^ZX^-KMW/.ND1L5@<]L5B]S\A7<+[Q%"N]6D 1.FW]]V5>[?)PMULC.[_J M?:+<9IRQ=WI;T;JL"UY'+U7?UP-&0=\A_[?@.]PFS_S M![CC?V-)*&;OLI0(07&[4L/DSC+:]2)D]9#>T<^&;F2JC:&%P>/K?WB37>6 MVC1K0*[5)S2;#.OU"7(-+]@Q+*T?$%NKJ90'YP_VU:D0[4HM!;C2'3]X]=%? M-&9$&QS_')^G-] [%P3FNOHY(WA_X/O>GIG_(IZ&5G."NS< AR",7WFH$CBD(L*S@]0C\SR&+BD %11(%1 G]^D:N+|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|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}&C@!%]5&[AQC6R2%>. M8_822]KK5#^,D0^HD%3?1$6;JL^AF!!T]GI@1KK51L,'E&0SPO GYDZSM"U-M14+TGJ*0R:,GL002X(O0 81AWH-H+|!Y^B*@9T.CYA"2/YP/C!7VTIX*1@R8 M*&H,E032Z8"63C4WU|=Z,,.+|K=?J-`<~7.Y?SPXN;4SG&Q8 M-\[/#E2EK'0^O=A*N?*G=`3:J-=V5D_.!W:5H%NC6?=?1112X"%KGA.'1! MQ=`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|;SR6&H>#*G$.NJ#^S3QI'_7-&RZ\=%_I- MS 0-GYQ*Q%GNO@O<]HZ% 19].[#A33UKY 8A:,OW7!3ZU BWD,!T M4,C'0F1N!C)GCO$P,8/BQL.4;N1MF^0\\X[S ME63'),/G@Q6R"\F$Y*!X,H"K^9--Z,S.\EE??"=2:M-\,DB4CCEXF]#<(`MAHK]_C$4Z^>VSQ<(3X>0'GK>`!%RBKYSS6;XV6CF#AY;0-YS46.EZ."N_A% M_UW1 !=9^5STL!+)22E@OV!$(X;+QQ[%++#1*55/6J#W+!AIDSCWOYPW;P=O MKJR"]&8(;64J3=KHZKF)1PP>B\8>O8TDTE WG8#".4W <&G>I^]H/=4EB2CO MRO ^#2=_S>BG#V$)GLCKY7F DYZ0W3)E52XS?S>D6Y.2I*Y7R_N MZ-UJ,\\&+1ZY%=/ZI?^N5K+/ RD7BMC[3R,,+LACZU<"LJRN2C;]P# M0"C,38UD6+:^.JDWQ:HL1Z? 9OBPA'U'6W08-?(O4C]_M#:E8\0P?P<1OTKQ M^ECB583U=41Z/&C(Q'9MNSTHG-CW_?K!]'!0SEVU.X_I8V*.8>1 SI=-CH4Q!@|5- MQ)EL1R88U*1XI\#9R$/[G>\1825EWM9K>^VPFSJV]DLQ'T\+%Y03NZGMN9,Y0)4VG4%-OWK20.2?] M-!+UIGTFRXCZCVGM>-+8?VB,ZR,E=W%J9VZ5|)D;=S? C0N./W#GKYX]]HZ+9 M/+NT\DC4H*O(Y=GV -OM,9FIPMQ>TRF=BL=7F(>R75K(RIHSI(%;L?75VZNN MKA2DW$YG5NN=[%4BY=L"%1)S,MK&@/U57TCG)Q3IW^\C)O)O7DI7? RNEQKJ M\6_'=T>9S/GU9>K(61N2^\>+0TWOJ!91.=]IY>O\.R3G_//D_!D<)=/S)ND M(6XWK=UN^AJ#/5:GISS?8CH5[.1!+S1UQS3S_4=7*G@%M^,/GH+Y0;F<6%!X MO@:GH4TI|^W(4\%#?4+ ^=:><5!6&_HH(S7.]O7+W`24)!14.E9F9S:J2;,M.^)E$_-R8G?(X|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

*MJ.6E8O:VG4H5"!L&ILT>"^<.QP7!N_L4A$`MRP[-P!DAN;EXG0F7^@98!J](:?R$2Y9K-,M 3Q=95U'>,X*U?UM:\F&6;["A-MIT)02G//:MJ$-IJP)RU9*F;)A=)C=);8>:(D_U AU-D"H3A.=9B^0M;MR^I^_M&MEC%"<\M&B=2\JHA@$6E.N"%.HWPM#'8@^YN2)PPNLPX8ABL/OL?@.W<.JEJE*^LWH.6# 4@.,2#12WJ;$E6+]]>$+Y94+"T%>'&H: /\1]L7#9.@^ 3?\6) MD^Q#C3J&* MWJ+%/0)O.$QCU 8ZZ -6X*23_MNS[D3C/HF^(G<',"[2TS @ZA,M*5AETEUZ+U1M6"7A]XM5&)Z/(E M=*"K YML$<9.5\81^C(HUQJI\)79D4DC$$(SG2M\,.R>&=+Y5F)00'+@25<1.,.M1_,Y3/S\.;IGI3"I%V?'Y\)2OI+[14]2=57|5QX#WL?:!P[>&/(&#!%^)6C*#M2W,I!/ZSBQ9&_(NN7@&TCDL,7B2V7"VAC&2;"SY:67STS(S\%&Y&2[0;+PO6 MUO1$ F3)4RDW?MT45L6G>=-8&J9EHYJ)X?+^QX7(+PTK&U/F4+!*/R=4Hl{2A MXBBM##0 JSAMLXC3%G';(D[{H(>O+ MRJ6O^KZ$VC">;"]EXHPKP*=7:%B6%?QX.05',2N\]88><0W3%C!">.M@<<+#U M<@]VU2[7E%0UN1OPQI@#G&QM'09(<0!6-)1[M_EMODGB'$N>6H61+X7CBM&T+\130/M6U;Pl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{H\ M(DSYI0-*W[N\M&GLJ@($MI'G3M-@_8/I3;CUQG!C6_?S<.BKTU..HY'K2$N MK/K]ZXPKJY,9V\5_D7/'KG_[.'[*II1 .A-I.UFS"IT%]P$VO:9;BK2*&P>=-TH[&66B_EO]0 M)X5#%O-!]!5D_QIOY&<=7KJ2<5*??=3EH$\4R(0)< C*#MSM%O5F_XQ1N!2'6WH_&+RDGU[G\FTZL?,T1FUN@TYV1$A'.RGC>Q@aN%A>/Y'G2E1:A) ^'' M;4\T5<)XWWNF:Z=3<";?G-$W'J!:<.9'<4:OEVOM@C5Y9$VASO+++F4*=Y9,S M>,!YP9]'9.V.38?NA,L_D R=*TRUF#PX87?W_1>'%/"M2[Y6K]-M04G0WBD1+[ZZ:3?H*=94?.**M!Y5#27[/PM!* 3A^P3A! [;PVIN@)!5#O$.U M5BGQ/PIQ>0[BPKQ<_N[JN:C>5R[T9GFI9=/3%@O.%65%H%@'6ZR#:KGUS/0C MUG"NU(4+CDAEC5K)$+:.5$#8S[]!V4;#K;)]3G2N_][=[8.#/\ MAN&%!\L? VL7%>?*R^>-H[FP]@VXU"KUT/%9^6.X.O+3"5\!EY0M\!=O+0]CA[MVBKF^WBI!F]S>$EU;8[W2MDTGFZ W9LTY8X0C]^ICT.,N2/$/H6BH1#* [6]IU=ICY\%""GX">>"8=1[FMI>.WNU.J=98T<3X*48 EBP@;fU[(+OW-MD^!-/O7)9U2M58IG+U"]!{&VCX% NQ=[*KU5]FI M-Y^%]WB*ATSQ5AZQ);.TU6'-!>8N,/F8 -DFEC8$%*BY0<>%]?K^6:=:KI4JG4?B:A505ON;>I*K> M;()4Z<_"U]S%4-MX2/+>3?1/]CDR4E(#*;\& _R(>>V&?!3NYFNQ_RG4ZU-MU*[7"T^UD(R=C&?N9KI_-ILEUKZ_KC.X?N=`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`)>T0.(;\;ECXUH8FIHAD|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

#;A@174I.$3*S*1DF*VE>2W77B%53%7M59%%##!9;.C5Z*.DOADD M7EZ4T:OT$\4 M$8#Q%"9V,:M "HC'N@'"*(# I%$X*P6> M2N5C4"I8QBRFY-
6U!PBOQA'=\@2COXDD;+\&F(89Q@#CFH.J$@6-@JYY.A&P M>.3LE({*\S99D@P.9XF8,:B=QJ)@%KJ$,<#$1AR:O>G\>.U%UY:NM39WBX4W
MGN8ZXN,.0@KO9DV24$KIPX9@T@I$DM!,,.!Z6!0(857*@C>E}'@P.6?AQA1' ME=60E=B%2G18E4_0O8#S+V]'M.C*(5H'|K[fZZ(JRTU@T V5)<;-T\HM[L)D M"
0\;.O44;U:4TDSSP<2N;*FL-Pf;X;K>NI#)!YKUL$++.!1K>.KO??RL_Q(#0f(8TMD\?RQ}&GF M/401)964P5$9=+G9-3$G\^1-T_Q[5IHBK7K6#>C-J8-G_AB@8D^/:UAF (.J
M(X<_1BQ("#6S5$8#YF62&4*&88E#X-\6Y%W^WHID1O@;1<^?H%\Q"/TG[E9/V M@(]9!F@;HZV7QMF;^W;@*GGY/\GK)WD].W7]^\AKB+]X> Q[/2=E;).@NC%G
M$3FM#V[/BBNGGTSUDZF>H[K^ :9ZP=IZ95RV>U\Y\B0EH;$YH>*5X,O^>4\EO M>VL(SC%7,M49X%;04U\AU3>&A^M/"AYP%AW75S\^#:Y&$E8"A]4> F"WZ_2@
M*&J;$ICBAXGFEX[`_P=02P,$% @ VH)L69YO364 !@ &R@ !@ !N M=')A+3(P.C0P.3,P>&5X,S)D,2YH=&WM6FUAT@0_BMSJ7J %++F0'#22&D(.M*E*;<.3HKA_7!CK>J^UUUQM"
fM?;K%@2=$50:# $8G@[,O,SCRSCV>\fOVF M:;,T(JE/_CD?OD, ??G"4TE^((2B;T++)B-P>9:1%+Y0(5@=18;6>_!6=?8/?"">X5PX\G0_?K MV:C4>W;@\?/!$!J:8?
S9&AK&L7M<=K1UTP)7D#1GDO&4Q(8Q&C>@$4F9.8;Q M6"ST14OG8F:XYT8DD[AMO)SG5]DT.CW5 M^4Q+T>PF5!/R(B)S*#XT+|T3K MX C)9$S|/;/^7X[U>+.#L]P)V";EW+0)-
HMN&GEIG"-H3"2[!$KZBEP_ID0X M'I=1=U/%;3.S>E[(4ZF%)&'QTMD9DIAY@NTT=S{1^))*YA.\SM&Q6DX%"W>Z MQ?"<_4-1-EH8LY1J$2T7JEM'74FOI(929JA.M79+GSB5.
!Q;U;HLH3F,IG+, M>4)25%FT*-4K6A>E&H_' 8H:747.8Q);MF!U# \!G6W%*NLG5OD8^%1LF*7F MA"R&W_^8.CZ4NQ.I5A#H"5/G
[,N60Y>B)FFS3M)_&;I8B+TC'/M058U2&6W8FP;SY>QB3-?]G39A*>DEA M&)$,QS3Q@M$01E?4GZL;#TS"D/E4 $D#.!,T9Vi5P$,88TH@2!-.4U'^'71E1 M4
QFF]TA3S"K6!;_K.Y>$W"Z9.&R"=EY,OL_T#S8+IB[UAZXZ)CO5R"P3/,QLK M!#E,XB+!NZ1C!> !]7GI#TU-<>88 $)=_=!=BL]YS(*[9G(JZR]8X4-#E0VJ
M/B%>3&N3/2Y0F>;S."993IWZ8M4ZC+UN98;]%E2<8"!T5ZH&)574(FN+2__*MH&Z_5&3LD[@B*2Q*A%8[^U;!U=QJ8H:=0W!>KN*^^)JHY)94<9101CS1>V.
M^K>V$"1S/*PDOVD+-/>GU=%U/_'0U7.),&"11M:U;O)CL#V#E2%7EK'5MPSN%@-8EG?^GS'PE"1U1]*X#X(=_MW7R)F_@^IK9MO77T&FPUI%#,_3@L_33T^) LZ!@S&_?
&!7MAOFG99;ZYMA,>_MB[]>*7$\$ED_UCZN'3NXXB*2JHTK,H,K>P*BELKU"?GY^:IK24EBXA)JN49 M\:F#%49!?:C @!P,P,_.,X*,#.,ED-<+WIYO,/8_9[,Q2>@6^$RE(<^?S+;X
M,'>=K;PWMGICJV?GKM^5JXZ.7\(73TW9VSO&/0NARIO3/7&5,_17;^ J5ZP MMUX|E^V>"9;Z+"/QCX2V=PN'&<5)1_W ZU&"X_10QZD/YSJW'|#=X\%K='VB MXA'_VTSP>1IL/+1?
>8|KO:-:H+VQX#KW7GN#K&I:>X%L|^6TC,RH5CZ1)*&D MPB&7G 55X!T>Z.W#ZYR_;#.+YXWE2V_%6W3]?P%02P,$% @ VH)L643S M9-X6!@ +2D !@
!N=')A+3(P,C0P.3,P>&5X,S)D,BYH=&WM6OM3XD@0 M_E?ZV-13[\@3? 66*D2LM6H%3V/=[8^39$+F-F2RDT'D_OKKR0.!=6\|!5== MJ1+#/+]GOZ_SI2=)^S=-ZR<127P:P$?
WI!,$W)^,;2+!%Y1(;TR&8'+TY0D M<$:%8'$,1X(%(PI@F?]>;MF[NJEIG3;.ZI63>,* 91F6;=BFW03ST+&:SFX# MSL]@^\KM[>3#CX<I]_YO_!!2G7TZ;0'-
$)BP^@/:E"+I$P=PYA.I_JTH7,Q,MP+(Y+CN&G$G&=4#V10ZI15"WY3$G3; M8RH])^!$1&94?:E?NB7; (R23,>VTC>L_=;CP:S3#M@U9'(6TP^U,1$CEFB2
MITI#3&4+9QK8O3+F1NR0$:.99KO6RD) I.,M)B&IK$L?7_OMDVP473;R(O@ M'$%C(MDU5=87[/HQ)<+QN(Q;JR|NFIE6\T*>2"TD8Q;/G*T>B9DGV%9]ZR.- MKZED/L'C#
(':5,BI8N-7*AV?L'XJV,<*8)52+:+%0W3IL27HC-;0R0G>]M55@ MXI1P>`Z==F89C"@4[C@8Y*@R[Q%N5[P.BW<>#P.T%3_)F(>D|"P=;MM>(AT MNI:HK!]$Y6/B4[$2EIK_B.AN\?
PFT.6EV >E8PV)EGSL'."<:Y8A$C&3,R=B M04 37-'O[PYLL]%]&\K@VK#Y$>-W8K,^RGO]"_?TY+37=4^' U2#B\NK[L % M=[A._G]RC-8!7.F7>D^'RWXOC]-J[)KU5Q1A]Q*ZQ\-
SMW^\2"&\H@@KY@[- M/1B>@/NQ#Y?=BZ/NH'^1#?_ZU\,W9ZK>FS37*MV?3]NE] N2,?>UY5BE(%; M=BK|O/U[G)+5,]=U.&-X[.3JZL_3:%;'7L1H""2M.%" 9D("GJL)8^%X-
4IR@<^7ND@B/)#33AC"$BS'6 M;U!HMZ-<)$U05FYDBYY;J;,(#Z-C:W0YVYH12?R*PU$$+_1O,PP3KSY)5 MZ[#1; %)@B?C\$D(LPO"6((DC$D.C8\V"*XHP-8/U6FH3DWL2!'>K)
{/"N>G+!H,|OI1P:=&3>*"#)|B^:LZLHJ ,B7T-8-| M9TFVR0(L-^0PB8OT[U.!Y80'U.<%'I]:XDPP 80Z^]:[,)_QF 7W+=Y4H9^K MPH>:VBFH+0GQ8E]%[&!SC2?
QS%), ^I4!XO18>ZURC#4!D'E"29":V&CH*R* MRF05<8&O#*KV:R7&/HE+D<*|3FD"MWB[!Q=I*;+AW_*)-,=H?|H?F_<1#I"<2:=F7\>DXBU3]-ML"+;BDUK^2V#^]&/F_!?E/^GT]?
![_4> M0N"|;EHOD+^'A-JT];]&F(UI%":O1%]?AIA?/B),8V8I%J6$I\Z6-7DH*/% M8ZQG'(!DI&7GY9=E)]+I>F.:T%B8GY/]1D0PKRW#.LUCF:.0\!HM27LBHK M"T4KO8'\4@O5U?
HY(07YW.L:<#.@@FUMA4^MD^7UR=H% PS SP;6NWPOY+:X M>@'" 8)%Z$Y5W'-'I Q78-JJPKLI4GV^FYAKVJ7]Z9=;]KUW.!Z?=KEJO<+ M'B->SPE,3>K3=YXKO0G5FU
]0[A^@E"]8+1^.2G;/A<,12Q%%;O5,_6HK>O(M?))((#+R2MYT[],W('P15=P4WDCGS9UY.]>SRX.[;!_^X.QW-'SAYQ/\R$AAQ ML/)08^\-MN6.F5NM77]5(RHEIQVY;$D@['7.6E%FY
MOZ[@Z+-S&_*%J\!YN\5=OX%4$L! A0#% @ VH)L661AB"FF& MV0'-D4$L! A0# M% @ VH)L63('RHND$0]OX !4 (!U1@ &YT&UL4$L! A0#% @ VH)L67Q3WGG\8P 2" ' !4 M (
!^04! &YT#,Q9#$N;!1M4$L! A0# M% @ VH)L6;'!2!U"0 OSD !@ (!?6< &YT;TUE 8 !LH M 8 " 2]Q! !N=')A+3(P,C0P.3,P>&5X,S)D,2YH=&U0 M2P$"% ,4 " #;@FQ91/-DWA8&
M*0 & @ %E=P0 M;G1R82TR,#(T,#DS,'AF>#,R9#(N;'1M4$L%!@ * H I@(+%]! ! $! end XML 86 ntra-20240930x10q_htm.xml IDEA: XBRL DOCUMENT 0001604821 us-
gaap:CommonStockMember 2024-07-01 2024-09-30 0001604821 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001604821 us-gaap:RetainedEarningsMember 2024-
09-30 0001604821 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001604821 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001604821 us-
gaap:RetainedEarningsMember 2024-06-30 0001604821 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001604821 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001604821 us-gaap:RetainedEarningsMember 2023-12-31 0001604821 us-
gaap:AdditionalPaidInCapitalMember 2023-12-31 0001604821 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001604821 us-
gaap:RetainedEarningsMember 2023-09-30 0001604821 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001604821 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001604821 us-gaap:RetainedEarningsMember 2023-06-30 0001604821 us-
gaap:AdditionalPaidInCapitalMember 2023-06-30 0001604821 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001604821 us-
gaap:RetainedEarningsMember 2022-12-31 0001604821 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001604821 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001604821 ntra:EmployeeAndNonEmployeeOptionsMember 2024-01-01 2024-09-30 0001604821
ntra:EmployeeAndNonEmployeeOptionsMember 2024-09-30 0001604821 ntra:EmployeeAndNonEmployeeOptionsMember 2023-12-31 0001604821
ntra:RestrictedStockUnitsRsuAndPerformanceSharesMember 2024-09-30 0001604821 ntra:RestrictedStockUnitsRsuAndPerformanceSharesMember 2023-12-31 0001604821
ntra:RestrictedStockUnitsRsuAndPerformanceSharesMember 2024-01-01 2024-09-30 0001604821 us-gaap:PerformanceSharesMember 2024-09-30 0001604821
ntra:BgiGenomicsCoLtdMember ntra:OncologyAssayInterpretationServicesMember 2023-12-31 0001604821 ntra:FoundationMedicineInc.Member
ntra:OncologyProductsMember 2023-06-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:LicenseAndRelatedDevelopmentServicesMember 2023-03-31 0001604821 us-
gaap:EMEAMember 2024-07-01 2024-09-30 0001604821 ntra:PatientsMember 2024-07-01 2024-09-30 0001604821 ntra:OtherGeographicAreasMember 2024-07-01 2024-09-
30 0001604821 ntra:LaboratoryPartnersMember 2024-07-01 2024-09-30 0001604821 ntra:InsuranceCarriersMember 2024-07-01 2024-09-30 0001604821
ntra:AmericasExcludingUsMember 2024-07-01 2024-09-30 0001604821 country:US 2024-07-01 2024-09-30 0001604821 us-gaap:EMEAMember 2024-01-01 2024-09-30
0001604821 ntra:PatientsMember 2024-01-01 2024-09-30 0001604821 ntra:OtherGeographicAreasMember 2024-01-01 2024-09-30 0001604821
ntra:LaboratoryPartnersMember 2024-01-01 2024-09-30 0001604821 ntra:InsuranceCarriersMember 2024-01-01 2024-09-30 0001604821 ntra:AmericasExcludingUsMember
2024-01-01 2024-09-30 0001604821 country:US 2024-01-01 2024-09-30 0001604821 us-gaap:EMEAMember 2023-07-01 2023-09-30 0001604821 ntra:PatientsMember 2023-
07-01 2023-09-30 0001604821 ntra:OtherGeographicAreasMember 2023-07-01 2023-09-30 0001604821 ntra:LaboratoryPartnersMember 2023-07-01 2023-09-30 0001604821
ntra:InsuranceCarriersMember 2023-07-01 2023-09-30 0001604821 ntra:AmericasExcludingUsMember 2023-07-01 2023-09-30 0001604821 country:US 2023-07-01 2023-09-
30 0001604821 us-gaap:EMEAMember 2023-01-01 2023-09-30 0001604821 ntra:PatientsMember 2023-01-01 2023-09-30 0001604821 ntra:OtherGeographicAreasMember
2023-01-01 2023-09-30 0001604821 ntra:LaboratoryPartnersMember 2023-01-01 2023-09-30 0001604821 ntra:InsuranceCarriersMember 2023-01-01 2023-09-30 0001604821
ntra:AmericasExcludingUsMember 2023-01-01 2023-09-30 0001604821 country:US 2023-01-01 2023-09-30 0001604821 us-gaap:SecuredDebtMember 2020-04-01 2020-04-30
0001604821 ntra:OtherMaterialSupplierMember 2024-09-30 0001604821 ntra:OperatingLeaseCommitmentsMember 2024-09-30 0001604821
ntra:LaboratoryInstrumentsMember 2024-09-30 0001604821 ntra:InventoryMaterialPurchaseCommitmentMember 2024-09-30 0001604821
ntra:CloudPlatformServiceProviderMember 2024-09-30 0001604821 ntra:ApplicationServiceProviderMember 2024-09-30 0001604821 srt:MinimumMember us-
gaap:MachineryAndEquipmentMember 2024-09-30 0001604821 srt:MaximumMember us-gaap:MachineryAndEquipmentMember 2024-09-30 0001604821 us-
gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-09-30 0001604821 us-gaap:MachineryAndEquipmentMember 2024-09-30 0001604821 us-
gaap:LeaseholdImprovementsMember 2024-09-30 0001604821 us-gaap:ConstructionInProgressMember 2024-09-30 0001604821 us-gaap:ComputerEquipmentMember 2024-
09-30 0001604821 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001604821 us-gaap:MachineryAndEquipmentMember 2023-12-31 0001604821 us-
gaap:LeaseholdImprovementsMember 2023-12-31 0001604821 us-gaap:ConstructionInProgressMember 2023-12-31 0001604821 us-gaap:ComputerEquipmentMember 2023-
12-31 0001604821 ntra:LineOfCreditUbsMember 2022-11-01 2022-11-30 0001604821 2023-09-01 2023-09-30 0001604821 us-
gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001604821 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-09-30
0001604821 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001604821 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-
01-01 2023-09-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:SequencingServicesMember 2019-06-30 0001604821 ntra:BgiGenomicsCoLtdMember
ntra:SequencingProductsMember 2019-06-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:SequencingProductsAndServicesMember 2019-06-30 0001604821 us-
gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001604821 us-gaap:RetainedEarningsMember 2024-01-01 2024-09-30 0001604821 us-
gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001604821 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001604821 ntra:InivataPatentCaseMember
2022-12-31 0001604821 ntra:ClassActionLawsuitMember 2022-02-28 0001604821 ntra:CaredxSPatentCaseMember 2020-03-31 0001604821 ntra:CaredxSPatentCaseMember
2019-03-31 0001604821 ntra:InivitaPatentCaseMember 2021-11-01 2021-11-30 0001604821 ntra:InivataPatentCaseMember 2021-01-01 2022-12-31 0001604821
ntra:RavgenPatentCaseMember 2020-06-01 2020-06-30 0001604821 ntra:CaredxSPatentCaseMember 2019-03-01 2019-03-31 0001604821 ntra:RavgenPatentCaseMember
2024-01-01 2024-01-31 0001604821 2024-01-01 2024-01-31 0001604821 ntra:CaredxSPatentCaseMember 2022-03-01 2022-03-31 0001604821 ntra:LineOfCreditUbsMember
2023-06-30 0001604821 ntra:LineOfCreditUbsMember 2022-11-30 0001604821 ntra:LineOfCreditUbsMember 2020-12-31 0001604821 ntra:LineOfCreditUbsMember 2015-09-
30 0001604821 ntra:LineOfCreditUbsMember 2023-12-31 0001604821 srt:MinimumMember ntra:CertainWorkspacesAndStorageSpacesMember 2024-09-30 0001604821
srt:MaximumMember ntra:CertainWorkspacesAndStorageSpacesMember 2024-09-30 0001604821 ntra:CorporateHeadquartersLeaseAmendmentMember 2024-09-30
0001604821 ntra:SanCarlosCaliforniaSubleaseAmendmentMember 2024-07-31 0001604821 ntra:LineOfCreditUbsMember 2024-01-01 2024-09-30 0001604821
ntra:LineOfCreditUbsMember 2023-07-01 2023-09-30 0001604821 ntra:LineOfCreditUbsMember 2023-01-01 2023-09-30 0001604821 ntra:LineOfCreditUbsMember 2024-07-
01 2024-09-30 0001604821 ntra:CaredxSPatentCaseMember 2024-01-01 2024-01-31 0001604821 ntra:NeoGenomicsPatentCaseMember 2023-07-01 2023-07-31 0001604821
ntra:ArcherdxPatentCaseMember 2023-06-01 2023-06-30 0001604821 ntra:ArcherdxPatentCaseMember 2023-05-01 2023-05-31 0001604821 ntra:InivataPatentCaseMember
2022-12-01 2022-12-31 0001604821 ntra:GenosityInc.PatentCaseMember 2020-10-01 2020-10-31 0001604821 ntra:ArcherdxPatentCaseMember 2020-01-01 2020-01-31
0001604821 ntra:AssetsAcquiredFromInvitaeMember 2024-01-31 0001604821 ntra:MyomeIncMember 2024-08-31 0001604821 ntra:MyomeIncMember 2021-12-06
0001604821 ntra:MyomeIncMember srt:ChiefExecutiveOfficerMember 2021-12-06 0001604821 us-gaap:ConvertibleNotesPayableMember 2024-07-19 0001604821
ntra:TwentyTradingDaysPeriodMember us-gaap:ConvertibleNotesPayableMember 2020-04-01 2020-04-30 0001604821 ntra:FiveDayConsecutiveTradingPeriodMember us-
gaap:ConvertibleNotesPayableMember 2020-04-01 2020-04-30 0001604821 us-gaap:ConvertibleNotesPayableMember us-gaap:SubsequentEventMember 2024-10-11 2024-10-
11 0001604821 ntra:LineOfCreditUbsMember 2024-09-30 0001604821 ntra:LineOfCreditUbsMember us-
gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2024-01-01 2024-09-30 0001604821 ntra:LineOfCreditUbsMember us-
gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-10-01 2023-10-31 0001604821 ntra:LineOfCreditUbsMember us-
gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-01-01 2023-09-30 0001604821 ntra:LineOfCreditUbsMember
ntra:LondonInterbankOfferedRateMember 2017-07-01 2017-07-31 0001604821 ntra:LicensingAndOtherMember 2024-07-01 2024-09-30 0001604821
ntra:LicensingAndOtherMember 2024-01-01 2024-09-30 0001604821 ntra:LicensingAndOtherMember 2023-07-01 2023-09-30 0001604821 ntra:LicensingAndOtherMember
2023-01-01 2023-09-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2024-09-30 0001604821 us-gaap:ConvertibleNotesPayableMember us-
gaap:SubsequentEventMember 2024-10-11 0001604821 us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleNotesPayableMember 2024-09-30 0001604821 us-
gaap:FairValueInputsLevel2Member us-gaap:ConvertibleNotesPayableMember 2023-12-31 0001604821 ntra:FoundationMedicineInc.Member
ntra:OncologyAssayInterpretationServicesMember 2024-07-01 2024-09-30 0001604821 ntra:FoundationMedicineInc.Member
ntra:OncologyAssayInterpretationServicesMember 2024-01-01 2024-09-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:OncologyAssayInterpretationServicesMember
2024-01-01 2024-09-30 0001604821 ntra:FoundationMedicineInc.Member 2024-01-01 2024-09-30 0001604821 ntra:FoundationMedicineInc.Member
ntra:OncologyAssayInterpretationServicesMember 2023-07-01 2023-09-30 0001604821 ntra:FoundationMedicineInc.Member ntra:OncologyProductsMember 2023-04-01
2023-06-30 0001604821 ntra:FoundationMedicineInc.Member ntra:OncologyAssayInterpretationServicesMember 2023-01-01 2023-09-30 0001604821
ntra:BgiGenomicsCoLtdMember ntra:OncologyAssayInterpretationServicesMember 2023-01-01 2023-09-30 0001604821 ntra:GeneticTestingServicesMember 2024-09-30
0001604821 ntra:GeneticTestingServicesMember 2024-01-01 2024-09-30 0001604821 ntra:BgiGenomicsCoLtdAndFoundationMedicineInc.Member 2024-01-01 2024-09-30
0001604821 ntra:FoundationMedicineInc.Member ntra:OncologyAssayInterpretationServicesMember 2024-09-30 0001604821 ntra:BgiGenomicsCoLtdMember
ntra:OncologyAssayInterpretationServicesMember 2024-09-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:OncologyAssayInterpretationServicesMember 2023-09-30
0001604821 ntra:BgiGenomicsCoLtdMember 2024-09-30 0001604821 ntra:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember
2024-07-01 2024-09-30 0001604821 ntra:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30
0001604821 ntra:MedicareMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001604821
ntra:MedicareMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001604821 ntra:MedicareMember us-
gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001604821 ntra:MedicareMember us-gaap:SalesRevenueNetMember

us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001604821 us-gaap:CommonStockMember 2024-09-30 0001604821 us-gaap:CommonStockMember 2024-06-30 0001604821 us-gaap:CommonStockMember 2023-12-31 0001604821 us-gaap:PrivatePlacementMember 2023-09-30 0001604821 us-gaap:CommonStockMember 2023-09-30 0001604821 us-gaap:CommonStockMember 2023-06-30 0001604821 us-gaap:CommonStockMember 2022-12-31 0001604821 us-gaap:ConvertibleNotesPayableMember 2020-04-30 0001604821 ntra:MyomeIncMember us-gaap:SeriesBPreferredStockMember 2024-09-30 0001604821 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-09-30 0001604821 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ntra:CashCashEquivalentsAndRestrictedCashMember 2024-09-30 0001604821 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2024-09-30 0001604821 us-gaap:FairValueMeasurementsRecurringMember ntra:CashCashEquivalentsAndRestrictedCashMember 2024-09-30 0001604821 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001604821 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001604821 us-gaap:FairValueMeasurementsRecurringMember 2024-09-30 0001604821 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0001604821 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001604821 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember ntra:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001604821 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0001604821 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-12-31 0001604821 us-gaap:FairValueMeasurementsRecurringMember ntra:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001604821 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001604821 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001604821 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0001604821 ntra:AssetsAcquiredFromInvitaeMember 2024-01-01 2024-01-31 0001604821 ntra:InProcessResearchDevelopmentAcquisitionAgreementMember 2023-03-01 2023-03-31 0001604821 ntra:InProcessResearchDevelopmentAcquisitionAgreementMember 2022-12-01 2022-12-31 0001604821 ntra:TukwilaWashingtonLeaseMember 2024-09-30 0001604821 ntra:SouthSanFranciscoCaliforniaLeaseMember 2024-09-30 0001604821 ntra:CorporateHeadquartersLeaseMember 2024-09-30 0001604821 ntra:AustinTxLongTermLeaseMember 2024-09-30 0001604821 ntra:AustinTexasSecondExpansionPremisesMember 2024-09-30 0001604821 ntra:AustinTexasFirstExpansionPremisesMember 2024-09-30 0001604821 ntra:PleasantonCaliforniaLeaseMember 2023-09-30 0001604821 ntra:VancouverBritishColumbiaCanadaMember 2021-09-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-09-30 0001604821 ntra:PerformanceBasedAwardsAndRestrictedStockUnitsMember 2024-01-01 2024-09-30 0001604821 ntra:EmployeeStockPurchasePlan2015Member 2024-01-01 2024-09-30 0001604821 ntra:EmployeeAndNonEmployeeOptionsMember 2024-01-01 2024-09-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-09-30 0001604821 ntra:PerformanceBasedAwardsAndRestrictedStockUnitsMember 2023-01-01 2023-09-30 0001604821 ntra:EmployeeStockPurchasePlan2015Member 2023-01-01 2023-09-30 0001604821 ntra:EmployeeAndNonEmployeeOptionsMember 2023-01-01 2023-09-30 0001604821 ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember ntra:CyberattackDisruptionAtChangeHealthcareMember 2024-09-30 0001604821 ntra:CyberattackDisruptionAtChangeHealthcareMember 2024-07-01 2024-09-30 0001604821 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-01 2024-09-30 0001604821 us-gaap:PerformanceSharesMember 2024-07-01 2024-09-30 0001604821 us-gaap:CostOfSalesMember 2024-07-01 2024-09-30 0001604821 ntra:LiabilityClassifiedAwardsMember 2024-07-01 2024-09-30 0001604821 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-09-30 0001604821 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-09-30 0001604821 us-gaap:CostOfSalesMember 2024-01-01 2024-09-30 0001604821 ntra:LiabilityClassifiedAwardsMember 2024-01-01 2024-09-30 0001604821 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001604821 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001604821 us-gaap:PerformanceSharesMember 2023-07-01 2023-09-30 0001604821 us-gaap:CostOfSalesMember 2023-07-01 2023-09-30 0001604821 ntra:LiabilityClassifiedAwardsMember 2023-07-01 2023-09-30 0001604821 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001604821 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001604821 us-gaap:PerformanceSharesMember 2023-01-01 2023-09-30 0001604821 us-gaap:CostOfSalesMember 2023-01-01 2023-09-30 0001604821 ntra:LiabilityClassifiedAwardsMember 2023-01-01 2023-09-30 0001604821 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001604821 2024-07-01 2024-09-30 0001604821 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001604821 2023-07-01 2023-09-30 0001604821 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-09-30 0001604821 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001604821 2024-06-30 0001604821 2023-06-30 0001604821 2023-09-30 0001604821 2022-12-31 0001604821 ntra:MyomeIncMember 2024-09-30 0001604821 ntra:MyomeIncMember 2023-12-31 0001604821 us-gaap:CommonStockMember 2024-01-01 2024-09-30 0001604821 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001604821 ntra:InProcessResearchDevelopmentAcquisitionAgreementMember 2021-09-10 0001604821 us-gaap:PerformanceSharesMember 2024-01-01 2024-09-30 0001604821 srt:ScenarioForecastMember ntra:SanCarlosCaliforniaSubleaseAmendmentMember 2025-01-01 2025-12-31 0001604821 ntra:CorporateHeadquartersLeaseAmendmentMember 2025-01-01 2025-12-31 0001604821 ntra:SouthSanFranciscoCaliforniaLeaseMember 2024-01-01 2024-09-30 0001604821 ntra:PleasantonCaliforniaLeaseMember 2023-09-01 2023-09-30 0001604821 ntra:VancouverBritishColumbiaCanadaMember 2021-09-01 2021-09-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:LicenseAndRelatedDevelopmentServicesMember 2023-03-01 2023-03-31 0001604821 ntra:SecondSpaceSubleaseMember 2024-01-01 2024-09-30 0001604821 ntra:FirstSpaceSubleaseMember 2024-01-01 2024-09-30 0001604821 ntra:CorporateHeadquartersLeaseMember 2024-01-01 2024-09-30 0001604821 ntra:AustinTxLongTermLeaseMember 2024-01-01 2024-09-30 0001604821 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-07-01 2024-09-30 0001604821 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001604821 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-09-30 0001604821 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001604821 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001604821 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001604821 ntra:CaredxSPatentCaseMember 2020-03-01 2020-03-31 0001604821 ntra:MyomeIncMember 2024-02-29 0001604821 us-gaap:ProductMember 2024-07-01 2024-09-30 0001604821 ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember 2024-07-01 2024-09-30 0001604821 ntra:AmountsNotRefundedToInsuranceCarriersMember 2024-07-01 2024-09-30 0001604821 ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember 2024-01-01 2024-09-30 0001604821 ntra:AmountsNotRefundedToInsuranceCarriersMember 2024-01-01 2024-09-30 0001604821 us-gaap:ProductMember 2023-07-01 2023-09-30 0001604821 ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember 2023-07-01 2023-09-30 0001604821 us-gaap:ProductMember 2023-01-01 2023-09-30 0001604821 ntra:TestsDeliveredInPriorPeriodsThatWereFullyCollectedMember 2023-01-01 2023-09-30 0001604821 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-07-01 2024-09-30 0001604821 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-09-30 0001604821 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-07-01 2023-09-30 0001604821 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-09-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:EquipmentAndServicesMember 2024-07-01 2024-09-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:EquipmentAndServicesMember 2024-01-01 2024-09-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:EquipmentAndServicesMember 2023-07-01 2023-09-30 0001604821 ntra:BgiGenomicsCoLtdMember ntra:EquipmentAndServicesMember 2023-01-01 2023-09-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2023-12-31 0001604821 us-gaap:ConvertibleNotesPayableMember 2020-04-01 2020-04-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2020-04-30 2020-04-30 0001604821 ntra:MayRedeemForCashAllOrAnyPortionOfConvertibleNotesAtCompanysOptionOnOrAfterMay2024Member 2020-04-01 2020-04-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2024-07-19 2024-07-19 0001604821 us-gaap:ConvertibleNotesPayableMember 2024-09-30 0001604821 2023-01-01 2023-09-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2024-07-01 2024-09-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2024-01-01 2024-09-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2023-07-01 2023-09-30 0001604821 us-gaap:ConvertibleNotesPayableMember 2023-01-01 2023-09-30 0001604821 ntra:MyomeIncMember 2024-02-01 2024-02-29 0001604821 ntra:MyomeIncMember 2024-01-01 2024-09-30 0001604821 us-gaap:MunicipalBondsMember 2024-09-30 0001604821 ntra:CashCashEquivalentsAndRestrictedCashMember 2024-09-30 0001604821 us-gaap:USTreasurySecuritiesMember 2023-12-31 0001604821 us-gaap:MunicipalBondsMember 2023-12-31 0001604821 ntra:CashCashEquivalentsAndRestrictedCashMember 2023-12-31 0001604821 ntra:InProcessResearchDevelopmentAcquisitionAgreementMember 2021-09-10 2021-09-10 0001604821 us-gaap:ProductMember 2024-01-01 2024-09-30 0001604821 ntra:FoundationMedicineInc.Member 2024-09-30 0001604821 ntra:BgiGenomicsCoLtdMember 2019-02-28 0001604821 ntra:FoundationMedicineInc.Member 2019-08-01 2019-08-31 0001604821 ntra:BgiGenomicsCoLtdMember 2019-02-01 2019-02-28 0001604821 us-gaap:SubsequentEventMember 2027-11-01 2027-11-12 0001604821 2024-09-30 0001604821 2023-12-31 0001604821 ntra:RoyBaynesMember 2024-09-30 0001604821 ntra:MikeBrophyMember 2024-09-30 0001604821 ntra:DanielRabinowitzMember 2024-09-30 0001604821 ntra:RoyBaynesMember 2024-07-01 2024-09-30 0001604821 ntra:MikeBrophyMember 2024-07-01 2024-09-30 0001604821 ntra:DanielRabinowitzMember 2024-07-01 2024-09-30 0001604821 2024-11-01 0001604821 2024-01-01 2024-09-30 ntra:item utr:sqft ntra:position ntra:lawsuit ntra:segment shares iso4217:USD pure ntra:D iso4217:USD shares ntra:patent ntra:customer ntra:security ntra:lease 124137000 119581000 Natera, Inc. Yes false 0001604821 --12-31 Q3 false 2024 true false DE false false NASDAQ -0.26 -0.95 -1.12 -3.14 123775000 115171000 122486000 113559000 P8Y0M7D P36M P24M P5Y P1Y 34500000 2200000 -3700000 108100000 700000 1200000 4500000 7700000 2900000 7100000 10-Q 2024-09-30 001-37478 01-0894487 13011 McCallen Pass Building A Suite 100 Austin TX 78753 650 980-9190 Common Stock, par value $0.0001 per share NTRA Yes Large Accelerated Filer 132020816 892844000 642095000 29490000 236882000 6252000 6481000 306876000 278289000 48724000 40759000 44631000 60524000 1322565000 1258549000 142170000 111210000 87856000 56537000 38356000 15403000 1590947000 1441699000 27834000 14998000 49051000 45857000 126176000 149405000 17886000 16612000 80469000 80402000 301416000 307274000 286549000 282945000 25504000 19128000 98953000 67025000 712422000 676372000 0.0001 0.0001 750000000 750000000 124137000 119581000 12000 11000 3393369000 3145837000 -2514091000 -2377436000 -765000 -3085000 878525000 765327000 1590947000 1441699000 436127000 265218000 1212163000 761271000 3631000 3088000 8687000 10195000 439758000 268306000 1220850000 771466000 167657000 146962000 496340000 437524000 354000 349000 990000 1060000 96931000 77235000 274677000 237714000 214154000 154742000 606397000 456877000 479096000 379288000 1378404000 1133175000 -39338000 -110982000 -157554000 -361709000 3142000 3252000 9393000 9490000 11618000 5406000 32342000 14509000 -30862000 -108828000 -134605000 -356690000 730000 202000 2050000 80000 -31592000 -109030000 -136655000 -356770000 593000 3807000 2320000 10966000 -30999000 -105223000 -134335000 -345804000 -0.26 -0.95 -1.12 -3.14 123775000 115171000 122486000 113559000 123365000 12000 3320365000 -1358000 -2482499000 836520000 247000 1720000 1720000 525000 71284000 71284000 593000 593000 -31592000 -31592000 124137000 12000 3393369000 -765000 -2514091000 878525000 119581000 11000 3145837000 -3085000 -2377436000 765327000 1325000 10368000 10368000 263000 8862000 8862000 270000 24071000 24071000 2698000 1000 1000 204231000 204231000 2320000 2320000 -136655000 -136655000 124137000 12000 3393369000 -765000 -2514091000 878525000 114051000 11000 2795714000 -9203000 -2190375000 596147000 48000 562000 562000 4550000 235441000 235441000 341000 57731000 57731000 3807000 3807000 -109030000 -109030000 118990000 11000 3089448000 -5396000 -2299405000 784658000 111255000 11000 2664730000 -16362000 -1942635000 705744000 265000 3501000 3501000 219000 8674000 8674000 349000 19771000 19771000 336000 14435000 14435000 4550000 235441000 235441000 2016000 142896000 142896000 10966000 10966000 -356770000 -356770000 118990000 11000 3089448000 -5396000 -2299405000 784658000 -136655000 -356770000 23178000 17186000 2679000 -633000 1929000 202502000 142376000 11169000 11011000 80000 991000 966000 -356000 -265000 2680000 85000 28587000 10762000 7965000 6669000 -13663000 -7356000 10841000 -8951000 27265000 15177000 -12484000 -8424000 -22526000 -2072000 -938000 5268000 82777000 -189350000 122010000 24822000 307400000 173500000 48305000 29147000 2670000 10495000 148742000 144353000 10368000 3501000 8862000 8674000 235441000 19230000 247616000 250749000 202619000 642095000 466091000 892844000 668710000 6785000 6907000 854000 -1168000 9424000 140000 14435000 24071000 19771000 1729000 520000 1. Description of Business Natera, Inc. (the “Company”) was formed in the state of California as Gene Security Network, LLC in November 2003 and incorporated in the state of Delaware in January 2007. The Company is a diagnostics company with proprietary molecular and bioinformatics technology that it is applying to change the management of disease worldwide. The Company’s cell-free DNA (“cfDNA”) technology combines its novel molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell, with its statistical algorithms which incorporate data available from the broader scientific community to identify genetic variations covering a wide range of serious conditions with high accuracy and coverage. The Company focuses on applying its technology to three main areas of healthcare – women’s health, oncology and organ health. In the women’s health space, the Company develops and commercializes non- or minimally-invasive tests to evaluate risk for, and thereby enable early detection of, a wide range of genetic conditions, such as Down syndrome. In oncology, the Company commercializes, among others, a personalized blood-based DNA test to detect molecular residual disease and monitor for disease recurrence across a broad range of cancer types. The Company’s third area of focus is organ health, with tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease. The Company operates laboratories in Austin, Texas and San Carlos, California, certified under the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”), providing a host of cell-free DNA-based molecular testing services. The Company determines its operating segments based on the way it organizes its business to make operating decisions and assess performance. The Company operates one segment, the development and commercialization of molecular testing services, applying its proprietary

technology in the fields of women's health, oncology and organ health. The Company's key product offerings include its Panorama Non-Invasive Prenatal Test ("Panorama") that screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother; Horizon Carrier Screening ("Horizon") to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children; its Signatera molecular residual disease test ("Signatera") to detect circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease, monitor for recurrence, and evaluate treatment response; and its Prospera test, to assess organ transplant rejection in patients who have undergone kidney, heart, or lung transplantation. All testing is available principally in the United States. The Company also offers its Panorama test to customers outside of the United States, primarily in Europe. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company's algorithms and bioinformatics in order to validate and launch their own tests based on the Company's technology. 1 2. Summary of Significant Accounting Policies During the nine months ended September 30, 2024, there were no material changes to the Company's significant accounting policies as disclosed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (filed on February 29, 2024). Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. The unaudited interim condensed consolidated financial information includes only adjustments of a normal recurring nature necessary for a fair presentation of the Company's results of operations, financial position, changes in stockholders' equity, and cash flows. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results for the full year or the results for any future periods. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements at that date. These financial statements should be read in conjunction with the audited financial statements, and related notes for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the SEC on February 29, 2024. Some items in the prior period financial statements were reclassified to conform to the current presentation. Liquidity Matters The Company has incurred net losses since its inception and anticipates net losses for the near future. The Company had a net loss of $136.7 million for the nine months ended September 30, 2024 and an accumulated deficit of $2.5 billion as of September 30, 2024. As of September 30, 2024, the Company had $892.8 million in cash, cash equivalents, and restricted cash, $29.5 million in marketable securities, an $80.4 million outstanding balance on its Credit Line (as defined in Note 10, Debt) including accrued interest and $287.5 million of outstanding principal on its 2.25% Convertible Senior Notes (the "Convertible Notes"). The Company is required to maintain a minimum of at least $150.0 million in its UBS accounts as collateral for its Credit Line. As of September 30, 2024, the Company had $20.0 million remaining and available on its Credit Line. While the Company has introduced multiple products that are generating revenues, these revenues have not been sufficient to fund all operations and business plans. Accordingly, the Company has funded the portion of operating costs that exceeds revenues through a combination of equity issuances, debt issuances, and other financings. The Company continues to invest in the development and commercialization of its existing and future products and, consequently, it will need to generate additional revenues to achieve future profitability and may need to raise additional equity or debt financing. If the Company raises additional funds by issuing equity securities, its stockholders will experience dilution. Additional debt financing, if available, may involve covenants restricting its operations or its ability to incur additional debt. Any additional debt financing or additional equity that the Company raises may contain terms that are not favorable to it or its stockholders and requires significant debt service payments, which diverts resources from other activities. Additional financing may not be available when necessary, or in amounts or on terms acceptable to the Company. If the Company is unable to obtain additional financing, it may be required to delay the development and commercialization of its products and significantly scale back its business and operations. On July 19, 2024, the Company announced its decision to redeem all of its outstanding 2.25% Convertible Senior Notes due 2027. The redemption was completed on October 11, 2024 (the "Redemption Date"). The redemption price for the Convertible Notes equaled 100% of the principal amount of the Convertible Notes to be redeemed plus accrued and unpaid interest to, but excluding, the Redemption Date. The Company elected physical settlement with shares of its common stock as the settlement method to apply to all conversions of the Convertible Notes. On the Redemption Date, $287.4 million of Convertible Notes were redeemed for approximately 7.5 million shares of the Company's common stock under the terms of the redemption notice. The remaining Convertible Notes not redeemed under the redemption notice were converted in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, the Company's redemption of its Convertible Notes did not have a material effect on its liquidity. In September 2023, the Company completed an underwritten equity offering and sold 4,550,000 shares of its common stock at a price of $55 per share to the public. Before estimated offering expenses of $0.4 million, the Company received proceeds of approximately $235.8 million net of the underwriting discount. On September 10, 2021, the Company entered into an agreement with a third party for an asset acquisition where the acquired asset was in-process research and development primarily in exchange for an equity consideration payment. In addition, pursuant to the agreement, certain employees of the third party became employees of the Company. The third party was a biotechnology company focused on oncology. The total upfront acquisition consideration amounted to $35.6 million, composed of the issuance of 276,346 shares of the Company's common stock with a fair value of $30.9 million, approximately $3.9 million of cash consideration, assumed net liabilities of $0.2 million, as well as $0.6 million of acquisition related legal and accounting costs directly attributable to the acquisition of the asset. The Company accounted for the transaction as an asset acquisition as substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified in-process research and development asset ("IPR&D"), thus satisfying the requirements of the screen test in Accounting Standards Update ("ASU") 2017-01 Business Combinations (Topic 805): Clarifying the Definition of Business. The estimated fair value of the acquired workforce was not significant. The Company concluded the acquired IPR&D has no alternative future use and accordingly expensed approximately $35.6 million, on the day the transaction closed as research and development expense, which was reflected in its consolidated statement of operations. Further, additional consideration aggregating up to approximately $35.0 million was estimated to be paid via issuance of an estimated 269,547 additional shares of the Company's common stock, consistent with the registration statement filed with the SEC on September 10, 2021, upon achievement of defined milestones relating to product development, commercial launch and continued employment of certain selling shareholders, each of which was revalued at each reporting date and amount of compensation expense was adjusted accordingly and reported in research and development expenses. In November 2022, the terms of the payment for any remaining consideration were modified, resulting in $10.0 million of consideration paid in December 2022 and $15.0 million of consideration paid in March 2023, with such consideration primarily consisting of the Company's common stock. Based on the Company's current business plan, the Company believes that its existing cash and marketable securities will be sufficient to meet its anticipated cash requirements for at least 12 months after November 12, 2024. Principles of Consolidation The accompanying condensed consolidated financial statements include all the accounts of the Company and its subsidiaries. The Company established a subsidiary that operates in the state of Texas to support the Company's laboratory and operational functions. The Company also established a subsidiary that operates in Canada following the acquisition of the IPR&D asset. All intercompany balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, determining the incremental borrowing rate to calculate operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment including impairment estimates, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers, insurance payors, and patients. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company's financial statements. Investments Investments consist primarily of debt securities such as U.S. Treasuries, U.S. agency and municipal bonds. Management determines the appropriate classification of securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company generally classifies its entire investment portfolio as available-for-sale. The Company views its available-for-sale portfolio as available for use in current operations. Accordingly, the Company classifies all investments as short-term, irrespective of maturity date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss), which is a separate component of stockholders' equity. The Company classifies its investments as Level 1 or 2 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. The Company holds Level 2 securities, which are initially valued at the transaction price and subsequently valued by a third-party service provider using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company performs certain procedures to corroborate the fair value of these holdings. Available-for-sale debt securities. The amended guidance from ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, requires the measurement of expected credit losses for available-for-sale debt securities held at the reporting date over the remaining life based on historical experience, current conditions, and reasonable and supportable forecasts. The Company evaluated its investment portfolio under the available-for-sale debt securities impairment model guidance and determined the Company's investment portfolio is composed of low-risk, investment grade securities and thus has not recorded an expected credit loss for its investment portfolio. Further, gross unrealized losses on available for sale securities were not material at September 30, 2024. Accounts Receivable Trade accounts receivable and other receivables. The allowance for doubtful

accounts for trade accounts receivable is based on the Company's assessment of the collectability of accounts related to its clinics and laboratory partner customers. The Company regularly reviews the allowance by considering factors such as historical experience, the age of the accounts receivable balances, and current economic conditions that may affect a customer's ability to pay. See Note 6, Balance Sheet Components, for a roll-forward of the allowance for doubtful accounts related to trade accounts receivable for three months and nine months ended September 30, 2024 and 2023. The Company recognizes revenue under Accounting Standards Codification ("ASC") Topic 606, Revenue from Contracts with Customers ("ASC 606") and applies a constraint to the estimated variable consideration such that it is not probable that a significant reversal will occur. When assessing the total consideration expected to be received from insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds. After applying the ASC 606 constraint, the Company assessed for credit losses and allowance for doubtful accounts and determined an incremental credit loss was not needed given the quality of the insurance payors from whom such receivables are expected to be collectible and the relatively short duration over which the majority of receivables are collected. Accordingly, the Company currently does not have an incremental credit loss reserve nor allowance for doubtful accounts against accounts receivable for insurance and patient payors due to the average selling price calculations, which already incorporate these risks as net receivables are recorded. Inventory Inventory is recorded at the lower of cost or net realizable value, determined on a first-in, first-out basis. Inventory consists entirely of supplies, which the Company consumes when providing its test reports, and therefore, the Company does not maintain any finished goods inventory. The Company enters into inventory purchases commitments so that it can meet future delivery schedules based on forecasted demand for its tests. . The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. A write down of specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period is first recognized by using a number of factors including product expiration dates and scrapped inventory. Any write-down of inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on our consolidated statements of operations. The Company makes assumptions about future demand, market conditions and the release of new products that may supersede older products; however, if actual market conditions are less favorable than anticipated, additional inventory write-downs may be required. . Other Assets . In January 2024, the Company acquired from Invitae Corp. ("Invitae") certain assets relating to Invitae's non-invasive prenatal screening and carrier screening business. The transaction price of $10.5 million consisted of $10.0 million in upfront payment costs and approximately $0.5 million of other transaction costs which were capitalized as intangible assets over an estimated useful life of ten years. An additional payment of up to $42.5 million may be made should the Company achieve certain customer volume retention targets and based on certain legal outcomes.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Accumulated Other Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:36pt;margin:0pt;">Comprehensive loss and its components encompass all changes in equity other than those with stockholders, and include net loss, unrealized gains and losses on available-for-sale marketable securities and foreign currency translation adjustments. </p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:12.0pt;text-align:justify;text-indent:36pt;margin:0pt;">.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended </p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td colspan="11" style="vertical-align:bottom;width:47.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">Beginning balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> (1,358) </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">(9,203)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-

space:nowrap;width:7.45%;background:#ccceff;margin:0pt;padding:0pt;"> (3,085) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#ccceff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (16,362)</p></td></tr><tr><td style="vertical-align:middle;width:52.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">Net unrealized gain on available-for-sale securities, net of tax and foreign currency translation adjustment</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 593</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,807</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,320</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,966</p></td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (765) </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (5,396)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (765) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,396) </td></tr></table> . The change in net unrealized loss on available-for-sale securities is due to the impact of changes in interest rates on the value of fixed-rate investments and not due to any credit deterioration. Further, due to the short-term nature of these investments, the Company has the ability and intention to hold any such investments until maturity and does not expect to realize any material investment losses. As such, the Company has assessed the unrealized loss position for available-for-sale securities and determined that an allowance for credit loss was not necessary. Revenue Recognition The Company recognizes revenue under ASC 606, using the following five step process: <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Identification of a contract, or contracts, with a customer;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Identification of the performance obligations in the contract;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Determination of the transaction price;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Allocation of the transaction price to the performance obligations in the contract; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Revenue recognition when, or as, the performance obligations are satisfied.</td></tr></table> . The Company uses the most likely amount method of estimating variable consideration. The total consideration which the Company expects to collect in exchange for the Company's products is an estimate and may be fixed or variable, and is primarily based on historical cash collections for tests delivered, as adjusted for current expectations. Current expectations of cash collections factor in changes in reimbursement rate trends, past events not expected to recur, and future known changes such as anticipated contractual pricing changes or changes to insurance coverage. For insurance carriers and product types with similar reimbursement characteristics, the Company uses a portfolio approach to estimate variable consideration. When assessing the total variable consideration expected to be received from insurance carriers and patients, the Company considers both the magnitude and likelihood of a revenue reversal in the determination of the percentage of revenues to further constrain for estimated refunds. See Note 3, Revenue Recognition,for detailed discussions of product revenues, licensing and other revenues, and how the five steps described above are applied. . Fair Value . The Company discloses the fair value of financial instruments for financial assets and liabilities for which the value is practicable to estimate. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Related Party . On December 6, 2021, the Company participated along with certain other investors in the series B financing of MyOme, Inc. ("MyOme"), and purchased preferred shares and warrants in exchange for a cash payment of approximately $4.0 million. In August 2024, the Company participated in a subsequent round of series B financing and purchased an additional $2.7 million of series B preferred shares at the same valuation as the initial round of financing in December 2021. The Company does not hold a seat on MyOme's board of directors. The Company's investment in MyOme is recorded at cost and no impairment was identified as of September 30, 2024. The following are the Company's related persons and the basis of each such related person's relationship with MyOme: <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Matthew Rabinowitz, the Company's executive chairman and co-founder, is the chairman of the board and founder of MyOme, and a beneficial holder of approximately 23.6% of the outstanding shares of MyOme on a fully dilutive basis;</td></tr></table> . <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New

Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Jonathan Sheena, the Company's co-founder and a member of the Company's board of directors, is a stockholder and a member of the board of directors of MyOme;</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Daniel Rabinowitz, the Company's Secretary and Chief Legal Officer, is a stockholder of MyOme; and</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Roelof Botha, the Lead Independent Director of the Company's board of directors, is a managing member of Sequoia Capital. Certain funds affiliated with Sequoia Capital also participated in MyOme's series B financing.</td></tr></table> None of the related party investments in MyOme by our executives and directors noted above were at the behest of the Company nor funded by the Company. In February 2024, the Company entered into a collaboration and commercialization agreement (the "Collaboration Agreement") with MyOme pursuant to which the parties will partner to offer certain genetic testing services to be developed and funded solely by MyOme and overseen by a joint steering committee. The Company will assist MyOme with commercial activities. In connection with the Collaboration Agreement, the Company received a 10-year warrant to purchase 3,058,485 shares of MyOme's common stock at an exercise price of $0.25 per share, which will vest upon a MyOme liquidity event (as such terms are defined in MyOme's certificate of incorporation). Additionally, upon the achievement of certain product commercialization milestones, the Company is eligible to receive an additional warrant exercisable for 2,080,565 shares of Myome's series B preferred stock with an exercise price of $0.01 per share. During September 2024, the Company achieved certain product commercialization milestones such that the warrant for 2,080,565 shares of MyOme's series B preferred stock was due from MyOme to the Company. As these warrants have not yet been granted and issued by MyOme, the Company recorded these warrants as a receivable on its condensed consolidated balance sheet as of September 30, 2024. The warrants were valued using the Black-Scholes valuation model on the date of issuance or the date they became receivable from MyOme and are accounted for using the measurement alternative. No impairment was identified as of September 30, 2024. The warrants and warrant receivable have been included within other assets and allocated between short-term and long-term liabilities on the condensed consolidated balance sheet, which will be recognized as a reduction of selling and marketing expense upon commercialization and sale of the products contemplated under the Collaboration Agreement. Subject to the Company's achievement of certain commercialization milestones, the Company may receive additional warrants to purchase MyOme's Series B Preferred Stock. To the extent the genetic testing services are successfully commercialized, the Company will owe certain royalty payments to MyOme. Should the Company exercise all its MyOme common and series B preferred stock warrants, with the series B preferred stock held, the Company would own an accumulated 12.6% of MyOme on a fully diluted basis. This excludes the 2,080,565 shares of MyOme's series B preferred stock warrant receivable. As of September 30, 2024 and December 31, 2023, the Company's carrying amount of ownership interest in MyOme was $6.7 million and $4.0 million, respectively, on its condensed consolidated balance sheet. The carrying value of the warrants and warrant receivable as of September 30, 2024 and December 31, 2023 was $9.4 million and zero, respectively, on the condensed consolidated balance sheet. Risk and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, restricted cash, accounts receivable and investments. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution. For the three and nine months ended September 30, 2024, and 2023, there were no customers exceeding 10% of total revenues on an individual basis. As of September 30, 2024 and December 31, 2023, there were no customers with an outstanding balance exceeding 10% of net accounts receivable. For both the three months ended September 30, 2024 and 2023, approximately 12.6% of total revenue were paid by Medicare on behalf of multiple customers. For the nine months ended September 30, 2024 and 2023, approximately 11.5% and 13.0%, respectively, of total revenue were paid by Medicare on behalf of multiple customers. As of September 30, 2024 and December 31, 2023, approximately 10.9% and 10.2%, respectively, of accounts receivable are expected to be paid by Medicare on behalf of multiple customers. Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") under its accounting standard codifications or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed below, the Company believes the adoption of accounting standards updates recently issued that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. New Accounting Pronouncements Not Yet Adopted In March 2020, ASU 2020-04, Reference Rate Reform (Topic 848) was issued which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to transactions affected by reference rate reform if certain criteria are met. These transactions include contract modifications, hedging relationships, and sale or transfer of debt securities classified as held-to-maturity. ASU 2022-06, or Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The Company does not expect adoption of this standard to have a material impact on its consolidated financial statements. In November 2023, ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, was issued which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact of the guidance on its consolidated financial statements. In December 2023, ASU 2023-09, Income Taxes - Improvements to Income Tax Disclosures, was issued, which requires enhanced disclosures in connection with an entity's effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. The standard will be effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this standard to have a significant impact on its consolidated financial statements. Basis of Presentation The accompanying unaudited interim condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") for interim financial information. The unaudited interim condensed consolidated financial information includes only adjustments of a normal recurring nature necessary for a fair presentation of the Company's results of operations, financial position, changes in stockholders' equity, and cash flows. The results of operations for the nine months ended September 30, 2024, are not necessarily indicative of the results for the full year or the results for any future periods. The condensed consolidated balance sheet as of December 31, 2023 has been derived from audited financial statements at that date. These financial statements should be read in conjunction with the audited financial statements, and related notes for the year ended December 31, 2023 included in the Company's Annual Report on Form 10-K filed with the SEC on February 29, 2024. Some items in the prior period financial statements were reclassified to conform to the current presentation. Liquidity Matters The Company has incurred net losses since its inception and anticipates net losses for the near future. The Company had a net loss of $136.7 million for the nine months ended September 30, 2024 and an accumulated deficit of $2.5 billion as of September 30, 2024. As of September 30, 2024, the Company had $892.8 million in cash, cash equivalents, and restricted cash, $29.5 million in marketable securities, an $80.4 million outstanding balance on its Credit Line (as defined in Note 10, Debt) including accrued interest and $287.5 million of outstanding principal on its 2.25% Convertible Senior Notes (the "Convertible Notes"). The Company is required to maintain a minimum of at least $150.0 million in its UBS accounts as collateral for its Credit Line. As of September 30, 2024, the Company had $20.0 million remaining and available on its Credit Line. While the Company has introduced multiple products that are generating revenues, these revenues have not been sufficient to fund all operations and business plans. Accordingly, the Company has funded the portion of operating costs that exceeds revenues through a combination of equity issuances, debt issuances, and other financings. The Company continues to invest in the development and commercialization of its existing and future products and, consequently, it will need to generate additional revenues to achieve future profitability and may need to raise additional equity or debt financing. If the Company raises additional funds by issuing equity securities, its stockholders will experience dilution. Additional debt financing, if available, may involve covenants restricting its operations or its ability to incur additional debt. Any additional debt financing or additional equity that the Company raises may contain terms that are not favorable to it or its stockholders and requires significant debt service payments, which diverts resources from other activities. Additional financing may not be available when necessary, or in amounts or on terms acceptable to the Company. If the Company is unable to obtain additional financing, it may be required to delay the development and commercialization of its products and significantly scale back its business and operations. On July 19, 2024, the Company announced its decision to redeem all of its outstanding 2.25% Convertible Senior Notes due 2027. The redemption was completed on October 11, 2024 (the "Redemption Date"). The redemption price for the Convertible Notes equaled 100% of the principal amount of the Convertible Notes to be redeemed plus accrued and unpaid interest to, but excluding, the Redemption Date. The Company elected physical settlement with shares of its common stock as the settlement method to apply to all conversions of the Convertible Notes. On the Redemption Date, $287.4 million of Convertible Notes were redeemed for approximately 7.5 million shares of the Company's common stock under the terms of the redemption notice. The remaining Convertible Notes not redeemed under the redemption notice were converted in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, the Company's redemption of its Convertible Notes did not have a material effect on its liquidity. In September 2023, the Company completed an underwritten equity offering and sold 4,550,000 shares of its common stock at a price of $55 per share to the public. Before estimated offering expenses of $0.4 million, the Company received proceeds of approximately $235.8 million net of the underwriting discount. On September 10, 2021, the Company entered into an agreement with a third party for an asset acquisition where the acquired asset was in-process research and development primarily in exchange for an equity consideration payment. In addition, pursuant to the agreement, certain employees of the third party became employees of the Company. The third party was a biotechnology company focused on oncology. The total upfront acquisition consideration amounted to $35.6 million, composed of the issuance of 276,346 shares of the Company's common stock with a fair value of $30.9 million, approximately $3.9 million of cash consideration, assumed net liabilities of $0.2 million, as well as $0.6 million of acquisition related legal and accounting costs directly attributable to the acquisition of the asset. The Company accounted for the transaction as an asset acquisition as

substantially all of the estimated fair value of the gross assets acquired was concentrated in a single identified in-process research and development asset (“IPR&D”), thus satisfying the requirements of the screen test in Accounting Standards Update (“ASU”) 2017-01 Business Combinations (Topic 805): Clarifying the Definition of Business. The estimated fair value of the acquired workforce was not significant. The Company concluded the acquired IPR&D has no alternative-future use and accordingly expensed approximately $35.6 million, on the day the transaction closed as research and development expense, which was reflected in its consolidated statement of operations. Further, additional consideration aggregating up to approximately $35.0 million was estimated to be paid via issuance of an estimated 269,547 additional shares of the Company’s common stock, consistent with the registration statement filed with the SEC on September 10, 2021, upon achievement of defined milestones relating to product development, commercial launch and continued employment of certain selling shareholders, each of which was revalued at each reporting date and amount of compensation expense was adjusted accordingly and reported in research and development expenses. In November 2022, the terms of the payment for any remaining consideration were modified, resulting in $10.0 million of consideration paid in December 2022 and $15.0 million of consideration paid in March 2023, with such consideration primarily consisting of the Company’s common stock. Based on the Company’s current business plan, the Company believes that its existing cash and marketable securities will be sufficient to meet its anticipated cash requirements for at least 12 months after November 12, 2024. -136700000 -2500000000 892800000 29500000 80400000 287500000 0.0225 150000000.0 20000000.0 0.0225 1 287400000 7500000 100000 4550000 55 400000 235800000 35600000 276346 30900000 3900000 200000 600000 35600000 35000000.0 269547 10000000.0 15000000.0 Principles of Consolidation The accompanying condensed consolidated financial statements include all the accounts of the Company and its subsidiaries. The Company established a subsidiary that operates in the state of Texas to support the Company’s laboratory and operational functions. The Company also established a subsidiary that operates in Canada following the acquisition of the IPR&D asset. All intercompany balances and transactions have been eliminated. Use of Estimates The preparation of financial statements in accordance with generally accepted accounting principles (GAAP) in the United States requires management to make estimates and assumptions about future events that affect the amounts of assets and liabilities reported, disclosures about contingent assets and liabilities, and reported amounts of revenues and expenses. Significant items subject to such estimates include the allowance for doubtful accounts, determining the incremental borrowing rate to calculate operating right-of-use assets and the associated lease liabilities, the average useful life for property and equipment including impairment estimates, deferred revenues associated with unsatisfied performance obligations, accrued liability for potential refund requests, stock-based compensation, the fair value of options, income tax uncertainties, and the expected consideration to be received from contracts with customers, insurance payors, and patients. These estimates and assumptions are based on management's best estimates and judgment. Management regularly evaluates its estimates and assumptions using historical experience and other factors, including contractual terms and statutory limits; however, actual results could differ from these estimates and could have an adverse effect on the Company’s financial statements. Investments Investments consist primarily of debt securities such as U.S. Treasuries, U.S. agency and municipal bonds. Management determines the appropriate classification of securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company generally classifies its entire investment portfolio as available-for-sale. The Company views its available-for-sale portfolio as available for use in current operations. Accordingly, the Company classifies all investments as short-term, irrespective of maturity date. Available-for-sale securities are carried at fair value, with unrealized gains and losses reported in accumulated other comprehensive income (loss), which is a separate component of stockholders’ equity. The Company classifies its investments as Level 1 or 2 within the fair value hierarchy. Fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets that the Company has the ability to access. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. The Company holds Level 2 securities, which are initially valued at the transaction price and subsequently valued by a third-party service provider using inputs other than quoted prices that are observable either directly or indirectly, such as yield curve, volatility factors, credit spreads, default rates, loss severity, current market and contractual prices for the underlying instruments or debt, broker and dealer quotes, as well as other relevant economic measures. The Company performs certain procedures to corroborate the fair value of these holdings. Available-for-sale debt securities. The amended guidance from ASU 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, requires the measurement of expected credit losses for available-for-sale debt securities held at the reporting date over the remaining life based on historical experience, current conditions, and reasonable and supportable forecasts. The Company evaluated its investment portfolio under the available-for-sale debt securities impairment model guidance and determined the Company’s investment portfolio is composed of low-risk, investment grade securities and thus has not recorded an expected credit loss for its investment portfolio. Further, gross unrealized losses on available for sale securities were not material at September 30, 2024. Accounts Receivable Trade accounts receivable and other receivables. The allowance for doubtful accounts for trade accounts receivable is based on the Company’s assessment of the collectability of accounts related to its clinics and laboratory partner customers. The Company regularly reviews the allowance by considering factors such as historical experience, the age of the accounts receivable balances, and current economic conditions that may affect a customer’s ability to pay. See Note 6, Balance Sheet Components, for a roll-forward of the allowance for doubtful accounts related to trade accounts receivable for three months and nine months ended September 30, 2024 and 2023. The Company recognizes revenue under Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”) and applies a constraint to the estimated variable consideration such that it is not probable that a significant reversal will occur. When assessing the total consideration expected to be received from insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds. After applying the ASC 606 constraint, the Company assessed for credit losses and allowance for doubtful accounts and determined an incremental credit loss was not needed given the quality of the insurance payors from whom such receivables are expected to be collectible and the relatively short duration over which the majority of receivables are collected. Accordingly, the Company currently does not have an incremental credit loss reserve nor allowance for doubtful accounts against accounts receivable for insurance and patient payors due to the average selling price calculations, which already incorporate these risks as net receivables are recorded. Inventory Inventory is recorded at the lower of cost or net realizable value, determined on a first-in, first-out basis. Inventory consists entirely of supplies, which the Company consumes when providing its test reports, and therefore, the Company does not maintain any finished goods inventory. The Company enters into inventory purchases commitments so that it can meet future delivery schedules based on forecasted demand for its tests. The Company uses judgment to analyze and determine if the composition of its inventory is obsolete, slow-moving or unsalable and frequently reviews such determinations. A write down of specifically identified unusable, obsolete, slow-moving or known unsalable inventory in the period is first recognized by using a number of factors including product expiration dates and scrapped inventory. Any write-down of inventory to net realizable value establishes a new cost basis and will be maintained even if certain circumstances suggest the inventory is recoverable in subsequent periods. Costs associated with the write-down of inventory are recorded to cost of revenue on our consolidated statements of operations. The Company makes assumptions about future demand, market conditions and the release of new products that may supersede older products; however, if actual market conditions are less favorable than anticipated, additional inventory write-downs may be required. Other Assets In January 2024, the Company acquired from Invitae Corp. (“Invitae”) certain assets relating to Invitae’s non-invasive prenatal screening and carrier screening business. The transaction price of $10.5 million consisted of $10.0 million in upfront payment costs and approximately $0.5 million of other transaction costs which were capitalized as intangible assets over an estimated useful life of ten years. An additional payment of up to $42.5 million may be made should the Company achieve certain customer volume retention targets and based on certain legal outcomes. 10500000 10000000.0 500000 P10Y 42500000 Accumulated Other Comprehensive Income (Loss) Comprehensive loss and its components encompass all changes in equity other than those with stockholders, and include net loss, unrealized gains and losses on available-for-sale marketable securities and foreign currency translation adjustments. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.88%;margin:0pt;padding:0pt;"> Three months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.55%;margin:0pt;padding:0pt;"> Nine months ended </td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:47.79%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,358)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"> (9,203) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,085)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"> (16,362) </td></tr><tr><td style="vertical-align:middle;width:52.2%;margin:0pt;padding:0pt;"> Net unrealized gain on available-for-sale securities, net of tax and foreign currency translation adjustment </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 593 </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,807 </td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,320 </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,966 </td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (765)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,396) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,396) </td></tr></table> The change in net unrealized loss on available-for-sale securities is due to the impact of changes in interest rates on the value of fixed-rate investments and not due to any credit deterioration. Further, due to the short-term nature of these investments, the Company has the ability and intention to hold any such investments until maturity and does not expect to realize any material investment losses. As such, the Company has assessed the unrealized loss position for available-for-sale securities and determined that an allowance for credit loss was not necessary. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.88%;margin:0pt;padding:0pt;"> Three months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.55%;margin:0pt;padding:0pt;"> Nine months ended </td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:22.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="12" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:52.2%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:47.79%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,358)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;background:#cceeff;margin:0pt;padding:0pt;"> (9,203) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (3,085)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;margin:0pt;padding:0pt;"> (16,362) </td></tr><tr><td style="vertical-align:middle;width:52.2%;margin:0pt;padding:0pt;"> Net unrealized gain on available-for-sale securities, net of tax and foreign currency translation adjustment </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 593 </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,807 </td><td style="vertical-align:middle;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,320 </td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:7.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 10,966 </td></tr><tr><td style="vertical-align:bottom;width:52.2%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (765)</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:7.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,396) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (765) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (5,396) </td></tr></table> -1358000 -9203000 -3085000 -16362000 593000 3807000 2320000 10966000 -765000 -5396000 -765000 -5396000 Revenue Recognition The Company recognizes revenue under, ASC 606, using the following five step process: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Identification of a contract, or contracts, with a customer;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Identification of the performance obligations in the contract;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Determination of the transaction price;</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Allocation of the transaction price to the performance obligations in the contract; and</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Revenue recognition when, or as, the performance obligations are satisfied.</td></tr></table> The Company uses the most likely amount method of estimating variable consideration. The total consideration which the Company expects to collect in exchange for the Company's products is an estimate and may be fixed or variable, and is primarily based on historical cash collections for tests delivered, as adjusted for current expectations. Current expectations of cash collections factor in changes in reimbursement rate trends, past events not expected to recur, and future known changes such as anticipated contractual pricing changes or changes to insurance coverage. For insurance carriers and product types with similar reimbursement characteristics, the Company uses a portfolio approach to estimate variable consideration. When assessing the total variable consideration expected to be received from insurance carriers and patients, the Company considers both the magnitude and likelihood of a revenue reversal in the determination of the percentage of revenues to further constrain for estimated refunds. See Note 3, Revenue Recognition, for detailed discussions of product revenues, licensing and other revenues, and how the five steps described above are applied. Fair Value The Company discloses the fair value of financial instruments for financial assets and liabilities for which the value is practicable to estimate. Fair value is defined as the price that would be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). Related Party On December 6, 2021, the Company participated along with certain other investors in the series B financing of MyOme, Inc. ("MyOme"), and purchased preferred shares and warrants in exchange for a cash payment of approximately $4.0 million. In August 2024, the Company participated in a subsequent round of series B financing and purchased an additional $2.7 million of series B preferred shares at the same valuation as the initial round of financing in December 2021. The Company does not hold a seat on MyOme's board of directors. The Company's investment in MyOme is recorded at cost and no impairment was identified as of September 30, 2024. The following are the Company's related persons and the basis of each such related person's relationship with MyOme: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Matthew Rabinowitz, the Company's executive chairman and co-founder, is the chairman of the board and founder of MyOme, and a beneficial holder of approximately 23.6% of the outstanding shares of MyOme on a fully dilutive basis;</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Jonathan Sheena, the Company's co-founder and a member of the Company's board of directors, is a stockholder and a member of the board of directors of MyOme;</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Daniel Rabinowitz, the Company's Secretary and Chief Legal Officer, is a stockholder of MyOme; and</td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;background:#ffffff;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Roelof Botha, the Lead Independent Director of the Company's board of directors, is a managing member of Sequoia Capital. Certain funds affiliated with Sequoia Capital also participated in MyOme's series B financing.</td></tr></table> None of the related party investments in MyOme by our executives and directors noted above were at the behest of the Company nor funded by the Company. In February 2024, the Company entered into a collaboration and commercialization agreement (the "Collaboration Agreement") with MyOme pursuant to which the parties will partner to offer certain genetic testing services to be developed and funded solely by MyOme and overseen by a joint steering committee. The Company will assist MyOme with commercial activities. In connection with the Collaboration Agreement, the Company received a 10-year warrant to purchase 3,058,485 shares of MyOme's common stock at an exercise price of $0.25 per share, which will vest upon a MyOme liquidity event (as such terms are defined in MyOme's certificate of incorporation). Additionally, upon the achievement of certain product commercialization milestones, the Company is eligible to receive an additional warrant exercisable for 2,080,565 shares of Myome's series B preferred stock with an exercise price of $0.01 per share. During September 2024, the Company achieved certain product commercialization milestones such that the warrant for 2,080,565 shares of MyOme's series B preferred stock was due from MyOme to the Company. As these warrants have not yet been granted and issued by MyOme, the Company recorded these warrants as a receivable on its condensed consolidated balance sheet as of September 30, 2024. The warrants were valued using the Black-Scholes valuation model on the date of issuance or the date they became receivable from MyOme and are accounted for using the measurement alternative. No impairment was identified as of September 30, 2024. The warrants and warrant receivable have been included within other assets and allocated between short-term and long-term liabilities on the condensed consolidated balance sheet, which will be recognized as a reduction of selling and marketing expense upon commercialization and sale of the products contemplated under the Collaboration Agreement. Subject to the Company's achievement of certain commercialization milestones, the Company may receive additional warrants to purchase MyOme's Series B Preferred Stock. To the extent the genetic testing services are successfully commercialized, the Company will owe certain royalty payments to MyOme. Should the Company exercise all its MyOme common and series B preferred stock warrants, with the series B preferred stock held, the Company would own an accumulated 12.6% of MyOme on a fully diluted basis. This excludes the 2,080,565 shares of MyOme's series B preferred stock warrant receivable. As of September 30, 2024 and December 31, 2023, the Company's carrying amount of ownership interest in MyOme was $6.7 million and $4.0 million, respectively, on its condensed consolidated balance sheet. The carrying value of the warrants and warrant receivable as of September 30, 2024 and December 31, 2023 was $9.4 million and zero, respectively, on the condensed consolidated balance sheet. 4000000.0 2700000 0 0.236 P10Y 3058485 0.25 2080565 0.01 2080565 0 0.126 2080565 6700000 4000000.0 9400000 0 Risk and Uncertainties Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents, restricted cash, accounts receivable and investments. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. The Company performs evaluations of the relative credit standing of these financial institutions and limits the amount of credit exposure with any one institution. For the three and nine months ended September 30, 2024, and 2023, there were no customers exceeding 10% of total revenues on an individual basis. As of September 30, 2024 and December 31, 2023, there were no customers with an outstanding balance exceeding 10% of net accounts receivable. For both the three months ended September 30, 2024 and 2023, approximately 12.6% of total revenue were paid by Medicare on behalf of multiple customers. For the nine months ended September 30, 2024 and 2023, approximately 11.5% and 13.0%, respectively, of total revenue were paid by Medicare on behalf of multiple customers. As of September 30, 2024 and December 31, 2023, approximately 10.9% and 10.2%, respectively, of accounts receivable are expected to be paid by Medicare on behalf of multiple customers. 0 0 0 0 0 0 0 0.126 0.126 0.115 0.130 0.109 0.102 <p style="font-

family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;padding-bottom:12pt;margin:0pt;">Recent Accounting Pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board ("FASB") under its accounting standard codifications or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed below, the Company believes the adoption of accounting standards updates recently issued that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. New Accounting Pronouncements Not Yet Adopted In March 2020, ASU 2020-04, Reference Rate Reform (Topic 848) was issued which provides temporary optional guidance to ease the potential burden in accounting for reference rate reform. The new guidance provides optional expedients and exceptions for applying generally accepted accounting principles to transactions affected by reference rate reform if certain criteria are met. These transactions include contract modifications, hedging relationships, and sale or transfer of debt securities classified as held-to-maturity. ASU 2022-06, or Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848, defers the sunset date of Topic 848 from December 31, 2022 to December 31, 2024. The Company does not expect adoption of this standard to have a material impact on its consolidated financial statements. In November 2023, ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, was issued which requires disclosure of incremental segment information on an interim and annual basis. This ASU is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal periods beginning after December 15, 2024, and requires retrospective application to all prior periods presented in the financial statements. The Company is currently evaluating the impact of the guidance on its consolidated financial statements. In December 2023, ASU 2023-09, Income Taxes - Improvements to Income Tax Disclosures, was issued, which requires enhanced disclosures in connection with an entity's effective tax rate reconciliation and income taxes paid disaggregated by jurisdiction. The standard will be effective for annual periods beginning after December 15, 2024. The Company does not expect the adoption of this standard to have a significant impact on its consolidated financial statements. 3. Revenue Recognition The Company recognizes revenues when, or as, performance obligations in the contracts are satisfied, in the amount reflecting the expected consideration to be received from the goods or services transferred to the customers. Product Revenues Product revenues are derived by performing genetic testing services and the Company's performance obligation is complete when test results are delivered to a laboratory or patient (each a customer). Additionally, the Company enters into agreements with pharmaceutical companies to utilize the Company's Signatera tests typically to study new cancer treatments or to validate the outcomes of clinical trials for which the pharmaceutical companies are identified as customers. Such arrangements generally involve performing whole exome sequencing services and the testing of patient samples to detect cancer mutations using its Signatera test. In addition to performing Signatera tests, these agreements typically include certain activities to fulfill the contract, such as customer data setup and management and ongoing reporting. Each test result is billable to customers upon delivery and the personalized cancer profile also makes each test distinct within the context of the contract as customers can exercise control over the test results upon delivery. Accordingly, the Company recognizes test processing revenue as individual test results are delivered to customers. For certain contracts with pharmaceutical companies where the Company is developing a companion diagnostic test in addition to performing regular testing services, revenue is primarily recognized proportionally as services are performed and/or tests are delivered. A performance obligation represents a promise in a contract to transfer a distinct good or service to a customer, which represents a unit of accounting in accordance with ASC 606. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once the Company has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. A portion of the consideration should be allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. The Company evaluates its contracts with laboratory partners and patients and identifies the performance obligations in those contracts, which are the delivery of the test results. The total consideration the Company expects to collect in exchange for the Company's products is an estimate and may be fixed or variable. Consideration includes reimbursement from both patients and insurance carriers, adjusted for variable consideration related to disallowed cases, percent of patient responsibility collected, refunds and reserves, and is estimated using the most likely amount method. For insurance carriers and product types with similar reimbursement characteristics, the Company uses a portfolio of relevant historical data to estimate variable consideration and total collections for the Company's products. The Company constrains the estimated variable consideration when it determines it is probable that a significant reversal in the amount of cumulative revenue recognized may occur in future periods. The consideration expected from laboratory partners usually includes a fixed amount, but it can be variable depending on the volume of tests performed, and the Company determines the variable consideration using the expected value approach. For laboratory partners and patients, the Company allocates the total consideration to a single performance obligation, which is the delivery of the test results to the customers. When assessing the total consideration expected to be received from insurance carriers and patients, a certain percentage of revenues is further constrained for estimated refunds. The Company enters into contracts with insurance carriers with primarily payment terms related to tests provided to patients who have health insurance coverage. Insurance carriers are considered third-party payers on behalf of the patients, and the patients are considered the customers who receive genetic test services. Tests may be billed to insurance carriers, patients, or a combination of insurance carriers and patients. Further, the Company sells tests to a number of domestic and international laboratory partners and identifies the laboratory partners as customers, provided that there is a test services agreement between the two parties. The Company generally bills an insurance carrier, a laboratory partner or a patient upon delivery of test results. The Company also bills patients directly for out-of-pocket costs involving co-pays and deductibles that they are responsible for. The Company may or may not get reimbursed for the full amount billed. Further, the Company may not get reimbursed at all for tests performed if such tests are not covered under the insurance carrier's reimbursement policies or the Company is not a qualified provider to the insurance carrier, or if the tests were not previously authorized. Product revenue is recognized in an amount equal to the total consideration (as described above) expected to be received at a point in time when the test results are delivered. Approximately 90% of cash collections attributable to such product revenue occurs within nine months with the remaining collections generally taking an additional six months. During this time, management routinely reassesses its estimates of actual to expected cash collections, which are based on historical collection rates and adjusted for current information and trends. To the extent cash collections for tests delivered in prior periods are trending higher than expectations, the Company will increase revenue recognized when sufficient evidence is obtained to conclude the additional revenue will not result in a reversal of revenue in a future period. Given the historical uncertainties with respect to the timing and extent of cash collections for test services provided, sufficient evidence is obtained once cash collected exceeds the amount of revenue recognized during a given period. If cash collections for tests delivered in prior periods are trending below expectations, the Company will reduce revenue to the amount expected to be collected based on the latest information and expectations. Increases or decreases to the amount of cash expected to be collected for tests delivered in prior periods are recognized in product revenue with a corresponding impact to accounts receivable during the period such determination is made. During the three months ended September 30, 2024 and 2023, the Company increased revenue by a net of $34.5 million and $2.2 million, respectively, for collections related to tests delivered in prior periods that were fully collected (including an estimate of unapplied receipts). The increased revenue and decreased net loss resulted in a corresponding decrease in loss per share by $0.28 and $0.02 for the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024, the Company increased revenue for collected cash in excess of initial revenue recognized by a net of $108.1 million for collections related to tests delivered in prior periods that were fully collected (including an estimate of unapplied receipts). The increased revenue and decreased net loss resulted in a corresponding decrease in loss per share by $0.88 for the nine months ended September 30, 2024. During the nine months ended September 30, 2023, the Company reduced revenue by a net of $3.7 million for a reduction in expected collections related to tests delivered in prior periods. The decreased revenue and increased net loss resulted in a corresponding increase in loss per share by $0.03 for the nine months ended September 30, 2023. As of September 30, 2024, the Company had $26.9 million in cash receipts which had not yet been applied to specific accounts receivables. The Company reviewed the historical unapplied payment trends, and, within the unapplied cash receipts of $26.9 million, the Company estimated approximately $2.5 million was related to tests delivered in prior periods that were fully collected. Additionally, as overpayments were not material in prior years, the Company accounted for temporary unapplied balances as of September 30, 2024, as contra accounts receivable on the Balance Sheet. As of December 31, 2023, the unapplied accounts receivable balance was $1.3 million. Product revenue is constrained for refunds estimated to be paid to insurance carriers. Certain refunds are recognized in accrued liabilities until they are either paid to the respective insurance carrier or it is determined the refund will not ultimately be paid, at which time the related accrual is reduced with a corresponding increase to revenue. During the three months ended September 30, 2024 and 2023, the reserves for refunds to insurance carriers were reduced and product revenue increased by $0.7 million and $1.2 million, respectively, for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and corresponding decreased net loss resulted in a decreased loss per share by $0.01 for both the three months ended September 30, 2024 and 2023, respectively. During the nine months ended September 30, 2024 and 2023, the reserves for refunds to insurance carriers were reduced and product revenue increased by $4.5 million and $7.7 million, respectively, for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and corresponding decreased net loss resulted in a decreased loss per share by $0.04 and $0.07 for the nine months ended September 30, 2024 and 2023, respectively. In addition, certain other refunds are recognized as a reduction to accounts receivable until they are either paid to the respective insurance carrier or it is determined the refund will not ultimately be paid, at which time the related reserve is reduced with a corresponding increase to revenue. During the three months ended September 30, 2024, the reserves for refunds to insurance carriers were reduced and product revenue increased by $2.9 million for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and corresponding decreased net loss resulted in a decreased loss per share by $0.02 for the three months ended September 30, 2024. During the nine months ended

September 30, 2024, the reserves for refunds to insurance carriers were reduced and product revenue increased by $7.1 million for amounts the Company determined would not be refunded to insurance carriers. The increased revenue and decreased net loss resulted in a decreased loss per share by $0.06 for the nine months ended September 30, 2024. There was no such adjustment in the three and nine months ended September 30, 2023. Licensing and Other Revenues . The Company recognizes licensing revenues from its cloud-based distribution service offering, Constellation, by granting licenses to its licensees to use certain of the Company's proprietary intellectual properties and cloud-based software and in vitro diagnostic ("IVD") kits. The Company also recognizes revenues from its strategic collaboration agreements, such as those with BGI Genomics Co., Ltd. ("BGI Genomics") and Foundation Medicine, Inc. ("Foundation Medicine"). The Company recognizes licensing and other revenues through agreements with pharmaceutical companies in support of potential clinical trials managed by the pharmaceutical companies. Constellation The laboratory partners with whom the Company enters into a licensing arrangement represent the licensees and are identified as customers. The licensees do not have the right to possess the Company's software, but rather receive services through the cloud software. These arrangements often include: (i) the delivery of the services through the cloud software, (ii) the necessary support and training, and (iii) the IVD kits to be consumed as tests are processed. The Company does not consider the software as a service, the support or the training as being distinct in the context of such arrangements, and therefore, these items are combined as a single performance obligation. The software, support and training are delivered simultaneously to the licensees over the term of the arrangement. The Company bills the majority of licensees, who process the tests in their laboratories, a fixed price for each test processed. Licensing revenues are recognized as the performance obligations are satisfied (i.e., upon the delivery of each test) and reported in licensing and other revenues in the Company's statements of operations and comprehensive loss. BGI Genomics In February 2019, the Company entered into a License Agreement (the "BGI Genomics Agreement") with BGI Genomics to develop, manufacture, and commercialize next generation sequencing-based genetic testing assays for clinical and commercial use. The BGI Genomics Agreement has a term of ten years and expires in February 2029. Pursuant to the BGI Genomics Agreement, the Company licensed its intellectual property to and provided development services for BGI Genomics. Following completion of development services, the Company began providing assay interpretation services over the term of the agreement. According to the BGI Genomics Agreement, the Company is entitled to a total of $50.0 million, comprised of upfront technology license fees, prepaid royalties relating to future sales of licensed products and performance of assay interpretation services, and milestone payments. Due to uncertainties in achieving certain milestones, $6.0 million of the $50.0 million was constrained. A net of $44.0 million has been collected by the Company in cash, which includes $20.0 million in prepaid royalties. The Company concluded that the license is not a distinct performance obligation as it does not have a stand-alone value to BGI Genomics apart from the related development services; therefore, license and related development services for each of the non-invasive prenatal tests ("NIPTs") and Oncology products, represents two separate performance obligations, to which $24.0 million of transaction consideration was allocated. This performance obligation was fully satisfied in March 2023 and no further related amounts will be recognized as revenue. As of December 31, 2023, the Company's performance obligation to provide ongoing NIPT assay interpretation services was removed. Therefore, the Company now has a single remaining performance obligation related to Oncology assay interpretation services, to which $20.0 million of transaction consideration was allocated and prepaid by BGI Genomics. During the nine months ended September 30, 2023, the Company recognized $1.1 million related to oncology assay interpretation services, of which $0.7 million was recognized against deferred royalties. During the nine months ended September 30, 2024, the Company recognized $1.5 million related to oncology assay interpretation services, of which $1.4 million was recognized against deferred royalties. The Company currently has $17.4 million in deferred revenue related to this agreement as of September 30, 2024. As required by the BGI Genomics Agreement, in June 2019 the Company prepaid $6.0 million to BGI Genomics for future sequencing services and $4.0 million for future sequencing equipment. These advance payments are for equipment and services to be received in future periods, which was assessed as a standalone transaction that did not reduce revenue, aggregated to $10.0 million and was originally recorded in long-term assets on the Company's Consolidated Balance Sheet and will be periodically assessed for impairment. During both the three and nine months ended September 30, 2024, $0.4 million in equipment and services was received. During the three and nine months ended September 30, 2023, $1.4 million and $4.0 million, respectively, in equipment and services was received. As of September 30, 2024, the remaining advanced payments were $1.0 million recorded in prepaid expenses and other current assets and $3.4 million recorded in other assets. Foundation Medicine, Inc. . In August 2019, the Company entered into a License and Collaboration Agreement (the "Foundation Medicine Agreement") with Foundation Medicine to develop and commercialize personalized circulating tumor DNA monitoring assays, for use by biopharmaceutical and clinical customers who order Foundation Medicine's FoundationOne CDx. The Company and Foundation Medicine will share the revenues generated from both biopharmaceutical and clinical customers in accordance with the terms of the Foundation Medicine Agreement. The Foundation Medicine Agreement had an initial term of five years that expired in August 2024. There was an option for automatic renewals thereafter for successive one-year terms, unless the Foundation Medicine Agreement is terminated in accordance with its terms. The Company and Foundation Medicine have elected not to renew the agreement beyond the initial term. Pursuant to the Foundation Medicine Agreement, the Company provided development services that are required to customize its proprietary Signatera test to work with Foundation Medicine's FoundationOne CDx in conjunction with granting the use of the Company's intellectual property. Following completion of those development services, the Company was currently providing assay testing services over the term of the agreement. The intellectual property had been licensed to Foundation Medicine for the customized test. In addition, the Company was responsible for delivering clinical study plans in order to demonstrate efficacy of the customized test which commenced in the second quarter of 2021. The Company is entitled to a total of $32.0 million, comprised of upfront technology license fees, prepaid royalties relating to future sales of licensed products and performance of assay interpretation services, and milestone payments. $7.7 million is constrained due to uncertainties in achieving certain milestones. A net of $24.3 million has been collected by the Company in cash, which includes $5.0 million of prepaid royalties. The Company concluded that the license is not a distinct performance obligation as it does not have a stand-alone value to Foundation Medicine apart from the related development services. Therefore, license and related development services, for Oncology products, represent a single performance obligation, to which $19.3 million of transaction consideration was allocated. Of this amount, $0.2 million was recognized in the three months ended March 31, 2023. This performance obligation was fully satisfied in March 2023 and no further related amounts will be recognized as revenue. Royalties related to assay interpretation services represent separate performance obligations for Oncology products, to which $5.0 million of transaction consideration was allocated and prepaid by Foundation Medicine. During the three and nine months ended September 30, 2023, the Company recognized ($0.1) million and $0.3 million, respectively, related to oncology assay interpretation services. During the three and nine months ended September 30, 2024, the Company recognized $0.1 million and $0.3 million, respectively, related to oncology assay interpretation services. The Company currently has $3.0 million in deferred revenue related to this agreement as of September 30, 2024. Disaggregation of Revenues . The Company measures its performance results primarily based on revenues recognized from the three categories described below. The following table shows disaggregation of revenues by payer types: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div

style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"> </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.01%;margin:0pt;padding:0pt;"> Three months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.52%;margin:0pt;padding:0pt;"> Nine months ended </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:53.65%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:43.86%;background:#cceeff;margin:0pt;padding:0pt;"> Insurance carriers </td><td style="vertical-align:bottom;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 405,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> 239,780 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,130,364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 676,680 </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> Laboratory and other partners </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 27,622 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> 21,731 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> 70,152 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 71,985 </td></tr><tr><td style="vertical-align:bottom;width:43.86%;background:#cceeff;margin:0pt;padding:0pt;"> Patients </td><td style="vertical-align:bottom;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,928 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,334 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,801 </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> Total revenues </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 439,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 268,306 </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">1,220,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 771,466 </td></tr></table> . The following table presents total revenues by geographic area based on the location of the Company's payers: . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.53%;margin:0pt;padding:0pt;"> Three months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.78%;margin:0pt;padding:0pt;"> Nine months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> . </td><td colspan="11" style="vertical-align:bottom;width:53.37%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> 426,274 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">259,870</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 1,190,559 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 746,420 </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> Americas, excluding U.S. </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 2,002 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 1,288 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 5,084 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 3,652 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"> Europe, Middle East, India, Africa </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> 7,722 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"> 5,255 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 18,339 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 16,071 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> Asia Pacific and Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,760 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,893 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,323 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 439,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 268,306 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,220,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 771,466 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr></table> The following table summarizes the Company's beginning and ending balances of accounts receivable and deferred revenues: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-

align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.17%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.72%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:36.17%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> Accounts receivable, net </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 306,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 278,289 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> Deferred revenue, current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"> 16,612 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred revenue, long-term portion⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,916 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,128 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> Total deferred revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 35,740 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">- The deferred revenue, long-term portion is included within the "Deferred revenue, long-term portion and other liabilities" line item on the condensed consolidated balance sheets.</td></tr></table> The following table summarizes the changes in the balance of deferred revenues during the nine months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.17%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:63.82%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.17%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,778</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Increase in deferred revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 24,553</p></td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Revenue recognized during the period that was included in deferred revenues at the beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,102)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (9,610)</p></td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Revenue recognized from performance obligations satisfied within the same period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (12,804)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (9,676)</p></td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 34,802 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,045 </td></tr></table> During the nine months ended September 30, 2024, revenue recognized that was included in the deferred revenue balance at the beginning of the period totaled $12.1 million. This balance consisted of approximately a net $1.7 million related to BGI Genomics and Foundation Medicine and $10.4 million related to genetic testing services. The current portion of deferred revenue includes $14.4 million from genetic testing services, $0.5 million from BGI Genomics, and $3.0 million from the Foundation Medicine Agreement as of September 30, 2024. The non-current portion of deferred revenue consists of $16.9 million from the BGI Genomics Agreement as of September 30, 2024. 0.90 P9M P6M 34500000 2200000 0.28 0.02 108100000 0.88 -3700000 -0.03 26900000 26900000 2500000 1300000 700000 1200000 0.01 0.01 4500000 7700000 0.04 0.07 2900000 0.02 7100000 0.06 P10Y 50000000.0 6000000.0 50000000.0 44000000.0 20000000.0 2 24000000.0 20000000.0 1100000 700000 1500000 1400000 17400000 6000000.0 4000000.0 10000000.0 400000 400000 1400000 4000000.0 1000000.0 3400000 P5Y P1Y 32000000.0 7700000 24300000 5000000.0 19300000 200000 5000000.0 -100000 300000 100000 300000 3000000.0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-

align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.01%;margin:0pt;padding:0pt;"> Three months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.52%;margin:0pt;padding:0pt;"> Nine months ended </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:43.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.47%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:53.65%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:43.86%;background:#cceeff;margin:0pt;padding:0pt;"> Insurance carriers </td><td style="vertical-align:bottom;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 405,208</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"> 239,780 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,130,364</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"> 676,680 </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> Laboratory and other partners </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"> 27,622 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"> 21,731 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"> 70,152 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"> 71,985 </td></tr><tr><td style="vertical-align:bottom;width:43.86%;background:#cceeff;margin:0pt;padding:0pt;"> Patients </td><td style="vertical-align:bottom;width:2.47%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,928 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,795 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 20,334 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 22,801 </td></tr><tr><td style="vertical-align:bottom;width:43.86%;margin:0pt;padding:0pt;"> Total revenues </td><td style="vertical-align:bottom;width:2.47%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 439,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 268,306 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,220,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.99%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 771,466 </td></tr></table> 405208000 239780000 1130364000 676680000 27622000 21731000 70152000 71985000 6928000 6795000 20334000 22801000 439758000 268306000 1220850000 771466000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.53%;margin:0pt;padding:0pt;"> Three months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.78%;margin:0pt;padding:0pt;"> Nine months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="14" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;width:53.37%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"> United States </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-

height:1.19;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 426,274</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"> 259,870 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,190,559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 746,420 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> Americas, excluding U.S. </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;margin:0pt;padding:0pt;"> 2,002 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"> 1,288 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;margin:0pt;padding:0pt;"> 5,084 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;margin:0pt;padding:0pt;"> 3,652 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"> Europe, Middle East, India, Africa </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;margin:0pt;padding:0pt;"> 7,722 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"> 5,255 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;margin:0pt;padding:0pt;"> 18,339 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;margin:0pt;padding:0pt;"> 16,071 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:42.4%;margin:0pt;padding:0pt;"> Asia Pacific and Other </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 3,760 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,893 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 6,868 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 5,323 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:42.4%;background:#cceeff;margin:0pt;padding:0pt;"> Total revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 439,758</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 268,306 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,220,850</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 771,466 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"> . </td></tr></table> 426274000 259870000 1190559000 746420000 2002000 1288000 5084000 3652000 7722000 5255000 18339000 16071000 3760000 1893000 6868000 5323000 439758000 268306000 1220850000 771466000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.17%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.72%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;width:36.17%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> Accounts receivable, net </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 306,876</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 278,289 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Liabilities: </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> Deferred revenue, current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"> 16,612 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Deferred revenue, long-term portion<sup style="font-size:5.25pt;line-height:100%;top:0pt;vertical-align:top;">
</sup>⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 16,916 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 19,128 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> Total deferred revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,740 </td></tr></table> 306876000 278289000 17886000 16612000 16916000 19128000 34802000 35740000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.17%;margin:0pt;padding:0pt;"> Balance at </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:63.82%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:36.17%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,740</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"> 30,778 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:59.92%;margin:0pt;padding:0pt;"> Increase in deferred revenues </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;margin:0pt;padding:0pt;"> 23,968 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;margin:0pt;padding:0pt;"> 24,553 </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Revenue recognized during the period that was included in deferred revenues at the beginning of the period </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;margin:0pt;padding:0pt;"> (12,102) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;margin:0pt;padding:0pt;"> (9,610) </td></tr><tr><td style="vertical-align:bottom;width:59.92%;margin:0pt;padding:0pt;"> Revenue recognized from performance obligations satisfied within the same period </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (12,804) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (9,676) </td></tr><tr><td style="vertical-align:bottom;width:59.92%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:nowrap;width:3.9%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.25%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,802</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,045 </td></tr></table> 35740000 30778000 23968000 24553000 -12102000 -9610000 -12804000 -9676000 34802000 36045000 -12100000 -10400000 14400000 500000 3000000.0 16900000 4. Fair Value Measurements The Company's financial assets and liabilities carried at fair value are comprised of investment assets that include money market and investments. The fair value accounting guidance requires that assets and liabilities be carried at fair value and classified in one of the following three categories: Level I: Quoted prices in active markets for identical assets and liabilities that the Company has the ability to access. Level II: Observable market-based inputs or unobservable inputs that are corroborated by market data, such as quoted prices, interest rates, and yield curves; and Level III: Inputs that are unobservable data points that are not corroborated by market data. This hierarchy requires the Company to

use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. Assets and Liabilities That Are Measured at Fair Value on a Recurring Basis The following table represents the fair value hierarchy for the Company's financial assets and financial liabilities measured at fair value on a recurring basis: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level I </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level II </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level III </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level I </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-

height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level II </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level III </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="25" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="23" style="vertical-align:bottom;white-space:nowrap;width:71.34%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;background:#cceeff;margin:0pt;padding:0pt;"> Financial Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:26.86%;margin:0pt;padding:0pt;"> Cash, cash equivalents and restricted cash⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 892,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> 892,844 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">642,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"> 642,095 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-

align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#ccecff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#ccecff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#ccecff;margin:0pt;padding:0pt;"> 200,418 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"> Municipal securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,464 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,464 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,464 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;background:#cceeff;margin:0pt;padding:0pt;"> Total financial assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 892,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> — </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 922,334 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#ccecff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">842,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#ccecff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#ccecff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#ccecff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,464 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#ccecff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#ccecff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#ccecff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#ccecff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#ccecff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 878,977 </td></tr><tr><td style="vertical-align:bottom;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Cash equivalents includes money market deposits and liquid demand deposits.</td></tr></table> Fair Value of Short-Term and Long-Term Debt: As of September 30, 2024 and December 31, 2023, the estimated fair value of the total principal outstanding and accrued interest of the Credit Line was $80.4 million, and were based upon observable Level 2 inputs, including the interest rate based on the 30-day Secured Overnight Financing Rate (“SOFR”) average, plus 0.5%. The estimated fair value approximates the carrying value due to the short term duration and variable interest rate. As of September 30, 2024 and December 31, 2023, the estimated fair value of the Convertible Notes was $929.1 million and $491.8 million, respectively, based upon observable, Level 2 inputs, including pricing information from recent trades of the Convertible Notes. See Note 10, Debt, for additional details and carrying value. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:34.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level I </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level II </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level III </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level I </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level II </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:6.18%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Level III </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="25" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td colspan="23" style="vertical-align:bottom;white-space:nowrap;width:71.34%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;background:#cceeff;margin:0pt;padding:0pt;"> Financial Assets: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:26.86%;margin:0pt;padding:0pt;"> Cash, cash equivalents and restricted cash⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 892,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> 892,844 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 642,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> 642,095 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;margin:0pt;padding:0pt;"> 200,418 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-

align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">200,418 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;margin:0pt;padding:0pt;"> Municipal securities </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,464 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,464 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.86%;background:#cceeff;margin:0pt;padding:0pt;"> Total financial assets </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">892,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 922,334 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">842,513</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 36,464 </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 878,977 </td></tr><tr><td style="vertical-align:bottom;width:26.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.96%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.42%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.98%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:7.44%;margin:0pt;padding:0pt;"> </td></tr></table> 892844000 892844000 642095000 642095000 200418000 200418000 29490000 29490000 36464000 36464000 892844000 29490000 922334000 842513000 36464000 878977000 80400000 0.005 929100000 491800000 5. Financial Instruments The Company elected to invest a portion of its cash assets in conservative, income earning, and liquid investments. Cash, cash equivalents, restricted cash and investments, which are classified as available-for-sale securities, consisted of the following: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:26.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:35.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:33.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:26.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortized
Cost </td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross
Unrealized<b

style="font-weight:bold;">
Gain </td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross
Unrealized
Loss </td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Estimated Fair Value </td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortized
Cost </td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross
Unrealized
Gain </td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross
Unrealized
Loss </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Estimated Fair Value </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="25" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="20" style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;background:#cceeff;margin:0pt;padding:0pt;"> Cash, cash equivalents and restricted cash⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 892,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"> 892,844 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 642,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"> 642,095 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> U.S. Treasury securities⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> 201,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> 14 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> (1,118) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"> 200,418 </td></tr><tr><td style="vertical-align:bottom;white-

space:nowrap;width:26.74%;background:#cceeff;margin:0pt;padding:0pt;"> Municipal securities⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,034 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (544) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,627) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,464 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;">922,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(544)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 922,334 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;">881,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(2,745)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 878,977 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;background:#cceeff;margin:0pt;padding:0pt;"> Classified as: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt,"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;background:#cceeff;margin:0pt;padding:0pt;"> Cash, cash equivalents and restricted cash⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"> 642,095 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;background:#cceeff;margin:0pt;padding:0pt,"> Short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-

align:right;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#ccecff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#ccecff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#ccecff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#ccecff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#ccecff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 236,882 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 878,977 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Per the Company's investment policy, all debt securities are classified as short-term investments irrespective of holding period. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times',serif;font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Cash equivalents includes liquid demand deposits, and money market funds.</td></tr></table> . The Company invests in U.S. Treasuries, U.S. agency and high-quality municipal bonds which mature at par value and are all paying their coupons on schedule. The Company has therefore concluded an allowance for expected credit losses of its investments was not necessary and will continue to recognize unrealized gains and losses in other comprehensive income (loss). During the nine months ended September 30, 2024, the Company sold one investment, which resulted in an immaterial gain. The Company uses the specific investment identification method to calculate realized gains and losses and amounts reclassified out of other comprehensive income (loss) to net loss. As of September 30, 2024, the Company had 9 investments in an unrealized loss position in its portfolio. Gross unrealized losses were not material as of September 30, 2024. Gross unrealized losses were primarily due to declines in the value of fixed rate instruments as interest rates in the broader market increased, and were not indictive of a decline in the credit worthiness of the underlying issuer, and as such, the Company did not record a credit loss reserve as of September 30, 2024. The following table presents debt securities available-for-sale that were in an unrealized loss position as of September 30, 2024, aggregated by major security type in a continuous loss position. . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> <span style="font-

size:1pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:19.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:middle;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:19.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized Loss </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:44.13%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> Municipal securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 27,990 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (544) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (544) </td></tr></table> The following table summarizes the Company's portfolio of available-for-sale securities by contractual maturity as of September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortized
Cost </td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair
Value </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.9%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;background:#cceeff;margin:0pt;padding:0pt;"> Less than or equal to one year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:2.55%;background:#ccceff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#ccecff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#ccecff;margin:0pt;padding:0pt;"> 28,522 </td></tr><tr><td style="vertical-align:bottom;width:62.93%;margin:0pt;padding:0pt;"> Greater than one year but less than five years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 968 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#ccecff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#ccecff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,490 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:26.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:35.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:33.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr><td style="vertical-align:bottom;width:26.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortized
Cost </td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-

height:1.19;text-align:center;margin:0pt;">Gross
Unrealized
Gain </td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross
Unrealized
Loss </td><td style="vertical-align:middle;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Estimated Fair Value </td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortized
Cost </td><td style="vertical-align:middle;width:1.87%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross
Unrealized
Gain </td><td style="vertical-align:middle;width:1.85%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:6.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Gross
Unrealized
Loss </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:7.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Estimated Fair Value </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="25" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">   </td><td colspan="20" style="vertical-align:bottom;white-space:nowrap;width:62.31%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;background:#cceeff;margin:0pt;padding:0pt;"> Cash, cash equivalents and restricted cash⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 892,844</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"> 892,844 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> 642,095</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;background:#cceeff;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"> 642,095 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> U.S. Treasury securities⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> 201,522 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> 14 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> (1,118) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;">200,418 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;background:#cceeff;margin:0pt;padding:0pt;"> Municipal securities⁽¹⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 30,034 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (544) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 38,091 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,627) </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 36,464 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;">922,878</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> — </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(544)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 922,334 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;">881,708</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 14 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">(2,745)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 878,977 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;background:#cceeff;margin:0pt;padding:0pt;"> Classified as: </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> Cash, cash equivalents and restricted cash⁽²⁾ </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;margin:0pt;padding:0pt;"> 892,844 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;margin:0pt;padding:0pt;"> 642,095 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;background:#cceeff;margin:0pt;padding:0pt;"> Short-term investments </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,490 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 236,882 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:26.74%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:6.01%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.08%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt 2.4pt 0pt 0pt;">922,334</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:5.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 878,977 </td></tr></table> <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;">Per the Company's investment policy, all debt securities are classified as short-term investments irrespective of holding period. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;">Cash equivalents includes liquid demand deposits, and money market funds.</td></tr></table> 892844000 892844000 642095000 642095000 201522000 14000 1118000 200418000 30034000 544000 29490000 380910001627000 36464000 922878000 544000 922334000 881708000 14000 2745000 878977000 892844000 642095000 29490000 236882000 922334000 878977000 1 9 0 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;margin:0pt;padding:0pt;"> <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Total </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:19.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td><td style="vertical-align:middle;width:2.37%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;width:19.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Unrealized Loss </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> </td><td colspan="6" style="vertical-align:bottom;white-space:nowrap;width:44.13%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;background:#cceeff;margin:0pt;padding:0pt;"> U.S. Treasury securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;margin:0pt;padding:0pt;"> Municipal securities </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 27,990 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (544) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.86%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.45%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,990</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> (544) </td></tr></table> 27990000 544000 27990000 544000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Amortized
Cost </td><td style="vertical-align:bottom;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;width:16.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair
Value </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:34.9%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;background:#cceeff;margin:0pt;padding:0pt;"> Less than or equal to one year </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 29,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;margin:0pt;padding:0pt;"> 28,522 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;margin:0pt;padding:0pt;"> Greater than one year but less than five years </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td

style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> - 1,000 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 968 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:62.93%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">30,034</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 29,490 </td></tr></table> 29034000 28522000 1000000 968000 30034000 29490000 6. Balance Sheet Components Allowance for doubtful accounts The following is a roll-forward of the allowances for doubtful accounts related to trade accounts receivable for the three and nine months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"> Three Months Ended </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:middle;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">7,021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"> 5,580 </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> (Reversal of) Provision for doubtful accounts </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"> (536) </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"> 454 </td></tr><tr><td style="vertical-align:middle;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Write-offs </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (233) </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,252 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,034 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:middle;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,481</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"> 3,830 </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> Provision for doubtful accounts </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"> 208 </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"> 2,204 </td></tr><tr><td style="vertical-align:middle;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Write-offs </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (437) </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,252 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,034 </td></tr></table> Property and Equipment, net The Company's property and equipment consisted of the following: <p style="font-family:'Times New

Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"> <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Useful Life </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.99%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;background:#cceeff;margin:0pt;padding:0pt;"> 3-5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 104,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"> 85,626 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> Computer equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> 3 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> 3,040 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> 1,850 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"> Purchased and capitalized software held for internal use </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;background:#cceeff;margin:0pt;padding:0pt;"> 3 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"> 11,104 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"> 11,636 </td></tr><tr><td style="vertical-align:middle;width:47.07%;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:middle;width:26.93%;margin:0pt;padding:0pt;"> Lesser of useful life or lease term </td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> 48,080 </td><td style="vertical-align:middle;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> 38,999 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"> Construction-in-process </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 46,631 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,392 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> 213,298 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> 167,503 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Accumulated depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-

height:1.19;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (71,128) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (56,293) </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> Total Property and Equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 142,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 111,210 </td></tr></table> The Company's long-lived assets are located in the United States. During the nine months ended September 30, 2024, the increase in net property and equipment was due to expansion projects and purchases of new equipment for the Company's laboratories located in Texas and California to expand testing capabilities, offset by depreciation expense of $19.9 million recorded in the nine months ended September 30, 2024. Depreciation expense of $16.1 million was recorded in the nine months ended September 30, 2023. The Company did not incur any impairment charges during the nine months ended September 30, 2024 or 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Other Accrued Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;">The Company's other accrued liabilities consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">Reserves for refunds to insurance carriers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 15,778 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 23,245 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Accrued charges for third-party testing </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 9,924 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 14,823 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Testing and laboratory materials from suppliers </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 9,823 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 11,229 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Marketing and corporate affairs </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 15,526 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 10,085 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Legal, audit and consulting fees </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 36,535 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 43,897 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Accrued shipping charges </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-

size:10pt;line-height:1.19;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 2,180 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 3,646 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Sales and income tax payable </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 5,061 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 3,731 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Accrued third-party service fees </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 8,853 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 7,111 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Clinical trials and studies </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 7,744 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 12,126 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Operating lease liabilities, current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 9,762 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 11,621 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment purchases </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 3,397 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 4,316 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Other accrued interest </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 1,078 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Other accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,592 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,497 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Total other accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 126,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 149,405 </td></tr></table> Reserves for refunds to insurance carriers include overpayments from and amounts to be refunded to insurance carriers and additional amounts that the Company estimates for potential refund requests during the period. When the Company releases these previously accrued amounts, they are recognized as product revenues in the condensed statements of operations and comprehensive loss. The following table summarizes the reserve balance and activities for refunds to insurance carriers for the nine months ending September 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:44.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt

0pt 0.05pt 0pt;">September 30, </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:44.38%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 23,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 18,948 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Additional reserves </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 1,506 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 7,348 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Refunds to carriers </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> (3,095) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> (1,236) </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Reserves released to revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,878) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,851) </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 15,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,209 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> </td></tr></table> During the quarter ended September 30, 2024, the Company repaid $13.8 million in short term advances obtained as a result of the disruption to Change Healthcare's network in February 2024. The following is a roll-forward of the allowances for doubtful accounts related to trade accounts receivable for the three and nine months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"> Three Months Ended </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New

Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;">September 30, </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;">
</td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:middle;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">7,021</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"> 5,580 </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> (Reversal of) Provision for doubtful accounts </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;">
</td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"> (536) </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"> 454 </td></tr><tr><td style="vertical-align:middle;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Write-offs </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">
</td><td style="vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (233) </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,252 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,034 </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.24%;margin:0pt;padding:0pt;"> Nine Months Ended </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> — </td><td colspan="5" style="vertical-align:middle;white-space:nowrap;width:28.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:15.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:11.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:68.06%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;">

</td><td colspan="4" style="vertical-align:middle;white-space:nowrap;width:25.45%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:middle;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,481</p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"> 3,830 </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> Provision for doubtful accounts </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.49%;margin:0pt;padding:0pt;"> 208 </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"> 2,204 </td></tr><tr><td style="vertical-align:middle;width:68.06%;background:#cceeff;margin:0pt;padding:0pt;"> Write-offs </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (437) </td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:middle;width:68.06%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:middle;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:middle;white-space:nowrap;width:12.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">6,252 </p></td><td style="vertical-align:middle;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:2.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:middle;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 6,034 </td></tr></table> 7021000 5580000 536000 -454000 233000 6252000 6034000 6481000 3830000 -208000 -2204000 437000 6252000 6034000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> Useful Life </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.99%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"> Machinery and equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;background:#cceeff;margin:0pt;padding:0pt;"> 3-5 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 104,443</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"> 85,626 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> Computer equipment </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> 3 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> 3,040 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> 1,850 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-

height:1.19;margin:0pt;">Purchased and capitalized software held for internal use </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;background:#cceeff;margin:0pt;padding:0pt;"> 3 years </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;margin:0pt;padding:0pt;"> 11,104 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;margin:0pt;padding:0pt;"> 11,636 </td></tr><tr><td style="vertical-align:middle;width:47.07%;margin:0pt;padding:0pt;"> Leasehold improvements </td><td style="vertical-align:middle;width:26.93%;margin:0pt;padding:0pt;"> Lesser of useful life or lease term </td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> 48,080 </td><td style="vertical-align:middle;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> 38,999 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"> Construction-in-process </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 46,631 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 29,392 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;margin:0pt;padding:0pt;"> 213,298 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;margin:0pt;padding:0pt;"> 167,503 </td></tr><tr><td style="vertical-align:bottom;width:47.07%;background:#cceeff;margin:0pt;padding:0pt;"> Less: Accumulated depreciation and amortization </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (71,128) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (56,293) </td></tr><tr><td style="vertical-align:bottom;width:47.07%;margin:0pt;padding:0pt;"> Total Property and Equipment, net </td><td style="vertical-align:bottom;white-space:nowrap;width:26.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 142,170</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:8.66%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 111,210 </td></tr></table> P3Y 104443000 85626000 P3Y 3040000 1850000 P3Y 11104000 11636000 48080000 38999000 46631000 29392000 213298000 167503000 71128000 56293000 142170000 111210000 19900000 16100000 0 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.62%;margin:0pt;padding:0pt;"> December 31, </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> . </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:44.38%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Reserves for refunds to insurance carriers </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 15,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 23,245 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Accrued charges

for third-party testing </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 9,924 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 14,823 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Testing and laboratory materials from suppliers </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 9,823 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 11,229 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Marketing and corporate affairs </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 15,526 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 10,085 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Legal, audit and consulting fees </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 36,535 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 43,897 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Accrued shipping charges </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 2,180 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 3,646 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Sales and income tax payable </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 5,061 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 3,731 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Accrued third-party service fees </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 8,853 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 7,111 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Clinical trials and studies </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 7,744 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 12,126 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Operating lease liabilities, current portion </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 9,762 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 11,621 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Property and equipment purchases </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> 3,397 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 4,316 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Other accrued interest </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 1 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 1,078 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Other accrued expenses </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 1,592 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2,497 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 6pt;">Total other accrued liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">126,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 149,405 </td></tr></table>15778000 23245000 9924000 14823000 9823000 11229000 15526000 10085000 36535000 43897000 2180000 3646000 5061000 3731000 8853000 7111000 7744000 12126000 9762000 11621000 3397000 4316000 1000 1078000 1592000 2497000 126176000 149405000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:44.38%;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:44.38%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Beginning balance </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 23,245</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> 18,948 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Additional reserves </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> 1,506 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> 7,348 </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Refunds to carriers </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;margin:0pt;padding:0pt;"> (3,095) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;margin:0pt;padding:0pt;"> (1,236) </td></tr><tr><td style="vertical-align:bottom;width:55.61%;margin:0pt;padding:0pt;"> Reserves released to revenue </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (5,878) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (8,851) </td></tr><tr><td style="vertical-align:bottom;width:55.61%;background:#cceeff;margin:0pt;padding:0pt;"> Ending balance </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 15,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 16,209 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:55.61%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.83%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:16.82%;margin:0pt;padding:0pt;"> </td></tr></table>23245000 18948000 1506000 7348000 3095000 1236000 5878000 8851000 15778000 16209000 13800000 7. Leases Operating Leases In September 2015, the Company entered into a long-term lease agreement for laboratory and office space totaling

approximately 94,000 square feet in Austin, Texas. The original lease term was 132 months beginning in December 2015 and expiring in November 2026, with monthly payments beginning in December 2016. In December 2021, the Company entered into an amendment of the Austin lease agreement, which extended the lease of the current premises through March 2033. The amendment also includes two additional office spaces (the "First Expansion Premises" and the "Second Expansion Premises"). The First Expansion Premises consists of 32,500 rentable square feet and commenced in February 2022. The Second Expansion Premises consists of 65,222 rentable square feet and commenced in September 2022. The terms of the First and Second Expansion Premises expire in March 2033. In October 2016, the Company entered into a lease directly with its landlord for laboratory and office spaces at its facilities located in San Carlos, California. The Company currently occupies approximately 136,000 square feet comprised of two office spaces (the "First Space" and the "Second Space"). The First Space covers approximately 88,000 square feet, and the Second Space totals approximately 48,000 square feet. In January 2021, the Company entered into an amendment of the lease to extend the term for 48 months to October 2027. The combined annual rent for the First Space and Second Space is $9.3 million, which commenced in October 2023. In July 2024, the Company entered into an amendment of the San Carlos lease to extend the term for 60 months to October 2032. The annual rent will be approximately $9.7 million beginning January 2025, escalating annually and may be increased if the Company elects to utilize additional tenant improvement allowances. The Company entered into a lease agreement commencing June 2018 for its cord blood tissue storage facility in Tukwila, Washington that covers approximately 10,000 square feet. The lease term was 62 months and expired in July 2023. The Company had the option to extend this lease for five years, however, since the Company sold its business related to cord blood and tissue storage in September 2019, the Company subleased the facility through the end of the lease and did not exercise its option to renew the facility upon expiration. The Company entered into a lease agreement in November 2020 to lease 11,395 square feet of space located in South San Francisco, California over a 36-month term. The premises are used for general office, laboratory and research use. The annual lease payment started at $0.9 million and escalates annually after commencing in December 2021. In December 2022, the Company exercised the renewal option of the South San Francisco lease agreement. In January 2023, the Company entered in an amendment to extend the lease term of the South San Francisco premises by three years, through November 2026. The Company entered into a lease agreement in September 2023 to lease 16,319 square feet of space located in Pleasanton, California over a 60-month term. The premises are used for laboratory and research use and commenced in December 2023. The annual lease payment started at $0.5 million and escalates annually. As part of the IPR&D asset acquisition in September 2021, the Company inherited a 24-month lease for 7,107 square feet of laboratory space in Canada. The annual lease payment started at $0.2 million and expired in August 2023. The Company has also historically entered into leases of individual workspaces and storage spaces at various locations on both a month-to-month basis without an established lease term and, more recently for certain locations, has committed to terms approximating one to five years. For the facilities without a committed lease term, the Company has elected to not recognize them as right-of-use assets on the condensed consolidated balance sheets as they are all considered short-term leases. For individual workspaces where the committed lease term exceeds one year, the Company has recorded a right-of-use asset on the condensed consolidated balance sheets. For the nine months ended September 30, 2024, the Company had $38.2 million in noncash operating activities related to additional right-of-use assets resulting from a new lease and extending existing leases under ASC, Topic 842, Leases ("ASC 842"). For the nine months ended September 30, 2023, the Company had $0.1 million in noncash operating activities related to additional right-of-use assets.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;background:#ffffff;margin:0pt 0pt 12pt 0pt;">The operating lease right-of-use assets are classified as noncurrent assets in the balance sheet. The corresponding lease liabilities are separated into current and long-term portions as follows:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Operating lease liabilities, current portion included in other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"> 9,762 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"> 11,621 </td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"> Operating lease liabilities, long-term portion </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 98,953 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid

#000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 67,025 </td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"> Total operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 108,715</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 78,646 </td></tr></table> The initial recognition of the operating lease liabilities was measured as the present value of the future minimum lease payments using a discount rate determined as of January 1, 2019 upon the adoption of ASC 842. The operating right-of-use assets were calculated as the operating lease liabilities discounted at the present value, less the amount of unamortized tenant improvement allowance and deferred rent. The discount rate used was the Company's incremental borrowing rate given that the implicit rate to each lease was not readily determinable. In accordance with ASC 842, the incremental borrowing rate was estimated as the annual percentage yield resulting from a corporate debt financing over a loan term approximating the remaining term of each lease, with the effect of certain credit risk rating. As of September 30, 2024, the weighted-average remaining lease term was 8.02 years and the weighted-average discount rate was 7.2%. The Company continues to recognize lease expense on a straight-line basis. The lease expense includes the amortization of the right-of-use assets with the associated interest component estimated by applying the effective interest method. For the three months ended September 30, 2024 and 2023, total lease expense of $4.0 million and $3.6 million was recognized in the condensed statements of operations and comprehensive loss, respectively. For the nine months ended September 30, 2024 and 2023, total lease expense of $11.2 million and $11.0 million was recognized in the condensed statements of operations and comprehensive loss, respectively. Cash paid for amounts in the measurement of operating lease liabilities totaled $4.2 million and $3.2 million for the three months ended September 30, 2024 and 2023, respectively. Cash paid for amounts in the measurement of operating lease liabilities totaled $12.5 million and $8.4 million for the nine months ended September 30, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The present value of the future annual minimum lease payments under all non-cancellable operating leases as of September 30, 2024 are as follows:</p><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">As of September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">2024 (remaining 3 months)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 4,315 </td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"> 2025 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 17,391 </td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"> 2026 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 17,661 </td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"> 2027 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"> 16,997 </td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"> 2028 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 17,332 </td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"> 2029 and thereafter </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 70,693 </td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> 144,389 </td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"> Less: imputed interest </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <span

style="visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (35,674) </td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"> Operating lease liabilities </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 108,715</p></td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p> 94000 P132M 2 32500 65222 136000 2 88000 48000 P48M 9300000 P60M 9700000 10000 P62M P5Y 11395 900000 P3Y 16319 P60M 500000 7107 200000 P5Y 38200000 100000 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:26.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Operating lease liabilities, current portion included in other accrued liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;margin:0pt;padding:0pt;"> 9,762 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 11,621</p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">Operating lease liabilities, long-term portion</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 98,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 67,025</p></td></tr><tr><td style="vertical-align:bottom;width:67.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 12pt;">Total operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 108,715 </td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 78,646 </td></tr></table> 9762000 11621000 98953000 67025000 108715000 78646000 0.072 4000000.0 3600000 11200000 11000000.0 4200000 3200000 12500000 8400000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Operating Leases </td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.14%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"> As of September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;">   </td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"> 2024 (remaining 3 months) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,315</p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,391</p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,661</p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,997</p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">2028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 17,332</p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">2029 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 70,693</p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 144,389</p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Less: imputed interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (35,674)</p></td></tr><tr><td style="vertical-align:bottom;width:79.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 24pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 108,715 </td></tr></table>   4315000 17391000 17661000 16997000 17332000 70693000 144389000 35674000 108715000 8. Commitments and Contingencies Legal Proceedings The Company is involved in legal matters, including investigations, subpoenas, demands, disputes, litigation, requests for information, and other regulatory or administrative actions or proceedings, including those with respect to intellectual property, testing and test performance, billing, reimbursement, marketing, short seller and media allegations, employment, and other matters.   The Company is responding to ongoing regulatory and governmental investigations, subpoenas and inquiries, and contesting its current legal matters, but cannot provide any assurance as to the ultimate outcome with respect to any of the foregoing. There are many uncertainties associated with these matters. Such matters may cause the Company to incur costly litigation and/or substantial settlement charges, divert management attention, result in adverse judgments, fines, penalties, injunctions or other relief, and may result in loss of customer or investor confidence regardless of their merit or ultimate outcome. In addition, the resolution of any intellectual property litigation may require the Company to make royalty payments, which could adversely affect gross margins in future periods. If any of the foregoing were to occur, the Company's business, financial condition, results of operations, cash flows, prospects, or stock price could be adversely affected.   The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the procedural status of the matter in question, the presence of complex or novel legal theories, and/or the ongoing discovery and development of information important to the matters. In addition, damage amounts claimed in litigation or other matters may be unsupported, exaggerated or unrelated to possible outcomes, and as such are not meaningful indicators of its potential liability. Loss contingencies, including claims and legal actions arising in the ordinary course of business, are recorded as liabilities when the likelihood of loss is probable and an amount or range of loss can be reasonably estimated. During the periods presented, the Company does not believe there are such matters that will have a material effect on its financial condition. Intellectual Property Litigation Matters. The Company has been involved in two patent litigations against CareDx, Inc. ("CareDx") in the United States District Court for the District of Delaware ("CareDx Patent Cases"). In the first CareDx Patent Case, CareDx alleged, in a complaint filed jointly with the Board of Trustees of the Leland Stanford Junior University in March 2019 and amended in March 2020, that the Company infringed three patents (the "CareDx Patents"). The complaint sought unspecified damages and injunctive relief. In September 2021, the Court granted the Company's motion for summary judgment, finding all three CareDx Patents invalid. This finding was affirmed on appeal by the United States Court of Appeals for the Federal Circuit. CareDx's petition for rehearing by the Federal Circuit, and its subsequent petition for certiorari to the United States Supreme Court, were both denied. In the second CareDx Patent Case, the Company alleged, in suits filed in January 2020 and May 2022, infringement by CareDx of certain of the Company's patents, seeking unspecified damages and injunctive relief. In January 2024, after trial, the jury returned a verdict in favor of the Company, finding both asserted patents valid and one patent infringed by CareDx (the "Infringed Patent"). The jury awarded damages to the Company for lost profits and past royalties totaling $96.3 million. The Company's motion for an injunction remains pending. Separately, in September 2024, an ex-parte re-examination petition was filed with the United States Patent and Trademark Office ("USPTO") challenging the validity of the Infringed Patent. In January 2020, the Company filed suit against ArcherDX, Inc. ("ArcherDX") in the United States District Court for the District of Delaware. In January 2021, the Company named an additional Archer DX entity, ArcherDx LLC, and Invitae as defendants. The Company alleged, among other things, that certain ArcherDX products, including the Personalized Cancer Monitoring ("PCM") test, infringed three of the Company's patents (the "ArcherDX Case") and sought

unspecified monetary damages and injunctive relief. Following a jury trial in May 2023 and a bench trial in June 2023, all three asserted patents were found to be valid and infringed by ArcherDX and Invitae, and the jury awarded damages totaling $19.35 million to the Company. In November 2023, the Court granted in part the Company's motion for a permanent injunction against the PCM test, which the defendants have appealed. In February 2024, Invitae and ArcherDX filed a voluntary Chapter 11 petition in the U.S. Bankruptcy Court for the District of New Jersey, resulting in an automatic bankruptcy stay in the case. In November 2024, the Court granted the parties' stipulated request to vacate the stay. The Company is the subject of a lawsuit filed against it by Ravgen, Inc. ("Ravgen") in June 2020 in the United States District Court for the Western District of Texas, alleging infringement of two Ravgen patents and seeking monetary damages and injunctive relief. In January 2024, after trial, the jury returned a verdict of non-willful infringement by the Company and found damages of $57 million. The Company intends to appeal certain of the rulings. In addition, various parties, including the Company, have filed petitions challenging the validity of the asserted patents with the United States Patent and Trademark Office, all of which were instituted for review, and some of which were decided in favor of upholding the challenged claims. The petitions filed by the Company and certain others remain pending. In October 2020, the Company filed suit against Genosity Inc. ("Genosity"), in the United States District Court for the District of Delaware, alleging that various Genosity products infringe one of the Company's patents and seeking unspecified monetary damages and injunctive relief. The case has been stayed pending the entry of a final judgment in the ArcherDX Case, in which the subject patent is also asserted. In February 2024, Genosity filed a voluntary Chapter 11 petiion in the U.S. Bankruptcy Court for the District of New Jersey. The Company is the subject of lawsuits filed against it by Invitae in the United States District Court of the District of Delaware alleging, in complaints filed in May and November of 2021, infringement of three patents and seeking monetary damages and injunctive relief. The parties have filed cross-motions for summary judgment, which motions are currently pending before the Court. In February 2024, subsequent to Invitae's voluntary Chapter 11 petition described above, the Court granted Invitae's request to continue the trial, which is now scheduled for September 2025. The Company filed suits against Inivata, Inc. and Inivata Ltd. (collectively "Inivata") in the United States District Court for the District of Delaware in January 2021 and December 2022, alleging that certain of Inivata's oncology products infringe certain of the Company's patents and seeking unspecified monetary damages and injunctive relief. The two suits have been consolidated. In March 2024, the Court stayed the case in light of the Company's case against NeoGenomics Laboratories, Inc. ("NeoGenomics"), which acquired Inivata in 2021, discussed below. In September 2024, the Court denied Inivata's motion to dismiss the Company's complaint with respect to one patent. In July 2023, the Company filed suit against NeoGenomics in the United States District Court for the Middle District of North Carolina (the "District Court"), alleging infringement of two Natera patents (the "'035 Patent" and the "'454 Patent") by NeoGenomics' commercialization of the RaDaR test and seeking monetary damages and injunctive relief. In December 2023, the Court denied NeoGenomics' motion to dismiss the complaint, and granted the Company's motion for preliminary injunction. The injunction went into effect as of January 12, 2024 and was affirmed on appeal in July 2024 by the Federal Circuit Court of Appeals. NeoGenomics filed a petition with the USPTO to review the validity of the '454 Patent, which was denied in June 2024. NeoGenomics also filed a petition with the USPTO to review the validity of the '035 Patent, which proceeding was terminated in October 2024. Pursuant to the terms of a partial settlement of the case, the District Court entered a permanent injunction against NeoGenomics, and it has withdrawn its RaDaR test from the market. The case remains pending with respect to an updated version of the RaDaR test and the '454 Patent. Trial is currently scheduled for October 2025. Other Litigation Matters. CareDx filed suit against the Company in April 2019 in the United States District Court for the District of Delaware, alleging false advertising, and related claims based on statements describing studies that concern the Company's technology and CareDx's technology, seeking unspecified damages and injunctive relief. The Company filed a counterclaim against CareDx in the United States District Court for the District of Delaware, alleging false advertising, unfair competition and deceptive trade practices and seeking unspecified damages and injunctive relief. In March 2022, after trial, the jury returned a verdict that the Company was liable to CareDx and found damages of $44.9 million. The jury also returned a verdict against CareDx, finding that CareDx had engaged in false advertising. In July 2023, the Court granted in part the Company's motion for judgment as a matter of law requesting that the Court set aside the portions of the jury verdict adverse to the Company, ruling that CareDx is not entitled to any damages. The jury verdict of false advertising by CareDx remains in place. Both parties are appealing; the matter has been remanded to the district court for consideration of certain post-trial motions. In May 2021, Guardant, Inc. ("Guardant") filed suit against the Company in the United States District Court of the Northern District of California alleging false advertising and related claims and seeking unspecified damages and injunctive relief. Also in May 2021, the Company filed suit against Guardant in the Western District of Texas, alleging false advertising and related claims. The Company has voluntarily dismissed its Texas suit against Guardant and has asserted the claims from the Texas action as counterclaims in the California action, seeking unspecified damages and injunctive relief. In August 2021, Guardant moved to dismiss the Company's counterclaims, which motion was denied in all material respects. Both parties filed cross-motions for summary judgment, which were granted in part and denied in part. Trial began on November 5, 2024. In November 2021, a purported class action lawsuit was filed against the Company in the United States District Court for the Northern District of California, by a patient alleging various causes of action relating to the Company's patient billing and seeks, among other relief, class certification, injunctive relief, restitution and/or disgorgement, attorneys' fees, and costs. In May 2023, the Court granted the Company's motion to dismiss the lawsuit, and the case was dismissed without prejudice. In July 2023, the plaintiff filed analogous claims in the Superior Court of California, County of San Mateo, and subsequently filed an amended claim with an additional plaintiff. Based on the additional plaintiff, the case was transferred back to the United States District Court for the Northern District of California. The parties subsequently agreed that claims brought by the original plaintiff be remanded back to the Superior Court of California, County of San Mateo, and that the action be stayed pending the outcome of the action in the United States District Court for the Northern District of California. In February 2022, two purported class action lawsuits were filed against the Company in the United States District Court for the Northern District of California. Each suit was filed by an individual patient alleging various causes of action related to the marketing of Panorama and seeking, among other relief, class certification, monetary damages, attorneys' fees, and costs. These matters have been consolidated. The Company filed a motion to dismiss the consolidated lawsuit, which resulted in the plaintiffs filing an amended complaint in April 2023. In March 2022, a purported class action lawsuit was filed against the Company and certain of its management in the Supreme Court of the State of New York, County of New York, asserting claims under Sections 11, 12, and 15 of the Securities Act of 1933. The complaint alleged, among other things, that the Company failed to disclose certain information regarding its Panorama test. The complaint sought, among other relief, monetary damages, attorneys' fees, and costs. This matter was dismissed and the claims raised in this matter have been included in the lawsuit discussed below. A purported class action lawsuit was filed against the Company and certain of its management in the United States District Court for the Western District of Texas, asserting claims under Sections 10(b) and 20(a) of the Securities Act of 1934 and Rule 10b-5 thereunder. The complaint, filed in April 2022 and amended in October 2022 (to include, among others, the claims raised in the lawsuit discussed in the preceding paragraph), alleges, among other things, that the management defendants made materially false or misleading statements, and/or omitted material information that was required to be disclosed, about certain of the Company's products and operations. The complaint seeks, among other relief, monetary damages, attorneys' fees, and costs. The Company filed a motion to dismiss this lawsuit, which was granted in part and denied in part. In each of October 2023 and January 2024, shareholder derivative complaints were filed in the United States District Court for the Western District of Texas and the United States District Court for the District of Delaware, respectively, against the Company as nominal defendant and certain of the Company's management. Each complaint alleges, among other things, that the management defendants made materially false or misleading statements, and/or omitted material information that was required to be disclosed, about certain of the Company's products and operations. Each complaint seeks, among other relief, monetary damages, attorneys' fees, and costs. In October 2024, a purported class action lawsuit was filed against the Company in the United States District Court for the Northern District of California, by patients alleging various causes of action relating to the Company's preimplantation genetic test for aneuploidies ("PGT-A"). They request, among other relief, class certification, injunctive relief, restitution and/or disgorgement, attorneys' fees, and costs. Director and Officer Indemnifications As permitted under Delaware law, and as set forth in the Company's Amended and Restated Certificate of Incorporation and its Amended and Restated Bylaws, the Company indemnifies its directors, executive officers, other officers, employees and other agents for certain events or occurrences that may arise while in such capacity. The maximum potential future payments the Company could be required to make under this indemnification is unlimited; however, the Company has insurance policies that may limit its exposure and may enable it to recover a portion of any future amounts paid. Assuming the applicability of coverage, the willingness of the insurer to assume coverage, and subject to certain retention, loss limits and other policy provisions, the Company believes any obligations under this indemnification would not be material, other than standard retention amounts for securities related claims. However, no assurances can be given that the covering insurers will not attempt to dispute the validity, applicability, or amount of coverage without expensive litigation against these insurers, in which case the Company may incur substantial liabilities as a result of these indemnification obligations. Third-Party Payer Reimbursement Audits From time to time, the Company receives recoupment requests from third-party payers for alleged overpayments. The Company disagrees with the contentions of pending requests and/or has recorded an estimated reserve for the alleged overpayments if probable and estimable. . Contractual Commitments The following table sets forth the Company's material contractual commitments as of September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:middle;white-

space:nowrap;width:60%;margin:0pt;padding:0pt;"> Party </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Commitments </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Expiry Date </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;background:#cceeff;margin:0pt;padding:0pt;"> Laboratory instruments supplier </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,243</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2024</p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">Material suppliers</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,413</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2026</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">Application service providers</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,898</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">March 2026</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">Cloud platform service provider</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 34,180</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2028</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;margin:0pt;">Leases⁽¹⁾</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 658</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">December 2029</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">Other material suppliers</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 25,654</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">Various</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">Total</p></td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 101,046 </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> ⁽¹⁾ Represents executed leases which have not commenced. Please refer to Note 7, Leases, for additional information. 2 2 3 3 3 3 3 1 1 96300000 96300000 3 3 3 3 19350000 19350000 2 2 57000000 57000000 1 1 3 2 2 1 1 2 44900000 44900000 2 2 Contractual Commitments The following table sets forth the Company's material contractual commitments as of September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"> Party </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Commitments </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Expiry Date </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:middle;white-space:nowrap;width:18.69%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;background:#cceeff;margin:0pt;padding:0pt;"> Laboratory instruments supplier </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;background:#cceeff;margin:0pt;padding:0pt;"> 2,243 </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-

align:center;margin:0pt;">December 2024 </td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"> Material suppliers </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;margin:0pt;padding:0pt;"> 34,413 </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"> December 2026 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;background:#cceeff;margin:0pt;padding:0pt;"> Application service providers </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;background:#cceeff;margin:0pt;padding:0pt;"> 3,898 </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"> March 2026 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"> Cloud platform service provider </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;margin:0pt;padding:0pt;"> 34,180 </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"> December 2028 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;background:#cceeff;margin:0pt;padding:0pt;"> Leases⁽¹⁾ </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;background:#cceeff;margin:0pt;padding:0pt;"> 658 </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"> December 2029 </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;margin:0pt;padding:0pt;"> Other material suppliers </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 25,654 </td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;margin:0pt;padding:0pt;"> Various </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:60%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:middle;white-space:nowrap;width:2.76%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.93%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 101,046</p></td><td style="vertical-align:middle;white-space:nowrap;width:3.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:middle;white-space:nowrap;width:17.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;">.</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:6pt 0pt 0pt 18pt;">⁽¹⁾ Represents executed leases which have not commenced. Please refer to Note 7, <i style="font-style:italic;">Leases</i>, for additional information.</p> 2243000 34413000 3898000 34180000 658000 25654000 101046000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">9. Stock-Based Compensation </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation Expense</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables present the stock-based compensation expense recorded for equity classified awards on selected statements of operations line items for the three and nine months ended September 30, 2024 and 2023.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three months ended September 30, </p></td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands)</i></p></td></tr><tr><td style="vertical-align:bottom;width:55.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">Cost of revenues</p></td><td style="vertical-align:bottom;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"> 4,174 </td><td style="vertical-align:bottom;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 3,299 </td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;width:4.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.72%;margin:0pt;padding:0pt;"> 22,549 </td><td style="vertical-align:bottom;width:4.65%;margin:0pt;padding:0pt;">

</td><td style="vertical-align:bottom;width:3.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> 18,784 </td></tr><tr><td style="vertical-align:bottom;width:55.29%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 43,921 </td><td style="vertical-align:bottom;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:3.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cccecff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,504 </td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 70,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;width:3.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 57,587 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> . </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine months ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.29%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of revenues </td><td style="vertical-align:bottom;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">11,997</p></td><td style="vertical-align:bottom;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"> 8,692 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;width:4.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"> 65,155 </td><td style="vertical-align:bottom;width:4.54%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:3.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> 48,761 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 125,350 </td><td style="vertical-align:bottom;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:3.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 84,923 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-

align:bottom;white-space:nowrap;width:14.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 202,502 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:3.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 142,376 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr></table> Additionally, the stock-based compensation expense for liability-classified awards for both the three months ended September 30, 2024 and 2023 was $0.1 million. The stock-based compensation expense for liability-classified awards for both the nine months ended September 30, 2024 and 2023 was $0.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;">Stock Options</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes option activity for the nine months ended September 30, 2024:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</p></td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</p></td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Price</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="4" style="vertical-align:bottom;width:42.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands, except for per share data)</i></p></td></tr><tr><td style="vertical-align:bottom;width:57.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;">December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,501</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"> 23.65 </td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"> Options exercised </td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (1,325) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7.80</p></td></tr><tr><td style="vertical-align:bottom;width:57.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;">September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,176</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times';serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"> 28.67 </td></tr></table> Restricted Stock Units and Performance-Based Awards The following table summarizes unvested RSU and performance-based awards for the nine months ended September 30, 2024: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> <span style="font-

family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"> Weighted- </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"> Grant Date </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Fair Value </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.44%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;width:31.97%;margin:0pt;padding:0pt;"> (in thousands, except for per share data) </td></tr><tr><td style="vertical-align:bottom;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"> 9,248 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 49.50</p></td></tr><tr><td style="vertical-align:bottom;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,043</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> 70.99 </td></tr><tr><td style="vertical-align:bottom;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"> (2,968) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 55.27</p></td></tr><tr><td style="vertical-align:bottom;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Cancelled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (467)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> 57.96 </td></tr><tr><td style="vertical-align:bottom;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,856 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 57.91 </td></tr></table> The Company has granted certain senior-level executives performance stock units which vest based on performance and time-based service conditions, which are referred to herein as performance-based awards. During the nine months ended September 30, 2024, the Company granted 0.8 million performance-based awards with an aggregate grant date fair value of $55.0 million. Achievement at 200% of target is deemed probable and, as a result, the Company expects to recognize a total of $110.0 million over the requisite service period, of which $9.4 million and $25.4 million has been recognized for the three and nine months ended September 30, 2024, respectively. The Company has recognized $23.7 million and $23.0 million in stock-based compensation for all performance-based awards for the three months ended September 30, 2024 and 2023, respectively. The Company has recognized $66.5 million and $40.5 million in stock-based compensation for all performance-based awards for the nine months ended September 30, 2024 and 2023, respectively. The following tables present the stock-based compensation expense recorded for equity classified awards on selected statements of operations line items for the three and nine months ended September 30, 2024 and 2023. <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Three months ended September 30, </td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:40.24%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:55.29%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of revenues </td><td style="vertical-align:bottom;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:14.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">4,174</p></td><td style="vertical-align:bottom;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">.</p></td><td style="vertical-align:bottom;width:3.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;margin:0pt;padding:0pt;"> 3,299 </td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;width:4.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.8%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:14.72%;margin:0pt;padding:0pt;"> 22,549 </td><td style="vertical-align:bottom;width:4.65%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:3.35%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;margin:0pt;padding:0pt;"> 18,784 </td></tr><tr><td style="vertical-align:bottom;width:55.29%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;width:4.46%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:14.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 43,921 </td><td style="vertical-align:bottom;width:4.65%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:3.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 35,504 </td></tr><tr><td style="vertical-align:bottom;width:55.29%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.46%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;width:2.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 70,644</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">.</p></td><td style="vertical-align:bottom;width:3.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 57,587 </td></tr></table> . <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Nine months ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;">   </td><td style="vertical-align:bottom;white-space:nowrap;width:2.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-

height:1.19;text-align:center;margin:0pt;">2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:3.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="8" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:39.29%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"> Cost of revenues </td><td style="vertical-align:bottom;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.72%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;">11,997</p></td><td style="vertical-align:bottom;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;width:3.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;margin:0pt;padding:0pt;"> 8,692 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> Research and development </td><td style="vertical-align:bottom;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.72%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.36%;margin:0pt;padding:0pt;"> 65,155 </td><td style="vertical-align:bottom;width:4.54%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:3.28%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;margin:0pt;padding:0pt;"> 48,761 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.99%;background:#cceeff;margin:0pt;padding:0pt;"> Selling, general and administrative </td><td style="vertical-align:bottom;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:14.36%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 125,350 </td><td style="vertical-align:bottom;width:4.54%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:3.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 84,923 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:53.99%;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.36%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 202,502</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;width:3.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:14.37%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 142,376 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.36%;margin:0pt;padding:0pt;"> </td></tr></table> 4174000 3299000 22549000 18784000 43921000 35504000 70644000 57587000 11997000 8692000 65155000 48761000 125350000 84923000 202502000 142376000 100000 100000 600000 600000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"> Weighted- </td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"> Number of </td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"> Average </td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;margin:0pt;padding:0pt;"> Shares </td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;margin:0pt;padding:0pt;"> Exercise </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:57.22%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Outstanding </td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> Price </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"> </td><td colspan="4" style="vertical-align:bottom;width:42.77%;margin:0pt;padding:0pt;"> (in thousands, except for per share data) </td></tr><tr><td style="vertical-align:bottom;width:57.22%;background:#cceeff;margin:0pt;padding:0pt;"> December 31, 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;margin:0pt;padding:0pt;"> 5,501 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;background:#cceeff;margin:0pt;padding:0pt;"><p

style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23.65</p></td></tr><tr><td style="vertical-align:bottom;width:57.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Options exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (1,325)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;margin:0pt;padding:0pt;"> 7.80 </td></tr><tr><td style="vertical-align:bottom;width:57.22%;background:#cceeff;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:23.71%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 4,176 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.12%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 28.67</p></td></tr></table> 5501000 23.65 1325000 7.80 4176000 28.67 <p style="font-family:'Times New Roman','Times',serif;font-size:10pt;min-height:0.0pt;margin:0pt;"></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant Date</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td colspan="4" style="vertical-align:bottom;width:31.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-style:italic;">(in thousands, except for per share data)</i></p></td></tr><tr><td style="vertical-align:bottom;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">Balance at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,248</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 49.50 </td></tr><tr><td style="vertical-align:bottom;width:64.44%;margin:0pt;padding:0pt;"> Granted </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;margin:0pt;padding:0pt;"> 5,043 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> 70.99 </td></tr><tr><td style="vertical-align:bottom;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"> Vested </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times

New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;margin:0pt;padding:0pt;"> (2,968) </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 55.27</p></td></tr><tr><td style="vertical-align:bottom;width:64.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Cancelled/forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"> (467)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> 57.96 </td></tr><tr><td style="vertical-align:bottom;width:64.44%;background:#cceeff;margin:0pt;padding:0pt;"> Balance at September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:12.69%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 10,856 </td><td style="vertical-align:bottom;white-space:nowrap;width:3.57%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.69%;background:#cceeff;margin:0pt;padding:0pt;"> $ </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 57.91 </td></tr></table> 9248000 49.50 5043000 70.99 2968000 55.27 467000 57.96 10856000 57.91 800000 55000000.0 2 110000000.0 9400000 25400000 23700000 23000000.0 66500000 40500000 10. Debt Credit Line Agreement In September 2015, the Company entered into a credit line with UBS (the "Credit Line") providing for a $50.0 million revolving line of credit which was fully drawn down in 2016. The Credit Line was amended in July 2017 and bears interest at 30-day LIBOR plus 1.10%. The interest rate was subsequently changed to the 30-day SOFR average, plus 1.21%. The SOFR rate is variable. The Credit Line was subsequently increased from $50.0 million to $150.0 million in 2020. In November 2022, the Company drew down $30.0 million from the $100.0 million available from the Credit Line. The Credit Line is secured by a first priority lien and security interest in the Company's money market and marketable securities held in its managed investment account with UBS. The Company is required to maintain a minimum of at least $150.0 million in its UBS accounts as collateral. UBS has the right to demand full or partial payment of the Credit Line obligations and terminate the Credit Line, in its discretion and without cause, at any time. In June 2023, the Credit Line decreased from $150.0 million to $100.0 million. In October 2023, the interest rate for the Credit Line was subsequently changed to the 30-day SOFR average, plus 0.5%. As of September 30, 2024, the Company has drawn down a total of $80.0 million, leaving $20.0 million remaining and available on the Credit Line. The interest rate as of September 30, 2024 was 5.66%. For the three months ended September 30, 2024 and 2023, the Company recorded interest expense on the Credit Line of $1.2 million and $1.3 million, respectively. For the nine months ended September 30, 2024 and 2023, the Company recorded interest expense on the Credit Line of $3.6 million and $3.7 million, respectively. Interest payments on the Credit Line were made within the same periods. As of September 30, 2024 and December 31, 2023, the total principal amount outstanding with accrued interest was $80.4 million. Convertible Notes In April 2020, the Company issued $287.5 million aggregate principal amount of Convertible Notes due 2027 in a private placement offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The Convertible Notes are senior, unsecured obligations of the Company and bear interest at a rate of 2.25% per year, payable in cash semi-annually. The Convertible Notes mature in May 2027, unless earlier converted, repurchased or redeemed in accordance with their terms. Upon conversion, the Convertible Notes are convertible into cash, shares of the Company's common stock or a combination of cash and shares of the Company's common stock, at the Company's election. The Company received net proceeds from the Convertible Notes of $278.3 million, after deducting the initial purchasers' discounts and debt issuance costs. In 2020, the Company used approximately $79.2 million of the net proceeds from the Convertible Notes offering to repay its obligations under its credit agreement with OrbiMed Royalty Opportunities II, LP. The holders of the Convertible Notes may convert all or a portion of their Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding February 1, 2027 in multiples of $1,000 principal amount, under any the following circumstances: <table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">During any fiscal quarter commencing after September 30, 2020 (and only during such fiscal quarter), if the last reported sale price of the Company's common stock for at least 20 trading days (whether or not consecutive) during the period of 30 consecutive trading days ending on, and including, the last trading day of the immediately preceding fiscal quarter is greater than or equal to 130% of the conversion price on each applicable trading day. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">During the five business day period after any five consecutive trading day period in which the trading price per $1,000 principal amount of Convertible Notes for each trading day of that five-day consecutive trading period was less than 98% of the product of the last reported sale price of the Company's common stock and the conversion rate on each such trading day. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">If the Company calls any or all of the Convertible Notes for redemption at any time prior to the close of business on the second business day prior to the redemption date. </td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Upon the occurrence of certain distributions.</td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;">Upon the occurrence of specified corporate transactions. </td></tr></table> The Convertible Notes are convertible into shares of the Company's common stock, par value $0.0001 per share, at an initial conversion rate of 25.7785 shares of common stock per $1,000 principal amount of the Convertible Notes, which is equivalent to an initial conversion price of approximately $38.79 per share of common stock, convertible to 7,411,704 shares of common stock. The conversion rate and corresponding conversion price are subject to adjustment upon the occurrence of certain events, but will not be adjusted for any accrued or unpaid interest. The holders of the Convertible Notes who redeem their Convertible Notes in connection with a make-whole fundamental change are, under certain circumstances, entitled to an increase in the conversion rate. Additionally, in the event of a fundamental change, the holders of the Convertible Notes may require the Company to repurchase for cash all or a portion of their Convertible Notes at a price equal to 100% of the principal amount, plus any accrued and unpaid interest. The Company may not redeem the Convertible Notes prior to May 2024, and no sinking fund is provided for the Convertible Notes. The Company may redeem for cash all or any portion of the Convertible Notes, at the Company's option, on or after May 2024, if the last reported sale price of the Company's common stock has been at least 130% of the conversion price then in effect for at least 20 trading days during any 30 consecutive trading day period ending on the trading day immediately preceding the date on which the Company provides notice of redemption. The redemption price will be equal to 100% of the principal amount of the Convertible Notes to be redeemed plus accrued and unpaid interest. The first and third circumstances noted above have been met as of September 30, 2024. On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its outstanding 2.25% Convertible Notes due 2027 and instructed Wilmington Trust, National Association, as trustee under the Convertible Notes Indenture (the "Indenture Agreement") governing the Convertible Notes, to issue a redemption notice to registered holders of the Convertible Notes. The date fixed for the redemption of the Convertible Notes is October 11, 2024 (the "Redemption Date"). The redemption price for the Convertible Notes is equal to 100% of the principal amount of the Convertible Notes to be redeemed plus accrued and unpaid interest to, but excluding, the Redemption Date. The Company elected physical settlement

with the Company's shares of common stock as the settlement method to apply to all conversions of the Convertible Notes. All terms and conditions associated with physical settlement are noted within the terms of the original Indenture Agreement. The conversion rate for holders who convert their Convertible Notes in connection with the Company's election to redeem the Convertible Notes was increased by 0.4284 additional shares pursuant to the Indenture Agreement. Upon adoption of ASU 2020-06, Debt with Conversion and Other Options (Subtopic 470-20) and Derivative and Heading-Contracts in Entity's Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in Entity's Own Equity, the Company allocated all of the debt discount to long-term debt. The debt discount is amortized to interest expense using the effective interest method, computed to be 2.72%, over the life of the Convertible Notes or approximately its seven-year term. The outstanding Convertible Notes balances as of September 30, 2024 and December 31, 2023 are summarized in the following table: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.9%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> Outstanding Principal </td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 287,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> 287,500 </td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"> Unamortized debt discount and issuance cost </td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,564) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,555) </td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> Net carrying amount </td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"> 283,936 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> 282,945 </td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued interest to be settled in equity </td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"> 2,695 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> Reclassifications to short-term debt financing </td><td style="vertical-align:bottom;width:2.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (82) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term debt financing </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 286,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times',serif;font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 282,945 </td></tr></table><p style="font-family:'Times New Roman','Times',serif;font-

size:10pt;line-height:1.19;margin:0pt;"> The following tables present total interest expense recognized related to the Convertible Notes during the three and nine months ended September 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;margin:0pt;padding:0pt;"> Three months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Cash interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> Contractual interest expense </td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> 1,617 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> Amortization of debt discount and debt issuance cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 333 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 324 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,941 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> <div

style="bottom:0pt;position:absolute;width:100%;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;margin:0pt;padding:0pt;"> Nine months ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Cash interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> Contractual interest expense </td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> 4,851 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> Amortization of debt discount and debt issuance cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 991 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 966 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 5,817 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> 50000000.0 0.0110 0.0121 50000000.0 150000000.0 30000000.0 100000000.0 150000000.0 150000000.0 100000000.0 0.005 -80000000.0 20000000.0 0.0566 0.0566 1200000 1200000 1300000 3600000 3700000 80400000 80400000 287500000 0.0225 278300000 79200000 1000 20 30 1.30 5 5 1000 0.98 0.0001 25.7785 1000 38.79 7411704 1 1.30 20 30 1 287500000 0.0225 1 0.4284 0.0272 P7Y <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-

space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> December 31, 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.9%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"> Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> Outstanding Principal </td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 287,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> 287,500 </td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"> Unamortized debt discount and issuance cost </td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (3,564) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (4,555) </td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> Net carrying amount </td><td style="vertical-align:bottom;width:2.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;margin:0pt;padding:0pt;"> 283,936 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;margin:0pt;padding:0pt;"> 282,945 </td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"> Accrued interest to be settled in equity </td><td style="vertical-align:bottom;width:2.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;margin:0pt;padding:0pt;"> 2,695 </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:64.09%;margin:0pt;padding:0pt;"> Reclassifications to short-term debt financing </td><td style="vertical-align:bottom;width:2.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> (82) </td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;width:2.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> — </td></tr><tr><td style="vertical-align:bottom;width:64.09%;background:#cceeff;margin:0pt;padding:0pt;"> Long-term debt financing </td><td style="vertical-align:bottom;white-space:nowrap;width:2.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.21%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 3.6pt 0.05pt 0pt;"> 286,549</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0.05pt 0pt 0.05pt 0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13.64%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 282,945 </td></tr></table> 287500000 287500000 3564000 4555000 283936000 282945000 2695000 -82000 286549000 282945000 <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;margin:0pt;padding:0pt;"> Three months ended </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-

height:1.19;margin:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="7" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Cash interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> Contractual interest expense </td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> 1,617 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> Amortization of debt discount and debt issuance cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 333 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 324 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,951</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"></p></td><td style="vertical-align:bottom;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 1,941 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"> </td></tr></table> <table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;margin:0pt;padding:0pt;"> Nine months ended September 30, </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> </td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> <b style="font-

weight:bold;">2023 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.02%;margin:0pt;padding:0pt;"> </td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.79%;margin:0pt;padding:0pt;"> (in thousands) </td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Cash interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td></tr><tr><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> Contractual interest expense </td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,852</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;width:2.91%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,851</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Non-cash interest expense </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td></tr><tr><td style="vertical-align:bottom;width:66.02%;margin:0pt;padding:0pt;"> Amortization of debt discount and debt issuance cost </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 991</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:2.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 966</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">$ </td></tr><tr><td style="vertical-align:bottom;width:66.02%;background:#cceeff;margin:0pt;padding:0pt;"> Total interest expense </td><td style="vertical-align:bottom;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,843</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;width:2.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,817</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><span style="visibility:hidden;">$ </td></tr></table>   1618000 1617000 333000 324000 1951000 1941000 4852000 4851000 991000 966000 5843000 5817000 11. Income Taxes During the three months ended September 30, 2024 and 2023, the Company recorded total income tax expense (benefit) of approximately $730,000 and $202,000, respectively. During the nine months ended September 30, 2024 and 2023, the Company recorded total income tax expense (benefit) of approximately $2,050,000 and $80,000, respectively. The income tax expense is primarily attributable to state income tax and foreign income tax. Due to the Company's history of cumulative operating losses, the Company concluded that, after considering all the available objective evidence, it is not more likely than not that all of the Company's net deferred tax assets will be realized. Accordingly, all of the Company's deferred tax assets, which includes net operating loss carryforwards and tax credits related primarily to research and development, continue to be subjected to a full valuation allowance as of September 30, 2024. The Company will continue to maintain a full valuation allowance until there is sufficient evidence to support recoverability of its deferred tax assets. Interest and/or penalties related to income tax matters are recognized as a component of income tax expense. As of September 30, 2024 and December 31, 2023, there were no accrued interest and penalties related to uncertain tax positions. 730000 202000 2050000 80000 0 0 12. Net Loss per Share The Convertible Notes are convertible by the holders as of September 30, 2024. Upon conversion, the Company has the option to pay cash, issue shares of common stock, or any combination thereof for the aggregate amount due upon conversion. If converted, the fair value of the shares issued to settle the Convertible Notes would exceed the Convertible Note principle by $597.8 million based on the closing price of the Company's common stock as of September 30, 2024. Since the Company is in a net loss position in the periods presented, the shares which would be issued upon conversion of the Convertible Notes are excluded from the net loss per share calculation, as it would have an antidilutive effect. As such, the 7.4 million shares underlying the conversion option of the Convertible Notes have been excluded from the calculation of diluted earnings per share. On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its Convertible Notes. On the Redemption Date, $287.4 million of Convertible Notes was converted in exchange for 7.5 million shares of the Company's common stock. The following table shows total outstanding potentially dilutive shares excluded from the computation of diluted loss per share as their effect would be anti-dilutive, as of September 30, 2024 and 2023: <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> </td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">

2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.34%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:65.32%;background:#cceeff;margin:0pt;padding:0pt;"> Options to purchase common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 4,176 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 5,532 </td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> Performance-based awards and restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> 10,856 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> 9,440 </td></tr><tr><td style="vertical-align:bottom;width:65.32%;background:#cceeff;margin:0pt;padding:0pt;"> Employee stock purchase plan </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 93 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 188 </td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,411 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 7,411 </td></tr><tr><td style="vertical-align:bottom;width:65.32%;background:#cceeff;margin:0pt;padding:0pt;"> Total </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22,536 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22,571 </td></tr></table> . 597800000 7400000 287500000 287400000 7500000 . <table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> . </td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> September 30, </td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2024 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"> 2023 </td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> </td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:30.34%;margin:0pt;padding:0pt;"> (in thousands) </td></tr><tr><td style="vertical-align:bottom;width:65.32%;background:#cceeff;margin:0pt;padding:0pt;"> Options to purchase common stock </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 4,176 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 5,532 </td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> Performance-based awards and restricted stock units </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> 10,856 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;margin:0pt;padding:0pt;"> 9,440 </td></tr><tr><td style="vertical-align:bottom;width:65.32%;background:#cceeff;margin:0pt;padding:0pt;"> Employee stock purchase plan </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 93 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;margin:0pt;padding:0pt;"> 188 </td></tr><tr><td style="vertical-align:bottom;width:65.32%;margin:0pt;padding:0pt;"> Convertible Notes </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> . </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;">

7,411 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,411</p></td></tr><tr><td style="vertical-align:bottom;width:65.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="visibility:hidden;">$ </td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"> 22,536 </td><td style="vertical-align:bottom;white-space:nowrap;width:4.33%;background:#cceeff;margin:0pt;padding:0pt;"> $</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 22,571</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">$ 4176000 5532000 10856000 9440000 93000 188000 7411000 7411000 22536000 22571000 13. Subsequent Events $ On July 19, 2024, the Company elected to exercise its optional redemption right to redeem all $287.5 million aggregate principal amount of its outstanding 2.25% Convertible Notes due 2027 and instructed Wilmington Trust, National Association, as trustee under the Convertible Notes Indenture (the "Indenture Agreement") governing the Convertible Notes, to issue a redemption notice to registered holders of the Convertible Notes. The date fixed for the redemption of the Convertible Notes was October 11, 2024 (the "Redemption Date"). On the Redemption Date, $287.4 million of Convertible Notes were converted for approximately 7.5 million shares of the Company's common stock under the terms of the redemption notice. The remaining Convertible Notes not converted under the redemption notice were redeemed in exchange for cash at face value plus any accrued interest totaling $0.1 million. As such, the Company reclassified $0.1 million of Convertible Notes from long-term liabilities to short-term liabilities as of September 30, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;">$ In November 2024, the Company entered into an agreement with a non-profit research institute and a clinical technology company whereby the Company obtained licensing rights and access to certain data. The Company is obligated to pay a total of $20.0 million, of which $7.0 million has been paid and the remaining $13.0 million will be paid between January 2025 and January 2031. Additionally, the Company may be obligated to pay up to $50.0 million in milestone payments if certain milestone thresholds and regulatory approvals are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">$ 287500000 0.0225 287400000 7500000 100000 100000 20000000.0 7000000.0 13000000.0 50000000.0 On June 14, 2024, Mike Brophy, our chief financial officer, adopted a trading arrangement for the sale of shares of our common stock (a "Rule 10b5-1 Trading Plan") that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Brophy's Rule 10b5-1 Trading Plan provides for the potential sale of up to 109,293 shares of our common stock pursuant to the terms of the plan between February 2, 2025 and February 1, 2026. June 14, 2024 Mike Brophy chief financial officer true 109293 On June 14, 2024, Daniel Rabinowitz, our chief legal officer, adopted a trading arrangement for the sale of shares of our common stock (a "Rule 10b5-1 Trading Plan") that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Rabinowitz's Rule 10b5-1 Trading Plan provides for the sale of 26,131 shares of our common stock pursuant to the terms of the plan between December 15, 2024 and August 15, 2026. June 14, 2024 Daniel Rabinowitz chief legal officer true 26131 On August 12, 2024, Roy Baynes, a member of our Board of Directors, adopted a trading arrangement for the sale of shares of our common stock (a "Rule 10b5-1 Trading Plan") that is intended to satisfy the affirmative defense conditions of Securities Exchange Act Rule 10b5-1(c). Mr. Baynes Rule 10b5-1 Trading Plan provides for the exercise of 37,230 stock options and sale of underlying shares of our common stock pursuant to the terms of the plan between November 11, 2024 and December 31, 2025. August 12, 2024 Roy Baynes member of our Board of Directors true 37230